COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS

Abstract

The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein.

Description

TECHNICAL FIELD

This application pertains to compounds that stabilize phenylalanine hydroxylase (PAH) mutations, pharmaceutical compositions comprising those compounds, and methods of using those compounds for treating phenylketonuria.

BACKGROUND

Phenylketonuria (PKU) is an autosomal recessive disorder affecting approximately 1:10,000 people worldwide (approx. 1:15,000-1:20,000 in the U.S.). The number of patients varies globally depending on region. PKU arises in patients who have mutations in the gene encoding the phenylalanine hydroxylase (PAH) enzyme responsible for converting phenylalanine to tyrosine. PAH is a tetrameric enzyme expressed in the liver requiring BH4 cofactor for activity. Reduction or loss of PAH activity results in toxic accumulation of phenylalanine (Phe) in the blood and brain. High levels of Phe damage brain white matter and interfere with neurotransmitter production. If untreated, high levels of Phe can result in mental retardation and decreased IQ in children and neurocognitive and psychiatric issues in adults, such as executive function deficits (for example, difficulty with attention, memory, flexible thinking, and organization/time management), psychological issues (for example, depression, anxiety, and mood swings), psychiatric and/or behavioral issues (for example, attention deficit hyperactivity disorder, self-harm, schizophrenia, agoraphobia, and agitation) and neurological abnormalities (for example, spasticity, tremor, gait disturbances, and seizures).

PKU phenotypes can vary from mild hyperphenylalaninemia (HPA) to more severe phenotypes that result in untreated blood Phe concentrations exceeding 1200 µM. American medical guidelines currently recommend maintaining blood Phe concentration in the range of 120 to 360 µM in both adults and children under the age of 12 years. European medical guidelines currently recommend maintaining blood Phe concentration below 360 µM in children under the age of 12 years and in pregnant women and below 600 µM in non-pregnant patients older than 12 years.

A standard of care for treating PKU is a Phe-restricted diet that severely limits the intake of natural protein. Such diets are very strict diets and challenging to adhere to. Two medications are currently approved for treating PKU, each having its own challenges. Kuvan (sapropterin dihydrochloride) is a synthetic BH4 cofactor approved in 2007 for use in infants to adults. Kuvan is not effective for all PKU patients, and the current guidelines suggest response testing in patients unless the patient is known to have two null mutations. Pegvaliase is an enzyme substitution therapy approved in 2018 for adults with a blood Phe concentration greater than 600 µM. despite prior management with available treatment options. Pegvaliase typically involves injection of a purified PEGylated form of phenylalanine ammonia lyase that reduces Phe by converting it to ammonia and trans-cinnamic acid instead of tyrosine. One of the main complications with enzyme substitution therapy is the attainment and maintenance of therapeutically effective amounts of protein in vivo due to rapid degradation or inactivation of the infused protein. A current approach to overcome this problem is to perform numerous costly high dose injections.

Pharmaceutical agents that enable patients to increase their intake of natural protein are desired.

SUMMARY

In some aspects, the disclosure provides compounds of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
  • m is 1 or 2;
  • R¹ is
  • x is 0 to 5:
  • each R^a independently is halo, C_1-6alkyl, C_3-6cycloalkyl, C_1-6haloalkyl, C_1-6alkoxy or C_1-6haloalkoxy;
  • R² is C_1-4alkyl, optionally substituted C_3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R³ is H or C_1-6alkyl;
  • R⁴ is H or C_1-6alkyl:
  • or R³ and R⁴, together with the atom to which they are attached, form a C_3-6cycloalkyl;
  • R⁵ is H or D;
  • R^5A is H or D; and
  • L is a bond, carbonyl, optionally substituted C_1-6alkylene, optionally substituted C_1-6alkylenecarbonyl, optionally substituted C_2-6alkenylenecarbonyl, optionally substituted C_1-6haloalkylenecarbonyl, or optionally substituted -C(O)NR^b(C_1-6alkylene)-, wherein the carbon atom of the carbonyl group is connected to N in Formula I; and
  • R^b is H or C_1-6alkyl.

In other aspects, the disclosure provides compounds of Formula 1-A, I-B. I-C, I-D, I-E, I-F, I-G, I-H, I-I, I-J, I-K, I-L, or I-M, or a pharmaceutically acceptable salt thereof:

Stereoisomers and mixtures of stereoisomers of the compounds of Formula I, I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H, I-I, I-J, I-K, I-L, and I-M, and the pharmaceutical salts thereof, are also described.

In further aspects, the disclosure provides pharmaceutical compositions comprising one or more compound described herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

In yet other aspects, the disclosure provides methods for stabilizing a mutant PAH protein, comprising contacting the protein with one or more compound as described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the mutant PAH protein contains at least one R408W. R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, 165T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

In still further aspects, the disclosure provides methods for reducing phenylalanine levels in a subject suffering from phenylketonuria comprising administering a therapeutically effective amount of one or more compound as described herein or a pharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

Definitions

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the disclosure.

As used in structures herein,

indicates the point of attachment of the particular depicted structure or substituent group to the appropriate atom(s) in the remainder of the molecule.

The articles “a” and “an” as used herein and in the appended claims are used herein to refer to one or to more than one (e.g., to at least one) of the grammatical object of the article unless the context clearly indicates otherwise. By way of example. “an element” means one element or more than one element.

“Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in a country other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans.

“Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic and may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like: or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, fumarate, tartrate, mesylate, acetate, maleate, oxalate and the like.

A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.

The term “alkyl,” when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C_1-12”), for example 1 to 6 carbons atoms (“C_1-6”), in the group. Examples of alkyl groups include methyl (C₁), ethyl (C₂), propyl (C₃) (e.g., n-propyl, isopropyl), butyl (C₄) (e.g., n-butyl, tert-butyl, sec-butyl, iso-butyl), pentyl (C₅) (e.g., n-pentyl, 3-pentyl, amyl, neopentyl, 3-methyl-2-butanyl, tertiary amyl), hexyl (C₆) (e.g., n-hexyl), heptyl (C₇) (e.g., n-heptyl), octyl (C₈) (e.g., n-octyl), and the like. In some embodiments, the alkyl group is a C_1-6alkyl; in other embodiments, it is a C_1-4alkyl; and in other embodiments, it is a C_1-3alkyl.

The term “alkylene,” when used alone or as part of a substituent group, refers to an alkyl diradical, i.e., a straight- or branched-chain hydrocarbon group that is attached to two other groups. For example, one embodiment of a C₂alkylene is the diradical —CH₂CH₂—. In some embodiments, the alkylene group is C_1-6alkylene; in other embodiments, it is C_1-4alkylene.

When a range of carbon atoms is used herein, for example, C_1-6, all ranges, as well as individual numbers of carbon atoms are encompassed. For example, “C_1-3” includes C_1-3, C_1-2, C_2-3, C₁, C₂, and C₃.

The term “cycloalkyl” when used alone or as part of a substituent group refers to cyclic-containing, non-aromatic hydrocarbon groups having from 3 to 10 carbon atoms (“C_3-10”), for example from 3 to 7 carbon atoms (“C_3-7”). Examples of cycloalkyl groups include cyclopropyl (C₃), cyclobutyl (C₄), cyclopentyl (C₅), cyclohexyl (C₆), cycloheptyl (C₇), and the like. In some embodiments, the cycloalkyl group is a C_3-4cycloalkyl; in other embodiments, it is a C_3-6cycloalkyl; and in other embodiments, it is C_3-8cycloalkyl. The cycloalkyl may be unsubstituted or substituted. In some embodiments, the cycloalkyl is substituted with two substituents. In further embodiments, the cycloalkyl is substituted with one substituent. In yet other embodiments, the cycloalkyl is substituted with three substituents. In still further embodiments, the cycloalkyl is unsubstituted.

The term “aryl” when used alone or as part of a substituent group also refers to a mono- or bicyclic- aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted. The term “aryl” also includes a mono- or bicyclic- aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein two adjacent carbon atoms in the ring are optionally substituted such that said two adjacent carbon atoms and their respective substituents form a cycloalkyl or heterocyclyl ring. Examples of aryl groups include phenyl, indenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, and the like. The aryl may be unsubstituted or substituted. In other embodiments, the optionally substituted phenyl has four substituents. In further embodiments, the optionally substituted phenyl has three substituents. In yet other embodiments, the optionally substituted phenyl has two substituents. In still further embodiments, the optionally substituted phenyl has one substituent. In other embodiments, the optionally substituted phenyl is unsubstituted.

As used herein, the term “alkenyl” refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C_2-12”) in the group, wherein the group includes at least one carbon-carbon double bond. Examples of alkenyl groups include vinyl (—CH═CH₂; C₂alkenyl), allyl (—CH₂—CH═CH₂; C₃alkenyl), propenyl (-CH=CHCH₃; C₃alkenyl), isopropenyl (—C(CH₃)═CH₂; C₃alkenyl), butenyl (—CH═CHCH₂CH₃; C₄alkenyl), sec-butenyl (—C(CH₃)═CHCH₃; C₄alkenyl), iso-butenyl (—CH═C(CH₃)₂; C₄alkenyl), 2-butenyl (CH₂CH═CHCH₃; C₄alkyl), pentenyl (—CH═CHCH₂CH₂CH₃; C₅alkenyl), and the like. In some embodiments, the alkenyl group is a C_2-6 alkenyl group; in other embodiments, it is C_2-4alkenyl.

As used herein, the term “alkynyl” refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C_2-12”) in the group, and wherein the group includes at least one carbon-carbon triple bond. Examples of alkynyl groups include ethynyl (—C═CH; C₂alkynyl), propargyl (—CH₂—C≡CH; C₃alkynyl), propynyl (—C≡CCH₃; C₃alkynyl), butynyl (—C≡CCH₂CH₃; C₄alkynyl), pentynyl (—C≡CCH₂CH₂CH₃; C₅alkynyl), and the like. In some embodiments, the alkynyl group is a C_2-6alkynyl group; in other embodiments, it is C_2-4alkynyl.

The term “carbonyl” as used by itself or as part of another group refers to C(O) or C(═O).

The term “alkylcarbonyl” as used by itself or as part of another group refers to an alkyl group as defined above wherein at least one carbon is bonded to an oxo group. For example, one embodiment of an C₃alkylcarbonyl is —CH₂C(O)CH₃. In some embodiments, the alkylcarbonyl group is a C_1-6alkylcarbonyl group.

The term “alkenylenecarbonyl” as used by itself or as part of another group refers to an —C(O)—(alkenylene) group, where alkenylene refers to an alkylene diradical. i.e., a straight- or branched-chain hydrocarbon group containing at least one carbon-carbon double bond that is attached to two other groups. For example, one embodiment of a —C(O)—C₂alkenylene is —C(O)—CH═CH—. In some embodiments, the alkenylene group of the alkenylenecarbonyl is a C_2-6alkenylene group; in other embodiments, the alkenylene group is C_2-4alkenylene.

The term “halo” or “halogen,” as used by itself or as part of another group refers to a fluorine, chlorine, bromine, or iodine atom.

As used herein, the term “haloalkyl” refers to an alkyl group wherein one or more of the hydrogen atoms has been replaced with one or more halogen atoms which may be the same or different. In some embodiments, the alkyl is substituted by at least one halogen. In other embodiments, the alkyl is substituted by one, two, or three F and/or Cl. Examples of haloalkyl groups include fluoromethyl (CH₂F), 1-fluoroethyl (CH(CH₃)F), 2-fluoroethyl, difluoromethyl (CHF₂), trifluoromethyl (CF₃), pentafluoroethyl, 1,1-difluoroethyl (C(CH₃)F₂), 2,2-difluoroethyl (CH₂CHF₂), 2,2,2-trifluoroethyl (CH₂CF₃), 2-fluoropropan-2-yl (C(CH₃)₂F), 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, trichloromethyl and the like. In some embodiments, the haloalkyl group is a C_1-6haloalkyl; in other embodiments, it is a C_1-4haloalkyl; and in other embodiments, it is a C_1-3haloalkyl.

The term “haloalkylenecarbonyl” as used by itself or as part of another group refers to a —C(O)—(haloalkylene) group, where the haloalkylene refers to a haloalkyl diradical. For example, one embodiment of a —C(O)—C₁haloalkylene is —C(O)—CF₂—. In some embodiments, the haloalkylene group is a C_1-6haloalkylene; in other embodiments, it is a C_1-4haloalkylene; and in other embodiments, it is a C_1-3haloalkylene.

The term “cyanoalkyl” as used by itself or as part of another group refers to an alkyl as defined herein that is substituted by one or more CN. In some embodiments, the alkyl is substituted by at least one CN. In other embodiments, the alkyl is substituted by one, two, or three CN. In further embodiments, the cyanoalkyl group is a C_1-6cyanoalkyl. In yet other embodiments, the cyanoalkyl is a C_1-4cyanoalkyl. Examples of cyanoalkyl groups include CH₂CN, CH₂CH₂CN, CH(CN)CH₃, CH₂CH₂CH₂CN, C(CH₃)₂CN, CH₂CH(CN)CH₃, CH(CN)CH₂CH₃, and the like.

The term “hydroxyalkyl” as used by itself or as part of another group refers to an alkyl group as defined herein wherein one or more of the hydrogen atoms has been replaced with one or more hydroxyl (i.e., —OH). In some embodiments, the hydroxyalkyl contains one OH. In other embodiments, the hydroxyalkyl contains two OH. In further embodiments, the hydroxyalkyl contains three OH. Examples of hydroxyalkyl groups include hydroxymethyl, hydroxyethyl (e.g., 1-hydroxyethyl, 2-hydroxyethyl), 1,2-dihydroxyethyl, hydroxypropyl (e.g., 2-hydroxypropyl, 3-hydroxypropyl), hydroxybutyl (e.g., 3-hydroxybutyl, 4-hydroxybutyl), 2-hydroxy-1-methylpropyl, 1,3-dihydroxyprop-2-yl, and the like. In some embodiments, the hydroxyalkyl group is C_1-6hydoxyalkyl; in other embodiments, it is C_1-4hydroxyalkyl; and in other embodiments, it is C_1-3hydroxyalkyl.

The term “cycloalkylsulfonyl” as used by itself or as part of another group refers to a cycloalkyl as defined herein that is bound to a sulfonyl, i.e., —SO₂—, and the sulfonyl group forms the point of attachment to the remainder of the molecule. In some embodiments, the cycloalkylsulfonyl is a C_3-8cycloalkylsulfonyl; in other embodiments, it is a C_3-6cycloalkylsulfonyl. Examples of cycloalkylsulfonyl groups include -SO₂-cyclopropyl, -SO₂-cyclobutyl, -SO₂-cyclopentyl, and the like

The term “alkylsulfonyl” as used by itself or as part of another group refers to an alkyl as defined herein that is bound to a sulfonyl, i.e., —SO₂—, and the sulfonyl group forms the point of attachment to the remainder of the molecule. In some embodiments, the alkylsulfonyl is C_1-6alkylsulfonyl; in other embodiments, it is a C_1-4alkylsulfonyl. Examples of alkylsulfonyl groups include —SO₂CH₃, —SO₂CH₂CH₃, and the like.

The term “alkylsulfonyl(alkylene)” as used by itself or as part of another group refers to an alkylene group as defined herein that is bound to the sulfonyl of an alkylsulfonyl group as defined herein. Examples of alkylsulfonyl(alkylene) groups include —C(CH₃)₂SO₂CH₃, —CH₂SO₂CH₃, —CH(CH₃)SO₂CH₃, and the like.

The term “alkoxy” as used by itself or as part of another group refers to an oxygen radical attached to an alkyl group by a single bond. Examples of alkoxyl groups include methoxy (OCH₃), ethoxy (OCH₂CH₃), propoxy (e.g., —OⁿPr, —OⁱPr), or butoxy (e.g., —OⁿBu, —OⁱBu, —O^sBu, —O^tBu), and the like. In other embodiments, the alkoxy group is a C_1-6alkoxy. In further embodiments, the alkoxy group is a C_1-4alkoxy.

The term “alkoxy(alkylene)” as used by itself or as part of another group refers to an alkylene group as defined herein that is bound to an alkoxy group as defined herein. Examples of alkoxy(alkylene) groups include —CH₂OCH₃, —CH₂CH₂OCH₃, and the like.

The term “haloalkoxy” as used by itself or as part of another group refers an oxygen radical attached to a haloalkyl group by a single bond, wherein haloalkyl is defined above. Examples of haloalkoxy groups include fluoromethoxy (OCH₂F), 2-fluoroethoxy, difluoromethoxy (OCHF₂), trifluoromethoxy (OCF₃), pentafluoroethoxy, 1,1-difluoroethoxy (OC(CH₃)F₂), 2,2-difluoroethoxy, 2,2.2-trifluoroethoxy (OCH₂CF₃), 3,3,3-trifluoropropoxy, 4,4,4-trifluorobutoxy, trichloromethoxy groups, and the like. In some embodiments, the haloalkoxy group is a C_1-6haloalkoxy; in other embodiments, it is C_1-4haloalkoxy; and in other embodiments, it is C_1-3haloalkoxy.

The term “haloalkoxy(alkylene)” as used by itself or as part of another group refers to an alkylene group as defined herein that is bound to an haloalkoxy group as defined herein. Examples of haloalkoxy(alkylene) groups include —CH₂OCF₃, and the like.

The term “heteroaryl” when used alone or as part of a substituent group refers to a mono- or bicyclic- aromatic ring structure including carbon atoms as well as up to four heteroatoms that are each independently nitrogen, oxygen, or sulfur. Heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms. In some embodiments, heteroaryl rings are characterized by the number of ring atoms in the heteroaryl group. For example, a 6-membered heteroaryl group refers to a heteroaryl group having 6 ring atoms in the group. Similarly, a 5-membered heteroaryl group refers to a heteroaryl group having 5 ring atoms in the group. The heteroaryl moiety can be unsubstituted, or one or more of the carbon atoms or nitrogen atoms in the ring can be substituted. Examples of heteroaryl groups include thienyl, benzo[b]thienyl, furanyl, benzofuryl, pyranyl, thiophenyl, isobenzofuranyl, benzoxazinyl, chromenyl, xanthenyl, 2H pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl. 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, quinoxalyl, phthalazinyl, naphthyridinyl, cinnolinyl, triazolyl, tetrazolyl, thiadiazolyl, oxadiazolyl, quinazolinyl, pteridinyl, pyrimidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, furazanyl, pyrazolo[1,5-a]pyridinyl, benzoisothiazolyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzoisoxazolyl, isothiazolyl, tetrahydropyrazolo[1,5-a]pyridinyl and the like. In some embodiments, the heteroaryl is thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furanyl, 3-furanyl, 4-furanyl), pyrrolyl (e.g., pyrrol-2-yl, pyrrol-3-yl), imidazolyl (e.g., imidazol-2-yl, imidazol-4-yl), pyrazolyl (e.g., pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl), pyridyl (e.g., pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl), isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl), pyrazinyl (e.g.. pyrazin-2-yl, pyrazin-3-yl, pyrazin-5-yl, pyrazin-6-yl), triazolyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl), thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thidiazolyl, 1,3,4-thiadiazolyl), oxadiazolyl (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl), indazolyl (e.g., indazol-3-yl), pyrazolo[1,5-a]pyridinyl (e.g., pyrazolo[1,5-a]pyridin-3-yl), imidazol[1,5-a]pyridinyl (e.g., imidazol[1,5-a]pyridin-1-yl), pyrrolo[1,2]pyridazinyl (e.g., pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazin-6-yl), benzo[d]thiazolyl (e.g., benzo[d]thiazol-3-yl, benzo[d]thiazol-2-yl), benzo[d]imidazolyl (e.g.. benzo[d]imidazol-2-yl), benzo[d]oxazolyl (e.g., benzo[d]oxazol-2-yl), benzo[d]isoxazolyl (e.g., benzo[d]isoxazol-3-yl), benzo[d]isothiazolyl (e.g., benzo[d]isothiazol-3-yl), benzo[c]isoxazolyl (e.g., benzo[c]isoxazol-3-yl), quinolinyl (e.g., quinolin-3-yl), and pyridazinyl (e.g., pyridazin-3-yl, pyridazin-4-yl). The term “heteroaryl” also includes N-oxides. The heteroaryl may be unsubstituted or substituted. In some embodiments, the heteroaryl is substituted with two substituents. In further embodiments, the heteroaryl is substituted with one substituent. In yet other embodiments, the heteroaryl is substituted with three substituents. In still further embodiments, the heteroaryl is unsubstituted. Substitution may occur on any available carbon or heteroatom (e.g., nitrogen), or both, as permitted by substituent valency.

In some embodiments, the heteroaryl is a 5- or 6-membered heteroaryl. In some embodiments, the heteroaryl is a 5-membered heteroaryl, i.e., the heteroaryl is a monocyclic aromatic ring system having 5 ring atoms wherein at least one carbon atom of the ring is replaced with a heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of 5-membered heteroaryl groups include thienyl, furyl, pyrrolyl, oxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, and isoxazolyl and the like. In other embodiments, the heteroaryl is a 6-membered heteroaryl, e.g., the heteroaryl is a monocyclic aromatic ring system having 6 ring atoms wherein at least one carbon atom of the ring is replaced with a nitrogen atom. Examples of 6-membered heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl and the like.

The term “heterocyclyl” as used by itself or as part of another group refers to non-aromatic, saturated or partially unsaturated, e.g., containing one or two double bonds, cyclic groups containing one, two, or three rings having from three to fourteen ring members, i.e., a 3-14-membered heterocyclyl, wherein at least one carbon atom of one of the rings is replaced with a heteroatom. Each heteroatom is independently selected from oxygen, sulfur, including sulfoxide and sulfone, and/or nitrogen atoms, which can be oxidized or quaternized. The term “heterocyclyl” also includes groups wherein a ring —CH₂— is replaced with a —C(O)—. The term “heterocyclyl” also includes groups having fused optionally substituted aryl groups, e.g., indolinyl or chroman-4-yl and groups having fused optionally substituted cycloalkyl groups, e.g., 6-azaspiro[2.5]octanyl. In some embodiments, the heterocyclyl group is a C_4-6heterocyclyl. i.e., a 4-, 5- or 6-membered cyclic group, containing one ring and one or two oxygen and/or nitrogen atoms. In other embodiments, the heterocyclyl is a C_4-6heterocyclyl containing one ring and one nitrogen atom. The heterocyclyl can be optionally linked to the rest of the molecule through any available carbon or heteroatom that results in a stable structure. Examples of heterocyclyl groups include azetidinyl, dioxanyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, indolinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, aziridinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, thianyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, tetrahydropyranyl, and the like. In some embodiments, the heterocyclyl group includes azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 6-azaspiro[2.5]octanyl. The heterocyclyl may be unsubstituted or substituted. In some embodiments, the heterocyclyl is substituted with two substituents. In further embodiments, the heterocyclyl is substituted with one substituent. In yet other embodiments, the heterocyclyl is substituted with three substituents. In still further embodiments, the heterocyclyl is unsubstituted.

The term “(heterocyclyl)alkylene” as used by itself or part of another group refers to an alkylene group as defined herein that is bound to a heterocyclyl group as defined herein.

The term “optionally substituted,” as used herein to describe a chemical moiety defined herein, means that the moiety may, but is not required to be, substituted with one or more suitable functional groups or other substituents as provided herein. For example, a substituent may be optionally substituted with one or more of: halo, cyano, —NO₂, —N₃, —OH, —SH. C_1-6alkyl, C_3-8cycloalkyl, C_3-8cycloalkenyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6alkylcarbonyl, C_1-6cyanoalkyl, C_1-6hydoxyalkyl, C_1-6alkylenethio. (CR^vR^x)_pNR^yR^z (wherein R^v and R^x are, independently, H or C_1-6alkyl; R^y and R^z, are independently, H, C_1-6alkyl, C_3-6cycloalkyl, C_1-6hydroxyalkyl, C_1-6haloalkyl, C_1-6alkoxy(alkylene), or C(O)OC₁-₆alkyl, and p is 0, 1, 2, or 3). —C(O)NH₂, -C(O)NHC_1-6alkyl, -C(0)N(C_1-6alkyl)₂, -C(O)NHC_3-6cycloalkyl, -C(O)N(C_3-6cycloalkyl)₂, -COOH, -C_1-6alkyleneCOOH,-C_3-6cycloalkylCOOH, -C_1-6alkyleneCONH₂, C_3-6cycloalkylCONH₂, -C_1-6alkyleneCONHC _1-6alkyl, -C_1-6alkyleneCON(C_1-6alkyl)₂, -C(O)OC_1-6alkyl, -NHCO(C_1-6alkyl), -N(C_1-6alkyl)C(O)(C_1-6alkyl), -S(O)C_1-6alkyl, -S(O)C_3-6cycloalkyl, C_1-6alkylsulfonyl, C_3-8cycloalkylsulfonyl, C_1-6alkylsulfonyl(alkylene). oxo (═O), 3-7-membered heterocyclyl, heterocyclyl(alkylene), aryl, aryl(alkylene), or heteroaryl groups. In some embodiments, the C_1-6alkyl group in any of the substituent groups in this paragraph is a C_1-4alkyl; in other embodiments it is C_1-3alkyl. In some embodiments, the C_1-6alkylene group in any of the substituent groups in this paragraph is a C_1-4alkylene. In some embodiments, the C_1-6haloalkyl substituent is a C_1-4haloalkyl; in other embodiments, it is C_1-3haloalkyl. In some embodiments, the C_3-6cycloalkyl substituent is a C_3-4cycloalkyl substituent. In some embodiments, the C_1-6alkoxy substituent is a C_1-3alkoxy. in other embodiments, it is C_1-4alkoxy. In some embodiments, the C_1-6haloalkoxy substituent is a C_1-3haloalkoxy: in other embodiments, it is C_1-4haloalkoxy.

In some embodiments, a substituent may be optionally substituted with one or more of: C_1-6alkyl, optionally substituted C_2-6alkenyl, halo, CN, C_1-6cyanoalkyl, C_1-6haloalkyl, OH, optionally substituted C_3-8ccycloalkyl, optionally substituted C_3-8cycloalkenyl, optionally substituted aryl, optionally substituted aryl(alkylene), optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), C_1-6hydroxyalkyl, C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6deuteratedalkoxy(alkylene). C_1-6alkylcarbonyl, C_3-8cycloalkylsulfonyl, C_1-6alkylsulfonyl(alkylene), (CR^vR^x)_pNR^yR^z (wherein R^v and R^×are, independently, H or C_1-6alkyl; R^y and R^z, are independently, H, C_1-6alkyl, C₃-₆cycloalkyl, C_1-6hydroxyalkyl, C_1-6haloalkyl. C_1-6alkoxy(alkylene), or C(O)OC_1-6alkyl, and p is 0, 1, 2, or 3), and C(O)NR^y2R^z2 (wherein R^y2 and R^z2, are independently, H, C_1-6alkyl, or C_3-6cycloalkyl).

The term “nitrogen protecting group” refers to a moiety that is attached to a nitrogen atom to prevent reaction at that nitrogen atom. Nitrogen protecting groups will be known by those skilled in the art and include those described in Wuts, P.G., Greene’s Protective Groups in Organic Synthesis. Wiley; 5th edition (Oct. 27, 2014), which is incorporated by reference herein.

Recitation of ranges of values herein are intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended to better illustrate the disclosure and is not a limitation on the scope of the disclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure

The term “about” when used in combination with a numeric value or range of values means the value or range of values may deviate to an extent deemed reasonable to one of ordinary skill in the art.

Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including supercritical fluid chromatography (SFC), chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts: or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981). Wilen et al., Tetrahedron 33:2725 (1977); Eliel. E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

Exemplary compounds of the disclosure including a chiral center may be depicted herein as having particular stereochemistries, but for which absolute stereochemistry has not been obtained. Absolute configurations can be obtained using methods known in the art.

As used herein, the term “stereoisomers” refers to compounds which have identical chemical constitution and connectivity but differ with regard to the arrangement of the atoms or groups in space, e.g., enantiomers or diastereomers.

When the stereochemical configuration at a chiral center in a compound having one or more chiral centers is depicted by its chemical name (e.g., where the configuration is indicated in the chemical name by “R” or “S”) or structure (e.g., the configuration is indicated by dashed or wedge bonds), the enrichment of the indicated configuration relative to the opposite configuration is greater than 50%. 60%, 70%, 80%, 90%, 99% or 99.9%. “Enrichment of the indicated configuration relative to the opposite configuration” is a mole percent and is determined by dividing the number of compounds with the indicated stereochemical configuration at the chiral center(s) by the total number of all of the compounds with the same or opposite stereochemical configuration in a mixture.

When a disclosed compound is named or depicted by structure without indicating stereochemistry, it is understood that the name or the structure encompasses one of the possible stereoisomers or geometric isomers free of the others, or a mixture of the encompassed stereoisomers or geometric isomers.

It will be understood that certain compounds disclosed herein may exist in tautomeric forms. Such forms are included as part of the present disclosure. Thus, when a compound herein is represented by a structural formula or designated by a chemical name herein, all tautomeric forms which may exist for the compound are encompassed by the structural formula.

When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers.

In some embodiments, the compounds described herein are isotopically enriched compound, e.g., an isotopologue. The term “isotopically enriched” refers to an atom having an isotopic composition other than the naturally abundant isotopic composition of that atom. “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom. In an isotopologue. “isotopic enrichment” refers to the percentage of incorporation of an amount of a specific isotope of a given atom in a molecule in the place of that atom’s natural isotopic composition. For example, deuterium enrichment of 1% at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%. In one embodiment, one or more hydrogen atoms on a described compound may be replaced by deuterium.

Thus, as used herein, and unless otherwise indicated, the term “isotopic enrichment factor” refers to the ratio between the isotopic composition and the natural isotopic composition of a specified isotope.

With regard to the compounds provided herein, when a particular atom’s position is designated as having deuterium or “D” or “²H”, it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.015%. A position designated as having deuterium typically has a minimum isotopic enrichment factor of, in particular embodiments, at least 1000 (15% deuterium incorporation), at least 2000 (30% deuterium incorporation), at least 3000 (45% deuterium incorporation), at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation) at each designated deuterium atom. The isotopic enrichment and isotopic enrichment factor of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

The term “patient” or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compounds or compositions according to the present disclosure is provided. For treatment of those conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present disclosure, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.

The terms “therapeutically effective amount” or “effective amount” means an amount or dose of a compound of the disclosure (or a pharmaceutically acceptable salt thereof) sufficient to generally bring about the desired therapeutic benefit in subjects in need of such treatment for the designated disease or disorder. Further, a therapeutically effective amount with respect to a compound of the disclosure means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or prevention of a disease.

“Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (e.g., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.

The terms “prevent,” “preventing,” and “prevention” refer to the prevention of the onset, recurrence, or spread of the disease in a subject resulting from the administration of a prophylactic or therapeutic agent.

Compounds

The present disclosure provides compounds of Formula I or pharmaceutically acceptable salts thereof:

In Formula I, m is 1 or 2. In some embodiments, m is 1. In other embodiments, m is 2.

In formula I, R¹ is

In the structures for R¹, x is 0 to 5. In some embodiments, x is 0. In other embodiments, x is 1. In further embodiments, x is 2. In yet other embodiments, x is 3. In still further embodiments, x is 4. In other embodiments, x is 5.

In further embodiments, R¹ is

and x is 0 or 1. such as

, or

In other embodiments, R¹ is

In yet other embodiments, R¹ is

In still other embodiments, R¹ is

In yet other embodiment, R¹ is

In still further embodiments, R¹ is

In other embodiments, R¹ is

In some embodiments, the compound is a single enantiomer and the R¹ moiety is in an alpha (α) configuration. In some embodiments, the compound is a single enantiomer and the R¹ moiety is in an beta (β) configuration.

In the structures for R¹, each R^a is independently halo, C_1-6alkyl, C_3-6cycloalkyl, C_1-6haloalkyl, C_1-6alkoxy or C_1-6haloalkoxy. In some embodiments, R^a is halo such as F, Cl, Br, or L In other embodiments, R^a is F, Br, or Cl. In still other embodiments, R^a is F. In further embodiments, R^a is Br. In yet other embodiments, R^a is Cl. In still further embodiments, R^a is I. In other embodiments, R^a is C_1-6alkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In further embodiments, R^a is methyl, ethyl, or isopropyl. In yet other embodiments, R^a is methyl. In further embodiments, R^a is C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In still further embodiments, R^a is cyclopropyl. In yet other embodiments, R^a is C_1-6haloalkyl such as CF₃, CHF₂, CH₂F, CH₂CF₃, C(CH₃)₂F, or C(CH₃)F₂. In still other embodiments, R^a is CF₃ or CHF₂. In further embodiments, R^a is C_1-6alkoxy such as methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy. In yet other embodiments, R^a is methoxy or ethoxy. In other embodiments, R^a is C_1-6haloalkoxy such as OCF₃ or OCH₂CF₃. In still other embodiments, one R^a is halo and the second R^a is C_1-6alkoxy or C_1-6alkyl.

In Formula I, R² is C_1-4alkyl, optionally substituted C₃-₈cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R² is optionally substituted C_3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In further embodiments, R² is unsubstituted C₃-₈cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl. In other embodiments, R² is substituted C₃. ₈cycloalkyl, substituted heterocyclyl, substituted aryl, or substituted heteroaryl. In some embodiments, R² is C_1-4alkyl such as methyl, ethyl, propyl, butyl, or tert-butyl. In other embodiments, R² is optionally substituted C_3-8cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. In further embodiments, R² is optionally substituted heterocyclyl such as azetidinyl. In still other embodiments, R² is optionally substituted aryl such as phenyl. In yet further embodiments, R² is optionally substituted heteroaryl such as pyridinyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, indazolyl, pyrazolo[1,5-a]pyridinyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl, benzo[d]thiazolyl, benzoldlisothiazolyl, benzoldlimidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, or benzo[d]isothiazolyl.

In Formula I. R³ is H or C_1-6alkyl. In some embodiments, R³ is H. In other embodiments, R³ is C_1-6alkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In further embodiments, R³ is methyl. In yet other embodiments, R³ is ethyl. In still further embodiments, R³ is propyl. In other embodiments, R³ is butyl. In further embodiments, R³ is pentyl. In yet other embodiments, R³ is hexyl.

In Formula I, R⁴ is H or C_1-6alkyl. In some embodiments, R⁴ is H. In other embodiments, R⁴ is C_1-6alkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In further embodiments, R⁴ is methyl. In yet other embodiments, R⁴ is ethyl. In still further embodiments, R⁴ is propyl. In other embodiments, R⁴ is butyl. In further embodiments, R⁴ is pentyl. In yet other embodiments, R⁴ is hexyl.

Alternatively, R³ and R⁴, together with the atom to which they are attached, form a C_3-6cycloalkyl. In some embodiments, R³ and R⁴ together form a cyclopropyl. In other embodiments, R³ and R⁴ together form a cyclobutyl. In further embodiments, R³ and R⁴ together form a cyclopentyl. In yet other embodiments. R³ and R⁴ together form a cyclohexyl.

In some embodiments, both R³ and R⁴ are H. In other embodiments, R³ is methyl and R⁴ is H. In still other embodiments, both R³ and R⁴ are methyl.

In Formula I, R⁵ is H or D. In some embodiments, R⁵ is H. In further embodiments, R⁵ is D.

In Formula I, R^5A is H or D. In some embodiments, R^5A is H. In further embodiments, R^5A is D.

In Formula I. L is a bond, carbonyl, optionally substituted C_1-6alkylene, optionally substituted C_1-6alkylenecarbonyl, optionally substituted C_2-6alkenylenecarbonyl, optionally substituted C_1-6haloalkylenecarbonyl, or optionally substituted -C(O)NR^b(C_1-6alkylene)-, wherein the carbon atom of the carbonyl group is connected to N in Formula I. In some embodiments. L is a bond. In other embodiments, L is carbonyl (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In further embodiments, L is optionally substituted C_1-6alkylene such as methylene, ethylene, propylene, butylene, pentylene, or hexylene. In other embodiments, L is C₁alkylene. In still other embodiments, L is C₂alkylene. In further embodiments, L is C₃alkylene. In yet other embodiments, L is C₄alkylene. In still further embodiments, L is C₅alkylene. In other embodiments, L is C₆alkylene. In yet other embodiments, L is optionally substituted C_1-6alkylenecarbonyl (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In further embodiments, L is -C₁alkyleneC(O)-. In other embodiments, L is -C₂alkylene-C(O)-. In further embodiments, L is -C₃alkylene-C(O)-. In yet other embodiments, L is -C₄alkylene-C(O)-. In still further embodiments, L is -C₅alkylene-C(O)-. In other embodiments, L is -C₆alkylene-C(O)-. In still further embodiments, L is optionally substituted C_2-6alkenylenecarbonyl (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In other embodiments, L is -C₂alkenylene-C(O)-. In further embodiments, L is -C₃alkenylene-C(O)-. In yet other embodiments, L is -C₄alkenylene-C(O)-. In still further embodiments, L is -C₃alkenylene-C(O)-. In other embodiments, L is -C₆alkenylene-C(O)-. In other embodiments, L is optionally substituted C_1-6haloalkylenecarbonyl (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In yet other embodiments, L is -C₁haloalkylene-C(O)-. In other embodiments, L is -C₂haloalkylene-C(O)-. In further embodiments, L is -C₃haloalkylene-C(O)-. In yet other embodiments, L is -C4haloalkylene-C(O)-. In still further embodiments. L is -Cshaloalkylene-C(O)-. In other embodiments, L is -C₆haloalkylene-C(O)-. In further embodiments, L is -C(O)NR^b(C_1-6alkylene)- (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In yet other embodiments, L is -C(O)NR^bC₁alkylene-. In other embodiments, L is -C(O)NR^bC₂alkylene-. In further embodiments, L is -C(O)N R^bC₃alkylene-. In yet other embodiments, L is -C(O)NR⁶C₄alkylene-. In still further embodiments, L is -C(O)NR^bCsalkylene-. In other embodiments, L is -C(O)NR^bC₆alkylene-.

In the structures for L, R^b is H or C_1-6alkyl. In some embodiments, R^b is H. In other embodiments, R^b is C_1-6alkyl, such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In further embodiments, R^b is methyl. In yet other embodiments, R^b is ethyl. In still further embodiments, R^b is propyl. In other embodiments, R^b is butyl. In further embodiments, R^b is pentyl. In yet other embodiments, R^b is hexyl.

In some embodiments, L is a bond, —C(O)—, —C(O)CH₂—, —C(O)CH₂CH₂—, —C(O)CH₂CH₂CH₂—, —C(O)CF₂—, —C(O)CHF—. —C(O)C(CH₃)₂—, —C(O)CH═CH—,

—C(O)NHCH₂—, —CH₂—, or —CH₂CH₂—. In yet other embodiments, L is a bond, —C(O)—, —C(O)CH₂—, or —C(O)CF₂.

In some embodiments. R² is cyclopentyl. cyclobutyl, cyclopropyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazolyl, thiadiazolyl, imidazol[1,5-a|pyridinyl, pyrrolo[1,2]pyridazinyl, thiophenyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[d]isothiazolyl, furanyl, or pyrazinyl, each of which is optionally substituted.

In further embodiments, R² is cyclopentyl, cyclobutyl, cyclopropyl, cyclohexyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-alpyridinyl, indazolyl, thiadiazolyl, imidazoll 1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophenyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[c]isoxazolyl, benzo[d]isothiazolyl, furanyl, pyrazinyl or quinolinyl, each of which is optionally substituted.

In other embodiments, R² is cyclopentyl, cyclobutyl, cyclopropyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazolyl, thiadiazolyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophenyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[d]isothiazolyl, furanyl, or pyrazinyl, each of which is unsubstituted.

In yet other embodiments, R² is cyclopentyl, cyclobutyl, cyclopropyl, cyclohexyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazolyl, thiadiazolyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophenyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[c]isoxazolyl, benzo[d]isothiazolyl, furanyl, pyrazinyl or quinolinyl, each of which is unsubstituted.

In further embodiments, R² is optionally substituted cyclopentyl. In further embodiments, R² is optionally substituted cyclobutyl. In still other embodiments, R² is optionally substituted cyclopropyl. In yet other embodiments, R² is optionally substituted cyclohexyl. In yet further embodiments, R² is optionally substituted azetidinyl. In other embodiments, R² is optionally substituted phenyl. In further embodiments, R² is optionally substituted pyrazolyl. In still other embodiments, R² is optionally substituted oxazolyl. In yet further embodiments, R² is optionally substituted thiazolyl. In other embodiments, R² is optionally substituted triazolyl. In further embodiments, R² is optionally substituted oxadiazolyl. In still other embodiments, R² is optionally substituted pyridinyl. In yet further embodiments, R² is optionally substituted pyrimidinyl. In other embodiments, R² is optionally substituted pyrazolo[1,5-a]pyridinyl. In further embodiments, R² is optionally substituted indazolyl. In yet other embodiments, R² is optionally substituted thiadiazolyl. In other embodiments, R² is optionally substituted imidazol[1,5-a]pyridinyl. In further embodiments, R² is optionally substituted pyrrolo[1.2]pyridazinyl. In still other embodiments, R² is optionally substituted thiophenyl. In yet further embodiments, R² is optionally substituted isoxazolyl. In further embodiments, R² is optionally substituted isothiazolyl. In other embodiments, R² is optionally substituted benzo[d]thiazolyl. In further embodiments, R² is optionally substituted benzo[d]imidazolyl. In still other embodiments, R² is optionally substituted benzo[d]oxazolyl. In yet further embodiments, R² is benzo[d]isoxazolyl. In yet other embodiments, R² is optionally substituted benzo[c]isoxazolyl. In still further embodiments, R² is optionally substituted benzo[d]isothiazolyl. In other embodiments, R² is optionally substituted furanyl. In yet other embodiments, R² is optionally substituted pyrazinyl. In still further embodiments, R² is optionally substituted quinolinyl.

In other embodiments, R² is azetidin-1-yl, azetidin-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3-triazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2.4-oxadiazol-5-yl, pyrazolo[1,5-a]pyridin-3-yl, indazol-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1,3,4-thiadiazol-2-yl, pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, imidazol[1.5-a]pyridin-1-yl, pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazin-6-yl, thiophen-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, benzo[d]thiazol-2-yl, benzo[d]thiazol-3-yl, benzo[d]imidazol-2-yl, benzo[d]oxazol-2-yl, benzo[d]isoxazol-3-yl, benzo[d]isothiazol-3-yl, furan-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, or pyrazin-2-yl, each of which is optionally substituted.

In yet other embodiments, R² is azetidin-1-yl, azetidin-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3-triazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1.2,4-oxadiazol-5-yl, pyrazolo[1,5-a]pyridin-3-yl, indazol-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1,3,4-thiadiazol-2-yl, pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, imidazol[1,5-a]pyridin-1-yl, pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazin-6-yl, thiophen-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, benzo[d]thiazol-2-yl, benzo[d]thiazol-3-yl, benzo[d]imidazol-2-yl, benzo[d]oxazol-2-yl, benzo[d]isoxazol-3-yl, benzo[d]isothiazol-3-yl, furan-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazin-2-yl, benzo[c]isoxazole-3-yl, or quinolin-3-yl, each of which is optionally substituted.

In further embodiments, R² is C_3-8cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted with one or more of C_1-6alkyl, optionally substituted C_2-6alkenyl, halo, CN, C_1-6cyanoalkyl, C_1-6haloalkyl, OH. optionally substituted C_3-8cycloalkyl, optionally substituted C_3-8cycloalkyl(alkylene), optionally substituted C_3-8cycloalkenyl, optionally substituted aryl, optionally substituted aryl(alkylene), optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), C_1-6hydroxyalkyl, C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6deuteratedalkoxy(alkylene), C_1-6alkylcarbonyl, C_3-8cycloalkylsulfonyl, C_1-6alkylsulfonyl, C_1-6alkylsulfonyl(alkylene), (CR^vR^x)_pNR^yR^z (wherein R^v and R^x are, independently, H or C_1-6alkyl; R^y and R^z, are independently, H, C_1-6alkyl, C_3-6cycloalkyl, C_1-6hydroxyalkyl, C_1-6haloalkyl, C_1-6alkoxy(alkylene), or C(O)OC_1-6alkyl and p is 0, 1, 2, or 3), or C(O)NR^y2R^z2 (wherein R^y2 and R^z2, are independently, H, C_1-6alkyl, or C_3-6cycloalkyl). In other embodiments, R² is optionally substituted with C_1-6alkyl, such as methyl, ethyl, propyl, isopropyl, or tert-butyl. In yet further embodiments, R² is optionally substituted with C_2-6alkenyl such as CH═CH₂, CH═CHC(CH₃)₂OH, or CH=CH-cyclopropyl. In further embodiments, R² is optionally substituted with halo such as Br, Cl, or F. In yet other embodiments, R² is optionally substituted with CN. In still further embodiments, R² is optionally substituted with C_1-6cyanoalkyl such as C(CH₃)₂CN. In other embodiments, R² is optionally substituted with C_1-6haloalkyl, such as CF₃, CHF₂, CH₂F, CH(CH₃)F, CH₂CF₃. C(CH₃)₂F, C(CH₃)F₂, or CH₂CHF₂. In further embodiments, R² is optionally substituted with OH. In still other embodiments, R² is optionally substituted with optionally substituted C_3-8cycloalkyl, such as optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, or optionally substituted cyclohexyl. In further embodiments, R² is optionally substituted with optionally substituted C_3-8cycloalkyl(alkylene) such as optionally substituted cyclopropyl(alkylene) or optionally substituted cyclobutyl(alkylene). In other embodiments, R² is optionally substituted with optionally substituted C_3-8cycloalkenyl, such as optionally substituted cyclohexenyl. In yet further embodiments, R² is optionally substituted with optionally substituted aryl such as optionally substituted phenyl. In further embodiments, R² optionally substituted with optionally substituted aryl(alkylene) such as optionally substituted benzyl. In other embodiments, R² is optionally substituted with optionally substituted heteroaryl, such optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, or optionally substituted pyrazinyl. In yet other embodiments, R² is optionally substituted with optionally substituted heteroaryl, such optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, or optionally substituted pyridazinyl. In further embodiments, R² is optionally substituted with optionally substituted heterocyclyl such as optionally substituted azetidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, or optionally substituted 6-azaspiro[2.5]octan-6-yl. In yet further embodiments, R² is optionally substituted with optionally substituted morpholinyl(alkylene), optionally substituted piperidinyl(alkylene), optionally substituted piperazinyl(alkylene), or optionally substituted azetidinyl(alkylene). In still other embodiments, R² is optionally substituted with C_1-6hydroxyalkyl such as C(CH₃)₂OH, CH(CH₃)OH, C(CH₃)₂CH₂OH, CH₂C(CH₃)₂OH, or CH(CH₂CH₃)OH. In yet further embodiments, R² is optionally substituted with C_1-6haloalkoxy such as OCF₃, OCH₂CF₃, or OCH₂CH₂CF₃. In still further embodiments, R² is optionally substituted with C_1-6haloalkoxy(alkylene) such as CH₂OCF₃. In other embodiments, R² is optionally substituted with C_1-6alkoxy, such as methoxy or ethoxy. In yet other embodiments, R² is optionally substituted with C_1-6alkoxy(alkylene), such as C(CH₃)₂OCH₃. CH₂OCH₃, or (CH₂)₂OCH₃. In further embodiments, R² is optionally substituted with C_1-6deuteratedalkoxy(alkylene) such as CH₂OCD₃. In further embodiments, R² is optionally substituted with C_1-6alkylcarbonyl, such as C(═O)CH₃ or CH₂C(═O)CH₃. In yet other embodiments, R² is optionally substituted with C_3-8cycloalkylsulfonyl such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In other embodiments, R² is optionally substituted with C_1-6alkylsulfonyl such as methylsulfonyl, ethylsulfonyl, or propylsulfonyl. In yet other embodiments, R² is optionally substituted with C_1-6alkylsulfonyl(alkylene), such as C(CH₃)₂SO₂CH₃. In still further embodiments, R² is optionally substituted with (CR^vR^x)_pNR^yR^z, wherein R^v, R^x, R^y, R^z, and p are defined above, such as NH₂, NHcyclopropyl, NHCH₃, N(CH₃)₂, CH₂N(CH₃)₂, (CH₂)₂N(CH₃)₂, CH₂N(CH₃)(CH₂CH₃), C(CH₃)₂NH(CH₃), C(CH₃)₂N(CH₃)₂, CH₂N(CH₃)cyclobutyl, or CH₂N(CH₃)(C(O)Otert-butyl). In some embodiments, p is 0. In other embodiments, p is 1. In further embodiments, p is 2. In still other embodiments, p is 3. In some embodiments, R^v and R^x are, independently, hydrogen or methyl. In other embodiments, R^y and R^z are, independently, hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, C(O)Omethyl. C(O)Oethyl. C(O)Opropyl, or C(O)Otert-butyl. In other embodiments, R² is C(O)NR^y2R^z2, wherein R^y2 and R^z2 are defined above, such as C(O)N(CH₃)₂ or C(O)NHcyclopropyl. In yet other embodiments, R^y2 and R^z2 are, independently, hydrogen, methyl, or cyclopropyl. In further embodiments, R² is substituted with one or more of methyl, ethyl, propyl, isopropyl, tert-butyl, CH═CH₂, CH═CHC(CH₃)₂OH, CH=CH-cyclopropyl, Br, Cl, F, CN, C(CH₃)₂CN, CF₃, CHF₂, CH₂F, CH(CH₃)F, CH₂CF₃, C(CH₃)₂F, C(CH₃)F₂, CH₂CHF₂, OH, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cyclohexenyl, optionally substituted cyclopropyl(alkylene), optionally substituted cyclobutyl(alkylene), optionally substituted phenyl, optionally substituted benzyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted azetidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, optionally substituted 6-azaspiro[2.5]octan-6-yl, optionally substituted morpholinyl(alkylene), optionally substituted piperidinyl(alkylene), optionally substituted piperazinyl(alkylene), or optionally substituted azetidinyl(alkylene), C(CH₃)₂OH, CH(CH₃)OH, C(CH₃)₂CH₂OH, CH₂C(CH₃)₂OH, CH(CH₂CH₃)OH, OCH₂CH₂CF₃, OCF₃, OCH₂CF₃, CH₂OCF₃, methoxy, ethoxy, C(CH₃)₂OCH₃, CH₂OCH₃, (CH₂)₂OCH₃, CH₂OCD₃, C(═O)CH₃, CH₂C(═O)CH₃, cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, C(CH₃)₂SO₂CH₃, NH₂, NHcyclopropyl, NHCH₃, N(CH₃)₂, CH₂N(CH₃)₂, (CH₂)₂N(CH₃)₂, CH₂N(CH₃)(CH₂CH₃), C(CH₃)₂NH(CH₃), C(CH₃)₂N(CH₃)₂, CH₂N(CH₃)cyclobutyl, CH₂N(CH₃)(C(O)Otert-butyl), C(O)N(CH₃)₂, or C(O)NHcyclopropyl.

In yet further embodiments, R² is

In other embodiments, R² is

In yet other embodiments, R² is

In some embodiments, R² is heterocyclyl, optionally substituted with one or more of halo, C_1-6haloalkyl, or optionally substituted heteroaryl. In still other embodiments, R² is

In yet other embodiments, R² is heterocyclyl, substituted with one or more of halo, C_1-6haloalkyl, or optionally substituted heteroaryl. In further embodiments, R² is

In still further embodiments, R² is

In some embodiments, R² is C_3-8cycloalkyl, optionally substituted with one or more of halo, C_1-6alkyl, C_1-6haloalkyl, or OH. In other embodiments, R² is C_3-8cycloalkyl, optionally substituted with one or more of halo or OH. In yet other embodiments, R² is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl,

In further embodiments, R² is C_3-8cycloalkyl, substituted with one or more of halo, C_1-6alkyl, C_1-6haloalkyl, or OH. In still further embodiments. R² is

In other embodiments, R² is

In some embodiments, R² is aryl, optionally substituted with one or more of halo or C_1-6alkoxy. In other embodiments, R² is unsubstituted phenyl,

In yet other embodiments, R² is aryl, substituted with one or more of halo or C_1-6alkoxy. In further embodiments, R² is

In some embodiments, R² is optionally substituted pyridinyl, optionally substituted pyrimidinyl, or optionally substituted pyrazinyl. In other embodiments, the pyridinyl, pyrimidinyl, or pyrazinyl group is substituted with one or more of halo, C_1-6haloalkyl, cyano, or NR^yR^z, wherein R^y and R^z are independently H or C_1-6alkyl.

In still further embodiments, R² is heteroaryl, substituted with one or more of C_1-6alkyl, C_1-6cyanoalkyl, C_1-6haloalkyl, or C_1-6hydroxyalkyl. In other embodiments, R² is heteroaryl substituted with one or more of C_1-6alkyl. In yet other embodiments, R² is heteroaryl substituted with one or more of C_1-6cyanoalkyl. In further embodiments. R² is heteroaryl substituted with one or more of C_1-6haloalkyl. In still further embodiments, R² is heteroaryl substituted with one or more of C_1-6fluoroalkyl. In yet other embodiments, R² is heteroaryl substituted with one or more of C_1-6hydroxyalkyl. In other embodiments, R² is heteroaryl, substituted with one or more of methyl, ethyl, isopropyl, tert-butyl, C(CH₃)₂CN, CH(CH₃)OH, C(CH₃)₂OH, C(CH₃)₂CH₂OH, CH(CH₂CH₃)OH, CH₂C(CH₃)₂OH, CH₂F, CHF₂, CF₃, CH₂CF₃. CH₂CHF₂, CH(CH₃)F, C(CH₃)F₂, or C(CH₃)₂F. In yet other embodiments, R² is heteroaryl, substituted with one or more of methyl, isopropyl, tert-butyl, C(CH₃)₂CN, CH(CH₃)OH, C(CH₃)₂OH, CHF₂, CF₃, CH₂CF₃, CH(CH₃)F, or C(CH₃)₂F. In other embodiments, R² is heteroaryl, substituted with methyl. In yet other embodiments, R² is heteroaryl, substituted with isopropyl. In other embodiments, R² is heteroaryl, substituted with tert-butyl. In yet other embodiments, R² is heteroaryl, substituted with C(CH₃)₂CN. In still further embodiments, R² is heteroaryl, substituted with CH(CH₃)OH. In other embodiments, R² is heteroaryl, substituted with C(CH₃)₂OH. In further embodiments, R² is heteroaryl, substituted with CHF₂. In still other embodiments. R² is heteroaryl, substituted with CF₃. In further embodiments, R² is heteroaryl, substituted with In still other embodiments, R² is heteroaryl, substituted with CH(CH₃)F. In other embodiments, R² is heteroaryl, substituted with C(CH₃)₂F.

In other embodiments, R² is heteroaryl, substituted with C_3-8cycloalkyl, wherein the C_3-8cycloalkyl itself is optionally substituted with one or more of halo, OH, C_1-6haloalkyl. C_1-6alkyl or C_1-6alkoxy. In yet other embodiments. R² is heteroaryl, substituted with an unsubstituted C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In further embodiments, R² is heteroaryl, substituted with cyclopropyl or cyclobutyl. In yet other embodiments, R² is heteroaryl, substituted with C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein the C_3-8cycloalkyl itself is substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl or C_1-6alkoxy. In some embodiments, the substituted C_3-8cycloalkyl is substituted with OH. In still further embodiments, the substituted C_3-8cycloalkyl is substituted with one or more of halo, such as F, Cl, or Br. In other embodiments, the substituted C_3-8cycloalkyl is substituted with C_1-6alkyl, such as methyl, ethyl, or propyl. In further embodiments, the substituted C_3-8cycloalkyl is substituted with C_1-6haloalkyl, such as CF₃, CH₂CF₃. or CHF₂. In still other embodiments, the substituted C_3-8cycloalkyl is substituted with C_1-6alkoxy, such as methoxy, ethoxy, or propoxy. In further embodiments, the substituted C_3-8cycloalkyl is cyclopropyl or cyclobutyl, each of which is substituted with one or more of F, OH, or methyl. In other embodiments, R² is heteroaryl, substituted with

In still other embodiments, R² is heteroaryl, substituted with

In other embodiments, R² is heteroaryl, substituted with aryl, wherein the aryl itself is optionally substituted with one or more of halo. C_1-6haloalkyl, C_1-6alkyl, or C_3-8cycloalkyl. In yet other embodiments, R² is heteroaryl, substituted with an unsubstituted phenyl. In further embodiments, R² is heteroaryl, substituted with aryl, such as phenyl, wherein the aryl itself is substituted with one or more of halo. C_1-6haloalkyl, C_1-6alkyl, or C_3-8cycloalkyl. In some embodiments, the substituted aryl is substituted with one or more of halo, such as F, Cl, or Br. In yet other embodiments, the substituted aryl is substituted with C_1-6haloalkyl, such as CF₃. CH₂CF₃, or CHF₂. In still further embodiments, the substituted aryl is substituted with C_1-6alkyl, such as methyl, ethyl, or propyl. In other embodiments, the substituted aryl is substituted with C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, or cyclopentyl. In yet other embodiments, the substituted aryl is phenyl that is substituted with one or more of F, methyl, or CF₃. In further embodiments, R² is heteroaryl, substituted with

In still further embodiments, R² is heteroaryl, substituted with

In still further embodiments, R² is heteroaryl, substituted with an optionally substituted heteroaryl. In some embodiments, the optionally substituted heteroaryl is optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, or optionally substituted pyrimidinyl. In yet other embodiments, the optional substitution on the heteroaryl is one or more of halo, C_1-6haloalkyl, C_1-6alkyl, C_1-6alkoxy, C_1-6haloalkoxy, C_3-8cycloalkyl or C_3-8cycloalkylsulfonyl. In other embodiments, the optionally substituted heteroaryl is substituted with one or more of halo, such as F. Cl, or Br. In still other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6haloalkyl, such as CF₃. CH₂CF₃, CH₂CHF₂, or CHF₂. In other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6alkyl, such as methyl, ethyl, propyl, or isopropyl. In still other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6alkoxy, such as methoxy, ethoxy, or propoxy. In other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6haloalkoxy, such as OCF₃. In yet other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_3-8cycloalkylsulfonyl, such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In still other embodiments, the optionally substituted heteroaryl is substituted with one or more of F, CF₃, CH₂CHF₂, CHF₂, methyl, methoxy, cyclobutyl, or cyclopropylsulfonyl.

In yet other embodiments, R² is heteroaryl, substituted with pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, imidazol-4-yl, or imidazol-5-yl, each of which can be optionally substituted. In further embodiments, R² is substituted with pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, imidazol-4-yl, imidazol-5-yl, pyridazin-3-yl, pyridazin-4-yl, each of which is optionally substituted. In still further embodiments, R² is substituted with optionally substituted pyrazol-1-yl. In other embodiments, R² is substituted with optionally substituted pyrazol-3-yl. In further embodiments, R² is substituted with optionally substituted pyrazol-4-yl. In yet further embodiments, R² is substituted with optionally substituted pyridin-2-yl. In other embodiments, R² is substituted with optionally substituted pyridin-3-yl. In further embodiments, R² is substituted with optionally substituted pyridin-4-yl. In further embodiments, R² is substituted with optionally substituted imidazol-4-yl. In yet other embodiments, R² is substituted with optionally substituted imidazol-5-yl. In further embodiments, R² is substituted with optionally substituted pyrimidin-2-yl. In other embodiments, R² is substituted with optionally substituted pyrimidin-4-yl. In still further embodiments, R² is substituted with optionally substituted pyrimidin-5-yl. In yet other embodiments, R² is substituted with optionally substituted pyrazin-2-yl. In other embodiments, R² is substituted with optionally substituted pyridazin-3-yl. In further embodiments, R² is substituted with optionally substituted pyridazin-4-yl.

In some embodiments, R² is heteroaryl, substituted with

In still further embodiments, R² is heteroaryl, substituted with

In still further embodiments, R² is heteroaryl, substituted with

In some embodiments, R² is heteroaryl, substituted with

In other embodiments, R² is heteroaryl, substituted with

In still other embodiments, R² is heteroaryl, substituted with

In other embodiments, R² is heteroaryl, substituted with heterocyclyl or heterocyclyl(alkylene), wherein the heterocyclyl and heterocyclyl(alkylene) groups themselves are each optionally substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C(O)O(C_1-6alkyl), or C_3-8cycloalkyl. In yet other embodiments, R² is heteroaryl, substituted with an unsubstituted heterocyclyl group such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or 6-azaspiro[2.5]octan-6-yl, or unsubstituted heterocyclyl(alkylene) group, such as azetidinyl(alkylene), pyrrolidinyl(alkylene), piperidinyl(alkylene), piperazinyl(alkylene), or morpholinyl(alkylene). In further embodiments, R² is heteroaryl, substituted with heterocyclyl, such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, or heterocyclyl(alkylene), such as azetidinyl(alkylene), pyrrolidinyl(alkylene), piperidinyl(alkylene), piperazinyl(alkylene), or morpholinyl(alkylene), wherein the heterocyclyl and heterocyclyl(alkylene) groups themselves are each substituted with one or more of halo. OH, C_1-6haloalkyl, C_1-6alkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C(O)O(C_1-6alkyl), or C_3-8cycloalkyl. In further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of halo, such as F, Cl, or Br. In yet further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of OH. In yet other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_1-6haloalkyl, such as CF₃, CH₂CF₃, or CHF₂. In still further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_1-6alkyl, such as methyl, ethyl, or propyl. In yet further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_1-6hydroxyalkyl such as C(CH₃)₂OH, or CH(CH₃)OH. In other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_1-6alkoxy, such as methoxy, ethoxy, or propoxy. In yet other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C(O)O(C_1-6alkyl), such as C(O)Omethyl, C(O)Oethyl, C(O)Opropyl, or C(O)Otert-butyl. In further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, or cyclopentyl. In yet other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of F, OH, or methyl. In yet other embodiments where R² is heteroaryl, the R² is substituted with

In still further embodiments where R² is heteroaryl, the R² is substituted with

In further embodiments. R² is

In yet further embodiments, R² is

.In still further embodiments, R² is,

In other embodiments, R² is

In further embodiments, R² is

In yet further embodiments, R² is

In still furtherembodiments, R² is

In yet other embodiments, R² is

In other embodiments, R² is

In further embodiments, R² is

In yet other embodiments, R² is

In still further embodiments, R² is

In other embodiments, R² is

In further embodiments, R² is

In still other embodiments, R² is

In yet further embodiments, R² is

In other embodiments, R² is

In further embodiments, R² is

In yet other embodiments, R² is

In still further embodiments. R² is

In other embodiments. R² is

In other embodiments, R² is

In further embodiments, R² is

In yet other embodiments, R² is

In these structures for R² R⁶ and R⁷ are each independently, H, CN, C_1-6alkyl, C_1-6haloalkyl, C_1-6cyanoalkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6deuteratedalkoxy(alkylene), halo, (CR^vR^x)_pNR^yR^z, C(O)NR^y2R^z2, C_1-6alkylcarbonyl, optionally substituted C_3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C_2-6alkenyl, optionally substituted C_3-8cycloalkenyl, optionally substituted (C_3-8cycloalkyl)alkylene, optionally substituted (aryl)alkylene, optionally substituted (heterocyclyl)alkylene, or C_1-6alkylsulfonyl; R⁸ is H, C_1-6alkyl, C_1-6haloalkyl, C_1-6alkoxy(alkylene), C_1-6alkylcarbonyl, C_1-6hydroxyalkyl, (CR^vR^x)_pNR^yR^z, optionally substituted C_3-8cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted (C_3-8cycloalkyl)alkylene; R^v and R^x are, independently, H or C_1-6alkyl; R^y and R^z are, independently, H, C_1-6alkyl, C_1-6alkoxy(alkylene), or C_3-6cycloalkyl; R^y2 and R^z2 are, independently, H, C_1-6alkyl, or C_3-6cycloalkyl; and p is 0, 1, 2, or 3. In some embodiments, R⁶, R⁷, and R⁸ are H.

In other embodiments, R⁶ is C_1-6alkyl, C_1-6haloalkyl, C_1-6cyanoalkyl, or C_1-6hydroxyalkyl. In further embodiments, R⁶ is C_1-6alkyl such as methyl, ethyl, isopropyl or tert-butyl. In still further embodiments, R⁶ is C_1-6haloalkyl such as CF₃, CHF₂, CH₂F, CH₂CF₃, CH(CH₃)F, C(CH₃)F₂, or C(CH₃)₂F. In further embodiments, R⁶ is C_1-6cyanoalkyl such as C(CH₃)₂CN. In other embodiments, R⁶ is C_1-6hydroxyalkyl such as C(CH₃)₂OH, CH(CH₃)OH, CH(CH₂CH₃)OH, CH₂C(CH₃)₂OH, or C(CH₃)₂CH₂OH. In further embodiments, R⁶ is methyl, isopropyl, tert-butyl, CF₃, CHF₂, C(CH₃)F₂, C(CH₃)₂F, C(CH₃)₂OH, or CH(CH₃)OH.

In other embodiments, R⁶ is C_3-6cycloalkyl optionally substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl, or C_1-6alkoxy. In further embodiments, R⁶ is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted with one or more of halo, OH. C_1-6haloalkyl, C_1-6alkyl, or C_1-6alkoxy. In still further embodiments. R⁶ is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In other embodiments, R⁶ is C_3-6cycloalkyl substituted with one or more halo such as F, Cl, or Br. In yet other embodiments, R⁶ is C_3-6cycloalkyl substituted with one or more OH. In still further embodiments, R⁶ is C_3-6cycloalkyl substituted with one or more C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂. In further embodiments, R⁶ is C_3-6cycloalkyl substituted with one or more C_1-6alkyl such as methyl, ethyl, or propyl. In still further embodiments, R⁶ is C_3-6cycloalkyl substituted with C_1-6alkoxy, such as one or more methoxy, ethoxy, or propoxy. In other embodiments, R⁶ is cyclopropyl, cyclobutyl, or cyclohexyl, each of which is optionally substituted with one or more of F, OH, or methyl. In other embodiments, R⁶ is

In other embodiments, R⁶ is

In further embodiments, R⁶ is aryl optionally substituted with one or more of halo. C_1-6haloalkyl, C_1-6alkyl or C_3-6cycloalkyl. In other embodiments. R⁶ is phenyl optionally substituted with one or more of halo, C_1-6haloalkyl, C_1-6alkyl or C_3-6cycloalkyl. In still other embodiments, R⁶ is aryl optionally substituted with one or more of halo such as F, Cl, or Br. In yet other embodiments. R⁶ is aryl optionally substituted with one or more of C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂. In other embodiments, R⁶ is aryl optionally substituted with one or more of C_1-6alkyl such as methyl, ethyl, or propyl. In yet other embodiments, R⁶ is aryl optionally substituted with one or more of C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, R⁶ is aryl (e.g.. phenyl) optionally substituted with F, methyl, or CF₃. In other embodiments, R⁶ is

In yet other embodiments, R⁶ is

In yet other embodiments, R⁶ is heteroaryl, optionally substituted with one or more of halo. C_1-6haloalkyl, C_1-6alkyl, C_1-6alkoxy, C_1-6haloalkoxy, C_3-6cycloalkyl, or C_3-6cycloalkylsulfonyl. In still other embodiments, R⁶ is pyridinyl, pyrazolyl, pyrazinyl, imidazolyl, or pyrimidinyl, each of which is optionally substituted. In still other embodiments, R⁶ is pyridinyl, pyrazolyl, pyrazinyl, pyridazinyl, imidazolyl, or pyrimidinyl, each of which is optionally substituted. In further embodiments, R⁶ is optionally substituted pyrazinyl such as pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, or pyrazin-5-yl. In other embodiments, R⁶ is optionally substituted pyrazolyl such as pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, or pyrazol-5-yl. In still further embodiments, R⁶ is optionally substituted pyridinyl such as pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl. In other embodiments, R⁶ is optionally substituted pyridazinyl such as pyridazin-3-yl or pyridazin-4-yl. In yet other embodiments, R⁶ is optionally substituted imidazolyl such as imidazol-4-yl or imidazol-5-yl. In further embodiments, R⁶ is optionally substituted pyrimidinyl such as pyridimidin-2-yl, pyrimidin-4-yl, or pyrimidin-5-yl. In other embodiments, R⁶ is pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-4-yl, imidazol-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, or pyrimidin-5-yl, each of which is optionally substituted. In yet other embodiments. R⁶ is pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-4-yl, imidazol-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl or pyridazin-4-yl, each of which is optionally substituted. In further embodiments, R⁶ is unsubstituted pyridin-2-yl, unsubstituted pyridin-3-yl, unsubstituted pyridin-4-yl, unsubstituted pyrimidin-2-yl, unsubstituted pyrimidin-4-yl, unsubstituted pyrimidin-5-yl, or unsubstituted pyrazin-2-yl. In further embodiments, R⁶ is unsubstituted pyridin-2-yl, unsubstituted pyridin-3-yl, unsubstituted pyridin-4-yl, unsubstituted pyrimidin-2-yl, unsubstituted pyrimidin-4-yl, unsubstituted pyrimidin-5-yl, unsubstituted pyrazin-2-yl, or pyridazin-3-yl. In other embodiments, R⁶ is optionally substituted with one or more halo such as F, Cl, or Br. In yet other embodiments, R⁶ is optionally substituted with one or more C_1-6haloalkyl such as CF₃. CH₂CF₃. or CHF₂. In other embodiments, R⁶ is optionally substituted with one or more C_1-6alkyl such as methyl, ethyl, propyl, or isopropyl. In still other embodiments, R⁶ is optionally substituted with one or more C_1-6alkoxy such as methoxy, ethoxy, or propoxy. In yet further embodiments, R⁶ is optionally substituted with one or more C_1-6haloalkoxy such as OCF₃. In further embodiments, R⁶ is optionally substituted with one or more C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, or cyclopentyl. In yet further embodiments, R⁶ is optionally substituted with one or more C_3-6cycloalkylsulfonyl such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In yet other embodiments, R⁶ is heteroaryl optionally substituted with one or more of F, CF₃, CH₂CF₃, CHF₂, methyl, methoxy, OCF₃, cyclobutyl, or cyclopropylsulfonyl.

In other embodiments, R⁶ is a five-membered heteroaryl, optionally substituted with one or more of CF₃. CH₂CF₃, CHF₂, methyl, cyclobutyl, or cyclopropylsulfonyl. In further embodiments, R⁶ is

In still further embodiments, R⁶ is

In other embodiments, R⁶ is

In still further embodiments, R⁶ is

In yet further embodiments, R⁶ is

In further embodiments, R⁶ is

In yet further embodiments, R⁶ is

In other embodiments, R⁶ is a six-membered heteroaryl, optionally substituted with one or more of F. CF₃, methoxy, OCF₃. or methyl. In still other embodiments, R⁶ is

In still further embodiments, R⁶ is

In yet other embodiments, R⁶ is

In yet other embodiments, R⁶ is heterocyclyl or heterocyclyl(alkylene), each optionally substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C(O)O(C_1-6alkyl), or C_3-6cycloalkyl. In further embodiments, R⁶ is optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, or optionally substituted morpholinyl. In other embodiments, R⁶ is optionally substituted azetidinyl. In yet other embodiments, R⁶ is optionally substituted pyrrolidinyl. In further embodiments, R⁶ is optionally substituted piperidinyl. In yet other embodiments, R⁶ is optionally substituted piperazinyl. In still further embodiments, R⁶ is optionally substituted morpholinyl. In other embodiments, R⁶ is optionally substituted morpholinyl(alkylene), optionally substituted piperidinyl(alkylene), optionally substituted piperazinyl(alkylene), or optionally substituted azetidinyl(alkylene). In further embodiments, R⁶ is unsubstituted azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl. In other embodiments, R⁶ is unsubstituted morpholinyl(alkylene), piperidinyl(alkylene), piperazinyl(alkylene), or azetidinyl(alkylene). In yet other embodiments, R⁶ is unsubstituted morpholinyl or morpholinyl(alkylene). In other embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more halo such as F, Cl, or Br. In yet other embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more OH. In further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂. In still further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_1-6alkyl such as methyl, ethyl, or propyl. In further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_1-6hydroxyalkyl such as C(CH₃)₂OH. In yet further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_1-6alkoxy, such as methoxy, ethoxy, or propoxy. In other embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C(O)O(C_1-6alkyl), such as C(O)Omethyl, C(O)Oethyl, C(O)Opropyl, or C(O)Otert-butyl. In still further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_3-6cycloalkyl such as one or more cyclopropyl, cyclobutyl, or cyclopentyl. In yet other embodiments, R⁶ is heterocyclyl and heterocyclyl(alkylene), each optionally substituted with one or more of F, OH, C(CH₃)₂(OH), methyl, C(O)O(tert-butyl), or cyclopropyl.

In further embodiments, R⁶ is

In yet otherembodiments, R⁶ is

In further embodiments, R⁶ is

In still further embodiments, R⁶ is

In yet other embodiments, R⁶ is

In other embodiments, R⁶ is

In yet further embodiments, R⁶ is

In further embodiments, R⁶ is H, CN, C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6deuteratedalkoxy(alkylene), halo, (CR^vR^x)_pNR^yR^z, C(O)NR^y2R^z2, C_1-6alkylcarbonyl, optionally substituted C_2-6alkenyl, optionally substituted C_3-6cycloalkenyl, optionally substituted (C_3-6cycloalkyl)alkylene, optionally substituted (aryl)alkylene, or C_1-6alkylsulfonyl. In other embodiments, R⁶ is H. In further embodiments, R⁶ is CN. In still other embodiments, R⁶ is C_1-6alkoxy such as methoxy. In yet other embodiments, R⁶ is C_1-6alkoxy(alkylene) such as CH₂OCH₃, C(CH₃)₂OCH₃. or (CH₂)₂OCH₃. In still other embodiments, R⁶ is C_1-6haloalkoxy such as OCF₃. OCHF₂, OCH₂F, or O(CH₂)₂CF₃. In other embodiments, R⁶ is C_1-6haloalkoxy(alkylene) such as CH₂OCF₃. In yet other embodiments, R⁶ is C_1-6deuteratedalkoxy(alkylene) such as CH₂OCD₃. In further embodiments, R⁶ is halo such as F, Br, or Cl. In yet further embodiments, R⁶ is (CR^vR^x)_pNR^yR^z such as NH₂, N(CH₃)₂, NHCH₂CF₃, NHCH₂CH₂OCH₃, NH(cyclopropyl), CH₂N(CH₃)₂, (CH₂)₂N(CH₃)₂, C(CH₃)₂NHCH₃, C(CH₃)₂N(CH₃)₂, CH₂NH(cyclopropyl), or CH₂CH₂NH(cyclopropyl). In other embodiments, R⁶ is C(O)NR^y2R^z2 such as C(O)N(CH₃)₂ or C(O)NH(cyclopropyl). In yet other embodiments, R⁶ is C_1-6alkylcarbonyl such as C(O)CH₃. In further embodiments, R⁶ is optionally substituted C_2-6alkenyl such as CH═CH₂, CH═CH—cyclopropyl, or CH=CHC(CH₃)₂OH. In yet other embodiments, R⁶ is optionally substituted C_3-6cycloalkenyl such as

In still other embodiments, R⁶ is optionally substituted (C_3-6cycloalkyl)alkylene such as CH₂-cyclopropyl, CH₂CH₂-cyclopropyl or C(CH₃)OH-cyclopropyl. In further embodiments, R⁶ is optionally substituted (aryl)alkylene such as benzyl. In other embodiments, C_1-6alkylsulfonyl(alkylene) such as C(CH₃)₂SO₂CH₃. In yet other embodiments, R⁶ is H, CH₂OCH₃, Cl, NH(cyclopropyl), or C(O)N(CH₃)₂.

In some embodiments, R⁷ is H, CN, C_1-6alkyl, C_1-6haloalkyl, halo, C_3-8cycloalkyl, aryl, or heteroaryl. In yet other embodiments, R⁷ is H. In still further embodiments, R⁷ is CN. In other embodiments, R⁷ is C_1-6alkyl, such as methyl, ethyl, or propyl. In further embodiments. R⁷ is methyl. In yet other embodiments, R⁷ is C_1-6haloalkyl, such as CHF₂, CH₂F, C(CH₃)F₂, CH₂CHF₂, or CF₃. In still further embodiments, R⁷ is CHF₂ or CF₃. In further embodiments, R⁷ is halo, such as F, Br, or Cl. In yet other embodiments, R⁷ is Br or Cl. In still further embodiments. R⁷ is C_3-6cycloalkyl, such as cyclopropyl. cyclobutyl, or cyclopentyl. In other embodiments, R⁷ is cyclopropyl. In further embodiments, R⁷ is aryl. In yet other embodiments, R⁷ is phenyl. In still further embodiments, R⁷ is heteroaryl. In other embodiments, R⁷ is pyridinyl. In further embodiments, R⁷ is H. CN, methyl, CF₃, CH₂F. CHF₂, CF₂(CH₃), CH₂CHF₂, Br, Cl, cyclopropyl, phenyl, or pyridinyl. In yet other embodiments, R⁷ is H, CN, methyl, CHF₂, CF₃, Br, Cl, cyclopropyl, phenyl, or pyridinyl.

In some embodiments of R², R⁸ is H. In other embodiments, R⁸ is C_1-6alkyl such as methyl, ethyl, isopropyl, or tert-butyl. In further embodiments, R⁸ is C_1-6haloalkyl such as CF₃, CHF₂, CH₂F, CH₂CF₃, CH₂CHF₂, C(CH₃)₂F, or C(CH₃)F₂. In still further embodiments, R⁸ is C_1-6alkoxy(alkylene) such as CH₂CH₂OCH₃. In other embodiments, R⁸ is C_1-6alkylcarbonyl such as CH₂C(═O)CH₃. In still other embodiments, R⁸ is C_1-6hydroxyalkyl such as CH₂C(CH₃)₂OH. In further embodiments, R⁸ is (CR^vR^x)_pNR^yR^z such as (CH₂)₂N(CH₃)₂. In yet other embodiments, R⁸ is optionally substituted C_3-8cycloalkyl such as optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, or optionally substituted cyclohexyl. In other embodiments, R⁸ is optionally substituted aryl such as optionally substituted phenyl. In further embodiments, R⁸ is optionally substituted heteroaryl, such as optionally substituted pyridinyl. In still further embodiments, R⁸ is optionally substituted heteroaryl such as optionally substituted pyridinyl. In yet other embodiments, R⁸ is optionally substituted (C_3-8cycloalkyl)alkylene such as

In still further embodiments, R⁸ is H, methyl, isopropyl, CHF₂, CH₂CF₃, CF₃, cyclopropyl, or

In some embodiments, one or both of R^v and R^x are H. In other embodiments, one or both of R^v and R^x are C_1-6alkyl such as methyl, ethyl, propyl, or butyl. In yet other embodiments, one or both of R^v and R^x are methyl. In some embodiments, one or both of R^y and R^z are H. In other embodiments, one or both of R^y and R^z are C_1-6alkyl such as methyl, ethyl, propyl, or butyl. In yet other embodiments, one or both of R^y and R^z are C_1-6alkoxy(alkylene) such as CH₂OCH₃. In further embodiments, one or both of R^y and R^z are C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, one or both of R^y2 and R^z2 are H. In other embodiments, one or both of R^y2 and R^z2 are C_1-6alkyl such as methyl, ethyl, propyl, or butyl. In further embodiments, one or both of R^y2 and R^z2 are C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In further embodiments, p is 0. In other embodiments, p is 1. In still further embodiments, p is 2. In yet other embodiments, p is 3.

In some embodiments, R² is

wherein: R⁶ is H. C_1-6alkyl, C_1-6haloalkyl, C_1-6cyanoalkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), optionally substituted C_3-6cycloalkyl, or optionally substituted heteroaryl; and R⁷ is H, CN, C_1-6alkyl, C_1-6haloalkyl, halo, C_3-6cycloalkyl, aryl, or heteroaryl. In further embodiments, R⁶ is H, C_1-6alkyl, C_1-6haloalkyl, C_1-6cyanoalkyl, C_1-6hydroxyalkyl, optionally substituted C_3-6cycloalkyl, or optionally substituted heteroaryl; and R⁷ is H, CN, C_1-6alkyl, C_1-6haloalkyl, halo, or C₃. ₆cycloalkyl. In other embodiments, R⁶ is H. In further embodiments, R⁶ is C_1-6alkyl. In still further embodiments, R⁶ is methyl, isopropyl, or tert-butyl. In yet other embodiments. R⁶ is C_1-6haloalkyl. In still further embodiments, R⁶ is CF₂H, C(CH₃)₂F, CH(CH₃)F, or CF₃. In other embodiments, R⁶ is C_1-6cyanoalkyl. In further embodiments, R⁶ is C(CH₃)₂CN. In yet other embodiments, R⁶ is C_1-6hydroxyalkyl. In still further embodiments, R⁶ is C(CH₃)₂OH. CH₂C(CH₃)₂OH, CH(CH₂CH₃)OH. C(CH₃)₂(CH₂OH), or CH(CH₃)OH. In other embodiments, R⁶ is C_1-6alkoxy. In still other embodiments, R⁶ is methoxy or ethoxy. In yet other embodiments, R⁶ is C_1-6alkoxy(alkylene). In further embodiments, R⁶ is CH₂OCH₃ or (CH₂)₂OCH₃. In other embodiments, R⁶ is optionally substituted C_3-6cycloalkyl. In yet other embodiments, the optionally substituted C_3-6cycloalkyl is substituted with one or more OH. In further embodiments, R⁶ is

In yet other embodiments, R⁶ is

In other embodiments, R⁶ is optionally substituted heteroaryl. In yet other embodiments, R⁶ is optionally substituted pyridinyl, optionally substituted pyrazolyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, or optionally substituted imidazolyl. In still other embodiments, the optionally substituted heteroaryl is substituted with one or more C_1-6alkyl such as methyl, ethyl, or isopropyl. In further embodiments, R⁶ is

In still further embodiments, R⁶ is

In other embodiments, R⁶ is H, methyl, tert-butyl, C(CH₃)₂F, C(CH₃)₂CN, C(CH₃)₂OH. CH(CH₃)OH, CH₂OCH₃, cyclopropyl,

In further embodiments, R⁶ is H, tert-butyl, C(CH₃)₂F, C(CH₃)₂CN, C(CH₃)₂OH, CH(CH₃)OH,

In yet other embodiments, R⁷ is H. In still further embodiments, R⁷ is CN. In other embodiments, R⁷ is C_1-6alkyl. In further embodiments. R⁷ is methyl. In yet other embodiments, R⁷ is C_1-6haloalkyl. In still further embodiments, R⁷ is CF₂H, CHF₂, CH₂F, C(CH₃)F₂, or CF₃. In other embodiments, R⁷ is CHF₂ or CF₃. In further embodiments, R⁷ is halo. In yet other embodiments, R⁷ is Br or Cl. In still further embodiments, R⁷ is C_3-6cycloalkyl. In other embodiments, R⁷ is cyclopropyl. In further embodiments, R⁷ is aryl. In yet other embodiments, R⁷ is phenyl. In still further embodiments, R⁷ is heteroaryl. In other embodiments, R⁷ is pyridinyl. In yet other embodiments, R⁷ is H, CN, methyl, CHF₂, CF₃, Br, Cl, cyclopropyl, phenyl, or pyridinyl. In still other embodiments, R⁷ is H, CN, methyl, CHF₂, CF₃, Br, Cl, or cyclopropyl.

In other embodiments, R² is

wherein: R⁶ is H, CN, C_1-6alkyl, C_1-6haloalkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), optionally substituted C_3-6cycloalkyl, optionally substituted heteroaryl; and R⁷ is H, C_1-6alkyl, C_1-6haloalkyl, halo, or C_3-6cycloalkyl. In yet other embodiments, R⁶ is H, C_1-6alkyl, C_1-6haloalkyl, or C_1-6hydroxyalkyl; and R⁷ is H. In further embodiments, R⁶ is H. In other embodiments, R⁶ is CN. In further embodiments, R⁶ is C_1-6alkyl. In still further embodiments. R⁶ is methyl, isopropyl, or tert-butyl. In yet other embodiments, R⁶ is C_1-6haloalkyl. In still further embodiments, R⁶ is CHF₂, C(CH₃)₂F, C(CH₃)F₂, or CF₃. In yet other embodiments, R⁶ is C_1-6hydroxyalkyl. In still further embodiments, R⁶ is C(CH₃)₂OH. In other embodiments, R⁶ is C_1-6alkoxy. In still further embodiments, R⁶ is methoxy or ethoxy. In yet other embodiments, R⁶ is C_1-6alkoxy(alkylene). In further embodiments, R⁶ is CH₂OCH₃. In other embodiments, R⁶ is optionally substituted C_3-6cycloalkyl. In yet further embodiments, R⁶ is

In other embodiments, R⁶ is optionally substituted heteroaryl. In yet other embodiments, R⁶ is optionally substituted pyridinyl or optionally substituted pyrazolyl. In further embodiments, R⁶ is

In other embodiments, R⁶ is H, tert-butyl, C(CH₃)₂F, C(CH₃)F₂, C(CH₃)₂OH, CH₂OCH₃,

In further embodiments, R⁶ is H or C(CH₃)₂F. In yet other embodiments, R⁷ is H. In other embodiments, R⁷ is C_1-6alkyl. In further embodiments, R⁷ is methyl. In yet other embodiments, R⁷ is C_1-6haloalkyl. In still further embodiments, R⁷ is CF₂H or CF₃. In further embodiments. R⁷ is halo. In yet other embodiments, R⁷ is Br or Cl. In still further embodiments, R⁷ is C_3-6cycloalkyl. In other embodiments, R⁷ is cyclopropyl. In still further embodiments, R⁷ is H, methyl, CF₂H, CF₃, Br, Cl, or cyclopropyl.

In further embodiments. R² is

wherein R⁶ and R⁷ are independently H, C_1-6alkyl, C_1-6haloalkyl, halo, optionally substituted C_3-6cycloalkyl, or optionally substituted aryl. In other embodiments, R⁶ and R⁷ are each H. In further embodiments, one of R⁶ or R⁷ is C_1-6alkyl such as methyl. In yet other embodiments, one of R⁶ or R⁷ is C_1-6haloalkyl such as CF₃. In still other embodiments, one of R⁶ or R⁷ is halo such as Br or Cl. In yet further embodiments, one of R⁶ or R⁷ is optionally substituted C_3-6cycloalkyl such as unsubstituted cyclopropyl. In other embodiments, one of R⁶ or R⁷ is optionally substituted aryl such as unsubstituted phenyl. In yet other embodiments, R⁶ is methyl, CF₃, Cl, cyclopropyl, or phenyl and R⁷ is H. In still other embodiments, R⁷ is methyl. CF₃, Cl, cyclopropyl, or phenyl and R⁶ is H.

In yet further embodiments, R² is

wherein R⁶ is H, C_1-6alkyl, halo, or optionally substituted aryl. In other embodiments, R⁶ is H. In further embodiments, R⁶ is C_1-6alkyl, such as methyl, ethyl, isopropyl, or tert-butyl. In other embodiments, R⁶ is methyl or ethyl. In other embodiments, R⁶ is halo, such as F, Br, or Cl. In further embodiments, R⁶ is Br. In other embodiments, R⁶ is optionally substituted aryl. In further embodiments, R⁶ is phenyl. In yet other embodiments, R⁶ is H, methyl, ethyl. Br, or phenyl. In still other embodiments, R⁶ is H, methyl, or phenyl.

In yet other embodiments, R² is

wherein R⁶ is H, C_1-6alkyl. C_1-6haloalkyl, C_1-6hydroxyalkyl, C(O)NR^y2R^z2, (CR^vR^×)_pNR^yR^z, optionally substituted C_3-6cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; R^v and R^x are, independently. H or C_1-6alkyl; R^y and R^z are, independently, H, C_1-6alkyl, C_1-6alkoxy(alkylene), or C_3-6cycloalkyl; R^y2 and R^z2 are, independently, H, C_1-6alkyl, or C_3-6cycloalkyl; and p is 0, 1, 2, or 3. In further embodiments, R⁶ is H, C_1-6alkyl, C_1-6haloalkyl, C_1-6hydroxyalkyl, optionally substituted C_3-6cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl. In some embodiments, R⁶ is H. In further embodiments, R⁶ is C_1-6alkyl. In other embodiments, R⁶ is methyl, ethyl, isopropyl, or tert-butyl. In further embodiments, R⁶ is methyl, isopropyl, or tert-butyl. In other embodiments, R⁶ is C_1-6haloalkyl. In further embodiments, R⁶ is CHF₂, CF₃, or C(CH₃)₂F. In still further embodiments, R⁶ is CF₃, CHF₂, C(CH₃)F₂, or C(CH₃)₂F. In yet other embodiments, R⁶ is C_1-6hydroxyalkyl. In still further embodiments, R⁶ is C(CH₃)₂OH or CH(CH₃)OH. In still other embodiments, R⁶ is C(O)NR^y2 R^z2. In yet further embodiments, R⁶ is C(O)N(CH₃)₂ or C(O)NH(cyclopropyl). In other embodiments, R⁶ is (CR^vR^x)_pNR^yR^z. In further embodiments, R⁶ is NH₂, N(CH₃)₂, NHCH₂CF₃, NHCH₂CH₂OCH₃, NH(cyclopropyl), CH₂N(CH₃)₂, CH₂NH(cyclopropyl), or CH₂CH₂NH(cyclopropyl). In yet other embodiments. R⁶ is optionally substituted C_3-6cycloalkyl. In still other embodiments, the optionally substituted C_3-6cycloalkyl is substituted with one or more of halo such as F or C_1-6alkyl such as methyl. In still further embodiments, R⁶ is

In other embodiments, R⁶ is optionally substituted aryl. In yet other embodiments, the optionally substituted aryl is substituted with one or more of halo such as F, C_1-6alkyl such as methyl, or C_1-6haloalkyl such as CF₃. In further embodiments, R⁶ is

In still other embodiments, R⁶ is optionally substituted heterocyclyl. In further embodiments, the optionally substituted heterocyclyl is substituted with one or more of halo such as F or C_1-6alkyl such as methyl. In yet further embodiments, R⁶ is

In yet other embodiments, R⁶ is

In other embodiments, R⁶ is optionally substituted heteroaryl such as optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridinyl, or optionally substituted pyrazinyl. In further embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6alkyl such as methyl, ethyl, or isopropyl, C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂, halo such as F, C_1-4alkoxy such as methoxy, ethoxy, or propoxy, C_3-6cycloalkyl such as cyclopropyl or cyclobutyl; or C_3-6cycloalkylsulfonyl such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In yet other embodiments, R⁶ is

In still other embodiments, R⁶ is

In further embodiments, R⁶ is methyl, isopropyl, tert-butyl, CHF₂, C(CH₃)₂F, C(CH₃)₂OH, CH(CH₃)OH, C(O)N(CH₃)₂, NH(cyclopropyl),

phenyl,

In still further embodiments, R⁶ is methyl, isopropyl, tert-butyl, CF₃, CHF₂, C(CH₃)F₂, C(CH₃)₂F, C(CH₃)₂OH,

In still further embodiments, R² is

wherein R⁶ and R⁷ are independently H, halo, C_1-6alkyl, or C_1-6haloalkyl; and R⁸ is H, C_1-6alkyl, C_1-6haloalkyl, C₃-₆cycloalkyl, optionally substituted aryl, or heteroaryl. In yet other embodiments, R⁶ and R⁷ are independently H, halo, C_1-6alkyL C_1-6haloalkyl, or NR^yR^z wherein R^y and R^z are, independently, H or C_1-6alkyl; R⁸ is H, C_1-6alkyl, C_1-6alkyl, C_3-6cycloalkyl, or heteroaryl. In other embodiments, one or both of R⁶ and R⁷ are H. In still other embodiments, one of R⁶ or R⁷ is halo. In further embodiments, one of R⁶ or R⁷ is Cl or Br. In still further embodiments, one of R⁶ or R⁷ is Cl. In yet other embodiments, one of R⁶ or R⁷ is C_1-6alkyl. In still further embodiments, one of R⁶ or R⁷ is methyl. In other embodiments, one of R⁶ or R⁷ is C_1-6haloalkyl. In further embodiments, one of R⁶ or R⁷ is CHF₂, CH₂CF₃, CF₂H, or CF₃. In other embodiments, one of R⁶ or R⁷ is CHF₂. In further embodiments, one of R⁶ or R⁷ is NR^yR^z wherein R^y and R^z are, independently, H or C_1-6alkyl, such as NH₂ In yet other embodiments, one of R⁶ or R⁷ is Cl, Br, methyl, CHF₂, or CF₃. In further embodiments, one of R⁶ or R⁷ is Cl, methyl, CHF₂, or NH₂. In other embodiments, one of R⁶ or R⁷ is methyl, Cl, CHF₂, or CF₃. In some embodiments, R⁸ is H. In other embodiments, R⁸ is C_1-6alkyl. In further embodiments, R⁸ is methyl, ethyl, isopropyl, or tert-butyl. In yet other embodiments, R⁸ is methyl or isopropyl. In still other embodiments, R⁸ is C_1-6haloalkyl. In yet further embodiments, R⁸ is CHF_2, CH₂CF₃, CF₂H, CH₂CHF_2, or CF₃. In yet further embodiments, R⁸ is CHF₂, CH₂CF₃, or CF₃. In other embodiments, R⁸ is C_3-6cycloalkyl. In further embodiments, R⁸ is cyclopropyl. In yet other embodiments, R⁸ is optionally substituted aryl. In still further embodiments, R⁸ is phenyl or fluorophenyl. In other embodiments, R⁸ is heteroaryl. In further embodiments, R⁸ is pyridinyl. In still other embodiments, R⁸ is H, methyl, isopropyl, tert-butyl, CHF₂, CH₂CF₃, CH₂CHF₂, CH₂C(═O)CH₃, CH₂C(CH₃)₂OH, (CH₂)₂N(CH₃)₂, cyclopropyl, fluorophenyl, pyridinyl, CH₂-cyclopropyl or CH₂-cyclobutyl. In yet other embodiments, R⁸ is methyl, isopropyl, CHF₂, CH₂CF₃, CF₃, cyclopropyl, and pyridinyl.

In further embodiments, R² is

wherein R⁶ is H, C_1-6alkyl, halo, C_1-6haloalkyl, or C_3-6cycloalkyl; and R⁸ is H, C_1-6alkyl, or C_1-6haloalkyl. In still further embodiments, R⁶ is H, C_1-6alkyl, halo, C_1-6haloalkyl, or C_3-6cycloalkyl; and R⁸ is H or C_1-6alkyl. In other embodiments, R⁶ is H. In still other embodiments, R⁶ is C_1-6alkyl, such as methyl. In yet other embodiments, R⁶ is halo such as Cl or Br. In further embodiments, R⁶ is Cl. In other embodiments, R⁶ is C_1-6haloalkyl such as CHF₂ or CF₃. In yet other embodiments, R⁶ is C_3-6cycloalkyl such as cyclopropyl. In still further embodiments, R⁶ is H, methyl, Cl, CHF₂, CF₃, or cyclopropyl. In some embodiments, R⁸ is H. In other embodiments, R⁸ is C_1-6alkyl such as methyl, ethyl, or isopropyl. In yet other embodiments, R⁸ is C_1-6haloalkyl, such as CF₃ or CHF₂. In other embodiments, R⁸ is methyl.

In yet other embodiments, R² is

In these structures, W is S or NR¹⁵; W¹ is S, O, or NR¹⁵; R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are each independently, H, C_1-6alkyl, C_1-6haloalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6hydroxyalkyl, C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_2-6alkenyl, CN, halo, (CR^vR^x)_pNR^yR^z, C(O)NR^y2R^z2, optionally substituted C_3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), optionally substituted aryl, or optionally substituted heteroaryl; R^v and R^x are, independently, H or C_1-6alkyl; R^y and R^z are, independently, H, C_1-6alkyl, C_3-6cycloalkyl, C_1-6hydroxyalkyl, C_1-6haloalkyl, C_1-6alkoxy(alkylene), or C(O)OC_1-6alkyl; R^y2 and R^z2, are independently, H, C_1-6alkyl, or C_3-6cycloalkyl; p is 0, 1, 2, or 3; and R¹⁵ is H or C_1-6alkyl.

In some embodiments, W is S. In other embodiments, W is NR¹⁵. In some embodiments, W¹ is S. In other embodiments, W¹ is O. In further embodiments, W¹ is NR¹⁵. In some embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are H. In further embodiments, R¹⁰, R¹¹, R¹², and R¹³ are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6alkyl. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6haloalkyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6alkoxy. In still other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6alkoxy(alkylene). In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6hydroxyalkyl. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6haloalkoxy. In still other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6haloalkoxy(alkylene). In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_2-6alkenyl. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is CN. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is halo. In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is (CR^vR^x)_pNR^yR^z_. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C(O)NR^y2R^z2_. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted C_3-8cycloalkyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted heterocyclyl. In still other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted heterocyclyl(alkylene). In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted aryl. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted heteroaryl. In some embodiments, one or both of R^v and R^x are H. In other embodiments, one or both of R^v and R^x is C_1-6alkyl. In some embodiments, one or both of R^y and R^z is H. In other embodiments, one or both of R^y and R^z is C_1-6alkyl. In further embodiments, one or both of R^y and R^z is C_3-6cycloalkyl. In yet other embodiments, one or both of R^y and R^z is C_1-6hydroxyalkyl. In still further embodiments, one or both of R^y and R^z is C_1-6haloalkyl. In further embodiments, one or both of R^y and R^z is C(O)OC_1-6alkyl. In some embodiments, one or both of R^y2 and R^z2 is H. In other embodiments, one or both of R^y2 and R^z2 is C_1-6alkyl. In further embodiments, one or both of R^y2 and R^z2 is C_3-6cycloalkyl. In some embodiments, p is 0. In other embodiments, p is 1. In further embodiments, p is 2. In yet other embodiments, p is 3. In some embodiments, R¹⁵ is H. In other embodiments, R¹⁵ is C_1-6alkyl.

In still further embodiments, R² is

wherein R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are each independently H, C_1-6alkyl, C_1-6haloalkyl, C_3-6cycloalkyl, C_1-6alkoxy, C_1-6calkoxy(alkylene), halo, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), optionally substituted heteroaryl, or (CR^vR^x)_pNR^yR^z. In other embodiments. R¹⁰, R¹¹_, R¹², R¹³, and R¹⁴ are each independently H, C_1-6alkyl, C_3-6cycloalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), optionally substituted heteroaryl, or (CR^vR^x)_pNR^yR^z_. In some embodiments, R¹⁰, R¹¹_, R¹², R¹³, and R¹⁴ are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6alkyl such as methyl or ethyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6alkyl such as methyl. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6haloalkyl such as CF₃, or C(CH₃)₂F. In yet further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and/or R¹⁴ is C_3-6cycloalkyl such as cyclopropyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6alkoxy such as methoxy. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6alkoxy(alkylene) such as CH₂OCH₃ or (CH₂)₂OCH₃. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹¹, and R¹⁴ is halo such as F, Br, or Cl. In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted aryl such as unsubstituted phenyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted heterocyclyl such as

In still other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted heterocyclyl such as

In other embodiments, the optionally substituted heterocyclyl is

In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted heterocyclyl(alkylene). In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is

In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is

In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is optionally substituted heteroaryl such as optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, or optionally substituted pyrazolyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is

In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is (CR^vR^x)_pNR^yR^z such as NH₂, NH(CH₃), N(CH₃)_2, CH₂N(CH₃)₂, or CH₂CH₂N(CH₃)₂. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is (CR^vR^x)pNR^yR^z such as N(CH₃)₂, CH₂N(CH₃)₂, or CH₂CH₂N(CH₃)₂. In further embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are each independently H, methyl, C(CH₃)₂F, cyclopropyl, methoxy, CH₂OCH₃, (CH₂)₂OCH₃, Br. F, Cl, phenyl,

N(CH₃)₂, CH₂N(CH₃)₂, or CH₂CH₂N(CH₃)₂. In yet other embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are each independently H, methyl, cyclopropyl, methoxy, CH₂OCH₃, (CH₂)₂OCH₃,

N(CH₃)₂, CH₂N(CH₃)₂, or CH₂CH₂N(CH₃)₂. In other embodiments, R¹⁰, R¹³, and R¹⁴ are each hydrogen. In further embodiments, R¹⁰, R¹³, and R¹⁴ are each hydrogen; and R¹¹ is halo.

In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R³⁴ is substituted heterocyclyl or substituted heterocyclyl(alkylene), substituted with one or more of halo such as F, Cl, or Br; C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂; C_1-6alkyl such as methyl, ethyl, or propyl; OH; C_1-6hydroxyalkyl such as C(CH₃)₂OH; C_1-6alkoxy such as methoxy, ethoxy, or propoxy; or C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more methyl. OH, or F.

In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is substituted heteroaryl, substituted with one or more of halo such as F, Cl, or Br; C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂; C_1-6alkyl such as methyl, ethyl, propyl, or isopropyl; C_1-6alkoxy such as methoxy, ethoxy, or propoxy; C_1-6haloalkoxy such as OCF₃; C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, or cyclopentyl; or C_3-6cycloalkylsulfonyl such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In yet other embodiments, the substituted heteroaryl is substituted with one or more of F, CF₃. CHF₂, or methyl. In further embodiments, the optionally substituted heteroaryl is pyrazolyl, substituted with one methyl.

In other embodiments, R² is

wherein R¹⁰, R¹¹, R¹², and R¹³ are each independently H, C_1-6alkyl, or halo and R¹⁵ is H or C_1-6alkyl. In further embodiments, R¹⁰, R¹¹, R¹², and R¹³ are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³ is C_1-6alkyl. In further embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³ is halo. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³ is Br. In some embodiments. R¹⁵ is H. In other embodiments, R¹⁵ is C_1-6alkyI. In further embodiments, R¹⁵ is methyl. In yet other embodiments, R¹⁵ is H or methyl.

In further embodiments. R² is

wherein R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are each independently H, halo, or C_1-6alkyl. In some embodiments, R² is

In other embodiments, R² is

In some embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is halo. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6alkyI.

In yet other embodiments, R² is

wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ are each independently H, halo, or C1-6alkyl. In some embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is halo. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is Br. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴ is C_1-6alkyl.

In still further embodiments, R² is

wherein R¹⁰, R¹¹, R¹², and R¹³ are each independently, H, C_1-6alkyl, or halo. In some embodiments, R² is

In other embodiments, R² is

In further embodiments, R² is

In some embodiments, R¹⁰, R¹¹, R¹², and R¹³ are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³ is halo. In further embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³ is F. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³ is C_1-6alkyl. In still further embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³ is methyl. In yet other embodiments. R¹⁰, R¹¹, R¹², and R¹³ are each independently H, methyl, or F.

In other embodiments. R² is

wherein R⁶ is defined herein and R⁷ is H. In yet other embodiments, R² is

In still other embodiments, R² is

In further embodiments. R² is

wherein R⁶ is defined herein and R⁷ is CH₃. In other embodiments, R² is

or

In yet other embodiments, R² is

In yet other embodiments, R² is

wherein R⁶ is defined herein and R⁷ is cyclopropyl. In further embodiments, R² is

In still further embodiments, R² is

In still further embodiments, R² is

wherein R⁶ is defined herein and R⁷ is CHF₂, In other embodiments, R² is

In yet otherembodiments, R² is

In other embodiments. R² is

wherein R⁶ is defined herein and R⁷ is CF₃. In still other embodiments, R² is

In yet other embodiments, R² is

In further embodiments, R² is

wherein R⁶ is defined herein and R⁷ is CN. In still further embodiments, R² is

In yet other embodiments, R² is

wherein R⁶ is defined herein and R⁷ is Br or Cl. In further embodiments, R² is

In still further embodiments, R² is

wherein R⁶ is defined herein and R⁷ is phenyl or pyridinyl. In other embodiments, R² is

In further embodiments. R² is

wherein R⁶ is defined herein and R⁷ is H. In yet other embodiments, R² is

In still other embodiments, R² is

In other embodiments, R² is

wherein R⁶—R⁸ are defined herein. In still other embodiments, R² is

In yet other embodiments, R² is

In further embodiments, R² is

wherein R⁶-R⁸ are defined herein. In still further embodiments, R² is

In yet other embodiments, R² is

In other embodiments, R² is

wherein R⁶ is optionally substituted heterocyclyl. In yet other embodiments, R² is

In still other embodiments, R² is

In further embodiments. R² is

wherein R⁶ is optionally substituted heteroaryl. In still further embodiments, R² is

In yet other embodiments, R² is

In other embodiments. R² is

wherein R⁶ is optionally substituted aryl. In still other embodiments, R² is

In further embodiments, R² is

wherein R⁶ is C_1-6alkyl, C_1-6haloalkyl, or C_1-6hydroxyalkyl. In still further embodiments. R² is

In yet other embodiments, R² is

In other embodiments, R² is

wherein R⁶ is optionally substituted C_3-8cycloalkyl. In yet other embodiments, R² is

In yet other embodiments, R² is

wherein R⁶ is C(O)NR^y2R^z2 or (CR^vR^x)_pNR^yR^z and R^y2, R^z2, p, R^v, R^x, R^y, and R^z are defined herein. In other embodiments, R² is

In other embodiments, R² is

wherein R⁶ is H, C_1-6alkyl, or optionally substituted aryl. In still other embodiments, R² is

In yet other embodiments, R² is

In further embodiments, R² is

wherein R⁶ is C_1-6hydroxyalkyl. In yet further embodiments, R² is

In other embodiments. R² is

wherein R⁸ is C_1-4alkyl and R⁶ is defined herein. In still other embodiments, R² is

In further embodiments, R² is

wherein R¹⁰-R¹⁴ are defined herein. In still further embodiments, R² is

In yet other embodiments, R² is

In other embodiments, R² is

wherein R¹³ is H and R¹⁰, R¹¹, R¹², R¹⁴, and R¹⁵ are defined herein. In yet other embodiments, R² is

In some embodiments, the compound of Formula I is of Formula I-A or a pharmaceutically acceptable salt thereof:

such as

or

wherein R¹, R², R⁵, L, and m are defined herein. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In other embodiments, the compound of Formula I is of Formula I-B or a pharmaceutically acceptable salt thereof:

such as

or

wherein R¹, R², R⁵, and m are defined herein. In further embodiments, the compound is

B-1 or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In further embodiments, the compound of Formula I is of Formula I—C or a pharmaceutically acceptable salt thereof:

such as

or

, wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In still other embodiments, the compound of Formula I is of Formula I-D or a pharmaceutically acceptable salt thereof:

such as

or

wherein R¹, R², R⁵, and m are defined herein. In some embodiments, the compound is

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In still further embodiments, the compound of Formula I is of Formula I-E or a pharmaceutically acceptable salt thereof:

such as

or

wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In other embodiments, the compound of Formula I is of Formula I-F or a pharmaceutically acceptable salt thereof:

such as

or

wherein R¹, R², R⁵, and m are defined herein. In yet other embodiments, the compound is

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In further embodiments, the compound of Formula I is of Formula I-G or a pharmaceutically acceptable salt thereof:

such as

or

wherein R¹, R², R⁵, and m are defined herein. In still further embodiments, the compound is

or a pharmaceutically acceptable salt thereof. In otherembodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In yet other embodiments, the compound of Formula I is of Formula I-H or a pharmaceutically acceptable salt thereof:

such as

or

wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In still further embodiments, the compound of Formula I is of Formula I-I or a pharmaceutically acceptable salt thereof.

such as

or

wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

or a pharmaceuticallyacceptable salt thereof. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In other embodiments, the compound of Formula I is of Formula I-J or a pharmaceutically acceptable salt thereof:

such as

or

wherein R¹, R², R⁵, and m are defined herein. In yet other embodiments, the compound is

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In further embodiments, the compound of Formula I is of Formula I-K or a pharmaceutically acceptable salt thereof:

such as

or

wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

or a pharmaceuticallyacceptable salt thereof. In other embodiments, the compound is

2 or a pharmaceutically acceptable salt thereof.

In still other embodiments, the compound of Formula I is of Formula I-L or a pharmaceutically acceptable salt thereof.

wherein R¹, R², R⁵, L. and m are defined herein. In further embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In yet further embodiments, the compound of Formula I is of Formula I-M or a pharmaceutically acceptable salt thereof.

wherein R¹, R², R⁵, L, and m are defined herein. In other embodiments, the compound is

or a pharmaceutically acceptable salt thereof.

In some embodiments, compounds of the disclosure are any one or more of the compounds of Table 1. and their pharmaceutically acceptable salts and/or isotopologues. Compounds having the Formula I are further disclosed in the Exemplification and are included in the present disclosure. Pharmaceutically acceptable salts thereof as well as the neutral forms are included.

The disclosure further provides R-enantiomers, S-enantiomers, or racemic mixtures of any of the compounds described herein. In some embodiments, the compound is an S-enantiomer. In other embodiments, the compound is the R-enantiomer. In further embodiments, the compound is racemic.

In another embodiment, the compounds of the disclosure may be enantiomerically enriched, e.g., the enantiomeric excess or “ee” of the compound is greater than about 5% as measured by chiral HPLC. In some embodiments, the ee is greater than about 10%. In other embodiments, the ee is greater than about 20%. In further embodiments, the ee is greater than about 30%. In yet other embodiments, the ee is greater than about 40%. In still further embodiments, the ee is greater than about 50%. In other embodiments, the ee is greater than about 60%. In further embodiments, the ee is greater than about 70%. In still other embodiments, the ee is greater than about 80%. In yet further embodiments, the ee is greater than about 85%. In other embodiments, the ee is greater than about 90%. In further embodiments, the ee is greater than about 91%. In yet other embodiments, the ee is greater than about 92%. In still further embodiments, the ee is greater than about 93%. In other embodiments, the ee is greater than about 94%. In further embodiments, the ee is greater than about 95%. In still other embodiments, the ee is greater than about 96%. In yet further embodiments, the ee is greater than about 97%. In other embodiments, the ee is greater than about 98%. In further embodiments, the ee is greater than about 99%.

The present disclosure encompasses the preparation and use of salts of compounds of the disclosure. Salts of compounds of the disclosure can be prepared during the final isolation and purification of the compounds or separately by reacting the compound with an acid or base as appropriate.

Treatment Methods

Compounds of the disclosure have several uses as described herein. In some embodiments, compounds of the disclosure are useful in methods for stabilizing mutant PAH proteins. These methods comprise contacting the protein with one or more compounds described herein or a pharmaceutically acceptable salt thereof. The compounds of the disclosure can provide for better Phe control for patients whose disease is not well-managed on diet alone and lessen the severity of a patient’s phenylketonuria. Thus, patients administered a compound of the disclosure will have a better quality of life, e.g., a more normal lifestyle and/or none or fewer dietary restrictions, as compared with phenylketonuria patients who have not been administered a compound of the disclosure. In some embodiments, patients administered a compound of the disclosure may experience increases in executive function, decreases in anxiety symptoms, and/or decreases in attention deficit hyperactivity disorder symptoms.

The term “mutant PAH gene” as used herein refers to the full DNA sequence of PAH that differs in one or more ways from the canonically accepted sequence (“the basis gene”) that is published in any one of a variety of curated databases. As one example, the sequence described by GenBank Accession number NG_008690.2 describes the basis gene.

The term “mutant PAH protein” as used herein refers to a PAH protein that contains at least one mutation in the amino acid sequence relative to that encoded by the reference. The reference human PAH protein is described by Genbank Accession number NP_000268 and contains 452 amino acids. PAH protein mutations can be identified using methods known in the art. In some embodiments, the mutant PAH protein contains at least one R408W. R261Q, R243Q, Y414C, L48S, A403V, 165T. R241C, L348V, R408Q. or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, 165T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation. In still other embodiments, the mutant PAH protein contains at least one R408W, R243Q, R408Q, V388M, or L348V mutation. In yet other embodiments, the mutant PAH protein contains at least one R408W mutation. In further embodiments, the mutant PAH protein contains at least two R408W mutations. In further embodiments, the mutant PAH protein contains at least one R261Q mutation. In yet other embodiments, the mutant PAH protein contains at least one R243Q mutation. In yet other embodiments, the mutant PAH protein contains at least one Y414C mutation. In still further embodiments, the mutant PAH protein contains at least one L48S mutation. In other embodiments, the mutant PAH protein contains at least one A403V mutation. In further embodiments, the mutant PAH protein contains at least one 165T mutation. In yet further embodiments, the mutant PAH protein contains at least one R241C mutation. In yet other embodiments, the mutant PAH protein contains at least one L348V mutation. In further embodiments, the mutant PAH protein contains at least one R408Q mutation. In other embodiments, the mutant PAH protein contains at least one V388M mutation. In other embodiments, the mutant PAH protein contains at least one F39L mutation. In still further embodiments, the mutant PAH protein contains at least one A300S mutation. In yet further embodiments, the mutant PAH protein contains at least one L48S mutation.

In other embodiments, the disclosure provides methods for stabilizing the activity of mutant phenylalanine hydroxylase (PAH) proteins as compared to wild type PAH. Such methods include contacting phenylalanine hydroxylase with one or more compounds described herein, or a pharmaceutically acceptable salt thereof. The term “stabilizing” as used herein refers to modulating the activity or quantity of a PAH enzyme so that it catalyzes hydroxylation of the aromatic side-chain of phenylalanine at a rate that is more similar to the PAH catalysis rate of a control population having wild type PAH, i.e., without a mutant PAH gene mutation, as compared to the baseline PAH catalysis rate. In some aspects, the term “stabilizing” refers to modulating the activity of a subject’s PAH so that it catalyzes hydroxylation of the aromatic side-chain of phenylalanine at a flux more similar to the PAH catalytic flux of a control subject population without a mutant PAH gene mutation. In some embodiments, “stabilizing” activity of PAH includes increasing levels of the enzyme PAH as compared to baseline. By increasing the buildup of stabilized active PAH protein, a subject’s toxic Phe levels can be reduced as compared to the subject’s baseline levels of dietary Phe prior to administration of a compound of the disclosure or a pharmaceutical composition comprising compounds of the disclosure.

In some embodiments, the disclosure provides methods for reducing blood phenylalanine concentrations in a subject suffering from phenylketonuria to a concentration less than or equal to about 600 µM. In other embodiments, the blood Phe concentration is reduced to a concentration less than or equal to about 360 µM. In other embodiments, the disclosure provides methods for reducing blood Phe concentrations as compared to untreated baseline. In some embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by a percentage including but not limited at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In other embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by at least about 10%. In further embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by at least about 20%. In yet other embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by at least about 30%. In still further embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by at least about 40%. In other embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by at least about 50%. In further embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by at least about 60%. In yet other embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by at least about 70%. In still further embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by at least about 80%. In other embodiments, a subject’s blood Phe concentration as compared to untreated baseline is reduced by at least about 90%. A subject’s Phe concentration can be determined by blood tests and methods for measuring such levels are known in the art. In some embodiments, the reduction in Phe concentration achieved using compounds of the disclosure is obtained in conjunction with the subject actively managing their dietary Phe intake. In other embodiments, the reduction in Phe concentration is obtained in conjunction with the subject maintaining a Phe-restricted diet.

In some embodiments, a subject is treated with compounds of the disclosure, or a pharmaceutical composition comprising compounds of the disclosure. The compound is administered in an amount sufficient for stabilizing the PAH protein, or for reducing blood phenylalanine concentration in a subject, or combinations thereof in the subject.

In further embodiments, the subject is a human patient, such as a human adult over 18 years old in need of treatment. In yet further embodiments, the human patient is a human child less than 18 years old. In still further embodiments, the human patient is a human child between 12 years and 18 years old. In yet other embodiments, the human patient is a human child less than 12 years old. In any of the embodiments, the subject has phenylketonuria (PKU), optionally classic PKU or severe PKU. In some embodiments, the subject has a blood Phe concentration greater than about 600 µM prior to administration of a compound of the disclosure or a pharmaceutical composition comprising compounds of the disclosure. In other embodiments, the subject’s blood Phe concentration prior to administration is greater than about 700 µM. In further embodiments, the subject’s blood Phe concentration prior to administration is greater than about 800 µM. In still further embodiments, the subject’s blood Phe concentration prior to administration is greater than about 900 µM. In yet other embodiments, the subject’s blood Phe concentration prior to administration is greater than about 1000 µM. In further embodiments, the subject’s blood Phe concentration prior to administration is greater than about 1100 µM. In other embodiments, the subject’s blood Phe concentration prior to administration is greater than about 1200 µM.

The present methods also encompass administering an additional therapeutic agent to the subject in addition to the compounds of the disclosure. In some embodiments, the additional therapeutic agent is selected from drugs known as useful in a stabilizing mutant PAH protein and/or reducing blood Phe concentrations. The additional therapeutic agent is different from the compounds of the disclosure. In some embodiments, the additional therapeutic agent is sapropterin or sepiapterin In other embodiments, the additional therapeutic agent is a nutritional supplement. Nutritional supplements that may be used include those that contain amino acids and other nutrients. In further embodiments, the nutritional supplement contains large neutral amino acids such as leucine, tyrosine, tryptophan, methionine, histidine, isoleucine, valine, threonine. In other embodiments, the nutritional supplement contains tyrosine. In further embodiments, the nutritional supplement contains casein glycomacropeptide, i.e., a milk peptide naturally free of Phe in its pure form. In other embodiments, the additional therapeutic agent is an enzyme substrate or enzyme co-factor. In yet other embodiments, the enzyme substrate or co-factor is tetrahydrobiopterin. In other embodiments, the additional therapeutic agent is a biopterin analogue. In further embodiments, the additional therapeutic agent is a biotherapeutic, synthetic biotic, microbiota or probiotic. In yet other embodiments, the biotherapeutic, synthetic biotic, microbiota or probiotic contains a genetically modified phenylalanine ammonia lyase (PAL) gene, such as, for example, E. coli Nissle PAL. Examples of genetically modified E. coli Nissle PAL biotherapeutics include SYNB1934 and SYNB1618, and the like. In still further embodiments, the additional therapeutic agent is an inhibitor of an amino acid transporter. In some embodiments, the amino acid transporter is B⁰AT1 (also referred to as SLC6A19), and the additional therapeutic agent is a SLC6A19 inhibitor. Examples of SLC6A19 inhibitors include nimesulide, benztropine, NSC63912, NSC22789, cinromide, CB3, E62, JNT-517, and the like.

Compounds of the disclosure and the additional therapeutic agents can be administered simultaneously or sequentially to achieve the desired effect. In addition, the compounds of the disclosure and additional therapeutic agent can be administered in a single composition or two separate compositions.

The additional therapeutic agent is administered in an amount to provide its desired therapeutic effect. The effective dosage range for each additional therapeutic agent is known in the art, and the additional therapeutic agent is administered to an individual in need thereof within such established ranges.

Compounds of the disclosure and the additional therapeutic agents can be administered together as a single-unit dose or separately as multi-unit doses, wherein the compounds of the disclosure are administered before the additional therapeutic agent or vice versa. One or more doses of the compounds of the disclosure and/or one or more dose of the additional therapeutic agents can be administered.

The compounds of the disclosure may also be administered sequentially or concurrently with non-pharmacological techniques. In some embodiments, the patient uses non-pharmacological techniques to maintain lower Phe levels. In other embodiments, the non-pharmacological technique is administering a diet that is low in Phe. One skilled in the art would be able to determine what type of diet to maintain appropriate levels of Phe. In some embodiments, a phenylamine diet containing about 200 to about 500 mg/day (patients 10 years or younger) of Phe or less than about 600 mg/day (patients over 10 years of age). In other embodiments, the diet may include restricting or eliminating one or more foods that are high in Phe, such as soybeans, egg whites, shrimp, chicken breast, spirulina, watercress, fish, nuts, crayfish, lobster, tuna, turkey, legumes, and low-fat cottage cheese.

An example of a dose is in the range of from about 0.001 to about 100 mg of compound per kg of subject’s body weight per day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, a suitable dosage amount is from about 0.05 to about 7 g/day.

In some embodiments, the therapeutically effective amount of one or more compounds described herein is an amount that is effective in stabilizing a mutant PAH protein described herein. In other embodiments, the therapeutically effective amount of one or more compounds described herein is an amount that is effective in reducing blood phenylalanine concentrations.

Unless otherwise noted, the amounts of the compounds described herein are set forth on a free base basis. That is, the amounts indicate that amount of the compound administered, exclusive of, for example, solvent or counterions (such as in pharmaceutically acceptable salts).

Pharmaceutical Compositions

The disclosure also provides pharmaceutical compositions comprising compounds of the disclosure and a pharmaceutically acceptable carrier or excipient.

The methods of the present disclosure can be accomplished by administering compounds of the disclosure as the neat compound or as a pharmaceutical composition. Administration of a pharmaceutical composition, or neat compound of the disclosure, can be performed at any time period as determined by the attending physician. Typically, the pharmaceutical compositions contain no toxic, carcinogenic, or mutagenic compounds that would cause an adverse reaction when administered.

Pharmaceutical compositions include those wherein compounds of the disclosure are administered in an effective amount to achieve its intended purpose. The exact formulation, route of administration, and dosage is determined by an individual physician.

Compounds of the disclosure can be administered by any suitable route, e.g., by oral, buccal, inhalation, sublingual, rectal, vaginal, intracisternal or intrathecal through lumbar puncture, transurethral, nasal, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and/or surgical implantation at a particular site) administration. Parenteral administration can be accomplished using a needle and syringe or using a high-pressure technique.

The above-mentioned additional therapeutically active agents, one or more of which can be used in combination with compounds of the disclosure, are prepared and administered as described in the art.

Compounds of the disclosure may be administered in admixture with pharmaceutical carriers selected with regard to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions for use in accordance with the present disclosure are formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of compounds of the disclosure.

Administration of the compounds or pharmaceutical compositions of the disclosure can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g., transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally.

The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. The desired dose can be administered in a single dose, or as multiple doses administered at appropriate intervals, e.g., as one, two, three, four or more subdoses per day. In some embodiments, the compounds disclosed herein are effective over a wide dosage range. For example, in the treatment of adult humans, dosage forms containing from about 0.01 to 2000 mg of a compound disclosed herein per day are examples of dosage forms that may be used. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g., by dividing such larger doses into several small doses for administration throughout the day.

In some embodiments, a compound of the disclosure is administered in a single dose.

Typically, such administration will be by a solid oral dosage form such as tablet or capsule. However, other routes may be used as appropriate. A single dose of a compound may also be used for treatment of an acute condition.

In some embodiments, a compound of the disclosure may be administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. In another embodiment, a compound described herein and another therapeutic agent are administered together about once per day to about 6 times per day. Administration of the compounds disclosed herein may continue as long as necessary. In some embodiments, a compound is administered chronically on an ongoing basis. e.g., for the treatment of chronic effects.

An effective amount of a compound of the disclosure may be administered in either single or multiple doses by any of the accepted modes of administration of therapeutic agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include one or more conventional pharmaceutical carriers or excipients and a compound disclosed herein as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

Exemplary parenteral administration forms include solutions or suspensions of the compound of the disclosure in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

Pharmaceutical Compositions for Oral Administration

In some embodiments, the disclosure provides a pharmaceutical composition for oral administration containing a compound of the disclosure and pharmaceutical excipients suitable for oral administration.

In some embodiments, the disclosure provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the disclosure: optionally (ii) an effective amount of a second therapeutic agent: and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further contains: (iv) an effective amount of a third therapeutic agent.

In some embodiments, the pharmaceutical composition may be a pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions containing a compound of the disclosure suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the compound of the disclosure into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the compound of the disclosure with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

This disclosure further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms containing a compound of the disclosure can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms containing a compound of the disclosure which contain lactose can be made anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.

The compound of the disclosure can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.

Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, com starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, colloidal silicon dioxide, microcrystalline cellulose, and mixtures thereof.

Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.

Disintegrants may be used in the compositions of the disclosure to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.

Lubricants which can be used to form pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, calcium stearate, magnesium stearate, sodium stearyl fumarate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 2 weight percent of the pharmaceutical composition.

When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.

The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

Surfactants which can be used to form pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.

A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (“HLB” value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.

Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical, and cosmetic emulsions.

Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides: lecithins and hydrogenated lecithins: lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyl lactylates: mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides: and mixtures thereof.

Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, Iysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholylsarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof.

Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides: alkylthioglucosides; lauryl macrogolglycerides: polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters: polyethylene glycol glycerol fatty acid esters: polyglycerol fatty acid esters: polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof: polyoxyethylated vitamins and derivatives thereof: polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.

Other hydrophilic-non-ionic surfactants include, without limitation, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate. PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate. PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-1000 succinate, PEG-24 cholesterol, polyglyceryl-10-oleate, Tween 40, Tween 60, sucrose monostearate, sucrose mono laurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers.

Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters: acetylated glycerol fatty acid esters: lower alcohol fatty acids esters: propylene glycol fatty acid esters: sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives: polyethylene glycol alkyl ethers; sugar esters: sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins/vitamin derivatives: and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.

In one embodiment, the composition may include a solubilizer to ensure good solubilization and/or dissolution of the compound of the disclosure and to minimize precipitation of the compound of the disclosure. This can be important for compositions for non-oral use, e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and/or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.

Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol (PEG), polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives: ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000. such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; polyethylene glycol 660 12-hydroxystearate; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, e-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, e-caprolactone and isomers thereof, δ-valerolactone and isomers thereof, β-butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water.

Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG having an average molecular weight of about 100 to about 8000 g/mole, glycofurol and propylene glycol.

The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a subject using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of less than about 10%, less than about 25%, less than about 50%, about 100%, or up to less than about 200% by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as less than about 5%, less than about 2%, less than about 1% or even less. Typically, the solubilizer may be present in an amount of less than about 1% to about 100%, more typically less than about 5% to less than about 25% by weight.

The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

Pharmaceutical Compositions for Injection

In some embodiments, the disclosure provides a pharmaceutical composition for injection containing a compound described herein and pharmaceutical excipients suitable for injection. Components and amounts of agents in the compositions are as described herein.

The forms in which the compositions of the disclosure may be incorporated for administration by injection include aqueous or oil suspensions or emulsions. Such compositions may comprise sesame oil, com oil, cottonseed oil, peanut oil, elixirs containing mannitol or dextrose, sterile water, and similar pharmaceutical vehicles.

Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

Sterile injectable solutions are prepared by incorporating the compound of the disclosure in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Other Pharmaceutical Compositions

Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for topical, sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data. Tenth Edition, McGraw-Hill, 2002: Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990: Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 2004: Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition. McGraw Hill, 2001: Remington’s Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety.

Synthesis of Compounds of the Disclosure

Compounds of the disclosure can be prepared by methods described in the General Schemes, procedures, and Examples set forth within, and by related methods known in the art. For example. Compounds of Formula I can be prepared by the general methods shown in General Schemes 1-11.

General Scheme 1: Preparation of Compounds of Formula I

Compounds of Formula I were obtained through the reactions depicted in General Scheme 1. An amine of formulas 1.1 or 1.2 and an aldehyde of formula 1.3 were first reacted under Pictet-Spengler reaction conditions to afford the core amine of formula 1.4. To the extent that an imine by-product is formed during the Pictet-Spengler reaction, the imine by-product can be converted to the core amine of formula 1.4 by reaction with sodium borohydride in an alcoholic solvent (for example, methanol or ethanol). Various L and R² groups were then installed by using either a nucleophilic substitution reaction (Method A1), a Buchwald or other similar cross-coupling reaction (Method A2), a reductive animation reaction (Method B), or amide coupling reactions (Methods C, D, E, and F). Under Method A1, a R² aryl or heteroaryl halide of formula 1.5 (wherein X is Br, Cl, or F) is coupled to the core amine of formula 1.4 using a nucleophilic substitution reaction under basic conditions, such as DIPEA, to afford compounds of formula 1.6. Under Method A2, a R² aryl or heteroaryl halide of formula 1.5 (wherein X is Br, Cl, or I) is coupled to the core amine of formula 1.4 using Buchwald coupling or cross-coupling conditions known in the art, such as using a palladium catalyst (for example, CPhos-Pd-G3, Pd(OAc)₂, Pd(dppf)Cl₂), and a base such as Cs₂CO₃ to afford compounds of formula 1.6. Under Method B. a R² aryl or heteroaryl aldehyde of formula 1.7 is coupled to the core amine of formula 1.4 under reductive animation reaction conditions using a hydride such as sodium triacetoxyborohydride to afford compounds of formula 1.8. Under Method C, a R² carboxylic acid of formula 1.9 or a basic salt (i.e., Li, K, or Na) thereof is coupled to core amine of formula 1.4 using acid coupling conditions known in the art, such as using one of the following reagents-HOBt, EDCI, HATU, T3P-along with a base, such as DIPEA (Hunig’s base), pyridine, or TEA, to afford compounds of formula 1.11, wherein L² is a bond, optionally substituted C_1-6alkylene, optionally substituted C_2-6alkenylene, or optionally substituted C_1-6haloalkylene. Alternatively, under Method D, a R² acid chloride of formula 1.10 is coupled to the core amine of formula 1.4 under basic conditions to afford compounds of formula 1.11, wherein L² is a bond, optionally C_1-6alkylene, optionally substituted C_2-6alkenylene, or optionally substituted C_1-6haloalkylene. Under Method E, a R² acid chloride of formula 1.12 is coupled to the core amine of formula 1.4 under basic conditions to afford compounds of formula 1.14, wherein L³ is a bond or optionally substituted C_1-6alkylene. Under Method F, an R² amine of formula 1.13 is coupled to the core amine of formula 1.4 and carbonyldiimidazole under basic conditions to afford compounds of formula 1.14, wherein L³ is a bond or optionally substituted C_1-6alkylene.

General Scheme 2: Preparation of Deuterated Core Amine Intermediates of Formula 2.2

Compounds of Formula I wherein R⁵ is D are prepared in accordance with General Scheme 2. An amine of formula 1.1 or 1.2 and an aldehyde of formula 1.3 are reacted under Pictet-Spengler reaction conditions to afford compounds of formula 2.1 or mixtures of compounds of formula 2.1 and the imine by-product of formula 2.1a. Compounds of formula 2.1 or mixtures of compounds of formulas 2.1 and 2.1a are then reacted with sodium borodeuteride in deuterated methanol to afford deuterated core amine of formula 2.2. Deuterated core amine intermediates of formula 2.2 can then be further coupled to various L and R² groups via methods A. B. C, D. E, and F as described in General Scheme 1 to afford Compounds of Formula I, wherein R⁵ is D.

General Scheme 3: Preparation of Oxazolyl R² Acid Intermediates

Oxazolyl R² carboxylic acid intermediates containing substitutions at the R⁶ and/or R⁷ positions were prepared in accordance with General Scheme 3. A carboxylic acid of formula 3.1 was reacted with oxalyl chloride and catalytic N,N-dimethylformamide to afford acid chloride of formula 3.2. Acid chloride of formula 3.2 was then reacted with an enamine of formula 3.3 to afford an enamide of formula 3.4. An enamide of formula 3.4 then underwent hypervalent iodine-mediated cyclization after reaction with [bis(trifluoroacetoxy)iodo]benzene and boron trifluoride diethyl etherate to afford oxazole of formula 3.5. Hydrolysis of the ester of the oxazole formula 3.5 with a base such as LiOH, KOH, or NaOH in THF/water afforded compounds of formula 3.6. Altematively, the basic salt (i.e., Li. K, or Na) of the carboxylic acid of formula 3.6 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

General Scheme 4: Preparation of Oxazolyl R² Acid Intermediates

Oxazolyl R² carboxylic acid intermediates containing substitutions at the R⁶ and/or R⁷ positions were prepared in accordance with General Scheme 4. A β-keto ester of formula 4.1 was halogenated with a chlorinating agent such as SOCl₂ or brominating agent such as NBS to yield compounds of formula 4.2 (wherein X¹ is Br or Cl). Compounds of formula 4.2 were reacted with urea to afford amine oxazole compounds of formula 4.3. In addition, compounds of formula 4.2 were reacted with amides of formula 4.5 to afford oxazole compounds of formula 4.6. The amine in compounds of formula 4.3 was subjected to Sandmeyer reaction conditions to afford compounds of formula 4.4 (wherein X is Cl, Br, or F) and compounds of formula 4.10. Altematively, compounds of formula 4.10 may be obtained by deprotonating a compound of formula 4.8 with a base such as LiHMDS followed by reaction in a nucleophilic substitution reaction with reagents of formula 4.9 (wherein Y is a suitable leaving group such as Br, Cl, mesylate, or tosylate) to afford compounds of formula 4.10. Hydrolysis of the ester of compounds of formulas 4.6 and 4.10 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formulas 4.7 and 4.11. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formulas 4.7 and 4.11 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

General Scheme 5: Synthesis of Thiazolyl and Oxazolyl R² Acid Intermediates

Oxazolyl and thiazolyl R² carboxylic acid intermediates containing substitutions at the R⁶ and/or R⁷ positions were prepared in accordance with General Scheme 5. Under Method A. a halide of formula 5.1 was reacted with a heteroaryl or aryl of formula 5.2 in either a Suzuki coupling (where Y is a boronic acid or ester) or a Stille coupling (where Y is SnR₃) to afford compounds of formula 5.3. Under Method B, compounds of formula 5.3 were obtained by reaction of a compound of formula 5.4 with a heteroaryl or aryl halide compound of formula 5.5 in a cross-coupling reaction using a metal catalyst such as a Buchwald catalyst or Ullman catalyst. Under Method C, a halide of formula 5.1 may also be reacted with an amine of formula 5.7 or a heterocyclic amine such as piperidine, morpholine, piperazine, azetidine, and pyrrolidine, and a base such as TEA in a displacement reaction to afford compounds of formula 5.8. Hydrolysis of the ester of compounds of formulas 5.3 and 5.8 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formulas 5.6 and 5.9. Altematively, the basic salt (i.e., Li, K. or Na) of the carboxylic acid of formulas 5.6 and 5.9 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

General Scheme 6: Synthesis of Thiazolyl and Oxazolyl R² Acid Intermediates

Oxazolyl and thiazolyl R² carboxylic acid intermediates containing hydroxyalkyl and haloalkyl substitutions were prepared in accordance with General Scheme 6. Under Method A, a halide of formula 6.1 was reacted with tributyl(1-ethoxyvinyl)stannane in a Stille coupling, followed by hydrolysis with acid/water such as TFA to afford compounds of formula 6.3. An alkyl group (“R”) is then added to the ketone in compounds of formula 6.3 using RMgBr or RLi or through reduction of the ketone with NaBR to afford compounds of formula 6.4. Under Method B, compounds of formula 6.4 may also be obtained starting with a compound of formula 6.1 through a Grignard addition reaction with a ketone of formula 6.2 (wherein R is an alkyl) or cyclobutanone and RMgCl such as iPrMgCl. The hydroxyl substituent in compounds of formula 6.4 was converted to a fluorine substituent using a fluorinating agent such as BAST to afford compounds of formula 6.6. Hydrolysis of the ester of compounds of formulas 6.4 and 6.6 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formulas 6.5 and 6.7. Alternatively, the basic salt (i.e., Li. K, or Na) of the carboxylic acid of formulas 6.5 and 6.7 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

General Scheme 7: Synthesis of Pyrazolo[1,5-a]pyridinyl R² Acid Intermediates

Substituted pyrazolo[1.5-a]pyridinyl R² carboxylic acid intermediates were prepared in accordance with General Scheme 7. Under Method A, a halide of formula 7.1 (wherein X¹ is Br or Cl) was reacted in a C-N cross-coupling reaction using a metal catalyst such as a Buchwald catalyst or Ullman catalyst with an amine of formula 7.2 or a heterocyclic amine such as piperidine, morpholine, piperazine, azetidine, and pyrrolidine to afford compounds of formula 7.3. Under Method B, a halide of formula 7.1 (wherein X¹ is Br or Cl) may also be reacted with a heteroaryl or aryl compound of formula 7.5 in either a Suzuki coupling (where Y is a boronic acid or ester) or a Stille coupling (where Y is SnR₃) to afford compounds of formula 7.6. Under Method C, a halide of formula 7.1 (wherein X¹ is Br or Cl) was reacted with 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane in a Suzuki coupling to afford compounds of formula 7.8. The olefin in compounds of formula 7.8 then underwent oxidative cleavage to an aldehyde to afford compounds of formula 7.9. Under Method D. the aldehyde in compounds of formula 7.9 was reduced to an alcohol with a hydride such as NaBH₄ in an alcoholic solvent such as methanol or ethanol to afford formula 7.13. The alcohol in compounds of formula 7.13 was alkylated with sodium hydride and an alkyl (“R”) halide of formula 7.14 (wherein X is Cl, Br, or F) to afford compounds of formula 7.15. Under Method E, a compound of formula 7.9 was reacted with an amine of formula 7.10 under reductive animation conditions to afford compounds of formula 7.11. Hydrolysis of the ester of compounds of formulas 7.3, 7.6. 7.11, and 7.15 with a base such as LiOH. KOH, or NaOH in THF/water affords compounds of formulas 7.4, 7.7, 7.12, and 7.16. Altematively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formulas 7.4, 7.7, 7.12, and 7.16 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

General Scheme 8: Synthesis of Pyrazolo[1,5-a]pyridinyls R² Acid Intermediates

Di-substituted pyrazolo[1,5-a]pyridinyl R² carboxylic acid intermediates were prepared in accordance with General Scheme 8. Starting reagent 3-bromo-4-chloropyridine was reacted with ethyl (E)-N-((mesitylsulfonyl)oxy)acetimidate to afford the N-aminopyridinium salt 8.1. A cycloaddition reaction of the N-aminopyridinium salt 8.1 with ethyl propiolate and base such as K₂CO₃ afforded ethyl 6-bromo-5-chloropyrazolo[1,5-a]pyridine-3-carboxylate 8.2. Compound 8.2 was reacted in a C-N cross-coupling reaction using a metal catalyst such as a Buchwald catalyst or Ullman catalyst with an amine of formula 8.4 or a heterocyclic amine such as piperidine, morpholine, piperazine, azetidine, and pyrrolidine to afford compounds of formula 8.5. Hydrolysis of the ester of compounds of formulas 8.2 and 8.5 with a base such as LiOH, KOH. or NaOH in THF/water affords compounds of formulas 8.3 and 8.6. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formulas 8.3 and 8.6 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

General Scheme 9: Synthesis of 1,3,4-Oxadiazolyl R² Acid Intermediates

Heteroaryl and aryl-substituted oxadiazolyl R² carboxylic acid intermediates were prepared in accordance with General Scheme 9. Under Method A, heteroaryl and aryl esters of formula 9.1 were reacted with hydrazine hydrate to afford hydrazines of formula 9.2. Compounds of formula 9.2 were then reacted with ethyl-2-chloro-2-oxoacetate to afford compounds of formula 9.3, which subsequently underwent intramolecular cyclization with p-toluenesulfonyl chloride and a base such as TEA to afford the 1,3,4-oxadiazole of formula 9.4. Alternatively, compounds of formula 9.4 can be made using Method B. Under Method B, ethyl 2-hydrazineyl-2-oxoacetate was reacted with 1,1′-thiocarbonyldiimidazole to form the 1,3,4-oxadiazole, which was then alkylated with methyl iodide and base such as TEA to afford ethyl 5-(methylthio)-1.3,4-oxadiazole-2-carboxylate. Ethyl 5-(methylthio)-1,3,4-oxadiazole-2-carboxylate was reacted with a heteroaryl or aryl boronic acid or ester of formula 9.5 in a desulfitative C-C cross coupling reaction (also known as Liebeskind-Srogl cross-coupling) to afford compounds of formula 9.4. Hydrolysis of the ester of compounds of formula 9.4 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formula 9.6. Altematively, the basic salt (i.e., Li, K. or Na) of the carboxylic acid of formula 9.6 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

General Scheme 10: Synthesis of 1,3,4-Oxadiazolyl R² Acid Intermediates

Substituted 1,3,4-oxadiazolyl R² carboxylic acid intermediates were prepared in accordance with General Scheme 10. Starting reagent ethyl 5-amino-1.3,4-oxadiazole-2-carboxylate was subjected to Sandmeyer reaction conditions to afford ethyl 5-bromo-1,3.4-oxadiazole-2-carboxylate (Compound 10.1). The bromo in compound 10.1 was reacted with an amine of formula 10.2 or a heterocyclic amine such as piperidine, morpholine, piperazine, azetidine, and pyrrolidine, and a base such as TEA to afford compounds of formula 10.3. Hydrolysis of the ester of compounds of formula 10.3 with a base such as LiOH, KOH, or NaOH in THF/water afforded compounds of formula 10.4. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formula 10.4 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

General Scheme 11: Preparation of Deuterated Core Amine Intermediates of Formulas 11.6 and 11.7

Compounds of Formula I wherein R^5A is D are prepared in accordance with General Scheme 11. An amine of formula 2.1, prepared according to General Scheme 2, is protected with a BOC protecting group or other suitable nitrogen protecting group to afford compounds of formula 11.1. The amine in formula 11.1 is then protected with a dimethylsulfamoyl protecting group to afford a mixture of compounds of formula 11.2 and 11.3, which are separated during purification. Deuterium is then incorporated at the R^5A position by deprotonating compounds of formula 11.2 with butyllithium and then adding D₂O to afford compounds of formulas 11.4 and 11.5. Deprotection of the nitrogen protecting groups with acid afforded deuterated core amine intermediates of formulas 11.6. Deuterated core amine intermediates of formulas 11.6 can be further coupled to various L and R² groups via methods A, B, C. D, E, and F as described in General Scheme 1 to afford Compounds of Formula I, wherein R^5A is D.

The present disclosure will be more fully understood by reference to the following examples. The examples provided herein are illustrative and should not, however, be construed as limiting the scope of the present disclosure.

EXAMPLES

In some embodiments, the disclosure provides specific examples of Formula I, and their pharmaceutically acceptable salts and/or isotopologues, as set forth in Table 1 below.

Pyrazolo[1,5-a]pyridines
Ex. #	Structure	Name
600		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
601		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
602		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(thiazol-5-yl)methanone
603		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(thiazol-5-yl)methanone
604		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
605		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
606		(S)-(4-methyloxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
607		(R)-(4-methyloxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
608		(S)-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-2-(4-(trifluoromethyl)thiazol-2-yl)ethanone
609		(R)-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-2-(4-(trifluoromethyl)thiazol-2-yl)ethanone
610		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(trifluoromethyl)oxazol-5-yl)methanone
611		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(trifluoromethyl)oxazol-5-yl)methanone
612		(S)-(2-(1,1-difluoroethyl)thiazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
613		(R)-(2-(1,1-difluoroethyl)thiazol-5-yl)(4-(pyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
614		(S)-2-cyclopropyl-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone
615		(R)-2-cyclopropyl-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone
616		(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)methanone
617		(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
618		(S)-(4-cyclopropyloxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
619		(R)-(4-cyclopropyloxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
620		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
621		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
622		(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-y)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
623		(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
624		(S)-(4-cyclopropyl-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
625		(R)-(4-cyclopropyl-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
626		(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
627		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
628		(S)-(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)methanone
629		(R)-(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
630		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
631		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
632		(S)-(2-cyclopropyl-4-(difluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
633		(R)-(2-cyclopropyl-4-(difluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
634		(S)-2-(1-hydroxycyclobutyl)-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone
635		(R)-2-(1-hydroxycyclobutyl)-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone
636		(S)-2-(3-fluorocyclobutyl)-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)ethenone
637		(R)-2-(3-fluorocyclobutyl)-1-(4-(pyrazolo[1,5-a|pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone
638		(S)-2,2-difluoro-2-(1-hydroxycyclobutyl)-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone
639		(R)-2,2-difluoro-2-(1-hydroxycyclobutyl)-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone
640		(S)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile
641		(R)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile
642		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)methanone
643		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)methanone
644		(S)-(4-(difluoromethyl)-2-(pyridin-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
645		(R)-(4-(difluoromethyl)-2-(pyridin-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
646		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
647		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
648		(S)-(5-(3,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
649		(R)-(5-(3,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
650		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
651		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
652		(S)-(5-(2,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
653		(R)-(5-(2,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
654		(S)-(5-(4-fluoro-2-methylphenyl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
655		(R)-(5-(4-fluoro-2-methylphenyl)-1,3,4-oxadiazol-2-y)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
656		(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
657		(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
658		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
659		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
660		(S)-(1-methyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo(4,5-c]pyridin-5(4H)-yl)methanone
661		(R)-(1-methyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
662		(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
663		(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
664		(R)-(3-chloro-1-methyl-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
665		(S)-(3-chloro-1-methyl-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
666		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
667		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)methanone
668		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(4-(trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
669		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(4-(trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
670		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
671		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
672		(R)-(5-(5-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
673		(S)-(5-(5-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
674		(S)-(3-chloro-1-(pyridin-2-yl)-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
675		(R)-(3-chloro-1-(pyridin-2-yl)-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
676		(S)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
677		(R)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
678		(S)-(5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
679		(R)-(5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
680		(S)-(3-chloro-1-methyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
681		(R)-(3-chloro-1-methyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
682		(S)-5-(4-(6-bromopyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile
683		(R)-5-(4-(6-bromopyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile
684		(S)-5-(4-(6-chloropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile
685		(R)-5-(4-(6-chloropyrazolo[1,5-a]pyridin-2-yl)-4,5.6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile
686		(S)-5-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile
687		(R)-5-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile
688		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
689		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
690		(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)((S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
691		(4-(difluoromethy)-2-((R)-1-hydroxyethyl)oxazol-5-yl)((R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
692		(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5-yl)((S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
693		(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5-yl)((R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
694		(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
695		(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
696		(S)-(4-(6-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
697		(R)-(4-(6-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
698		(R)-2-(4-(difluoromethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4.5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazol-2-yl)-2-methylpropanenitrile
699		(S)-2-(4-(difluoromethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazol-2-yl)-2-methylpropanenitrile
700		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)methanone
701		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)methanone
702		((S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)methanone
703		((R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)methanone
704		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)methanone
705		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)methanone
706		((S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((R)-1-hydroxyethyl)-4-methyloxazol-5-yl)methanone
707		((R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((R)-1-hydroxyethyl)-4-methyloxazol-5-yl)methanone
708		((S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)methanone
709		((R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)methanone
710		(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)((s)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
711		(4-(difluoromethy)-2-((R)-1-hydroxyethyl)oxazol-5-yl)(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
712		(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxarol-5-yl)((S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
713		(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5-yi)((R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
714		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
715		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
716		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(trifluoromethyl)-1H-pyrazol-5-yl)methanone
717		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(trifluoromethyl)-1H-pyrazol-5-yl)methanone
718		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazol-2-yl)methanone
719		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
720		(S)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
721		(R)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
722		(S)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
723		(R)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
724		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone
725		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone
726		((S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((R)-1-hydroxyethyl)-4-methyloxazol-5-yl)methanone
727		((R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((R)-1-hydroxyethyl)-4-methyloxazol-5-yl)methanone
728		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
729		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3.4-oxadiazol-2-yl)methanone
730		(5)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)ethanone
731		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
732		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3.4-oxadiazol-2-yl)methanone
733		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
734		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
735		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
736		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
737		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
738		(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)((S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
739		(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)((R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
740		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
741		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
742		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
743		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
744		(5)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)methanone
745		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)methanone
746		(S)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
747		(R)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
748		(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
749		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
750		(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)((S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
751		(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)((R)-4-(4-methylpyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
752		(2-((R)-1-hydroxyethyl)-4-methyloxazol-5-yl)((S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
753		(2-((R)-1-hydroxyethyl)-4-methyloxazol-5-yl)((R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
754		(S)-(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
755		(R)-(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-y1)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
756		(S)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
757		(R)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
758		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
759		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
760		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
761		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
762		(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
763		(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
764		(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
765		(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
766		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
767		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
768		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
769		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
770		(S)-(4-methyloxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
771		(R)-(4-methyloxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
772		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(trifluoromethyl)oxazol-5-yl)methanone
773		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(trifluoromethyl)oxazol-5-yl)methanone
774		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-methyloxazol-5-yl)methanone
775		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-methyloxazol-5-yl)methanone
776		(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
777		(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
778		(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
779		(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
780		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)methanone
781		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)methanone
782		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(difluoromethyl)-1H-pyrazol-5-yl)methanone
783		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(1-(difluoromethyl)-1H-pyrazol-5-yl)methanone
784		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(3-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
785		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(3-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
786		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(3-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
787		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(3-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
788		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3.4-oxadiazol-2-yl)methanone
789		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
790		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
791		(5)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
792		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
793		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
794		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
795		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
796		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
797		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
798		(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
799		(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3.4-oxadiazol-2-yl)methanone
800		(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
801		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
802		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
803		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
804		(S)-(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
805		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
806		(S)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
807		(R)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
808		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
809		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
810		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
811		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
812		(S)-(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
813		(R)-(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
814		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
815		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
816		(R)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
817		(S)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
818		(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
819		(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
820		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
821		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
822		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
823		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
824		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
825		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
826		(S)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
827		(R)-(5-(pyridin-2-yl)-1,3.4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
828		(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
829		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
830		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)methanone
831		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)methanone
832		(S)-(5-(1-cyclobutyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
833		(R)-(5-(1-cyclobutyl-1H-pyrazol-4-yl)-1.3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
834		(S)-(5-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
835		(R)-(5-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
836		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
837		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
838		(S)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
839		(R)-(1-methyl-1H-1,2.4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
840		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-1H-1,2,4-triazol-5-yl)methanone
841		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-1H-1,2,4-triazol-5-yl)methanone
842		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(trifluoromethyl)-1H-pyrazol-5-yl)methanone
843		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(trifluoromethyl)-1H-pyrazol-5-yl)methanone
844		(S)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
845		(R)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
846		(S)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
847		(R)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
848		(S)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
849		(R)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
850		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)methanone
851		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)methanone
852		(S)-(5-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
853		(R)-(5-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
854		(S)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
855		(R)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
856		(S)-(1-isopropyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
857		(R)-(1-isopropyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
858		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-isopropyl-1H-pyrazol-5-yl)methanone
859		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-isopropyl-1H-pyrazol-5-yl)methanone
860		(S)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
861		(R)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
862		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin-2-yl)-1H-pyrazol-5-yl)methanone
863		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin-2-yl)-1H-pyrazol-5-yl)methanone
864		(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
865		(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
866		(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
867		(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4-methylpyrazolol[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
868		(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
869		(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
870		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
871		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
872		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-(trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
873		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-(trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
874		(R)-(5-(5-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
875		(S)-(5-(5-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
876		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
877		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
878		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-(trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
879		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-(trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
880		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
881		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
882		(R)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
883		(S)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
884		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-1H-pyrazol-5-yl)methanone
885		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-1H-pyrazol-5-yl)methanone
886		(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
887		(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
888		(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
889		(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
890		(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
891		(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
892		(S)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
893		(R)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
894		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3.4-oxadiazol-2-yl)methanone
895		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
896		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
897		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
898		(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin-2-yl)-1H-pyrazol-5-yl)methanone
899		(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin-2-yl)-1H-pyrazol-5-yl)methanone
900		(S)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
901		(R)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
902		(S)-(4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
903		(R)-(4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
904		(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
905		(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
906		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
907		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
908		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
909		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
910		(S)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
911		(R)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
912		(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
913		(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
914		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
915		(R)-(5-(1-(dilfluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
916		(S)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
917		(R)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
918		(S)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
919		(R)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
920		(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
921		(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
922		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
923		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
924		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
925		(R)-(5-cyclopropyl-1.3,4-oxadiazol-2-yl)(4-(4-methylpyrazolol[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
926		(S)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
927		(R)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
928		(S)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
929		(R)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
930		(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
931		(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
932		(S)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
933		(R)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
934		(S)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
935		(R)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
936		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
937		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
938		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
939		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
940		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
941		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
942		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
943		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
944		(S)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
945		(R)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
946		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
947		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
948		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
949		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
950		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
951		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
952		(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
953		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
954		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
955		(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
956		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
957		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
958		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)oxazol-5-yl)ethanone
959		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)oxazol-5-yl)methanone
960		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)methanone
961		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)methanone
962		(S)-(4-(4-fluoropyrazolol1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
963		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
964		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
965		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
966		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
967		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
968		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
969		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-y1)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
970		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
971		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
972		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)methanone
973		(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
974		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
975		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
976		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
977		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo(4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
978		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
979		(S)-(4-(7-chloropyrazolo[1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
980		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
981		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
982		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
983		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
984		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
985		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
986		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
987		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
988		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)methanone
989		(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
990		(S)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
991		(R)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
992		(S)-2-methyl-2-(4-methyl-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazol-2-yl)propanenitrile
993		(R)-2-methyl-2-(4-methyl-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazol-2-yl)propanenitrile
994		(S)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
995		(R)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
996		(4-bromo-2-(1-hydroxyethyl)oxazol-5-yl)((S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer#1(Rt=5.586 min)
997		(4-bromo-2-(1-hydroxyethyl)oxazol-5-yl)((S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer#2(Rt=5.796 min)
998		(4-bromo-2-(1-hydroxyethyl)oxazol-5-yl)((R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer#1(Rt=4.830 min)
999		(4-bromo-2-(1-hydroxyethyl)oxazol-5-yl)((R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer#2(Rt=5.133 min)
1000		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone
1001		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone
1002		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo(1,5-a)pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1003		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1004		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1005		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1006		(S)-(4-(difluoromethyl)-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1007		(R)-(4-(difluoromethyl)-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1008		(S)-(4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1009		(R)-(4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1010		(S)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)methanone
1011		(R)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1012		(S)-(5-(4-fluoropiperidin-1-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1013		(R)-(5-(4-fluoropiperidin-1-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1014		(S)-(5-(4-fluoropiperidin-1-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1015		(R)-(5-(4-fluoropiperidin-1-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1016		(S)-(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1017		(R)-(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1018		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1019		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1020		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1021		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1022		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolol1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1023		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1024		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1025		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1026		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1027		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1028		(S)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1029		(R)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1030		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1031		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-S(4H)-yl)methanone
1032		(S)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo(4,5-c]pyridin-5(4H)-yl)methanone
1033		(R)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1034		(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1035		(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1036		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1037		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1038		(S)-(5-(1-cyclobutyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1039		(R)-(5-(1-cyclobutyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1040		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1041		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1042		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1043		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-y1)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1044		(S)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1045		(R)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1046		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1047		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1048		(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1049		(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1050		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-ylX1-methyl-1H-1,2,4-triazol-5-yl)methanone
1051		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-1H-1,2,4-triazol-5-yl)methanone
1052		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone
1053		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone
1054		(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1055		(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1056		(S)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1057		(R)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1058		(S)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)methanone
1059		(R)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1060		(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1061		(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1062		(S)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1063		(R)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1064		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(difluoromethyl)-1H-pyrazol-5-yl)methanone
1065		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(1-(difluoromethyl)-1H-pyrazol-5-yl)methanone
1066		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1067		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1068		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1069		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1070		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1071		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1072		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)methanone
1073		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-y1)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3-cyclopropyl-1-methyl-1H-1,2,4-triarol-5-yl)methanone
1074		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-y1)(1,3-dimethyl-1H-1,2,4-triazol-5-yl)methanone
1075		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1.3-dimethyl-1H-1,2.4-triazol-5-yl)methanone
1076		(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1077		(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1078		(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1079		(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1080		(R)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1081		(S)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1082		(S)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1083		(R)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1084		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1085		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1086		(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1087		(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-y1)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1088		(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1089		(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1090		(S)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1091		(R)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1092		(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1093		(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1094		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methanone
1095		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methanone
1096		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1097		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1098		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1099		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1100		(S)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1101		(R)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1102		(S)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1103		(R)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1104		(S)-(4(difluoromethyl)oxaiol-5-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1105		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1106		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone
1107		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone
1108		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1109		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1110		(S)-(5-(tert-butyl)-1.3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1111		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1112		(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1113		(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6-methylpyrazolo[1,5-a)pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1114		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1115		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1116		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1117		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(6-(trifluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1118		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1119		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1120		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1121		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1122		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1123		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1124		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1125		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(6-fluoropyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1126		(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1127		(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1128		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1129		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1130		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1131		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1132		(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1133		(R)-(1-(difluoromethyl)-1H-pyrazol-5-y1)(4-(5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo(4,5-c]pyridin-5(4H)-yl)methanone
1134		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1135		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1136		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methanone
1137		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-y1)(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methanone
1138		(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1139		(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1140		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1141		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo| 1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1142		(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1143		(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1144		(S)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1145		(R)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1146		(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(trifluoromethyl)oxazol-5-yl)methanone
1147		(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(trifluoromethyl)oxazol-5-yl)methanone
1148		(S)-(4-methyloxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1149		(R)-(4-methyloxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1150		(S)-(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1151		(R)-(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)(4-(7-methylpyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1152		(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5-yl)((S)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1153		(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5-yl)((R)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1154		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1155		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1156		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1157		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1158		(S)-oxazol-5-yl(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1159		(R)-oxazol-5-yl(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1160		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1161		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1162		(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1163		(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1164		(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)((S)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1165		(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)((R)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1166		(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
1167		(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
1168		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1169		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1170		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1171		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1172		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(trifluoromethyl)oxazol-5-yl)methanone
1173		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(trifluoromethyl)oxazol-5-yl)methanone
1174		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-methyloxazol-5-yl)methanone
1175		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(4-methyloxazol-5-yl)methanone
1176		(S)-(4-(trifluoromethyl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1177		(R)-(4-(trifluoromethyl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1178		(S)-(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1179		(R)-(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1180		(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)((S)4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1181		(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)((R)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1182		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1183		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1184		(R)-(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
1185		(S)-(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazolo[4.5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
1186		(R)-(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazolo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
1187		(S)-(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5-yl)methanone
1188		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadizol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-y1)methanone
1189		(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1190		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadizol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1191		(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1192		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)methanone
1193		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5-yl)methanone
1194		((R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5-yl)methanone
1195		((S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5-yl)methanone
1196		((S)-4-(7-chloropyrazolo[1,5-]alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)methanone
1197		((R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5-yl)methanone
1198		(S)-(4-(trifluoromethyl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1199		(R)-(4-methyloxalol-5-)-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1200		(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5-yl)((S)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1201		(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5-yl)((R)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1202		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1203		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1204		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1205		(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1206		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1207		(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1208		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1209		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1210		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone
1211		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone
1212		((S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)methanone
1213		((R)-4-(7-chloropyrazolol1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)methanone
1214		(S)-(4-(4-chloropyrazolo[1,5-alpyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1215		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1216		(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1217		(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1218		(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1219		(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1220		(S)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)melhanone
1221		(R)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1222		(S)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1223		(R)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1224		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-cpyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1225		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1226		(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1227		(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1228		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)methanone
1229		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)methanone
1230		(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1231		(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1232		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)methanone
1233		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)methanone
1234		(S)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1235		(R)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1236		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)methanone
1237		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)methanone
1238		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1239		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1240		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1241		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1242		(S)-(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1243		(R)-(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1244		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1245		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1246		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c(pyridin-5(4H)-yl)methanone
1247		(R)-(5-cyclopropyl-1.3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1248		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1249		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1250		(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1251		(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1252		(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1253		(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1254		(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1255		(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1256		(S)-(5-(2-fluoropropan-2-yl)-1,3.4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c(pyridin-5(4H)-yl)methanone
1257		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1258		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-4-y1)-1,3,4-oxadiazol-2-yl)methanone
1259		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1260		(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1261		(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1262		(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1263		(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1264		(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1265		(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1266		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)methanone
1267		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-y1)methanone
1268		(S)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1269		(R)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1270		(S)-pyrazolo[1,5-a]pyridin-3-yl(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1271		(R)-pyrazolo[1,5-a]pyridin-3-yl(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1272		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
1273		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
1274		(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1275		(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1276		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)methanone
1277		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)methanone
1278		(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1279		(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-2yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1280		(S)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-(6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1281		(R)-(4-(difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1282		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone
1283		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone
1284		(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1285		(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1286		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
1287		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
1288		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
1289		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
1290		(R)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1291		(S)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1292		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1293		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1294		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1295		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1296		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone
1297		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone
1298		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1299		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-y1)-1,3,4-oxadiazol-2-y1)methanone
1300		(S)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1301		(R)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1302		(S)-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1303		(R)-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1304		(S)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1305		(R)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1306		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1307		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1308		(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1309		(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1310		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1311		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1312		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1313		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1314		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1315		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3.4-oxadiazol-2-yl)methanone
1316		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1317		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1318		(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)melhanone
1319		(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1320		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone
1321		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone
1322		(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1323		(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1324		(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1325		(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1326		(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1.5-a]pyridin-3-yl)methanone
1327		(R)-(4-(4-methoxypyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
1328		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1329		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-y1)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1330		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1331		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1332		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiarol-2-yl)methanone
1333		(R)-(4-(4-chloropyrazolol 1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1.3,4-oxadiazol-2-yl)methanone
1334		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1335		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1336		(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1337		(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1338		(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1339		(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1340		(S)-(5-(pyridin-3-vi)-1,3.4-oxadiazol-2--%.I)(4-(7-I (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1341		(R)-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1342		(S)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1343		(R)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1344		(S)-(5-(6-methoxypyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1345		(R)-(5-(6-methoxypyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1346		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3.4-oxadiazol-2-yl)methanone
1347		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1348		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1349		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1350		(S)-(4-(4-(difluoromethyl)pyrazolof[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1351		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1352		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1353		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1354		(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1355		(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1356		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3.4-oxadiazol-2-yl)methanone
1357		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)- 1,3.4-oxadiazol-2-yl)methanone
1358		(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1359		(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1360		(R)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1361		(S)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1362		(S)-(5-(pyrazin-2-yl)-1.3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1363		(R)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1364		(S)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-(6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1365		(R)-(5-(2-methylpyridin-3-yl)-1,3.4-oxadiazol -2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1366		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1367		(R)-(4-(7-(difluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1368		(S)-(4-(4-chloropyrazolo[1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)methanone
1369		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo(4,5-c]pyridin-5(4H)-yl)(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)methanone
1370		(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1371		(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-6.7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1372		(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-clpyridin-5(4H)-yl)methanone
1373		(R)-(3-(difluoromethyl)- 1 -methyl-1H-pyrazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-clpyridin-5(4H)-yl)methanone
1374		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1375		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1376		(R)-(5-(l -(difluoromethyl)- I H-pyrazol-3-yi)- 1,3,4-oxadiazol-2-v1)(4-(4-(difluoromethyl)pyrazolof 1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1377		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1378		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone
1379		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone
1380		(R)-(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1381		(S)-(5-(pyrimidin-2-yl)- 1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1382		(S)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1 H-imidazo[4,5-c]pyridin-5(4H)-yl)melhanone
1383		(R)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1384		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)methanone
1385		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)methanone
1386		(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1387		(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7-(triftuoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1388		(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1389		(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1390		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1391		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1392		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1393		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1394		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1395		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1396		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1397		(R)-( 4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1398		(S)-(4-(7-methylpyrazolol 1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1399		(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1400		(S)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1401		(R)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1402		(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1403		(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1404		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1405		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1406		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-vl)-1.3,4-oxadiazol-2-yl)methanone
1407		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1408		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1409		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1410		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1411		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1412		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1413		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1414		(S)-(4-(4-(difluoromethyl)pyrazolof 1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c|pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3.4-oxadiazol-2-yl)methanone
1415		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1416		(S)-(4-(pyrazolol 1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1417		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1418		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1419		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-IH-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1420		(R)-(4-(7-(difluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c|pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1.3,4-oxadiazol-2-yl)methanone
1421		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1422		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1423		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1424		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3.4-oxadiazol-2-yl)methanone
1425		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1426		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1427		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1428		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3.4-oxadiazol-2-yl)methanone
1429		(S)-(4-(4-methylpyrazolo| 1,5-alpyridin-2--%.I)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1430		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1431		(S)-(4-(4-chloropyrazolo| 1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1432		(R)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1433		(S)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1434		(S)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo| 1,5-a]pyridin-3-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1435		(R)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1.5-a]pyridin-3-y1)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1436		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1437		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-l,3,4-oxadiazol-2-yl)methanone
1438		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1439		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1440		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1441		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1442		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1443		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1444		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)–1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1445		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1446		(S)-(4-(7-methylpyrazolol[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c|pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1447		(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1448		(S)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1449		(R)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo(1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1450		(S)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1451		(R)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1452		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4-oxadiazol-2-yl)methanone
1453		(R)-(4-(4-fluoropyrazolo[1,5-a|pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4-oxadiazol-2-yl)methanone
1454		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-cyclopropyl-1,3,4-oxadiazole
1455		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- cyclopropyl-1,3,4-oxadiazole
1456		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1457		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1458		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1459		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1460		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1461		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1462		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1463		(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1464		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1465		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1466		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxide-oxadiazol-2-yl)methanone
1467		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1468		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1469		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1470		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1471		(R)-(4-(4-fluoropyrazol[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1472		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1473		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1474		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiarol-2-yl)methanone
1475		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1476		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrarol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1477		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1478		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1479		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrarol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1480		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1481		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1482		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiarol-2-yl)methanone
1483		(R)-(4-(4-fluoropyrazolo[1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1484		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3.4-oxadiazol-2-yl)methanone
1485		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4-oxadiazol-2-yl)methanone
1486		(S)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1487		(R)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1488		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4-oxadiazol-2-yl)methanone
1489		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4-oxadiazol-2-yl)methanone
1490		(S)-(5-isopropyl-1,3,4-oxadizol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1491		(R)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1492		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4-oxadiazol-2-yl)methanone
1493		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4-oxadiazol-2-yl)methanone
1494		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1495		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1496		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1497		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1498		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1499		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1500		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1501		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1502		(S)-(4-(7-(difluoromethyl)pyrazolof 1,5-a|pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1503		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo-[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1504		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1505		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanonepyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1506		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1507		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1508		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidaro[4,5-c]pyridin-5(4H)-yl)5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1509		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluororomethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1510		(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1511		(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethy1)-1H-pyrazol-3-y1)-1,3,4-oxadiazol-2-yl)methanone
1512		(S)-(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1513		(R)-(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1514		(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1515		(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1516		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-cyclobutyl-1,3,4-oxadiazol-2-yl)methanone
1517		(S)-(4-(4-chloropyrazolo| 1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-cyclobutyl-1,3,4-oxadiazol-2-yl)methanone
1518		(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1519		(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1520		(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1521		(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1522		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1523		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1524		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1525		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1526		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihdro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1527		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1528		(S)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1529		(R)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c|pyridin-5(4H)-yl)methanone
1530		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo(4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1531		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1532		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1533		(R)-(4-(4-(dilfluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1534		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1535		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c|pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3.4-oxadiazol-2-yl)methanone
1536		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-3-yl)1,3,4-oxidiazol-2-yl)methanone
1537		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1538		(S)-(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1539		(R)-(5-(1-trifluoromethyl)-1H-pyrarol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazol[4,5-c]pyridin-5(4H)-yl)methanone
1540		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1541		(R)-(4-(4-fluoropyrazolol l,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trfluoeomethyl)-1H-pyrazol-4-yl)-1,3,4-oxidiazol-2-yl)methanone
1542		(S)-(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1543		(R)-(5-(1-(tritluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1544		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1545		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1 546		(S)-(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1547		(R)-(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1548		(S)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1549		(R)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1550		(S)-(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1551		(R)-(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1552		(S)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1553		(R)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1554		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4-oxadiazol-2-yl)methanone
1555		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4-oxadiazol-2-yl)methanone
1556		(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1557		(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1558		(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c[pyridin-5(4H)-yl)methanone
1559		(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1560		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-cyclobutyl-1,3,4-oxadiazol-2-yl)methanone
1561		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-cyclobutyl-1,3,4-oxadiazol-2-yl)methanone
1562		(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1563		(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1 564		(R)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1565		(S)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)melhanone
1 566		(S)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1567		(R)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
l 568		(S)-(4-(4-(difluoromelhyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1569		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1570		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1571		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1572		(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1573		(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1574		(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1575		(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1576		(R)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)benzo[d]oxazole
1577		(S)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c] pyridin-5(4H)-yl)benzol d |oxazole
1578		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1579		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1580		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1581		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1582		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1583		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1584		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1585		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1586		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3,3-difluorocyclobuyl)-1,3,4-oxadiazol-2-yl)methanone
1587		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)methanone
1588		(R)-2-cyclopropyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1589		(S)-2-cyclopropyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1590		(R)-2-cyclopropyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1591		(S)-2-cyclopropyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3.4-oxadiazole
1592		(S)-4-(pyrazolo[1,5-a|pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1593		(R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1594		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1595		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1596		(S)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1597		(R)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a)pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1598		(S)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1599		(R)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1600		(S)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1601		(R)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1602		(S)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1603		(R)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)methanone
1604		(S)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a)pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1605		(R)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1606		(R)-2-cyclopropyl-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1607		(S)-2-cyclopropyl-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1608		(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1609		(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1610		(S)-2-(pyridin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1611		(R)-2-(pyridin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1612		(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1613		(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1614		(S)-(6-morpholinopyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1615		(R)-(6-morpholinopyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1616		(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1617		(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1618		(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1619		(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1620		(R)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1621		(S)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1622		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1.3,4-oxadiazole
1623		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1624		(S)-(6-(methoxymethyl)pyrazolo[1,5-a|pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1625		(R)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1626		(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1627		(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1628		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1629		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c)pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1630		(S)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1631		(R)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1632		(S)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1633		(R)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1634		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl )(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1635		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1636		(R)-2-(4-(4-methylpyrazolo| 1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1637		(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1638		(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1639		(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1640		(S)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4-oxadiazole
1641		(R)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3.4-oxadiazole
1642		(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)benzo[d]oxazole
1643		(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)benzo[d]oxazole
1644		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1645		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1646		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1647		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1648		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1649		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1650		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a|pyridin-3-yl)methanone
1651		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1652		(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1653		(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1654		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1655		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-(6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1656		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1657		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin-2-yl)- 1,3,4-oxadiazol-2-yl)methanone
1658		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1659		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1660		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1661		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1662		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1663		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1664		(S)4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1665		(R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1666		(S)-(6-methylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo| 1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1667		(R)-(6-methylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1668		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-alpyridin-3-yl)methanone
1669		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
1670		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
1671		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
1672		(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1673		(R)-(6-cyclopropylpyrazolo[1,5-a|pyridin-3-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1674		(S)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1675		(R)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1676		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
1677		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
1678		(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1679		(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1680		(S)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1681		(R)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1682		(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1683		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1684		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo| 1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1685		(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1686		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1687		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1688		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1689		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1690		(S)-(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1691		(R)-(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1692		(S)-5-(pyrimidin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1693		(R)-5-(pyrimidin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5.6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1694		(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1695		(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1696		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
1697		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
1698		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
1699		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
1700		(R)-5-(pyrazin-2-yl)-4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1701		(S)-5-(pyrazin-2-yl)-4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1702		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1703		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1704		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1705		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1706		(S)-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1707		(R)-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1708		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1709		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1710		(R)-2-(difluoromethyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1711		(S)-2-(difluoromethyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1712		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
1713		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
1714		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
1715		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
1716		(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1717		(R)-(6-cyclopropylpyrazolo[1,5-a|pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1718		(S)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1719		(R)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1720		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
1721		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
1722		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1723		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1724		(S)-(5-cyclopropyl-1.3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1725		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1726		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1727		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1728		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1729		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1730		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
1731		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
1732		(R)-2-(difluoromethyl)-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1733		(S)-2-(difluoromethyl)-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1734		(R)-2-(difluoromethyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-,3,4-oxadiazole
1735		(S)-2-(difluoromethyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1736		(R)-2-(difluoromethyl)-5-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1737		(S)-2-(difluoromethyl)-5-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1738		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
1739		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
1740		(R)-2-(difluoromethyl)-5-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1741		(S)-2-(difluoromethyl)-5-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1742		(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1743		(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1744		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)methanone
1745		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)methanone
1746		(S)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolol1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1747		(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1748		(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-y1)(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1749		(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1750		(S)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1751		(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1752		(S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1753		(R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1754		(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1755		(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1756		(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1757		(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1758		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1759		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1760		(S)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1761		(R)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1762		(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1763		(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1764		(R)-5-(pyrimidin-2-yl)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1765		(S)-5-(pyrimidin-2-yl)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1766		(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1767		(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1768		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)methanone
1769		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)methanone
1770		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone
1771		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone
1772		(S)-(6-(dimethylamino)pyrazolo[1,5-alpyridin-3-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1773		(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1774		(S)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1775		(R)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1776		(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1777		(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1778		(S)-4-(4-fluoropyrazolol1,5-alpyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1779		(R)-4-(4-fluoropyrazolol1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1780		(S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1781		(R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1782		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1783		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1784		(S)-(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1785		(R)-(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1786		(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
1787		(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
1788		(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1789		(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1790		(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1791		(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1792		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone
1793		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone
1794		(S)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1795		(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
1796		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1797		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone
1798		(R)-2-(tert-butyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1799		(S)-2-(tert-butyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1800		(S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1801		(R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1802		(S)-4-(7-methylpyrazolol1,5-alpyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1803		(R)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1804		(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1805		(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1806		(R)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1807		(S)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1808		(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1809		(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1810		(S)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1811		(R)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1812		(S)-4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1813		(R)-4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1814		(S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1815		(R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1816		(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1817		(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1818		(R)-5-(pyrazin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1819		(S)-5-(pyrazin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1820		(R)-2-(trifluoromethyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1821		(S)-2-(trifluoromethyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1822		(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazol4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1823		((S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1824		(R)-2-(tert-butyl)-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1825		(S)-2-(tert-butyl)-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1826		(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)pyrimidin-5-amine
1827		(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)pyrimidin-5-amine
1828		(R)-5-(6-chloropyrazin-2-yl)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1829		(S)-5-(6-chloropyrazin-2-yl)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1830		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-cyclobutyl-1,3,4-oxadiazole
1831		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-cyclobutyl-1,3,4-oxadiazole
1832		(R)-2-(tert-butyl)-5-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1833		(S)-2-(tert-butyl)-5-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1834		(R)-2-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5-amine
1835		(S)-2-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5-amine
1836		(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5-amine
1837		(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5-amine
1838		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1839		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1840		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1841		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1842		(R)-2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1843		(S)-2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1844		(R)-2-(2,6-difluorophenyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1845		(S)-2-(2,6-difluorophenyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1846		(R)-2-(2,6-difluorophenyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1847		(S)-2-(2,6-difluorophenyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
1848		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1849		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1850		(S)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1851		(R)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
1852		(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5-amine
1853		(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5-amine
1854		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1855		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1856		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1857		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-intidazo[4,5-c]pyridin-5-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1858		(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone
1859		(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone
1860		(R)-2-(4-fluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
1861		(S)-2-(4-fluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
1862		(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6-difluorophenyl)-1,3,4-oxadiazole
1863		(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6-difluorophenyl)-1,3,4-oxadiazole
1864		(R)-2-(2,6-difluorophenyl)-5-(4-(4-fluoropyrazolo[1,5-alpyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
1865		(S)-2-(2,6-difluorophenyl)-5-(4-(4-fluoropyrazol[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
1866		(S)-(2-(tert-butyl)oxazol-5-yl)(4-(pyrazolo[1,5-alpyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1867		(R)-(2-(tert-butyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1868		(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1869		(R)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1870		(S)-5-(pyridin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1871		(R)-5-(pyridin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1872		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5-amine
1873		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5-amine
1874		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1875		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1876		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1877		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1878		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1879		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1880		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1881		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1882		(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1883		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1884		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1885		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1886		(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1887		(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1888		(R)-(4-(4-bromopyrazolo[1.5-a]pyridin-2-yl)-1.4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1889		(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1890		(R)-2-(4-fluorophenyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
1891		(S)-2-(4-fluorophenyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
1892		(R)-2-(4-fluorophenyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
1893		(S)-2-(4-fluorophenyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
1894		(R)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1895		(S)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1896		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1897		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3.4-oxadiazol-2-yl)methanone
1898		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1899		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1900		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1901		(R)-(4-(4-cyclopropylpyrazolo[1.5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1902		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1903		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1904		(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1905		(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1906		(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
1907		(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1908		(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methanone
1909		(R)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-cyclopropyl-1,3.4-oxadiazol-2-yl)methanone
1910		(R)-(4-(4-bromopyrazolol 1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1911		(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1912		(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1.4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4-fluorophenyl)-1,3,4-oxadiazole
1913		(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidaao[4,5-c]pyridin-5-yl)-5-(4-fluorophenyl)-1,3,4-oxadiazole
1914		(S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1915		(R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1916		(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1917		(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1918		(S)-(2-cyclopropyloxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1919		(R)-(2-cyclopropyloxazol-5-yl)(4-(4-methylpyrazolo[1.5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
1920		(S)-(2-(tert-butyl)oxazol-5-yl)(4-(4-methylpyrazolo[1.5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1921		(R)-(2-(tert-butyl)oxazol-5-yl)(4-(4-methylpyrazolol[1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1922		(S)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1923		(R)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2-fluoropropan-2-yl)-1,3.4-oxadiazol-2-yl)methanone
1924		(S)-(4-(4-ethylpyrarolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3.4-oxadiazol-2-yl)methanone
1925		(R)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1926		(R)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1927		(S)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3.4-oxadiazol-2-yl)methanone
1928		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1929		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3.4-oxadiazol-2-yl)methanone
1930		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1931		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1932		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1933		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1934		(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1935		(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1936		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1.5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1937		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1938		(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadadiazol-2-yl)methanone
1939		(R)-(4-(4-bromopyrazolol[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1940		(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1941		(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1942		(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1943		(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1944		(S)-(4-cyclopropyloxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1945		(R)-(4-cyclopropyloxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1946		(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1947		(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
1948		(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)- 1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
1949		(R)-(S-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1950		(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1951		(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1952		(R)-2-(4-fluorophenyl)-5-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
1953		(S)-2-(4-fluorophenyl)-5-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)-1,3,4-oxadiazole
1954		(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(6-fluoropyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1955		(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(6-fluoropyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1956		(R)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1957		(S)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1958		(R)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1959		(S)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
1960		(S)-(2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1961		(R)-(2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1962		(S)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1963		(R)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
1964		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2-yl)oxazol-5-yl)methanone
1965		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2-yl)oxazol-5-yl)methanone
1966		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl)methanone
1967		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl)methanone
1968		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl)methanone
1969		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1.3,4-thiadiazol-2-yl)methanone
1970		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3.4-thiadiazol-2-yl)methanone
1971		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3.4-thiadiazol-2-yl)methanone
1972		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1973		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1974		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1975		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)methanone
1976		(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1977		(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1978		(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1979		(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
1980		(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone-
1981		(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
1982		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1.3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1983		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
1984		(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1985		(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
1986		(S)-(4-cyclopropyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1987		(R)-(4-cyclopropyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1988		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(oxazol-2-yl)methanone
1989		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(oxazol-2-yl)methanone
1990		(R)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1991		(S)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1992		(R)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1993		(S)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1994		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-yl)methanone
1995		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-yl)methanone
1996		(R)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
1997		(S)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1998		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
1999		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2000		(S)-benzo[d]thiazol-2-yl(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2001		(R)-benzo[d]thiazol-2-yl(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2002		(S)-benzo[d]thiazol-2-yl(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2003		(R)-benzo[d]thiazol-2-yl(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2004		(S)-(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2005		(R)-(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2006		(R)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2007		(S)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2008		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4-fluorophenyl)-1,3,4-oxadiazole
2009		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4-fluorophenyl)-1,3,4-oxadiazole
2010		(S)-2-(4-fluorophenyl)-5-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2011		(R)-2-(4-fluorophenyl)-5-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2012		(R)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2013		(S)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2014		(S)-(4-cyclopropyloxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2015		(R)-(4-cyclopropyloxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2016		(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2017		(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2018		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2-yl)methanone
2019		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2-yl)methanone
2020		(S)-benzo[d]oxazol-2-yl(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2021		(R)-benzo[d]oxazol-2-yl(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2022		(S)-benzo[d]thiazol-2-yl(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2023		(R)-benzo[d]thiazol-2-yl(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2024		(S)-cyclopropyl(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2025		(R)-cyclopropyl(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2026		((R)-2,2-difluorocyclopropyl)((R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2027		((R)-2,2-difluorocyclopropyl)((S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2028		((S)-2,2-difluorocyclopropyl)((S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2029		((S)-2,2-difluorocyclopropyl)((R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2030		((S)-2,2-difluorocyclopropyl)((S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2031		((S)-2,2-difluorocyclopropyl)((R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2032		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2-yl)oxazol-5-yl)methanone
2033		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2-yl)oxazol-5-yl)methanone
2034		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2-yl)oxazol-5-yl)methanone
2035		(R)-(4-(4-(difluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2-yl)oxazol-5-yl)methanone
2036		(S)-(2-(pyridin-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2037		(R)-(2-(pyridin-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2038		(R)-(4-cyclopropyloxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2039		(S)-(4-cyclopropyloxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2040		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)(4-cyclopropyloxazol-5-yl)methanone
2041		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(4-cyclopropyloxazol-5-yl)methanone
2042		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(4-cyclopropyloxazol-5-yl)methanone
2043		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(4-cyclopropyloxazol-5-yl)methanone
2044		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2045		(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2046		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2047		(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2048		(S)-benzo[d]oxazol-2-yl(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2049		(R)-benzo[d]oxazol-2-yl(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2050		(S)-benzo[d]oxazol-2-yl(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2051		(R)-benzo[d]oxazol-2-yl(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2052		(S)-benzo[d]oxazol-2-yl(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2053		(R)-benzo[d]oxazol-2-yl(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2054		(S)-benzo[d]oxazol-2-yl(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2055		(R)-benzo[d]oxazol-2-yl(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2056		(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2057		(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2058		(R)-2-cyclopropyl-5-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2059		(S)-2-cyclopropyl-5-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2060		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-y1)(5-(2-fluoropropan-2-yl)-1,3.4-oxadiazol-2-yl)methanone
2061		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
2062		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6-difluorophenyl)-1,3,4-oxadiazole
2063		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6-difluorophenyl)-1,3,4-oxadiazole
2064		(S)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2065		(R)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2066		(S)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2067		(R)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2068		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)methanone
2069		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)methanone
2070		(S)-(4-cyclopropyloxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2071		(R)-(4-cyclopropyloxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2072		(R)-(4-cyclopropyl-2-(1-methyl- 1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2073		(S)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2074		(S)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2075		(R)-(4-cyclopropyl-2-(1-methyl- 1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2076		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(oxazol-2-yl)methanone
2077		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(oxazol-2-yl)methanone
2078		(S)-oxazol-2-yl(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2079		(R)-oxazol-2-yl(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2080		(S)-cyclobutyl(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2081		(R)-cyclobutyl(4-(4-fluoropyrazolo[1,5-alpyridin-2-yl)-1.4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2082		(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-methyl-1,3,4-oxadiazole
2083		(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-methyl- 1,3,4-oxadiazole
2084		(R)-2-(difluoromethyl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2085		(S)-2-(difluoromethyl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2086		(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4-fluorophenyl)-1,3,4-oxadiazole
2087		(R)-2-(4-(7-chloropyrazolo[1,5-alpyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4-fluorophenyl)-1,3,4-oxadiazole
2088		(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6-difluorophenyl)-1,3,4-oxadiazole
2089		(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6-difluorophenyl)-1,3,4-oxadiazole
2090		(R)-2-(2,6-difluorophenyl)-5-(4-(7-methylpyrazolo[1.5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2091		(S)-2-(2,6-difluorophenyl)-5-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2092		(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6-difluorophenyl)-1,3,4-oxadiazole
2093		(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6-difluorophenyl)-1,3,4-oxadiazole
2094		(R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2095		(S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2096		(R)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2097		(S)-4-(7-methylpyrazolo[1,5-alpyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2098		(S)-(2-cyclopropyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2099		(R)-(2-cyclopropyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2100		(S)-(2-(tert-butyl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2101		(R)-(2-(tert-butyl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2102		(S)-(2-cyclopropyloxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2103		(R)-(2-cyclopropyloxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2104		(S)-(2-(tert-butyl)oxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2105		(R)-(2-(tert-butyl)oxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2106		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(2-fluoropropan-2-yl)oxazol-5-yl)methanone
2107		(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(2-fluoropropan-2-yl)oxazol-5-yl)methanone
2108		(R)-(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2109		(S)-(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2110		(S)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2111		(R)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2112		(S)-(4-cyclopropyloxazol-5-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2113		(R)-(4-cyclopropyloxazol-5-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2114		(S)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-alpyridin-2-yl)-1.4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2115		(R)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2116		(S)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-1.4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2117		(R)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-1.4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2118		(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo(4,5-c]pyridin-5-yl)methanone
2119		(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2120		(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2121		(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1.5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo(4,5-c]pyridin-5-yl)methanone
2122		(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2123		(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2124		(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2125		(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2126		(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2127		(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4.5-c]pyridine
2128		(R)-2-(4-fluorophenyl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2129		(S)-2-(4-fluorophenyl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2130		(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4-fluorophenyl)-1,3,4-oxadiazole
2131		(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4-fluorophenyl)-1,3,4-oxadiazole
2132		(R)-2-(2,6-difluorophenyl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2133		(S)-2-(2,6-difluorophenyl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2134		(R)-5-(6-fluoropyridin-2-yl)-4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2135		(S)-5-(6-fluoropyridin-2-yl)-4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2136		(S)-4-(7-chloropyrazolo[1,5-a|pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2137		(R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2138		(S)-4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2139		(R)-4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2140		(S)-(2-cyclopropyloxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2141		(R)-(2-cyclopropyloxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2142		(S)-(2-(tert-butyl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2143		(R)-(2-(tert-butyl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2144		(S)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2145		(R)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2146		(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2147		(S)-2-(4-(4-isopropylpyrazolo[1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2148		(S)-4-(4-isopropylpyrazolo[1,5-alpyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2149		(R)-4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2150		(R)-2-(difluoromethyl)-5-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2151		(S)-2-(difluoromethyl)-5-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2152		(R)-2-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
2153		(S)-2-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
2154		(R)-2-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3.4-oxadiazole
2155		(S)-2-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1.4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2156		(R)-2-(4-(4-methylpyrazolo[1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1,3,4-oxadiazole
2157		(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1,3,4-oxadiazole
2158		(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1,3,4-oxadiazole
2159		(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1.3,4-oxadiazole
2160		(R)-2-(4-(4-chloropyrazolo[1,5-alpyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1.3,4-oxadiazole
2161		(S)-2-(4-(4-chloropyrazolo[1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1,3,4-oxadiazole
2162		(S)-2-(pyrimidin-4-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2163		(R)-2-(pyrimidin-4-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2164		(S)-2-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2165		(R)-2-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2166		(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
2167		(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(difluoromethyl)-1,3,4-oxandizole
2168		(R)-2-cyclopropyl-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2169		(S)-2-cyclopropyl-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2170		(S)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2171		(R)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2172		(S)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2173		(R)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2174		(S)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2175		(R)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2176		(R)-2-(4-(4-isopropylpyrazolo)[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1,3,4-oxadiazole
2177		(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1,3,4-oxadiazole
2178		(S)-2-(4-(4-fluoropyrazolol[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin-4-yl)-1,3,4-oxadiazole
2179		(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin-4-yl)-1,3,4-oxadiazole
2180		(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin-4-yl)-1,3,4-oxadiazole
2181		(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin-4-yl)-1,3,4-oxadiazole
2182		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin-4-yl)-1,3.4-oxadiazole
2183		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin-4-yl)-1,3,4-oxadiazole
2184		(R)-4-(4-isopropylpyrazolo[1,5-a|pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2185		(S)-4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2186		(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-methyl-1.3,4-oxadiazole
2187		(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-methyl-1,3,4-oxadiazole
2188		(R)-2-(1-methylcyclopropyl)-5-(4-(4-methylpyrazolo[1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2189		(S)-2-(1-methylcyclopropyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2190		(R)-2-(1,1-difluoroethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2191		(S)-2-(1,1-difluoroethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2192		(R)-2-(1,1-difluoroethyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2193		(S)-2-(1,1-difluoroethyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2194		(R)-2-(1,1-difluoroethyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2195		(S)-2-(1,1-difluoroethyl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2196		(R)-2-(1,1-difluoroethyl)-5-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)-1,3,4-oxadiazole
2197		(S)-2-(1,1-difluoroethyl)-5-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2198		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridazin-3-yl)-1,3,4-oxadiazole
2199		(R)-2-(4-(4-chloropyrazolo[1,5-alpyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridazin-3-yl)-1,3,4-oxadiazole
2200		(S)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2201		(R)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2202		(R)-2-(1,1-difluoroethyl)-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2203		(S)-2-(1,1-difluoroethyl)-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2204		(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1,1-difluoroethyl)-1,3,4-oxadiazole
2205		(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1,1-difluoroethyl)-1,3,4-oxadiazole
2206		(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3.4-oxadiazole
2207		(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2208		(S)-2-(2-methylpyridin-3-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2209		(R)-2-(2-methylpyridin-3-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2210		(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-y)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2211		(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2212		(S)-2-(4-(4-fluoropyrazolol 1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2213		(R)-2-(4-(4-fluoropyrazolo[ 1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2214		(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2215		(R)-(3-(difluoromethyl)-1-methyl-1 H-1,2,4-triazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2216		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)oxazol-5-yl)methanone
2217		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)oxazol-5-yl)methanone
2218		(S)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2219		(R)-(S-methyl-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2220		(R)-2-(difluoromethyl)-5-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2221		(S)-2-(difluoromethyl)-5-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2222		((R)-2,2-difluorocyclopropyl)((R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)methanone
2223		((R)-2,2-di fl uorocyclopropyl)((S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2224		(R)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2225		(S)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2226		(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1-methylcyclopropyl)-1,3.4-oxadiazole
2227		(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1-methylcyclopropyl)-1,3.4-oxadiazole
2228		(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl-5-(1-methylcyclopropyl)-1,3,4-oxadiazole
2229		(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1-methylcyclopropyl)-1.3,4-oxadiazole
2230		(R)-2-(1,1-difluoroethyl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)-1,3,4-oxadiazole
2231		(S)-2-(1,1-difluoroethyl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2232		(R)-2-(4-(4-chloropyrazolo[1,5-a] pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1,1-difluoroethyl)-1,3.4-oxadiazole
2233		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl-5-(1,1-difluoroethyl)-1,3,4-oxadiazole
2234		(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2235		(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2236		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2237		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3.4-oxadiazole
2238		(R)-5-phenyl-4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2239		(S)-5-phenyl-4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2240		(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyrazin-2-yl)oxazol-5-yl)methanone
2241		(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyrazin-2-yl)oxazol-5-yl)methanone
2242		(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a|pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyrazin-2-yl)oxazol-5-yl)methanone
2243		(R)-(4-(4-(difluoromethyl)pyrazolo[1.5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c[pyridin-5-yl)(2-(pyrazin-2-yl)oxazol-5-yl)methanone
2244		(S)-(2-(pyrazin-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2245		(R)-(2-(pyrazin-2-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2246		(R)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2247		(S)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2248		(R)-2-methyl-5-(4-(4-(trifluoromethoxy)pyrazolo[1,5-alpyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2249		(S)-2-methyl-5-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2250		(R)-2-(difluoromethyl)-5-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2251		(S)-2-(difluoromethyl)-5-(4-(4-(trifluoromethoxy)pyrazolo[1.5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2252		(R)-2-(4-(4-(trifluoromethoxy)pyrazolo[1.5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2253		(S)-2-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2254		(S)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2255		(R)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2256		(S)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2257		(R)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2258		(R)-2-(4-(4-chloropyrazolo[1,5-alpyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1-methylcyclopropyl)-1.3,4-oxadiazole
2259		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1-methylcyclopropyl)-1,3,4-oxadiazole
2260		(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridin-3-yl)-1,3,4-oxadiazole
2261		(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridin-3-yl)-1.3,4-oxadiazole
2262		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridin-3-yl)-1.3,4-oxadiazole
2263		(R)-2-(4-(4-chloropyrazolo[1,5-a] pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridin-3-yl)-1,3.4-oxadiazole
2264		(S)-2-(2-fluoropyridin-3-yl)-5-(4-(4-methylpyrazolo| 1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)-1,3,4-oxadiazole
2265		(R)-2-(2-fluoropyridin-3-yl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)-1,3,4-oxadiazole
2266		(R)-2-(3-methylpyridin-2-yl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2267		(S)-2-(3-methylpyridin-2-yl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2268		(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2269		(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2270		(S)-5-(pyrimidin-2-yl)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2271		(R)-5-(pyrimidin-2-yl)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2272		(S)-4-(4-(difluoromethoxy)pyrazolo| 1,5-alpyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2273		(R)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2274		(S)-2-(2-fluoropyridin-3-yl)-5-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2275		(R)-2-(2-fluoropyridin-3-yl)-5-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2276		(S)-2-(3-methylpyridin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2277		(R)-2-(3-methylpyridin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2278		(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2279		(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3.4-oxadiazole
2280		(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2281		(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3.4-oxadiazole
2282		(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2283		(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2284		(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2285		(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2286		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2287		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2288		(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazole
2289		(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazole
2290		(R)-(5-(5-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo| 1,5-alpyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2291		(S)-(5-(5-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2292		(S)-(5-(4-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2293		(R)-(5-(4-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2294		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(5-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
2295		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(5-methyl-1H-pyrazol-3-yl)-1,3.4-oxadiazol-2-yl)methanone
2296		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(4-methyl-1H-pyrazol-3-yl)-1,3.4-oxadiazol-2-yl)methanone
2297		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(4-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone
2298		(R)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2299		(S)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2300		(R)-2-isopropyl-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2301		(S)-2-isopropyl-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2302		(R)-2-isopropyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3.4-oxadiazole
2303		(S)-2-isopropyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2304		(R)-2-isopropyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2305		(S)-2-isopropyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2306		(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3.4-oxadiazole
2307		(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3.4-oxadiazole
2308		(R)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2309		(S)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2310		(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-phenyl-4,5,6,7-tetrahydro-1H-imidazo[4.5-c]pyridine
2311		(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-phenyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2312		(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-phenyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2313		(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-phenyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2314		(S)-2-cyclopropyl-5-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2315		(R)-2-cyclopropyl-5-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2316		(S)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2317		(R)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2318		(R)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2319		(S)-4-(4-(difluoromethoxy)pyrazolo| 1,5-alpyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4.5-c]pyridine
2320		(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl-1,3,4-oxadiazole
2321		(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl-1 .3,4-oxadiazole
2322		(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl-1,3,4-oxadiazole
2323		(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl-1,3.4-oxadiazole
2324		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl-1,3,4-oxadiazole
2325		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl-1,3,4-oxadiazole
2326		(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1,1-difluoroethyl)-1,3,4-oxadiazole
2327		(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1,1-difluoroethyl)-1,3,4-oxadiazole
2328		(R)-2-(1,1-difluoroethyl)-5-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2329		(S)-2-(1,1-difluoroethyl)-5-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2330		(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3.4-oxadiazole
2331		(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2332		(S)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2333		(R)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-methylpyridin-3-yl)-1,3,4-oxadiazole
2334		(R)-2-(2-fluoropyridin-3-yl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2335		(S)-2-(2-fluoropyridin-3-yl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2336		(S)-2-(3-methylpyridin-2-yl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2337		(R)-2-(3-methylpyridin-2-yl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c)pyridin-5-yl)-1,3,4-oxadiazole
2338		(S)-2-(3-fluoropyridin-2-yl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2339		(R)-2-(3-fluoropyridin-2-yl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2340		(R)-2-(3-fluoropyridin-2-yl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2341		(S)-2-(3-fluoropyridin-2-yl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2342		(S)-2-(6-methylpyridin-2-yl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)-1,3,4-oxadiazole
2343		(R)-2-(6-methylpyridin-2-yl)-5-(4-(pyrazolo| 1,5-a]pyridin-2-yl)-1,4,6.7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2344		(R)-2-(4-(4-methylpyrazolo(1,5-alpyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6-methylpyridin-2-yl)-1,3,4-oxadiazole
2345		(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6-methylpyridin-2-yl)-1,3,4-oxadiazole
2346		(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1.4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6-methylpyridin-2-yl)-1,3,4-oxadiazole
2347		(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6-methylpyridin-2-yl)-1,3,4-oxadiazole
2348		(S)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2349		(R)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2350		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-fluoropyridin-3-yl)-1,3,4-oxadiazole
2351		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2-fluoropyridin-3-yl)-1,3,4-oxadiazole
2352		(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3.4-oxadiazole
2353		(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1.4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3-methylpyridin-2-yl)-1,3,4-oxadiazole
2354		(R)-2-(3-fluoropyridin-2-yl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2355		(S)-2-(3-fluoropyridin-2-yl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2356		(R)-2-(6-methylpyridin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2357		(S)-2-(6-methylpyridin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2358		(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6-methylpyridin-2-yl)-1,3,4-oxadiazole
2359		(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6-methylpyridin-2-yl)-1,3,4-oxadiazole
2360		(R)-2-(6-fluoropyridin-2-yl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2361		(S)-2-(6-fluoropyridin-2-yl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4.6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)-1,3,4-oxadiazole
2362		(R)-2-(6-fluoropyridin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2363		(S)-2-(6-fluoropyridin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2364		(R)-(5-(5-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2365		(S)-(5-(5-fl uoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2366		(S)-(S-(difluoromethyl)-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2367		(R)-(5-(difluoromethyl)-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-y l)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2368		(S)-(5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2369		(R)-(5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2370		(S)-(3-amino-1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2371		(R)-(3-amino-1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2372		(S)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2373		(R)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2374		(4-chloro-2-(1-hydroxyethyl)oxazol-5-yl)((R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #2 (Rt=7.091 min)
2375		(4-chloro-2-(1-hydroxyethyl)oxazol-5-yl)((R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #1 (Rt=6.819 min)
2376		(4-chloro-2-(1-hydroxyethyl)oxazol-5-yl)((S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #1 (Rt=5.341 min)
2377		(4-chloro-2-(1-hydroxyethyl)oxazol-5-yl)((S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #2 (Rt=6.340 min)
2378		(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-hydroxypropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
2379		(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-hydroxypropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone
2380		(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2381		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(6-methylpyrazolo[1.5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2382		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)oxazol-5-yl)methanone
2383		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2-hydroxypropan-2-yl)oxazol-5-yl)methanone
2384		(S)-(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
2385		(R)-(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
2386		(S)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2387		(R)-(1-cyclopropyl-1H-pyrazol-5-yl)4-(pyrazolo[1,5-alpyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2388		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin-2-yl)-1H-pyrazol-5-yl)methanone
2389		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1 -(pyridin-2-yl)-1H-pyrazol-5-yl)methanone
2390		(S)-(1,3-dimethyl- 1H-pyrazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2391		(R)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2392		(R)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2393		(S)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2394		(R)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2395		(S)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2396		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)methanone
2397		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)methanone
2398		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone
2399		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone
2400		(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2401		(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2402		(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2403		(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2404		(S)-(5-cyclopropyl-1,3.4-oxadiazol-2-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2405		(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2406		(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2407		(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4-(5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2408		(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2409		(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2410		(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2411		(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5-yl)(4-(5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2412		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone
2413		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone
2414		(S)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2415		(R)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2416		(S)-(5-(1-methy)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2417		(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2418		(R)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2419		(S)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2420		(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2421		(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2422		(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)((S)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2423		(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)((R)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2424		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
2425		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone
2426		(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
2427		(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
2428		(S)-(5-(1-(trifluoromethyl)-1H-pyazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2429		(R)-(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2430		(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2431		(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2432		(R)-2-cyclopropyl-5-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2433		(S)-2-cyclopropyl-5-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2434		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
2435		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone
2436		(S)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2437		(R)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2438		(S)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2439		(R)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2440		(S)-2-(pyridin-2-yl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2441		(R)-2-(pyridin-2-yl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2442		(R)-2-methyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2443		(S)-2-methyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2444		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
2445		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
2446		(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2447		(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2448		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
2449		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone
2450		(S)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2451		(R)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2452		(S)-(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2453		(R)-(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2454		(S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2455		(R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
2456		(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-methyl-1,3,4-oxadiazole
2457		(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-methyl-1,3,4-oxadiazole
2458		(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
2459		(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
2460		(R)-2-(difluoromethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2461		(S)-2-(difluoromethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2462		(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2463		(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2464		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
2465		(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methoxypyrazolo[1,5-a]pyridin-3-yl)methanone
2466		(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-methyl-1,3,4-oxadiazole
2467		(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-methyl-1,3,4-oxadiazole
2468		(R)-(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2469		(S)-(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2470		(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
2471		(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-methylpyrazolo[1,5-a]pyridin-3-yl)methanone
2472		(S)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2473		(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2474		(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone
2475		(R)-(4-(7-chloropynazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone
2476		(S)-(6-(2-(dimethylamino)ethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2477		(R)-(6-(2-(dimethylamino)ethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyarolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2478		(S)-(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2479		(R)-(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone
2480		(R)-2-cyclobutyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2481		(S)-2-cyclobutyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2482		(S)-2-cyclobutyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2483		(R)-2-cyclobutyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2484		(R)-2-cyclobutyl-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2485		(S)-2-cyclobutyl-5-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole
2486		(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2487		(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2488		(S)-(4-(6-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
2489		(R)-(4-(6-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone
2490		(R)-2-(trifluoromethyl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2491		(S)-2-(trifluoromethyl)-5-(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2492		(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2493		(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
2494		(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4.5-c]pyridin-5-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone
2495		(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone
2496		(S)-(2-cyclopropyloxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2497		(R)-(2-cyclopropyloxazol-5-yl)(4-(pyrazolo| 1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2498		(R)-(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2499		(S)-(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2500		(R)-(5-methyl-1,3,4-thiadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2501		(S)-(5-methyl-1,3,4-thiadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2502		(S)-benzo[d]thiazol-2-yl(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2503		(R)-benzo[d]thiazol-2-yl(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2504		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)methanone
2505		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)methanone
2506		(S)-(2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2507		(R)-(2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone
2508		(R)-2-cyclopropyl-5-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2509		(S)-2-cyclopropyl-5-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2510		(S)-2-(pyrazin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2511		(R)-2-(pyrazin-2-yl)-5-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2512		(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridazin-3-yl)-1.3,4-oxadiazole
2513		(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridazin-3-yl)-1,3,4-oxadiazole
2514		(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1-methylcyclopropyl)-1,3,4-oxadiazole
2515		(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1-methylcyclopropyl)-1,3,4-oxadiazole
2516		(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyrazin-2-yl)oxazol-5-yl)methanone
2517		(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyrazin-2-yl)oxazol-5-yl)methanone
2518		(R)-2-(3,3-difluorocyclobutyl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2519		(S)-2-(3,3-difluorocyclobutyl)-5-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2520		(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1,3,4-oxadiazole
2521		(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2-yl)-1,3,4-oxadiazole
2522		(R)-2-(1,1-difluoroethyl)-5-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2523		(S)-2-(1,1-difluoroethyl)-5-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole
2524		(5-(2,6-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

In further embodiments, the compound of Formula 1 is one or more of the compounds in Table 1 that is the S-enantiomer, or a pharmaceutically acceptable salt thereof.

In still further embodiments, the compound of Formula I is one or more of Examples 605, 626, 640, 670, 688, 708, 710, 726, 728, 733, 748, 760, 762, 764, 791, 836, 840, 906, 922, 938, 942, 944, 946, 948, 950, 952, 954, 957, 958, 960, 962, 964, 966, 969, 971, 972, 975, 976, 979, 980, 982, 984, 988, 1381, 1438, 1461, 1506, 1531, 1548, 1589, 1607, 1613, 1628, 1652, 1657, 1728, 1737, 1757, 1807, 1809, 1823, 1843, 1849, 1850, 1943, 1953, 1986, 2218, 2221, and 2223, or a pharmaceutically acceptable salt thereof. In yet other embodiments, the compound of Formula I is one or more of Examples 640, 670, 688, 708, 710, 726, 728, 733, 748, 760, 762, 764, 836, 840, 906, 922, 938, 942, 944, 946, 948, 950, 952, 954, 957, 960, 962, 969, 971, 972, 975, 976, 979, 980, 984, 988, 1438, 1461, 1506, 1548, 1628, 1652, 1657, 1728, 1737, 1757, 1809, 1849, 1850, 1953, 1986, 2218, and 2221, or a pharmaceutically acceptable salt thereof. In still other embodiments, the compound of Formula I is one or more of Examples 640, 670, 688, 708, 710, 726, 728, 733, 748, 760, 762, 764, 836, 840, 906, 922, 938, 942, 944, 946, 948, 950, 952, 954, 957, 960, 962, 969, 971, 972, 975, 976, 979, 980, 984, 988, 1438, 1461, 1506, 1548, 1628, 1652, 1657, 1728, 1986, and 2218, or a pharmaceutically acceptable salt thereof.

Abbreviations and terms list
aq      aqueous
min     minute(s)
hrs     hours
mL      milliliter
µL      microliter
mmol    millimole(s)
µmol    micromole(s)
mol     mole(s)
M       molar
eq      equivalents
LCMS    Liquid chromatography mass spectrometry
NMR     nuclear magnetic resonance
TLC     thin layer chromatography
HPLC    high-performance liquid chromatography
SFC     supercritical fluid chromatography
sat     saturated
°C      degrees Celsius
rt      room temperature
N2      nitrogen gas
Hz      Hertz
δ       chemical shift
s       singlet
d       doublet
t       triplet
q       quartet
m       multiplet
br      broad
dd      doublet of doublets
ddd     doublet of doublet or doublets
td      triplet of doublets
dt      doublet of triplets
CDCl3   chloroform-d
CD3OD   methanol-d4
DMSO-d6 dimethylsulfoxide-d6

Solvents and reagents
DCE             1,2-dichloroethane
DCM             dichloromethane
DMAc            dimethylacetamide
DME             dimethoxvethane
DMF             dimethylformamide
EtOH            ethyl alcohol
EtOAc           ethyl acetate
i-PrOHorIPA     isopropanol
MeOH            methyl alcohol
TAA             tert-amyl alcohol
MeCNorACN       acetonitrile
PE              petroleum ether
TBME            tert-butylmethyl ether
H2O             water
THF             tetrahydrofuran
HOAc            acetic acid
HCI             hydrochloric acid
H2SO4           sulfuric acid
FA              formic acid
TFA             trifluoroacetic acid
TsOH            p-toluenesulfonic acid
TosCl or TsCl   p-toluenesulfonyl chloride
NH4C1           ammonium chloride
KOH             Potassium hydroxide
LiOH            lithium hydroxide
K2CO3           potassium carbonate
Na2CO3          sodium carbonate
Cs2CO3          cesium carbonate
Na2SO4          sodium sulfate
NaHCO3          sodium bicarbonate
Na2S2O3         sodium thiosulfate
Et3NorTEA       triethylamine
DIPEA           N,N-diisopropylethylamine
Py              pyridine
KOAc            potassium acetate
KF              potassium fluoride
CsF             cesium fluoride
NH3             ammonia
LDA             lithium diisopropylamine
LiHMDS          lithium bis(trimethylsilyl)amide
MeMgBr          methylmagnesium bromide
iPrMgCl.LiCl    isopropylmagnesium chloride lithium chloride complex
PFIB            perfluoroisobutene
BuOK            potassium t-butoxide
CAN             cerium ammonium nitrate
DIBAL-H         diisobutylaluminium hydride
NaOMe           sodium methoxide
DMP             Dess-Martin periodinane
MnO2            manganese(IV) oxide
IBX             2-iodoxybenzoic acid
t-BuONO         tert-butyl nitrite
PIDA            (diacetoxviodo)benzene
NFSI            N-fluorodi(benzenesulfonyl)amine
NBS             N-bromosuccinimide
NCS             N-chlorosuccinimide
MeI             methyl iodide
LiBH4           lithium borohydride
NaBH4           sodium borohydride
NaBH(OAc)3      Sodium triacetoxyborohydride
EDCI            1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
HOBt            1-hydroxybenzotriazole
HATU            1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
T3P             Propanephosphonic acid anhydride
CDI             carbonyldiimidazole
Thio-CDI        1,1′-Thiocarbonyldiimidazole
DPPA            diphenylphosphoryl azide
BCl3            boron trichloride
Boc2O           di-tert-butyl dicarbonate
DHP             Dihydropyran
Pd/C            palladium on carbon
Pd(PPh3)2Cl2    bis(triphenylphosphine)palladiom(II) dichloride
Pd2(dba)3       tris(dibenzylideneacetone)dipalladium
Pd(dppf)Cl2     (1,1′-Bis(diphenylphosphino)ferrocene)palladium(II) dichloride
Pd(OAc)2        palladium(II) acetate
Xantphos        4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
t-BuXPhos-Pd-G3 [(2-Di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-amino-1,1′-biphenyl)] palladium(II) methanesulfonate
CPhos-Pd-G3     [(2-Dicyclohexylphosphine-2′,6′-bis(N,N-dimethylamino)-1,1′-biphenyl)-2-(2′-amino-1,1′-biphenyl)] palladium(II) methanesulfonate
PPh3            triphenylphosphine
DEAD            diethyl azodicarboxylate
Pin2B2          bis(pinacolato)diborane
CuI             copper iodide
CuBr2           copper (II) bromide
Zn(CN)2         zinc cyanide
H2              hydrogen gas
SiO2            silica
TFAA            Trifluoroacetic anhydride
K2OsO4.2H2O     potassium osmate(VI) dihydrate
NaIO4           sodium periodate

General Experimental

In the following examples, the reagents and solvents were purchased from commercial sources (such as Alfa, Acros, AstaTech, CombiBlocks, Enamine. Sigma Aldrich, TCI, PharmaBock, Bide Pharmatech Ltd., Accela ChemBio, Aladdin, Shanghai Haohong Pharmaceutical Co., Ltd, Amkchem, Beijing Ouhe Technology Co.. Ltd, Haoyuan Chemexpress Co.. Ltd, Hualun, Coolpharm, Scochem, Titan and WuXi LabNetwork, and used without further purification unless otherwise specified. Flash chromatography was performed on a CombiFlashRf 150 (ISCO) via column with silica gel particles of 200-300 mesh. HPLC was performed on an Agilent 1100 Liquid Chromatography (Agilent, USA) and a Shimadzu LC 20/20A (Shimadzu, Japan). Supercritical fluid chromatography was performed on a Waters Prep SFC 150 AP /80Q /200 / 350 system (Waters, USA). Analytical and preparative thin layer chromatography plates (TLC) were HSGF 254 (0.15-0.2 mm thickness, Shanghai Anbang Company, China). Nuclear magnetic resonance (NMR) spectra were obtained on a Brucker AV-400 NMR or Bruker AVIII 500 MHz NMR (Broker, Switzerland). Chemical shifts were reported in parts per million (ppm, δ) downfield from tetramethylsilane. Mass spectra were given with electrospray ionization (ESI) from a Waters LCT TOF Mass Spectrometer (Waters, USA). LC-MS was performed on an Agilent Prime-6125B/ Agilent LC1260-MS6150/ Agilent LC1260-MS6125B/ Agilent LC1200-MS6110 (Agilent, USA) and a Shimadzu LC20-MS2020. Microwave reactions were run on an Initiator 2.5 Microwave Synthesizer (Biotage, Sweden).

Intermediate (1-(1H-imidazol-5-yl)cyclopropyl)methanamine hydrochloride

Step 1: Preparation of 2-(3-tritylimidazol-4-yl)acetonitrile (B2)

B2 was prepared starting with 2-(1H-imidazol-5-yl)acetonitrile (B1) in accordance with literature procedures. See, e.g., WO2008/003766 (page 19).

Step 2: Preparation of 1-(3-tritylimidazol-4-yl)cyclopropanecarbonitrile (B3)

To a solution of 2-(3-tritylimidazol-4-yl)acetonitrile (B2) (10 g, 28.6 mmol) in THF (200 mL) was added LDA (2 M, 42.9 mL, 3 eq) dropwise at -78° C. After addition was complete, the reaction mixture was stirred at -20° C. to -10° C. for 1 hr. The reaction mixture was then cooled to -78° C., and 1,2-dibromoethane (10.75 g, 57.2 mmol, 4.32 mL, 2 eq) was added dropwise at -78° C. After the addition was complete, the reaction mixture was warmed to rt slowly and stirred for another 2 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was quenched with sat. NH₄Cl solution (200 mL) and stirred at rt for 0.5 hr. The aqueous portion was extracted with EtOAc (100 mL x 3), and the combined organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness. The residue (combined with two other reactions performed using 10 g of B2) was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, eluent of 0~40% EtOAc/PE, gradient @ 40 mL/min) to give B3 (23.4 g, 72% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.30-7.52 (m, 10 H), 7.09 (dd, 6 H), 6.84 (d, 1 H), 1.51-1.66 (m, 2 H). 1.29-1.46 (m, 2 H).

Step 3: Preparation of 1-(3-tritylimidazol-4-yl)cyclopropyl]methanamine (B4)

A mixture of 1-(3-tritylimidazol-4-yl)cyclopropanecarbonitrile (B3) (19 g, 50.6 mmol), Raney-Ni (4.60 g, 53.7 mmol, 1.06 eq), NH₃.H₂O (591 mg, 5.06 mmol, 650 µL, 30% purity, 0.1 eq) in MeOH (200 mL) was degassed and purged with H₂ 3 times, and then the reaction mixture was stirred at 45° C. for 16 hrs under H₂ (45 psi) atmosphere. Reaction progress was tracked using TLC (DCM:MeOH=10:1). The reaction mixture was filtered, and additional Raney-Ni (4.60 g, 53.7 mmol, 1.06 eq) was added. The reaction mixture was stirred at 45° C. under H₂ (45 psi) atmosphere for another 24 hrs. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated to dryness to give B4 (18 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 7.33-7.44 (m, 9 H), 7.18-7.25 (m, 1 H), 7.04-7.13 (m, 6 H), 6.64-6.71 (m, 1 H), 3.17 (br s, 2 H), 2.58-2.74 (m, 2 H), 0.60-0.82 (m, 4 H).

Step 4: Preparation of [1-(1H-imidazol-5-yl)cyclopropyl]methanamine hydrochloride (B5)

To a solution of [1-(3-tritylimidazol-4-yl)cyclopropyl]methanamine (B4) (18 g, 47.4 mmol) in MeOH (100 mL) was added HCl/MeOH (4 M, 100 mL, 8.4 eq). The reaction mixture was stirred at 60° C. for 16 hrs. Reaction progress was tracked using LC-MS. The reaction mixture was concentrated to dryness, and the residue was triturated with EtOAc(40 mL) and stirred for 15 min. The precipitate was collected by filtration and then dried in vacuo to give B5 (8.5 g, 2HCl salt). ¹H NMR (400 MHz, DMSO-d₆) δ 14.73 (br s, 1 H), 9.04 (s, 1 H), 8.27 (br s, 2 H), 7.51 (s, 1 H), 2.98-3.22 (m, 2 H), 0.90-1.23 (m, 4 H).

Intermediate 2-(1H-imidazol-5-yl)-2-methylpropan-1-amine Hydrochloride

Step 1: Preparation of (2-methyl-2-(3-tritylimidazol-4-yl)propanenitrile (B6)

To a solution of 2-(3-tritylimidazol-4-yl)acetonitrile (B2) (12 g, 34.3 mmol) in THF (400 mL) was drop-wise added LiHMDS (1 M, 96.2 mL, 2.8 eq) at -78° C. The reaction mixture was stirred at -78° C. for 15 min. and then MeI was added (14.62 g, 103 mmol, 6.41 mL, 3 eq). The reaction mixture was stirred at -78° C. for 1 hr, and then warmed to rt for 18 hrs. Reaction progress was tracked using TLC (PE:EtOAc = 1:1). The reaction mixture was cooled to 0° C., quenched by the addition of sat. NH₄Cl solution (15 mL) and then H₂O (60 mL) was added. The aqueous portion was extracted with EtOAc (60 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na₂SO₄, and concentrated to dryness. The residue (combined with the residue from another reaction performed using 2 g of B2) was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, eluent of 0~80% EtOAc/PE. gradient @ 60 mL/min) to give B6 (14 g, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, 1 H), 7.32-7.39 (m, 9 H), 7.08-7.16 (m, 6 H), 6.81 (d, 1 H), 1.69 (s, 6 H).

Step 2: Preparation of (2-methyl-2-(3-tritylimidazol-4-yl)propan-1-amine (B7)

To a solution of 2-methyl-2-(3-tritylimidazol-4-yl)propanenitrile (B6) (14 g, 37.1 mmol) in MeOH (350 mL) was added Raney-Ni (2 g, 23.3 mmol, 0.63 eq) under N₂. The reaction mixture was degassed under vacuum and purged with H₂ several times. The reaction mixture was stirred under H₂ (50 psi) at 40° C. for 36 hrs. Reaction progress was tracked using TLC (PE:EtOAc ::: 1:1). The reaction mixture was filtered through of pad of celite, and the filtrate was concentrated to dryness to afford B7 (12 g, 85% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.38 (s, 1 H), 7.29-7.36 (m, 9 H), 7.10-7.18 (m, 6 H), 6.55 (s, 1 H), 3.49 (br s, 1 H), 2.74 (s, 2 H), 1.20 (s, 6 H); LCMS: m/z 382.2 [M+H]⁺.

Step 3: Preparation of (2-(1H-imidazol-5-yl)-2-methyl-propan-1-amine (B8)

To a solution of 2-methyl-2-(3-tritylimidazol-4-yl)propan-1-amine (B7) (14 g, 36.7 mmol) in MeOH (150 mL) was added HCl/MeOH (4 M. 150 mL, 16.4 eq), and the reaction mixture was stirred at 50° C. for 18 hrs. Reaction progress was tracked using TLC (EtOAc). The reaction mixture was concentrated to dryness, and 200 mL of EtOAc was added. The mixture was stirred at 60° C. for 1 hr. The precipitate was collected by filtration and rinsed with EtOAc, and then dried in vacuo to give B8 (7.0 g, 90% yield, 2HCl salt). ¹H NMR (400 MHz, CD₃OD) δ 8.96 (s, 1 H), 7.52 (s, 1 H), 3.20-3.27 (m, 2 H), 1.49 (s, 6 H).

Intermediate 2-(1H-imidazol-5-yl)propan-1-amine Hydrochloride

Step 1: Preparation of 2-(3-tritylimidazol-4-yl)propanenitrile (B9)

To a solution of 2-(3-tritylimidazol-4-yl)acetonitrile (B2) (15 g, 42.9 mmol) in THF (120 mL) was added LiHMDS (1 M, 51.5 mL, 1.2 eq) dropwise at -78° C. After addition, the reaction mixture was stirred for 0.5 hr, and then MeI (10.97 g, 77.3 mmol, 4.81 mL, 1.8 eq) was added dropwise at -78° C. The reaction mixture was stirred at -78° C. for 2 hrs. Reaction progress was tracked using TLC (PE: EtOAc=2: 1). The reaction mixture was quenched by the addition of sat. NH₄CI solution (120 mL) and stirred for 15 min. The aqueous portion was extracted with EtOAc (400 mL), and the organic layer washed by water (100 mL) and brine (60 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue (combined with the residue from another reaction performed using 15 g of B2) was purified by column chromatography on silica gel (PE:EtOAc=20: 1 to 2:1) to give B9 (33.5 g, 75% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.38-7.45 (m, 10 H), 7.06-7.13 (m, 6 H), 6.82-6.92 (m, 1 H). 4.12-4.23 (m, 1 H). 1.48 (d, 3 H).

Step 2: Preparation of 2-(3-tritylimidazol-4-yl)propan-1-amine (B10)

A mixture of 2-(3-tritylimidazol-4-yl)propanenitrile (B9) (16.5 g, 45.4 mmol), Raney-Ni (4.08 g, 47.7 mmol, 1.05 eq), NH₃.H₂O (910 mg, 7.79 mmol, 1 mL, 30% purity) in MeOH (300 mL) was degassed under vacuum and purged with H₂ 3 times. The reaction mixture was stirred at 45° C. for 16 hrs under H₂ (45 psi) atmosphere. Reaction progress was tracked using TLC (PE:EtOAc=2:1). The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated to dryness to afford B10 (33 g), which was used without further purification. ¹H NMR (400 MHz, CD₃OD) δ 7.36-7.44 (m, 10 H), 7.13-7.20 (m, 6 H), 6.72 (br s, 1 H), 2.57-2.92 (m, 3 H), 1.21 (br d, 3 H).

Step 3: Preparation of 2-(1H-imidazol-5-yl)propan-1-amine (B11)

To a solution of 2-(3-tritylimidazol-4-yl)propan-1-amine (B10) (23 g, 62.6 mmol) in MeOH (100 mL) was added HCl/MeOH (4 M, 100 mL). The mixture was stirred at rt for 12 hrs. Reaction progress was tracked using TLC (EtOAc). The reaction mixture (combined with the reaction mixture from another reaction performed using 23 g of B10) was concentrated to dryness. H₂O (40 mL) was added to the residue, and the aqueous layer washed with EtOAc (50 mL). The aqueous layer was lyophilized to give B11 (21 g, 2HCl). ¹H NMR (400 MHz, CD₃OD) δ 8.96 (d, 1 H), 7.56 (s, 1 H), 3.43-3.51 (m, 1 H), 3.17-3.32 (m, 2 H), 1.29-1.53 (m, 3 H).

Intermediate 2-[(2R)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione and 2-[(2S)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione

Step 1: Preparation of 2-[2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (B13)

To a solution of 2-(1H-imidazol-5-yl)propan-1-amine (B11) (10 g, 50.5 mmol, 2HC1) and phthalic anhydride (7.85 g, 53.0 mmol, 1.05 eq) in i-PrOH (400 mL) was added Et₃N (15.32 g, 151 mmol, 21.1 mL, 3 eq). The reaction mixture was stirred at 100° C. for 18 hrs under N₂ atmosphere. After cooling, the reaction mixture was concentrated to dryness. Water (200 mL) was then added, and the mixture was stirred at rt for 10 mins. The precipitate was collected by filtration, rinsed with water (100 mL), and dried in vacuo to afford B13 (13 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 7.71-7.89 (m, 4 H), 7.49 (S, 1 H), 6.79 (s, 1 H), 3.70-3.76 (m, 1 H), 3.60-3.65 (m, 1 H), 3.15-3.23 (m, 1 H), 1.16 (d, 3 H).

Step 2: SFC Separation

Compound 2-[2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (13 g) was separated by SFC separation (column: DAICEL CHIRALPAK AD(250 mm*50 mm,10 um);mobile phase: [0.1%NH₃H₂O ETOH];B%: 40%-40%,min) to afford Enantiomer 1 (4.8 g. 37% yield, Rt = 3.953 min) and Enantiomer 2 (5.2 g, 40% yield, Rt = 4.652 min).

Enantiomer 1: 2-[(2R)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (B13A). ¹H NMR (400 MHz, CD₃OD) δ 7.73-7.89 (m, 4 H), 7.56 (d, 1 H), 6.82 (s, 1 H), 3.84-3.93 (m, 1 H), 3.70-3.82 (m, 1 H), 3.36-3.39 (m, 1 H), 1.31 (d, 3 H); SFC: 98.4% ee.

Enantiomer 2: 2-[(2S)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (B13B). ¹H NMR (400 MHz, CD₃OD) δ 7.77-7.88 (m, 4 H), 7.55 (d, 1 H), 6.82 (s, 1 H), 3.84-3.97 (m, 1 H), 3.72-3.82 (m, 1 H), 3.36-3.42 (m, 1 H), 1.31 (d, 3 H); SFC: 99.1% ee.

Intermediate Pyrazolo[1,5-a]pyridine-2-carbaldehyde

Step 1: Preparation of N-methoxy-N-methyl-pyrazolo[1,5-a]pyridine-2-carboxamide (C2)

To a solution of pyrazolo[1,5-alpyridine-2-carboxylic acid (C1) (12.5 g, 77.1 mmol) and N-methoxymethanamine (9.42 g, 96.6 mmol, 1.25 eq, HCl) in DMF (200 mL) was added EDCI (22.17 g, 116 mmol, 1.5 eq), DIPEA (29.89 g, 231 mmol, 40.3 mL, 3 eq) and HOBt (15.63 g. 116 mmol. 1.5 eq). The reaction mixture was stirred at rt for 12 hrs. Reaction progress was checked using TLC (PE:EtOAc=1: 1). The reaction mixture was combined with the reaction mixture from another reaction performed using 12.5 g of C1 and concentrated to dryness. The residue was dissolved in DCM (200 mL), and the organic layer washed with sat. Na₂CO₃ solution (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1 to 1:1) to give C2 (30.5 g, 96% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.47-8.54 (m, 1 H), 7.59 (d, 1 H), 7.16 (ddd, 1 H), 7.02 (s, 1 H), 6.86 (td. 1 H), 3.81 (s, 3 H). 3.51 (s, 3 H).

Step 2: Preparation of Pyrazolo[1,5-a]pyridine-2-carbaldehyde (C3)

To a solution of N-methoxy-N-methyl-pyrazolo[1,5-a]pyridine-2-carboxamide (C2) (15 g, 73.1 mmol) in THF (150 mL) was added DIBAL-H (1 M, 146.2 mL, 2 eq) dropwise at -78° C. under N₂, and then the reaction mixture was stirred at -78° C. for 2 hrs under N₂. Reaction progress was tracked using TLC (PE:EtOAc= 1:1). The reaction mixture was combined with the reaction mixture from another reaction performed using 15 g of C2 and was quenched by the addition of sat. NH₄Cl solution (200 mL) slowly and stirred for 15 min. 1 M HCl solution was added until a clear solution was observed. The aqueous portion was extracted with EtOAc (250 mL × 3), and the combined organic layer was washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1 to 1:1) to give C3 (14.2 g). ¹H NMR (400 MHz, DMSO-d₆) δ 10.14 (s. 1 H), 8.81 (dd. 1 H), 7.84 (d, 1 H), 7.34 (t, 1 H), 7.10-7.15 (m, 2 H).

Intermediate 3-methylpyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 3-methylpyrazolo[1.5-a]pyridine-2-carboxylic acid.

Intermediate 3-bromopyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 3-bromopyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 4-chloropyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 4-chloropyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 6-bromopyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 6-bromopyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 6-chloropyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 6-chloropyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 7-methylpyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 7-methylpyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 4-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde

Step 1: Preparation of 3-(3-fluoro-2-pyridyl)prop-2-yn-1yl Acetate (C5)

A mixture of 2-bromo-3-fluoro-pyridine (C4) (30 g, 170 mmol), prop-2-yn-1yl acetate (23.41 g, 239 mmol, 1.4 eq), Pd(PPh₃)₂Cl₂ (5.98 g, 8.52 mmol, 0.05 eq), CuI (1.62 g, 8.52 mmol, 0.05 eq) and TEA (51.75 g, 511 mmol, 71.2 mL, 3 eq) in dioxane (300 mL) was degassed and purged with N₂ 3 times, and then the reaction mixture was stirred at 50° C. for 6 hrs under N₂ atmosphere. Reaction progress was checked using TLC (PE:EtOAc=5:1). The reaction mixture was concentrated to dryness. EtOAc (600 mL) was added to the residue, and the organic portion washed with water (300 mL) and brine (300 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, eluent of 0~20% EtOAc/PE, gradient @120 mL/min) to give C5 (23.4 g, 71% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.43 (d, 1 H), 7.46 (td, 1 H). 7.32 (dt, 1 H), 4.99 (s, 2 H), 2.16 (s, 3 H).

Step 2: Preparation of 3-(3-fluoro-2-pyridyl)prop-2-yn-1-ol (C6)

To a solution of 3-(3-fluoro-2-pyridyl)prop-2-ynyl acetate (C5) (23.4 g, 121 mmol) in THF (300 mL) and H₂O (150 mL) and was added LiOH.H₂O (5.34 g, 127 mmol, 1.05 eq) at 0° C. The reaction mixture was stirred at rt for 2 hrs. Reaction progress was checked using TLC (PE:EtOAc= 1:1). EtOAc (600 mL) was added to the reaction mixture, and the organic layer washed with H₂O (400 mL) and brine (400 mL), dried over Na₂SO₄, filtered and concentrated to dryness to afford C6 (17.5 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.34-8.53 (m, 1 H), 7.72-7.88 (m, 1 H), 7.50 (dt, 1 H), 5.54 (t, 1 H), 4.38 (d, 2 H).

Step 3: Preparation of 1-amino-3-fluoro-2-(3-hydroxyprop-1-yn-1-yl)pyridin-1-ium2,4.6-trimethylbenzenesulfonate (C7)

To a mixture of H₂O (35 mL, 1.94 mol, 17.3 eq) and TFA (308.0 g, 2.70 mol, 200 mL. 24.0 eq) was added ethyl (1E)-N-(2,4,6-trimethylphenyl)sulfonyloxyethanimidate (33.70 g, 118 mmol, 1.05 eq) at 0° C., and the reaction mixture was stirred at 0° C. for 2 hrs. The reaction was quenched with ice-water (40 mL). The precipitate was filtered and washed with water (20 mL × 2). The precipitate was then dissolved in DCM (200 mL) and dried over Na₂SO₄ and filtered. To the filtrate was added 3-(3-fluoro-2-pyridyl)prop-2-yn-1-ol (C6) (17 g, 112 mmol, 1 eq) at 0° C. The reaction mixture was warmed to rt for 16 hrs. Reaction progress was checked using TLC (PE:EtOAc=1:1). TBME (400 mL) was slowly added to the reaction mixture, and the precipitate was collected by filtration. The precipitate was rinsed with TBME (200 mL × 2) to afford C7 (26 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.66-8.88 (m, 3 H), 8.32 (t. 1 H), 8.01 (dt, 1 H), 6.75 (s, 2 H), 4.58 (s, 2 H), 3.17 (s, 1 H), 2.49 (s, 6 H), 2.17 (s, 3 H).

Step 4: Preparation of (4-fluoropyrazolo[1,5-a]pyridin-2-yl) Methanol (C8)

To a solution of 1-amino-3-fluoro-2-(3-hydroxyprop-1-yn-1-yl)pyridin-1-ium 2,4,6-trimethylbenzenesulfonate (C7) (26 g, 71.0 mmol) in MeOH (250 mL) was added NaOMe (5.4 M, 26.3 mL, 2 eq) at 0° C. The reaction mixture was stirred at rt for 1 hr. The reaction progress was tracked by TLC (PE:EtOAc=1:1). The reaction mixture was quenched by the addition of ice-cold H₂O (200 mL), concentrated to remove most of the MeOH, and extracted with EtOAc (200 mL × 3). The combined organic layer was washed with brine (400 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give C8 (7.5 g), which was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, 1 H), 6.62-6.88 (m, 3 H), 4.94 (s, 2 H).

Step 5: Preparation of 4-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde (C9)

To a solution of (4-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C8) (7.5 g, 45.1 mmol) in MeCN (150 mL) was added IBX (15.17 g, 54.2 mmol, 1.2 eq). The reaction mixture was stirred at 80° C. for 3 hrs. Reaction progress was checked using TLC (PE:EtOAc=5:1). The reaction mixture was filtered and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~4% EtOAc/PE, gradient @40 mL/min) to give C9 (4 g, 54% yield). ¹H NMR (400 MHz, CDCl₃) δ 10.22 (s, 1 H), 8.33-8.41 (m, 1 H), 7.20 (d, 1 H), 6.85-6.98 (m, 2 H).

Intermediate 4-methylpyrazolo[1,5-alpyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-3-methylpyridine.

Intermediate 4-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-3-(trifluoromethyl)pyridine.

Intermediate 4-methoxypyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-3-methoxypyridine.

Intermediate 5-methylpyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-4-methylpyridine.

Intermediate 5-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-4-fluoropyridine.

Intermediate 5-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 4-(trifluoromelhyl)pyridine.

Intermediate 6-methylpyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-5-methylpyridine.

Intermediate 6-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9. starting with 2-bromo-5-fluoropyridine.

Intermediate 6-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-5-(trifluoromethyl)pyridine.

Intermediate 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde

Step 1: Preparation of 1-amino-2-(trifluoromethyl)pyridin-1-ium 2,4,6-trimethylbenzenesulfonate (C11)

To a mixture of TFA (215.60 g, 1.89 mol. 140 mL, 27.8 eq) and H₂O (20.00 g, 1.11 mol, 20.0 mL, 16.3 eq) was added ethyl (1E)-N-(2,4,6-trimethylphenyl) sulfonyloxyethanimidate (21.34 g, 74.8 mmol, 1.1 eq) at 0° C., and the reaction mixture was stirred at 0° C. for 2 hrs. The reaction was quenched by the addition of ice-water (100 mL), and the precipitate was filtered and rinsed with water (50 mL × 2). The precipitate was then dissolved in DCM (140 mL), dried over Na₂SO₄ and filtered. To the filtrate was added 2-(trifluoromethyl)pyridine (C10) (10 g, 68.0 mmol, 7.87 mL) at 0° C. The reaction mixture was warmed to rt and stirred for 16 hrs. TBME (100 mL) was slowly added to the reaction mixture, and the precipitate was collected and rinsed with TBME (40 mL × 3), and then dried in vacuo to give C11 (8.5 g, 35% yield), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.06 (d, 1 H), 8.40-8.60 (m, 2 H), 8.20-8.26 (m, 1 H), 8.12 (s, 2 H), 6.60 (s, 2 H), 2.34 (s, 6 H), 2.02 (s, 3 H).

Step 2: Preparation of Dimethyl 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2.3-dicarboxylate (C12)

To a mixture of 1-amino-2-(trifluoromethyl)pyridin-1-ium 2,4,6-trimethylbenzenesulfonate (C11) (8.5 g, 23.5 mmol) and K₂CO₃ (6.49 g, 46.9 mmol, 2 eq) in DMF (100 mL) was added dimethyl but-2-ynedioate (6.66 g, 46.9 mmol. 2 eq) at 0° C., The reaction mixture was warmed to rt and stirred for 16 hrs. Reaction progress was tracked by TLC (PE:EtOAc=1:1). Water (200 mL) was added, and the solution was stirred for 30 mins. The resulting precipitate was collected by vacuum filtration, rinsed with water, and dried. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, eluent of 0~40% EtOAc:PE @ 60 mL/min) to give C12 (2.85 g, 40% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (d, 1 H), 7.74-7.96 (m, 2 H), 3.85-3.96 (m, 6 H).

Step 3: Preparation of 2-(methoxycarbonyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (C13)

To a solution of dimethyl 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2,3-dicarboxylate (C12) (2.85 g, 9.43 mmol) in THF (20 mL) was added LiOH.H₂O (1.58 g, 37.7 mmol, 4 eq) in H₂O (20 mL), and the reaction mixture was stirred at rt for 16 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was concentrated in vacuo to remove most of THF, and the aqueous phase was adjusted to pH ~2 with 4 M HCl. The precipitate was collected by filtration and then dried in vacuo to give C13 (2.25 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (d, 1 H), 7.85 (d, 1 H), 7.71-7.76 (m, 1 H).

Step 4: Preparation of 7-(trifluoromethyl) Pyrazolo[1,5-a]pyridine-2-carboxylic Acid (C14)

A mixture of 2-(methoxycarbonyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (C13) (2.25 g, 8.21 mmol) in H₂SO₄ (41.40 g, 422 mmol, 22.5 mL, 51.4 eq) and H₂O (11.25 g. 624 mmol, 11.3 mL, 76.1 eq) was stirred at 90° C. for 16 hrs. Reaction progress was tracked using LC-MS. The reaction mixture was cooled to rt, and water (60 mL) was added. The precipitate was collected by filtration and then dried in vacuo to give C14 (1.7 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.14 (d, 1 H), 7.71 (d, 1 H), 7.41-7.49 (m, 1 H), 7.32 (s, 1 H).

Step 5: Preparation of N-methoxy-N-methyl-7-(trifluoromethyl)pyrazolo[1.5-a]pyridine-2-carboxamide (C15)

To a solution of 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxylic acid (C14) (8.00 g, 34.8 mmol) and N-methoxymethanamine (10.17 g, 104 mmol, 3 eq, HCl) in DMF (80 mL) was added HOBt (7.05 g, 52.1 mmol, 1.5 eq), EDCI (10.00 g, 52.1 mmol. 1.5 eq) and DIPEA (13.48 g. 104 mmol, 18.2 mL, 3 eq). The mixture was stirred at rt for 16 hrs. Reaction progress was tracked using TLC (DCM:MeOH=10:1). DCM (150 mL) was added, and the organic portion washed with sat. Na₂CO₃ solution (100 mL × 2) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, eluent of 0~10% MeOH:DCM @ 60 mL/min) to give C15 (6 g, 60% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.11 (d, 1 H), 7.67 (d, 1 H). 7.37-7.49 (m, 1 H), 7.21 (s. 1 H), 3.77 (s, 3 H), 2.50-2.52 (m, 3 H); LCMS: m/z 274.1 [M+H]⁺.

Step 6: Preparation of 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde (C16)

To a solution of N-methoxy-N-methyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxamide (C15) (6 g, 22.0 mmol) in THF (60 mL) was added DIBAL-H (1 M, 65.9 mL, 3 eq) dropwise at -78° C. under N₂, and then the reaction mixture was stirred at -78° C. for 2 hrs under N₂. Reaction progress was tracked using TLC (PE:EtOAc=5:1). The reaction mixture was quenched by the addition of sat. NH₄Cl solution (150 mL), and then 4 M HCl solution (80 mL) was added. The aqueous portion was extracted with EtOAc (100 mL × 2), and the combined organic layer was washed with water (80 mL) and brine (80 mL). The organic layer was dried over Na₂SO₄, filtered, and evaporated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0~30% EtOAc:PE @ 40 mL/min) to give C16 (3.95 g, 68% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 10.20 (s, 1 H), 8.20 (d, 1 H), 7.79 (d. 1 H), 7.49 (dd. 1 H), 7.40 (s, 1 H).

Intermediate 7-chloropyrazolo[1.5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C16, starting with 2-chloropyridine.

Intermediate 5-(trifluoromethyl)pyrazolo[1,5-alpyridine-2-carbaldehyde was prepared following the general procedure described above for C16, starting with 4-(trifluoromethyl)pyridine.

Intermediate 7-fluoropyrazolo| 1,5-alpyridine-2-carbaldehyde

Step 1: Preparation of Ethyl 7-fluoropyrazolo[1,5-a] pyridine-2-carboxylate (C18)

To a solution of ethyl 7-bromopyrazolo[1,5-a]pyridine-2-carboxylate (C17) (1 g, 3.72 mmol) in DMA (8 mL) was added CsF (1.69 g, 11.2 mmol, 411 µL, 3 eq), the reaction mixture was stirred at 150° C. for 1 hr under microwave. Reaction progress was tracked using LCMS. DCM (60 mL) was added to the reaction mixture, and the organic portion washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 4/1) to give C18 (450 mg, 29% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, 1 H), 7.18-7.26 (m, 2 H), 6.64 (ddd, 1 H), 4.52 (q, 2 H), 1.48 (t, 3 H); LCMS: m/z 208.8 [M+H]⁺.

Step 2: Preparation of (7-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C19)

To a solution of ethyl 7-fluoropyrazolo[1,5-a]pyridine-2-carboxylate (C18) (450 mg, 2.16 mmol) in THF (4 mL) and EtOH (2 mL) was added LiBH₄ (260 mg, 11.9 mmol, 5.5 eq) at 0° C. The reaction mixture was stirred at rt for 2 hrs. Reaction progress was tracked using LCMS. The reaction mixture was quenched by the addition of sat. NH₄Cl solution (10 mL), and the aqueous portion extracted with EtOAc (30 mL). The organic layer was washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give C19 (360 mg), which was used without further purification. LCMS: m/z 167.0 [M+H]⁺.

Step 3: Preparation of 7-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde (C20)

To a solution of (7-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C19) (360 mg, 2.17 mmol) in MeCN (5 mL) was added IBX (971 mg, 3.47 mmol, 1.6 eq), and the reaction mixture was stirred at 80° C. for 1 hr. Reaction progress was tracked using LCMS. The reaction mixture was filtrated and concentrated to dryness to give C20 (355 mg), which was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 10.26-10.46 (m, 1 H). 7.52 (dd, 1 H), 7.22-7.28 (m, 1 H), 7.16 (d, 1 H), 6.69 (ddd. 1 H); LCMS: m/z 165.0 [M+H]⁺.

Intermediate 4-(difluoromethyl)oxazole-5-carboxylic Acid According to General Scheme 4

Step 1: Preparation of Ethyl 2-bromo-4,4-difluoro-3-oxo-butanoate (E1)

To a solution of ethyl 4,4-difluoro-3-oxo-butanoate (20 g, 120 mmol) in DCM (240 mL) was added TsOH (4.15 g, 24.1 mmol, 0.2 eq) and NBS (22.50 g, 126 mmol, 1.05 eq) in portions at 0° C. After addition was complete, the reaction mixture was stirred at rt for 1 hr. The reaction progress was checked using TLC (PE:EtOAc=5:1). DCM was added (100 mL), and the organic portion was washed with sat. Na₂CO₃ solution (100 mL) and brine (150 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to afford E1 (34 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 5.81-6.16 (m, 1 H), 4.34-4.41 (m, 1 H), 4.12-4.20 (m, 2 H), 1.17-1.23 (m, 3 H).

Step 2: Preparation of Ethyl 2-amino-4-(difluoromethyl) Oxazole-5-carboxylate (E2)

A mixture of E1 (37 g. 151 mmol) and urea (45.34 g, 755 mmol, 40.5 mL, 5 eq) in DMF (30 mL) was stirred at 120° C. for 12 hrs. The reaction progress was checked using LC-MS. The reaction mixture was cooled to rt and poured into 100 mL of water. The reaction mixture was stirred for 15 min at 0° C., and the precipitate was collected by filtration, rinsed with water (50 mL), dried in vacuo to give E2 (15.5 g, 63% yield for steps 1 and 2). LC-MS: m/z 207.2 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.86 (s, 2 H), 6.84-7.44 (m, 1 H), 4.27 (q, 2 H). 1.28 (t, 3 H).

Step 3: Preparation of Ethyl 4-(difluoromethyl)oxazole-5-carboxylate (E3)

To a solution of ethyl 2-amino-4-(difluoromethyl)oxazole-5-carboxylate (20 g, 97.0 mmol) in THF (300 mL) was added t-BuONO (30.01 g, 291 mmol, 34.6 mL, 3 eq) dropwise at 0° C. the reaction mixture was stirred at rt for 12 hrs. DCM (300 mL) was added, and the organic portion was washed with water (200 mL) and brine (200 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 10/1) to give E3 (12.7 g, 69% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.05 (s, 1 H), 6.93-7.27 (m, 1 H), 4.44 (q, 2 H), 1.40 (t, 3 H).

Step 5: Preparation of 4-(difluoromethyl)oxazole-5-carboxylic Acid (E4)

To a solution of ethyl 4-(difluoromethyl)oxazole-5-carboxylate (12.7 g, 66.5 mmol) in THF (100 mL) and H₂O (20 mL) was added LiOH.H₂O (3.07 g, 73.1 mmol, 1.1 eq). The reaction mixture was stirred at rt for 1 hr and then concentrated in vacuo to remove THF. Water (80 mL) was added, and the aqueous portion extracted with TBME (50 mL). The aqueous layer was then adjusted to pH~6 by the addition of 0.5 M HCl. The aqueous layer was concentrated to dryness to give E4 (11 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.30 (s, 1 H), 7.34-7.76 (m, 1 H).

Intermediate Ethyl 2-bromo-4-(difluoromethyl)oxazole-5-carboxylate according to General Scheme 4

Preparation of Ethyl 2-bromo-4-(difluoromethyl)oxazole-5-carboxylate (E5)

To a solution of ethyl 2-amino-4-(difluoromethyl)oxazole-5-carboxylate (E2) (25 g, 121 mmol) in MeCN (200 mL) was added CuBr₂ (40.63 g, 182 mmol, 8.5 mL, 1.5 eq) at 0° C. The mixture turned dark green and further stirred for 15 min at rt. t-BuONO (18.76 g, 182 mmol, 21.6 mL, 1.5 eq) was added at 0° C. The reaction was stirred at rt for 2 hrs, and then was heated to 50° C. and stirred for 12 hrs. Reaction progress was tracked using TLC (EtOAc:PE=5:1). The reaction mixture was filtered. DCM (200 mL) was added to the filtrate, and the organic layer was washed by water (100 mL) and brine (100 mL), dried over Na₂SO₄. filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0∼20% EtOAc/PE gradient @ 100 mL/min) to afford E5 (19 g, 58% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.02 (t, 1 H), 4.39 (q, 2 H), 1.35 (t, 3 H).

Intermediate 4-(difluoromethyl)-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylic Acid According to General Scheme 6, Method A

Step 1: Preparation of Ethyl 2-acetyl-4-(difluoromethyl)oxazole-5-carboxylate (E6)

To a solution of ethyl 2-bromo-4-(difluoromethyl)oxazole-5-carboxylate (E5) (10 g, 37.0 mmol) in toluene (150 mL) was added Pd(PPh₃)₂Cl₂ (2.60 g, 3.70 mmol. 0.1 eq) and tributyl(1-ethoxyvinyl)stannane (17.39 g, 48.1 mmol, 16.3 mL, 1.3 eq). The mixture was stirred at 85° C. for 12 hrs under N₂ atmosphere. The reaction progress was checked using TLC (PE:EtOAc). EtOAc (100 mL) was added to the reaction mixture, and the organic portion washed with sat. KF solution (150 mL) and brine (100 mL), dried over Na₂SO₄. filtered, and concentrated to dryness. The residue was dissolved in THF (60 mL) and treated with HCl (4 M, 60 mL), and then was stirred at 40° C. for 12 hrs. The reaction progress was checked by TLC (Petroleum ether:EtOAc=10:1). EtOAc (100 mL) was added to the reaction mixture, and the organic portion washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0∼20% EtOAc/PE gradient @ 40 mL/min) to give E6 (7.1 g. 82% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.00-7.36 (m, 1 H), 4.48 (q, 2 H), 2.66-2.86 (m, 3 H), 1.43 (t, 3 H).

Step 2: Preparation of Ethyl 4-(difluoromethyl)-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylate (E7)

To a solution of E6 (2.5 g, 10.7 mmol) in THF (120 mL) was added MeMgBr (3 M, 7.15 mL, 2 eq) at -78° C. The mixture was stirred at -78° C. for 1 hr. The reaction progress was checked by TLC (PE:EtOAc=2:1). The reaction mixture was quenched by addition of sat. NH₄Cl solution (50 mL) and then water (100 mL) was added. The aqueous portion was extracted with EtOAc (100 mL x 3). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0∼12% EtOAc/PE gradient @ 40 mL/min) to give E7 (3.2 g, 60% yield). ¹H NMR (400 MHz, CDCl₃) δ 6.94-7.29 (m, 1 H), 4.46 (q, 2 H), 2.86 (s, 1 H), 1.72 (s, 6 H), 1.44 (t, 3 H). The starting material E6 (300 mg) was also recovered.

Step 3: Preparation of 4-(difluoromethyl)-2-(1-hydroxy-1-methylethyl)oxazole-5-carboxylic Acid (E8)

To a solution of E7 (3.9 g, 15.7 mmol) in THF (40 mL) and H₂O (40 mL) was added LiOH.H₂O (690 mg, 16.4 mmol, 1.05 eq). The mixture was stirred at rt for 1 hr. The reaction progress was checked using TLC (PE:EtOAc=5:1). The reaction mixture was concentrated to remove THF. The aqueous mixture was then adjusted to pH~3 by the addition of 1 M HCl, and then lyophilized in vacuo to give E8 (4 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 7.35-7.71 (m, 1 H), 5.68 (br s, 1 H), 1.50 (s, 6 H).

Intermediate 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazole-5-carboxylic Acid

Step 1: Preparation of Ethyl 4-(trifluoromethyl)oxazole-5-carboxylate (E10)

To a solution of ethyl 2-amino-4-(trifluoromethyl)oxazole-5-carboxylate (2.00 g, 8.92 mmol) in THF (60 mL) was added t-BuONO (1.84 g, 17.9 mmol, 2.12 mL, 2 eq). The reaction mixture was stirred at 55° C. for 24 hrs. EtOAc (120 mL) was added to the reaction mixture, and the organic portion washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 8/1) to give E10 (1.2 g. 64% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1 H), 4.39 (q, 2 H), 1.34 (t, 3 H).

Step 2: Preparation of Ethyl 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazole-5-carboxylate (E11)

To a solution of ethyl 4-(trifluoromethyl)oxazole-5-carboxylate (1.2 g, 5.74 mmol) in THF (30 mL) was added LiHMDS (1 M, 8.61 mL, 1.5 eq) at -78° C., and the reaction mixture was stirred at -78° C. for 0.5 hr. Cyclobutanone (1.21 g, 17.2 mmol, 1.29 mL, 3 eq) in THF (5 mL) was added to the reaction mixture, and the mixture was stirred at -78° C. for 2 hrs under N₂ atmosphere. The reaction mixture was quenched by the addition of sat. NH₄Cl solution (30 mL), and the aqueous portion extracted with EtOAc (100 mL). The organic layer washed by water (70 mL) and brine (70 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 10/1) to give E11 (600 mg, 37% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.29 (q, 2 H), 2.78-2.94 (m, 1 H), 2.52-2.65 (m, 2 H), 2.24-2.38 (m, 2 H), 1.78-1.98 (m, 3 H), 1.26 (t, 3 H).

Step 3: Preparation of 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazole-5-carboxylic Acid (E12)

To a solution of ethyl 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazole-5-carboxylate (600 mg, 2.15 mmol) in H₂O (2 mL) and THF (10 mL) was added LiOH.H₂O (99.2 mg, 2.36 mmol, 1.1 eq) at 0° C. The reaction mixture was stirred at rt for 2 hrs and concentrated in vacuo to remove THF. Water (10 mL) was added, and the aqueous portion extracted with TBME (30 mL). The aqueous layer was then adjusted to pH~6 by the addition of 0.5 M HCl and concentrated to dryness to give E12 (540 mg), which was used without further purification. ¹H NMR (400 MHz, CD₃OD) δ 2.54-2.67 (m, 2 H), 2.19-2.34 (m, 2 H), 1.81-1.95 (m, 1 H), 1.66-1.80 (m, 1 H).

Intermediate Ethyl 4-bromo-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylate According to General Scheme 6

Step 1: Preparation of Ethyl 4-bromooxazole-5-carboxylate (E14)

Ethyl oxazole-5-carboxylate (E13) (500 mg, 3.54 mmol) was added in THF (2.50 mL) and DMF (2.50 mL) at approximately 10° C. The reaction mixture was cooled to -80° C. and LiHMDS (1 M, 4.61 mL, 1.30 eq) was added dropwise at approximately -80° C. The reaction mixture was stirred at approximately -80° C. for 0.5 hr. Br₂ (736 mg, 4.61 mmol, 1.3 eq) was then added dropwise at approximately -80° C. The reaction mixture was stirred at approximately -80° C. for 0.5 hr. The reaction progress was checked using LC-MS. The reaction mixture was combined with 19 other reactions performed using 500 mg of E13. The combined reaction mixture was poured into sat. citric acid at approximately -10° C. The aqueous portion was extracted with EtOAc (50 mL x 3). The combined organic layer was washed with brine (50 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) to give E14 (3.00 g, 19% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (s, 1 H), 4.29-4.34 (m, 2 H), 1.29 (t, 3 H); LC-MS: m/z 219.9 & 221.9 (M+H)⁺.

Step 2: Preparation of Ethyl 4-bromo-2-iodooxazole-5-carboxylate (E15)

Ethyl 4-bromooxazole-5-carboxylate (E14) (3.15 g, 14.3 mmol, 1.00 eq) was added in THF (15.0 mL) at rt. LiHMDS (1 M, 17.2 mL, 1.20 eq) was added dropwise at approximately -80° C. I₂ (5.45 g. 21.5 mmol, 1.50 eq) in THF (15.0 mL) was then added dropwise at approximately -80° C. The reaction mixture was stirred at approximately -80° C. for 1 hr. The reaction progress was checked using TLC (PE/EtOAc). The reaction mixture was poured into saturated citric acid (30 mL) at approximately -10° C. The aqueous phase was extracted with ethyl acetate (30 mL x 3). The combined organic layer was washed with brine (30 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) to afford E15 (1.10 g, 22% yield). ¹H NMR (400 MHz, DMSO-d₆) δ: 4.29-4.35 (m, 2 H), 1.30 (t, 3 H). LC-MS: m/z 345.8 & 347.9 (M+H)⁺.

Step 3: Preparation of Ethyl 4-bromo-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylate (E16)

Ethyl 4-bromo-2-iodooxazole-5-carboxylate (E15) (1.10 g, 3.18 mmol) was added in THF (10 mL) at approximately 10° C. under N₂. The reaction mixture was degassed under vacuum and purged with N₂ three times. The mixture was cooled to -80° C. and iPr-MgC1.LiCl (1.3 M. 2.45 mL. 1 eq) was added dropwise at approximately -80° C. The reaction mixture was stirred at approximately -80° C. for 0.5 hr, and then acetone (222 mg, 3.82 mmol, 1.20 eq) was added dropwise at approximately -80° C. The mixture was stirred at approximately -80° C. for 0.5 hr. The reaction progress was checked using TLC (PE/EtOAc=5/1). The reaction mixture was poured into sat. citric acid solution (5 mL) at approximately -10° C. The aqueous portion was extracted with ethyl acetate (5 mL x 3). The combined organic layer was washed with brine (5 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) and further purified by prep-HPLC (column: Phenomenex luna C18 80 x 40 mm x 3 um; mobile phase: [water (0.04% HCl)-ACN]; B%: 18%-45%, 7 min) to afford E16 (140 mg, 16% yield). ¹H NMR (400 MHz, DMSO-d₆) δ: 5.93 (s, 1 H), 4.30 - 4.37 (m, 2 H), 1.50 (s, 6 H), 1.32 (t, 3 H). LC-MS: m/z 277.9 & 279.9 (M+H)⁺.

Intermediate Ethyl 4-chloro-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylate according to General Scheme 6

Step 1: Preparation of Ethyl 4-chlorooxazole-5-carboxylate (E17)

Ethyl oxazole-5-carboxylate (E13) (10.0 g, 70.9 mmol) was added in DMF (50 mL) at approximately 10° C. The reaction mixture was cooled to -80° C. and LiHMDS (1 M, 92.1 mL, 1.3 eq) was added dropwise at approximately -80° C. The reaction mixture was stirred at approximately -80° C. for 0.5 hr, and NCS (12.3 g, 92.1 mmol, 1.3 eq) in THF (50 mL) was then added dropwise at approximately -80° C. The mixture was stirred at approximately -80° C. for 0.5 hr. The reaction progress was checked using TLC (PE/EtOAc=5/1). The reaction mixture was combined for workup with seven other reactions each performed using 10 g of E13. The combined reaction mixture was poured into sat. citric acid solution (100 mL) at approximately -10° C. The aqueous portion was extracted with ethyl acetate (100 mL x 3). The combined organic layer was washed with brine (50 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) to afford E17 (18.0 g, 18% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1 H), 4.44 (q, 2 H), 1.42 (t, 3 H); LC-MS: m/z 176.0 (M+H)⁺.

Step 2: Preparation of Ethyl 4-chloro-2-iodooxazole-5-carboxylate (E18)

Three reactions were carried out in parallel. Ethyl 4-chlorooxazole-5-carboxylate (E17) (6.00 g, 34.2 mmol) was dissolved in THF (30 mL) at rt. LiHMDS (1 M, 41.0 mL, 1.2 eq) was added dropwise at approximately -80° C., followed by the dropwise addition of I₂ (13.0 g, 51.3 mmol, 1.5 eq) in THF (30 mL) at approximately -80° C. The reaction mixture was stirred at approximately -80° C. for 1 hr. The reaction progress was checked using TLC (PE/EtOAc=5/1). The three parallel reactions were combined together for workup. The combined reaction mixture was poured into sat. citric acid solution (100 mL) at approximately -5° C. The aqueous portion was extracted with ethyl acetate (100 mL x 3). The combined organic layer was washed with brine (50 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) to afford E18 (10.0 g, 32% yield). ¹H NMR (400 MHz. DMSO-d₆) δ 4.20 - 4.27 (m, 2 H), 1.21 (t, 3 H); LC-MS: m/z 301.9 (M+H)⁺.

Step 3: Preparation of Ethyl 4-chloro-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylate (E19)

Two reactions were carried out in parallel. Compound E18 (5.00 g, 16.6 mmol) was added in THF (50 mL) at approximately 10° C. under N₂. The suspension was degassed under vacuum and purged with N₂ three times. The mixture was cooled to -80° C., and iPr-MgCl.LiCl (1.3 M, 12.8 mL, 1 eq) was added dropwise at approximately -80° C. The mixture was stirred at approximately -80° C. for 0.5 hr, and acetone (1.16 g, 19.9 mmol, 1.2 eq) was then added dropwise at approximately -80° C. The mixture was stirred at approximately -80° C. for 0.5 hr. The reaction progress was checked using TLC (PE/EtOAc=5/1). The two parallel reactions were combined together for workup. The combined reaction mixture was poured into sat. citric acid solution (50 mL) at approximately -10° C. The aqueous portion was extracted with ethyl acetate (50 mL × 3). The combined organic layer was washed with brine (50 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) and further purified by prep-HPLC (column: Phenomenex luna C18 (250 × 70 mm. 15 um); mobile phase: [water (0.05% HCl)-ACN]; B%: 20%-50%, 23 min) to afford E19 (1.80 g, 23% yield). ¹H NMR (400 MHz, DMSO-d₆) δ: 5.92 (s, 1 H), 4.32 - 4.37 (m, 2H), 1.51 (s, 6 H), 1.31 (t, 3H); LC-MS: m/z 234.0 (M+H)⁺.

Intermediate 4-(difluoromethyl)-2-(2-cyanopropan-2-yl)oxazole-5-carboxylic Acid

Step 1: Preparation of 2-cyano-2-methyl-propanoyl Chloride (E20)

To a solution of 2-cyano-2-methyl-propanoic acid (2 g, 17.7 mmol) and DMF (129 mg, 1.77 mmol, 136 µL, 0.1 eq) in DCM (20 mL) was added oxalyl chloride (2.69 g, 21.2 mmol, 1.86 mL, 1.2 eq) dropwise at 0° C., and then the reaction mixture was stirred at rt for 1 hr. The reaction mixture was concentrated to dryness to afford E20 (2.5 g), which was used without further purification.

Step 2: Preparation of Ethyl (Z)-3-[(2-cyano-2-methyl-propanoyl)amino]-4,4-difluoro-but-2-enoate (E21)

To a solution of ethyl (Z)-3-amino-4.4-difluoro-but-2-enoate (2 g, 12.1 mmol) in dioxane (20 mL) was added a solution of 2-cyano-2-methyl-propanoyl chloride (E20) (2.39 g, 18.2 mmol, 1.5 eq) in dioxane (20 mL) at rt. The reaction mixture was stirred at 110° C. for 12 hrs. The reaction progress was checked using TLC (PE/Ethyl acetate=5/1). The reaction mixture was concentrated to dryness, and the residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0~7% EtOAc/PE gradient @ 40 mL/min) to give E21 (2.4 g, 76% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 10.90 (s. 1 H), 6.95-7.27 (m. 1 H), 5.81 (s, 1 H). 4.12-4.29 (m, 2 H), 1.51-1.69 (m, 6 H), 1.20 (t, 3 H); LCMS: m/z 259.1 [M+H]⁺.

Step 3: Preparation of Ethyl 2-(1-cyano-1-methyl-ethyl)-4-(difluoromethyl)oxazole-5-carboxylate (E22)

To a solution of ethyl (Z)-3-[(2-cyano-2-methyl-propanoyl)amino]-4,4-difluoro-but-2-enoate (E21) (2.4 g, 9.22 mmol) in DCE (20 mL) was added BF₃.Et₂O (2.62 g, 18.4 mmol, 2.28 mL, 2 eq) and PIDA (4.16 g, 12.9 mmol, 1.4 eq) at rt. The mixture was stirred at 90° C. for 18 hrs. The reaction progress was checked by TLC (PE/EtOAc). The reaction mixture was concentrated to dryness. DCM (100 mL) was added to the residue, and the organic layer washed with sat. Na₂CO₃ solution (10 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, eluent of 0~7% EtOAc/PE gradient @ 30 mL/min) to give E22 (0.25 g, 11% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.03-7.55 (m, 1 H), 4.35 (q, 2 H), 1.77 (s, 6 H), 1.29 (t, 3 H).

Step 4: Preparation of 2-(1-cyano-1-methyl-ethyl)-4-(difluoromethyl)oxazole-5-carboxylic Acid (E23)

To a solution of ethyl 2-(1-cyano-1-methyl-ethyl)-4-(difluoromethyl)oxazole-5-carboxylate (E22) (0.25 g, 968 µmol) in THF (3 mL) and H₂O (1 mL) was added LiOH.H₂O (48.8 mg, 1.16 mmol, 1.2 eq). The mixture was stirred at rt for 18 hrs. Reaction completeness was checked using TLC (PE:EtOAc=5:1). The reaction mixture was concentrated under reduced pressure to remove THF. The aqueous portion was adjusted with 2 M HCl to pH ~7, and then lyophilized under vacuo to give E23 (0.22 g, 99% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.23-7.74 (m, 1 H), 1.73 (s, 6 H).

Intermediate 4-(difluoromethyl)-2-(pyrimidin-2-yl)oxazole-5-carboxylic Acid According to General Scheme 5, Method B

Step 1: Preparation of Ethyl 4-(difluoromethyl)-2-pyrimidin-2-yl-oxazole-5-carboxylate (E24)

To a solution of ethyl 4-(difluoromethyl)oxazole-5-carboxylate (E4) (1 g. 5.23 mmol), Pd₂(dba)₃ (240 mg, 262 µmol, 0.05 eq), (5-diphenylphosphanyl-9,9-dimethyl-xanthen-4-yl)-diphenyl-phosphane (151 mg, 262 µmol, 0.05 eq) and Cs₂CO₃ (3.41 g, 10.5 mmol, 2 eq) in 1,2-dimethoxyethane (3 mL) was added 2-chloropyrimidine (599 mg, 5.23 mmol) under N₂ atmosphere. The reaction mixture was stirred at 90° C. for 12 hrs. DCM (50 mL) was added to the reaction mixture, and the organic portion washed by water (40 mL) and brine (40 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 1/1) to give E24 (400 mg, 25% yield). ¹H NMR (400 MHz, CDCl₃) δ 9.02 (br d, 2 H). 7.52 (t, 1 H), 7.38 (s, 1 H), 7.24 (s, 1 H), 7.11 (s, 1 H), 4.54 (q, 2 H), 1.48 (t, 3 H).

Step 2: Preparation of 4-(difluoromethyl)-2-pyrimidin-2-yl-oxazole-5-carboxylic Acid (E25)

To a solution of ethyl 4-(difluoromethyl)-2-pyrimidin-2-yl-oxazole-5-carboxylate (E24) (450 mg, 1.67 mmol) in THF (2 mL) and H₂O (2 mL) was added LiOH.H₂O (77.2 mg, 1.84 mmol, 1.1 eq). The reaction mixture was stirred at rt for 1 hr. The reaction mixture was concentrated to remove THF, and H₂O (10 mL) was added. The aqueous layer was extracted with TBME (30 mL). The aqueous layer was then adjusted to pH~6 with 0.5 M HCl and extracted with DCM/MeOH (30/3 mL) 3 times. The combined DCM/MeOH organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness to afford E25 (350 mg), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.06 (d, 2 H), 7.75 (t, 1 H), 7.20-7.57 (m, 1 H).

Intermediate 2-(1-hydroxy-1-methyl-ethyl)-4-methyl-oxazole-5-carboxylic Acid According to General Scheme 4 and General Scheme 6, Method A

Step 1: Preparation of Ethyl 2-amino-4-methyl-oxazole-5-carboxylate (E26)

A mixture of ethyl 2-chloro-3-oxo-butanoate (55 g, 334 mmol, 46.2 mL) and urea (100.34 g, 1.67 mol, 89.6 mL, 5 eq) in DMF (100 mL) was stirred at 120° C. for 12 hours. Reaction progress was checked using TLC (PE:EtOAc=5:1). The reaction mixture was cooled to rt, poured into H₂O (400 ml), and stirred at 0° C. for 30 min. The solid was collected by filtration, rinsed with water (30 mL), and then dried in vacuo to give E26 (22.2 g, 39% yield). ¹H NMR (400 MHz, CD₃OD) δ 4.29 (q, 2 H), 2.32 (s, 3 H), 1.35 (t, 3 H).

Step 2: Preparation of Ethyl 2-bromo-4-methyl-oxazole-5-carboxylate (E27)

To a solution of E26 (11.1 g, 65.2 mmol) in MeCN (120 mL) was added CuBr₂ (21.85 g, 97.9 mmol, 4.58 mL, 1.5 eq) at 0° C. The mixture turned dark green and was further stirred for 15 min at rt. t-BuONO (10.09 g, 97.9 mmol, 11.6 mL, 1.5 eq) was added. The reaction was stirred at rt for 2 hrs and then heated at 50° C. for 4 hrs. Reaction progress was checked using TLC (Petroleum ether:EtOAc=3:1). The reaction mixture was concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash®: Silica Flash Column, eluent of 0~5% EtOAc/PE gradient @ 100 mL/min) to give E27 (8.5 g, 56% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.25-4.35 (m, 2 H), 2.45 (s, 3 H), 1.32 (t, 3 H).

Step 3: Preparation of Ethyl 2-acetyl-4-methyloxazole-5-carboxylate (E28)

A mixture of E27 (9.5 g, 40.6 mmol), tributyl(1-ethoxyvinyl) stannane (17.59 g, 48.7 mmol, 16.4 mL, 1.2 eq) and Pd(PPh₃)₂Cl₂ (2.85 g, 4.06 mmol, 0.1 eq) in toluene (200 mL) was stirred at 90° C. for 12 hrs under N₂ atmosphere. Reaction progress was checked using TLC (Petroleum ether:EtOAc=5:1). EtOAc (300 ml) was added, followed by sat. KF solution (500 ml). The resulting mixture was stirred at rt for 40 min, the mixture filtered, and the filtrate separated. The organic layer was washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was dissolved in THF (300 ml), and 4 N HCl (300 ml) was added. The mixture was stirred at rt for 12 hrs. LCMS indicated the desired mass was detected. The reaction mixture was extracted with DCM (100 mL × 3). The combined organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 24 g SepaFlash® Silica Flash Column, eluent of 0~10% EtOAc/PE gradient @ 35 mL/min) to give E28 (6.8 g, 85% yield). ¹H NMR (400 MHz. CDCl₃) δ 4.35 (q. 2 H), 2.62 (s, 3 H), 2.48 (s. 3 H), 1.34 (t, 3 H); LCMS: m/z 198.1 (M+H)⁺.

Step 4: Preparation of Ethyl 2-(2-hydroxypropan-2-yl)-4-methyloxazole-5-carboxylate (E29)

To a solution of E28 (2.5 g, 12.7 mmol) in THF (25 mL) was added MeMgBr (3 M, 12.7 mL, 3 eq) dropwise under N₂ at -78° C. The reaction was stirred at -78° C. for 1.5 hr. Reaction progress was checked using TLC (Petroleum ether:EtOAc=5:1, by UV). The reaction was quenched by the addition of sat. NH₄Cl solution (30 mL) slowly and then the organic portion extracted with EtOAc (30 mL × 3). The combined organic phase was washed with brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, Petroleum ether/EtOAc=1/0 to 1/1) to give E29 (1.7 g, 63% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.39 (q. 2 H), 2.47 (s, 3 H). 1.67 (s, 6 H), 1.40 (t, 3 H).

Altematively, E29 can be prepared by reacting 2-hydroxy-2-methylpropanamide with ethyl 2-chloro-3-oxo-butanoate in a neat reaction at 150° C. for 6 hrs.

Step 5: Preparation of Ethyl 2-(2-hydroxypropan-2-yl)-4-methyloxazole-5-carboxylic Acid (E30)

To a solution of E29 (3.4 g, 16.0 mmol) in THF (30 mL) and H₂O (15 mL) was added LiOH.H₂O (803 mg, 19.1 mmol, 1.2 eq). The reaction was stirred at rt for 1.5 hr. Reaction progress was tracked using LCMS. The reaction mixture was adjusted to pH 7 with HCl (1 M) and concentrated to dryness to afford E30 (4 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 5.67 (s, 1 H), 2.30 (s, 2 H), 1.44 (s, 6 H); LCMS: m/z 186.1 (M+H)⁺.

Intermediate 4-cyclopropyl-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylic Acid According to General Scheme 4

Step 1: Preparation of Ethyl 2-bromo-3-cyclopropyl-3-oxo-propanoate (E31)

To a solution of ethyl 3-cyclopropyl-3-oxo-propanoate (8 g, 51.2 mmol) in DCM (100 mL) was added NBS (9.12 g, 51.2 mmol) and TsOH.H₂O (1.95 g, 10.2 mmol, 0.2 eq). The reaction mixture was stirred at rt for 2 hrs. Reaction progress was tracked using TLC (PE:EtOAc=10:1). The reaction mixture was concentrated to dryness. EtOAc (120 mL) was added to the residue, and the mixture filtered. The filtrate was washed with sat. NaHCO₃ solution (2 × 100 mL) and water (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1:0 to 10:1) to give E31 (12 g, 100% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 5.71 (s, 1 H), 4.18 (q, 2 H), 2.14-2.28 (m, 1 H), 1.18 (t, 3 H), 1.01-1.08 (m, 2 H), 0.89-0.96 (m, 2 H); LCMS: m/z 235.0 [M+H]⁺.

Step 2: Preparation of Ethyl 4-cyclopropyl-2-(1-hydroxy-1-methylethyl)oxazole-5-carboxylate (E32)

To a solution of ethyl 2-bromo-3-cyclopropyl-3-oxo-propanoate (E31) (1 g, 4.25 mmol) in DMF (2 mL) was added 2-hydroxy-2-methyl-propanamide (2.19 g, 21.3 mmol, 5 eq). The mixture was stirred at 110° C. for 40 hrs. Reaction progress was tracked using LC-MS. The reaction mixture was adjusted to pH~8 by addition of sat. aq. NaHCO₃ at 0° C. H₂O (50 mL) was added, and the aqueous portion extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1:0 to 2:1) to give E32 (0.15 g, 14% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 5.70 (s. 1 H), 4.29 (q, 2 H), 2.40-2.45 (m, 1 H). 1.43 (s, 6 H), 1.27 (t, 3 H), 0.94-1.04 (m, 2 H), 0.79-0.92 (m, 2 H); LCMS: m/z 240.0 [M+H]⁺.

Step 3: Preparation of 4-cyclopropyl-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylic Acid (E33)

To a solution of ethyl 4-cyclopropyl-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylate (E32) (590 mg, 2.47 mmol) in THF (4 mL) and H₂O (4 mL) was added LiOH.H₂O (114 mg. 2.71 mmol, 1.1 eq). The reaction mixture was stirred at rt for 16 hrs. Reaction progress was tracked using LC-MS. The reaction mixture was concentrated to remove THF. The aqueous portion was adjusted to pH~7 by the addition of HCl (1 M) and then lyophilized to give E33 (550 mg, 90% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 2.70-2.84 (m. 1 H), 1.39 (s, 6 H). 0.62-0.81 (m, 4 H); LCMS: m/z 212.0 [M+H]⁺.

Intermediate 4-cyanooxazole-5-carboxylic Acid

Step 1: Preparation of Ethyl 4-cyanooxazole-5-carboxylate (E34)

To a solution of ethyl 4-bromooxazole-5-carboxylate (E14) (10 g, 45.5 mmol) in THF (30 mL) and H₂O (150 mL) was added Zn(CN)₂ (3.74 g, 31.8 mmol, 2.02 mL, 0.7 eq) and t-BuXPhos-Pd-G3 (1.81 g, 2.27 mmol, 0.05 eq). The reaction mixture was degassed under vacuum and purged with N₂ 3 times, and then the mixture was stirred at 40° C. for 16 hrs under N₂. Reaction progress was tracked using TLC (PE:EtOAc=5:1). EtOAc(300 mL) was added to the reaction mixture, and the organic layer washed with H₂O (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=100/1 to 10/1) to give E34 (7.5 g, 99% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.89 (s, 1 H), 4.37 (q, 2 H), 1.30 (t, 3 H).

Step 2: Preparation of (4-cyanooxazole-5-carbonyl)oxylithium (E35)

To a solution of E34 (5 g, 30.1 mmol) in THF (40 mL) and H₂O (80 mL) was added LiOH.H₂O (1.33 g, 31.6 mmol, 1.05 eq). The mixture was stirred at rt for 2 hrs. Reaction progress was tracked using TLC (PE:EtOAc=5:1). The reaction mixture was concentrated in vacuo to remove most of the THF and then lyophilized in vacuo to give E35 (4.5 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (s, 1 H).

Intermediate [5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carbonyl]oxylithium According to General Scheme 9

Step 1: Preparation of Ethyl 5-methylsulfanyl-1,3,4-oxadiazole-2-carboxylate (E36)

A mixture of ethyl 2-hydrazino-2-oxo-acetate (16 g, 121 mmol) and di(1H-imidazol-1-yl)methanethione (25.90 g, 145 mmol, 1.2 eq) in THF (300 mL) was stirred at rt for 12 hrs, and then heated to 75° C. for 4 hrs. After cooling to rt, K₂CO₃ (50.21 g, 363 mmol, 3 eq) and CH₃I (85.95 g, 606 mmol, 37.7 mL, 5 eq) were added. The resulting mixture was stirred at rt for 2 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was combined with another reaction performed with 8.5 g of ethyl 2-hydrazino-2-oxo-acetate and quenched by the addition of H₂O (100 mL). DCM (500 mL) was added, and the organic layer was separated and washed with brine (2 × 100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (Eluent of 0~25% PE:EtOAc @ 40 mL/min) to give E36 (25 g). ¹H NMR (400 MHz, CDCl₃) δ 4.43 (q, 2 H), 2.72 (s, 3 H), 1.38 (t, 3 H).

Step 2: Preparation of Ethyl 5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carboxylate (E37)

A mixture of E36 (233 mg, 1.24 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)pyrazole (410 mg, 1.49 mmol, 1.2 eq), Na₂CO₃ (394 mg, 3.71 mmol, 3 eq), thiophene-2-carbonyloxycopper (472 mg, 2.48 mmol, 2 eq) and Pd(dppf)Cl₂ (181 mg, 248 µmol, 0.2 eq) in dioxane (9 mL) was degassed and purged with N₂ 3 times, and then the reaction mixture was stirred at 75° C. for 16 hrs under N₂. Reaction progress was tracked using TLC (PE:EtOAc=2:1). EtOAc (100 mL) was added to the reaction mixture, and the organic layer washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 2/1) to give E37 (140 mg, 39% yield). ¹H NMR (400 MHz, CD₃OD) δ 8.61 (s, 1 H). 8.22 (s. 1 H), 5.12 (q, 2 H), 4.51 (q, 2 H), 1.44 (t, 3 H); LCMS: m/z 291.1 (M+H)⁺.

Step 3: Preparation of [5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carbonyl]oxylithium (E38)

To a solution of E37 (140 mg. 482 µmol) in THF (1.5 mL) was added LiOH.H₂O (22.3 mg, 531 µmol, 1.1 eq) in H₂O (3 mL). The reaction mixture was stirred at rt for 2 hrs. Reaction progress was tracked using TLC (DCM:MeOH). The reaction mixture was concentrated in vacuo to remove most of the THF and then lyophilized in vacuo to give E38 (115 mg), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.58 (s, 1 H), 8.14 (s, 1 H), 5.27 (q, 2 H).

Alternatively, ethyl 5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carboxylate (E37) can be prepared accordingly to the following scheme.

Step A: Preparation of Ethyl 1-(2,2.2-trifluoroethyl)pyrazole-4-carboxylate (E39)

To a solution of ethyl 1H-pyrazole-4-carboxylate (10 g, 71.4 mmol) and K₂CO₃ (19.72 g. 142 mmol, 2 eq) in DMF (45 mL) was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (21.53 g, 92.8 mmol, 1.3 eq) dropwise, and then the resulting mixture was stirred at 50° C. for 6 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). EtOAc (300 mL) was added to the reaction mixture, and the organic layer washed with H₂O (100 mL) and brine (2 × 100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0~12% PE/EtOAc @ 60 mL/min) to give E39 (16 g). ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, 2 H), 4.73 (q, 2 H), 4.32 (q, 2 H), 1.36 (t, 3 H).

Step B: Preparation of 1-(2,2,2-trifluoroethyl)pyrazole-4-carbohydrazide (E40)

To a solution of E39 (16 g, 72.0 mmol) in THF (100 mL) was added NH₂NH₂.H₂O (7.73 g. 151 mmol. 7.5 mL, 98% purity. 2.1 eq), and then the reaction mixture was stirred at 80° C. for 15 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was concentrated to dryness. The residue was triturated with TBME (50 mL) and stirred for 15 min. The precipitate was collected by filtration, and then dried in vacuo to give E40 (13 g). ¹H NMR (400 MHz, CD₃OD) δ 8.19 (s, 1 H), 7.93 (s, 1 H), 4.98 (q, 2 H).

Step C: Preparation of Ethyl N-[[1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino] carbamate (E41)

To a solution of E40 (3 g, 14.4 mmol) in THF (70 mL) was added ethyl 2-chloro-2-oxo-acetate (2.36 g, 17.3 mmol, 1.9 mL, 1.2 eq) dropwise at 0° C., and then the reaction mixture was stirred at rt for 3 hrs. The precipitate was collected by filtration and rinsed with TBME (30 mL), and then dried in vacuo to give E41 (1.5 g. 37% yield). ¹H NMR (400 MHz, CDCl₃) δ 9.75 (br s, 1 H), 9.06 (br s, 1 H), 8.25 (s, 1 H), 7.99 (s, 1 H), 4.76 (q, 2 H), 4.42 (q, 2 H), 1.42 (t, 3 H).

Step D: Preparation of Ethyl 5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carboxylate (E37)

To a solution of E41 (1.5 g, 5.35 mmol) and Et₃N (271 mg, 2.68 mmol, 373 µL, 0.5 eq) in DCM (30 mL) was added TsCl (491 mg, 6.96 mmol, 1.3 eq) in portions at 0° C., and then the resulting mixture was stirred at rt for 18 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). DCM (100 mL) was added to the reaction mixture, and the organic layer washed with sat. Na₂CO₃ solution (60 mL) and brine (60 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~16% PE/EtOAc @ 40 mL/min) to give E37 (0.65 g, 42% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.16-8.29 (m, 2 H), 4.80 (q, 2 H), 4.53 (q, 2 H). 1.47 (t, 3 H).

Intermediate Lithium 5-morpholino-1,3,4-oxadiazole-2-carboxylate According to General Scheme 10

Step 1: Preparation of Ethyl 5-bromo-1, 3, 4-oxadiazole-2-carboxylate (E42)

To a solution of ethyl 5-amino-1,3.4-oxadiazole-2-carboxylate (5 g, 31.8 mmol) in MeCN (60 mL) was added CuBr₂ (10.66 g, 47.7 mmol, 2.2 mL, 1.5 eq) at 0° C. The reaction mixture turned dark green and was stirred for 15 min at rt. t-BuONO (4.92 g, 47.7 mmol. 5.7 mL, 1.5 eq) was added at 0° C., and the reaction mixture was stirred at rt for 2 hrs, then heated at 50° C. for another 12 hrs. The reaction progress was checked using TLC (PE/EtOAc=1/1). The reaction mixture was filtered and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0~50% EtOAc/PE gradient @ 40 mL/min) to give E42 (4.5 g, 64% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.52 (q, 2 H), 1.45 (t, 3 H).

Step 2: Preparation of Ethyl 5-morpholino-1,3,4-oxadiazole-2-carboxylate (E43)

To a solution of ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate (E42) (1 g, 4.52 mmol) and morpholine (473 mg, 5.43 mmol, 478 µL, 1.2 eq) in THF (40 mL) was added DIPEA (1.17 g, 9.05 mmol, 1.6 mL, 2 eq) at 0° C. The mixture was stirred at rt for 1 hr. The reaction progress was checked using TLC (PE/EtOAc=1/1). EtOAc (100 mL) was added to the reaction mixture, and the organic portion washed with water (30 mL) and brine (30 mL × 2), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~30% EtOAc/PE gradient @ 35 mL/min) to give E43 (800 mg, 78% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 4.37 (q, 2 H). 3.68-3.74 (m, 4 H), 3.48-3.52 (m, 4 H), 1.31 (t, 3 H).

Step 3: Preparation of (5-morpholino-1, 3, 4-oxadiazole-2-carbonyl) oxylithium (E44)

To a solution of ethyl 5-morpholino-1, 3, 4-oxadiazole-2-carboxylate (E43) (800 mg, 3.52 mmol) in THF (8 mL) and H₂O (12 mL) was added LiOH.H₂O (162 mg, 3.87 mmol, 1.1 eq). The reaction mixture was stirred at rt for 12 hrs. The reaction progress was checked using TLC (PE/EtOAc=1/1). The reaction mixture was concentrated to dryness to afford E44 (600 mg), which was used without further purification. ¹H NMR (400 MHz. DMSO-d₆) δ 3.62-3.74 (m, 4 H), 3.36 (br d, 4 H).

Intermediate [5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carbonyl]oxylithium According to General Scheme 9, Method A

Step 1: Preparation of Methyl 5-fluoropyridine-2-carboxylate (E45)

A solution of 5-fluoropyridine-2-carbonitrile (15 g. 123 mmol) in HCl/MeOH (4 M, 180 mL. 5.9 eq) was stirred at 60° C. for 12 hrs. The reaction mixture was concentrated in vacuo, and the residue was dissolved in EtOAc (150 mL), washed with sat. NaHCO₃ solution (50 mL) and brine (20 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~25% EtOAc/PE gradient @ 60 mL/min) to give E45 (15.24 g, 80% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, 1 H), 8.20 (dd, 1 H), 7.53 (ddd, 1 H), 4.00 (s, 3 H).

Step 2: Preparation of 5-fluoropyridine-2-carbohydrazide (E46)

A mixture of methyl 5-fluoropyridine-2-carboxylate (E45) (16 g, 103 mmol), NH₂NH₂.H₂O (11.06 g, 217 mmol, 10.7 mL, 98% purity, 2.1 eq) in EtOH (70 mL) was degassed and purged with N₂ for 3 times, and then the reaction mixture was stirred at rt for 3 hrs under N₂ atmosphere. The reaction mixture was concentrated to dryness to give E46 (15 g, 94% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 9.89 (br s, 1 H). 8.61 (d, 1 H). 8.07 (dd, 1 H), 7.88 (td, 1 H), 4.57 (br s, 2 H).

Step 3: Preparation of Ethyl 2-[2-(5-fluoropyridine-2-carbonyl)hydrazino]-2-oxo-acetate (E47)

To a mixture of 5-fluoropyridine-2-carbohydrazide (E46) (13.5 g, 87.0 mmol) and TEA (17.61 g, 174 mmol, 24.2 mL, 2 eq) in DCM (500 mL) was added ethyl 2-chloro-2-oxo-acetate (15.45 g, 113 mmol, 12.7 mL, 1.3 eq) over a period of 10 min at 0° C. The reaction mixture was stirred for 2 hrs at rt. H₂O (100 mL) was added to the reaction mixture, and the aqueous portion extracted with DCM (300 mL × 3). The combined organic layer was washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~2.5% EtOAc/PE gradient @ 60 mL/min) to give E47 (16 g, 53% yield). ¹H NMR (400 MHz, CDCl₃) δ 10.03-10.15 (m, 1 H), 9.65 (br d, 1 H), 8.35-8.42 (m, 1 H), 8.11-8.18 (m, 1 H), 7.51 (td, 2 H). 4.35 (q, 1 H), 1.34 (t, 3 H); LCMS: m/z 256.2 [M+H]⁺.

Step 4: Preparation of Ethyl 5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carboxylate (E48)

To a solution of ethyl 2-[2-(5-fluoropyridine-2-carbonyl)hydrazino]-2-oxo-acetate (E47) (16 g, 62.7 mmol) in DCM (350 mL) was added TEA (8.25 g, 81.5 mmol, 11.3 mL, 1.3 eq) and TosCl (5.98 g, 31.4 mmol, 0.5 eq) in 3 portions at 0° C. The mixture was stirred at rt for 3 hrs. Sat. NaHCO₃ solution (200 mL) was added, and the aqueous portion extracted with DCM (400 mL × 3). The combined organic layer was washed with brine (200 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®, 120 g SepaFlash® Silica Flash Column, Eluent of 0~2.5% MeOH/DCM@ 85 mL/min) to give E48 (8.2 g, 49% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, 1 H), 8.39 (dd, 1 H), 7.66 (ddd, 1 H), 4.59 (q, 2 H), 1.51 (t, 3 H); LCMS: m/z 238.2 [M+H]⁺.

Step 5: Preparation of [5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carbonyl]oxylithium (E49)

To a solution of ethyl 5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carboxylate (E48) (12 g. 50.6 mmol) in THF (140 mL) and H₂O (180 mL) was added LiOH.H₂O (2.23 g, 53.1 mmol, 1.05 eq). The mixture was stirred at rt for 2 hrs. The reaction mixture was concentrated in vacuo to remove most of THF, and the aqueous portion was lyophilized in vacuo to give E49 (11.5 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.79 (d, 1 H). 8.24 (dd, 1 H), 7.99 (td, 1 H).

Intermediate 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylic Acid

Step 1: Preparation of Ethyl 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate (E50)

To a solution of (Z)-ethyl 2-(ethoxymethylene)-4,4-difluoro-3-oxobutanoate (1 g, 4.52 mmol) in THF (8 mL) was added 2,2,2-trifluoroethylhydrazine (670 mg, 5.88 mmol, 1.3 eq) dropwise at 0° C. The reaction mixture was stirred at 0° C. for 1 hr, and then stirred at rt for 16 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated to dryness, and the residue was purified by flash silica gel chromatography (Eluent: 0~5% EtOAc/PE gradient) to give E50 (850 mg, 69% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.02 (s, 1 H), 7.38-7.75 (m, 1 H), 4.95 (q, 2 H), 4.37 (q, 2 H). 1.40 (t, 3 H); LCMS: m/z 273.1 [M+H]⁺.

Step 2: Preparation of 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylic acid (E51)

To a solution of ethyl 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate (E50) (910 mg, 3.34 mmol) in THF (5 mL) and H₂O (5 mL) was added LiOH.H₂O (224 mg. 5.35 mmol, 1.6 eq). The mixture was stirred at rt for 2 hrs. The reaction progress was checked using TLC (PE:EtOAc=2:1). The reaction mixture was concentrated to remove THF. The aqueous portion was adjusted to pH~6 by the addition of HCl (1 M). The resulting precipitate was collected by filtration and then dried in vacuo to give E51 (816 mg, 100% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.08 (s, 1 H), 7.45-7.78 (m, 1 H), 5.30 (q, 2 H).

Intermediate Ethyl 2-(2-pyridyl)pyrazole-3-carboxylate

Step 1: Preparation of Ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate (E52)

Ethyl 2-oxopropanoate (2 g, 17.2 mmol, 1.9 mL) and 1,1-dimethoxy-N,N-dimethyl-methanamine (2.09 g, 17.6 mmol, 2.3 mL, 1.02 eq) were stirred at rt for 12 hrs. The reaction progress was checked using TLC (PE:EtOAc=10:1). The reaction mixture was concentrated to dryness to give E52 (2.4 g), which was used without further purification.

Step 2: Preparation of Ethyl 2-(2-pyridyl)pyrazole-3-carboxylate (E53)

A mixture of ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate (E52) (2.4 g, 14.0 mmol) and 2-pyridylhydrazine (1.53 g, 14.0 mmol) in HOAc (100 mL) was stirred at 110° C. for 12 hrs. The reaction progress was checked using TLC (PE:EtOAc=10:1). The reaction mixture was adjusted to pH ~9 by the addition of sat. Na₂CO₃ solution. The aqueous portion was extracted with EtOAc (300 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=100/1 to 50/1) to give E53 (1.03 g, 34% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.48 (dt, 1 H), 8.05 (td, 1 H), 7.83-7.96 (m, 1 H), 7.76 (d, 1 H), 7.49 (ddd, 1 H), 6.96-7.05 (m, 1 H), 4.21 (q, 2 H), 1.05-1.23 (m, 3 H); LCMS: m/z 218.1 [M+H]⁺.

Ethyl 1-(2-pyridyl)pyrazole-3-carboxylate (E53a) was also obtained (190 mg, 6% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.70-8.81 (m, 1 H), 8.54 (dd, 1 H), 7.92-8.13 (m, 2 H), 7.47 (ddd, 1 H), 7.02 (d, 1 H), 4.35 (q, 2 H), 1.34 (t, 3 H). The regiochemistry of E53 and E53a were confirmed by HSQC and HMBC NMR analysis.

Step 3: Preparation of 2-(2-pyridyl)pyrazole-3-carboxylic Acid (E54)

To a solution of ethyl 2-(2-pyridyl)pyrazole-3-carboxylate (E53) (1 g, 4.60 mmol) in THF (10 mL) and H₂O (10 mL) was added LiOH.H₂O (386 mg, 9.21 mmol, 2 eq), and the reaction mixture was stirred at rt for 12 hrs. The reaction progress was checked using TLC (PE/EtOAc=1/1). The reaction mixture was concentrated under reduced pressure to remove THF. The aqueous portion was adjusted to pH~7 by the addition of 2 M HCl and lyophilized in vacuo to give (E54) (1.2 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36-8.44 (m, 1 H), 7.88 (td, 1 H), 7.44-7.53 (m, 2 H), 7.35 (ddd. 1 H), 6.44 (d. 1 H).

Intermediate [5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carbonyl]oxylithium

Step 1: Preparation of Tert-butyl (Z)-2-(1-amino-2-ethoxy-2-oxoethylidene)hydrazine-1-carboxylate (E55)

Tert-butyl (Z)-2-(1-amino-2-ethoxy-2-oxoethylidene)hydrazine-1-carboxylate was prepared from ethyl 2-amino-2-thioxoacetate following the procedure in Bioorg. Med. Chem., 26 (2016) 3223-3225. The reaction was heated to reflux.

Step 2: Preparation of Ethyl 3-(difluoromethyl)-1H-1,2,4-triazole-5-carboxylate (E56)

Reagent 2,2-difluoroacetyl chloride was prepared by adding oxalyl dichloride (18.90 g, 149 mmol, 13.0 mL, 1.1 eq) dropwise at 0° C. to a solution of 2,2-difluoroacetic acid (13 g, 135 mmol, 8.5 mL) and DMF (989 mg, 13.5 mmol, 1.0 mL, 0.1 eq) in DCM (80 mL). The reaction mixture was stirred at rt for 1 hr, and the solution was used without further purification.

To a solution of tert-butyl (Z)-2-(1-amino-2-ethoxy-2-oxoethylidene)hydrazine-1-carboxylate (E55) (13 g, 56.2 mmol) in pyridine (90 mL) was added 2.2-difluoroacetyl chloride (15.47 g, 135 mmol, 2.4 eq). The reaction mixture was heated to 120° C. and stirred for 12 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated to dryness. DCM (200 mL) was added to the residue, and the organic portion washed with 1 M HCl (30 mL) and brine (60 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1 to 2:1) to give E56 (8.87 g, 83% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.01-7.32 (m, 1 H), 4.36 (q, 2 H), 1.30 (t, 3 H); LCMS: m/z 192.0 [M+H]⁺.

Step 3: Preparation of Ethyl 5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carboxylate (E57)

To a solution of ethyl 3-(difluoromethyl)-1H-1,2,4-triazole-5-carboxylate (E56) (10 g, 52.3 mmol) in DMF (80 mL) was added MeI (22.28 g, 157 mmol, 9.8 mL, 3 eq) and K₂CO₃ (21.69 g, 157 mmol, 3 eq). The mixture was stirred at rt for 12 hrs. Reaction progress was checked using TLC (PE:EtOAc=1:1). The reaction mixture was filtered, and the precipitate was rinsed with EtOAc (150 mL). The filtrate was washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1 to 1:1) to give E57 (4.46 g, 42% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 6.99-7.34 (m, 1 H), 4.39 (q, 2 H), 4.11-4.22 (m, 3 H), 1.35 (t. 3 H).

Step 4: Preparation of [5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carbonyl]oxylithium (E58)

To a solution of ethyl 5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carboxylate (E57) (2.35 g, 11.5 mmol) in THF (40 mL) and H₂O (10 mL) was added LiOH.H₂O (505 mg, 12.0 mmol, 1.05 eq). The reaction mixture was stirred at rt for 1 hr. Reaction progress was checked using TLC (PE:EtOAc=2:1). The reaction mixture was concentrated in vacuo to remove THF. H₂O (20 mL) was added, and the aqueous portion extracted with TBME (20 mL), and then lyophilized in vacuo to give E58 (2.15 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 6.75-7.21 (m, 1 H), 4.09 (s, 3 H).

Intermediate Ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate

Step 1: Preparation of N′,2-dihydroxy-2-methyl-propanamidine (E59)

To a solution of 2-hydroxy-2-methyl-propanenitrile (2.14 g, 25.2 mmol, 2.3 mL) in EtOH (20 mL) was added hydroxylamino hydrochloride (3.49 g, 50.3 mmol, 2 eq) and Na₂CO₃ (5.33 g, 50.3 mmol, 2 eq), and then the reaction was stirred at 70° C. for 16 hrs. The reaction mixture was concentrated to dryness. EtOAc (200 mL) was added to the residue, and the organic portion washed twice with water (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to afford E59 (1 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 10.11 (s, 1 H), 8.86 (s. 1 H), 5.03 (br s, 1 H), 1.70 (s, 3 H), 1.66 (s, 3 H).

Step 2: Preparation of Ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate (E60)

To a solution of N′,2-dihydroxy-2-methyl-propanamidine (E59) (520 mg, 4.40 mmol) and pyridine (696 mg, 8.80 mmol, 711 µL, 2 eq) in toluene (15 mL) was added ethyl 2-chloro-2-oxo-acetate (601 mg, 4.40 mmol, 493 µL) at 0° C. The reaction mixture was stirred at rt for 1 hr, and then stirred at 100° C. for 15 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 2/1) and further purified by prep-HPLC (column: Boston Uni C18 40*150*5 um;mobile phase: [water(0.225%FA)-ACN];B%: 16%-46%,7.7 min) to give E60 (250 mg. 28% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.52 (q, 2 H), 2.65 (br s, 1 H), 1.67 (s, 6 H), 1.45 (t, 3 H); LCMS: m/z 201.1 [M+H]⁺.

Step 3: Preparation of Ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate (E61)

To a solution of ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate (E60) (200 mg, 999 µmol) in THF (5 mL) and H₂O (5 mL) was added LiOH.H₂O (41.9 mg, 999 µmol), and then the reaction mixture was stirred at rt for 1 hr. The solvent was removed in vacuo, and the aqueous portion was lyophilized in vacuo to give E61 (170 mg), which was used without further purification.

Intermediates E62, E63, E64, E65, E66. and E67

Step A: Preparation of Methyl 6-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E62) and Methyl 6-bromo-7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E63)

To a solution of methyl 6-bromopyrazolo[1,5-a]pyridine-3-carboxylate (1 g, 3.92 mmol) in THF (10 mL) was added i-PrMgCl-LiCl (1.3 M, 6.03 mL, 2 eq) at -78° C. The reaction mixture was stirred at -78° C. for 15 min, then acetone (1.37 g, 23.5 mmol, 1.7 mL, 6 eq) was added dropwise to the reaction mixture. The reaction mixture was stirred at -78° C. for 1 hr. Reaction progress was checked using LCMS. The reaction mixture was dropwise added to 10 mL of aq. NH₄Cl solution. Water (30 mL) was added, and the aqueous portion extracted with EtOAc (25 mL x 2). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 20:1) to give E62 (320 mg, 34% yield) and E63 (300 mg, 23% yield).

E62: ¹H NMR (400 MHz, CD₃OD) δ 8.40-8.54 (m. 1 H), 8.14 (dd, 1 H), 7.57 (dd, 1 H), 7.27 (dd, 1 H), 3.88-4.03 (m, 3 H), 1.77-1.92 (m, 6 H); LCMS: m/z 235.2 [M+H]⁺.

E63: ¹H NMR (400 MHz, CD₃OD) δ 8.46 (s, 1 H), 8.02 (d, 1 H), 7.76 (d, 1 H), 3.93 (s, 3 H), 1.95 (s, 6 H): LCMS: m/z 313.0 [M+H]⁺.

Step B: Preparation of 6-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic Acid (E64)

To a solution of methyl 6-(1-hydroxy-1-methyl-ethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E62) (500 mg, 2.13 mmol) in MeOH (3 mL) and H₂O (1 mL) was added LiOH.H₂O (116 mg, 2.77 mmol, 1.3 eq). The reaction mixture was stirred at 40° C. for 12 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated in vacuo to remove MeOH, and water (50 mL) was added. The aqueous portion was extracted with TBME (30 mL), and the aqueous layer was then adjusted to pH ~6 by the addition of 0.5 M HCl. The resulting suspension was extracted with DCM/MeOH (100/10 mL) 3 times. The combined DCM/MeOH organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness to afford E64 (420 mg, 89% yield). LCMS: m/z 221.1 [M+H]⁺.

Step C: Preparation of 6-bromo-7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic Acid (E65)

To a solution of methyl 6-bromo-7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E63) (120 mg, 383 µmol) in MeOH (2 mL) and H₂O (1 mL) was added LiOH.H₂O (17.69 mg, 422 µmol, 1.1 eq), the mixture was stirred at 40° C. for 12 hr. Reaction progress was checked using LCMS. The reaction mixture was concentrated in vacuo to remove MeOH, and water (10 mL) was added. The aqueous portion was extracted with TBME (30 mL) and was then adjusted to pH ~6 by the addition of 0.5 M HCl. The resulting suspension was extracted with DCM/MeOH (30/3 mL) 3 times. The combined DCM/MeOH organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness to afford E65 (100 mg, 87% yield). ¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1 H), 8.07 (d, 1 H), 7.74 (d, 1 H), 1.96 (s, 6 H): LCMS: m/z 301.1 [M+H]⁺.

Step D: Preparation of Methyl 7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E66)

To a solution of methyl 6-bromo-7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E63) (450 mg. 1.44 mmol) in MeOH (10 mL) was added Pd/C (100 mg, 10% purity) under N₂. The resulting mixture was degassed under vacuum and purged with H₂ 3 times, and then the mixture was stirred at rt for 1 hr under H₂ (15 psi). Reaction progress was checked using LCMS. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated in vacuo to afford E66 (350 mg), which was used without further purification. LCMS: m/z 234.9 [M+H]⁺.

Step E: Preparation of 7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic Acid (E67)

To a solution of methyl 7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E66) (350 mg, 1.49 mmol) in MeOH (5 mL) and H₂O (1 mL) was added NaOH (89.64 mg, 2.24 mmol, 1.5 eq), the mixture was stirred at 40° C. for 12 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated in vacuo to remove MeOH, and water (10 mL) was added. The aqueous portion was extracted with TBME (30 mL), and then adjusted to pH ~6 by the addition of 0.5 M HCl. The resulting suspension was extracted with DCM/MeOH (30/3 mL) 3 times. The combined DCM/MeOH organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness to afford E67 (320 mg), which was used without further purification. LCMS: m/z 220.9 [M+H]⁺.

Intermediate E72 According to General Scheme 7, Methods C and D

Step A: Preparation of Methyl 6-vinylpyrazolo[1,5-a]pyridine-3-carboxylate (E68)

A mixture of 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (8.15 g, 52.9 mmol. 8.98 mL), methyl 6-bromopyrazolo[1,5-a]pyridine-3-carboxylate (9 g, 35.3 mmol), K₃PO₄ (22.47 g, 106 mmol) and Pd(dppf)Cl₂ (1.29 g, 1.76 mmol) in dioxane (80 mL) and H₂O (40 mL) was stirred at 80° C. for 12 hrs under N₂. Reaction progress was checked using LCMS. The reaction mixture was combined with another 1 g batch reaction, and DCM (200 mL) was added. The organic layer was washed with brine (2 x 80 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 4/1) to give E68 (6.4 g. 80.2% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.37 (s, 1 H), 8.30 (s, 1 H), 8.03 (d, 1 H), 7.52 (dd, 1 H), 6.61 (dd, 1 H), 5.76 (d, 1 H), 5.34 (d, 1 H), 3.84 (s, 3 H); LCMS: m/z 203.1 [M+H]⁺.

Step B: Preparation of Methyl 6-formlylpyrazolo[1,5-a]pyridine-3-carboxylate (E69)

To a solution of methyl 6-vinylpyrazolo[1,5-a]pyridine-3-carboxylate (E68) (6.4 g, 31.7 mmol) in THF (80 mL) and H₂O (80 mL) was added K₂O_SO₄.2H₂O (583 mg, 1.58 mmol) and NaIO₄ (16.92 g, 79.1 mmol, 4.38 mL) at 0° C., and then the reaction mixture was stirred at rt for 12 hrs. Reaction progress was checked using LCMS. DCM (200 mL) was added to the reaction mixture, and the organic layer was washed with brine (2 x 80 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, DCM/EtOAc=1/0 to 6/1) to give E69 (5.9 g, 91.3% yield). ¹H NMR (400 MHz, CDCl₃) δ 9.94 (s, 1 H), 8.90-8.98 (m, 1 H), 8.48 (s, 1 H), 8.18 (d, 1 H), 7.80 (dd, 1 H), 3.88 (s, 3 H); LCMS: m/z 204.9 [M+H]⁺.

Step C: Preparation of Methyl 6-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E70)

To a solution of methyl 6-formylpyrazolo[1,5-a]pyridine-3-carboxylate (E69) (2.4 g, 11.8 mmol) in THF (30 mL) and MeOH (30 mL) was added NaBH₄ (1.78 g, 47.0 mmol) at 0° C., and then the reaction mixture was stirred at rt for 1 hr. Reaction progress was checked using LCMS. The reaction mixture was quenched by the addition of sat. aq. NH₄Cl (50 mL), and the aqueous portion extracted with EtOAc (100 mL). The organic layer was washed with water (50 mL) and brine (40 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give E70 (2.3 g, 94.9% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.54 (s, 1 H). 8.38 (s, 1 H), 8.11 (d. 1 H), 7.41 (dd. 1 H), 4.78 (s, 2 H), 3.93 (s. 3 H); LCMS: m/z 207.0 [M+H]⁺.

Step D: Preparation of Methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E71)

To a solution of methyl 6-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E70) (2.2 g, 10.7 mmol) in THF (50 mL) was added NaH (512 mg, 12.8 mmol, 60% purity) at 0° C. The reaction mixture was stirred at 0° C. for 15 min, and then MeI (1.82 g. 12.8 mmol, 797 µL) was added to the reaction mixture. The reaction mixture was stirred at rt for 1 hr, and reaction progress was checked using LCMS. The reaction mixture was quenched by the addition of sat. aq. NH₄Cl (40 mL), and the aqueous portion extracted with DCM (2 x 60 mL). The combined organic layer was washed by water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 5/1) to give E71 (1.8 g, 76.6% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.52 (s, 1 H), 8.41 (s, 1 H), 8.16 (d, 1 H), 7.42 (dd, 1 H). 4.53 (s, 2 H), 3.94 (s, 3 H), 3.46 (s, 3 H); LCMS: m/z 221.1 [M+H]⁺.

Step E: Preparation of 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylic Acid (E72)

To a solution of methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E71) (1.8 g. 8.17 mmol) in MeOH (40 mL) and H₂O (40 mL) was added NaOH (719 mg, 18.0 mmol), and the reaction mixture was stirred at 40° C. for 12 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated to remove MeOH, and then H₂O (10 mL) was added. The pH of the aqueous mixture was adjusted to ~6 by the addition of 0.5 M HCl, and the aqueous mixture was filtered. The precipitate was dried in vacuo to give E72 (1.6 g, 94.9% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.57 (s, 1 H), 8.45-8.51 (m, 1 H), 8.21 (d, 1 H), 7.48 (dd, 1 H). 4.55 (s. 2 H), 3.48 (s, 3 H): LCMS: m/z 206.7 [M+H]⁺.

Intermediate E78 According to General Scheme 9, Method A

Step A: Preparation of 2,6-difluorobenzohydrazide (E73)

To a solution of methyl 2,6-difluorobenzoate (25 g, 145 mmol) in MeOH (250 mL) was added NH₂NH₂.H₂O (18.18 g, 363 mmol, 17.7 mL), and the reaction mixture was stirred at 60° C. for 12 hrs. Reaction progress was checked using TLC. Additional NH₂NH₂.H₂O (7.27 g. 145 mmol. 7.05 mL) was added, and the reaction mixture was stirred at 60° C. for another 3 hrs. The reaction mixture was concentrated in vacuo to give E73 (25 g), which was used without further purification. ¹H NMR (400 MHz. CDCl₃) δ 7.37 (s, 1 H), 6.93 (t. 2 H), 3.45-3.89 (m, 2 H).

Step B: Preparation of Methyl 2-[2-(2,6-difluorobenzoyl)hydrazino]-2-oxo-acetate (E74)

To a solution of 2,6-difluorobenzohydrazide (E73) (25 g, 145 mmol) in THF (250 mL) was added methyl 2-chloro-2-oxo-acetate (19.57 g, 160 mmol, 14.7 mL) at 0° C., and the reaction mixture was stirred at 0° C. for 1 hr. Reaction progress was checked using TLC. The reaction mixture was filtered. The precipitate was washed with MTBE (800 mL), and then dried in vacuo to give E74 (37 g). ¹H NMR (400 MHz. DMSO-d₆) δ 7.59 (ddd. 2 H), 7.21 (t, 1 H), 3.83 (s, 2 H).

Step C: Preparation of Methyl 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2 -carboxylate (E75)

To a solution of methyl 2-[2-(2,6-difluorobenzoyl)hydrazino]-2-oxo-acetate (E74) (15 g, 58.1 mmol) in DCM (250 mL) was added Et₃N (23.52 g, 232 mmol, 32.4 mL) and TosCl (14.40 g, 75.5 mmol) in portions at 0° C. The reaction mixture was allowed to warm to rt and stirred at rt for 12 hrs. Reaction progress was checked using TLC. DCM (100 mL) was added to the reaction mixture, and the organic layer was washed with sat. aq. NaHCO₃ (100 mL) and water (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 1/1) to give E75 (4.3 g, 30.8% yield). ¹H NMR (400 MHz. CDCl₃) δ 7.61 (tt, 1 H), 7.14 (t. 2 H), 4.10 (s, 3 H).

Step D: Preparation of 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylic Acid (E76)

To a solution of methyl 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylate (E75) (300 mg, 1.25 mmol) in H₂O (2 mL) and THF (4 mL) was added LiOH.H₂O (52.4 mg, 1.25 mmol). The reaction mixture was stirred at rt for 1 hr. Reaction progress was checked using LCMS. The reaction mixture was concentrated in vacuo to give E76 (300 mg), which was used without further purification. LCMS: m/z 226.8 [M+H]⁺

Step E: Preparation of 2-(2,6-difluorophenyl)-1,3,4-oxadiazole (E77)

To a solution of 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylic acid (E76) (4 g, 17.7 mmol) in H₂O (20 mL) was added HCl (1 M, 35.4 mL), and the reaction mixture was stirred at rt for 1 hr. Reaction progress was checked using LCMS and TLC. DCM (60 mL) was added to the reaction mixture, and the organic layer washed by water (20 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 1/1) to give E77 (1.5 g, 46.6% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.63 (s, 1 H), 7.57 (tt, 1 H), 7.12 (t, 2 H); LCMS: m/z 182.8 [M+H]⁺.

Step F: Preparation of 2-bromo-5-(2,6-difluorophenyl)-1,3,4-oxadiazole (E78)

To a solution of 2-(2,6-difluorophenyl)-1,3,4-oxadiazole (E77) (1.5 g, 8.24 mmol) in THF (50 mL) was added LiHMDS (1 M, 16.5 mL) dropwise at -78° C. The reaction mixture was stirred at -78° C. for 30 min, then Br₂ (2.63 g, 16.5 mmol. 849 µL) was added to the reaction mixture at -78° C. dropwise. The reaction mixture was stirred at -78° C. for 2 hrs. Reaction progress was checked using TLC. Sat. aq. NH₄Cl (100 mL) was added to the reaction mixture, and the aqueous portion extracted with DCM (3 x 50 mL). The combined organic layer was washed with brine (40 mL), dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 3/1) to give E78 (1.6 g, 54.2% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.79 (tt, 1 H), 7.41 (t, 2 H), LCMS: m/z 341.2 [M+H]⁺.

Preparation of Examples 640 and 641 According to General Scheme 1, Method C

Step 1: Preparation of 4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

A mixture of pyrazolo[1,5-a]pyridine-2-carbaldehyde (C3) (9.2 g, 63.0 mmol), 2-(1H-imidazol-5-yl)ethanamine (15.06 g, 81.8 mmol, 1.3 eq, 2HCl salt) and K₂CO₃ (17.40 g, 126 mmol, 2 eq) in EtOH (300 mL) was stirred at 80° C. for 16 hrs under N₂. Reaction progress was checked using LCMS. The reaction mixture was combined with another reaction mixture performed using 5 g of C3 and filtered, and the filtrate was concentrated to dryness. The residue was purified by column chromatography on silica gel (DCM:MeOH=20:1 to 10:1) to give 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (11.4 g). ¹H NMR (400 MHz, CD₃OD) δ 8.48 (d, 1 H), 7.54-7.62 (m, 2 H), 7.09-7.29 (m, 1 H), 6.82-6.90 (m, 1 H), 6.44 (s, 1 H), 5.28 (s, 1 H), 3.28 (dt, 1 H), 3.04-3.12 (m, 1 H), 2.73-2.80 (m, 2 H): LC-MS: m/z 240.2 (M+H)⁺.

Step 2: Preparation of 5-(4-pyrazolo[1.5-a]pyridin-2-yl-1,4,6.7-tetrahydroimidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile

To a solution of 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (4 g, 16.7 mmol) and (4-cyanooxazole-5-carbonyl)oxylithium (E35) (3.37 g, 23.4 mmol, 1.4 eq) in DMF (90 mL) was added HATU (7.63 g, 20.1 mmol, 1.2 eq) and pyridine (3.97 g, 50.2 mmol, 4.1 mL, 3 eq). The reaction mixture was stirred at rt for 2 hrs. Reaction progress was checked using LCMS, and the reaction mixture was stirred at rt for another 12 hrs. Reaction progress was checked using TLC (DCM:MeOH=10:1). DCM (300 mL) was added, and the organic portion was washed with sat. NaHCO₃ solution (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~8.5% MeOH/DCM @ 35 mL/min) to give 5-(4-pyrazolo[1,5-a]pyridin-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile (2.6 g). ¹H NMR (400 MHz, CD₃OD) δ 8.51 (s, 1 H), 8.46 (d, 1 H), 7.69 (s, 1 H), 7.57-7.65 (m, 1 H), 7.17-7.23 (m, 1 H), 6.83-6.91 (m, 2 H), 6.59-6.72 (m, 1 H), 4.40 (br d, 1 H), 3.77 (br d, 1 H), 3.19 (s, 1 H). 2.85 (br s, 1 H); LC-MS: m/z 360.2 (M+H)⁺.

Step 3: SFC Separation

5-(4-pyrazolo[1,5-a]pyridin-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile (2.6 g) was separated by SFC (column: DAICEL CHIRALPAK AD(250 mm*50 mm,10 um);mobile phase: [Neu-ETOH];B%: 45%-45%,min) to afford Enantiomer 1 (650 mg, Rt= 1.884 min) and Enantiomer 2 (450 mg, Rt=2.124 min).

Enantiomer 1 (Example 640): (S)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile. ¹H NMR (400 MHz, CD₃OD) δ 8.52 (s, 1 H), 8.46 (dd, 1 H), 7.71 (s, 1 H), 7.62 (br d, 1 H), 7.17-7.26 (m, 1 H), 6.85-6.92 (m, 1.7 H), 6.48-6.69 (m, 1.3 H), 4.77-4.87 (m, 0.4 H), 4.40 (br d, 0.6 H), 3.79 (br s, 1 H), 3.10-3.19 (m, 1 H), 2.79-2.91 (m, 1 H): LC-MS: m/z 360.1 (M+H)⁺; SFC: 94.1% ee.

Enantiomer 2 (Example 641): (R)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile. ¹H NMR (400 MHz. CD₃OD) δ 8.51 (s, 1 H), 8.46 (dd, 1 H), 7.71 (s, 1 H), 7.62 (br d, 1 H), 7.13-7.26 (m, 1 H), 6.84-6.94 (m, 1.7 H), 6.49-6.70 (m, 1.3 H), 4.77-4.87 (m, 0.4 H), 4.40 (br d, 0.6 H), 3.71-3.91 (m, 1 H), 3.08-3.19 (m, 1 H), 2.79-2.89 (m, 1 H), LC-MS: m/z 360.2 (M+H)⁺; SFC: 96.7% ee.

Preparation of Examples 836 and 837 According to General Scheme 1, Method C

Step 1: Preparation of (5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

To a solution of 4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-4,5,6,7-tetrahydro-1H -imidazo[4,5-c]pyridine (150 mg, 488 µmol) and 5-(1-methylpyrazol-3-yl)-1,3,4 -oxadiazole-2-carboxylic acid (prepared in accordance with General Scheme 9. Method A, starting with methyl 1-methyl-1H-pyrazole-3-carboxylate) (142 mg, 732 µmol) in DMSO (3 mL) was added pyridine (116 mg, 1.46 mmol, 118 µL) and HATU (241 mg, 635 µmol) at rt. The reaction mixture was stirred at rt for 16 hrs. Reaction progress was checked using LCMS. The reaction mixture was submitted to prep-HPLC (column: Welch Xtimate C18 150^∗30 mm^∗5 um;mobile phase: [water(0.05%NH₃H₂O+10mM NH₄HCO₃)-ACN];B%: 27%-57%,9 min) to give (5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone. (100 mg, 42.4% yield). LCMS: m/z 484.1 [M+H]⁺.

Step 2: SFC Separation

Compound (5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 207 µmol) was separated by SFC (column: Phenomenex-Cellulose-2 (250 mm*50 mm, 10 um):mobile phase: [0.1%NH₃H₂O EtOH]:B%: 50%-50%,min) to afford Enantiomer 1 (46.1 mg, 46.1% yield. Rt=5.268 min) and Enantiomer 2 (46.2 mg, 45.6% yield, Rt=10.218 min).

Enantiomer 1 (Example 836): (S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone. ¹H NMR (400 MHz, CD₃OD) δ 8.59-8.76 (m, 1 H), 7.81 (d, 1 H), 7.74 (s, 1 H), 7.53-7.66 (m, 1 H), 6.86-7.12 (m, 3 H), 6.76-6.84 (m, 1 H), 5.08 (br dd, 1 H), 4.03 (s, 3 H), 3.72-3.84 (m, 0.6 H), 3.41 (td, 0.4 H), 3.13-3.27 (m, 0.6 H), 2.95-3.09 (m, 0.4 H), 2.77-2.94 (m, 1 H); LCMS: m/z 484.2 [M+H]⁺; SFC: 100% ee.

Enantiomer 2 (Example 837): (R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone. ¹H NMR (400 MHz, CD₃OD) δ 8.42-8.69 (m, 1 H), 7.60-7.79 (m, 2 H), 7.41-7.57 (m, 1 H), 6.80-6.97 (m, 3 H), 6.60-6.75 (m, 1 H), 4.96 (br dd, 1 H), 3.92 (s, 3 H), 3.60-3.73 (m, 0.5 H), 3.24-3.37 (m, 0.5 H), 3.03-3.17 (m, 0.5 H), 2.84-3.00 (m, 0.5 H), 2.68-2.80 (m, 1 H); LCMS: m/z 484.2 [M+H]⁺; SFC: 98.7% ee.

Preparation of Examples 1628 and 1629 According to General Scheme 1, Method C

Step 1: Preparation of (4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone

To a solution of 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E72) (144 mg, 700 µmol) and 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (150 mg, 583 µmol) in DMF (3 mL) was added HATU (333 mg, 875 µmol) and Py (185 mg. 2.33 mmol, 188.2 µL), and the reaction mixture was stirred at rt for 12 hrs. Reaction progress was checked using LCMS. DCM (30 mL) was added to the reaction mixture, and the organic layer washed with sat. aq. Na₂CO₃ solution (10 mL) and brine (10 mL), dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by prep-HPLC (column: Boston Prime C18 150^∗30 mm^∗5 um;mobile phase: [water(NH₃H₂O+NH₄HCO₃)-ACN];B%: 25%-55%,7 min) to give (4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone (108 mg, 41.6% yield). LCMS: m/z 446.2 [M+H]⁺.

Step 2: SFC Separation

The compound (4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone (100 mg, 224 µmol) was separated by SFC (column: Phenomenex-Cellulose-2 (250 mm*30 mm,10 um);mobile phase: [0.1%NH₃H₂O EtOH];B%:55%%, isocratic elution mode) to give Enantiomer 1 (20.1 mg, 19.5% yield, Rt = 1.879 min) and Enantiomer 2 (23.3 mg, 22.7% yield, Rt = 4.054 min).

Enantiomer 1 (Example 1628): (S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone. ¹H NMR (400 MHz, CD₃OD) δ 8.32-8.78 (m, 3 H), 7.97 (d, 1 H), 7.68 (s, 1 H), 7.45 (d, 1 H), 6.54-7.10 (m, 4 H), 4.62-4.75 (m, 1 H), 4.55 (s, 2 H), 3.40-3.60 (m, 4 H), 3.02-3.17 (m, 1 H), 2.79 (br dd, 1 H); LCMS: m/z 446.1 [M+H]⁺; SFC: 100%.

Enantiomer 2 (Example 1629): (R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone. ¹H NMR (400 MHz, CD₃OD) δ 8.31-8.88 (m, 3 H), 7.97 (d, 1 H), 7.68 (s, 1 H), 7.45 (dd, 1 H), 6.55-7.06 (m, 4 H), 4.62-4.73 (m, 1 H), 4.55 (s, 2 H), 3.40-3.76 (m, 4 H), 2.99-3.17 (m, 1 H), 2.79 (br dd, 1 H); LCMS: m/z 446.2 [M+H]⁺; SFC: 99.8%.

Preparation of Examples 1756 and 1757 According to General Scheme 1, Method A2

Step 1: Preparation of 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1.4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]ethanone

To a solution of 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo [4,5-c]pyridine (7.3 g, 28.4 mmol) and Et₃N (11.49 g, 114 mmol, 15.8 mL) in DCM (150 mL) was added TFAA (15.50 g. 73.8 mmol, 10.3 mL) dropwise at 0° C. After the addition was complete, the reaction mixture was stirred at rt for 3 hrs. Reaction progress was checked using TLC. DCM (150 mL) was added to the reaction mixture, and the organic layer was washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~15% MeOH/DCM @ 60 mL/min) to give compound 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]ethanone (10 g, 94.4% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.55-8.68 (m, 1 H), 7.60-7.76 (m, 1 H), 7.15 (dd, 1 H), 6.90 (td, 1 H). 6.66-6.73 (m, 1 H). 6.63 (s. 1 H), 4.10 (br s, 1 H), 3.67-3.80 (m, 1 H), 2.70-2.88 (m, 2 H); LCMS: m/z 354.2 [M+H]⁺.

Step 2: Preparation of 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a] pyridin-2-yl)-1-tetrahydropyran-2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridin-5-yl]ethanone

To a solution of 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]ethanone (10 g, 28.3 mmol) and DHP (7.14 g, 84.9 mmol, 7.76 mL) in toluene (140 mL) was added TsOH (487 mg, 2.83 mmol), and the reaction mixture was stirred at 120° C. for 12 hrs. Reaction progress was checked using LCMS and TLC. EtOAc (150 ml) was added, and the organic layer washed with brine (40 ml × 2), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®: 80 g SepaFlash® Silica Flash Column. Eluent of 0~10% MeOH/DCM gradient @ 60 mL/min) to give compound 2,2.2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a] pyridin-2-yl)-1-tetrahydropyran-2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridin-5-yl]ethanone (8.9 g, 64.8% yield). ¹HNMR (400 MHz, DMSO-d₆) δ 8.54-8.66 (m, 1 H), 7.73-7.90 (m, 1 H), 7.11-7.20 (m, 1 H), 6.67-6.93 (m, 2 H), 6.12-6.61 (m, 1 H), 5.14-5.37 (m, 1 H), 3.92-4.16 (m, 2 H), 3.60-3.84 (m, 2 H), 2.80-2.97 (m, 2 H), 1.87-2.06 (m, 3 H), 1.49-1.70 (m, 3 H); LCMS: m/z 438.3 [M+H]⁺.

Step 3: Preparation of 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1-tetrahydropyran-2-yl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine

A mixture of 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1-tetrahydropyran-2 -yl-6,7-dihydro-4H-imidazo[4,5-c]pyridin-5-yl]ethanone (8.8 g, 20.1 mmol) and K₂CO₃ (12.51 g, 90.5 mmol) in MeOH (100 mL) was degassed and purged with N₂ for 3 times, and then the reaction mixture was stirred at rt for 12 hrs under N₂ atmosphere. Reaction progress was checked using LCMS and TLC. DCM (150 mL) was added to the reaction mixture, and the organic layer washed with H₂O (2 × 40 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®: 80 g SepaFlash® Silica Flash Column, Eluent of 0~10% MeOH:DCM @ 60 mL/min) to give compound 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1-tetrahydropyran-2-yl-4.5,6,7-tetrahydroimidazo[4,5-c]pyridine (5.8 g, 79.4% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.52 (d, 1 H), 7.62 (d, 1 H), 7.02-7.10 (m, 1 H), 6.77-6.85 (m, 1 H), 6.49 (d, 1 H), 5.15-5.24 (m, 1 H), 5.06 (d, 1 H), 3.95-4.11 (m, 2 H), 3.56-3.69 (m, 1 H), 2.94 (br dd, 1 H), 2.57-2.70 (m. 2 H), 1.89-2.06 (m, 3 H), 1.46-1.70 (m. 3 H); LCMS: m/z 342.2 [M+H]⁺.

Step 4: Preparation of 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-pyrazin-2-yl-1-tetrahydropyran-2-yl-6,7 -dihydro-4H-imidazo[4,5-c]pyridine

A mixture of 2-bromopyrazine (1.40 g, 8.79 mmol), 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1-tetrahydropyran-2-yl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine (1.5 g, 4.39 mmol), CPhos-Pd-G3 (177.15 mg, 220 µmol), Cs₂CO₃ (4.29 g, 13.2 mmol) in tert-amyl alcohol (20 mL) was degassed and purged with N₂ for 3 times, and then the reaction mixture was stirred at 100° C. for 12 hrs under N₂ atmosphere. Reaction progress was checked using LCMS. DCM (100 mL) was added to the reaction mixture, and the organic layer washed with water (40 mL) and brine (40 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 24 g SepaFlash® Silica Flash Column, Eluent of 0~10% MeOH:DCM @ 30 mL/min) to give 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-pyrazin-2-yl-1-tetrahydropyran-2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridine (1 g, 50.3% yield). LCMS: m/z 420.2 [M+H|⁺.

Step 5: Preparation of 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

To a solution of 4-(4-fluoropyrazolo[1,5-alpyridin-2-yl)-5-pyrazin-2-yl-1-tetrahydropyran -2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridine (1 g, 2.38 mmol) in MeOH (15 mL) was added HCl (4 M, 20.0 mL) at rt. The reaction mixture was stirred at 70° C. for 12 hrs. Reaction progress was checked using LCMS. DCM (100 mL) was added, and the organic layer washed with sat. aq. Na₂CO₃ (50 mL × 2) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 24 g SepaFlash® Silica Flash Column. Eluent of 0~10% MeOH:DCM @ 30 mL/min) to give 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (500 mg, 58.3% yield). LCMS: m/z 336.2 [M+H]⁺.

Step 6: SFC Separation

The compound 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (1.2 g, 3.58 mmol) was separated by SFC (column: DAICEL CHIRALPAK AD(250 mm*30 mm,10 um);mobile phase: [CO₂-EtOH(0.1%NH₃H₂O)];B%:40%%, isocratic elution mode) to give Enantiomer 1 (370 mg, 28.8% yield, Rt=0.530 min) and Enantiomer 2 (433 mg, 33.4% yield, Rt=0.931 min).

Enantiomer 1 (Example 1756): (R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. ¹H NMR (400 MHz, CD₃OD) δ 8.46 (s, 1 H), 8.34 (d, 1 H), 8.16 (s, 1H), 7.80 (d, 1 H), 7.65 (s, 1 H), 6.88-7.00 (m, 1 H), 6.77-6.87 (m, 2 H), 6.66 (s, 1 H), 4.71 (br dd, 1 H), 3.56-3.67 (m, 1 H), 2.92 - 3.05 (m, 1 H), 2.76 (dd, 1 H); LCMS: m/z 336.1 [M+H]⁺; SFC: 100% ee.

Enantiomer 2 (Example 1757): (S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. ¹H NMR (400 MHz, CD₃OD) δ 8.46 (d, 1 H), 8.30-8.37 (m, 1 H), 8.13-8.19 (m, 1 H), 7.80 (d, 1 H), 7.65 (s, 1 H), 6.94 (dd, 1 H), 6.77-6.87 (m, 2 H), 6.65 (s, 1 H), 4.71 (dd, 1 H), 3.61 (ddd, 1 H), 2.92-3.03 (m, 1 H), 2.76 (dd, 1 H); LCMS: m/z 336.2 [M+H]⁺; SFC: 99.7% ee.

Preparation of Examples 1842 and 1843 According to General Scheme 1, Method A1

Step 1: Preparation of 2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4.5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole

To a solution of 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (200 mg, 836 µmol) in DMF (2 mL) was added DIPEA (432 mg, 3.34 mmol, 582 µL) and 2-bromo-5-(2.6-difluorophenyl)-1,3,4-oxadiazole (E78) (262 mg, 1.00 mmol), and the reaction mixture was stirred at rt for 12 hrs. Reaction progress was checked using TLC. DCM (20 mL) was added to the reaction mixture, and the organic layer was washed by water (20 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by prep-HPLC (column: Welch Xtimate C18 150*30 mm*5 um;mobile phase: [water(NH₃H₂O+NH₄HCO₃)-ACN];B%: 30%-60%,7 min) to afford 2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole (150 mg, 40.8% yield). LCMS: m/z 420.1 [M+H]⁺.

Step 2: SFC Separation

The compound 2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole (100 mg, 238 µmol) was separated by SFC (column: DAICEL CHIRALPAK AD(250 mm*30mm,10um);mobile phase: [0.1%NH₃H₂O EtOH];B%: 45%-45%,45 min) to give Enantiomer 1 (46.8 mg, 46.6% yield, Rt=1.780 min) and Enantiomer 2 (47.0 mg, 46.8% yield, Rt=1.990 min).

Enantiomer 1 (Example 1842): (R)-2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole. ¹H NMR (400 MHz, CD₃OD) δ 8.45 (d, 1 H), 7.49-7.76 (m, 3 H), 7.09-7.30 (m, 3 H), 6.86 (td, 1 H). 6.60 (s. 1H), 6.41 (s, 1 H), 4.35 (dd, 1 H), 3.73-3.88 (m, 1 H), 2.99-3.17 (m, 1 H), 2.84 (dd, 1 H); LCMS: m/z 420.2 [M+H]⁺; SFC: 99.3% ee.

Enantiomer 2 (Example 1843): (S)-2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole. ¹H NMR (400 MHz. CD₃OD) δ 8.45 (d, 1 H), 7.49-7.79 (m, 3 H), 7.12-7.30 (m, 3 H), 6.86 (td, 1 H), 6.61 (s, 1 H), 6.41 (s, 1 H), 4.36 (dd, 1 H), 3.68-3.90 (m, 1 H), 3.00-3.17 (m, 1 H), 2.85 (dd, 1 H); LCMS: m/z 420.1 [M+H]⁺; SFC: 99.2% ee.

The compounds of Table 1 were characterized using proton NMR and LCMS and the enantiomeric excess determined. See Table 2.

Ex. #	1H NMR (400 MHz unless otherwise noted)	LCMS: m/z	% ee
600	(CD3OD) δ 8.22-8.79 (m, 3 H), 7.98 (d, 1 H), 7.67 (s, 1 H), 7.60 (d, 1 H), 7.39-7.49 (m, 1 H), 7.15-7.24 (m, 1 H), 7.02-7.13 (m, 1 H), 6.87 (br s, 1 H), 6.56 (br s, 1 H), 4.64 (br s, 1H), 3.38-3.77 (m, 1 H), 2.97-3.18 (m, 1 H), 2.97-3.18 (m, 1 H), 2.70-2.87 (m, 1 H)	384.2 [M+H]+	100%
601	(CD3OD) δ 8.33-8.97 (m, 3 H), 7.98 (d. 1H), 7.68 (br s, 1H), 7.60 (d, 1H), 7.44 (t, 1H), 7.21 (t, 1H), 7.07 (t, 1 H), 6.87 (br s, 1H), 6.56 (br s, 1H), 4.65 (br s, 1H), 3.38-3.83 (m. 1H), 3.02-3.16 (m, 1H), 2.70-2.85 (m, 1H)	384.2 [M+H]+	99.4%
602	(CD3OD) δ 9.18 (s, 1H), 8.19-8.81 (m, 2 H), 7.69 (s, 1H), 7.61 (d. 1H), 7.22 (br t. 1H), 6.89 (t. 1.5 H). 6.30-6.69 (m, 1.5 H), 4.06-4.85 (m, 1H), 3.77 (br s, 1H), 2.95-3.10 (m, 1H), 2.78 (d, 1H)	351.1 [M+H]+	100%
603	(CD3OD) δ 9.18 (s, 1H). 8.16-8.80 (m, 2 H). 7.69 (s. 1H), 7.61 (d, 1H), 7.22 (t, 1H), 6.80-6.95(m, 1.5 H), 6.25-6.72 (m, 1.5 H), 4.14-4.84 (m, 1H), 3.52-3.89 (m, 1H), 3.52-3.53 (m. 1H), 2.95-3.15 (m, 1H), 2.70-2.85 m, 1H)	351.1 [M+H]+	100%
604	(CD3OD) δ 8.70-8.85 (m, 1 H), 8.38-8.53 (m, 2 H), 8.31 (dd, 1 H), 8.09 (td, 1H), 7.52-7.74 (m, 2.3 H), 7.17-7.32 (m, 1H), 7.10 (s, 0.7 H), 6.83-6.96 (m, 1H), 6.67-6.80 (m, 1H), 5.12 (dd. 1 H), 3.69-3.86 (m, 0.7 H), 3.41-3.49 (m, 0.3 H), 3.19-3.28 (m, 0.4 H), 3.01-3.18 (m, 0.6 H), 2.91-2.99 (m, 1H)	413.0 [M+H]+	99.5%
605	(CD3OD) δ 8.72-8.81 (m, 1H), 8.34-8.51 (m, 1 H). 8.25-8.33 (m, 1 H), 8.07 (td, 1 H), 7.45-7.76 (m, 3.4 H), 7.12-7.26 (m, 1 H), 6.97 (s, 0.6 H), 6.78-6.90 (m. 1 H), 6.52-6.74 (m. 1H), 4.99 (br dd, 1 H), 3.72-3.88 (m, 0.7 H), 3.42 (td, 0.3 H), 3.14-3.23 (m, 0.5 H), 2.92-3.07 (m, 0.5 H), 2.79-2.89 (m, 1 H)	413.0 [M+H]+	100%
606	(CD3OD) δ 8.44 (d, 1 H), 8.25 (s, 1 H), 7.51-7.72 (m, 2 H), 7.10-7.24 (m, 1 H), 6.84 (t, 1.6 H), 6.61 (br s, 1.4 H), 4.30 (br s, 1 H), 3.53-3.86 (m, 1 H), 2.93-3.11 (m, 1 H), 2.78 (br d, 1 H), 2.38 (s, 3 H)	349.0 [M+H]+	100%
607	(CD3OD) δ 8.44 (d, 1 H), 8.25 (s, 1 H), 7.51-7.73 (m, 2 H), 7.10-7.30 (m, 1 H), 6.73-6.95 (m, 1.7 H), 6.60 (br s, 1.3 H), 4.31 (br s, 1 H), 3.51-3.81 (m, 1 H), 2.95-3.17 (m, 1 H), 2.69-2.89 (m, 1 H), 2.38 (s, 3 H)	349.0 [M+H]+	99.8%
608	(CD3OD) δ 8.39-8.56 (m, 1 H), 8.10-8.17 (m, 1 H), 7.67 (br d, 1 H), 7.58 (d, 1 H), 7.18-7.23 (m, 1 H), 6.84-6.93 (m, 1.6 H), 6.44-6.62 (m, 1.4 H), 4.77-4.89 (m, 1.4 H), 4.67-4.76 (m, 0.4 H), 4.39-4.47 (m, 0.6 H), 4.30 (dd, 0.6 H), 3.62-3.74 (m, 0.6 H), 3.19 (td, 0.4 H), 2.82-3.01 (m, 1 H), 2.67-2.81 (m, 1 H)	433.1 [M+H]+	100%
609	(CD3OD) δ 8.40-8.55 (m, 1 H), 8.09-8.17 (m, 1 H), 7.65-7.69 (m, 1 H), 7.58 (d, 1 H), 7.17-7.23 (m, 1 H), 6.83-6.93 (m, 1.6 H), 6.44-6.59 (m, 1.4 H), 4.81-4.89 (m, 1.5 H), 4.68-4.77 (m, 0.4 H), 4.40-4.46 (m, 0.5 H), 4.30 (dd, 0.6 H), 3.69 (ddd, 0.6 H), 3.19 (td, 0.4 H), 2.81-3.01 (m, 1 H), 2.68-2.81 (m, 1 H)	433.1 [M+H]+	99.8%
610	(CD3OD) δ 8.34-8.55 (m, 2 H), 7.49-7.74 (m, 2 H), 7.13-7.24 (m, 1 H), 6.79-6.94 (m, 2 H), 6.59 (s, 0.6 H), 6.38 (s, 0.2 H), 5.98 (br s, 0.2 H), 4.82 (br d, 0.3 H), 3.65-3.85 (m, 1.5 H), 3.39-3.49 (m, 0.2 H), 2.70-3.02 (m, 2 H)	403.1 [M+H]+	99.0%
611	(CD3OD) δ 8.35-8.54 (m, 2 H), 7.45-7.75 (m, 2 H), 7.12-7.28 (m, 1 H), 6.79-6.96 (m, 2 H), 6.60 (s, 0.6 H), 6.39 (s, 0.2 H), 5.99 (br s, 0.2 H), 4.83 (br d, 0.3 H), 3.66-3.87 (m, 1.4 H), 3.45 (td, 0.3 H), 2.70-3.04 (m, 2 H)	403.1 [M+H]+	97.5%
612	(CD3OD) δ 8.42-8.66 (m, 1.5 H), 8.18 (br s, 0.5 H), 7.65 (s, 1 H), 7.57 (br d, 1 H), 7.13-7.23 (m, 1 H), 6.85 (br s, 1 H), 6.28-6.66 (m, 2 H), 4.23 (br s, 1 H), 3.76 (br s, 1 H), 3.01 (br s, 1 H), 2.75 (br d, 1 H), 2.10 (t, 3 H)	415.0 [M+H]+	99.2%
613	(CD3OD) δ 8.39-8.68 (m, 1.6 H), 8.18 (br s, 0.4 H), 7.65 (s, 1 H), 7.57 (br d, 1 H), 7.12-7.23 (m, 1 H), 6.86 (br s, 1 H), 6.22-6.65 (m, 2 H), 4.22 (br s, 1 H), 3.76 (br s, 1 H), 3.01 (br s, 1 H), 2.75 (br d, 1 H), 2.10 (t, 3 H)	415.0 [M+H]+	99.3%
614	(CD3OD) δ 8.40-8.52 (m, 1 H), 7.54-7.68 (m, 2 H), 7.16-7.24 (m, 1 H), 6.81-6.95 (m, 1.6 H), 6.55 (s, 0.6 H), 6.42 (s, 0.4 H), 6.26 (s, 0.4 H), 4.82-4.88 (m, 0.6 H), 4.16 (dd, 0.4 H), 3.56-3.68 (m, 0.6 H), 3.14 (td, 0.4 H), 2.41-2.99 (m, 4 H), 1.03-1.13 (m, 1 H), 0.48-0.62 (m, 2 H), 0.16-0.29 (m, 2 H)	322.1 [M+H]+	99.9%
615	(CD3OD) δ 8.40-8.53 (m, 1 H), 7.53-7.69 (m, 2 H), 7.14-7.24 (m, 1 H), 6.80-6.95 (m, 1.6 H), 6.55 (s, 0.6 H), 6.42 (s, 0.4 H), 6.26 (s, 0.4 H), 4.81-4.87 (m, 0.4 H), 4.16 (dd, 1 H), 3.56-3.67 (m, 0.6 H), 3.08-3.20 (m, 0.4 H), 2.42-2.97 (m, 4 H), 1.03-1.15 (m, 1 H), 0.48-0.62 (m, 2 H), 0.17-0.29 (m, 2 H)	322.2 [M+H]+	99.9%
616	(CD3OD) δ 8.57-8.68 (m, 1 H), 8.33-8.48 (m, 1 H), 7.91 (t, 1 H), 7.70-7.78 (m, 1 H), 7.68 (s, 1 H), 7.53-7.61 (m, 1 H), 7.46 (s, 0.3 H), 7.09-7.26 (m, 1 H), 6.95 (s, 0.7 H), 6.75-6.88 (m, 1 H), 6.53-6.68 (m, 1 H), 4.95 (br d, 1 H), 3.72-3.86 (m, 0.8 H), 3.37-3.46 (m, 0.2 H), 2.94-3.26 (m, 1 H), 2.83 (br d, 1 H)	431.1 [M+H]+	100%
617	(CD3OD) δ 8.53-8.80 (m, 1 H), 8.31-8.50 (m, 1 H), 7.85-7.98 (m, 1 H), 7.70-7.77 (m, 1 H), 7.68 (s, 1 H), 7.52-7.62 (m, 1 H), 7.46 (s, 0.3 H), 7.10-7.23 (m, 1 H), 6.95 (s, 0.7 H), 6.75-6.88 (m, 1 H), 6.56-6.69 (m, 1 H), 4.95 (br d, 1 H), 3.72-3.84 (m, 0.7 H), 3.35-3.47 (m, 0.5 H), 2.93-3.21 (m, 1 H), 2.74-2.90 (m, 1 H)	431.1 [M+H]+	100%
618	(CD3OD) δ 8.41 (d, 1 H), 8.11 (s, 1 H), 7.51-7.66 (m, 2 H), 7.11-7.20 (m, 1 H), 6.82 (td, 2 H), 6.56 (br s, 1 H), 4.34 (br s, 1 H), 3.51-3.86 (m, 1 H), 2.92-3.12 (m, 1 H), 2.76 (br dd, 1 H), 2.19-2.42 (m, 1 H), 0.84-1.03 (m, 4 H)	375.0 [M+H]+	99.8%
619	(CD3OD) δ 8.42 (d, 1 H), 8.11 (s, 1 H), 7.51-7.67 (m, 2 H), 7.11-7.21 (m, 1 H), 6.77-6.85 (m, 2 H), 6.56 (br s, 1 H), 4.32 (br s, 1 H), 3.68 (br s, 1 H), 3.01 (br s, 1 H), 2.76 (br dd, 1 H), 2.32 (br s, 1 H), 0.84-1.00 (m, 4 H)	375.0 [M+H]+	99.7%
620	(CD3OD) δ 8.42-8.48 (m, 1 H), 7.70 (s, 1 H), 7.57-7.63 (m, 1 H), 7.18-7.24 (m, 1 H), 6.83-6.95 (m, 2 H), 6.53-6.64 (m, 1 H), 4.99 (br dd, 1 H), 3.69-3.79 (m, 0.7 H), 3.35-3.44 (m, 0.3 H), 3.07-3.20 (m, 0.7 H), 2.91-3.04 (m, 0.3 H), 2.77-2.87 (m, 1 H), 2.26-2.39 (m, 1 H), 1.19-1.33 (m, 4 H)	376.0 [M+H]+	100%
621	(CD3OD) δ 8.41-8.48 (m, 1 H), 7.69 (s, 1 H), 7.57-7.64 (m, 1 H), 7.18-7.24 (m, 1 H), 6.80-6.97 (m, 2 H), 6.53-6.65 (m, 1 H), 4.99 (br dd, 1 H), 3.74 (ddd, 0.7 H), 3.36-3.44 (m, 0.3 H), 3.07-3.20 (m, 0.7 H), 2.90-3.03 (m, 0.3 H), 2.75-2.88 (m, 1 H), 2.26-2.39 (m, 1 H), 1.17-1.32 (m, 4 H)	376.0 [M+H]+	99.9%
622	(CD3OD) δ 8.65 (br d, 1 H), 8.43 (br d, 1 H), 7.89-8.18 (m, 2 H), 7.65 (br s, 1 H), 7.58 (br d, 1 H), 7.48-7.54 (m, 1 H), 7.13-7.22 (m, 1 H), 6.61-6.92 (m, 3 H), 4.49 (br s, 1 H), 3.76 (br s, 1 H), 3.18 (br s, 1 H), 2.80 (br d, 1 H), 2.40 (br s, 1 H), 0.87-1.14 (m, 4 H)	452.2 [M+H]+	99.7%
623	(CD3OD) δ 8.65 (br d, 1 H), 8.43 (br d, 1 H), 7.85-8.16 (m, 2 H), 7.65 (s, 1 H), 7.57 (br d, 1 H), 7.47-7.54 (m, 1 H), 7.14-7.20 (m, 1 H), 6.58-6.93 (m, 3 H), 4.42-4.63 (m, 1 H), 3.76 (br s, 1 H), 3.18 (br s, 1 H), 2.80 (br d, 1 H), 2.40 (br s, 1 H), 0.89-1.14 (m, 4 H)	452.2 [M+H]+	99.6%
624	(CD3OD) δ 8.42 (d, 1 H), 7.52-7.66 (m, 2 H), 7.13-7.21 (m, 1 H), 6.82 (t, 2 H), 6.59 (s, 1 H), 4.35 (br s, 1 H), 3.69 (br s, 1 H), 3.09 (br d, 1 H), 2.76 (br d, 1 H), 2.33 (br s, 1 H), 1.55 (br s, 6 H), 0.80-1.05 (m, 4 H)	433.2 [M+H]+	100%
625	(CD3OD) δ 8.42 (d, 1 H), 7.52-7.66 (m, 2 H), 7.13-7.20 (m, 1 H), 6.82 (t, 2 H), 6.59 (s, 1 H), 4.34 (br s, 1 H), 3.66 (br s, 1 H), 2.90-3.17 (m, 1 H), 2.76 (br d, 1 H), 2.33 (br s, 1 H), 1.55 (br s, 6 H), 0.79-1.04 (m, 4 H)	433.1 [M+H]+	99.5%
626	(CD3OD) δ 8.36-8.48 (m, 2 H), 8.10 (s, 1 H), 7.68 (s, 1 H), 7.53-7.63 (m, 1 H), 7.14-7.23 (m, 1 H), 6.94 (br s, 1 H), 6.81-6.89 (m, 1 H), 6.52-6.65 (m, 1 H), 4.96-5.10 (m, 0.7 H), 4.68-4.79 (m, 0.4 H), 4.00 (s, 3 H), 3.71-3.81 (m, 0.7 H), 3.36-3.51 (m, 0.4 H), 2.95-3.23 (m, 1 H), 2.83 (br d, 1 H)	416.2 [M+H]+	100%
627	(CD3OD) δ 8.34-8.48 (m, 2 H), 8.11 (s, 1 H), 7.69 (s, 1 H), 7.53-7.63 (m. 1 H), 7.14-7.25 (m. 1 H), 6.96 (br s, 1 H), 6.80-6.90 (m, 1 H), 6.54-6.65 (m, 1 H), 5.06 (br dd, 0.7 H), 4.76-4.80 (m, 0.6 H), 4.01 (s, 3 H), 3.72-3.82 (m, 0.6 H), 3.40 (td, 0.4 H), 2.93-3.23 (m, 1 H), 2.83 (br d, 1 H)	416.2 [M+H]+	99.6%
628	(CD3OD) δ 8.47 (br d, 1 H), 7.53-7.77 (m. 2 H), 7.15-7.27 (m, 1 H), 6.83-6.95 (m, 2 H), 6.44-6.67 (m, 1 H), 3.80 (br d, 1.5 H), 3.41-3.55 (m, 0.5 H), 2.74-3.07 (m, 2 H), 1.55-1.74 (m, 6 H)	461.0 [M+H]+	100%
629	(CD3OD) δ 8.39-8.51 (m, 1 H), 7.55-7.72 (m, 2 H), 7.31-7.53 (m, 0.5 H), 7.15-7.26 (m, 1 H), 6.80-6.95 (m, 1.5 H), 6.42-6.65 (m, 1 H), 3.80 (br d, 1.4 H), 3.50 (br d, 0.6 H), 2.73-3.10 (m, 2 H), 1.51-1.73 (m, 6 H)	461.0 [M+H]+	99.6%
630	(DMSO-d6) δ 11.89-12.21 (m, 1 H), 8.51-8.79 (m, 2 H), 7.44-7.76 (m. 2 H), 7.07-7.41 (m. 2 H), 6.28-6.94 (m. 3 H), 4.69 (br s, 0.4 H), 4.23 (br d, 0.6 H), 3.57-3.81 (m, 0.5 H), 3.17-3.29 (m, 0.5 H), 2.58-2.98 (m. 2 H)	385.1 [M+H]+	100%
631	(CD3OD) δ 8.39-8.48 (m, 2 H). 7.68 (s, 1 H), 7.59 (br d, 1 H), 6.99-7.30 (m, 2 H), 6.44-6.92 (m, 3 H), 4.96-5.10 (m, 0.5 H), 4.31 (br d, 0.7 H), 3.73 (br s, 0.5 H), 3.48 (br d, 0.3 H), 2.92-3.16 (m, 1H), 2.80 (br d, 1 H)	385.1 [M+H]+	99.7%
632	(CD3OD) δ 8.43 (br d, 1 H), 7.65 (s, 1 H), 7.57 (d, 1 H), 6.91-7.27 (m, 2 H), 6.73-6.91 (m, 1.6 H), 6.57 (br s. 1.4 H). 4.65-4.79 (m, 0.5 H), 4.30 (br s, 0.5 H), 3.37-3.91 (m, 1 H), 2.88-3.11 (m, 1 H), 2.79 (br d, 1 H). 2.00-2.34 (m, 1 H). 0.98-1.26 (m, 4 H)	425.0 [M+H]+	95.8%
633	(CD3OD) δ 8.43 (br d, 1 H). 7.65 (s, 1 H), 7.57 (d. 1 H), 7.02-7.33 (m, 2 H), 6.73-7.01 (m, 2 H), 6.50-6.60 (m, 1 H), 4.69-4.80 (m. 0.5 H). 4.31 (br s, 0.5 H), 3.67 (br s, 1 H). 2.92-3.21 (m, 1 H), 2.79 (br d, 1 H), 1.97-2.38 (m, 1 H), 1.05-1.26 (m, 4 H)	425.0 [M+H]+	99.1%
634	(CD3OD) δ 8.28-8.41 (m, 1 H), 7.41-7.57 (m, 2 H), 7.03-7.12 (m, 1 H), 6.83 (s. 0.6 H). 6.69-6.79 (m, 1 H). 6.29-6.47 (m, 1.4 H), 4.73 (br d, 0.5 H), 4.17 (br dd, 0.5 H). 3.41-3.54 (m, 0.6 H), 2.95-3.06 (m, 1 H), 2.55-2.90 (m, 3.4 H), 1.91-2.16 (m, 4 H), 1.50-1.76 (m. 2 H)	352.2 [M+H]+	100%
635	(CD3OD) δ 8.37-8.54 (m, 1 H), 7.52-7.71 (m, 2 H), 7.13-7.25 (m, 1 H), 6.95 (s, 0.6 H), 6.79-6.90 (m, 1 H), 6.40-6.58 (m, 1.4 H), 4.85 (br d, 0.4 H), 4.30 (dd. 0.6 H). 3.59 (ddd, 0.6 H), 3.11-3.16 (m, 1 H), 2.67-3.03 (m, 3.4 H), 2.03-2.27 (m, 4 H), 1.62-1.88 (m, 2 H)	352.2 [M+H]+	99.5%
636	(CD3OD) δ 8.40-8.54 (m, 1 H), 7.62-7.69 (m, 1 H), 7.58 (d. 1 H), 7.15-7.24 (m, 1 H), 6.79-6.93 (m, 2 H), 6.37-6.54 (m, 1 H), 4.82 (br dd, 1 H), 4.16 (br dd, 1 H), 3.47-3.66 (m, 1 H), 2.87-3.18 (m, 2 H), 2.68-2.82 (m, 3 H), 2.30-2.51 (m, 2 H), 2.19 (br d, 2 H)	354.2 [M+H]+	100%
637	(CD3OD) δ 8.38-8.53 (m, 1 H), 7.61-7.69 (m, 1 H), 7.57 (d. 1 H), 7.14-7.23 (m, 1 H), 6.77-6.92 (m, 2 H), 6.36-6.54 (m, 1 H), 5.03-5.25 (m, 1 H), 4.15 (br dd, 1 H), 3.46-3.66 (m, 1 H), 2.85-3.15 (m, 2 H), 2.66-2.81 (m, 3 H), 2.29-2.60 (m, 2 H), 2.07-2.25 (m. 2 H)	354.2 [M+H]+	83.3%
638	(CD3OD) δ 8.43 (br d, 1 H), 7.48-7.68 (m. 2 H), 7.10-7.23 (m, 1 H), 6.71-6.88 (m, 2 H), 6.40-6.59 (m, 1 H), 4.54-4.64 (m, 1 H), 3.46-3.65 (m, 1 H), 2.83-3.06 (m, 1 H), 2.67-2.79 (m, 1 H), 2.55-2.66 (m. 2 H), 2.02-2.16 (m, 2 H), 1.91-2.02 (m. 1 H), 1.77 (br d, 1 H)	388.2 [M+H]+.	100%
639	(CD3OD) δ 8.43 (br d, 1 H), 7.47-7.71 (m. 2 H), 7.09-7.22 (m, 1 H). 6.71-6.93 (m, 2 H). 6.40-6.59 (m, 1 H). 4.58 (br dd. 1 H), 3.58 (br t, 1 H), 2.811-3.04 (m, 1 H), 2.67-2.78 (m, 1 H), 2.55-2.66 (m, 2 H), 2.08 (br d, 2 H), 1.98 (dt, 1 H). 1.70-1.84 (m, 1 H)	388.1 [M+H]+	99.6%
640	Data provided above
641	Data provided above
642	(CD3OD) δ 8.33-8.68 (m, 3 H), 7.96 (d, 2 H), 7.73 (br s, 1 H), 7.49-7.67 (m, 1.4 H), 7.17-7.31 (m, 1 H), 7.00 (br s, 0.6 H), 6.78-6.95 (m. 1 H), 6.56-6.74 (m, 1 H), 5.10 (br dd, 0.7 H), 4.96-4.99 (m. 0.3 H), 3.76-3.90 (m, 0.6 H), 3.40-3.53 (m, 0.4 H), 2.99-3.28 (m, 1 H), 2.88 (br d, 1 H)	480.2 [M+Hl+	100%
643	(CD3OD) & 8.13-8.55 (m, 3 H), 7.83 (br d, 2 H), 7.32-7.74 (m, 2 H), 7.00-7.18 (m, 1 H), 6.66-6.96 (m, 2 H), 6.38-6.61 (m, 1 H), 4.97 (br dd, 1 H), 3.59-3.83 (m, 0.7 H), 3.28-3.36 (m, 0.3 H), 2.85-3.15 (m. 1 H), 2.77 (br s. 1 H)	480.2 [M+H]+	99.2%
644	(CD3OD) δ 8.74 (br d, 1 H). 8.47 (br d. 1 H), 8.30 (br d, 1 H). 7.90-8.10 (m, 1 H), 7.54-7.77 (m, 3 H), 7.05-7.42 (m, 2 H), 6.58-6.97 (m. 3 H), 4.52 (br d, 1 H). 3.43-3.86 (m, 1 H), 2.92-3.25 (m, 1 H), 2.78-2.91 (m, 1 H)	462.1 [M+Hl+	100%
645	(CD3OD) δ 8.74 (br d, 1 H), 8.47 (br d, 1 H), 8.13-8.34 (m, 1 H), 7.89-8.10 (m, 1 H), 7.56-7.79 (m, 3 H), 7.05-7.40 (m. 2 H), 6.51-7.00 (m, 3 H), 4.51 (br d. 1 H), 3.45-3.87 (m. 1 H), 2.92-3.26 (m, 1 H). 2.86 (br d. 1 H)	462.1 [M+H]+	99.5%
646	(CD3OD) δ 8.59 (s, 1 H). 8.37-8.48 (m, 1 H). 8.22 (s. 1 H), 7.54-7.72 (m, 2 H), 7.13-7.24 (m, 1 H), 6.78-6.99 (m. 2 H), 6.53-6.66 (m, 1 H), 5.02-5.17 (m. 3 H), 3.74-3.81 (m, 0.5 H), 3.38-3.47 (m, 0.5 H). 2.77-3.23 (m, 2 H)	484.1 [M+H]+	100%
647	(CD3OD) δ 8.59 (s, 1 H), 8.37-8.47 (m, 1 H), 8.22 (s, 1 H), 7.54-7.72 (m, 2 H), 7.14-7.24 (m, 1 H), 6.80-6.99 (m, 2 H), 6.54-6.67 (m, 1 H), 5.02-5.16 (m, 3 H), 3.72-3.82 (m, 0.6 H), 3.38-3.45 (m, 0.4 H), 2.80-3.16 (m, 2 H)	484.1 [M+H]+	98.3%
648	(CD3OD) δ 8.35-8.56 (m, 1 H), 8.06-8.15 (m, 1 H), 7.98-8.05 (m, 1 H), 7.71 (br s, 1 H), 7.49-7.66 (m, 2.4 H), 7.15-7.28 (m. 1 H), 6.98 (s, 0.6 H), 6.81-6.94 (m, 1 H), 6.56-6.71 (m, 1 H), 5.09 (dd, 0.7 H), 4.94-4.96 (m, 0.3 H), 3.71-3.88 (m, 0.7 H), 3.43 (td, 0.3 H), 3.13-3.26 (m, 0.7 H), 2.95-3.08 (m, 0.3 H), 2.86 (br d, 1 H)	448.1 [M+H]+	100%
649	(CD3OD) δ 8.35-8.63 (m, 1 H), 8.05-8.15 (m, 1 H). 7.97-8.05 (m, 1 H), 7.71 (br s, 1 H), 7.47-7.66 (m, 2.4 H), 7.08-7.32 (m, 1 H), 6.76-7.06 (m, 1.6 H), 6.51-6.74 (m. 1 H), 5.08 (br dd, 0.7 H), 4.95-5.00 (m, 0.3 H), 3.70-3.89 (m, 0.7 H), 3.38-3.48 (m, 0.3 H), 3.11-3.28 (m, 0.7 H), 2.96-3.09 (m, 0.3 H), 2.86 (br d, 1 H)	448.1 [M+H]+	100%
650	(CD3OD) δ 8.93 (br d, 1 H), 8.24-8.57 (m, 2 H), 7.46-7.89 (m, 3 H), 7.21 (br s, 1 H), 6.74-7.07 (m, 2 H), 6.50-6.69 (m, 1 H), 5.05 (br s. 1 H), 3.79 (br s. 1 H), 2.75-3.26 (m. 2 H)	452.0 [M+H]+	100%
651	(CD3OD) δ 8.94 (s. 1 H), 8.31-8.50 (m, 2 H), 7.48-7.86 (m. 3 H), 7.14-7.31 (m, 1 H), 6.78-7.03 (m, 2 H), 6.52-6.69 (m. 1 H), 5.07 (br dd, 1 H), 3.36-3.87 (m, 1 H), 2.79-3.25 (m, 2 H)	452.0 [M+H]+	99.6%
652	(CD3OD) δ 8.39-8.52 (m, 1 H), 8.17-8.31 (m. 1 H), 7.71 (s, 1 H), 7.53-7.66 (m, 1.3 H). 7.16-7.38 (m, 3 H). 6.98 (s. 0.7 H). 6.82-6.93 (m, 1 H), 6.57-6.70 (m, 1 H), 5.03 (dd, 0.7 H), 4.94-4.96 (m, 0.3 H), 3.74-3.86 (m, 0.7 H), 3.43 (td. 0.3 H). 3.16-3.26 (m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.81-2.91 (m, 1 H)	448.2 [M+H]+	100%
653	(CD3OD) δ 8.26-8.39 (m, 1 H), 8.11 (td, 1 H), 7.64 (br s, 1 H), 7.41-7.54 (m, 1.3 H), 7.07-7.25 (m, 3 H), 6.87 (s, 0.7 H), 6.71-6.80 (m, 1 H), 6.46-6.58 (m, 1 H), 4.92 (br dd, 0.7 H), 4.82-4.85 (m, 0.3 H), 3.63-3.73 (m, 0.7 H), 3.27-3.36 (m, 0.3 H), 3.06-3.14 (m, 0.7 H). 2.85-297 (m, 0.3 H), 2.69-2.80 (m, 1 H)	448.2 [M+H]+	98.6%
654	(DMSO-d6) δ 11.97-12.17 (m, 1 H), 8.48-8.69 (m, 1 H), 7.88-8.08 (m, 1 H), 7.50-7.70 (m, 2 H), 7.33-7.40 (m, 1 H), 7.13-7.32 (m, 2 H). 7.08 (s. 0.2 H), 6.95 (br s, 1.2 H). 6.48-6.61 (m, 1.6 H), 4.67-4.86 (m, 1 H), 3.62-3.79 (m, 1 H), 2.71-3.1 1 (m, 2 H), 2.58-2.67 (m, 3 H)	444.1 [M+H]+	100%
655	(DMSO-d6) δ 12.03-12.18 (m. 1 H), 8.54-8.70 (m. 1 H), 7.95-8.07 (m, 1 H), 7.57-7.71 (m, 2 H), 7.36-7.43 (m, 1 H), 7.27-7.35 (m, 2 H), 6.80-6.90 (m, 1 H), 6.55-6.63 (m, 1 H), 4.72-4.88 (m, 1 H), 3.61-3.85 (m, 1 H), 2.89-3.18 (m, 1 H), 2.79 (br d, 1 H), 2.61-2.69 (m, 3 H)	444.1 [M+H]+	100%
656	(CD3OD) δ 8.42-8.56 (m, 1 H), 7.50-7.84 (m, 4 H). 6.73-7.26 (m, 4 H), 6.24-6.64 (m, 1 H), 4.81 (br s, 1 H), 4.07 (br d, 0.5 H), 3.71 (br t, 0.5 H). 2.99 (br s, 1 H). 2.75 (br d, 1 H)	384.1 [M+H]+	100%
657	(CD3OD) δ 8.41-8.57 (m, 1 H), 7.48-7.85 (m, 4 H), 6.73-7.25 (m, 4 H), 6.23-6.66 (m, 1 H), 4.75-4.86 (m, 1 H), 4.01-4.12 (m, 0.5 H), 3.71 (br s, 0.5 H). 2.99 (br s, 1 H), 2.75 (br d, 1 H)	384.1 [M+H]+	99.7%
658	(CD3OD) δ 8.34-8.58 (m, 1 H), 7.46-7.90 (m, 3.3 H), 7.10-7.34 (m, 1 H), 6.77-7.02 (m, 2.7 H), 6.47-6.73 (m, 1 H), 5.03 (br dd, 1 H), 4.05 (s, 3 H), 3.79 (br 1, 1 H), 2.71-3.21 (m. 2 H)	416.1 [M+H]+	98.1%
659	(CD3OD) δ 8.31-8.58 (m, 1 H), 7.44-7.96 (m, 3.3 H), 7.14-7.33 (m, 1 H), 6.80-7. 10 (m, 2.7 H), 6.52-6.71 (m, 1 H), 5.03 (br dd, 1 H), 4.05 (s, 3 H), 3.70-3.88 (m, 1 H), 2.71-3.23 (m, 2 H)	416.1 [M+H]+	90.6%
660	(CD3OD) δ 8.42-8.61 (m, 1 H), 7.48-7.75 (m, 3 H), 7.16-7.27 (m, 1 H), 6.76-7.03 (m, 2 H), 6.53-6.71 (m, 1 H), 6.35 (br s, 1 H), 4.04-4.19 (m, 1 H), 3.93 (s, 3 H), 3.61-3.79 (m, 1 H), 2.98 (br s, 1 H). 2.66-2.87 (m, 1 H)	348.1 [M+H]+	100%
661	(CD3OD) δ 8.42-8.61 (m, 1 H), 7.47-7.75 (m, 3 H), 7.16-7.28 (m. 1 H), 6.76-7.03 (m, 2 H), 6.52-6.72 (m. 1 H), 6.34 (br s. 1 H), 4.03-4.20 (m, 1 H), 3.93 (s, 3 H), 3.59-3.78 (m, 1 H), 2.98 (br s, 1 H), 2.76 (br d, 1 H)	348.1 [M+H]+	96.8%
662	(CD3OD) δ 8.30-8.64 (m, 1.5 H), 7.97 (br s, 0.5 H), 7.45-7.75 (m, 2 H), 7.14-7.23 (m, 1 H), 6.75-7.03 (m, 2.6 H), 6.17-6.64 (m, 1.4 H), 4.02-4.16 (m, 1 H), 3.96 (s, 3 H), 3.34-3.80 (m, 1 H), 2.93 (br t, 1 H), 2.70 (br dd, 1 H)	398.1 [M+H]+	100%
663	(CD3OD) δ 8.25-8.66 (m, 1.5 H), 7.97 (br s, 0.5 H), 7.50-7.70 (m, 2 H), 7.12-7.27 (m, 1 H), 6.70-7.08 (m, 2.5 H), 6.08-6.69 (m, 1.5 H), 4.01-4.19 (m, 1 H), 3.96 (s, 3 H), 3.34-3.80 (m, 1 H), 2.93 (br t. 1 H), 2.60-2.77 (m, 1 H)	398.1 [M+H]+	99.3%
664	(CD3OD) δ 8.17-8.60 (m, 1.5 H), 7.90 (br s, 0.5 H), 7.50-7.69 (m, 2 H), 7.18 (ddd, 1 H), 6.78-7.02 (m, 1.6 H), 6.12-6.68 (m, 1.4 H), 4.81 (br s, 0.5 H), 4.05 (br d, 0.5 H), 3.88 (s, 3 H), 3.71 (br s, 0.5 H), 3.15-3.30 (m, 0.5 H), 2.90-3.01 (m, 1 H), 2.72 (br dd, 1 H)	382.2 [M+H]+	100%
665	(CD3OD) δ 8.19-8.58 (m, 1.5 H), 7.90 (br s, 0.5 H), 7.50-7.69 (m, 2 H), 7.17 (dd, 1 H), 6.78-7.01 (m, 1.6 H), 6.14-6.66 (m, 1.4 H), 4.69-4.83 (m, 0.6 H), 4.04 (br d, 0.4 H), 3.87 (s, 3 H), 3.69 (br s, 0.5 H), 3.24 (br s, 0.5 H), 2.88-3.00 (m, 1 H), 2.71 (br dd, 1 H)	382.2 [M+H]+	99.6%
666	(CD3OD) δ 8.34-8.49 (m, 2 H), 7.52-7.86 (m, 3.3 H), 7.15-7.29 (m, 2 H), 6.83-7.00 (m, 1.7 H), 6.57-6.70 (m, 1 H), 5.03 (dd. 1 H), 3.72-3.86 (m, 0.7 H), 3.38-3.51 (m, 0.3 H), 2.96-3.27 (m, 1 H), 2.79-2.93 (m, 1 H)	452.2 [M+H]+	100%
667	(CD3OD) δ 8.32-8.51 (m, 2 H), 7.53-7.85 (m, 3.5 H), 7.14-7.26 (m, 2 H), 6.81-7.01 (m, 1.5 H), 6.58-6.69 (m, 1 H), 5.03 (dd, 1 H), 3.80 (ddd, 0.7 H), 3.43 (td, 0.3 H), 2.97-3.27 (m, 1 H), 2.86 (br dd, 1 H)	452.3 [M+H]+	97.2%
668	(CD3OD) δ 9.04 (d, 1 H), 8.55 (s, 1 H), 8.37-8.49 (m, 1 H), 7.96 (d, 1 H), 7.67-7.74 (m, 1 H), 7.51-7.64 (m, 1.3 H), 7.15-7.24 (m, 1 H), 6.98 (s, 0.7 H), 6.80-6.90 (m, 1 H), 6.58-6.69 (m, 1 H), 5.03 (dd, 1 H), 3.81 (ddd, 0.7 H), 3.39-3.50 (m, 0.4 H), 3.11-3.23 (m, 0.6 H), 2.97-3.07 (m, 0.4 H), 2.78-2.92 (m, 1 H)	481.1 [M+H]+	100%
669	(CD3OD) δ 9.04 (d, 1 H), 8.55 (s, 1 H), 8.37-8.50 (m, 1 H), 7.96 (d, 1 H), 7.70 (s, 1 H), 7.50-7.63 (m, 1.3 H), 7.14-7.25 (m, 1 H), 6.98 (s, 0.7 H), 6.80-6.90 (m, 1 H), 6.58-6.69 (m, 1 H), 5.02 (br dd, 1 H), 3.76-3.85 (m, 0.7 H), 3.40-3.49 (m, 0.3 H), 3.16-3.25 (m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.78-2.90 (m, 1 H)	481.1 [M+H]+	98.4%
670	(CD3OD) δ 8.34 (d, 1 H), 7.37-7.67 (m, 2 H), 6.99-7.19 (m, 2 H), 6.68-6.93 (m, 2 H), 6.51 (s, 1 H), 4.22 (br d, 1 H), 3.26-3.80 (m, 1 H), 2.59-3.10 (m, 2 H), 1.45-1.66 (m, 6 H)	443.2 [M+H]+	100%
671	(CD3OD) δ 8.33 (br d, 1 H), 7.41-7.71 (m, 2 H), 6.99-7.19 (m, 2 H), 6.71-6.94 (m, 2 H), 6.51 (s, 1 H), 4.23 (br d, 1 H), 3.28-3.78 (m, 1 H), 2.58-3.11 (m, 2 H), 1.42-1.67 (m, 6 H)	443.1 [M+H]+	98.9%
672	(CD3OD) δ 8.59 (s, 1 H), 8.32-8.50 (m, 1 H), 8.07-8.24 (m, 1 H), 7.80-7.95 (m, 1 H), 7.67 (s, 1 H), 7.43-7.62 (m, 1.4 H), 7.10-7.24 (m, 1 H), 6.94 (s, 0.6 H), 6.74-6.89 (m, 1 H), 6.49-6.68 (m, 1 H), 4.97 (br dd, 1 H), 3.67-3.86 (m, 0.7 H), 3.39 (td, 0.3 H), 3.17 (br s, 0.7 H), 2.91-3.04 (m, 0.3 H), 2.82 (br d, 1 H), 2.45 (s, 3 H)	427.1 [M+H]+	100%
673	(CD3OD) δ 8.59 (s, 1 H), 8.30-8.48 (m, 1 H), 8.09-8.22 (m, 1 H), 7.83-7.93 (m, 1 H), 7.67 (s, 1 H), 7.42-7.63 (m, 1.4 H), 7.09-7.25 (m, 1 H), 6.94 (s, 0.6 H), 6.72-6.88 (m, 1 H), 6.49-6.68 (m, 1 H), 4.97 (br dd, 1 H), 3.77 (ddd, 0.7 H), 3.39 (td, 0.3 H), 3.10-3.23 (m, 0.7 H), 2.91-3.06 (m, 0.3 H). 2.82 (br dd, 1 H), 2.45 (s, 3 H)	427.1 [M+H]+	98.3%
674	(CD3OD) δ 8.82-9.33 (m, 1 H), 8.35-8.61 (m, 2 H), 7.88-8.02 (m. 2 H), 7.51-7.72 (m, 2 H), 7.37 (br t, 1 H), 7.20 (dd, 1 H), 6.58-7.05 (m, 2 H), 6.22-6.39 (m, 1 H), 4.10 (br d, 1 H), 3.76 (br s, 1 H), 3.00 (br s, 1 H), 2.76 (br d, 1 H)	445.2 [M+H]+	100%
675	(CD3OD) δ 8.81-9.31 (m, 1 H), 8.40-8.59 (m, 2 H), 7.90-8.01 (m, 2 H), 7.52-7.70 (m, 2 H), 7.37 (br t, 1 H), 7.20 (dd, 1 H), 6.61-7.04 (m, 2 H), 6.23-6.38 (m, 1 H), 4.10 (br d, 1 H), 3.76 (br s, 1 H), 3.00 (br t, 1 H), 2.75 (br d, 1 H)	445.2 [M+H]+	99.6%
676	(CD3OD) δ 8.46 (d, 1 H), 7.68 (s, 1 H), 7.61 (br d, 1 H), 7.13-7.30 (m, 1 H), 6.87 (td, 1.3 Hz, 1.7 H), 6.48-6.73 (m, 1 H), 6.39 (br s, 0.3 H), 4.78 (br s. 0.3 H), 4.16 (br d, 0.7 H), 3.69-3.91 (m, 0.7 H), 3.42 (br s, 0.3 H), 2.92-3.24 (m, 1 H), 2.82 (br d, 1 H), 1.53-1.70 (m, 6 H)	471.0 [M+H]+	100%
677	(CD3OD) δ 8.46 (d, 1 H), 7.68 (s, 1 H), 7.62 (br d, 1 H), 7.13-7.28 (m, 1 H), 6.87 (td, 1.6 H), 6.49-6.72 (m, 1 H), 6.38 (br s, 0.4 H), 4.79 (br s, 0.3 H), 4.16 (br d, 0.7 H), 3.70-3.88 (m, 0.7 H), 3.42 (br s, 0.3 H), 3.12 (br d, 1 H), 2.82 (br d, 1 H), 1.52-1.72 (m, 6 H)	471.0 [M+H]+	99.7%
678	(CD3OD) δ 8.58 (s, 1 H), 8.36-8.50 (m, 1 H), 7.71 (s, 1 H), 7.49-7.65 (m, 1.3 H), 7.15-7.27 (m, 1 H), 6.80-7.02 (m, 1.7 H), 6.53-6.68 (m, 1 H), 4.99 (br dd, 1 H), 4.07 (s, 3 H), 3.72-3.85 (m, 0.7 H), 3.41 (td, 0.3 H), 3.13-3.26 (m, 0.7 H), 2.93-3.09 (m, 0.3 H), 2.77-2.92 (m, 1 H)	484.1 [M+H]+	100%
679	(CD3OD) δ 8.58 (s, 1 H), 8.37-8.54 (m, 1 H), 7.71 (s, 1 H), 7.47-7.65 (m, 1.3 H), 7.14-7.27 (m, 1 H), 6.78-7.01 (m, 1.7 H), 6.52-6.71 (m, 1 H), 4.99 (br dd, 1 H), 4.07 (s, 3 H), 3.73-3.84 (m, 0.7 H), 3.37-3.45 (m, 0.3 H), 3.12-3.26 (m, 0.7 H), 2.94-3.07 (m, 0.3 H), 2.77-2.91 (m, 1 H)	484.1 [M+H]+	100%
680	(CD3OD) δ 8.40-8.59 (m, 1 H), 7.50-7.71 (m, 2 H), 7.19 (ddd, 1 H), 6.74-7.01 (m, 2 H), 6.45-6.69 (m, 1 H), 6.31 (br d, 1 H), 4.80 (br s, 0.4 H), 3.98-4.14 (m, 0.6 H), 3.81-3.89 (m, 3 H), 3.61-3.78 (m, 0.7 H), 3.29 (br s, 0.3 H), 2.90-3.04 (m, 1 H), 2.75 (br d, 1 H)	382.2 [M+H]+	100%
681	(CD3OD) δ 8.40-8.59 (m, 1 H), 7.51-7.72 (m, 2 H), 7.19 (ddd, 1 H), 6.72-7.00 (m, 2 H), 6.47-6.67 (m, 1 H), 6.31 (br d, 1 H), 4.81 (br s, 0.5 H), 4.00-4.13 (m, 0.5 H), 3.85 (s, 3 H), 3.62-3.77 (m, 0.6 H), 3.25 (br s, 0.4 H), 2.89-3.03 (m, 1 H), 2.75 (br d, 1 H)	382.2 [M+H]+	99.2%
682	(CD3OD) δ 8.44-8.71 (m, 2 H), 7.68 (s, 1 H), 7.53 (br d, 1 H), 7.26 (dd, 1 H), 6.45-6.88 (m, 2 H), 4.39 (br d, 1 H), 3.35-3.94 (m. 1 H), 2.73-3.20 (m, 2 H)	440.1 [M+H]+	100%
683	(CD3OD) δ 8.37-8.78 (m, 2 H), 7.68 (s, 1 H), 7.55 (br d, 1 H), 7.27 (dd, 1 H), 6.37-6.93 (m, 2 H), 4.39 (br d, 1 H), 3.34-3.94 (m, 1 H), 2.73-3.23 (m, 2 H)	440.1 [M+H]+	99.8%
684	(CD3OD) δ 8.40-8.62 (m, 2 H), 7.52-7.72 (m, 2 H). 7.19 (dd, 1 H), 6.52-6.90 (m, 2 H), 4.38 (br d, 1 H), 3.33-3.92 (m, 1 H), 2.72-3.22 (m, 2 H)	394.0 [M+H]+	100%
685	(CD3OD) δ 8.40-8.62 (m, 2 H), 7.52-7.76 (m, 2 H), 7.20 (dd, 1 H), 6.46-6.91 (m, 2 H), 4.39 (br d, 1 H), 3.35-3.90 (m, 1 H), 3.11 (br s, 1 H). 2.72-2.95 (m, 1 H)	394.0 [M+H]+	99.8%
686	(CD3OD) δ 8.38-8.54 (m, 2 H), 7.62-7.79 (m, 1 H), 7.30 (d, 1 H), 6.48-7.00 (m, 3 H), 4.40 (br d, 1 H), 3.77 (br s, 1 H), 2.77-3.19 (m, 2 H)	394.2 [M+H]+	98.6%
687	(CD3OD) δ 8.39-8.56 (m, 2 H), 7.69 (s, 1 H), 7.30 (d, 1 H), 6.46-6.94 (m, 3 H), 4.41 (br d, 1 H), 3.78 (br d, 1 H), 2.77-3.20 (m, 2 H)	394.2 [M+H]+	94.5%
688	(CD3OD) δ 8.33-8.48 (m, 2 H), 7.98-8.17 (m, 1 H), 7.53-7.72 (m, 1.3 H), 7.21-7.36 (m, 1 H), 6.60-7.03 (m, 2.7 H), 4.92-5.10 (m, 1 H), 4.00 (s, 3 H), 3.76 (ddd, 0.6 H), 3.35-3.44 (m, 0.4 H), 2.92-3.22 (m, 1 H), 2.79-2.89 (m, 1 H)	450.2 [M+H]+	100%
689	(CD3OD) δ 8.35-8.49 (m, 2 H), 8.04-8.16 (m, 1 H), 7.50-7.74 (m, 1.3 H), 7.24-7.35 (m, 1 H), 6.68-6.97 (m, 2.7 H), 4.92-5.12 (m, 1 H), 4.00 (s, 3 H), 3.71-3.83 (m, 0.7 H), 3.40 (td, 0.3 H), 2.93-3.23 (m, 1 H), 2.77-2.90 (m, 1H)	450.2 [M+H]+	99.3%
690	(CD3OD) δ 8.44 (br d, 1 H), 7.54-7.70 (m, 2 H), 7.10-7.28 (m, 2 H), 6.81-7.01 (m, 2 H), 6.60 (br s, 1 H), 4.94-5.00 (m, 1 H), 4.33 (br d, 1 H), 3.72 (br s, 1 H), 2.92-3.20 (m, 1 H), 2.80 (br d, 1 H), 1.61 (br d, 3 H)	429.3 [M+H]+	99.6%
691	(CD3OD) δ 8.44 (br d, 1 H), 7.53-7.71 (m, 2 H), 7.10-7.29 (m, 2 H), 6.79-7.02 (m, 2 H), 6.60 (s, 1 H), 4.94-5.01 (m, 1 H), 4.34 (br d, 1 H), 3.73 (br s, 1 H), 2.90-3.19 (m, 1 H), 2.81 (br d, 1 H), 1.50-1.68 (m, 3 H)	429.2 [M+H]+	99.7%
692	(CD3OD) δ 8.44 (br d, 1 H), 7.68 (s, 1 H), 7.59 (br d, 1 H), 7.27 (s, 0.2 H), 7.16-7.23 (m, 1 H), 6.97-7.14 (m, 0.8 H), 6.85 (br t, 2 H), 6.61 (s, 1 H), 4.97 (br d, 1 H), 4.35 (br d, 1 H), 3.63-3.80 (m, 0.7 H), 3.37-3.49 (m, 0.3 H), 2.91-3.20 (m, 1 H), 2.81 (br d, 1 H), 1.60 (br d, 3 H)	429.2 [M+H]+	100%
693	(CD3OD) δ 8.44 (br d, 1 H), 7.68 (s, 1 H), 7.59 (br d, 1 H), 7.26 (s, 0.2 H), 7.16-7.22 (m, 1 H), 6.98-7.14 (m, 0.8 H), 6.86 (br t, 2 H), 6.61 (s, 1 H), 4.97 (br d, 1 H), 4.34 (br d, 1 H), 3.72 (br s, 0.7 H), 3.48 (br s, 0.4 H), 2.89-3.19 (m, 1 H), 2.81 (br d, 1 H), 1.61 (br d, 3 H)	429.2 [M+H]+	100%
694	(CD3OD) δ 8.40-8.48 (m, 1 H), 7.65-7.70 (m, 1 H), 7.51-7.61 (m, 1 H), 7.13-7.24 (m, 1 H), 6.80-6.94 (m, 2 H), 6.35-6.64 (m, 1 H), 4.83 (br s, 0.3, 4.44 (dd, 0.7 H), 4.02 (s, 3 H), 3.59-3.73 (m, 0.7 H), 3.09-3.27 (m, 1H), 2.90-3.01 (m, 0.3 H), 2.70-2.85 (m, 1 H)	383.2 [M+H]+	99.0%
695	(CD3OD) δ 8.40-8.48 (m, 1 H), 7.65-7.71 (m, 1 H), 7.50-7.61 (m, 1 H), 7.13-7.23 (m, 1 H), 6.79-6.93 (m, 2 H), 6.34-6.63 (m, 1 H), 4.83 (br s, 0.3, 4.44 (dd, 0.7 H), 4.02 (s, 3 H), 3.66 (ddd, 0.7 H), 3.08-3.27 (m, 1 H), 2.90-3.00 (m, 0.3 H), 2.70-2.85 (m, 1 H)	383.2 [M+H]+	98.6%
696	(CD3OD) δ 8.49-8.63 (m, 1 H), 8.32 (br s, 1H), 8.08 (s, 1H), 7.53-7.70 (m, 2.3 H), 7.08-7.27 (m, 1 H), 6.91 (s, 0.7 H), 6.58-6.73 (m, 1 H), 5.07 (br dd, 0.5 H), 3.99 (s, 3 H), 3.66-3.85 (m, 1 H), 3.39 (td, 0.5 H), 2.73-3.24 (m, 2 H)	450.2 [M+H]+	100%
697	(CD3OD) δ 8.50-8.62 (m, 1 H), 8.38 (s, 1H), 8.03-8.15 (m, 1 H), 7.51-7.74 (m, 2.4 H), 7.13-7.30 (m, 1 H), 6.92 (s, 0.6 H), 6.60-6.73 (m, 1 H), 5.07 (br dd, 0.5 H), 4.00 (s, 3 H), 3.67-3.83 (m, 1 H), 3.33-3.48 (m, 0.5 H), 2.72-3.23 (m, 2 H)	450.2 [M+H]+	99.7%
698	(CD3OD) δ 8.35 (d, 1 H), 7.38-7.71 (m, 2 H), 6.86-7.29 (m, 2 H), 6.38-6.81 (m, 3 H), 4.21 (br d, 1 H), 3.29-3.78 (m, 1 H), 2.58-3.15 (m, 2 H), 1.54-1.90 (m, 6 H)	452.2 [M+H]+	98.3%
699	(CD3OD) δ 8.47 (d, 1 H), 7.52-7.79 (m, 2 H), 6.99-7.36 (m, 2 H), 6.45-6.93 (m, 3 H), 4.33 (br d, 1 H), 3.38-3.85 (m, 1 H), 2.69-3.27 (m, 2 H), 1.67-2.01 (m, 6 H))	452.2 [M+H]+	98.4%
700	(CD3OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 6.94-7.35 (m, 2 H), 6.51-6.93 (m, 3 H), 4.36 (br d, 1 H), 3.33-3.82 (m, 1 H), 2.70-3.18 (m, 2 H), 1.54-1.73 (m, 6 H)	477.2 [M+H]+	94.7%
701	(CD3OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 6.94-7.38 (m, 2 H), 6.51-6.93 (m, 3 H), 4.35 (br d, 1 H), 3.37-3.88 (m, 1 H), 2.73-3.23 (m, 2 H), 1.55-1.74 (m, 6 H)	477.2 [M+H]+	99.4%
702	(CD3OD) δ 8.44 (d, 1 H), 7.68 (s, 1H), 7.30 (d, 1 H), 6.94-7.27 (m, 1 H), 6.85 (t, 1.7 H), 6.49-6.77 (m, 1.3 H), 4.97 (br d, 1.3 H), 4.36 (br d, 0.7 H), 3.36-3.85 (m, 1 H), 2.73-3.23 (m, 2 H), 1.49-1.71 (m, 3 H)	463.0 [M+H]+	98.1%
703	(CD3OD) δ 8.43 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.97-7.27 (m, 1 H), 6.85 (t, 1.6 H), 6.54-6.78 (m, 1.4 H), 4.97 (br d, 1.3 H), 4.37 (br d, 0.7 H), 3.37-3.81 (m, 1 H), 2.75-3.21 (m, 2 H), 1.46-1.67 (m, 3 H)	463.0 [M+H]+	96.7%
704	(CD3OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.95-7.27 (m, 1 H), 6.85 (t, 1.6 H), 6.54-6.77 (m, 1.4 H), 4.40 (br d, 1 H), 3.36-3.83 (m, 1 H), 2.70-3.21 (m, 2 H), 1.20-1.46 (m, 4 H)	475.2 [M+H]+	98.7%
705	(CD3OD) δ 8.44 (d, 1 H), 7.72 (br s, 1 H). 7.30 (d, 1 H). 6.95-7.27 (m, 1 H), 6.85 (t, 1.6 H), 6.74 (s, 1.4 H), 4.41 (br d, 1 H), 3.72 (br s, 1 H), 2.73-3.23 (m, 2 H), 1.23-1.44 (m, 4 H)	475.1 [M+H]+	99.2%
706	(CD3OD) δ 8.43 (d, 1 H), 7.67 (s, 1 H), 7.29 (d, 1 H), 6.34-6.98 (m, 3 H), 4.91 (br s, 1 H), 4.28-4.79 (m, 1 H), 3.37-3.83 (m, 1 H), 2.68-3.20 (m, 2 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)	427.2 [M+H]+	98.7%
707	(CD3OD) δ 8.43 (d, 1 H), 7.66 (s. 1 H), 7.28 (d, 1 H), 6.41-6.93 (m, 3 H), 4.88-4.94 (m, 1 H), 4.36 (br s, 1 H), 3.39-3.79 (m, 1 H), 2.68-3.21 (m, 2 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)	427.2 [M+H]+	97.7%
708	(CD3OD) δ 8.43 (d, 1H), 7.66 (s, 1 H), 7.28 (d, 1 H), 6.41-6.93 (m, 3 H), 4.88-4.94 (m, 1 H), 4.36 (br s, 1 H), 3.39-3.79 (m, 1 H), 2.68-3.21 (m, 2 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)	427.2 [M+H]+	97.7%
709	(CD3OD) δ 8.43 (d, 1 H), 7.67 (s, 1H), 7.29 (d, 1 H), 6.32-6.97 (m, 3 H), 4.89-4.93 (m, 1 H), 4.34 (br s, 1 H), 3.37-3.83 (m, 1 H), 2.68-3.23 (m, 2 H), 2.37 (s, 3 H), 1.56 (br s, 3 H)	427.2 [M+H]+	99.5%
710	(CD3OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.91-7.29 (m, 2 H), 6.49-6.90 (m, 3 H), 4.97 (br d, 1.3 H), 4.36 (br d, 0.7 H), 3.34-3.80 (m, 1 H), 2.70-3.21 (m, 2 H), 1.49-1.68 (m, 3 H)	447.1 [M+H]+	98.9%
711	(CD3OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.92-7.31 (m, 2 H), 6.51-6.90 (m, 3 H), 4.97 (br d, 1.4 H), 4.36 (br d, 0.6 H), 3.37-3.85 (m, 1 H), 2.68-3.21 (m, 2 H), 1.46-1.67 (m, 3 H)	447.1 [M+H]+	99.5%
712	(CD3OD) δ 8.33 (d, 1 H), 7.61-7.72 (m, 1 H), 6.93-7.31 (m, 2 H), 6.52-6.90 (m, 3 H), 4.97 (br d, 1 H), 4.36 (br d, 1 H), 3.37-3.80 (m, 1 H), 2.72-3.21 (m, 2 H), 1.61 (br d, 3 H)	447.1 [M+H]+	95.9%
713	(CD3OD) δ 8.33 (d, 1 H), 7.62-7.74 (m, 1 H), 6.91-7.30 (m, 2 H), 6.48-6.90 (m. 3 H), 4.97 (br d, 1 H). 4.30-4.45 (m, 1 H). 3.36-3.80 (m, 1 H), 2.72-3.22 (m, 2 H), 1.48-1.69 (m, 3 H)	447.1 [M+H]+	98.8%
714	(CD3OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.90-7.28 (m, 2 H), 6.49-6.89 (m, 3 H). 4.33 (br s, 1 H), 3.37-3.86 (m, 1 H), 2.74-3.20 (m, 2 H), 1.66 (br s, 6 H)	461.1 [M+H]+	99.7%
715	(CD3OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.90-7.30 (m, 2 H), 6.50-6.89 (m, 3 H). 4.34 (br d. 1 H), 3.36-3.84 (m, 1 H), 2.73-3.22 (m, 2 H), 1.56-1.71 (m, 6 H)	461.1 [M+H]+	99.6%
716	(CD3OD) δ 8.40-8.57 (m, 1 H). 7.89 (br s, 1 H), 7.51-7.75 (m, 2 H), 7.17-7.30 (m, 1 H), 6.84-7.06 (m, 2 H), 6.58-6.80 (m, 1 H), 5.92-6.41 (m, 1 H), 4.85 (br d, 0.4 H). 3.70-3.83 (m, 1.2 H), 3.36-3.45 (m, 0.4 H), 2.67-3.09 (m, 2 H)	402.20 [M+H]+	100%
717	(CD3OD) δ 8.41-8.59 (m, 1 H), 7.89 (br s, 1 H), 7.49-7.79 (m, 2 H), 7.14-7.30 (m, 1 H), 6.85-7.04 (m, 2 H), 6.59-6.82 (m, 1 H), 5.96-6.42 (m, 1 H), 4.85 (br d, 0.4 H), 3.69-3.83 (m, 1.2 H), 3.36-3.46 (m, 0.4 H), 2.64-3.04 (m, 2 H)	402.20 [M+H]+	100%
718	(CD3OD) δ 8.36-8.50 (m, 2 H), 8.05-8.18 (m, 1 H), 7.53-7.76 (m, 1.3 H), 7.24-7.35 (m, 1 H), 6.92 (s, 0.7 H), 6.65-6.88 (m, 2 H), 5.07 (br dd. 1 H), 3.98 (s, 3 H), 3.67-3.82 (m, 0.7 H), 3.32-3.45 (m, 0.3 H), 2.92-3.21 (m, 1 H), 2.78-2.89 (m, 1 H)	450.1 [M+H]+	100%
719	(CD3OD) δ 8.32-8.47 (m, 2 H), 8.09 (d, 1 H), 7.73-7.87 (m, 1 H), 7.22-7.61 (m, 1.3 H), 6.95 (s, 0.7 H), 6.67-6.89 (m. 2 H), 5.08 (br dd, 1 H), 3.98 (s, 3 H), 3.66-3.79 (m, 0.6 H), 3.33-3.42 (m. 0.4 H). 2.93-3.22 (m, 1 H). 2.84 (br d, 1 H)	450.0 [M+H]+	99.0%
720	(CD3OD) δ 8.46 (d. 1 H), 7.70 (s, 1 H). 7.32 (d, 1 H), 6.82-7.00 (m, 1.7 H), 6.76 (br s, 1 H), 6.45 (br s, 0.3 H), 4.82 (br s, 0.4 H), 4.24 (br d. 0.6 H). 3.68-3.91 (m, 0.6 H), 3.41 (br s, 0.4 H), 2.92-3.25 (m, 1 H), 2.70-2.91 (m, 1 H), 1.51-1.70 (m, 6 H)	461.2 [M+H]+	100%
721	(CD3OD) δ 8.46 (d, 1 H), 7.70 (s, 1 H), 7.31 (d, 1 H), 6.81-6.93 (m, 1.7 H), 6.76 (br s, 1 H), 6.45 (br s, 0.3 H). 4.79 (br s, 0.3 H), 4.24 (br d, 0.7 H), 3.78 (br t, 0.7 H), 3.41 (br s, 0.3 H), 3.15 (br s, 1 H), 2.84 (br d, 1 H), 1.52-1.72 (m, 6 H)	461.1 [M+H]+	100%
722	(CD3OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.84 (t, 1.6 H), 6.25-6.76 (m. 1.4 H). 4.79 (br s, 0.4 H), 4.17 (br d, 0.6 H), 3.36-3.84 (m, 1 H), 2.75-3.23 (m, 2 H), 1.49-1.69 (m, 6 H)	507.1 [M+H]+	96.2%
723	(CD3OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.84 (t, 1.6 H), 6.31-6.76 (m, 1.4 H), 4.82 (br s, 0.4 H), 4.17 (br d, 0.6 H), 3.36-3.83 (m, 1 H), 2.75-3.22 (m, 2 H), 1.52-1.71 (m, 6 H)	507.2 [M+H]+	98.3%
724	(CD3OD) δ 8.43 (d, 1 H), 7.56-7.74 (m, 1 H), 7.29 (d, 1 H), 6.42-6.93 (m, 3 H), 4.24-4.44 (m, 1 H). 3.39-3.80 (m, 1 H). 2.70-3.23 (m, 2 H), 2.37 (s, 3 H), 1.62 (br s, 6 H)	441.3 [M+H]+	98.3%
725	(CD3OD) δ 8.44 (d, 1 H), 7.67 (s, 1 H), 7.29 (d, 1 H), 6.43-6.95 (m. 3 H), 4.35 (br s, 1 H), 3.38-3.80 (m, 1 H), 2.73-3.22 (m, 2 H), 2.37 (s, 3 H), 1.62 (br s, 6 H)	441.3 [M+H]+	99.8%
726	(CD3OD) δ 8.33 (d, 1 H), 7.66 (s, 1 H), 6.95 (dd, 1 H), 6.46-6.89 (m, 3 H). 4.89 (br d. 1 H), 4.35 (br s, 1 H), 3.38-3.80 (m. 1 H), 2.70-3.20 (m, 2 H), 2.36 (s, 3 H), 1.56 (br s, 3 H)	411.2 [M+H]+	98.4%
727	(CD3OD) δ 8.33 (d, 1 H), 7.66 (s, 1 H), 6.95 (dd, 1 H), 6.42-6.90 (m. 3 H), 4.90 (br d, 1 H). 4.36 (br s, 1 H). 3.36-3.79 (m, 1 H). 2.70-3.20 (m, 2 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)	411.2 [M+H]	99.9%
728	(CD3OD) δ 8.25-8.46 (m, 2 H), 8.10 (s, 1 H), 7.56-7.73 (m, 1.3 H), 6.92-7.00 (m, 1.7 H), 6.68-6.89 (m, 2 H), 5.09 (br dd, 1 H), 4.00 (s, 3 H), 3.70-3.83 (m, 0.7 H), 3.40 (td, 0.3 H), 2.93-3.22 (m. 1 H), 2.79-2.89 (m. 1 H)	434.1 [M+H]+	99.8%
729	(CD3OD) δ 8.26-8.42 (m, 2 H), 8.10 (s, 1 H), 7.56-7.72 (m. 1.3 H), 6.92-7.00 (m, 1.7 H), 6.68-6.89 (m, 2 H), 5.09 (br dd, 1 H), 4.00 (s, 3 H), 3.70-3.84 (m, 0.7 H), 3.40 (td, 0.3 H), 2.93-3.22 (m, 1 H), 2.77-2.90 (m, 1 H)	434.1 [M+H]+	97.8%
730	(CD3OD) δ 8.24-8.40 (m, 1 H), 7.81 (d, 1 H), 7.70 (s, 1 H), 7.51 (s, 0.3 H), 6.90-7.03 (m, 2.7 H), 6.71-6.88 (m, 2 H), 5.04 (br dd, 1 H). 4.03 (s, 3 H), 3.78 (ddd. 0.6 H). 3.37-3.45 (m, 0.4 H), 2.79-3.24 (m, 2 H)	434.2 [M+H]+	100%
731	(CD3OD) δ 8.25-8.39 (m, 1 H), 7.81 (d, 1 H), 7.69 (s, 1 H), 7.51 (br s, 0.3 H), 6.91-7.02 (m, 2.7 H), 6.72-6.88 (m, 2 H), 4.96-5.10 (m. 1 H), 4.03 (s, 3 H), 3.73-3.83 (m, 0.6 H), 3.38-3.45 (m, 0.4 H), 2.80-3.23 (m. 2 H)	434.3 [M+H]+	99.8%
732	(CD3OD) δ 8.78 (d, 1 H). 8.25-8.42 (m, 2 H). 8.02-8.16 (m, 1 H), 7.43-7.77 (m, 2.3 H), 6.90-7.06 (m, 1.7 H), 6.73-6.90 (m, 2 H). 4.93-5.08 (m, 1 H). 3.74-3.87 (m, 0.7 H), 3.43 (td, 0.3 H), 2.82-3.26 (m, 2 H)	431.3 [M+H]+	98.9%
733	(CD3OD) δ 8.78 (d, 1 H), 8.22-8.42 (m, 2 H), 8.08 (td, 1 H), 7.43-7.76 (m, 2.3 H), 6.91-7.03 (m, 1.7 H), 6.74-6.88 (m, 2 H), 4.93-5.06 (m, 1 H), 3.74-3.86 (m, 0.7 H), 3.38-3.50 (m, 0.3 H), 2.81-3.25 (m. 2 H)	431.2 [M+H]+	99.8%
734	(CD3OD) δ 8.78 (dd, 1 H), 8.36-8.49 (m, 1 H). 8.31 (dd, 1 H). 8.08 (td, 1 H), 7.60-7.75 (m, 2 H), 7.49 (br s, 0.3 H), 7.23-7.38 (m, 1 H), 6.97 (s, 0.7 H), 6.69-6.90 (m, 2 H), 4.95-5.08 (m, 1 H), 3.79 (ddd. 0.7 H). 3.37-3.51 (m, 0.3 H), 2.78-3.24 (m. 2 H)	447.3 [M+H]+	99.6%
735	(CD3OD) δ 8.77 (d. 1 H), 8.35-8.50 (m. 1 H), 8.31 (d, 1 H), 8.08 (td, 1 H), 7.62-7.76 (m, 2 H), 7.49 (br s, 0.3 H), 7.23-7.37 (m, 1 H), 6.97 (br s, 0.7 H), 6.71-6.88 (m. 2 H), 4.95-5.06 (m. 1 H), 3.72-3.86 (m, 0.7 H), 3.38-3.49 (m, 0.3 H), 2.82-3.26 (m, 2 H)	447.3 [M+H]+	100%
736	(CD3OD) δ 8.30 (d, 1 H), 7.69 (br s, 1 H), 7.11-7.30 (m, 1 H), 6.99 (br d, 1 H), 6.86 (br s, 1 H), 6.79 (t, 1 H), 6.52-6.70 (m, 1 H), 4.69-4.83 (m, 0.4 H), 4.25-4.40 (m, 0.6 H), 3.74 (br t, 0.6 H), 3.43 (br s, 0.4 H). 2.91-3.21 (m, 1 H). 2.83 (br d, 1 H), 2.45 (s, 3 H), 1.49-1.76 (m, 6 H)	457.4 [M+H]+	100%
737	(CD3OD) δ 8.30 (d, 1 H), 7.68 (br s, 1 H), 7.10-7.30 (m, 1 H), 6.99 (br d, 1 H), 6.86 (br s, 1 H), 6.78 (t, 1 H), 6.53-6.70 (m, 1 H), 4.80 (br s, 0.2 H), 4.24-4.40 (m, 0.6 H), 3.65-3.83 (m, 0.6 H). 3.44 (br s, 0.4 H), 2.92-3.23 (m, 1 H), 2.82 (br d, 1 H), 2.44 (s, 3 H), 1.50-1.74 (m, 6 H)	457.4 [M+H]+	99.5%
738	(CD3OD) δ 8.30 (br d, 1 H), 7.68 (s, 1 H), 7.09-7.31 (m, 1 H), 6.99 (br d, 1 H), 6.86 (br s. 1 H), 6.78 (t, 1 H), 6.61 (br s, 1 H), 4.97 (q, 1 H), 4.77 (br s, 0.3 H), 4.35 (br d, 0.6 H), 3.74 (br t, 0.6 H). 3.44 (br s, 0.3 H), 2.90-3.19 (m, 1 H), 2.81 (br d, 1 H), 2.44 (s, 3 H), 1.61 (br d, 3 H)	443.3 [M+H]+	99.6%
739	(CD3OD) δ 8.30 (br d, 1 H), 7.68 (s, 1 H), 7.09-7.31 (m, 1 H), 6.99 (br d, 1 H), 6.86 (br s, 1 H), 6.78 (t, 1 H), 6.51-6.70 (m, 1 H), 4.97 (q, 1 H), 4.78 (br s, 0.1 H), 4.35 (br d, 0.6 H), 3.64-3.81 (m, 0.6 H), 3.46 (br d, 0.4 H), 2.91-3.19 (m, 1 H), 2.81 (br d, 1 H), 2.44 (s, 3 H), 1.60 (br d, 3 H)	443.3 [M+H]+	99.3%
740	(CD3OD) δ 8.77 (d, 1 H), 8.20-8.36 (m, 2 H), 8.08 (td, 1 H), 7.60-7.75 (m, 2 H), 7.50 (s, 0.3 H), 6.92-7.04 (m, 1.7 H), 6.71-6.84 (m, 1 H), 6.57-6.68 (m, 1 H), 5.00 (br dd, 1 H), 3.74-3.86 (m, 0.6 H), 3.43 (td, 0.3 H), 2.96-3.26 (m, 1 H), 2.79-2.90 (m, 1 H), 2.39-2.49 (m, 3 H)	427.3 [M+H]+	99.6%
741	(CD3OD) δ 8.77 (d, 1 H), 8.20-8.36 (m, 2 H), 8.08 (td, 1 H), 7.61-7.74 (m, 2 H), 7.50 (s, 0.3 H), 6.93-7.04 (m, 1.7 H), 6.72-6.83 (m, 1 H), 6.57-6.68 (m, 1 H), 5.00 (br dd, 1 H), 3.73-3.87 (m, 0.6 H), 3.43 (td, 0.4 H), 2.95-3.27 (m, 1 H), 2.85 (br d, 1 H), 2.39-2.48 (m, 3 H)	427.3 [M+H]+	100%
742	(CD3OD) δ 8.20-8.34 (m, 1 H), 7.81 (d, 1 H), 7.69 (s, 1 H), 7.52 (s, 0.5 H), 6.91-7.03 (m, 2.5 H), 6.71-6.85 (m, 1 H), 6.52-6.66 (m, 1 H), 5.01 (br dd, 1 H), 4.02 (s, 3 H), 3.72-3.83 (m, 0.7 H), 3.41 (td, 0.4 H), 3.12-3.24 (m, 0.8 H), 2.93-3.06 (m, 0.4 H), 2.75-2.88 (m, 1 H), 2.35-2.48 (m, 3 H)	430.4 [M+H]+	100%
743	(CD3OD) δ 8.21-8.35 (m, 1 H), 7.81 (s, 1 H), 7.69 (s, 1 H), 7.52 (s, 0.5 H), 6.93-7.02 (m, 2.5 H), 6.71-6.82 (m, 1 H), 6.53-6.66 (m, 1 H), 5.01 (br dd, 0.4 H), 4.03 (s, 3 H), 3.72-3.84 (m, 0.7 H), 3.35-3.46 (m, 1 H), 3.12-3.24 (m, 0.6 H), 2.94-3.06 (m, 0.4 H), 2.83 (br d, 1 H), 2.40-2.49 (m, 3 H)	430.4 [M+H]+	100%
744	(CD3OD) δ 8.25-8.43 (m, 1 H), 7.55-7.78 (m, 1 H), 6.93-7.02 (m, 1 H), 6.79-6.92 (m, 1.7 H), 6.55-6.75 (m, 1 H), 6.05 (br s, 0.3 H), 4.81-4.87 (m, 0.3 H), 3.67-3.86 (m, 1.4 H), 3.45 (td, 0.3 H), 2.71-3.08 (m, 2 H), 1.54-1.71 (m, 6 H)	479.2 [M+H]	98.4%
745	(CD3OD) δ 8.29-8.40 (m, 1 H), 7.63-7.73 (m, 1 H), 6.92-7.02 (m, 1 H), 6.78-6.91 (m, 1.7 H), 6.58-6.75 (m, 1 H), 6.04 (br s, 0.3 H), 4.81-4.87 (m, 0.2 H), 3.68-3.86 (m, 1.4 H), 3.45 (td, 0.4 H), 2.72-3.07 (m, 2 H), 1.53-1.71 (m, 6 H)	479.2 [M+H]	98.9%
746	(CD3OD) δ 8.34 (d, 1 H), 7.67 (s, 1 H), 6.96 (dd, 1 H), 6.83 (td, 1.7 H), 6.63-6.78 (m, 1 H), 6.38 (br s, 0.3 H), 4.72-4.82 (m, 0.4 H), 4.16 (br d, 0.6 H), 3.37-3.84 (m, 1 H), 2.75-3.22 (m, 2 H), 1.52-1.66 (m. 6 H)	489.2 [M+H]	98.8%
747	(CD3OD) δ 8.34 (d, 1 H), 7.67 (s. 1 H), 6.96 (dd, 1 H), 6.83 (td, 1.7 H), 6.64-6.78 (m, 1 H), 6.38 (br s, 0.3 H), 4.81 (br s, 0.4 H), 4.16 (br d, 0.6 H), 3.36-3.86 (m, 1 H), 2.75-3.20 (m, 2 H), 1.52-1.65 (m, 6 H)	489.1 [M+H]	99.7%
748	(CD3OD) δ 8.39 (s, 1 H), 8.21-8.33 (m, 1 H), 8.10 (s, 1 H), 7.52-7.74 (m, 1 H), 6.92-7.03 (m, 2 H), 6.71-6.82 (m. 1 H), 6.53-6.65 (m, 1 H), 5.06 (dd, 1 H), 4.00 (s, 3 H), 3.70-3.85 (m, 0.7 H), 3.40 (td. 0.3 H). 3.10-3.23 (m, 0.7 H), 2.93-3.06 (m. 0.3 H). 2.78-2.88 (m, 1 H), 2.37-2.49 (m, 3 H)	430.3 [M+H]+	99.4%
749	(CD3OD) δ 8.38 (s, 1 H), 8.20-8.34 (m, 1 H), 8.09 (s, 1 H), 7.54-7.73 (m, 1 H). 6.91-7.03 (m, 2 H), 6.70-6.82 (m, 1 H), 6.52-6.65 (m, 1 H), 5.06 (dd, 1 H), 4.00 (s, 3 H), 3.71-3.82 (m, 0.7 H), 3.40 (td, 0.3 H), 3.09-3.23 (m. 0.7 H), 2.91-3.04 (m, 0.3 H), 2.76-2.89 (m, 1 H), 2.36-2.49 (m, 3 H)	430.3 [M+H]+	98.6%
750	(CD3OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 6.98 (d, 1 H), 6.49-6.89 (m, 3 H), 4.90-4.94 (m, 1 H), 4.73 (br s, 0.3 H), 4.34 (br d, 0.7 H), 3.38-3.79 (m, 1 H), 3.09 (br s, 1 H), 2.79 (br d, 1 H), 2.44 (s, 3 H), 2.36 (s, 3 H), 1.55 (br s, 3 H)	407.3 [M+H]+	99.1%
751	(CD3OD) δ 8.30 (d, 1 H), 7.66 (s, 1 H), 6.98 (d, 1 H), 6.72-6.89 (m, 1.7 H), 6.48-6.70 (m, 1.3 H), 4.89-4.93 (m, 1 H), 4.67-4.76 (m, 0.4 H), 4.32 (br s, 0.6 H), 3.39-3.81 (m, 1 H), 3.10 (br s, 1 H), 2.79 (br d, 1 H), 2.44 (s, 3 H), 2.36 (s, 3 H), 1.56 (br s, 3 H)	407.4 [M+H]+	99.4%
752	(CD3OD) δ 8.29 (d, 1 H), 7.66 (s. 1 H), 6.98 (d, 1 H), 6.84 (br s, 0.6 H), 6.77 (t, 1 H), 6.48-6.70 (m, 1.4 H), 4.91-4.94 (m, 1 H), 4.72 (br s, 0.5 H), 4.34 (br s, 0.5 H), 3.54-3.81 (m, 1 H), 3.11 (br s, 1 H), 2.79 (br d, 1 H), 2.44 (s, 3 H), 2.36 (s, 3 H), 1.43-1.63 (m, 3 H)	407.3 [M+H]+	100%
753	(CD3OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 6.98 (d, 1 H), 6.84 (br s, 0.6 H), 6.77 (t, 1 H), 6.46-6.72 (m, 1.4 H), 4.90-4.94 (m, 1 H), 4.73 (br s, 0.4 H), 4.33 (br s, 0.6 H), 3.39-3.80 (m, 1 H), 3.10 (br s, 1 H), 2.79 (br d, 1 H), 2.44 (s, 3 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)	407.4 [M+H]+	99.8%
754	(CD3OD) δ 8.29 (d, 1 H), 7.75 (br s, 1 H), 6.98 (d, 1 H), 6.55-6.90 (m, 3 H), 4.60-4.78 (m, 0.5 H), 4.35 (br s, 0.5 H), 3.38-3.81 (m, 1 H), 3.12 (br d, 1 H), 2.80 (br d, 1 H), 2.32-2.50 (m, 6 H), 1.61 (br s, 6 H)	421.4 [M+H]+	100%
755	(CD3OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 6.97 (d, 1 H), 6.47-6.90 (m, 3 H), 4.63-4.77 (m, 0.5 H), 4.33 (br s, 0.5 H), 3.38-3.82 (m, 1 H), 3.11 (br s, 1 H), 2.79 (br d, 1 H), 2.33-2.48 (m, 6 H), 1.61 (br s, 6 H)	421.4 [M+H]+	99.8%
756	(CD3OD) δ 8.34 (d, 1 H), 7.68 (s, 1 H), 6.96 (dd, 7.7 Hz, 1 H), 6.65-6.89 (m, 2.7 H), 6.43 (br s, 0.3 H), 4.15-4.82 (m, 1 H), 3.38-3.84 (m, 1 H), 2.79-3.18 (m, 2 H), 1.53-1.68 (m, 6 H)	445.3 [M+H]+	100%
757	(CD3OD) δ 8.34 (d, 1 H), 7.68 (s, 1 H), 6.96 (dd, 1 H), 6.63-6.89 (m, 2.7 H), 6.43 (br s, 0.3 H), 4.13-4.81 (m, 1 H), 3.37-3.82 (m, 1 H), 2.78-3.18 (m, 2 H), 1.52-1.67 (m, 6 H)	445.3 [M+H]+	100%
758	(CD3OD) δ 8.43 (s, 1 H), 8.34 (d, 1 H), 7.68 (s, 1 H), 6.91-7.31 (m, 2 H), 6.40-6.89 (m, 3 H), 4.28-4.83 (m, 1 H), 3.37-3.82 (m, 1 H), 2.74-3.16 (m, 2 H)	403.3 [M+H]	99.7%
759	(CD3OD) δ 8.43 (s, 1 H), 8.34 (d, 1 H), 7.68 (s, 1 H), 6.92-7.31 (m, 2 H), 6.45-6.92 (m, 3 H), 4.27-4.83 (m, 1 H), 3.37-3.78 (m, 1 H), 2.77-3.13 (m, 2 H)	403.2 [M+H]	99.3%
760	(CD3OD) δ 8.25-8.49 (m, 2 H), 7.58-8.13 (m, 2 H), 6.92-7.01 (m, 1 H), 6.53-6.91 (m, 3 H), 4.48 (br s, 1 H), 3.41-3.83 (m, 1 H), 2.74-3.15 (m, 2 H)	353.2 [M+H]+	100%
761	(CD3OD) δ 8.26-8.50 (m, 2 H), 7.64-8.14 (m, 2 H), 6.92-7.01 (m, 1 H), 6.53-6.92 (m, 3 H), 4.39-4.79 (m, 1 H), 3.37-3.84 (m, 1 H), 2.73-3.17 (m, 2 H)	353.3 [M+H]+	99.3%
762	(CD3OD) δ 8.35 (br d, 1 H), 7.70 (d, 1 H), 6.88-7.02 (m, 2 H), 6.50-6.88 (m, 2 H), 4.48 (dd, 1 H), 4.00-4.05 (m, 3 H), 3.62-3.71 (m, 0.6 H), 2.92-3.22 (m, 1.4 H), 2.71-2.87 (m, 1 H)	401.2 [M+H]+	100%
763	(CD3OD) δ 8.35 (br d, 1 H), 7.70 (br d, 1 H), 6.88-7.01 (m, 2 H), 6.50-6.87 (m, 2 H), 4.48 (dd, 1 H), 3.98-4.07 (m, 3 H), 3.60-3.72 (m, 0.6 H), 2.92-3.24 (m, 1.4 H), 2.69-2.86 (m, 1 H)	401.2 [M+H]+	100%
764	(CD3OD) δ 8.35 (t, 1 H), 7.70 (br d, 1 H), 6.68-7.03 (m, 4.6 H), 6.53 (s. 0.4 H), 4.47 (dd, 1 H). 4.06-4.16 (m, 3 H). 3.62-3.74 (m, 0.6 H), 2.93-3.24 (m, 1.4 H), 2.68-2.87 (m, 1 H)	417.2 [M+H]+	100%
765	(CD3OD) δ 8.29-8.41 (m, 1 H), 7.70 (br s, 1 H), 6.70-7.02 (m, 4.7 H), 6.53 (s, 0.3 H), 4.47 (dd, 1 H), 4.06-4.15 (m, 3 H), 3.63-3.75 (m, 0.6 H), 2.93-3.23 (m, 1.4 H), 2.70-2.89 (m, 1 H)	417.2 [M+H]+	100%
766	(CD3OD) δ 8.39 (s, 2 H), 7.59-8.16 (m. 2 H), 7.29 (d, 1 H), 6.53-6.91 (m. 3 H), 4.45-4.85 (m, 1 H), 3.74 (br s, 1 H), 2.71-3.17 (m. 2 H)	369.2 [M+H]+	100%
767	(CD3OD) δ 8.40 (s, 2 H), 7.68-8.13 (m, 2 H), 7.30 (d, 1 H), 6.57-6.93 (m, 3 H), 4.42-4.84 (m, 1 H), 3.74 (br s, 1 H), 2.77-3.17 (m, 2 H)	369.2 [M+H]+	99.1%
768	(CD3OD) δ 8.24-8.43 (m, 2 H), 8.08 (br s, 0.4 H), 7.77 (br s, 0.6 H), 7.68 (s, 1 H), 6.99 (br d, 1 H), 6.88 (br s, 1 H), 6.78 (br t, 1 H). 6.40-6.69 (m, 1 H). 4.47 (br s, 1 H). 3.76 (br s, 1 H), 2.91-3.17 (m, 1 H), 2.80 (br s, 1 H), 2.44 (s, 3 H)	348.9 [M+H]+	100%
769	(CD3OD) δ 8.23-8.45 (m, 2 H), 8.08 (br s, 0.4 H), 7.61-7.86 (m, 1.6 H). 6.99 (br d, 1 H), 6.88 (br s, 1 H), 6.78 (br t, 1 H), 6.41-6.67 (m, 1 H), 4.78 (br s, 0.5 H), 4.47 (br s, 0.5 H), 3.76 (br s, 0.6 H), 3.35 (br s, 0.4 H). 2.91-3.16 (m, 1 H), 2.77 (br d. 1 H), 2.44 (s, 3 H)	349.0 [M+H]+	99.8%
770	(CD3OD) δ 8.19-8.35 (m, 2 H), 7.67 (s, 1 H), 6.98 (d, 1 H), 6.71-6.90 (m, 2 H), 6.61 (br s, 1 H), 4.31 (br s, 1 H). 3.71 (br s, 1 H), 2.92-3.15 (m, 1 H), 2.78 (br d, 1 H), 2.33-2.51 (m, 6 H)	363.1 [M+H]+	100%
771	(CD3OD) δ 8.17-8.38 (m, 2 H), 7.67 (s, 1 H), 6.98 (d, 1 H), 6.73-6.90 (m, 2 H), 6.60 (br s, 1 H), 4.29 (br s, 1 H), 3.72 (br s, 1 H), 2.90-3.18 (m, 1 H), 2.78 (br d, 1 H), 2.32-2.49 (m, 6 H)	363.0 [M+H]+	99.5%
772	(CD3OD) δ 8.46-8.53 (m, 1 H), 8.31-8.39 (m, 1 H). 7.66-7.75 (m, 1 H), 6.81-7.03 (m, 3 H), 6.74 (s, 0.6 H), 6.54 (s, 0.2 H), 6.03 (s, 0.2 H), 3.41-3.88 (m. 2 H), 2.76-3.00 (m, 2 H)	421.0 [M+H]+	99.6%
773	(CD3OD) δ 8.44-8.49 (m, 1 H), 8.29-8.36 (m, 1 H), 7.64-7.72 (m, 1 H), 6.79-7.01 (m, 3 H), 6.72 (s, 0.6 H), 6.52 (s, 0.2 H), 6.01 (br s, 0.2 H), 3.37-3.88 (m. 2 H), 2.89-2.99 (m, 1 H), 2.74-2.86 (m, 1 H)	421.0 [M+H]+	99.4%
774	(CD3OD) δ 8.33 (d, 1 H), 8.25 (s, 1 H), 7.67 (s, 1 H), 6.95 (dd, 1 H), 6.49-6.88 (m, 3 H), 4.21-4.83 (m, 1 H), 3.38-3.85 (m, 1 H), 3.06 (br s, 1 H), 2.78 (br d, 1 H), 2.38 (s, 3 H)	367.1 [M+H]+	99.2%
775	(CD3OD) δ 8.33 (d, 1 H), 8.25 (s, 1 H), 7.67 (s, 1 H), 6.96 (dd, 1 H), 6.49-6.88 (m, 3 H), 4.26-4.83 (m, 1 H), 3.35-3.82 (m, 1 H), 2.96-3.14 (m, 1H), 2.78 (br d, 1 H), 2.38 (s, 3 H)	367.0 [M+H]+	99.7%
776	(CD3OD) & 8.28-8.48 (m, 1 H), 7.50-7.84 (m, 3 H), 6.74-7.08 (m. 4 H), 6.15-6.56 (m, 1 H), 4.82 (br s, 0.5 H), 4.05-4.14 (m, 0.5 H), 3.64-3.78 (m, 0.5 H), 3.12-3.29 (m, 0.5 H), 2.70-3.06 (m, 2 H)	[M+H]+	99.5%
777	(CD3OD) δ 8.29-8.47 (m, 1 H), 7.50-7.84 (m, 3 H), 6.25-7.11 (m, 5 H), 4.84 (br d, 0.5 H), 4.04-4.12 (m, 0.5 H), 3.61-3.78 (m, 0.5 H), 3.19-3.28 (m. 0.5 H). 2.92-3.06 (m, 1 H). 2.75 (br d. 1 H)	402.0 [M+H]+	99.3%
778	(CD3OD) δ 8.78 (br d, 1 H), 8.26-8.36 (m, 1 H), 7.99-8.14 (m, 2 H), 7.59-7.74 (m, 2 H), 7.50 (s, 0.3 H), 6.97 (s, 0.7 H), 6.72-6.84 (m, 1 H), 6.63-6.71 (m, 1 H), 6.54-6.62 (m, 1 H), 5.00 (dd, 1 H), 3.86-4.06 (m, 3 H), 3.72-3.85 (m, 0.7 H), 3.43 (td, 0.3 H), 2.93-3.29 (m, 1 H), 2.86 (br dd, 1 H)	443.0 [M+H]+	100%
779	(CD3OD) δ 8.78 (br d, 1 H), 8.28-8.34 (m, 1 H), 7.99-8.16 (m, 2 H), 7.61-7.78 (m, 2 H), 7.50 (s, 0.3 H), 6.97 (s, 0.7 H), 6.74-6.83 (m, 1 H), 6.63-6.72 (m, 1 H), 6.52-6.62 (m, 1 H), 5.00 (br dd, 1 H). 3.92-4.00 (m, 3 H). 3.72-3.84 (m, 0.7 H), 3.43 (td, 0.3 H), 2.96-3.27 (m, 1 H), 2.86 (br dd, 1 H)	443.0 [M+H]+	100%
780	(CD3OD) δ 8.40-8.53 (m, 1 H), 7.70 (d, 1 H), 7.24-7.33 (m, 1 H), 6.67-7.00 (m, 3.7 H), 6.51 (s, 0.3 H), 4.92 (br d, 0.3 H), 4.47 (dd, 0.7 H), 4.05-4.15 (m, 3 H), 3.68 (ddd, 0.5 H), 2.93-3.27 (m, 1.5 H), 2.72-2.88 (m, 1 H)	[M+H]+	100%
781	(CD3OD) δ 8.36-8.52 (m, 1 H), 7.70 (d. 1 H), 7.24-7.36 (m. 1 H), 6.65-7.01 (m, 3.7 H), 6.51 (s, 0.3 H), 4.92 (br d, 0.4 H), 4.47 (dd, 0.6 H). 4.05-4.17 (m, 3 H), 3.68 (ddd, 0.6 H), 2.92-3.27 (m. 1.4 H), 2.71-2.89 (m, 1 H)	432.9 [M+H]+	99.5%
782	(CD3OD) δ 8.40-8.58 (m, 1 H), 7.49-7.85 (m, 3 H), 7.30 (d, 1 H), 6.71-7.11 (m, 3.2 H), 6.25-6.54 (m, 0.8 H), 4.83 (br s, 0.5 H), 4.02-4.14 (m, 0.5 H), 3.71 (br t, 0.5 H), 3.17-3.29 (m, 0.5 H), 2.93-3.06 (m, 1 H), 2.75 (br d, 1 H)	417.9 [M+H]+	99.6%
783	(CD3OD) δ 8.36-8.59 (m, 1 H), 7.47-7.88 (m, 3 H). 7.30 (d, 1 H), 6.67-7.13 (m, 3.2 H), 6.18-6.57 (m, 0.8 H), 4.82 (br s, 0.5 H), 4.09 (br dd, 0.5 H), 3.62-3.79 (m, 0.5 H), 3.15-3.28 (m, 0.5 H), 2.90-3.07 (m, 1 H), 2.76 (br d, 1 H)	418.0 |M+H]+	99.6%
784	(CD3OD) δ 8.27-8.50 (m, 2 H), 7.51-7.76 (m, 2 H), 7.03-7.25 (m, 2 H), 6.89-7.02 (m, 1 H), 6.81 (br t, 1 H), 4.26 (br s, 1 H), 4.06 (br s, 1 H). 3.05 (br d. 1 H), 2.86 (br d, 1 H). 2.34-2.63 (m, 3 H)	399.0 [M+H]+	100%
785	(CD3OD) δ 8.42 (br s, 1 H), 8.31-8.38 (m, 1 H), 7.65 (s, 1 H), 7.53-7.62 (m. 1 H), 7.03-7.22 (m. 2 H), 6.95 (br d, 1 H). 6.82 (br s, 1 H), 4.26 (br s, 1 H), 4.06 (br s, 1 H), 2.99-3.12 (m, 1 H), 2.86 (dd, 1 H), 2.47 (br s, 3 H)	399.0 [M+H]+	99.8%
786	(CD3OD) δ 8.35 (d. 1 H), 7.74 (s, 1 H), 7.59 (br d, 1 H), 7.15-7.20 (m, 1 H), 6.88-7.14 (m, 2 H), 6.82 (td, 1 H), 4.29 (br s, 1 H), 4.07 (br s, 1 H), 3.13 (br d, 1 H), 2.89 (dd, 1 H), 2.47 (br s, 3 H), 1.67 (s, 6 H)	457.0 [M+H]+	97.5%
787	(CD3OD) δ 8.35 (d, 1 H), 7.93 (br s, 1 H), 7.60 (br d, 1 H), 7.18 (t. 1 H), 6.89-7.10 (m. 2 H), 6.84 (td, 1 H), 4.32 (br s, 1 H), 4.05 (br s, 1 H), 3.15 (br s, 1 H), 2.80-2.97 (m, 1 H), 2.48 (br s, 3 H), 1.67 (s, 6 H)	[M+H]+	99.0%
788	(CD3OD) δ 8.44 (d, 1 H), 8.22-8.38 (m, 2 H), 7.70 (s, 1 H), 7.51-7.63 (m, 1.3 H), 6.91-7.01 (m, 1.7 H), 6.74-6.88 (m, 2 H), 4.94-5.08 (m, 1 H), 3.99 (s, 3 H), 3.72-3.85 (m, 0.7 H), 3.42 (td, 0.3 H), 2.96-3.25 (m, 1 H), 2.78-2.91 (m, 1 H)	461.1 [M+H]+	96.7%
789	(CD3OD) δ 8.44 (d, 1 H), 8.21-8.39 (m, 2 H), 7.70 (s, 1 H), 7.51-7.63 (m, 1.3 H), 6.92-7.01 (m, 1.7 H), 6.72-6.88 (m, 2 H), 4.93-5.08 (m, 1 H), 3.99 (s, 3 H), 3.73-3.85 (m, 0.7 H), 3.42 (td, 0.3 H), 2.97-3.24 (m, 1 H), 2.85 (br d, 1 H)	461.2 [M+H]+	90.1%
790	(CD3OD) δ 8.64 (d, 1 H), 8.27-8.39 (m, 1 H), 7.94 (t, 1 H), 7.67-7.80 (m, 2 H), 7.46 (s, 0.4 H), 6.94-7.00 (m, 1.6 H), 6.71-6.89 (m, 2 H), 4.98 (br dd, 1 H), 3.74-3.85 (m, 0.7 H), 3.38-3.50 (m, 0.3 H), 2.97-3.26 (m, 1 H), 2.85 (br d, 1 H)	449.1 [M+H]+	98.8%
791	(CD3OD) δ 8.64 (d, 1 H), 8.26-8.38 (m, 1 H), 7.93 (td, 1 H), 7.68-7.79 (m, 2 H), 7.46 (s, 0.4 H), 6.93-6.99 (m, 1.6 H), 6.76-6.89 (m, 2 H), 4.98 (dd, 1 H), 3.76-3.85 (m, 0.7 H), 3.43 (td, 0.3 H), 2.98-3.26 (m, 1 H), 2.81-2.91 (m, 1 H)	449.1 [M+H]+	98.4%
792	(CD3OD) δ 8.43 (s, 1 H), 7.66 (s, 1 H), 7.45 (br s, 1 H), 6.96-7.30 (m, 2 H), 6.34-6.96 (m, 3 H), 4.18-4.43 (m, 1 H), 3.36-3.98 (m, 1 H), 2.89-3.16 (m, 1 H), 2.80 (dd, 1 H), 2.65 (br s, 3 H)	399.2 [M+H]+	100%
793	(CD3OD) δ 8.43 (s, 1 H), 7.67 (s, 1 H), 7.46 (br d, 1 H), 6.97-7.29 (m, 2 H), 6.38-6.94 (m, 3 H), 4.29 (br s, 1 H), 3.35-3.97 (m, 1 H), 3.01 (br s, 1 H), 2.80 (dd, 1 H), 2.65 (br s, 3 H)	399. 1 [M+H]+	100%
794	(CD3OD) δ 7.66 (s, 1 H), 7.46 (br s, 1 H), 6.93-7.28 (m, 2 H), 6.41-6.90 (m, 3 H), 4.74-4.87 (m, 0.7 H), 4.33 (br s, 0.3 H), 3.36-3.93 (m, 1 H), 2.76-3.18 (m, 2 H), 2.55-2.72 (m, 3 H), 1.36-1.81 (m, 6 H)	457.2 [M+H]+	100%
795	(CD3OD) δ 7.67 (s, 1 H), 7.45 (br s, 1 H), 6.94-7.27 (m, 2 H), 6.44-6.90 (m, 3 H), 4.75-4.86 (m, 0.5 H), 4.34 (br d, 0.5 H), 3.35-3.93 (m, 1 H), 2.74-3.17 (m, 2 H), 2.55-2.72 (m, 3 H), 1.54-1.72 (m, 6 H)	457.2 [M+H]+	99.2%
796	(CD3OD) δ 8.92 (s, 1 H), 8.27-8.39 (m, 2 H), 7.46-7.85 (m, 2.3 H), 6.91-7.05 (m, 1.7 H), 6.71-6.88 (m, 2 H), 4.92-5.13 (m, 1 H), 3.37-3.84 (m, 1 H), 2.90-3.22 (m, 1 H), 2.84 (br d, 1 H)	470.1 [M+H]+	100%
797	(CD3OD) δ 8.92 (s, 1 H), 8.25-8.40 (m, 2 H), 7.48-7.83 (m, 2.4 H), 6.92-7.01 (m, 1.6 H), 6.72-6.88 (m, 2 H), 4.92-5.14 (m, 1 H), 3.37-3.84 (m, 1 H), 2.95-3.24 (m, 1 H), 2.86 (br d, 1 H)	470.1 [M+H]+	99.4%
798	(CD3OD) δ 8.74-8.82 (m, 1 H), 8.26-8.37 (m, 1 H), 8.09 (tt, 1 H), 7.60-7.75 (m, 2 H), 7.38-7.54 (m, 1.5 H), 7.04-7.18 (m, 1 H), 7.00 (s, 0.5 H), 6.60-6.77 (m, 1.6 H), 6.45 (s, 0.4 H), 4.92-5.04 (m, 1 H), 3.89-4.00 (m, 0.5 H), 3.35-3.43 (m, 0.5 H), 2.96-3.25 (m, 1 H), 2.82-2.92 (m, 1 H), 2.44-2.71 (m, 3 H)	427.1 [M+H]+	100%
799	(CD3OD) δ 8.73-8.81 (m, 1 H), 8.27-8.35 (m, 1 H), 8.08 (tt, 1 H), 7.62-7.74 (m, 2 H), 7.37-7.52 (m, 1.5 H), 7.05-7.15 (m, 1 H), 7.00 (s, 0.5 H), 6.59-6.76 (m, 1.6 H), 6.44 (s, 0.4 H), 4.93-5.03 (m, 1 H), 3.93 (br t, 0.5 H), 3.35-3.43 (m. 0.5 H), 2.94-3.25 (m, 1 H), 2.82-2.91 (m, 1 H), 2.44-2.70 (m, 3 H)	427.2 [M+H]+	100%
800	(CD3OD) δ 8.39 (d, 1 H), 8.09 (s, 1 H), 7.68 (d, 1 H), 7.38-7.52 (m, 1.5 H), 7.10 (ddd, 1 H), 6.97 (s, 0.5 H), 6.41-6.76 (m, 2 H), 4.91-5.11 (m, 1 H), 4.00 (d, 3 H), 3.85-3.95 (m, 0.6 H), 3.34-3.40 (m, 0.4 H), 2.93-3.22 (m, 1 H), 2.84 (dt, 1 H), 2.48-2.69 (m, 3 H)	430.2 [M+H]+	100%
801	(CD3OD) δ 8.39 (s, 1 H), 8.10 (s, 1 H), 7.69 (d, 1 H), 7.39-7.52 (m, 1.5 H), 7.10 (ddd, 1 H), 6.98 (s, 0.5 H), 6.42-6.75 (m, 2 H), 4.92-5.11 (m, 1 H), 4.00 (d, 3 H), 3.86-3.95 (m, 0.5 H), 3.33-3.41 (m, 0.5 H), 2.94-3.21 (m, 1 H), 2.84 (dt, 1 H), 2.48-2.69 (m, 3 H)	430.2 [M+H]+	99.4%
802	(CD3OD) δ 7.81 (dd, 1 H), 7.70 (d, 1 H), 7.36-7.52 (m, 1.5 H), 7.05-7.16 (m, 1 H), 6.98 (s, 1.5 H), 6.64-6.77 (m, 1 H), 6.35-6.63 (m, 1 H), 5.01 (br dd, 1 H), 4.03 (d, 3 H), 3.84-3.95 (m, 0.6 H), 3.33-3.39 (m, 0.4 H), 2.93-3.22 (m, 1 H), 2.78-2.90 (m, 1 H), 2.47-2.68 (m, 3 H)	430.2 [M+H]+	100%
803	(CD3OD) δ 7.82 (dd, 1 H), 7.69 (d, 1 H), 7.38-7.53 (m, 1.5 H), 7.04-7.18 (m, 1 H), 6.99 (d, 1.5 H), 6.64-6.76 (m, 1 H), 6.41-6.64 (m, 1 H), 5.01 (br dd, 1 H), 4.03 (d, 3 H), 3.84-3.96 (m, 0.6 H), 3.34-3.39 (m, 0.4 H), 2.93-3.24 (m, 1 H), 2.80-2.91 (m, 1 H), 2.45-2.72 (m, 3 H)	430.2 [M+H]+	100%
804	(CD3OD) δ 8.24 (s, 1 H), 7.67 (br s, 1 H), 7.49 (br d, 1 H), 7.11-7.28 (m, 0.7 H), 7.08 (d, 1 H), 6.99 (s, 0.3 H), 6.47-6.88 (m, 2 H), 4.31 (br d, 1 H), 3.73 (br s, 1 H), 2.91-3.20 (m, 1 H), 2.81 (br d, 1 H), 2.32 (s, 3 H), 1.51-1.72 (m, 6 H)	457.1 [M+H]+	100%
805	(CD3OD) δ 8.24 (s, 1 H), 7.66 (br s, 1 H), 7.49 (br d, 1 H), 7.11-7.29 (m, 0.8 H), 7.08 (d, 1 H), 6.99 (s, 0.2 H), 6.46-6.89 (m, 2 H), 4.31 (br d, 1 H), 3.73 (br s, 1 H), 2.90-3.20 (m, 1 H), 2.81 (br d, 1 H), 2.25-2.35 (m, 3 H), 1.52-1.76 (m, 6 H)	457.2 [M+H]+	99.2%
806	(CD3OD) δ 8.24-8.37 (m, 1 H), 8.00 (s, 1 H), 7.81-7.89 (m, 1 H), 7.46-7.75 (m, 1.4 H), 6.93-7.09 (m, 1.6 H), 6.73-6.86 (m, 1 H), 6.53-6.70 (m, 1 H), 5.07 (dd, 1 H), 4.05-4.15 (m, 3 H), 3.37-3.85 (m, 1 H), 2.96-3.27 (m, 1 H), 2.79-2.93 (m, 1 H), 2.36-2.52 (m, 3 H)	430.2 [M+H]+	100%
807	(CD3OD) δ 8.25-8.37 (m, 1 H), 8.00 (s, 1 H), 7.83-7.94 (m, 1 H), 7.54-7.80 (m, 1.3 H), 6.96-7.09 (m, 1.7 H), 6.73-6.87 (m, 1 H), 6.51-6.69 (m, 1 H), 5.07 (dd, 1 H), 4.09-4.19 (m, 3 H), 3.38-3.89 (m, 1 H), 2.95-3.26 (m, 1 H), 2.78-2.91 (m, 1 H), 2.40-2.52 (m, 3 H)	430.2 [M+H]+	93.0%
808	(CD3OD) δ 8.31-8.45 (m, 1 H), 8.00 (s, 1 H), 7.83-7.91 (m, 1 H), 7.50-7.80 (m, 1.4 H), 6.94-7.06 (m, 1.6 H), 6.72-6.91 (m, 2 H), 5.10 (dd, 1 H), 4.10-4.20 (m, 3 H), 3.38-3.88 (m, 1 H), 2.96-3.29 (m, 1 H), 2.80-2.93 (m, 1 H)	434.2 [M+H]+	92.5%
809	(CD3OD) δ 8.29-8.40 (m, 1 H), 7.99 (s, 1 H), 7.84-7.89 (m, 1 H), 7.50-7.76 (m, 1.4 H), 6.94-7.04 (m, 1.6 H), 6.74-6.90 (m, 2 H), 4.94-5.13 (m, 1 H), 4.10-4.14 (m, 3 H), 3.38-3.87 (m, 1 H), 2.97-3.28 (m, 1 H), 2.80-2.91 (m, 1 H)	434.2 [M+H]+	100%
810	(CD3OD) δ 8.69 (d, 1 H), 7.69 (s, 1 H), 7.63 (br d, 1 H), 7.10-7.29 (m, 1 H), 6.96-7.01 (m, 1 H), 6.54-6.90 (m. 2 H), 4.37 (br d, 1 H), 3.74 (br s, 1 H), 2.71-3.21 (m, 2 H), 1.55-1.70 (m, 6 H)	511.2 [M+H]+	98.3%
811	(CD3OD) δ 8.69 (d, 1 H), 7.61-7.71 (m, 2 H), 7.11-7.27 (m, 1 H), 6.99 (t, 1 H), 6.57-6.91 (m, 2 H), 4.37 (br d, 1 H), 3.64-3.84 (m, 1 H), 2.75-3.21 (m, 2 H), 1.53-1.69 (m, 6 H)	511.2 [M+H]+	99.6%
812	(CD3OD) δ 8.77 (br d, 1 H), 8.15-8.39 (m, 2 H), 8.09 (br t, 1 H), 7.61-7.73 (m, 2 H), 7.40-7.57 (m, 1 H), 7.02-7.14 (m, 1 H), 6.96 (s, 1 H), 6.46-6.64 (m, 1 H), 4.98 (br dd, 1 H), 3.74-3.85 (m, 0.9 H), 3.40 (br d, 0.1 H), 2.93-3.26 (m, 1 H), 2.84 (br d, 1 H), 2.23-2.37 (m, 3 H)	427.2 [M+H]+	100%
813	(CD3OD) δ 8.77 (dd, 1 H), 8.15-8.34 (m, 2 H), 8.03-8.12 (m, 1 H), 7.62-7.72 (m, 2 H), 7.41-7.53 (m, 1 H), 7.01-7.12 (m, 1 H), 6.95 (s, 1 H), 6.49-6.60 (m, 1 H), 4.98 (br dd, 1 H), 3.74-3.88 (m, 0.8 H), 3.38-3.49 (m, 0.2 H), 3.13-3.26 (m, 0.7 H), 2.93-3.06 (m, 0.3 H), 2.78-2.89 (m, 1 H), 2.23-2.36 (m, 3 H)	427.2 [M+H]+	99.9%
814	(CD3OD) δ 8.15-8.29 (m, 1 H), 7.81 (d, 1 H), 7.68 (s, 1 H), 7.41-7.54 (m, 1 H), 7.03-7.12 (m, 1 H), 6.98-7.01 (m, 1 H), 6.94 (s, 1 H), 6.45-6.60 (m. 1 H), 5.00 (br dd, 1 H), 3.99-4.07 (m, 3 H), 3.71-3.82 (m, 0.7 H), 3.36-3.45 (m, 0.3 H), 2.93-3.23 (m, 1 H), 2.83 (br d, 1 H), 2.25-2.35 (m, 3 H)	430.2 [M+H]+	100%
815	(CD3OD) δ 8.17-8.29 (m. 1 H), 7.78-7.84 (m, 1 H), 7.69 (s, 1 H), 7.41-7.56 (m, 1 H), 7.03-7.13 (m, 1 H), 6.97-7.02 (m, 1 H), 6.94 (s, 1 H), 6.42-6.61 (m, 1 H), 5.00 (br dd, 1 H), 4.00-4.06 (m, 3 H), 3.70-3.83 (m, 0.6 H), 3.34-3.45 (m, 0.4 H), 2.92-3.24 (m, 1 H), 2.74-2.89 (m, 1 H), 2.26-2.35 (m, 3 H)	430.2 [M+H]+	99.9%
816	(CD3OD) δ 8.42 (d, 1 H), 8.18-8.32 (m, 2 H), 7.70 (s, 1 H), 7.49-7.62 (m, 1 H), 6.92-7.01 (m, 2 H), 6.69-6.80 (m, 1 H), 6.55-6.66 (m, 1 H), 5.01 (br dd, 1 H), 3.97 (s, 3 H), 3.68-3.87 (m, 0.7 H), 3.37-3.49 (m, 0.3 H), 2.93-3.25 (m, 1 H), 2.77-2.89 (m, 1 H), 2.35-2.48 (m, 3 H)	457.2 [M+H]+	100%
817	(CD3OD) δ 8.43 (d, 1 H), 8.14-8.34 (m, 2 H), 7.69-7.78 (m, 1 H), 7.51-7.63 (m, 1 H), 6.92-7.03 (m, 2 H), 6.70-6.83 (m, 1 H), 6.53-6.68 (m, 1 H), 5.02 (br dd, 1 H), 3.98 (s, 3 H), 3.71-3.85 (m, 0.7 H), 3.42 (td, 0.3 H), 3.12-3.26 (m, 0.7 H), 2.95-3.07 (m, 0.3 H), 2.76-2.91 (m, 1 H), 2.39-2.49 (m, 3 H)	457.2 [M+H]+	100%
818	(CD3OD) δ 8.58-8.66 (m, 1 H), 8.19-8.34 (m, 1 H), 7.83-7.98 (m, 1 H), 7.64-7.77 (m, 2 H), 7.46 (s, 0.3 H), 6.90-7.03 (m, 1.7 H), 6.70-6.82 (m, 1 H), 6.55-6.67 (m, 1 H), 4.92-5.01 (m, 1 H), 3.70-3.86 (m, 0.7 H), 3.44 (td, 0.3 H), 2.95-3.27 (m, 1 H), 2.76-2.91 (m, 1 H), 2.35-2.50 (m, 3 H)	445.2 [M+H]+	99.4%
819	(CD3OD) δ 8.58-8.68 (m, 1 H), 8.20-8.34 (m, 1 H), 7.92 (t, 1 H), 7.65-7.80 (m, 2 H), 7.46 (s, 0.3 H), 6.90-7.02 (m, 1.7 H), 6.70-6.84 (m, 1 H), 6.56-6.69 (m, 1 H), 4.92-5.01 (m, 1 H), 3.72-3.86 (m, 0.7 H), 3.44 (td, 0.3 H), 3.15-3.27 (m, 0.7 H), 2.95-3.07 (m, 0.3 H), 2.85 (br dd, 1 H), 2.34-2.49 (m, 3 H)	445.2 [M+H]+	99.6%
820	(CD3OD) δ 8.92 (s, 1 H), 8.21-8.40 (m, 2 H), 7.49-7.81 (m, 2 H), 6.92-7.03 (m, 2 H), 6.71-6.83 (m, 1 H), 6.51-6.67 (m, 1 H), 4.98-5.12 (m, 1 H), 3.70-3.87 (m, 0.7 H), 3.38-3.47 (m, 0.3 H), 2.94-3.23 (m, 1 H), 2.77-2.91 (m, 1 H), 2.37-2.48 (m, 3 H)	466.2 [M+H]+	98.8%
821	(CD3OD) δ 8.77-9.00 (m, 1 H), 8.20-8.40 (m, 2 H), 7.48-7.82 (m, 2 H), 6.98 (br t, 2 H), 6.70-6.82 (m, 1 H). 6.54-6.68 (m, 1 H), 5.06 (br dd, 1 H), 3.67-3.86 (m, 0.7 H), 3.41 (td, 0.3 H), 2.93-3.26 (m, 1 H). 2.85 (br d. 1 H), 2.35-2.51 (m, 3 H)	466.2 [M+H]+	99.5%
822	(CD3OD) δ 8.20-8.37 (m, 2 H), 7.48-7.85 (m, 2 H), 7.17-7.25 (m, 1 H), 6.92-7.03 (m, 2 H), 6.70-6.82 (m, 1 H), 6.53-6.66 (m, 1 H), 5.02 (dd, 1 H), 3.73-3.86 (m, 0.7 H), 3.42 (td, 0.3 H), 2.94-3.25 (m, 1 H), 2.77-2.89 (m, 1 H), 2.38-2.48 (m, 3 H)	466.2 [M+H]+	1 00%
823	(CD3OD) δ 8.21-8.35 (m, 2 H), 7.82 (s, 0.3 H), 7.69 (d, 1 H), 7.53 (s, 0.6 H), 7.18-7.23 (m, 1 H), 6.93-7.02 (m, 2 H), 6.71-6.81 (m, 1 H), 6.53-6.66 (m, 1 H), 5.02 (dd, 1 H), 3.72-3.85 (m, 0.7 H), 3.42 (td, 0.3 H), 2.95-3.25 (m, 1 H), 2.76-2.89 (m. 1 H), 2.39-2.48 (m, 3 H)	466.2 [M+H]+	100%
824	(CD3OD) δ 8.26-8.39 (m, 2 H), 7.50-7.84 (m, 2.4 H), 7.21 (d, 1 H), 6.93-7.01 (m, 1.6 H). 6.70-6.88 (m, 2 H), 4.92-5.08 (m, 1 H), 3.74-3.86 (m, 0.7 H), 3.42 (br dd, 0.3 H), 3.15-3.24 (m, 0.7 H), 2.96-3.04 (m, 0.3 H), 2.80-2.91 (m, 1 H)	470.2 [M+H]+	99.5%
825	(CD3OD) δ 8.23-8.43 (m, 2 H), 7.47-7.88 (m, 2.4 H), 7.21 (d, 1 H), 6.91-7.04 (m, 1.6 H), 6.72-6.89 (m, 2 H), 5.04 (br dd, 1 H), 3.73-3.85 (m. 0.5 H). 3.38-3.45 (m, 0.5 H), 3.12-3.24 (m. 0.8 H). 2.97-3.05 (m, 0.2 H), 2.78-2.91 (m, 1 H)	470.2 [M+H]+	100%
826	(CD3OD) δ 8.63-8.80 (m, 2 H), 8.31 (d, 1 H), 8.09 (td, 1 H), 7.59-7.72 (m, 3 H), 6.72-7.10 (m, 3 H). 4.92-5.07 (m, 1 H). 3.38-3.85 (m, 1 H), 2.83-3.25 (m, 2 H)	481.2 [M+H]+	1 00%
827	(CD3OD) δ 8.63-8.80 (m, 2 H), 8.31 (d, 1 H), 8.08 (td, 1 H), 7.58-7.72 (m, 3 H), 6.75-7.07 (m. 3 H), 4.93-5.07 (m. 1 H), 3.39-3.83 (m. 1 H), 2.84-3.26 (m. 2 H)	481.2 [M+H]+	98.1%
828	(CD3OD) δ 8.00-8.73 (m, 1 H), 8.39-8.43 (m, 1 H). 8.08-8.17 (m. 1H), 7.72 (s, 1 H), 7.59-7.66 (m, 1H), 6.93-7.05 (m, 2 H), 6.76-6.84 (m, 1H). 4.94-5.16 (m, 1H). 4.02 (s. 3 H), 3.41-3.81 (m, 1 H), 2.84-3.22 (m, 2 H)	484.2 [M+H]+	1 00%
829	(CD3OD) δ 8.66-8.73 (m, 1 H), 8.39-8.43 (m, 1 H), 8.09-8.15 (m, 1 H), 7.62-7.73 (m, 2 H), 6.94-7.05 (m, 2 H), 6.77-6.83 (m, 1 H), 4.95-5.17 (m, 1 H), 4.02 (s, 3 H), 3.41-3.82 (m, 1 H), 2.84-3.22 (m. 2 H)	484.2 [M+H]+	98.2%
830	(CD3OD) δ 8.83 (d. 2 H), 8.23-8.43 (m. 1 H), 8.03-8.19 (m. 2 H), 7.46-7.80 (m, 1.3 H), 6.90-7.06 (m. 1.7 H), 6.71-6.89 (m, 2 H), 5.07 (br dd, 0.7 H), 4.92-4.97 (m, 0.3 H), 3.80 (br t, 0.7 H), 3.43 (br t, 0.3 H), 2.96-3.25 (m. 1 H), 2.89 (br s, 1 H)	431.2 [M+H]+	1 00%
831	(CD3OD) δ 8.83 (d, 2 H), 8.26-8.42 (m, 1 H), 8.12 (d, 2 H), 7.46-7.83 (m, 1.3 H), 6.91-7.08 (m, 1.7 H), 6.64-6.89 (m, 2 H), 5.07 (br dd, 0.7 H), 4.92-4.97 (m, 0.3 H), 3.80 (br t, 0.7 H), 3.38-3.50 (m, 0.3 H). 2.96-3.26 (m, 1 H), 2.87 (br s, 1 H)	431.2 [M+H]+	99.7%
832	(CD3OD) δ 8.48 (s, 1 H), 8.25-8.39 (m, 1 H), 8.14 (s, 1 H), 7.52-7.76 (m, 1.4 H), 6.90-7.04 (m, 1.6 H), 6.78-6.89 (m, 1 H), 6.69-6.78 (m, 1 H), 5.10 (br dd, 0.5 H), 4.95 (br s, 0.5 H), 3.71-3.84 (m, 0.8 H), 3.38-3.43 (m, 0.2 H), 2.94-3.23 (m, 2 H), 2.84 (br d, 1 H), 2.48-2.65 (m, 4 H), 1.88-1.98 (m, 2 H)	474. 2 [M+H]+	100%
833	(CD3OD) δ 8.48 (s, 1 H), 8.24-8.39 (m, 1 H), 8.14 (s, 1 H), 7.55-7.75 (m, 1.4 H), 6.90-7.02 (m, 1.6 H), 6.80-6.88 (m, 1 H), 6.68-6.78 (m, 1 H), 4.98-5.15 (m, 1 H), 3.72-3.83 (m, 0.8 H), 3.42 (br d, 0.2 H), 2.93-3.26 (m, 2 H), 2.84 (br d, 1 H), 2.48-2.64 (m, 4 H), 1.88-1.97 (m, 2 H)	474.2 [M+H]+	99.4%
834	(CD3OD) δ 8.98 (s, 1 H). 8.46 (s. 1 H), 8.26-8.39 (m. 1 H), 7.49-7.77 (m, 1 H), 6.90-7.03 (m, 2 H), 6.79-6.89 (m, 1 H), 6.72-6.78 (m, 1 H), 5.08 (dd, 1 H), 3.71-3.85 (m, 1 H), 3.36-3.52 (m, 1 H), 2.92-3.26 (m, 2 H), 2.85 (br d, 1 H), 1.41-1.55 (m, 2 H), 1.25-1.32 (m, 2 H)	524.2 [M+H]+	1 00%
835	(CD3OD) δ 8.98 (s, 1 H). 8.46 (s. 1 H), 8.24-8.38 (m. 1 H), 7.51-7.78 (m. 1 H), 6.90-7.02 (m, 2 H), 6.80-6.89 (m. 1 H), 6.71-6.78 (m, 1 H), 5.08 (br dd, 1 H), 3.65-3.92 (m, 1 H), 3.36-3.51 (m, 1 H), 2.94-3.24 (m. 2 H), 2.77-2.91 (m, 1 H), 1.42-1.53 (m, 2 H), 1.23-1.32 (m. 2 H)	524.2 [M+H]+	99.5%
836	Data provided above
837	Data provided above
838	(CD3OD) δ 8.22-8.41 (m, 1 H), 7.94-8.07 (m, 1 H), 7.70 (s. 1 H), 6.74-7.07 (m, 3 H), 6.64 (s, 0.6 H), 6.34 (s, 0.4 H), 4.94 (br d, 0.4 H), 4.40 (dd, 0.6 H), 3.98-4.12 (m, 3 H), 3.65-3.75 (m, 0.5 H), 2.71-3.29 (m, 2.5 H), 2.37-2.51 (m, 3 H)	363.2 [M+H]+	100%
839	(CD3OD) δ 8.14-8.27 (m, 1 H), 7.84-7.94 (m, 1 H), 7.59 (d, 1 H), 6.62-6.94 (m, 3 H), 6.52 (s, 0.6 H), 6.22 (s, 0.4 H), 4.82 (br s, 0.4 H), 4.28 (dd, 0.6 H), 3.84-4.01 (m, 3 H), 3.53-3.63 (m, 0.5 H), 2.59-3.17 (m, 2.5 H), 2.22-2.42 (m, 3 H)	363.2 [M+H]+	98.9%
840	(CD3OD) δ 8.31-8.39 (m, 1 H), 8.00 (s, 1 H), 7.69 (d, 1 H), 6.73-7.02 (m. 3.5 H), 6.49 (s, 0.5 H), 4.90-4.94 (m, 0.5 H), 4.40 (dd, 0.5 H), 4.00-4.09 (m. 3 H), 3.61-3.72 (m, 0.5 H), 2.70-3.27 (m, 2.5 H)	367.2 [M+H]+	98.5%
841	(CD3OD) δ 8.33-8.41 (m, 1 H), 8.02 (s, 1 H), 7.71 (d, 1 H), 6.74-7.02 (m, 3.5 H), 6.51 (s, 0.5 H), 4.92-4.96 (m, 0.5 H), 4.42 (dd, 0.5 H), 4.04-4.09 (m, 3 H), 3.64-3.73 (m, 0.5 H), 2.71-3.30 (m, 2.5 H)	367.2 [M+H]+	98.3%
842	(CD3OD) δ 8.33-8.45 (m, 1 H), 7.86-7.92 (m, 1 H), 7.70 (br d, 1 H), 6.94-7.03 (m, 2 H), 6.69-6.93 (m, 2.3 H), 6.48 (s, 0.3 H), 6.03 (s, 0.4 H), 4.86 (br d, 0.6 H), 3.69-3.88 (m, 1 H), 3.35-3.42 (m, 0.4 H), 2.69-3.05 (m. 2 H)	420.1 [M+H]+	96.9%
843	(CD3OD) δ 8.31-8.47 (m, 1 H), 7.83-7.96 (m, 1 H), 7.70 (br d, 1 H), 6.94-7.04 (m, 2 H), 6.83-6.92 (m, 1 H), 6.71-6.81 (m, 1.3 H), 6.48 (s, 0.3 H), 6.03 (s, 0.4 H), 4.86 (br d, 0.6 H), 3.69-3.86 (m, 1 H), 3.34-3.43 (m, 0.4 H), 2.68-3.05 (m, 2 H)	420.2 [M+H]+	92.8%
844	(CD3OD) δ 8.23-8.34 (m, 2 H), 7.52-7.72 (m, 1 H), 6.93-7.04 (m, 2 H), 6.52-6.85 (m, 2 H), 5.06 (br dd, 1 H), 3.92 (s, 3 H), 3.72-3.81 (m, 1 H), 2.79-3.22 (m, 2 H), 2.51-2.56 (m, 3 H), 2.40-2.47 (m, 3 H))	444.2 [M+H]+	98.0%
845	(CD3OD) δ 8.20-8.34 (m, 2 H), 7.53-7.71 (m, 1 H), 6.90-7.05 (m, 2 H), 6.48-6.83 (m, 2 H), 5.06 (br dd, 1 H), 3.92 (s, 3 H), 3.71-3.83 (m, 1 H), 2.77-3.22 (m, 2 H), 2.51-2.57 (m, 3 H), 2.38-2.49 (m, 3 H)	444.2 [M+H]+	98.3%
846	(CD3OD) δ 8.24-8.38 (m, 2 H), 7.53-7.72 (m, 1 H), 6.68-7.02 (m, 4 H), 5.09 (dd, 1 H), 3.92 (s, 3 H), 3.70-3.80 (m, 1 H), 2.73-3.24 (m, 2 H), 2.45-2.59 (m, 3 H)	448.2 [M+H]+	98.2%
847	(CD3OD) δ 8.27-8.37 (m, 2 H), 7.47-7.71 (m, 1 H). 6.65-7.04 (m, 4 H), 5.09 (br dd, 1 H), 3.92 (s, 3 H), 3.72-3.82 (m, 1 H), 2.74-3.28 (m, 2 H), 2.47-2.64 (m, 3 H)	448.2 [M+H]+	98.8%
848	(CD3OD) δ 8.16-8.70 (m, 1 H), 7.70 (br s, 1 H), 7.50 (s, 1 H), 6.94-7.07 (m. 1.6 H). 6.68-6.93 (m, 2 H). 6.42-6.61 (m, 1 H). 6.16 (br s, 0.4 H), 3.95 (br dd, 1 H), 3.59-3.83 (m, 1.6 H), 3.35-3.45 (m, 0.4 H), 2.89-3.11 (m, 1 H), 2.68-2.89 (m, 1 H), 1.12 (br s, 1 H), 0.63-0.99 (m, 3 H)	392.2 [M+H]+	99.6%
849	(CD3OD) δ 8.31-8.53 (m, 1 H), 7.70 (br s, 1 H), 7.50 (s, 1 H), 6.94-7.13 (m. 1.6 H). 6.68-6.93 (m, 2 H). 6.39-6.61 (m, 1 H), 6.16 (br s, 0.4 H), 3.95 (br dd, 1 H), 3.56-3.82 (m, 1.6 H), 3.36-3.45 (m, 0.4 H), 2.89-3.11 (m, 1 H), 2.70-2.87 (m, 1 H), 1.12 (br s, 1 H), 0.64-1.01 (m, 3 H)	392.2 [M+H]+	99.1%
850	(CD3OD) δ 8.83 (br d, 2 H), 8.19-8.36 (m, 1 H), 8.12 (d, 2 H), 7.49-7.77 (m, 1 H), 6.94-7.04 (m, 2 H). 6.72-6.85 (m, 1 H), 6.52-6.67 (m, 1 H), 5.05 (br dd, 0.5 H), 3.72-3.89 (m, 1 H), 3.37-3.51 (m, 0.5 H), 2.95-3.26 (m. 1 H), 2.88 (br s, 1 H), 2.38-2.51 (m. 3 H)	427.2 [M+H]+	100%
85 1	(CD3OD) δ 8.83 (br d, 2 H), 8.19-8.38 (m, 1 H), 8.12 (d, 2 H), 7.41-7.80 (m, 1 H), 6.91-7.06 (m, 2 H). 6.71-6.84 (m, 1 H), 6.49-6.68 (m, 1 H), 5.05 (br dd, 0.5 H), 3.71-3.90 (m, 1 H), 3.43 (br t, 0.5 H). 2.97-3.27 (m, 1 H). 2.88 (br s, 1 H), 2.38-2.50 (m, 3 H)	427.2 [M+H]+	98.3%
852	(CD3OD) δ 8.99 (s. 1 H), 8.46 (s, 1 H). 8.20-8.36 (m, 1 H). 7.54-7.71 (m, 1 H), 6.74-7.09 (m, 3 H), 6.52-6.68 (m, 1 H), 4.96-5.20 (m, 1 H), 3.79 (br t, 1 H), 3.04-3.24 (m, 2 H), 2.85 (br d, 1 H), 2.42-2.46 (m, 3 H), 1.44-1.51 (m, 2 H), 1.28 (br d, 2 H)	520.2 [M+H]+	100%
853	(CD3OD) δ 8.99 (s, 1 H). 8.46 (s. 1 H), 8.19-8.36 (m. 1 H), 7.57-7.97 (m, 1 H), 6.50-7.20 (m, 4 H), 5.03-5.15 (m, 1 H), 3.68-3.89 (m, 1 H), 2.99-3.26 (m, 2 H), 2.88 (br d. 1 H), 2.39-2.50 (m, 3 H), 1.44-1.52 (m, 2 H), 1.28 (br d, 2 H)	520.2 [M+H]+	99.3%
854	(CD3OD) δ 8.14-8.38 (m, 1 H), 7.48-7.73 (m, 1 H), 6.71-7.08 (m, 4 H), 6.49-6.68 (m, 1 H), 5.00 (br dd, 1 H), 3.90 (s, 3 H), 3.71-3.84 (m, 1 H), 2.94-3.23 (m, 1 H), 2.83 (br d, 1 H), 2.38-2.47 (m, 6 H)	444.2 [M+H]+	96.4%
855	(CD3OD) δ 8.21-8.35 (m, 1 H), 7.49-7.71 (m, 1 H), 6.71-7.08 (m, 4 H), 6.50-6.67 (m, 1 H), 5.00 (br dd, 1 H), 3.90 (s, 3 H), 3.36-3.83 (m, 1 H), 2.95-3.24 (m. 1 H), 2.83 (br d, 1 H), 2.36-2.48 (m, 6 H)	444.2 [M+H]+	90.2%
856	(CD3OD) δ 8.33-8.58 (m, 1 H), 7.47-8.01 (m, 3 H), 7.19 (br t, 1 H), 6.15-7.02 (m. 4 H), 4.69 (br d, 2 H), 3.63-4.07 (m, 1 H). 2.66-3.18 (m, 2 H), 1.22-1.57 (m, 6 H)	376.2 [M+H]+	99.9%
857	(CD3OD) δ 8.34-8.61 (m, 1 H), 7.44-7.78 (m, 3 H), 7.19 (br t, 1 H), 6.12-7.04 (m. 4 H), 4.69 (br d, 2 H). 3.60-4.03 (m, 1 H). 2.60-3.09 (m, 2 H), 1.25-1.51 (m, 6 H)	376.2 [M+H]+	99.9%
858	(CD3OD) δ 8.23-8.53 (m, 1 H), 7.49-7.74 (m, 2 H), 6.07-7.13 (m, 5 H), 4.55-4.82 (m, 2 H), 3.60-4.09 (m, 1 H), 2.66-3.07 (m, 2 H), 1.25-1.53 (m, 6 H)	394.2 [M+H]+	99.5%
859	(CD3OD) & 8.23-8.49 (m, 1 H), 7.43-7.78 (m, 2 H), 6.15-7.04 (m, 5 H), 4.54-4.80 (m, 2 H), 3.61-4.14 (m, 1 H), 2.68-3.10 (m, 2 H), 1.42 (br d, 6 H)	394.2 [M+H]+	98.6%
860	(CD3OD) δ 8.18-8.57 (m, 1 H), 7.70 (br s, 1 H), 7.50 (d, 1 H), 6.94-7.10 (m, 1.6 H), 6.77-6.87 (m, 1 H), 6.74 (br s, 0.4 H), 6.06-6.70 (m, 2 H), 3.92 (br dd, 1 H), 3.75 (br t, 0.6 H), 3.66 (br d, 1 H), 3.36-3.48 (m, 0.4 H), 2.88-3.12 (m, 1 H), 2.70-2.87 (m, 1 H), 2.33-2.53 (m, 3 H), 0.78-1.16 (m, 4 H)	388.2 [M+H]+	98.4%
861	(CD3OD) δ 8.23-8.56 (m, 1 H), 7.63-7.80 (m, 1 H). 7.50 (d, 1 H), 6.94-7.10 (m, 1.6 H), 6.78-6.86 (m, 1 H), 6.74 (br s, 0.4 H), 6.10-6.70 (m, 2 H), 3.92 (br dd. 1 H), 3.74 (br t, 0.6 H), 3.66 (br d, 1 H), 3.39 (br d, 0.4 H), 2.88-3.11 (m, 1 H), 2.67-2.87 (m, 1 H). 2.39-2.54 (m, 3 H). 0.77-1.16 (m, 4 H)	388.2 [M+H]+	99.2%
862	(CD3OD) δ 8.32 (dd. 1 H), 7.66-7.89 (m. 4 H), 7.46-7.57 (m. 1 H), 7.02-7.13 (m, 1.6 H), 6.99 (s, 1 H), 6.73-6.86 (m, 1.4 H), 5.83-6.71 (m, 2 H), 3.42-3.77 (m, 2 H). 2.58-3.13 (m, 2 H). 2.36-2.51 (m, 3 H)	425.2 [M+H]+	88.7%
863	(CD3OD) & 8.24-8.36 (m, 1 H), 7.65-7.91 (m, 4 H), 7.44-7.56 (m, 1 H), 7.02-7.14 (m, 1.6 H), 6.94-7.00 (m, 1 H), 6.73-6.86 (m, 1.4 H), 5.83-6.72 (m, 2 H), 3.41-3.79 (m, 2 H), 2.56-3.13 (m, 2 H). 2.37-2.52 (m, 3 H)	425.2 [M+H]+	85.6%
864	(CD3OD) δ 8.30-8.49 (m, 1 H). 7.69 (s. 1 H), 6.70-7.07 (m. 5 H), 6.28-6.65 (m, 1 H), 4.76-4.86 (m, 0.4 H), 4.03-4.18 (m, 0.6 H), 3.95 (s, 3 H), 3.72 (br t. 0.6 H). 3.26 (br s, 0.4 H), 2.90-3.05 (m, 1 H), 2.76 (br d, 1 H)	416.2 [M+H]+	100%
865	(CD3OD) δ 8.29-8.50 (m, 1 H), 7.69 (s, 1 H), 6.13-7.06 (m, 5 H), 6.25-6.65 (m, 1 H), 4.77-4.86 (m, 0.4 H), 4.09 (br d, 0.6 H), 3.95 (s, 3 H), 3.72 (br t. 0.6 H), 3.27 (br s, 0.4 H). 2.90-3.07 (m, 1 H), 2.76 (br d, 1 H)	416.2 [M+H]+	100%
866	(CD3OD) δ 8.25-8.42 (m, 1 H), 7.68 (s, 1 H), 6.87-7.05 (m, 2 H), 6.72-6.84 (m, 2 H), 6.62 (s, 1 H), 6.30 (br s, 1 H), 4.01-4.16 (m, 1 H), 3.94 (s, 3 H), 3.64-3.82 (m, 1 H), 2.96 (br d, 1 H), 2.76 (br d, 1 H), 2.36-2.48 (m, 3 H)	412.2 [M+H]+	98.4%
867	(CD3OD) δ 8.26-8.42 (m, 1 H), 7.68 (s, 1 H), 6.86-7.06 (m. 2 H), 6.71-6.82 (m, 2 H), 6.62 (s, 1 H), 6.31 (br s, 1 H), 4.00-4.15 (m, 1 H). 3.94 (s, 3 H), 3.65-3.82 (m. 1 H), 2.96 (br d, 1 H), 2.76 (br d, 1 H), 2.34-2.50 (m, 3 H)	412.2 [M+H]+	97.6%
868	(CD3OD) δ 8.47 (br s, 1 H), 7.49-7.99 (m, 4 H), 7.03-7.38 (m, 2 H), 6.43-6.96 (m, 3 H), 4.47 (br s, 1 H), 3.87-4.17 (m, 3 H), 3.37-3.85 (m, 1 H), 2.74-3.23 (m, 2 H)	465.2 [M+H]+	99.6%
869	(CD3OD) δ 8.47 (br s, 1 H), 7.47-8.01 (m, 4 H), 7.04-7.38 (m, 2 H). 6.51-6.97 (m, 3 H), 4.44 (br s, 1 H), 3.91-4.17 (m, 3 H), 3.37-3.84 (m, 1 H), 2.74-3.22 (m, 2 H)	465.2 [M+H]+	99.7%
870	(CD3OD) δ 8.60 (s, 1 H), 8.14-8.34 (m, 2 H), 7.89 (br d, 1 H), 7.45-7.73 (m, 1 H), 6.92-7.03 (m, 2 H), 6.70-6.83 (m. 1 H), 6.53-6.66 (m, 1 H), 4.99 (br dd, 1 H), 3.72-3.86 (m, 0.7 H), 3.36-3.49 (m, 0.3 H), 3.13-3.25 (m. 0.7 H). 2.95-3.06 (m, 0.3 H), 2.80-2.94 (m, 1 H), 2.38-2.50 (m, 6 H)	441.2 [M+H]+	100%
871	(CD3OD) δ 8.61 (s, 1 H), 8.15-8.33 (m, 2 H), 7.90 (br d, 1 H), 7.46-7.73 (m, 1 H), 6.93-7.04 (m, 2 H), 6.71-6.84 (m. 1 H), 6.54-6.69 (m, 1 H), 4.99 (br dd, 1 H), 3.72-3.87 (m, 0.7 H), 3.37-3.51 (m, 0.3 H), 3.14-3.24 (m, 0.7 H), 2.94-3.07 (m, 0.3 H), 2.84 (br d, 1 H), 2.38-2.51 (m, 6 H)	441.2 [M+H]+	99.7%
872	(CD3OD) δ 9.11 (s, 1 H), 8.46-8.55 (m, 1 H), 8.38-8.45 (m. 1 H), 8.19-8.34 (m, 1 H), 7.46-7.75 (m, 1 H), 6.91-7.04 (m, 2 H), 6.70-6.84 (m, 1 H), 6.55-6.67 (m. 1 H), 5.00 (br dd, 1 H). 3.75-3.85 (m, 0.7 H), 3.43 (td, 0.4 H), 2.95-3.26 (m, 1 H), 2.79-2.90 (m, 1 H), 2.36-2.50 (m, 3 H)	495.2 [M+H]+	100%
873	(CD3OD) δ 9.11 (s. 1 H), 8.45-8.53 (m. 1 H), 8.36-8.44 (m. 1 H), 8.20-8.33 (m, 1 H), 7.66-7.78 (m, 1 H), 7.51 (s, 0.3 H), 6.91-7.05 (m, 1.7 H), 6.71-6.84 (m, 1 H), 6.55-6.68 (m, 1 H), 5.01 (br dd, 1 H), 3.70-3.87 (m, 0.7 H), 3.39-3.51 (m, 0.3 H), 2.95-3.26 (m, 1 H), 2.79-2.91 (m. 1 H), 2.37-2.52 (m. 3 H)	495.2 [M+H]+	100%
874	(CD3OD) δ 8.69 (d, 1 H). 8.21-8.40 (m, 2 H). 7.87 (td, 1 H). 7.46-7.75 (m, 1 H), 6.93-7.02 (m, 2 H), 6.71-6.82 (m, 1 H), 6.55-6.67 (m. 1 H), 5.00 (br dd, 1 H). 3.72-3.86 (m, 0.7 H), 3.43 (td, 0.3 H), 3.13-3.25 (m, 0.7 H), 2.95-3.07 (m, 0.3 H), 2.78-2.89 (m, 1 H), 2.39-2.47 (m, 3 H)	445.2 [M+H]+	100%
875	(CD3OD) δ 8.69 (d, 1 H). 8.19-8.40 (m, 2 H). 7.87 (td, 1 H). 7.45-7.74 (m, 1 H), 6.89-7.04 (m, 2 H), 6.71-6.83 (m, 1 H), 6.53-6.67 (m. 1 H), 5.00 (br dd, 1 H). 3.72-3.85 (m, 0.7 H), 3.43 (td, 0.3 H), 3.12-3.26 (m. 0.7 H). 2.94-3.07 (m, 0.3 H), 2.78-2.89 (m. 1 H), 2.38-2.46 (m, 3 H)	445.2 [M+H]+	99.4%
876	(CD3OD) δ 8.62 (s, 1 H), 8.27-8.38 (m, 1 H), 8.15-8.23 (m, 1 H), 7.90 (br d, 1 H), 7.70 (s, 1 H), 7.50 (s, 0.3 H), 7.18 (br s, 0.2 H), 6.92-7.00 (m, 1.5 H), 6.75-6.87 (m, 2 H), 5.02 (br dd, 1 H), 3.76-3.85 (m, 0.7 H), 3.37-3.50 (m, 0.3 H), 2.78-3.26 (m, 2 H), 2.48 (s, 3 H)	445.2 [M+H]+	100%
877	(CD3OD) δ 8.62 (s, 1 H), 8.26-8.39 (m, 1 H), 8.15-8.23 (m, 1 H), 7.87-7.94 (m, 1 H). 7.70 (s. 1 H), 7.50 (s, 0.3 H), 7.20 (br s, 0.2 H), 6.93-7.00 (m, 1.5 H), 6.75-6.87 (m, 2 H), 5.02 (br dd, 1 H), 3.74-3.85 (m, 0.6 H), 3.36-3.49 (m, 0.4 H), 2.80-3.25 (m, 2 H), 2.48 (s, 3 H)	445.2 [M+H]+	100%
878	(CD3OD) δ 9.11 (s, 1 H), 8.23-8.56 (m, 3 H), 7.43-7.78 (m, 1.3 H). 6.90-7.07 (m, 1.7 H), 6.74-6.88 (m, 2 H), 4.94-5.06 (m. 1 H), 3.75-3.86 (m, 0.7 H), 3.43 (td, 0.3 H), 2.81-3.27 (m, 2 H)	499.2 [M+H]+	100%
879	(CD3OD) δ 9.11 (s, 1 H), 8.23-8.57 (m, 3 H), 7.46-7.78 (m, 1.3 H), 6.90-7.04 (m. 1.7 H). 6.71-6.87 (m, 2 H). 4.94-5.07 (m, 1 H). 3.75-3.87 (m, 0.6 H), 3.44 (td, 0.4 H), 2.82-3.25 (m, 2 H)	499.2 [M+H]+	100%
880	(CD3OD) δ 8.70 (d, 1 H), 8.23-8.44 (m, 2 H), 7.88 (td, 1 H), 7.70 (s, 1 H), 7.51 (s, 0.3 H), 6.91-7.04 (m, 1.7 H), 6.72-6.89 (m, 2 H), 4.93-5.08 (m, 1 H), 3.79 (ddd, 0.7 H), 3.43 (td, 0.3 H), 2.81-3.25 (m, 2 H)	449.2 [M+H]+	100%
881	(CD3OD) δ 8.70 (d, 1 H), 8.24-8.43 (m, 2 H), 7.88 (td, 1 H), 7.70 (s, 1 H). 7.51 (s. 0.3 H), 6.90-7.03 (m, 1.7 H), 6.73-6.88 (m, 2 H), 4.94-5.07 (m, 1 H), 3.73-3.86 (m, 0.7 H), 3.43 (td, 0.3 H), 2.79-3.25 (m. 2 H)	449.2 [M+H]+	100%
882	(CD3OD) δ 8.20-8.41 (m, 1 H), 7.44-7.77 (m, 1 H), 6.66-7.11 (m, 5 H), 5.02 (br dd, 1 H), 3.90 (s, 3 H), 3.68-3.85 (m, 1 H), 2.81-3.25 (m, 2 H), 2.39 (s, 3 H)	448.2 [M+H]+	99.7%
883	(CD3OD) δ 8.20-8.43 (m, 1 H), 7.47-7.76 (m, 1 H). 6.62-7.12 (m, 5 H), 5.02 (br dd, 1 H), 3.90 (s, 3 H), 3.71-3.84 (m, 1 H), 2.76-3.24 (m, 2 H), 2.39 (s, 3 H)	448.2 [M+H]+	99.4%
884	(CD3OD) δ 8.32-8.47 (m, 1 H), 7.68 (s, 1 H), 7.52 (br s, 1 H), 6.91-7.01 (m, 1.5 H), 6.72-6.89 (m, 2 H), 6.30-6.64 (m, 1.5 H), 4.11 (br d, 1 H), 3.47-3.97 (m, 4 H), 2.71-3.02 (m, 2 H)	366.2 [M+H]+	99.8%
885	(CD3OD) δ 8.29-8.49 (m, 1 H), 7.69 (s, 1 H), 7.53 (br s, 1 H), 6.91-7.02 (m, 1.5 H), 6.73-6.89 (m, 2 H), 6.31-6.63 (m, 1.5 H), 4.10 (br s, 1 H), 3.93 (s, 4 H), 2.71-3.04 (m, 2 H)	366.2 [M+H]+	99.6%
886	(CD3OD) δ 8.02-8.21 (m, 1 H), 7.34-7.72 (m, 1 H), 6.86-7.06 (m. 1 H), 6.73-6.85 (m. 2 H), 6.53-6.68 (m. 2 H), 6.31 (br d, 1 H), 4.72-4.85 (m, 1 H), 4.05 (br d, 0.5 H), 3.90-3.98 (m, 6 H), 3.70 (br t. 0.5 H), 2.97 (br s, 1 H), 2.67-2.83 (m. 1 H)	428.2 [M+H]+	99.1%
887	(CD3OD) δ 8.04-8.20 (m, 1 H), 7.67 (s, 1 H), 6.87-7.06 (m, 1 H), 6.71-6.84 (m, 2 H), 6.64 (br d, 1 H), 6.57 (d, 1 H), 6.31 (br d, 1 H), 4.76-4.83 (m, 0.4 H), 4.00-4.13 (m, 0.6 H), 3.89-3.98 (m, 6 H), 3.70 (br t, 0.7 H). 3.27 (br s, 0.3 H), 2.90-3.04 (m, 1 H), 2.68-2.82 (m, 1 H)	428.2 [M+H]+	99.1%
888	(CD3OD) δ 8.36 (br s, 1 H), 7.45-8.01 (m, 3 H), 7.03-7.36 (m, 1 H), 6.58-7.03 (m. 4 H), 4.47 (br d, 1 H). 3.92-4.16 (m, 3 H). 3.36-3.85 (m, 1 H), 2.74-3.22 (m, 2 H)	483.2 [M+H]+	99.3%
889	(CD3OD) δ 8.36 (br s, 1 H), 7.49-8.01 (m, 3 H), 7.03-7.39 (m, 1 H), 6.60-7.03 (m, 4 H), 4.46 (br s, 1 H), 3.90-4.17 (m, 3 H), 3.37-3.86 (m, 1 H), 2.74-3.22 (m, 2 H)	483.2 [M+H]+	99.6%
890	(CD3OD) δ 8.32 (br d, 1 H), 7.48-8.00 (m, 3 H), 6.94-7.38 (m, 2 H). 6.48-6.93 (m, 3 H), 4.47 (br s, 1 H), 3.90-4.16 (m, 3 H), 3.39-3.88 (m, 1 H), 2.74-3.25 (m, 2 H), 2.45 (s, 3 H)	479.3 [M+H]+	99.5%
891	(CD3OD) δ 8.31 (br d, 1 H), 7.45-7.98 (m, 3 H), 6.96-7.38 (m, 2 H), 6.50-6.94 (m, 3 H), 4.46 (br s, 1 H), 3.90-4.16 (m, 3 H), 3.37-3.85 (m, 1 H), 2.74-3.21(m, 2 H), 2.44 (s, 3 H)	479.2 [M+H]+	99.7%
892	(CD3OD) δ 8.28-8.65 (m, 1 H), 7.43-7.78 (m, 2 H), 7.21 (dd, 1 H), 6.80-7.04 (m. 1.5 H), 6.49-6.74 (m, 1 H). 6.36 (br s, 1.3 H), 4.80-4.87 (m, 0.8 H), 4.05-4.21 (m, 0.5 H), 3.84 (s, 3 H), 3.70 (br t, 0.5 H), 2.66-3.04 (m, 2 H), 2.20-2.36 (m, 3 H)	362.2 [M+H]+	100%
893	(CD3OD) δ 8.11-8.58 (m, 1 H), 7.28-7.70 (m, 2 H), 6.89-7.25 (m, 1 H), 6.66-6.88 (m, 1.5 H), 6.30-6.63 (m, 1 H), 6.23 (br s, 1.3 H), 4.65-4.76 (m, 1 H), 3.92-4.08 (m, 0.5 H), 3.53-3.77 (m, 3.5 H), 2.52-2.97 (m, 2 H), 2.02-2.24 (m. 3 H)	362.2 [M+H]+	99.7%
894	(CD3OD) δ 9.31 (d, 1 H), 8.80 (dd, 1 H), 8.55 (dd, 1 H), 8.18-8.36 (m, 1 H), 7.63-7.74 (m. 2 H), 7.56 (s, 0.3 H), 6.94-7.04 (m, 1.7 H), 6.72-6.84 (m, 1 H), 6.53-6.67 (m, 1 H), 5.07 (dd, 1 H), 3.80 (ddd, 0.6 H), 3.37-3.51 (m, 0.4 H), 2.95-3.26 (m, 1 H), 2.76-2.92 (m, 1 H), 2.38-2.48 (m, 3 H)	427.2 [M+H]+	100%
895	(CD3OD) δ 9.31 (d, 1 H), 8.80 (dd, 1 H), 8.55 (dt, 1 H), 8.20-8.35 (m, 1 H), 7.63-7.74 (m. 2 H), 7.56 (s, 0.3 H), 6.91-7.03 (m, 1.7 H), 6.72-6.85 (m, 1 H), 6.53-6.67 (m, 1 H), 5.07 (dd, 1 H), 3.76-3.86 (m, 0.6 H), 3.44 (td, 0.4 H), 2.95-3.26 (m, 1 H), 2.79-2.90 (m, 1 H). 2.37-2.50 (m, 3 H)	427.2 [M+H]+	99.3%
896	(CD3OD) δ 9.31 (d, 1 H), 8.80 (dd. 1 H), 8.49-8.62 (m. 1 H), 8.24-8.42 (m, 1 H), 7.66-7.71 (m, 2 H), 7.57 (s, 0.3 H), 6.93-7.01 (m, 1.7 H), 6.73-6.88 (m, 2 H), 4.96-5.15 (m, 1 H), 3.75-3.86 (m, 0.7 H), 3.38-3.52 (m, 0.3 H), 2.82-3.23 (m, 2 H)	431.2 [M+H]+	99.8%
897	(CD3OD) δ 9.31 (d, 1 H), 8.80 (dd, 1 H), 8.55 (dd, 1 H), 8.28-8.39 (m, 1 H). 7.65-7.73 (m, 2 H). 7.57 (s. 0.3 H), 6.90-7.03 (m, 1.7 H), 6.72-6.89 (m, 2 H), 5.10 (dd, 1 H), 3.72-3.87 (m, 0.7 H), 3.40-3.49 (m, 0.3 H), 2.81-3.24 (m, 2 H)	431.1 [M+H]+	98.3%
898	(CD3OD) δ 8.05-8.17 (m, 1 H), 7.52-7.95 (m, 5 H). 7.08-7.21 (m, 1 H), 6.60-7.02 (m, 4 H), 5.84-6.59 (m, 1 H), 3.94-4.06 (m, 3 H), 3.37-3.83 (m. 2 H), 2.57-3.18 (m, 2 H)	441.2 [M+H]+	100%
899	(CD3OD) δ 8.01-8.16 (m, 1 H), 7.48-7.95 (m, 5 H), 7.04-7.21 (m, 1 H), 6.59-6.99 (m, 4 H), 5.82-6.57 (m, 1 H), 3.89-4.06 (m, 3 H). 3.39-3.80 (m, 2 H). 2.56-3.15 (m, 2 H)	441.2 [M+H]+	92.8%
900	(CD3OD) δ 8.13-8.49 (m. 1 H), 7.65 (s, 1 H). 6.83-7.18 (m, 2 H). 6.75 (br s, 1 H), 6.44-6.63 (m, 1 H), 6.31 (br t, 1 H), 4.02-4. 16 (m, 1 H). 3.80 (s. 3 H), 3.68 (br t. 1 H), 2.65-3.05 (m, 2 H), 2.33-2.48 (m, 3 H), 2.23 (br s, 3 H)	376.2 [M+H]+	100%
901	(CD3OD) δ 8.20-8.42 (m, 1 H), 7.65 (s, 1 H), 6.87-7.07 (m, 2 H), 6.76 (br s, 1 H), 6.37-6.62 (m, 1 H), 6.19-6.36 (m, 1 H), 3.97-4.18 (m, 1 H), 3.54-3.86 (m, 4 H), 2.65-3.04 (m, 2 H), 2.33-2.48 (m, 3 H), 2.23 (br s, 3 H)	376.2 [M+H]+	99.3%
902	(CD3OD) δ 7.83-8.43 (m, 3 H), 7.68 (s, 1 H), 7.02-7.36 (m, 1 H), 6.93-7.00 (m, 1 H), 6.61-6.90 (m, 3 H). 4.36-4.61 (m, 1 H). 3.97 (br s, 3 H), 3.76 (br s, 0.6 H), 3.36-3.51 (m, 0.4 H), 2.72-3.23 (m, 2 H)	483.2 [M+H]+	99.3%
903	(CD3OD) δ 7.74-8.32 (m, 3 H), 7.59 (s, 1 H), 6.93-7.25 (m, 1 H), 6.87 (dd, 1 H), 6.51-6.79 (m, 3 H), 4.31-4.51 (m, 1 H), 3.87 (br s, 3 H), 3.66 (br s, 0.6 H), 3.24-3.43 (m. 0.4 H), 2.61-3.13 (m, 2 H)	483.2 [M+H]+	98.9%
904	(CD3OD) δ 8.62-8.74 (m, 2 H), 7.88-8.08 (m, 2 H), 7.53-7.78 (m, 2 H), 6.84-7.07 (m. 3 H), 5.05 (br dd, 1 H), 3.40-3.82 (m, 1 H), 3.00-3.28 (m, 1 H), 2.86-2.95 (m, 1 H)	499.2 [M+H]+	99.0%
905	(CD3OD) δ 8.62-8.72 (m, 2 H), 7.46-7.96 (m, 4 H), 6.81-7.02 (m, 3 H). 4.98 (br dd. 1 H), 3.39-3.83 (m, 1 H), 2.98-3.27 (m. 1 H), 2.86 (br dd, 1 H)	499.2 [M+H]+	94.9%
906	(CD3OD) δ 8.89-8.94 (m, 1 H), 8.64-8.71 (m, 1 H), 8.30-8.38 (m, 1 H), 7.50-7.80 (m, 3.5 H), 6.77-7.01 (m, 2.5 H), 4.95-5.13 (m, 1 H), 3.36-3.81 (m, 1 H), 2.95-3.23 (m, 1 H), 2.80-2.89 (m, 1 H)	520.2 [M+H]+	100%
907	(CD3OD) δ 8.90-8.94 (m, 1 H), 8.64-8.71 (m, 1 H), 8.26-8.41 (m, 1 H), 7.49-7.82 (m, 3.5 H), 6.77-7.02 (m, 2.5 H), 4.95-5.13 (m, 1 H), 3.39-3.82 (m, 1 H), 2.95-3.22 (m, 1 H), 2.79-2.89 (m, 1 H)	520.2 [M+H]+	95.7%
908	(CD3OD) δ 8.62-8.73 (m, 1 H), 8.33 (d. 1 H), 7.50-7.84 (m, 3 H), 6.74-7.24 (m, 4 H), 4.95-5.09 (m, 1 H), 3.36-3.82 (m, 1 H), 2.96-3.25 (m. 1 H), 2.79-2.90 (m, 1 H)	520.2 [M+H]+	100%
909	(CD3OD) δ 8.62-8.73 (m, 1 H), 8.33 (d, 1 H). 7.52-7.83 (m, 3 H), 6.76-7.22 (m, 4 H), 4.94-5.09 (m, 1 H), 3.36-3.83 (m, 1 H), 2.97-3.24 (m, 1 H), 2.79-2.92 (m, 1 H)	520.2 [M+H]+	100%
910	(CD3OD) δ 8.41-8.47 (m, 1 H), 8.25 (dd, 1 H), 7.56-7.73 (m, 2 H), 7.41-7.52 (m, 1.5 H), 6.98-7.15 (m, 1.5 H), 6.58-6.76 (m, 1.6 H), 6.44 (s, 0.4 H), 4.94-5.06 (m, 1 H), 3.99 (d, 3.7 H), 3.35-3.42 (m, 0.3 H), 2.82-3.24 (m, 2 H), 2.45-2.71 (m, 3 H)	457.2 [M+H]+	100%
911	(CD3OD) δ 8.39-8.49 (m, 1 H), 8.25 (dd. 1 H), 7.56-7.76 (m. 2 H), 7.39-7.53 (m, 1.5 H), 6.97-7.18 (m, 1.5 H), 6.59-6.76 (m, 1.6 H). 6.44 (s. 0.4 H). 4.94-5.06 (m, 1 H). 3.99 (d, 3.6 H), 3.36-3.42 (m, 0.4 H), 2.80-3.24 (m, 2 H), 2.44-2.70 (m, 3 H)	457.2 [M+H]+	100%
912	(CD3OD) δ 8.58-8.69 (m, 1 H), 7.87-7.99 (m, 1 H), 7.64-7.80 (m, 2 H), 7.36-7.52 (m, 1.4 H), 6.95-7.19 (m, 1.6 H), 6.58-6.76 (m, 1.6 H), 6.44 (s, 0.4 H), 4.93-4.99 (m, 1 H), 3.86-4.00 (m, 0.6 H), 3.34-3.42 (m, 0.4 H), 2.81-3.26 (m, 2 H), 2.44-2.70 (m, 3 H)	445.2 [M+H]+	100%
913	(CD3OD) δ 8.64 (t, 1 H), 7.86-8.00 (m, 1 H), 7.60-7.80 (m, 2 H), 7.35-7.53 (m, 1.5 H), 6.93-7.18 (m, 1.5 H), 6.55-6.80 (m, 1.6 H), 6.44 (s, 0.4 H), 4.93-5.01 (m, 1 H), 3.93 (br t. 0.5 H). 3.34-3.44 (m, 0.5 H), 2.79-3.25 (m, 2 H), 2.41-2.75 (m, 3 H)	445.2 [M+H]+	100%
914	(CD3OD) δ 8.92 (d, 1 H), 8.35 (s, 1 H), 7.39-7.84 (m, 3.5 H), 6.94-7.19 (m. 1.5 H). 6.40-6.77 (m, 2 H). 4.92-5.10 (m, 1 H). 3.85-3.99 (m, 0.6 H), 3.35-3.44 (m, 0.4 H), 2.81-3.23 (m, 2 H), 2.47-2.74 (m, 3 H)	466.2 [M+H]+	100%
915	(CD3OD) δ 8.92 (d. 1 H), 8.35 (s, 1 H). 7.40-7.86 (m, 3.5 H), 6.90-7.22 (m, 1.5 H), 6.40-6.77 (m. 2 H), 4.93-5.11 (m. 1 H), 3.87-3.99 (m, 0.6 H), 3.34-3.44 (m, 0.4 H), 2.81-3.21 (m, 2 H), 2.46-2.72 (m. 3 H)	466.2 [M+H]+	100%
916	(CD3OD) δ 8.28-8.36 (m, 1 H), 7.70 (d. 1 H), 6.74-7.08 (m. 3 H), 6.23-6.68 (m, 1 H), 4.93 (br s, 0.4 H), 4.36 (dd, 0.6 H), 3.96 (d, 3 H), 3.65-3.75 (m, 0.6 H), 3.26 (td, 0.4 H), 2.93-3.19 (m, 1 H), 2.72-2.88 (m, 1 H), 2.36-2.49 (m, 6 H)	377.2 [M+H]+	99.7%
917	(CD3OD) δ 8.27-8.38 (m, 1 H), 7.70 (d, 1 H), 6.73-7.07 (m, 3 H), 6.22-6.66 (m, 1 H), 4.93 (br s, 0.4 H), 4.36 (dd, 0.6H), 3.96 (d, 3 H), 3.70 (ddd, 0.6 H), 3.26 (td, 0.4 H), 2.93-3.18 (m, 1 H), 2.71-2.88 (m. 1 H), 2.34-2.51 (m. 6 H)	377.2 [M+H]+	99.1%
918	(CD3OD) δ 8.06-8.22 (m. 1 H), 7.69 (s, 1 H). 6.94 (br s, 0.6 H), 6.75-6.86 (m, 1 H), 6.46-6.72 (m, 2 H), 6.35 (br s, 1.4 H), 4.78-4.87 (m, 1 H), 4.04-4.19 (m, 0.5 H), 3.97 (br s, 3 H). 3.83 (s, 3 H), 3.62-3.75 (m, 0.5 H), 2.66-3.06 (m, 2 H), 2.27 (br s, 3 H)	392.2 [M+H]+	98.8%
919	(CD3OD) δ 7.95-8.35 (m, 1 H), 7.69 (br s, 1 H), 6.94 (br s, 0.6 H), 6.80 (br s, 1 H), 6.47-6.73 (m, 2 H), 6.35 (br s. 1.4 H). 4.79-4.87 (m, 0.7 H), 4.12 (br d, 0.5 H), 3.97 (br s, 3 H), 3.83 (s, 3 H), 3.61-3.77 (m, 0.5 H), 3.24-3.32 (m, 0.3 H), 2.56-3.16 (m, 2 H), 2.27 (br s, 3 H)	392.2 [M+H]+	98.3%
920	(CD3OD) δ 8.34 (d, 1 H), 7.56-8.05 (m, 3 H), 7.03-7.37 (m, 1 H). 6.68-7.02 (m, 4 H), 4.46-4.59 (m, 1 H). 3.83 (br s, 4 H), 2.79-3.25 (m, 2 H)	483.2 [M+H]+	99.0%
921	(CD3OD) δ 8.34 (d, 1 H), 7.63-8.01 (m, 3 H), 7.04-7.45 (m, 1 H), 6.70-7.02 (m, 4 H), 4.44-4.59 (m, 1 H), 3.65-3.90 (m, 4 H), 2.74-3.25 (m. 2 H)	483.2 [M+H]+	96.9%
922	(CD3OD) δ 8.08-8.25 (m, 1 H), 7.59 (s, 1 H), 7.30 (s, 0.3 H), 6.80-6.93 (m, 1.7 H), 6.61-6.75 (m, 1 H), 6.35-6.59 (m, 1 H), 4.80-4.87 (m, 1 H). 3.65 (ddd, 0.7 H), 3.29 (td, 0.3 H), 2.82-3.11 (m, 1 H), 2.72 (dd, 1 H), 2.28-2.37 (m, 3 H), 1.72-1.84 (m, 6 H)	410.2 [M+H]+	100%
923	(CD3OD) δ 8.22-8.34 (m, 1 H), 7.69 (s, 1 H), 7.40 (s, 0.3 H), 6.90-7.03 (m. 1.7 H). 6.72-6.82 (m, 1 H). 6.46-6.66 (m, 1 H). 4.90-4.98 (m, 1 H), 3.68-3.80 (m, 0.7 H), 3.39 (td, 0.3 H), 2.92-3.21 (m, 1 H), 2.83 (br dd, 1 H), 2.38-2.48 (m, 3 H). 1.81-1.95 (m, 6 H)	410.2 [M+H]+	99.6%
924	(CD3OD) δ 8.23-8.33 (m, 1 H), 7.68 (s, 1 H), 7.45 (s, 0.3 H), 6.94-7.02 (m, 1 H), 6.91 (s, 0.7 H), 6.70-6.83 (m, 1 H), 6.48-6.65 (m, 1 H), 4.97 (dd, 1 H), 3.72 (ddd, 0.7 H), 3.33-3.41 (m, 0.3 H), 2.89-3.19 (m, 1 H), 2.74-2.86 (m, 1 H), 2.38-2.47 (m. 3 H), 2.24-2.36 (m, 1 H), 1.14-1.32 (m, 4 H)	390.2 [M+H]+	100%
925	(CD3OD) δ 8.22-8.33 (m, 1 H), 7.68 (s, 1 H), 7.45 (s, 0.3 H), 6.95-7.03 (m, 1 H), 6.91 (s, 0.7 H), 6.71-6.82 (m, 1 H), 6.47-6.64 (m, 1 H), 4.97 (dd, 1 H), 3.72 (ddd, 0.7 H), 3.37 (td, 0.3 H), 2.89-3.19 (m, 1 H), 2.70-2.87 (m. 1 H), 2.37-2.51 (m. 3 H), 2.21-2.36 (m, 1 H), 1.11-1.32 (m. 4 H)	390.2 [M+H]+	99.9%
926	(CD3OD) δ 8.18-8.37 (m, 1 H), 7.70 (s, 1 H), 7.45-7.50 (m, 1 H), 6.70-7.10 (m, 3 H), 6.55-6.67 (m, 1 H), 5.06 (dd, 1 H), 4.19-4.27 (m, 3 H), 3.76-3.86 (m, 0.7 H), 3.38-3.49 (m, 0.3 H), 2.77-3.28 (m, 2 H), 2.34-2.46 (m, 6 H)	444.2 [M+H]+	100%
927	(CD3OD) δ 8.21-8.38 (m, 1 H), 7.70 (s, 1 H), 7.43-7.53 (m, 1 H), 6.70-7.10 (m. 3 H), 6.55-6.68 (m, 1 H), 5.06 (br dd, 1 H), 4. 17-4.28 (m, 3 H), 3.66-3.84 (m, 0.7 H), 3.38-3.49 (m, 0.3 H), 2.96-3.27 (m, 1 H), 2.80-2.90 (m, 1 H), 2.33-2.46 (m, 6 H)	444.2 [M+H]+	100%
928	(CD3OD) δ 8.25-8.39 (m, 1 H), 7.70 (s, 1 H), 7.43-7.51 (m, 1 H), 6.79-7.15 (m, 3 H), 6.73-6.78 (m, 1 H), 5.09 (dd, 0.6 H), 4.20-4.25 (m, 3 H). 3.65-3.85 (m, 1 H), 3.35-3.46 (m, 0.4 H), 2.96-3.26 (m, 1 H), 2.79-2.88 (m, 1 H), 2.29-2.48 (m, 3 H)	448.2 [M+H]+	100%
929	(CD3OD) δ 8.26-8.41 (m, 1 H), 7.70 (s, 1 H), 7.38-7.59 (m, 1 H), 6.78-7. 12 (m, 3 H), 6.73-6.78 (m, 1 H). 4.92-5.12 (m, 1 H). 4.18-4.28 (m, 3 H), 3.72-3.88 (m, 0.7 H), 3.37-3.50 (m, 0.3 H), 2.77-3.26 (m, 2 H), 2.28-2.45 (m, 3 H)	448.2 [M+H]+	100%
930	(CD3OD) δ 8.30 (br d, 1 H), 7.63-8.08 (m, 3 H), 6.36-7.44 (m, 5 H), 4.53 (br s, 1 H), 3.82 (br s, 4 H), 2.72-3.26 (m, 2 H), 2.45 (s, 3 H)	479.2 [M+H]+	99.3%
931	(CD3OD) δ 8.30 (d, 1 H), 7.51-8.10 (m, 3 H), 6.46-7.40 (m, 5 H), 4.51 (br s, 1 H), 3.82 (br s, 4 H), 2.78-3.26 (m, 2 H), 2.45 (s, 3 H)	479.3 [M+H]+	97.7%
932	(CD3OD) δ 8.63-8.72 (m, 1 H), 8.43 (d, 1 H), 8.25 (d, 1 H), 7.71 (s. 1 H), 7.58-7.65 (m. 2 H), 6.91-7.04 (m. 2 H), 6.77-6.83 (m, 1 H), 4.93-5.09 (m. 1 H), 3.98 (s, 3 H), 3.37-3.83 (m, 1 H), 2.96-3.25 (m. 1 H), 2.85 (br dd, 1 H)	511.2 [M+H]+	1 00%
933	(CD3OD) δ 8.62-8.72 (m, 1 H), 8.43 (d, 1 H), 8.24 (d, 1 H), 7.71 (s, 1 H), 7.56-7.66 (m, 2 H), 6.89-7.05 (m, 2 H), 6.74-6.83 (m, 1 H), 4.93-5.09 (m, 1 H), 3.98 (s, 3 H), 3.37-3.83 (m, 1 H), 2.96-3.25 (m, 1 H). 2.79-2.91 (m, 1 H)	511.2 [M+H]+	94.9%
934	(CD3OD) δ 8.62-8.72 (m, 1 H), 7.97 (s, 1 H), 7.76-7.87 (m. 1 H), 7.59-7.71 (m, 2 H), 6.88-7.06 (m, 2 H), 6.76-6.84 (m, 1 H), 4.92-5.13 (m, 1 H), 4.07-4.11 (m, 3 H), 3.37-3.83 (m, 1 H), 2.96-3.23 (m, 1 H), 2.78-2.90 (m, 1 H)	484.2 [M+H]+	1 00%
935	(CD3OD) δ 8.63-8.73 (m, 1 H), 7.97 (s, 1 H), 7.79-7.88 (m, 1 H), 7.70 (s. 1 H), 7.59-7.66 (m. 1 H), 6.91-7.02 (m. 2 H), 6.76-6.83 (m, 1 H), 4.93-5.13 (m, 1 H), 4.08-4.11 (m, 3 H), 3.38-3.83 (m, 1 H). 2.96-3.24 (m, 1 H). 2.79-2.89 (m, 1 H)	484.2 [M+H]+	92.0%
936	(CD3OD) δ 8.33 (dd. 1 H), 7.83 (d. 0.2 H). 7.64-7.75 (m, 1.5 H), 7.37-7.55 (m, 1.8 H), 7.21 (t, 1 H), 7.03-7.15 (m, 1 H), 6.99 (s, 0.5 H), 6.58-6.76 (m. 1.6 H). 6.43 (s, 0.4 H), 4.92-5.06 (m, 1 H). 3.85-3.98 (m, 0.5 H), 3.33-3.41 (m, 0.5 H), 2.80-3.24 (m, 2 1-1). 2.44-2.72 (m, 3 H)	466.2 [M+H]+	1 00%
937	(CD3OD) δ 8.33 (dd. 1 H), 7.83 (d. 0.3 H). 7.62-7.75 (m, 1.5 H), 7.37-7.57 (m, 1.7 H), 7.21 (t, 1 H), 7.03-7.17 (m, 1 H), 6.99 (s, 0.5 H), 6.57-6.79 (m. 1.6 H). 6.44 (s, 0.4 H), 4.93-5.07 (m, 1 H). 3.86-3.98 (m, 0.5 H), 3.34-3.41 (m, 0.5 H), 2.80-3.24 (m, 2 1-1). 2.44-2.72 (m, 3 H)	466.2 [M+H]+	99.5%
938	(CD3OD) δ 7.68 (d, 1 H), 7.27-7.53 (m, 1.4 H), 7.04-7.16 (m. 1 H). 6.96 (s, 0.6 H), 6.39-6.76 (m, 2 H). 4.90-4.97 (m, 1 H). 3.89 (br t, 1 H), 2.79-3.20 (m, 2 H), 2.53-2.72 (m, 3 H), 1.81-1.95 (m, 6 H)	410.2 [M+H]+	1 00%
939	(CD3OD) δ 7.68 (d, 1 H), 7.29-7.52 (m, 1.4 H), 7.06-7.17 (m, 1 H), 6.96 (s, 0.6 H), 6.36-6.75 (m, 2 H), 4.90-4.94 (m, 1 H), 3.82-3.96 (m, 1 H), 2.78-3.20 (m, 2 H), 2.54-2.71 (m, 3 H), 1.80-1.95 (m, 6 H)	410.2 [M+H]+	99.1%
940	(CD3OD) δ 7.66 (d, 1 H), 7.32-7.51 (m, 1.4 H), 7.06-7.16 (m, 1 H), 6.93 (br s, 0.6 H), 6.36-6.76 (m, 2 H), 4.97 (br dd, 1 H), 3.78-3.95 (m, 0.5 H), 3.33-3.38 (m. 0.5 H), 2.75-3.19 (m, 2 H), 2.55-2.73 (m, 3 H), 2.31 (tq, 1 H), 1.13-1.32 (m, 4 H)	390.2 [M+H]+	1 00%
941	(CD3OD) δ 7.66 (d, 1 H), 7.28-7.54 (m, 1.4 H), 7.04-7.17 (m, 1 H), 6.94 (s, 0.6 H), 6.38-6.77 (m, 2 H), 4.97 (br dd, 1 H), 3.81-3.93 (m, 0.5 H), 3.34-3.40 (m, 0.5 H), 2.76-3.17 (m, 2 H), 2.56-2.72 (m, 3 H), 2.24-2.37 (m, 1 1-1). 1.10-1.40 (m, 4 H)	390.2 [M+H]+	99.9%
942	(CD3OD) δ 8.62-8.72 (m, 1 H), 7.69 (s, 1 H), 7.59-7.65 (m, 1 H), 6.84-7.04 (m, 2 H), 6.70-6.80 (m, 1 H), 4.89-5.05 (m. 1 H), 3.35-3.77 (m, 1 H), 2.92-3.16 (m, 1 H), 2.76-2.86 (m, 1 H), 2.24-2.36 (m, 1 H). 1.18-1.29 (m, 4 H)	444.2 [M+H]+	98.9%
943	(CD3OD) δ 8.62-8.72 (m, 1 H), 7.57-7.73 (m, 2 H), 6.85-7.03 (m, 2 H), 6.67-6.81 (m, 1 H), 4.89-5.05 (m, 1 H), 3.34-3.76 (m, 1 H), 2.91-3.18 (m, 1 H), 2.76-2.86 (m, 1 H), 2.25-2.36 (m, 1 H), 1.19-1.29 (m. 4 H)	444.2 [M+H]+	94.9%
944	(CD3OD) δ 8.64-8.72 (m, 1 H), 7.76-7.81 (m, 1 H), 7.58-7.66 (m, 1 H), 6.88-7.07 (m, 2 H), 6.73-6.82 (m, 1 H), 4.90-5.04 (m, 1 H), 3.35-3.78 (m, 1 H), 2.95-3.19 (m, 1 H), 2.79-2.87 (m, 1 H), 2.63 (s, 3 H)	418.2 [M+H]+	1 00%
945	(CD3OD) δ 8.63-8.72 (m, 1 H), 7.77-7.86 (m, 1 H), 7.58-7.66 (m, 1 H), 6.89-7.04 (m, 2 H), 6.73-6.83 (m, 1 H), 4.90-5.06 (m, 1 H), 3.35-3.77 (m, 1 H), 2.94-3.19 (m, 1 H), 2.78-2.88 (m, 1 H), 2.63 (s, 3 H)	418.2 [M+H]+	92.1%
946	(CD3OD) δ 8.26-8.38 (m, 1 H), 7.68 (s, 1 H), 7.45 (s, 0.3 H), 6.87-7.01 (m, 1.7 H), 6.78-6.87 (m. 1H), 6.65-6.75 (m. 1 H), 4.99 (dd, 1 H), 3.72 (ddd, 0.7 H), 3.35-3.42 (m, 0.3 H), 2.74-3.20 (m. 2 H), 2.26-2.38 (m. 1 H), 1.18-1.30 (m. 4 H)	394.2 IM+Hl′	99.3%
947	(CD3OD) δ 8.27-8.38 (m, 1 H), 7.69 (s. 1 H), 7.45 (s, 0.3 H), 6.87-7.02 (m, 1.7 H), 6.78-6.87 (m, 1 H), 6.63-6.77 (m, 1 H), 4.99 (dd. 1 H), 3.63-3.80 (m. 0.7 H). 3.37-3.44 (m, 0.3 H), 2.77-3.17 (m, 2 H), 2.24-2.40 (m, 1 H), 1.20-1.32 (m, 4 H)	394.2 [M+H]+	98.3%
948	(CD;OD) δ 8.62-8.72 (m, 1 H), 7.69 (s, 1 H), 7.58-7.65 (m, 1 H), 6.93-7.44 (m, 2 H), 6.71-6.80 (m, 1 H), 4.90-5.03 (m, 1 H). 3.35-3.76 (m, 1 H), 2.80-3.15 (m, 2 H), 1.45-1.49 (m, 9 H)	460.2 [M+H]+	99.3%
949	(CD3OD) δ 8.63-8.71 (m, 1 H), 7.69 (s, 1 H), 7.59-7.65 (m, 1 H), 6.94-7.44 (m, 2 H), 6.72-6.81 (m, 1 H), 4.90-5.03 (m. 1 H), 3.35-3.76 (m, 1 H), 2.80-3.17 (m, 2 H), 1.45-1.49 (m, 9 H)	460.2 [M+H]+	98.2%
950	(CD3OD) δ 8.70 (d, 1 H), 7.56-7.76 (m, 2 H), 7.41 (br s, 0.4 H), 6.92-7.03 (m, 1.6 H), 6.69-6.83 (m, 1 H), 4.98 (br dd, 1 H), 3.69-3.79 (m, 0.6 H), 3.35 (s, 0.4 H), 2.81-3.20 (m, 2 H), 1.75-2.02 (m, 6 H)	464.2 [M+H]	97.2%
951	(CD3OD) δ 8.69 (d. 1 H), 7.57-7.76 (m. 2 H), 7.41 (s, 0.4 H), 6.92-7.03 (m, 1.6 H), 6.71-6.81 (m, 1 H), 4.98 (br dd, 1 H), 3.69-3.79 (m, 0.6 H), 3.34-3.41 (m, 0.4 H), 2.79-3.21 (m, 2 H), 1.79-1.98 (m. 6 H)	464.2 [M+H]+	94.7%
952	(CD3OD) δ 8.40 (s. 1 H), 8.10 (d, 1 H), 7.79-7.91 (m, 1 H), 7.66-7.75 (m, 1 H), 7.54-7.63 (m, 0.5 H), 7.24-7.38 (m, 2 H), 6.86 (s, 1 H), 6.66 (s. 0.5 H). 5.08-5.14 (m, 0.5 H), 4.94 (br s, 1 H), 4.02 (d, 3 H), 3.79-3.98 (m, 0.5 H), 2.99 (s, 1 H), 2.82-2.91 (m, 1 H)	484.2 [M+H]+	1 00%
953	(CD3OD) δ 8.39 (s, 1 H), 8.09 (d, 1 H), 7.78-7.89 (m, 1 H), 7.65-7.74 (m. 1 H), 7.54-7.61 (m, 0.5 H). 7.32 (br d, 2 H), 6.85 (s, 1 H), 6.65 (s, 0.5 H), 5.10 (br dd, 0.5 H), 4.93-5.01 (m, 1 H), 4.00 (d. 3 H), 3.95 (br dd, 0.5 H), 2.94-3.18 (m, 1 H), 2.85 (br d, 1 H)	484.2 [M+H]+	99.2%
954	(CD3OD) δ 8.23-8.40 (m, 1 H), 7.96-8.04 (m, 1 H), 7.53-7.76 (m, 1.3 H), 6.91-7.06 (m, 1.7 H), 6.65-6.89 (m, 2 H), 5.03-5.26 (m, 1 H), 3.69-3.93 (m, 3.7 H), 3.36-3.48 (m, 0.3 H), 2.92-3.25 (m, 1 H), 2.79-2.90 (m, 1 H), 2.57-2.75 (m, 3 H)	448.2 [M+H]+	98.7%
955	(CD3OD) δ 8.24-8.40 (m, 1 1-1). 7.90-8.04 (m, 1 H), 7.51-7.74 (m, 1.4 H), 6.89-7.01 (m, 1.6 H), 6.64-6.88 (m, 2 H), 5.05-5.22 (m, 1 H), 3.67-3.91 (m, 3.5 1-1). 3.35-3.48 (m, 0.5 H), 2.91-3.24 (m. 1 H), 2.74-2.90 (m. 1 H), 2.58-2.72 (m. 3 H)	448.2 [M+H]+	96. 7%
956	(CD3OD) δ 9.40-9.53 (m, 1 H), 8.82-8.91 (m, 2 H), 8.22-8.37 (m, 1 H), 7.73 (s, 1 H), 7.52 (s, 0.3 H), 6.97-7.03 (m, 1.7 H), 6.73-6.88 (m, 1 H), 6.59-6.68 (m, 1 H), 5.02 (br dd, 0.5 H), 3.77-3.89 (m, 0.5 H), 3.46 (td, 0.5 H), 2.97-3.28 (m, 1.5 H), 2.80-2.93 (m, 1 H), 2.43-2.49 (m, 3 H)	428.2 [M+H]+	99.7%
957	(CD3OD) δ 9.34-9.52 (m, 1 H), 8.84 (br d, 2 H), 8.19-8.36 (m, 1 H). 7.70 (s, 1 H), 7.50 (s, 0.3 H), 6.96-7.01 (m, 1.7 H), 6.74-6.83 (m, 1 H), 6.59-6.66 (m, 1 H), 5.00 (br dd, 0.5 H), 3.75-3.87 (m, 0.5 H), 3.45 (td, 0.5 H), 2.95-3.27 (m, 1.5 H), 2.80-2.90 (m, 1 H), 2.42-2.46 (m, 3 H)	428.2 [M+H]+	99.3%
958	(CD3OD) δ 8.42 (s, 1 H), 7.72 (s, 1 H), 7.60 (br d, 1 H), 7.12-7.31 (m, 2 H), 7.01-7.05 (m, 1 H), 6.56-6.93 (m, 2 H), 4.24-4.43 (m, 1 H), 3.77-3.95 (m, 1 H), 2.78-3.08 (m, 2 H)	419.1 [M+H]+	99.6%
959	(CD3OD) δ 8.44 (s, 1 H), 7.71 (s, 1 H), 7.62 (br d, 1 H), 7.15-7.31 (m, 2 H), 7.03-7.06 (m, 1 H), 6.51-6.95 (m, 2 H), 4.25-4.43 (m, 1 H), 3.73-3.98 (m. 1 H), 2.80-3.11 (m. 2 H)	419.1 [M+H]+	99.9%
960	(CD3OD) δ 7.67 (s, 1 H), 7.61 (br d, 1 H), 6.98-7.28 (m, 3 H). 6.78 (br s, 2 H), 4.26-4.48 (m, 1 H), 3.75-4.00 (m, 0.5 H), 3.35-3.52 (m. 0.5 H). 2.77-3.16 (m, 2 H). 1.57-1.70 (m, 6 H)	477. 1 [M+H]+	100%
961	(CD3OD) δ 7.67 (s, 1 H), 7.60 (br d, 1 H), 6.99-7.28 (m, 3 H), 6.62-6.90 (m, 2 H), 4.27-4.41 (m, 1 H), 3.80-3.97 (m, 0.5 H), 3.37-3.51 (m, 0.5 H), 2.77-3.16 (m. 2 H), 1.58-1.69 (m, 6 H)	477.1 [M+H]+	98.3%
962	(CD3OD) δ 9.38-9.55 (m, 1 H), 8.81-8.95 (m, 2 H), 8.28-8.38 (m, 1 H), 7.70 (s, 1 H), 6.70-7.05 (m, 4 H), 5.03 (br dd, 0.5 H), 3.75-3.85 (m, 0.5 H), 3.43 (td, 0.5 H), 2.94-3.28 (m, 1.5 H), 2.80-2.91 (m, 1 H)	432.1 [M+H]+	100%
963	(CD3OD) δ 9.45-9.52 (m, 1 H), 8.78-8.90 (m, 2 H), 8.26-8.44 (m, 1 H), 7.71 (s, 1 H), 6.74-7.08 (m, 4 H), 5.03 (br dd, 0.5 H). 3.72-3.88 (m, 0.5 H), 3.38-3.51 (m, 0.5 H), 2.98-3.26 (m, 1.5 H), 2.86 (br d, 1 H)	432.1 [M+H]+	99.7%
964	(CD3OD) δ 8.35 (dd, 1 H), 7.62-7.84 (m, 2.5 H), 7.50-7.58 (m, 1 H), 7.14-7.25 (m, 2 H), 6.98-7.07 (m, 1.5 H), 6.60-6.84 (m, 1 H), 5.07 (br dd, 1 H), 3.89-3.97 (m, 0.5 H), 3.37-3.44 (m, 0.5 H), 2.85-3.24 (m, 2 H)	486.1 [M+H]+	99. 7%
965	(CD3OD) δ 8.30-8.38 (m, 1 H), 7.59-7.87 (m, 2.5 H), 7.49-7.58 (m, 1 H), 7.12-7.25 (m, 2 H), 6.97-7.07 (m, 1.5 H), 6.61-6.84 (m, 1 H), 5.07 (br dd, 1 H), 3.87-4.00 (m, 0.6 H), 3.38-3.44 (m, 0.4 H), 2.84-3.25 (m, 2 H)	486.1 [M+H]+	99.5%
966	(CDCl3) δ 8.06-8.22 (m, 1 H), 7.53-7.63 (m, 1 H), 7.43 (s, 0.3 H), 7.30-7.38 (m, 1 H), 6.95 (s, 0.7 H), 6.93 (br d, 1 H), 6.50 (s. 1 H), 5.17 (br dd, 0.7 H), 4.94 (br dd, 0.3 H), 3.76-3.85 (m, 0.7 H), 3.44-3.51 (m, 0.3 H), 3.10-3.20 (m, 0.7 H), 2.94-3.05 (m, 0.5 H), 2.81 (br d, 0.5 H), 2.73 (br d, 0.3 H), 2.22-2.29 (m, 4 H), 1.19-1.28 (m, 4 H)	390.2 [M+H]+	100%
967	(CDCl3) δ 8.08-8.21 (m, 1 H), 7.57-7.62 (m, 1 H), 7.45 (s. 0.3 H), 7.31-7.38 (m, 1 H), 6.96 (s, 0.7 H), 6.93 (br d, 1 H), 6.51 (s, 1 H), 5.18 (dd, 0.7 H), 4.96 (dd, 0.3 H), 3.76-3.87 (m, 0.7 H), 3.45-3.54 (m, 0.3 H), 3.11-3.21 (m, 0.7 H), 2.93-3.06 (m, 0.5 H), 2.82 (br d, 0.5 H), 2.74 (br d, 0.3 H), 2.26-2.31 (m, 4 H), 1.21-1.28 (m, 4 H)	390.2 [M+H]+	100%
968	(CD3OD) δ 7.71 (d, 1 H), 7.56-7.65 (m, 1 H), 7.46 (s, 0.4 H), 7.14-7.23 (m, 1 H), 7.02-7.08 (m, 1 H), 6.97 (s, 0.6 H), 6.60-6.83 (m, 1 H), 4.95-5.03 (m, 1 H), 3.83-3.96 (m, 0.6 H), 3.36-3.43 (m, 0.4 H). 2.82-3.18 (m, 2 H), 1.87-1.94 (m, 6 H)	430.2 [M+H]+	99.6%
969	(CD3OD) δ 7.59 (d, 1 H), 7.43-7.52 (m, 1 H), 7.33 (s. 0.4 H), 7.02-7.10 (m, 1 H), 6.92 (d, 1 H), 6.85 (s, 0.6 H), 6.50-6.69 (m, 1 H), 4.85-4.90 (m, 1 H), 3.72-3.82 (m, 0.6 H), 3.24-3.31 (m, 0.4 H), 2.71-3.05 (m, 2 H), 1.74-1.82 (m, 6 H)	430.1 [M+H]+	99.5%
970	(CD3OD) δ 7.99-8.14 (m, 1 H), 7.70 (s, 1 H), 6.89-7.47 (m, 1 H), 6.77-6.83 (m, 1 H), 6.52-6.72 (m, 2 H), 4.97 (br d, 1 H), 3.89-4.02 (m, 3 H), 3.37-3.82 (m, 1 H), 2.75-3.23 (m, 2 H), 1.82-2.00 (m, 6 H)	426.2 [M+H]+	98.8%
971	(CD3OD) δ 7.87-8.04 (m, 1 H), 7.59 (s, 1 H), 6.78-7.37 (m, 1 H), 6.68 (q, 1 H), 6.38-6.58 (m, 2 H), 4.85 (br d, 1 H), 3.79-3.90 (m, 3 H), 3.25-3.71 (m, 1 H), 2.65-3.12 (m, 2 H), 1.72-1.84 (m, 6 H)	426.1 [M+H]+	98.4%
972	(CD3OD) δ 8.40-8.50 (m, 1 H), 7.99-8.03 (m, 1 H), 7.71 (s, 1 H), 7.53-7.66 (m, 1.3 H), 7.16-7.26 (m, 1 H), 6.97 (s, 0.7 H), 6.83-6.92 (m, 1 H), 6.57-6.67 (m, 1 H), 4.99-5.12 (m, 1 H), 3.90 (s, 3 H), 3.73-3.84 (m. 0.7 H), 3.42 (td, 0.3 H), 2.96-3.26 (m, 1 H), 2.80-2.91 (m, 1 H), 2.66-2.72 (m, 3 H)	430.2 [M+H]+	100%
973	(CD3OD) δ 8.39-8.50 (m, 1 H), 8.00-8.03 (m, 1 H), 7.71 (br s, 1 H), 7.56-7.65 (m, 1.3 H), 7.17-7.25 (m, 1 H), 6.97 (s, 0.7 H), 6.83-6.92 (m, 1 H), 6.57-6.68 (m, 1 H), 5.09 (br dd, 1 H), 3.91 (s, 3 H), 3.72-3.84 (m, 0.7 H), 3.42 (td, 0.3 H), 2.96-3.26 (m. 1 H), 2.86 (br d, 1 H), 2.6-2.72 (m, 3 H)	430.2 [M+H]+	98.6%
974	(CD3OD) δ 8.79 (d, 1 H), 8.28-8.41 (m, 1 H), 8.10 (td, 1 H), 7.63-7.79 (m. 2 H), 7.42-7.60 (m, 1.5 H), 7.18-7.34 (m, 1 H), 7.00 (s, 0.5 H), 6.71-6.87 (m, 1 H), 6.54-6.70 (m, 1 H), 5.06 (br dd. 1 H), 3.79-3.93 (m. 0.6 H), 3.46 (td, 0.4 H), 2.98-3.29 (m, 1 H), 2.82-2.95 (m, 1 H)	431.1 [M+H]+	99.7%
975	(CD3OD) δ 8.79 (d, 1 H), 8.29-8.42 (m, 1 H), 8.11 (td, 1 H), 7.64-7.77 (m, 2 H), 7.40-7.59 (m, 1.4 H), 7.17-7.34 (m, 1 H), 7.00 (s, 0.6 H), 6.71-6.89 (m, 1 H), 6.59-6.70 (m. 1 H), 5.06 (br dd, 1 H), 3.80-3.96 (m, 0.5 H), 3.41-3.53 (m, 0.5 H), 2.95-3.28 (m, 1 H), 2.88 (dd, 1 H)	431.2 [M+H]+	97.2%
976	(CD3OD) δ 7.80 (dd, 1 H), 7.69 (d, 1 H), 7.49-7.62 (m, 1.5 H), 7.16 (dd, 1 H), 6.95-7.03 (m, 2.5 H), 6.60-6.78 (m, 1 H), 5.05 (br dd, 1 H), 4.02 (d, 3 H), 3.90 (ddd, 0.6 H), 3.33-3.41 (m, 0.4 H), 2.82-3.20 (m, 2 H)	450.1 [M+H]+	100%
977	(CD3OD) δ 7.80 (dd, 1 H), 7.70 (br d, 1 H), 7.50-7.63 (m, 1.5 H), 7.10-7.21 (m, 1 H), 6.94-7.04 (m, 2.5 H), 6.60-6.80 (m, 1 H), 5.05 (br dd, 1 H), 4.02 (d, 3 H), 3.84-3.95 (m, 0.6 H), 3.34-3.41 (m, 0.4 H), 2.82-3.21 (m, 2 H)	450.1 [M+H]+	100%
978	(CD3OD) δ 9.28-9.45 (m, 1 H), 8.64-8.86 (m. 2 H), 7.62 (br s, 1 H), 7.18-7.58 (m, 2 H), 6.82-7.18 (m, 2 H), 6.48-6.81 (m, 1 H), 4.82-5.00 (m, 1 H), 3.25-3.91 (m, 1 H), 2.72-3.16 (m, 2 H)	448.1 [M+H]+	98.7%
979	(CD3OD) δ 9.42-9.54 (m, 1 H), 8.76-8.91 (m, 2 H), 7.74 (br d, 1 H), 7.43-7.70 (m, 2 H), 6.98-7.23 (m, 2 H), 6.62-6.86 (m, 1 H), 4.94-5.11 (m, 1 H), 3.38-4.01 (m, 1 H), 2.84-3.28 (m, 2 H)	448.1 [M+H]+	96.9%
980	(CD3OD) δ 8.48-8.6-4 (m, 1 H), 7.69 (s, 1 H), 7.39-7.50 (m, 1.2 H), 7.08-7.13 (m, 0.4 H). 6.61-7.00 (m, 3.4 H), 5.00 (br dd, 1 H), 3.64-3.77 (m, 0.5 H), 3.39 (br d, 0.5 H), 2.77-3.18 (m, 2 H), 2.27-2.35 (m, 1 H), 1.19-1.31 (m, 4 H)	426.2 [M+H]+	100%
981	(CD3OD) δ 8.52-8.61 (m. 1 H), 7.69 (s, 1 H), 7.38-7.49 (m, 1.2 H), 7.07-7.15 (m, 0.4 H), 6.68-7.00 (m, 3.4 H), 5.00 (br dd, 1 H), 3.66-3.78 (m, 0.5 H), 3.34-3.40 (m, 0.5 H), 2.78-3.19 (m, 2 H), 2.25-2.36 (m, 1 H), 1.20-1.30 (m, 4 H)	426.2 [M+H]+	100%
982	(CD3OD) δ 8.62-8.69 (m, 1 H), 7.91-8.01 (m, 1 H), 7.68-7.80 (m, 2 H), 7.55-7.66 (m, 1 H), 7.48 (s, 0.4 H), 7.13-7.24 (m, 1 H), 6.97-7.08 (m. 1.6 H), 6.64-6.84 (m, 1 H), 4.98-5.10 (m, 1 H), 3.87-4.00 (m, 0.6 H), 3.38-3.48 (m, 0.4 H), 2.85-3.26 (m, 2 H)	465.1 [M+H]+	98.6%
983	(CD3OD) δ 8.64 (d, 1 H), 7.94 (br t, 1 H), 7.68-7.79 (m, 2 H), 7.55-7.65 (m, 1 H), 7.47 (s, 0.4 H), 7.17 (dt, 1 H), 6.95-7.07 (m, 1.6 H), 6.61-6.84 (m, 1 H), 4.98-5.04 (m, 1 H), 3.93 (br s, 0.6 H), 3.36-3.46 (m, 0.4 H), 2.84-3.22 (m, 2 H)	465.1 [M+H]+	96.2%
984	(CD3OD) δ 8.83-9.06 (m, 1 H), 8.37 (s, 1 H), 7.42-7.87 (m, 3.5 H), 7.19-7.33 (m, 1 H), 6.98 (s, 0.5 H), 6.80 (d, 0.5 H), 6.59-6.73 (m, 1.5 H), 5.12 (br dd, 1 H), 3.75-3.91 (m, 0.6 H), 3.39-3.48 (m, 0.4 H), 3.13-3.26 (m, 0.7 H), 3.02 (br t, 0.3 H), 2.87 (br d, 1 H)	470.2 [M+H]+	98.6%
985	(CD3OD) δ 8.84-9.10 (m, 1 H), 8.37 (s, 1 H), 7.42-7.88 (m, 3.5 H), 7.19-7.34 (m, 1 H), 6.98 (s. 0.5 H), 6.80 (d, 0.5 H), 6.57-6.74 (m, 1.5 H), 5.12 (br dd, 1 H), 3.79-3.91 (m, 0.7 H), 3.40-3.49 (m, 0.3 H), 3.12-3.24 (m, 1 H), 2.87 (br d, 1 H)	470.2 [M+H]+	95.7%
986	(CD3OD) δ 7.65-7.95 (m, 1 H), 7.21-7.52 (m, 2 H), 6.53-7.08 (m, 3 H), 4.99 (br d, 1 H), 3.38-3.88 (m, 1 H), 2.79-3.25 (m, 2 H), 1.79-2.01 (m, 6 H)	414.2 [M+H]+	99.4%
987	(CD3OD) δ 7.63-8.07 (m, 1 H), 7.20-7.53 (m, 2 H), 6.53-7.16 (m, 3 H), 4.97-5.02 (m, 1 H), 3.36-3.86 (m, 1 H), 2.80-3.25 (m, 2 H), 1.82-1.99 (m, 6 H)	414.2 [M+H]+	95.1%
988	(CD3OD) δ 8.19-8.35 (m, 1 H), 7.95-8.06 (m, 1 H), 7.52-7.74 (m, 1.4 H), 6.95-7.06 (m, 1.6 H), 6.55-6.86 (m, 2 H), 5.09 (br dd, 1 H), 3.70-3.99 (m, 3.7 H), 3.36-3.50 (m, 0.4 H), 2.94-3.28 (m, 1 H), 2.79-2.91 (m, 1 H), 2.60-2.74 (m, 3 H), 2.34-2.54 (m, 3 H)	444.2 [M+H]+	97.4%
989	(CD3OD) δ 8.18-8.34 (m, 1 H), 7.93-8.04 (m, 1 H), 7.48-7.76 (m, 1.4 H), 6.95-7.06 (m, 1.6 H), 6.51-6.85 (m, 2 H), 5.07 (br dd, 1 H), 3.66-3.93 (m, 3.7 H), 3.35-3.48 (m, 0.3 H), 2.94-3.23 (m, 1 H), 2.78-2.92 (m, 1 H), 2.58-2.71 (m, 3 H), 2.31-2.51 (m, 3 H)	444.2 [M+H]+	97.7%
990	(CD3OD) δ 8.46 (d, 1 H), 7.50-7.75 (m, 2 H), 7.18-7.24 (m, 1 H), 6.87 (td, 1.6 H), 6.33-6.72 (m, 1.4 H), 4.79 (br s. 0.4 H), 4.21 (br d, 0.6 H), 3.79 (br t, 0.6 H), 3.37-3.52 (m, 0.4 H), 2.91-3.21 (m, 1 H), 2.83 (br d, 1 H), 1.51-1.69 (m, 6 H)	427.2 [M+H]+	100%
991	(CD3OD) δ 8.46 (d, 1 H), 7.54-7.76 (m, 2 H), 7.20 (t, 1 H), 6.86 (td, 1.6 H), 6.32-6.69 (m, 1.4 H), 4.80 (br s, 0.3 H), 4.21 (br d, 0.7 H), 3.79 (br t, 0.7 H), 3.41 (br s, 0.3 H), 2.92-3.22 (m, 1 H), 2.83 (br d, 1 H), 1.55-1.70 (m, 6 H)	427.3 [M+H]+	95.9%
992	(CD3OD) δ 8.45 (br d, 1 H), 7.50-7.75 (m, 2 H), 7.10-7.28 (m, 1 H), 6.85 (br t, 1.5 H), 6.34-6.71 (m, 1.5 H), 4.27 (br d, 1 H), 3.34-3.91 (m, 1 H), 2.70-3.21 (m, 2 H), 2.37 (s, 3 H), 1.57-2.02 (m, 6 H)	416.2 [M+H]+	100%
993	(CD3OD) δ 8.44 (brd, 1 H), 7.49-7.75 (m, 2H), 7.18 (dd, 1 H), 6.36-6.92 (m, 3 H), 4.04-4.43 (m, 1 H), 3.35-3.84 (m, 1 H), 2.64-3.22 (m, 2 H), 2.37 (s, 3 H), 1.64-2.06 (m, 6 H)	416.3 [M+H]+	99.6%
994	(CD3OD) δ 8.46 (dd, 1 H), 7.69 (s, 1 H), 7.61 (br d, 1 H), 7.11-7.30 (m, 2 H), 6.80-7.05 (m, 2 H), 6.63 (s. 1 H), 4.39 (br d, 1 H), 3.73 (br s, 1 H), 2.74-3.27 (m, 2 H), 1.26-1.58 (m, 4 H)	441.2 [M+H]+	99.3%
995	(CD3OD) δ 8.34 (dd, 1 H), 7.57 (s, 1 H), 7.49 (br d, 1 H), 7.00-7.20 (m, 2 H), 6.68-6.92 (m. 2 H), 6.51 (s, 1 H). 4.13-4.37 (m, 1 H), 3.51-3.77 (m, 1 H), 2.65-3.12 (m, 2 H), 1.14-1.49 (m, 4 H)	441.2 [M+H]+	99.3%
996	(CD3OD) δ 8.42 (d, 1 H), 7.50-7.69 (m, 2 H), 7.17 (t, 1 H), 6.77-6.88 (m, 1.6 H), 6.29-6.64 (m, 1.4 H), 4.97-5.14 (m, 1 H), 4.75 (br d. 0.4 H). 4.12 (br d. 0.6 H). 3.74 (br t, 0.6 H), 3.38 (br s, 0.4 H), 2.90-3.13 (m, 1 H), 2.78 (br dd, 1 H), 1.55 (br d, 3 H)	459.2 [M+H]+	94.9%
997	(CD3OD) δ 8.46 (d, 1 H), 7.57-7.80 (m, 2 H), 7.21 (t, 1 H), 6.82-6.91 (m, 1.7 H), 6.38-6.67 (m, 1.3 H), 4.97-5.11 (m, 1 H), 4.74-4.83 (m, 0.4 H), 4.18 (br d, 0.6 H), 3.78 (br t, 0.6 H), 3.42 (br s, 0.4 H), 2.92-3.20 (m, 1 H), 2.83 (br dd, 1 H), 1.59 (br d, 3 H)	459.1 [M+H]+	97.0%
998	(CD3OD) δ 8.42 (d, 1 H), 7.51-7.70 (m, 2 H), 7.12-7.23 (m, 1 H), 6.79-6.89 (m, 1.6 H), 6.25-6.64 (m, 1.4 H), 4.94-5.11 (m, 1 H). 4.77 (br s, 0.4 H), 4.12 (br d, 0.6 H), 3.69-3.82 (m, 0.6 H), 3.38 (br s, 0.4 H), 2.89-3.16 (m, 1 H), 2.78 (br dd, 1 H), 1.55 (br d, 3 H)	459.2 [M+H]+	93.1%
999	(CD3OD) δ 8.46 (d, 1 H), 7.54-7.74 (m, 2 H), 7.21 (br t. 1 H), 6.87 (t, 1.7 H), 6.35-6.69 (m, 1.3 H), 4.97-5.05 (m, 1 H), 4.74-4.84 (m, 0.4 H), 4.16 (br d, 0.6 H), 3.74-3.93 (m. 0.6 H). 3.42 (br s, 0.4 H), 2.93-3.19 (m, 1 H), 2.82 (br dd, 1 H), 1.59 (br d, 3 H)	459.2 [M+H]+	98.8%
1000	(CD3OD) δ 8.34 (d, 1 H), 7.67 (s, 1 H), 6.96 (dd, 1 H), 6.47-6.87 (m, 3 H), 4.26-4.81 (m, 1 H), 3.35-3.78 (m, 1 H), 2.90-3.22 (m, 1 H), 2.80 (br d, 1 H), 2.37 (s, 3 H), 1.49-1.67 (m, 6 H)	425.0 [M+H]+	98.6%
1001	(CD3OD) δ 8.34 (d, 1 H), 7.67 (s, 1 H). 6.96 (dd, 1 H), 6.45-6.87 (m, 3 H), 4.27-4.84 (m, 1 H), 3.35-3.79 (m, 1 H), 2.66-3.22 (m, 2 H), 2.37 (s, 3 H), 1.49-1.70 (m, 6 H)	425.1 [M+H]+	99.8%
1002	(CD3OD) δ 8.69 (d, 1 H), 8.42 (s, 1 H), 7.70 (s, 1 H), 7.63 (d, 1 H), 7.10-7.31 (m, 1 H), 6.55-7.02 (m. 3 H), 4.33 (br s, 1 H), 3.73 (br s, 1 H), 2.73-3.14 (m, 2 H)	453.1 [M+H]+	99.7%
1003	(CD3OD) δ 8.69 (d, 1 H), 8.42 (s, 1 H), 7.69 (s, 1 H), 7.63 (d, 1 H), 7.11-7.29 (m, 1 H), 6.56-7.02 (m, 3 H), 4.35 (br d. 1 H), 3.73 (br s, 1 H), 2.74-3.15 (m. 2 H)	453.1 [M+H]+	99.2%
1004	(CD3OD) δ 8.44 (s, 1 H), 8.33 (d. 1 H), 7.72 (s, 1 H), 7.01-7.41 (m, 2 H), 6.61-6.92 (m, 2 H), 6.40-6.57 (m, 1 H), 4.26-4.84 (m, 1 H), 3.48-3.82 (m, 1 H), 3.08 (br s, 1 H), 2.81 (br d, 1 H), 2.38 (s, 3 H)	399.2 [M+H]+	99.7%
1005	(CD3OD) δ 8.44 (s, 1 H), 8.33 (d, 1 H), 7.69 (s, 1 H), 7.00-7.41 (m, 2 H), 6.61-6.92 (m, 2 H), 6.49 (br s, 1 H), 4.24-4.79 (m, 1 H), 3.41-3.83 (m, 1 H), 2.96-3.16 (m, 1 H), 2.81 (br d, 1 H), 2.38 (s, 3 H)	399.2 [M+I]+	98.5%
1006	(CD3OD) δ 8.74 (d, 1 H), 8.19-8.40 (m, 2 H), 8.06 (br s, 1 H), 7.59-7.78 (m, 2 H), 6.73-7.40 (m, 5 H), 4.80-4.86 (m, 0.4 H), 4.54 (br d, 0.6 H), 3.51-3.87 (m, 1 H), 2.99-3.32 (m, 1 H), 2.87 (br d, 1 H)	480.2 [M+H]+	100%
1007	(CD3OD) δ 8.74 (d, 1 H), 8.16-8.50 (m, 2 H), 8.05 (br d, 1 H), 7.54-7.78 (m, 2 H), 6.64-7.47 (m, 5 H), 4.78-4.87 (m, 0.4 H), 4.54 (br d, 0.6 H), 3.53-3.90 (m, 1 H), 2.96-3.30 (m, 1 H), 2.87 (br d, 1 H)	480.2 [M+H]+	99.3%
1008	(CD3OD) δ 7.87-8.40 (m, 3 H), 7.77 (br s, 1 H), 7.05-7.37 (m, 1 H), 6.94-7.04 (m, 1 H), 6.53-6.92 (m, 3 H), 4.50 (br s, 1 H), 3.98 (br s, 3 H). 3.77 (br s, 0.6 H), 3.49 (br s, 0.4 H), 2.71-3.26 (m, 2 H), 2.45 (s, 3 H)	479.2 [M+H]+	95.3%
1009	(CD3OD) δ 7.85-8.39 (m, 3 H), 7.71 (s, 1 H), 7.04-7.35 (m, 1 H), 6.99 (d, 1 H), 6.48-6.92 (m, 3 H), 4.32-4.72 (m, 1 H), 3.97 (br s, 3 H), 3.68-3.85 (m, 0.6 H), 3.46 (br d, 0.4 H), 2.73-3.23 (m, 2 H), 2.44 (s, 3 H)	479.2 [M+H]+	92.8%
1010	(CD3OD) δ 8.23-8.33 (m, 1 H), 7.43-7.71 (m, 1.3 H), 6.90-7.01 (m, 1.7 H), 6.72-6.81 (m, 1 H), 6.51-6.63 (m, 1 H), 4.90-4.97 (m, 1 H), 3.74 (ddd, 0.7 H), 3.38 (td, 0.3 H), 3.07-3.18 (m, 0.6 H), 2.90-3.02 (m, 0.4 H), 2.81 (br dd, 1 H), 2.60-2.65 (m, 3 H), 2.39-2.47 (m, 3 H)	364.2 [M+H]+	100%
1011	(CD3OD) δ 8.23-8.35 (m, 1 H), 7.72-7.83 (m, 1 H), 7.49 (s, 0.3 H), 6.92-7.01 (m. 1.7 H). 6.71-6.83 (m, 1 H). 6.49-6.65 (m, 1 H), 4.92-4.99 (m, 1 H), 3.74 (ddd, 0.7 H), 3.38 (td, 0.3 H), 3.07-3.19 (m, 0.7 H), 2.92-3.02 (m, 0.3 H), 2.77-2.87 (m, 1 H), 2.59-2.67 (m, 3 H), 2.38-2.48 (m, 3 H)	364.2 [M+H]+	100%
1012	(CD30D)δ 8.31 (d, 1 H), 7.69 (s, 1.3 H), 6.89-7.07 (m, 1.7 H), 6.74-6.86 (m. 1 H), 6.54-6.66 (m. 1 H), 5.21 (dd, 0.7 H). 4.92-5.04 (m, 1 H), 3.53-3.88 (m, 5 H), 3.39 (br dd, 0.3 H), 2.75-3.22 (m. 2 H), 2.40-2.49 (m. 3 H), 1.86-2.17 (m, 4 H)	451.3 [M+H]+	100%
1013	(CD3OD) δ 8.22-8.38 (m, 1 H), 7.57-7.80 (m, 1.3 H), 6.74-7.11 (m, 2.7 H), 6.56-6.70 (m, 1 H), 5.21 (dd, 0.7 H), 4.97 (br s, 1 H), 3.62-3.80 (m, 5 H). 3.37-3.45 (m, 0.3 H), 2.75-3.19 (m, 2 H), 2.41-2.51 (m, 3 H), 1.89-2.15 (m, 4 H)	451.3 [M+H]+	100%
1014	(CD3OD) δ 8.35 (d, 1 H), 7.54-782 (m, 1.4 H), 6.81-7.12 (m. 2.6 H), 6.75 (s, 1 H), 5.23 (dd, 0.6 H), 4.97 (br d, 1 H), 3.61-3.82 (m, 5 H), 3.35-3.47 (m, 0.6 H), 2.74-3.22 (m, 2 H), 1.76-2.24 (m, 4 H)	455.2 [M+H]+	100%
1015	(CD3OD) δ 8.23 (d, 1 H), 7.41-7.74 (m, 1.3 H), 6.68-6.91 (m, 2.7 H), 6.63 (s, 1 H), 5.11 (br dd, 1 H), 4.85 (br s, 1 H), 3.52-3.68 (m, 5 H), 3.24-3.30 (m, 0.6 H), 2.61-3.09 (m, 2 H), 1.74-2.01 (m, 4 H)	455.2 |M+H]+	99.0%
1016	(CD3OD) δ 8.20-8.33 (m, 1 H), 7.51-7.73 (m, 2.3 H), 7.03-7.09 (m, 1 H), 6.93-7.01 (m, 1.7 H), 6.71-6.83 (m, 1 H), 6.54-6.67 (m, 1 H), 5.04 (dd, 1 H), 4.26-4.36 (m. 3 H), 3.79 (ddd. 0.7 H). 3.35-3.52 (m, 0.3 H), 2.76-3.25 (m, 2 H), 2.36-2.51 (m, 3 H)	430.2 [M+H]+	99.5%
1017	(CD3OD) & 8.20-8.33 (m, 1 H), 7.48-7.75 (m, 2.3 H), 7.04-7.11 (m, 1 H), 6.91-7.03 (m, 1.7 H), 6.71-6.83 (m, 1 H), 6.53-6.67 (m, 1 H), 4.98-5.12 (m, 1 H), 4.24-4.37 (m, 3 H), 3.71-3.86 (m, 0.7 H), 3.36-3.52 (m. 0.3 H), 2.73-3.26 (m, 2 H), 2.37-2.49 (m, 3 H)	430.2 [M+H]+	99.4%
1018	(CD3OD) δ 8.26-8.37 (m, 1 H), 7.49-7.73 (m, 2.3 H), 7.05-7.11 (m, 1 H), 6.90-7.02 (m, 1.7 H), 6.78-6.87 (m, 1 H), 6.72-6.78 (m, 1 H), 5.07 (dd, 1 H), 4.28-4.33 (m, 3 H), 3.78 (ddd, 0.7 H), 3.41 (td, 0.3 H), 2.75-3.26 (m, 2 H)	434.2 [M+H]+	99.3%
1019	(CD3OD) δ 8.25-8.38 (m, 1 H), 7.51-7.73 (m, 2.3 H), 7.05-7.11 (m, 1 H), 6.91-7.02 (m, 1.7 H), 6.78-6.87 (m, 1 H), 6.72-6.78 (m, 1 H), 5.07 (dd, 1 H), 4.25-4.36 (m, 3 H), 3.72-3.84 (m, 0.7 H), 3.36-3.48 (m, 0.3 H), 2.77-3.25 (m, 2 H)	434.2 [M+H]+	99.2%
1020	(CD3OD) δ 7.68 (d, 1 H), 7.35-7.54 (m, 1.4 H), 7.04-7.19 (m, 1 H), 6.96 (s, 0.6 H), 6.67-6.75 (m, 1 H), 6.42-6.61 (m, 1 H), 4.92-4.99 (m, 1 H), 3.82-3.94 (m, 0.5 H), 3.34-3.40 (m, 0.5 H), 2.76-3.20 (m, 2 H), 2.57-2.70 (m, 3 H), 1.47 (d, 9 H)	406.2 [M+H]+	98.7%
1021	(CD3OD) δ 7.68 (d, 1H), 7.33-7.53 (m, 1.4 H), 7.05-7.18 (m, 1 H), 6.95 (s, 0.6 H), 6.66-6.75 (m, 1 H), 6.40-6.63 (m, 1 H), 4.92-4.99 (m, 1 H), 3.87 (br t, 0.5 H), 3.34-3.42 (m, 0.5 H), 2.77-3.19 (m, 2 H), 2.55-2.72 (m, 3 H), 1.47 (d, 9 H)	406.3 [M+H]+	95.3%
1022	(CD3OD) δ 8.20-8.33 (m, 1 H), 7.69 (s, 1 H), 7.41 (s, 0.3 H), 6.91-7.04 (m, 1.7 H), 6.73-6.82 (m, 1 H), 6.50-6.66 (m, 1 H), 4.95 (br dd, 1 H), 3.69-3.78 (m, 0.5 H), 3.34-3.43 (m, 0.5 H), 2.92-3.20 (m, 1 H), 2.82 (br dd, 1 H), 2.38-2.50 (m, 3 H), 1.41-1.56 (m, 9 H)	406.2 [M+H]+	100%
1023	(CD3OD) δ 8.22-8.32 (m, 1 H), 7.71-7.78 (m, 1 H), 7.42 (s, 0.3 H), 6.90-7.03 (m, 1.7 H) 6.72-6.83 (m, 1 H), 6.49-6.66 (m, 1 H), 4.96 (dd, 1 H), 3.67-3.80 (m, 0.6 H), 3.38 (td, 0.4 H), 2.90-3.21 (m, 1 H), 2.83 (br dd, 1 H), 2.36-2.50 (m, 3 H), 1.45-1.50 (m, 9 H)	406.2 [M+H]+	99.6%
1024	(CD3OD) δ 8.27-8.36 (m, 1 H), 7.69 (s, 1 H), 7.41 (s, 0.4 H), 6.91-7.00 (m, 1.6 H), 6.78-6.88 (m, 1 H), 6.66-6.77 (m, 1 H), 4.94-4.99 (m, 1 H), 3.70-3.82 (m, 0.7 H), 3.37 (br s, 0.3 H), 2.83 (br dd, 2 H), 1.83-1.95 (m, 6 H)	414.2 [M+H]+	96.1%
1025	(CD3OD) δ 8.26-8.40 (m, 1 H), 7.69 (s, 1 H), 7.41 (s, 0.4 H), 6.92-7.00 (m, 1.6 H), 6.79-6.87 (m, 1 H), 6.66-6.76 (m, 1 H), 4.93-5.00 (m, 1 H), 3.75 (br s, 1 H), 2.79-3.21 (m, 2 H), 1.79-1.95 (m, 6 H)	414.2 [M+H]+	95.0%
1026	(CD3OD) δ 8.25-8.38 (m, 1 H), 7.69 (s, 1 H), 7.40 (br s, 0.3 H), 6.89-7.02 (m, 1.7 H), 6.78-6.88 (m, 1 H), 6.63-6.77 (m, 1 H), 4.91-5.03 (m, 1 H), 3.66-3.80 (m, 0.7 H), 3.35-3.44 (m, 0.3 H), 2.77-3.21 (m, 2 H), 1.45-1.51 (m, 9 H)	410.2 [M+H]+	100%
1027	(CD3OD) δ 8.27-8.38 (m, 1 H), 7.69 (s, 1 H), 7.40 (br s, 0.3 H), 6.89-7.01 (m, 1.7 H), 6.78-6.87 (m, 1 H), 6.62-6.78 (m, 1 H), 4.90-5.01 (m, 1 H), 3.65-3.81 (m, 0.7 H), 3.35-3.42 (m, 0.3 H), 2.74-3.19 (m, 2 H), 1.44-1.52 (m, 9 H)	410.2 [M+H]+	100%
1028	(CD3OD) δ 8.78 (t, 1 H), 8.31 (d, 1 H), 8.04-8.16 (m, 1 H), 7.80-7.91 (m, 1 H), 7.65-7.75 (m, 2 H), 7.54-7.61 (m, 0.5 H), 7.29 (br s, 2H), 6.88 (s, 1 H), 6.68 (s, 0.5 H), 4.94-5.08 (m, 1 H), 3.90-4.07 (m, 0.5 H), 3.34-3.37 (m, 0.5 H), 2.84-3.26 (m, 2 H)	481.2 [M+H]+	100%
1029	(CD3OD) δ 8.77 (t, 1 H), 8.30 (d, 1 H), 8.04-8.13 (m, 1 H), 7.78-7.90 (m, 1 H), 7.63-7.74 (m, 2 H), 7.57 (s, 0.5 H), 7.22-7.36 (m, 2 H), 6.85-7.01 (m, 1 H), 6.67 (s, 0.5 H), 4.93-5.04 (m, 1 H), 3.97 (br s, 0.5 H), 3.33-3.38 (m, 0.5 H), 2.83-3.25 (m, 2 H)	481.2 [M+H]+	99.8%
1030	(CD3OD) δ 7.76-7.87 (m, 2 H), 7.69 (br d, 1 H), 7.58 (s, 0.5 H), 7.18-7.34 (m, 2 H), 6.82-6.99 (m, 2 H), 6.66 (s, 0.5 H), 4.96-5.08 (m, 1 H), 4.01 (d. 3.8 H), 3.36 (br d, 0.2 H), 3.17 (br s, 0.5 H), 2.96 (br dd, 0.5 H), 2.85 (br d, 1 H)	484.2 [M+H]+	100%
1031	(CD3OD) δ 7.77-7.88 (m, 2 H), 7.54-7.59 (m, 1 H), 7.58 (s, 0.5 H), 7.20-7.34 (m, 2 H), 6.84-6.97 (m, 2 H), 6.66 (s, 0.5 H), 4.92-5.07 (m, 1 H), 4.01 (d, 3.8 H), 3.32-3.37 (m, 0.2 H), 3.10-3.21 (m, 0.5 H), 2.98 (s, 0.5 H), 2.81-2.89 (m, 1 H)	484.2 [M+H]+	100%
1032	(CD3OD) δ 7.97 (d, 1 H), 7.80-7.90 (m, 2 H), 7.66-7.75 (m, 1 H), 7.54 (s, 0.5 H), 7.23-7.36 (m, 2 H), 6.85-6.99 (m, 1 H), 6.66 (s, 0.5 H), 5.08 (br dd, 0.5 H), 4.93-4.97 (m, 1 H), 4.09 (s, 3 H), 3.90-4.00 (m, 0.5 H), 2.94-3.04 (m, 1 H), 2.82-2.90 (m, 1 H)	484.2 [M+H]+	100%
1033	(CD3OD) δ 7.97 (d, 1 H), 7.80-7.89 (m, 2 H), 7.79 (s, 1 H), 7.55 (s, 0.5 H), 7.22-7.36 (m, 2 H), 6.85-7.01 (m, 1 H), 6.68 (s, 0.5 H), 5.10 (dd, 0.5 H), 4.90-4.98 (m, 1 H), 4.09 (s, 3 H), 3.90-3.99 (m, 0.5 H), 2.94-3.04 (m, 1 H), 2.83-2.91 (m, 1 H)	484.2 [M+H]+	99.5%
1034	(CD3OD) δ 8.60-8.74 (m, 1 H), 7.88-8.00 (m, 1.5 H), 7.73-7.86 (m, 2 H), 7.54-7.72 (m, 1 H), 7.24-7.39 (m, 2 H), 6.68-7.03 (m, 1.5 H), 5.02 (br d, 1 H), 3.92-4.07 (m, 0.5 H), 3.37-3.42 (m, 0.5 H), 2.86-3.23 (m, 2 H)	499.2 [M+H]+	100%
1035	(CD3OD) δ 8.65 (t, 1 H), 7.87-7.98 (m, 1.5 H), 7.71-7.84 (m, 2 H), 7.52-7.69 (m, 1 H), 7.21-7.38 (m, 2 H), 6.66-7.00 (m, 1.5 H), 4.96 (br t, 1 H), 3.89-4.05 (m, 0.5 H), 3.34-3.41 (m, 0.5 H), 2.84-3.22 (m, 2 H)	499.2 [M+H]+	100%
1036	(CD3OD) δ 8.34 (dd, 1 H), 7.50-7.91 (m, 3.5 H), 7.19-7.39 (m, 3 H), 6.65-7.01 (m, 1.5 H), 4.97-5.09 (m, 1 H), 3.88-4.07 (m, 0.5 H), 3.33-3.51 (m, 0.5 H), 2.85-3.22 (m, 2 H)	520.2 [M+H]+	98.0%
1037	(CD3OD) δ 8.33 (dd, 1 H), 7.51-7.90 (m, 3.5 H), 7.19-7.38 (m, 3 H), 6.64-7.01 (m, 1.5 H), 4.94-5.04 (m, 1 H), 3.97 (br d, 0.5 H), 3.33-3.39 (m, 0.5 H), 2.85-3.21 (m, 2 H)	520.2 [M+H]+	98.8%
1038	(CD3OD) δ 8.46-8.50 (m, 1 H), 8.23-8.33 (m, 1 H), 8.14 (s, 1 H), 7.69 (s, 1 H), 7.57 (s, 0.3 H), 6.93-7.02 (m, 1.7 H), 6.73-6.82 (m, 1 H), 6.53-6.66 (m, 1 H), 4.99-5.11 (m, 2 H), 3.71-3.83 (m, 0.6 H), 3.36-3.47 (m, 0.4 H), 3.11-3.23 (m, 0.7 H), 2.92-3.06 (m, 0.3 H), 2.78-2.90 (m, 1 H), 2.57-2.67 (m, 2 H), 2.47-2.57 (m, 2 H), 2.39-2.47 (m, 3 H), 1.85-2.00 (m, 2 H)	470.2 [M+H]+	100%
1039	(CD3OD) δ 8.46-8.50 (m, 1 H), 8.23-8.33 (m, 1 H), 8.14 (s, 1 H), 7.69 (s, 1 H), 7.57 (s, 0.3 H), 6.93-7.02 (m, 1.7 H), 6.73-6.82 (m, 1 H), 6.53-6.66 (m, 1 H), 4.99-5.11 (m, 2 H), 3.71-3.83 (m, 0.6 H), 3.36-3.47 (m, 0.4 H), 3.11-3.23 (m, 0.7 H), 2.92-3.06 (m, 0.3 H), 2.78-2.90 (m, 1 H), 2.57-2.67 (m, 2 H), 2.47-2.57 (m, 2 H), 2.39-2.47 (m, 3 H), 1.85-2.00 (m, 2 H)	470.2 [M+H]+	98.5%
1040	(CD3OD) δ 8.91 (d, 1 H), 8.35 (d, 1 H), 7.73-7.91 (m, 2 H), 7.64-7.68 (m, 1 H), 7.50-7.57 (m, 0.6 H), 7.24-7.37 (m, 2 H), 6.84-6.99 (m, 1 H), 6.66 (s, 0.4 H), 5.10 (br dd, 1 H), 3.91-4.02 (m, 1 H), 2.84-3.18 (m, 2 H)	520.1 [M+H]+	100%
1041	(CD3OD) δ 8.89 (d, 1 H), 8.33 (d, 1 H), 7.69-7.89 (m, 2 H), 7.63-7.68 (m, 1 H), 7.48-7.55 (m, 0.6 H), 7.22-7.37 (m, 2 H), 6.83-6.98 (m, 1 H), 6.64 (s, 0.4 H), 5.09 (dd, 1 H), 3.87-4.02 (m, 1 H), 2.84-3.20 (m, 2 H)	520.1 [M+H]+	98.3%
1042	(CD3OD) δ 8.76 (dd, 1 H), 8.24-8.35 (m, 1 H), 8.07 (tdd, 1 H), 7.54-7.71 (m, 3H), 7.48 (s, 0.4H), 7.10-7.21 (m, 1H), 6.94-7.04 (m, 1.6 H), 6.60-6.81 (m, 1 H), 4.96-5.07 (m, 1 H), 3.88-3.95 (m, 0.5 H), 3.38 (td, 0.5 H), 2.82-3.23 (m, 2 H)	447.1 [M+H]+	100%
1043	(CD3OD) δ 8.76 (dd, 1 H), 8.24-8.35 (m, 1 H), 8.07 (tdd, 1 H), 7.54-7.71 (m, 3 H), 7.48 (s, 0.4 H), 7.10-7.21 (m, 1 H), 6.94-7.04 (m, 1.6 H), 6.60-6.81 (m, 1 H), 4.96-5.07 (m, 1 H), 3.88-3.95 (m, 0.5 H), 3.38 (td, 0.5 H), 2.82-3.23 (m, 2 H)	447.1 [M+H]+	97.2%
1044	(CD3OD) δ 8.71 (br d, 1 H), 7.94-8.05 (m, 1 H), 7.70 (d, 1 H), 7.58-7.66 (m, 1 H), 6.50-7.02 (m, 3 H), 4.91-4.96 (m, 0.5 H), 4.42 (dd, 0.5 H), 4.03-4.08 (m, 3 H), 3.66 (ddd, 0.6 H), 3.10-3.25 (m, 1 H), 2.93-3.03 (m, 0.4 H), 2.70-2.86 (m, 1 H)	417.1 [M+H]+	100%
1045	(CD3OD) δ 8.71 (br d, 1 H), 7.96-8.03 (m, 1 H), 7.67-7.72 (m, 1 H), 7.58-7.65 (m, 1 H), 6.51-7.01 (m, 3 H), 4.91-4.96 (m, 0.4 H), 4.42 (dd, 0.6 H), 4.03-4.07 (m, 3 H), 3.66 (ddd, 0.6 H), 3.11-3.25 (m, 1 H), 2.93-3.02 (m, 0.4 H), 2.71-2.86 (m, 1 H)	417.2 [M+H]+	99.7%
1046	(CD3OD) δ 8.36-8.47 (m, 1 H), 7.69 (br s, 1 H), 7.40 (br s, 0.2 H), 7.23-7.33 (m, 1 H), 6.92 (br s, 0.6 H), 6.80-6.88 (m, 1 H), 6.62-6.76 (m, 1 H), 4.95-5.01 (m, 1 H), 3.62-3.86 (m, 0.7 H), 3.33-3.41 (m, 0.4 H), 2.72-3.23 (m, 2 H), 1.42-1.52 (m, 9 H)	426.1 [M+H]+	100%
1047	(CD3OD) δ 8.37-8.47 (m, 1 H), 7.70 (s, 1 H), 7.41 (br s, 0.2 H), 7.26-7.33 (m, 1 H), 6.93 (s, 0.5 H), 6.81-6.89 (m, 1 H), 6.65-6.77 (m, 1 H), 4.95-5.01 (m, 1 H), 3.66-3.80 (m, 0.7 H), 3.37-3.42 (m, 0.2 H), 2.79-3.22 (m, 2 H), 1.42-1.54 (m, 9 H)	426.1 [M+H]+	99.8%
1048	(CD3OD) δ 8.25-8.38 (m, 1 H), 7.67 (d, 1 H), 7.24-7.40 (m, 1 H), 6.67-6.98 (m, 3 H), 6.48 (s, 0.6 H), 6.22 (s, 0.4 H), 4.42 (dd, 0.5 H), 4.05-4.13 (m, 3 H), 3.67 (ddd, 0.5 H), 2.91-3.30 (m, 2 H), 2.70-2.86 (m, 1 H), 2.30-2.39 (m, 3 H)	413.2 [M+H]+	100%
1049	(CD3OD) δ 8.30-8.37 (m, 1 H), 7.69 (d, 1 H), 7.27-7.42 (m, 1 H), 6.69-7.00 (m, 3 H), 6.50 (s, 0.6 H), 6.24 (s, 0.4 H), 4.44 (dd, 0.5 H), 4.07-4.14 (m, 3 H), 3.69 (ddd, 0.5 H), 2.93-3.31 (m, 2 H), 2.72-2.88 (m, 1 H), 2.33-2.41 (m, 3 H)	413.2 [M+H]+	98.0%
1050	(CD3OD) δ 8.40-8.47 (m, 1 H), 8.00 (s, 1 H), 7.69 (d, 1 H), 7.24-7.31 (m, 1 H), 6.80-6.95 (m, 2 H), 6.74 (s, 0.6 H), 6.47 (s, 0.4 H), 4.39 (m, 1 H), 4.03-4.07 (m, 3 H), 3.66 (m, 0.6 H), 3.08-3.26 (m, 1 H), 2.92-3.01 (m, 0.4H), 2.69-2.85 (m, 1 H)	383.1 [M+H]+	99.9%
1051	(CD3OD) δ 8.40-8.47 (m, 1 H), 7.99 (s, 1 H), 7.69 (d, 1 H), 7.24-7.31 (m, 1 H), 6.80-6.95 (m, 2 H), 6.73 (s, 0.6 H), 6.46 (s, 0.4 H), 4.39 (m, 1 H), 4.03-4.06 (m, 3 H), 3.65 (m, 0.6 H), 3.08-3.26 (m, 1 H), 2.91-3.01 (m, 0.4 H), 2.69-2.85 (m, 1 H)	383.1 [M+H]+	99.7%
1052	(CD3OD) δ 8.40-8.49 (m, 1 H), 7.73 (s, 1 H), 7.23-7.34 (m, 1 H), 6.81-6.97 (m, 2 H), 6.75 (s, 0.6 H), 6.55 (s, 0.4 H), 4.92 (br s, 0.4 H), 4.49 (m, 0.6 H), 4.12-4.19 (m, 3 H), 3.69 (m, 0.6 H), 3.13-3.29 (m, 1 H), 2.94-3.04 (m, 0.4 H), 2.74-2.89 (m, 1 H)	451.1 [M+H]+	99.9%
1053	(CD3OD) δ 8.40-8.48 (m, 1 H), 7.70 (d, 1 H), 7.25-7.33 (m, 1 H), 6.80-6.98 (m, 2 H), 6.74 (s, 0.6 H), 6.53 (s, 0.3 H), 4.92 (br s, 0.5 H), 4.47 (m, 0.5 H), 4.11-4.20 (m, 3 H), 3.68 (m, 0.6 H), 3.11-3.29 (m, 1 H), 2.94-3.03 (m, 0.4 H), 2.73-2.88 (m, 1 H)	451.1 [M+H]+	98.0%
1054	(CD3OD) δ 8.44 (m, 1 H), 7.70 (d, 1 H), 7.24-7.32 (m, 1 H), 6.80-6.94 (m, 2 H), 6.73 (s, 0.6 H), 6.51 (s, 0.3 H), 4.48 (m, 0.1 H), 3.99-4.06 (m, 3 H), 3.66 (m, 0.6 H), 3.09-3.25 (m, 1 H), 2.91-3.02 (m, 0.4 H), 2.71-2.86 (m, 1 H)	417.1 [M+H]+	100%
1055	(CD3OD) δ 8.44 (m, 1 H), 7.66-7.73 (m, 1 H), 7.24-7.32 (m, 1 H), 6.81-6.95 (m, 2 H), 6.73 (s, 0.6 H), 6.51 (s, 0.4 H). 4.48 (m, 1 H), 4.02-4.05 (m, 3 H), 3.66 (m, 0.6 H), 3.09-3.25 (m, 1 H), 2.92-3.02 (m, 0.3 H), 2.72-2.86 (m, 1 H)	417.1 [M+H]+	99.3%
1056	(CD3OD) δ 8.22-8.38 (m, 1 H), 7.69 (d. 1 H), 6.85-7.05 (m, 2 H), 6.72-6.81 (m, 1 H), 6.36-6.66 (m, 1 H), 4.45 (dd, 1 H), 4.14 (s, 3 H), 3.69 (ddd, 0.6 H), 3.10-3.29 (m, 1 H), 2.66-3.07 (m, 1.4 H), 2.33-2.49 (m, 3 H)	431.2 [M+H]+	100%
1057	(CD3OD) δ 8.30 (dd, 1 H), 7.69 (d, 1 H), 6.86-7.05 (m, 2 H), 6.73-6.82 (m, 1 H), 6.31-6.65 (m, 1 H), 4.45 (dd, 1 H), 4.14 (s, 3 H), 3.69 (ddd, 0.6 H), 3.09-3.26 (m, 1 H), 2.70-3.07 (m, 1.4 H), 2.37-2.46 (m, 3 H)	[M+H]+	99.5%
1058	(CD3OD) δ 8.23-8.33 (m, 1 H), 7.68 (d, 1 H), 6.86-7.08 (m, 1.6 H), 6.69-6.84 (m, 1.4 H), 6.30-6.67 (m, 1 H). 4.84 (br s, 0.5 H), 4.31 (dd, 0.5 H), 3.93 (d, 3 H), 3.57-3.72 (m, 0.5 H), 2.91-3.29 (m, 1.5 H), 2.68-2.87 (m, 1 H), 2.36-2.49 (m, 3 H), 1.93-2.08 (m, 1 H), 0.86-1.02 (m, 4 H)	403.2 [M+H]+	99.2%
1059	(CD3OD) δ 8.20-8.35 (m, 1 H), 7.69 (d, 1 H), 6.87-7.06 (m, 1.6 H), 6.78 (q, 1.4 H), 6.29-6.66 (m, 1 H), 4.85 (br d, 0.5 H), 4.31 (dd, 0.5 H), 3.93 (d, 3 H), 3.67 (ddd, 0.5 H), 3.05-3.29 (m, 1 H), 2.67-3.01 (m, 1.5 H), 2.36-2.48 (m, 3 H), 1.96-2.08 (m, 1 H), 0.88-1.02 (m, 4 H)	403.2 [M+H]+	98.5%
1060	(CD3OD) δ 8.67-8.73 (m, 1 H), 7.70 (d, 1 H), 7.62 (dd, 1 H), 6.55-7.05 (m, 4 H), 4.94 (br s, 0.4 H), 4.48 (dd. 0.6 H). 4.07-4.15 (m, 3 H), 3.68 (ddd, 0.6 H), 3.13-3.27 (m, 1 H), 2.94-3.04 (m, 0.4 H), 2.73-2.87 (m, 1 H)	467.1 [M+H]+	100%
1061	(CD3OD) δ 8.67-8.73 (m, 1 H), 7.70 (d. 1 H), 7.57-7.67 (m, 1 H), 6.55-7.04 (m, 4 H), 4.94 (br s, 0.4 H), 4.48 (dd, 0.6 H), 4.08-4.14 (m, 3 H), 3.63-3.72 (m, 0.6 H), 3.13-3.27 (m, 1 H), 2.94-3.04 (m, 0.4 H), 2.73-2.87 (m, 1 H)	467.2 [M+H]+	99.7%
1062	(CD3OD) δ 8.67-8.73 (m, 1 H), 7.71 (d, 1 H). 7.57-7.68 (m, 1 H), 6.91-7.02 (m, 2 H), 6.62-6.82 (m, 1 H), 4.94-4.97 (m, 0.4 H), 4.50 (dd, 0.6 H), 4.11-4.20 (m, 3 H), 3.68 (ddd, 0.6 H), 3.13-3.29 (m, 1 H), 2.94-3.04 (m, 0.4 H), 2.74-2.87 (m, 1 H)	485.1 [M+H]+	99.9%
1063	(CD3OD) δ 8.67-8.73 (m, 1 H), 7.70 (d, 1 H), 7.56-7.68 (m, 1 H), 6.89-7.03 (m. 2 H), 6.59-6.83 (m, 1 H), 4.93 (br s, 0.4 H), 4.49 (dd, 0.6 H), 4.10-4.20 (m, 3 H), 3.68 (ddd, 0.6 H), 3.12-3.29 (m, 1 H), 2.94-3.05 (m, 0.4 H), 2.73-2.88 (m, 1 H)	485.1 [M+H]+	98.8%
1064	(CD3OD) δ 7.55-7.91 (m, 4 H), 6.92-7.35 (m, 3 H), 6.80 (br d, 1 H), 6.21-6.56 (m, 1 H), 4.04 (br dd, 1 H), 3.66-3.83 (m, 1 H), 2.70-3.04 (m, 2 H)	418.1 [M+H]+	98.4%
1065	(CD3OD) δ 7.51-7.98 (m, 4 H), 6.91-7.38 (m, 3 H), 6.79 (br d, 1 H), 6.27-6.56 (m, 1 H), 4.03 (br dd, 1 H), 3.74 (br s, 1 H), 2.68-3.06 (m, 2 H)	418.1 [M+H]+	97.4%
1066	(CD3OD) δ 8.39 (s, 1 H), 8.10 (s, 1 H), 7.69 (d, 1 H), 7.62 (d, 1.5 H), 7.12-7.23 (m, 1 H), 6.95-7.07 (m, 1.5 H), 6.61-6.80 (m, 1 H), 5.10 (br dd, 1 H), 3.98-4.04 (m, 3 H), 3.82-3.96 (m, 0.6 H), 3.34-3.44 (m, 0.4 H), 2.82-3.20 (m, 2 H)	450.1 [M+H]+	99.6%
1067	(CD3OD) δ 8.37 (br s, 1 H), 8.08 (s, 1 H), 7.69 (br d, 1 H), 7.52-7.63 (m, 1.5 H), 7.10-7.21 (m, 1 H), 6.93-7.05 (m, 1.5 H), 6.60-6.80 (m, 1 H), 5.09 (br dd, 1 H), 3.99 (br d, 3 H), 3.84-3.94 (m, 0.6 H), 3.35-3.42 (m, 0.4 H), 2.81-3.18 (m, 2 H)	450.1 [M+H]+	94.0%
1068	(CD3OD) δ 8.11-8.80 (m, 2 H), 7.53-7.75 (m, 2 H), 6.97-7.28 (m, 2 H), 6.43-6.90 (m, 2 H), 4.69-4.86 (m, 0.4 H), 4.21-4.39 (m, 0.6 H), 3.35-3.90 (m, 1 H), 2.71-3.16 (m. 2 H)	403.1 [M+H]+	99.4%
1069	(CD3OD) δ 8.26-8.61 (m, 2 H), 7.52-7.79 (m, 2 H), 6.94-7.34 (m, 2 H), 6.44-6.91 (m, 2 H), 4.04-4.56 (m, 1 H), 3.35-3.86 (m, 1 H), 2.75-3.18 (m, 2 H)	403.1 [M+H]+	100%
1070	(CD3OD) δ 8.51 (br d, 1 H), 7.51-7.77 (m, 2 H), 6.93-7.31 (m, 2 H), 6.68 (s, 2 H), 4.32 (br d, 1 H), 3.73 (br s, 1 H), 2.72-3.20 (m, 2 H), 1.57-1.68 (m, 6 H)	461.2 [M+H]+	100%
1071	(CD3OD) δ 8.51 (br d, 1 H), 7.53-7.74 (m, 2 H), 6.95-7.33 (m, 2 H), 6.48-6.95 (m, 2 H), 4.11-4.47 (m, 1 H), 3.37-3.90 (m, 1 H), 2.76-3.19 (m, 2 H), 1.57-1.70 (m, 6 H)	461.2 [M+H]+	100%
1072	(CD3OD) δ 8.44 (m, 1 H), 7.69 (d, 1 H), 7.29 (m, 1 H), 6.80-6.94 (m, 2 H), 6.73 (s. 0.5 H). 6.50 (s, 0.4 H), 4.82-4.85 (m, 0.5 H), 4.34 (m, 0.5 H), 3.94 (d, 3 H), 3.64 (m, 0.6 H), 3.22 (m, 0.4 H), 3.05-3.14 (m, 0.6 H), 2.91-3.01 (m, 0.4 H), 2.69-2.85 (m, 1 H), 1.98-2.06 (m, 1 H), 0.89-1.01 (m, 4 H)	423.2 [M+H]+	99.9%
1073	(CD3OD) δ 8.45 (m, 1 H), 7.70 (d, 1 H), 7.30 (m, 1 H), 6.82-6.94 (m, 2 H), 6.74 (s, 0.5 H), 6.51 (s, 0.5 H), 4.86 (br s, 0.4 H), 4.34 (m, 0.6 H), 3.95 (d, 3 H), 3.65 (m, 0.6 H), 3.22 (m, 0.4 H), 3.05-3.15 (m, 0.6 H), 2.91-3.01 (m, 0.4 H), 2.70-2.86 (m, 1 H), 1.97-2.07 (m, 1 H), 0.90-1.01 (m, 4 H)	423.1 [M+H]+	99.8%
1074	(CD3OD) δ 8.45 (m, 1 H), 7.70 (m, 1 H), 7.25-7.33 (m, 1 H), 6.80-6.98 (m, 2 H), 6.74 (s, 0.5 H), 6.45 (s, 0.4 H), 4.36 (m, 0.5 H), 3.96 (m, 3 H), 3.66 (m, 0.5 H), 2.70-3.23 (m, 2 H), 2.35 (m, 3 H)	397.2 [M+H]+	100%
1075	(CD3OD) δ 8.45 (m, 1 H), 7.70 (d. 1 H), 7.29 (m, 1 H), 6.81-6.96 (m, 2 H). 6.74 (s, 0.6 H), 6.45 (s, 0.4 H), 4.36 (m, 0.5 H), 3.96 (d, 3 H), 3.61-3.71 (m, 0.5 H), 2.70-3.25 (m, 2 H), 2.33-2.38 (m, 3 H)	397.2 [M+H]+	99.4%
1076	(CD3OD) δ 8.21-8.39 (m, 1 H), 7.69 (d. 1 H), 6.86-7.07 (m, 2 H), 6.73-6.84 (m, 1 H), 6.61 (s, 0.6 H), 6.36 (s, 0.4 H), 4.82-4.86 (m, 0.4 H). 4.45 (dd, 0.6 H), 3.91-4.09 (m, 3 H), 3.59-3.75 (m, 0.6 H), 3.06-3.29 (m, 1 H), 2.90-3.04 (m, 0.4 H), 2.68-2.86 (m, 1 H), 2.31-2.47 (m, 3 H)	397.1 [M+H]+	100%
1077	(CD3OD) δ 8.20-8.39 (m, 1 H), 7.69 (br d, 1 H), 6.88-7.02 (m, 2 H), 6.78 (q, 1 H), 6.61 (s, 0.6 H), 6.36 (s, 0.4 H), 4.81-4.86 (m, 0.4 H), 4.45 (dd, 0.6 H), 3.98-4.07 (m, 3 H), 3.67 (ddd, 0.6 H), 3.08-3.29 (m, 1 H), 2.90-3.04 (m, 0.4 H), 2.70-2.88 (m, 1 H), 2.32-2.50 (m, 3 H)	397.1 [M+H]+	100%
1078	(CD3OD) δ 8.70 (d, 1 H), 7.70 (d, 1 H), 7.57-7.67 (m, 1 H), 6.50-7.11 (m, 3 H), 4.97 (br s, 0.4 H), 4.49 (dd, 0.6 H), 3.97-4.13 (m, 3 H), 3.60-3.72 (m, 0.6 H), 3.09-3.24 (m, 1 H), 2.89-3.04 (m, 0.4 H), 2.70-2.88 (m, 1 H)	451.1 [M+H]+	100%
1079	(CD3OD) δ 8.70 (br d, 1 H), 7.65-7.78 (m, 1 H), 7.57-7.65 (m, 1 H), 6.56-7.01 (m, 3 H). 4.97 (br s, 0.4 H), 4.50 (dd, 0.6 H), 4.01-4.06 (m, 3 H), 3.62-3.70 (m, 0.6 H), 3.09-3.25 (m, 1 H), 2.92-3.02 (m, 0.4 H), 2.69-2.87 (m, 1 H)	451.1 [M+H]+	99.2%
1080	(CD3OD) δ 8.70 (dd, 1 H), 7.69 (d. 1 H), 7.59-7.66 (m. 1 H), 6.57-7.05 (m, 3 H), 4.86 (br s, 0.5 H), 4.35 (dd, 0.5 H), 3.94 (d, 3 H), 3.59-3.69 (m, 0.6 H), 3.05-3.27 (m, 1 H), 2.90-3.02 (m. 0.4 H), 2.70-2.86 (m, 1 H), 1.97-2.07 (m, 1 H), 0.89-1.00 (m, 4 H)	457.2 [M+H]+	97.0%
1081	(CD3OD) δ 8.70 (dd, 1 H), 7.69 (d, 1 H), 7.62 (t, 1 H), 6.57-7.02 (m, 3 H), 4.94-5.00 (m, 0.5 H), 4.35 (dd, 0.5 H), 3.95 (d, 3 H), 3.59-3.69 (m, 0.6 H), 3.06-3.26 (m, 1 H), 2.90-3.02 (m, 0.4 H), 2.70-2.86 (m, 1 H), 1.98-2.06 (m, 1 H), 0.89-1.00 (m, 4 H)	457.2 [M+H]+	99.5%
1082	(CD3OD) δ 8.71 (d, 1 H), 7.73 (d, 1 H), 7.58-7.66 (m, 1 H), 6.46-7.06 (m, 3 H), 4.94-4.97 (m, 0.5 H), 4.39 (dd, 0.5 H), 3.91-4.01 (m, 3 H), 3.61-3.71 (m, 0.6 H), 3.06-3.24 (m, 1 H), 2.91-3.02 (m, 0.4 H), 2.69-2.88 (m, 1 H), 2.31-2.40 (m, 3 H)	431.2 [M+H]+	100%
1083	(CD3OD) δ 8.71 (d, 1 H), 7.70 (d, 1 H), 7.58-7.67 (m, 1 H), 6.41-7.07 (m, 3 H), 4.93 (br s, 0.5 H), 4.38 (dd, 0.5 H), 3.88-4.04 (m, 3 H), 3.59-3.71 (m, 0.6 H), 3.06-3.24 (m, 1 H), 2.91-3.02 (m, 0.4 H), 2.70-2.86 (m, 1 H), 2.35 (d, 3 H)	431.2 [M+H]+	99.6%
1084	(CD3OD) δ 8.49 (dd, 1 H), 7.69 (s, 1 H), 6.99-7.32 (m, 2 H), 6.53-6.92 (m. 3 H), 4.35 (br d, 1 H), 3.74 (br s, 1 H), 2.97-3.23 (m, 1 H), 2.83 (br d, 1 H), 1.51-1.82 (m, 6 H)	461.2 [M+H]+	100%
1085	(CD3OD) δ 8.49 (dd, 1 H), 7.69 (s, 1 H), 6.94-7.43 (m, 2 H), 6.48-6.88 (m, 3 H). 4.35 (br d. 1 H), 3.62-3.84 (m, 1 H), 2.94-3.24 (m, 1 H), 2.83 (br d, 1 H), 1.49-1.80 (m, 6 H)	461.2 [M+H]+	99.5%
1086	(CD3OD) δ 7.69 (d, 1 H), 7.47 (dd, 1 H), 7.13 (dt, 1 H), 6.94 (s, 1 H), 6.73 (d. 1 H), 6.62 (s, 0.6 H), 6.34 (s, 0.4 H), 4.93 (br s, 0.5 H), 4.41 (dd, 0.5 H), 3.92-4.09 (m, 3 H), 3.72-3.86 (m, 0.5 H), 3.25-3.31 (m, 0.5 H). 3.08-3.21 (m, 0.7 H), 2.92-3.05 (m, 0.3 H), 2.73-2.90 (m, 1 H), 2.57-2.71 (m, 3 H)	397.1 [M+H]+	98.9%
1087	(CD3OD) δ 7.69 (d, 1 H), 7.47 (dd, 1 H), 7.08-7.19 (m, 1 H), 6.94 (s, 1 H), 6.73 (d, 1 H), 6.62 (s, 0.5 H), 6.34 (s, 0.5 H), 4.97-4.98 (m, 0.5 H), 4.41 (dd, 0.5 H), 3.91-4.08 (m, 3 H), 3.73-3.86 (m, 0.5 H), 3.28 (br d, 0.5 H), 3.07-3.20 (m, 0.7 H), 2.92-3.04 (m, 0.3 H), 2.73-2.89 (m, 1 H), 2.60-2.72 (m, 3 H)	397.2 [M+H]+	96.9%
1088	(CD3OD) δ 8.44-8.74 (m, 1 H), 7.48-7.87 (m, 4 H), 7.22 (br t, 1 H), 6.65-7.13 (m, 2 H), 6.19-6.53 (m, 1 H), 4.82 (br d, 0.7 H), 3.63-4.15 (m, 1 H), 3.16-3.27 (m, 0.3 H), 2.65-3.07 (m, 2 H)	402.1 [M+H]+	100%
1089	(CD3OD) δ 8.33-8.76 (m, 1 H), 7.48-7.86 (m, 4 H). 7.22 (br t, 1 H), 6.64-7.13 (m, 2 H), 6.16-6.51 (m, 1 H), 4.73-4.85 (m, 0.7 H), 3.63-4.13 (m, 1 H), 3.17-3.27 (m, 0.3 H), 2.66-3.07 (m, 2 H)	402.1 [M+H]+	99.5%
1090	(CD3OD) δ 8.69-8.87 (m, 1 H), 8.43-8.59 (m, 1 H). 8.24-8.39 (m, 1 H), 8.08 (td, 1 H), 7.41-7.88 (m, 3.4 H), 7.13-7.41 (m, 1 H), 6.49-7.08 (m, 1.6 H), 4.99 (br dd, 1 H), 3.37-3.92 (m, 1 H), 2.75-3.27 (m, 2 H)	431.2 [M+H]+	100%
1091	(CD3OD) & 8.74-8.83 (m, 1 H), 8.43-8.59 (m, 1 H), 8.27-8.37 (m, 1 H), 8.08 (td, 1 H). 7.45-7.83 (m, 3.4 H), 7.11-7.32 (m, 1 H), 6.59-7.01 (m, 1.6 H), 5.00 (br dd, 1 H), 3.36-3.89 (m, 1 H), 2.76-3.25 (m, 2 H)	431.1 [M+H]+	99.2%
1092	(CD3OD) & 8.41-8.68 (m, 1 H), 7.49-7.89 (m, 3 H), 7.26-7.44 (m, 1 H), 6.18-7.10 (m, 4 H), 4.82-4.86 (m, 0.4 H), 3.99-4.18 (m, 0.6 H), 3.72 (br t, 0.6 H), 2.95-3.31 (m, 1.4 H), 2.76 (br d, 1 H)	402.2 [M+H]+	100%
1093	(CD3OD) δ 8.30-8.53 (m, 1 H), 7.38-7.79 (m, 3 H), 7.10-7.29 (m, 1 H), 6.10-7.00 (m, 4 H), 4.69-4.75 (m, 0.4 H), 3.91-4.05 (m, 0.6 H), 3.60 (br t, 0.6 H), 2.84-3.19 (m, 1.4 H), 2.64 (br d, 1 H)	402.1 [M+H]+	99.9%
1094	(CD3OD) δ 8.40-8.46 (m, 1 H), 7.70 (s, 1 H), 7.46 (s, 0.3 H), 7.27-7.33 (m, 1 H), 6.91 (s, 0.6 H), 6.82-6.88 (m, 1 H), 6.67-6.74 (m, 1 H), 5.00 (dd, 0.4 H), 3.68-3.75 (m, 0.6 H), 3.26-3.40 (m, 0.2 H), 3.13-2.79 (m, 1 H), 2.82 (br dd, 1 H), 2.28-2.36 (m, 1 H), 1.18-1.31 (m, 4 H)	410.1 [M+H]+	100%
1095	(CD3OD) δ 8.40-8.46 (m, 1 H), 7.70 (s, 1 H), 7.46 (s, 0.3 H), 7.27-7.33 (m, 1 H), 6.91 (s, 0.6 H), 6.82-6.88 (m, 1 H), 6.67-6.74 (m, 1 H), 4.98-5.03 (m, 0.5 H), 3.68 - 3.75 (m. 1 H), 3.36-3.41 (m, 0.3 H), 2.91-3.18 (m, 1 H), 2.79-2.84 (m, 1 H), 2.28-2.36 (m, 1 H), 1.18-1.31 (m, 4 H)	410.1 [M+H]+	100%
1096	(CD3OD) δ 8.44 (t, 1 H), 8.26 (dd, 1 H), 7.71 (d, 1 H). 7.55-7.66 (m, 2 H), 7.52 (s, 0.4 H), 7.13-7.24 (m, 1 H), 6.97-7.08 (m, 1.6 H), 6.61-6.83 (m, 1 H), 5.06 (br dd, 1 H), 4.00 (d, 3 H), 3.87-3.98 (m, 0.6 H), 3.36-3.45 (m, 0.4 H), 2.84-3.24 (m, 2 H)	477.1 [M+H]+	100%
1097	(CD3OD) δ 8.45 (d, 1 H), 8.27 (dd, 1 H), 7.71 (d, 1 H), 7.59-7.67 (m, 2 H), 7.52 (s, 0.5 H), 7.15-7.22 (m. 1 H), 6.99-7.07 (m. 1.5 H), 6.60-6.85 (m, 1 H), 5.03-5.08 (m, 1 H), 4.00 (d, 3 H), 3.94 (br d, 1 H), 2.87-3.23 (m, 2 H)	477.2 [M+H]+	100%
1098	(CD3OD) δ 7.98 (s. 1 H), 7.84 (dd. 1 H), 7.71 (d, 1 H), 7.48-7.66 (m, 1.5 H), 7.13-7.25 (m, 1 H), 6.97-7.06 (m, 1.5 H), 6.63-6.82 (m. 1 H), 5.10 (br dd, 1 H), 4.11 (s, 3 H), 3.87-3.99 (m, 0.6 H). 3.37-3.47 (m, 0.4 H), 2.87 (br dd, 2 H)	450.1 [M+H]+	98.1%
1099	(CD3OD) δ 7.86 (s, 1 H), 7.72 (d, 1 H), 7.59 (d, 1 H), 7.36-7.54 (m, 1.5 H), 7.01-7.12 (m, 1 H), 6.85-6.94 (m, 1.5 H), 6.52-6.70 (m, 1 H), 4.87-5.04 (m, 1 H), 3.99 (s, 3 H), 3.75-3.89 (m, 0.6 H), 3.24-3.30 (m, 0.4 H), 2.73-3.12 (m, 2 H)	450.1 [M+H]+	94.5%
1100	(CD3OD) δ 8.45-8.57 (m, 1 H), 8.38 (s, 1 H), 8.09 (s, 1 H), 7.51-7.75 (m. 2.4 H), 7.13-7.31 (m, 1 H). 6.92 (s, 0.6 H), 6.55-6.75 (m. 1 H), 5.05 (br dd, 1 H), 4.00 (s, 3 H), 3.34-3.81 (m. 1 H), 2.76-3.22 (m, 2 H)	434.2 [M+H]+	99.4%
1101	(CD3OD) δ 8.45-8.54 (m, 1 H), 8.38 (s. 1 H), 8.09 (s, 1 H), 7.54-7.70 (m, 2.4 H), 7.12-7.28 (m, 1 H), 6.92 (s, 0.6 H), 6.54-6.76 (m, 1 H), 5.05 (br dd, 1 H), 4.00 (s, 3 H), 3.34-3.82 (m, 1 H), 2.76-3.22 (m, 2 H)	434.2 [M+H]+	98.8%
1102	(CD3OD) δ 8.34-8.60 (m, 1 H), 7.81 (d, 1 H), 7.68 (s, 2 H), 7.50 (s, 0.4 H), 7.11-7.27 (m, 1 H), 6.86-7.01 (m, 1.6 H), 6.52-6.75 (m, 1 H), 5.00 (br dd, 0.7 H), 3.92-4.10 (m, 3 H), 3.35-3.83 (m, 1.3 H), 2.77-3.22 (m, 2 H)	434.2 [M+H]+	100%
1103	(CD3OD) δ 8.37-8.62 (m, 1 H), 7.81 (d. 1 H), 7.56-7.72 (m, 2 H), 7.50 (s, 0.4 H), 7.12-7.28 (m, 1 H), 6.80-7.07 (m, 1.6 H), 6.56-6.75 (m, 1 H), 5.00 (br dd, 0.7 H), 3.92-4.07 (m, 3 H), 3.34-3.85 (m, 1.3 H), 2.80-3.22 (m, 2 H)	434.1 [M+H]+	100%
1104	(CD3OD) δ 8.92 (s, 1 H), 8.42 (s, 1 H), 7.65-7.82 (m, 2 H), 7.35 (br d, 1 H), 6.99-7.28 (m, 1 H), 6.53-6.90 (m, 2 H), 4.34 (br d, 1 H), 3.66-3.80 (m, 0.7 H), 3.34-3.49 (m, 0.3 H), 2.93-3.16 (m, 1 H), 2.80 (br d, 1 H)	453.1 [M+H]+	99.6%
1105	(CD3OD) δ 8.92 (s, 1 H), 8.42 (s, 1 H), 7.63-7.86 (m, 2 H), 7.35 (d, 1 H), 6.99-7.28 (m, 1 H), 6.47-6.92 (m, 2 H), 4.34 (br d, 1 H), 3.74 (br t, 0.7 H), 3.35-3.48 (m, 0.3 H), 2.91-3.15 (m, 1 H), 2.79 (br d, 1 H)	453.1 [M+H]+	98.6%
1106	(CD3OD) δ 8.38-8.45 (m, 1 H), 7.69 (s, 1 H), 7.47 (s, 0.3 H), 7.24-7.32 (m, 1 H), 6.67-6.93 (m, 2.7 H), 4.96 (dd, 1 H), 3.68-3.77 (m, 0.7 H), 3.33-3.42 (m, 0.3 H). 2.91-3.17 (m, 1 H), 2.79 -2.84 (m, 1 H), 2.60-2.66 (m. 3 H)	384.1 [M+H]+	100%
1107	(CD3OD) δ 8.40-8.46 (m, 1 H), 7.71 (s, 1 H), 7.47 (s, 0.3 H), 7.26-7.32 (m, 1 H), 6.68-6.94 (m, 2.7 H), 4.94 - 4.99 (m, 1 H), 3.68-3.77 (m, 0.7 H), 3.33-3.41 (m, 0.4 H), 2.91-3.19 (m, 1 H), 2.79 - 2.84 (m, 1 H), 2.60-2.66 (m, 3 H)	384.2 [M+H]+	99.5%
1108	(CD3OD) δ 8.38-8.47 (m, 1 H), 7.70 (s, 1 H), 7.40 (s, 0.3 H), 6.93 (s, 0.6 H), 6.64-6.88 (m, 2 H), 4.97 (br dd, 1 H), 3.74 (ddd, 0.6 H), 3.36-3.42 (m, 0.3 H), 2.80-3.21 (m, 2 H), 1.83-1.95 (m, 6 H)	430.1 [M+H]+	100%
1109	(CD3OD) δ 8.37-8.47 (m, 1 H), 7.69 (s, 1 H), 7.40 (s, 0.3 H), 7.27-7.33 (m, 1 H), 6.93 (s, 0.6 H), 6.63-6.88 (m, 2 H), 4.92-4.99 (m, 1 H), 3.67-3.78 (m, 0.7 H), 3.34-3.42 (m, 0.4 H), 2.80-3.16 (m, 2 H), 1.84-1.93 (m, 6 H)	430.1 [M+H]+	99.4%
1110	(CD3OD) δ 8.17-8.29 (m, 1 H), 7.67 (s, 1 H), 7.44-7.53 (m, 1 H), 7.39 (br s, 0.3 H), 7.02-7.11 (m, 1 H), 6.91 (br s. 0.7 H), 6.54 (s, 0.7 H), 6.45 (s, 0.3 H), 4.90-5.00 (m, 1 H), 3.72 (td. 0.7 H), 3.33-3.42 (m, 0.3 H), 3.07-3.21 (m, 0.7 H), 2.91-3.02 (m, 0.3 H), 2.81 (br d, 1 H), 2.26-2.36 (m, 3 H), 1.47 (s, 9 H)	406.2 [M+H]+	100%
1111	(CD3OD) δ 8.16-8.33 (m, 1 H), 7.69 (d, 1 H), 7.43-7.53 (m, 1 H), 7.40 (s, 0.3 H), 7.04-7.13 (m, 1 H), 6.91 (s, 0.7 H), 6.43-6.59 (m, 1 H), 4.91-4.97 (m, 1 H), 3.68-3.77 (m, 0.7 H), 3.33-3.43 (m, 0.3 H), 3.06-3.19 (m, 0.7 H), 2.90-3.02 (m, 0.3 H), 2.81 (br d, 1 H), 2.28-2.35 (m. 3 H), 1.47 (s, 9 H)	406.2 [M+H]+	99.8%
1112	(CDCl3) δ 8.12-8.29 (m, 1 H), 7.30-7.80 (m, 4 H), 6.96 (br d, 2 H), 6.43-6.63 (m, 1 H), 6.34 (br d, 1 H), 4.00-4.97 (m, 1 H), 3.23-3.80 (m, 1 H), 2.86-3.12 (m, 1 H), 2.67-2.78 (m, 1 H), 2.32 (br s, 3 H)	398.2 [M+H]+	98.6%
1113	(CDCl3) δ 8.13-8.27 (m, 1 H), 7.31-7.80 (m, 4 H), 6.90-7.03 (m, 2 H), 6.39-6.67 (m, 1 H), 6.34 (br d, 1 H), 4.04-4.95 (m, 1 H), 3.24-3.83 (m, 1 H), 2.87-3.13 (m, 1 H), 2.65-2.80 (m, 1 H), 2.32 (br s, 3 H)	398.2 [M+H]+	100%
1114	(CD3OD) δ 8.40-8.59 (m, 1 H), 7.53-7.78 (m, 2 H), 7.39 (s, 0.3 H), 7.13-7.30 (m. 1 H), 6.91 (s, 0.7 H), 6.47-6.78 (m, 1 H), 4.92-4.98 (m, 1 H), 3.36-3.81 (m, 1 H), 2.75-3.21 (m, 2 H), 1.82-1.96 (m, 6 H)	414.2 [M+H]+	100%
1115	(CD3OD) δ 8.36-8.59 (m, 1 H), 7.55-7.74 (m, 2 H), 7.39 (s, 0.4 H), 7.14-7.28 (m, 1 H), 6.91 (s, 0.6 H), 6.54-6.76 (m, 1 H), 4.92-4.99 (m, 1 H), 3.35-3.79 (m, 1 H), 2.75-3.21 (m, 2 H), 1.84-1.95 (m, 6 H)	414.2 [M+H]+	99.4%
1116	(CD3OD) δ 8.92 (s, 1 H), 7.77 (br d, 1 H), 7.68 (s, 1 H), 7.35 (br d, 1 H), 6.97-7.27 (m, 1 H), 6.78-6.87 (m, 1.6 H), 6.61 (br s, 0.4 H), 4.82 (br s, 0.4 H), 4.32-4.41 (m, 0.6 H), 3.74 (br t, 0.6 H), 3.36-3.49 (m, 0.4 H), 2.74-3.20 (m, 2 H), 1.55-1.69 (m, 6 H)	511.2 [M+H]+	100%
1117	(CD3OD) δ 8.92 (s, 1 H), 7.77 (br d, 1 H), 7.68 (s, 1 H), 7.35 (d, 1 H), 6.97-7.27 (m, 1 H), 6.79-6.87 (m, 1.7 H), 6.61 (br d, 0.3 H). 4.81 (br s, 0.3 H), 4.36 (br d, 0.7 H), 3.69-3.79 (m, 0.7 H), 3.34-3.49 (m, 0.3 H), 2.77-3.18 (m, 2 H), 1.55-1.68 (m, 6 H)	511.2 [M+H]+	98.5%
1118	(CD3OD) δ 8.31-8.48 (m, 2 H), 7.83 (s, 0.2 H), 7.49-7.72 (m, 2 H), 7.19-7.33 (m, 2 H), 6.70-6.99 (m, 2.6 H), 4.99-5.08 (m, 1 H), 3.72-3.83 (m, 0.6 H). 3.41 (td, 0.4 H), 2.94-3.25 (m, 1 H), 2.80-2.90 (m, 1 H)	486.2 [M+H]+	100%
1119	(CD3OD) δ 8.29-8.48 (m, 2 H), 7.82 (s, 0.2 H), 7.49-7.74 (m, 2 H), 7.18-7.35 (m, 2 H), 6.69-6.99 (m, 2.8 H), 5.02 - 5.07 (m, 1 H), 3.72-3.82 (m, 0.7 H), 3.37 - 3.44 (m, 0.3 H), 2.96-3.26 (m, 1 H). 2.83 - 2.87 (m, 1 H)	486.1 [M+H]+	99.8%
1120	(CD3OD) δ 8.93 (s, 1 H), 8.36 (s, 1 H), 7.51-7.74 (m, 3.4 H), 7.14-7.23 (m, 1 H), 6.98-7.08 (m, 1.6 H), 6.64-6.82 (m, 1 H), 5.11 (dd. 1 H), 3.88-3.97 (m, 0.6 H), 3.37-3.44 (m, 0.4 H), 2.99-3.24 (m, 1 H), 2.88 (dd, 1 H)	486.1 [M+H]+	100%
1121	(CD3OD) δ 8.81 (s, 1 H), 8.24 (s, 1 H), 7.38-7.64 (m, 3.4 H), 7.02-7.12 (m, 1 H), 6.86-6.95 (m, 1.6 H). 6.53-6.70 (m, 1 H). 5.00 (br dd, 1 H), 3.74-3.86 (m, 0.6 H), 3.25-3.34 (m, 0.4 H), 2.86-3.13 (m, 1 H). 2.76 (dd, 1 H)	486.1 [M+H]+	100%
1122	(CD3OD) δ 7.59 (d. 1 H), 7.45-7.54 (m, 1 H), 7.34 (s, 0.4 H), 7.04-7.12 (m, 1 H), 6.91-6.97 (m, 1 H), 6.86 (s, 0.6 H), 6.51-6.71 (m, 1 H), 4.89 (br dd, 1 H), 3.71-3.81 (m, 0.6 H), 3.25-3.32 (m, 0.4 H), 2.71-3.10 (m, 2 H), 1.37-1.39 (m, 9 H)	426.2 [M+H]+	100%
1123	(CD3OD) δ 7.70 (d, 1 H), 7.57-7.65 (m, 1 H), 7.44 (s, 0.4 H), 7.16-7.23 (m, 1 H), 7.02-7.07 (m, 1 H), 6.97 (s, 0.6 H), 6.63-6.81 (m, 1 H), 5.00 (dd, 1 H), 3.81-3.93 (m, 0.6 H), 3.36-3.43 (m, 0.4 H), 2.81-3.21 (m, 2 H), 1.47-1.50 (m, 9 H)	426.2 [M+H]+	98.0%
1124	(CD3OD) δ 8.39-8.55 (m, 1 H), 7.53-7.72 (m, 2 H), 7.39 (s, 0.3 H), 7.13-7.28 (m, 1 H), 6.90 (s, 0.7 H), 6.58-6.73 (m, 1 H), 4.96 (br s, 1 H), 3.68-3.77 (m, 0.7 H), 3.34-3.41 (m, 0.3 H), 2.78-3.18 (m, 2 H), 1.47 (s, 9 H)	410.2 [M+H]+	100%
1125	(CD3OD) δ 8.39-8.61 (m, 1 H). 7.52-7.75 (m, 2 H), 7.39 (s. 0.3 H), 7.14-7.27 (m, 1 H), 6.90 (s, 0.7 H), 6.56-6.72 (m, 1 H), 4.96 (br d, 1 H), 3.63-3.81 (m, 0.7 H), 3.36-3.41 (m, 0.3 H), 2.74-3.21 (m, 2 H), 1.47 (s, 9 H)	410.2 [M+H]+	99.7%
1126	(CD3OD) δ 8.90-8.96 (m, 1 H), 7.68-7.80 (m, 2 H), 7.31-7.37 (m. 1 H), 6.93-6.98 (m, 1 H), 6.79-6.85 (m, 1 H), 6.69-6.72 (m, 0.5 H), 6.62 (s, 0.5 H), 4.93 (br d, 0.4 H), 4.48 (dd, 0.6 H), 4.07-4.13 (m, 3 H), 3.68 (ddd, 0.6 H), 3.11-3.28 (m, 1 H), 2.93-3.04 (m, 0.4 H), 2.71-2.86 (m, 1 H)	467.1 [M+H]+	100%
1127	(CD3OD) δ 8.93 (br d, 1 H), 7.66-7.81 (m, 2 H), 7.31-7.38 (m, 1 H), 6.92-6.98 (m. 1 H), 6.79-6.85 (m, 1 H), 6.69-6.72 (m, 0.5 H). 6.62 (s, 0.5 H), 4.90-4.95 (m, 0.7 H), 4.48 (dd, 0.3 H), 4.08-4.12 (m, 3 H), 3.68 (ddd, 0.6 H), 3.12-3.28 (m, 1 H), 2.94-3.04 (m, 0.4 H), 2.71-2.86 (m, 1 H)	467.1 [M+H]+	100%
1128	(CD3OD) δ 8.85-8.96 (m, 1 H), 7.67-7.84 (m, 3 H), 7.51 (s, 0.2 H), 7.31-7.38 (m. 0.8 H), 6.94-7.00 (m, 2 H). 6.76-6.83 (m, 1 H). 5.05 (br dd, 0.6 H), 4.95 (br d, 0.4 H), 4.03 (s, 3 H), 3.74-3.84 (m, 0.6 H), 3.36-3.46 (m, 0.4 H), 3.12-3.24 (m, 0.7 H), 2.94-3.06 (m, 0.3 H), 2.83 (br d, 1 H)	484.2 [M+H]+	89.9%
1129	(CD3OD) δ 8.86-8.97 (m, 1 H), 7.68-7.83 (m, 3 H), 7.51 (br s, 0.3 H), 7.31-7.39 (m, 0.7 H). 6.93-7.01 (m, 2 H). 6.75-6.85 (m, 1 H), 5.05 (br dd, 0.7 H), 4.95 (br d, 0.3 H), 4.03 (s, 3 H), 3.74-3.84 (m, 0.7 H), 3.36-3.50 (m, 0.3 H), 3.10-3.24 (m, 0.8 H), 2.93-3.06 (m, 0.2 H), 2.79-2.88 (m, 1 H)	484.2 [M+H]+	94.9%
1130	(CD3OD) δ 8.38-8.52 (m, 1 H), 7.23-7.74 (m, 2.3 H), 6.71-6.95 (m, 1.7 H), 6.51-6.67 (m, 1 H), 4.97-5.04 (m, 1 H), 3.73 (ddd, 0.6 H), 3.37-3.42 (m. 0.4 H), 2.91-3.20 (m, 1 H), 2.75-2.86 (m, 1 H), 2.24-2.41 (m, 1 H), 1.17-1.33 (m, 4 H)	394.1 [M+H]+	99.9%
1131	(CD3OD) δ 8.38-8.55 (m, 1 H), 7.25-7.82 (m, 2.3 H), 6.75-7.01 (m, 1.7 H), 6.49-6.63 (m, 1 H), 4.96-5.06 (m, 1 H), 3.73 (ddd, 0.6 H), 3.35-3.43 (m, 0.4 H), 2.90-3.21 (m, 1 H), 2.74-2.88 (m, 1 H), 2.21-2.45 (m, 1 H). 1.20-1.38 (m, 4 H)	394.2 [M+H]+	99.9%
1132	(CD3OD) δ 8.57-8.79 (m, 1 H), 8.04 (br d, 1 H), 7.44-7.87 (m, 3 H), 6.58-7.15 (m, 3.6 H), 6.31 (br s, 0.4 H), 4.82 (br s, 0.5 H), 4.09 (br dd, 0.5 H), 3.71 (br t, 0.5 H), 3.15-3.30 (m, 0.5 H), 2.68-3.06 (m, 2 H)	452.2 [M+H]+	100%
1133	(CD3OD) δ 8.58-8.79 (m, 1 H), 8.04 (br d, 1 H), 7.46-7.88 (m, 3 H), 6.58-7.17 (m, 3.6 H), 6.31 (br s, 0.4 H). 4.82 (br s, 0.5 H), 4.09 (br dd, 0.5 H), 3.65-3.78 (m, 0.5 H), 3.17-3.29 (m, 0.5 H), 2.66-3.09 (m, 2 H)	452.1 [M+H]+	99.7%
1134	(CD3OD) δ 8.90 (br s, 1 H), 8.30-8.48 (m, 2 H), 7.49-7.80 (m, 2 H), 7.22-7.33 (m, 1 H), 6.66-6.98 (m, 3 H), 5.03-5.11 (m, 1 H), 3.77 (br t, 0.7 H). 3.35-3.45 (m, 0.3 H), 3.11-3.23 (m, 1 H), 2.78-3.03 (m, 1 H)	486.1 [M+H]+	100%
1135	(CD3OD) δ 8.90 (s, 1 H), 8.31-8.46 (m, 2 H), 7.47-7.81 (m, 2 H), 7.24-7.32 (m, 1 H), 6.69-6.99 (m, 3 H), 5.07 (br dd, 1 H), 3.71-3.82 (m, 0.7 H), 3.40 (td. 0.3 H), 3.12-3.23 (m, 1 H). 2.79-3.04 (m, 1 H)	486.1 [M+H]+	98.3%
1136	(CD3OD) δ 7.82-7.92 (m, 1 H), 7.46-7.56 (m, 1 H), 7.40 (s, 0.3 H), 7.04-7.14 (m, 1 H), 6.85-6.97 (m, 1.7 H), 6.56-6.73 (m, 1 H), 4.95 (br dd, 1 H), 3.66-3.77 (m, 0.6 H), 3.24-3.32 (m, 0.4 H), 2.84-3.08 (m, 1 H), 2.70-2.81 (m, 1 H). 2.16-2.29 (m, 1 H). 1.15-1.19 (m, 2 H), 1.08-1.13 (m, 2 H)	410.1 [M+H]+	99.5%
1137	(CD3OD) δ 7.60 (d, 1 H), 7.49 (dd, 1 H), 7.34 (s, 0.3 H), 7.03-7.11 (m, 1 H), 6.81-6.96 (m, 1.7 H), 6.50-6.69 (m, 1 H), 4.89 (br d, 1 H), 3.67-3.83 (m, 0.6 H), 3.26 (br s, (0.4 H), 3.02 (br d, 1 H), 2.72 (br dd, 1 H), 2.17-2.25 (m, 1 H), 1.14-1.19 (m, 2 H), 1.07-1.14 (m, 2 H)	410.1 [M+H]+	99.7%
1138	(CD3OD) δ 8.87-9.07 (m, 1 H), 7.50-7.82 (m, 4 H), 7.35 (dd, 1 H), 6.89-7.09 (m, 1 H), 6.80 (br d, 1 H), 6.23-6.62 (m, 1 H), 4.78-4.84 (m, 0.5 H), 4.10 (br dd, 0.5 H), 3.72 (br t, 0.5 H), 3.21-3.30 (m, 0.5 H), 2.93-3.06 (m, 1 H), 2.75 (br d, 1 H)	452.1 [M+H]+	100%
1139	(CD3OD) δ 8.87-9.09 (m, 1 H), 7.48-7.85 (m, 4 H), 7.35 (dd, 1 H), 6.90-7.09 (m, 1 H), 6.80 (br d, 1 H), 6.24-6.60 (m, 1 H), 4.77-4.83 (m, 0.5 H), 4.10 (br dd, 0.5 H), 3.72 (br t, 0.5 H), 3.21-3.30 (m, 0.5 H), 2.94-3.06 (m, 1 H), 2.75 (br d, 1 H)	452.1 [M+H]+	100%
1140	(CD3OD) δ 7.74 (dd, 1 H), 7.51-7.65 (m, 1 H), 7.40 (s, 0.5 H), 7.11-7.29 (m, 2 H), 6.67-6.94 (m, 1 H), 6.53 (s, 0.5 H), 4.89 (br s, 1 H), 3.61-3.95 (m, 0.5 H), 2.67-3.19 (m, 2.5 H), 2.05-2.34 (m, 1 H), 1.09-1.21 (m, 4 H)	444.2 [M+H]+	100%
1141	(CD3OD) δ 7.74 (dd, 1 H), 7.51-7.64 (m, 1 H), 7.21-7.44 (m, 1.5 H), 7.10-7.21 (m, 1 H), 6.81 (s, 0.5 H), 6.44-6.77 (m, 1 H), 4.90 (br dd, 1 H), 3.73-3.87 (m, 0.5 H), 2.68-3.18 (m, 2.5 H), 2.13-2.36 (m, 1 H), 1.09-1.20 (m, 4 H)	444.1 [M+H]+	97.6%
1142	(CD3OD) δ 7.72 (d, 1 H), 7.55-7.66 (m, 1 H), 7.16-7.24 (m, 1 H), 7.02-7.11 (m, 1 H), 6.93 (s, 1 H), 6.48-6.84 (m, 1 H), 4.41 (br dd, 0.7 H), 4.06 (d, 3 H), 3.71-3.82 (m, 0.7 H), 2.79-3.22 (m, 2.6 H)	417.1 [M+H]+	99.4%
1143	(CD3OD) δ 7.60 (br d, 1 H), 7.43-7.53 (m, 1 H), 7.02-7.11 (m, 1 H), 6.94 (d, 1 H), 6.81 (s, 1 H), 6.37-6.69 (m, 1 H), 4.28 (br dd, 0.7 H), 3.94 (d. 3 H), 3.59-3.69 (m, 0.7 H). 2.62-3.12 (m, 2.6 H)	417.1 [M+H]+	97.7%
1144	(CD3OD) δ 8.02 (d, 1 H), 7.79-7.94 (m, 1 H), 7.72 (d, 1 H), 7.38 (d, 1 H), 7.18-7.32 (m, 1 H), 6.94-7.08 (m, 1 H), 6.88 (s, 0.5 H), 6.55 (s, 0.5 H), 4.99 (br s. 0.6 H), 4.23-4.29 (m, 0.4 H), 4.03 (d, 3 H), 3.75 (td, 0.6 H), 2.69-3.30 (m, 2.4 H)	417.2 [M+H]+	99.3%
1145	(CD3OD) δ 7.90 (d, 1 H), 7.67-7.80 (m, 1 H), 7.59 (d, 1 H), 7.23-7.30 (m, 1 H), 7.10-7.22 (m, 1 H), 6.81-6.99 (m, 1 H), 6.76 (s, 0.5 H), 6.42 (s, 0.5 H), 4.86 (br d, 0.5 H), 4.14 (br dd, 0.5 H), 3.91 (d, 3 H), 3.58-3.67 (m, 0.5 H), 2.57-3.18 (m, 2.5 H)	417.2 [M+H]+	99.3%
1146	(CD3OD) δ 8.39-8.64 (m, 1 H), 7.65-7.76 (m, 1 H), 7.41-7.56 (m, 1 H), 7.08-7.19 (m, 1 H), 6.93 (s, 0.7 H), 6.73 (d, 1 H), 6.59 (s, 0.7 H), 6.36 (s, 0.3 H), 6.09 (s, 0.3 H), 3.76-3.94 (m. 1.5 H), 3.43-3.57 (m, 0.5 H), 2.74-3.04 (m, 2 H), 2.62-2.72 (m, 3 H)	417.1 [M+H]+	99.8%
1147	(CD3OD) δ 8.35-8.64 (m, 1 H), 7.64-7.75 (m, 1 H), 7.38-7.56 (m, 1 H), 7.05-7.20 (m, 1 H), 6.93 (s, 0.7 H), 6.73 (d, 1 H), 6.59 (s, 0.7 H), 6.36 (s, 0.3 H), 6.09 (br s, 0.3 H), 3.74-3.94 (m, 1.5 H), 3.41-3.54 (m, 0.5 H), 2.74-3.03 (m, 2 H), 2.60-2.71 (m, 3 H)	417.1 [M+H]+	99.8%
1148	(CD3OD) δ 8.26 (s, 1 H), 7.67 (s, 1 H), 7.47 (br d, 1 H), 7.12 (dd, 1 H), 6.90 (br s, 0.6 H), 6.71 (d. 1 H), 6.60 (br s, 1.4 H), 4.64-4.73 (m, 0.5 H), 4.18-4.42 (m, 0.5 H), 3.72-4.00 (m, 0.6 H), 3.37-3.56 (m, 0.4 H), 2.90-3.12 (m, 1 H), 2.82 (br d, 1 H), 2.67 (s, 3 H), 2.38 (s, 3 H)	363.2 [M+H]+	100%
1149	(CD3OD) δ 8.26 (s, 1 H), 7.67 (s, 1 H), 7.47 (br d, 1 H), 7.12 (dd, 1 H), 6.89 (br s, 0.6 H), 6.71 (d. 1 H), 6.59 (br s, 1.4 H), 4.70-4.86 (m, 0.4 H), 4.32 (br s, 0.6 H), 3.86 (br s, 0.6 H), 3.37-3.55 (m, 0.4 H), 3.02 (br s, 1 H), 2.80 (dd, 1 H), 2.66 (s, 3 H), 2.38 (s, 3 H)	363.2 [M+H]+	100%
1150	(CD3OD) δ 7.58-7.84 (m, 1 H), 7.40-7.54 (m, 1 H), 7.07-7.19 (m, 1 H), 6.92 (s, 0.6 H), 6.73 (d, 1 H), 6.60 (s, 0.6 H), 6.40 (s, 0.4 H), 6.14 (br s, 0.4 H), 3.73-3.96 (m, 1.5 H), 3.40-3.56 (m, 0.5 H), 2.92-3.07 (m, 1 H), 2.75-2.91 (m, 1 H), 2.60-2.72 (m, 3 H), 1.59-1.69 (m, 6 H)	475.2 [M+H]+	99.3%
1151	(CD3OD) δ 7.62-7.77 (m, 1 H), 7.42-7.55 (m, 1 H), 7.08-7.21 (m, 1 H), 6.92 (s, 0.6 H), 6.73 (d, 1 H), 6.60 (s, 0.6 H), 6.40 (s, 0.4 H), 6.14 (s, 0.4 H), 3.77-3.95 (m, 1.4 H), 3.49 (td, 0.6 H), 2.92-3.07 (m, 1 H), 2.75-2.90 (m, 1 H), 2.64-2.73 (m, 3 H). 1.61-1.69 (m, 6 H)	475.2 [M+H]+	99.2%
1152	(CD3OD) δ 7.55 (s, 1 H), 7.36 (br d, 1 H), 6.95-7.17 (m, 2 H), 6.30-6.91 (m, 3 H). 4.84-4.90 (m, 1 H). 4.53-4.67 (m, 0.5 H), 4.17-4.32 (m, 0.5 H), 3.66-3.86 (m, 0.5 H), 3.27-3.42 (m, 0.5 H), 2.64-3.06 (m, 2 H), 2.44-2.63 (m, 3 H), 1.32-1.65 (m, 3 H)	443.2 [M+H]+	99.5%
1153	(CD3OD) δ 7.55 (s, 1 H), 7.36 (br d, 1 H), 6.92-7.20 (m, 2 H), 6.33-6.88 (m, 3 H), 4.87 (q, 1 H), 4.50-4.67 (m, 0.5 H), 4.15-4.33 (m, 0.5 H), 3.66-3.85 (m, 0.5 H), 3.26-3.47 (m, 0.5 H), 2.64-3.09 (m, 2 H), 2.55 (br s, 3 H). 1.49 (br s. 3 H)	443.2 [M+H]+	98.8%
1154	(CD3OD) δ 8.32 (s, 1 H), 7.48-7.81 (m, 2 H), 7.22-7.34 (m, 1 H), 6.48-7.20 (m, 4 H), 4.20 (br s, 1 H), 3.79 (br d, 1 H), 2.91 (br s, 1 H), 2.70 (dd, 1 H)	453.1 [M+H]+	99.4%
1155	(CD3OD) δ 8.32 (s, 1 H), 7.54-7.85 (m, 2 H), 7.20-7.34 (m, 1 H), 6.47-7.19 (m, 4 H), 4.21 (br s, 1 H), 3.78 (br s, 1 H), 2.92 (br d, 1 H), 2.70 (dd, 1 H)	453.1 [M+H]+	97.8%
1156	(CD3OD) δ 7.87 (br s, 1 H), 7.69 (s, 1 H), 7.35-7.41 (m, 1 H), 6.68-7.32 (m, 4 H), 4.36 (br d, 1 H), 3.92 (br s, 1 H), 2.92-3.15 (m, 1 H), 2.83 (br d, 1 H), 1.53-1.76 (m, 6 H)	511.2 [M+H]+	99.8%
1157	(CD3OD) δ 7.87 (br s, 1 H), 7.69 (s, 1 H), 7.33-7.45 (m, 1 H), 6.61-7.33 (m, 4 H), 4.37 (br d, 1 H), 3.91 (br s, 1 H), 2.93-3.13 (m, 1 H), 2.83 (br d, 1 H), 1.52-1.76 (m, 6 H)	511.2 [M+H]+	96.9%
1158	(CD3OD) δ 8.68 (br s, 1 H), 8.39 (s, 1 H), 7.74-8.09 (m, 1 H), 7.69 (s, 1 H), 7.62 (br d, 1 H), 6.63-7.03 (m, 3 H), 4.73-4.87 (m, 1 H), 4.51 (br s, 0.4 H), 3.75 (br s, 0.6 H), 3.09 (br s, 1 H), 2.82 (br d, 1 H)	403.1 [M+H]+	99.6%
1159	(CD3OD) δ 8.68 (br s, 1 H), 8.39 (s, 1 H), 7.73-8.09 (m, 1 H), 7.69 (s, 1 H), 7.62 (br d. 1 H), 6.63-7.03 (m, 3 H), 4.73-4.87 (m, 1 H), 4.51 (br s, 0.4 H), 3.74 (br s, 0.6 H), 3.09 (br s, 1 H), 2.82 (br d, 1 H)	403.1 [M+H]+	99.7%
1160	(CD3OD) δ 7.87 (dd, 1 H), 7.59-7.77 (m, 1 H), 7.53 (br s, 0.5 H), 7.24-7.43 (m, 2 H), 6.87 (s, 1 H), 6.67 (s, 0.5 H), 4.95-5.02 (m, 1 H), 3.96 (br s, 0.5 H), 2.73-3.31 (m, 2.5 H), 1.82-1.99 (m, 6 H)	464.2 [M+H]+	99.1%
1161	(CD3OD) δ 7.74 (dd, 1 H), 7.50-7.65 (m, 1 H), 7.41 (s, 0.5 H), 7.08-7.27 (m, 2 H), 6.67-6.89 (m, 1 H), 6.55 (s, 0.5 H), 4.84-4.89 (m, 1 H), 3.75-3.91 (m, 0.5 H), 2.70-3.19 (m, 2.5 H), 1.72-1.86 (m, 6 H)	464.2 [M+H]+	98.0%
1162	(CD3OD) δ 7.68-7.80 (m. 1 H), 7.60 (d, 1 H), 7.26 (br d, 1 H), 7.13-7.20 (m, 1 H), 7.01 (s, 0.5 H), 6.72-6.88 (m, 1 H), 6.44 (s, 0.5 H), 4.84 (br s, 0.5 H), 4.24 (dd, 0.5 H), 3.89 (d, 3 H), 3.56-3.73 (m, 0.5 H), 2.92-3.15 (m, 1 H), 2.79-2.92 (m, 0.5 H), 2.59-2.77 (m, 1 H)	451.1 [M+H]+	98.4%
1163	(CD3OD) δ 7.81-7.91 (m, 1 H), 7.72 (d, 1 H), 7.34-7.43 (m, 1 H), 7.23-7.33 (m, 1 H), 7.13 (s, 0.5 H), 6.84-6.96 (m, 1 H), 6.57 (s, 0.5 H), 4.95 (br d, 0.5 H), 4.36 (dd. 0.5 H). 4.01 (d, 3 H), 3.70-3.81 (m, 0.5 H), 3.07-3.27 (m, 1 H), 2.91-3.03 (m, 0.5 H), 2.71-2.90 (m, 1 H)	451.1 [M+H]+	99.1%
1164	(CD3OD) δ 7.68 (s, 1 H), 7.47 (br s, 1 H), 6.97-7.28 (m, 2 H), 6.90 (br s, 0.4 H), 6.73 (br d, 1.3 H), 6.42-6.65 (m, 1.3 H), 4.96-5.01 (m, 1.8 H), 4.37 (br s, 0.2 H), 3.89 (br s, 0.5 H), 3.36-3.53 (m, 0.5 H), 2.90-3.12 (m, 1 H), 2.76-2.88 (m, 1 H), 2.68 (br s, 3 H), 1.62 (br s, 3 H)	443.1 [M+H]+	98.9%
1165	(CD3OD) δ 7.70 (s, 1 H), 7.48 (br s, 1 H), 6.95-7.30 (m, 2 H), 6.90 (br s, 0.5 H), 6.73 (br d, 1.3 H), 6.43-6.66 (m, 1.2 H), 4.96-5.00 (m, 1.7 H), 4.38 (br s, 0.3 H), 3.88 (br s, 0.5 H), 3.50 (s, 0.5 H), 2.90-3.18 (m, 1 H), 2.83 (dd, 1 H), 2.68 (br s, 3 H), 1.61 (br s, 3H)	443.2 [M+H]+	98.3%
1166	(CD3OD) δ 8.29 (s, 1 H), 7.98 (br s, 1.5 H), 7.66 (br s, 0.5 H), 7.56 (s, 1 H), 6.58-6.85 (m, 2 H), 6.33-6.57 (m, 2 H), 4.37 (br s, 1 H), 3.85 (s, 3 H), 3.64 (br d, 1 H), 2.96 (br s, 1 H), 2.59-2.78 (m, 1H)	365.2 [M+H]+	1 00%
1167	(CD3OD) δ 8.29 (s, 1 H), 7.98 (br s, 1.5 H), 7.67 (br s, 0.5 H), 7.56 (s, 1 H), 6.57-6.82 (m, 2 H), 6.34-6.58 (m, 2 H), 4.36 (br s, 1 H), 3.85 (s, 3 H), 3.64 (br d, 1 H), 2.79-3.07 (m, 1 H), 2.59-2.79 (m, 1 H)	365.1 [M+-H]+	99.2%
1168	(CD3OD) δ 7.98-8.17 (m, 1 H), 7.69 (s, 1 H), 6.87-7.49 (m, 1 H), 6.74-6.84 (m, 1 H), 6.65 (s, 1H), 6.56-6.62 (m, 1 H), 4.98 (br dd, 1 H), 3.92-4.00 (m, 3 H), 3.36-3.79 (m, 1 H), 2.77-3.21 (m, 2 H), 2.28-2.38 (m, 1 H), 1.20-1.33 (m, 4 H)	406.2 [M+H]+	98.8%
1169	(CD3OD) δ 7.87-8.04 (m, 1 H), 7.57 (s, 1 H), 6.74-7.41 (m, 1 H), 6.65-6.71 (m, 1 H), 6.40-6.59 (m, 2 H), 4.86 (br dd, 1 H), 3.79-3.91 (m, 3 H), 3.24-3.66 (m, 1 H), 2.59-3.05 (m, 2 H), 2.08-2.33 (m, 1 H), 1.07-1.21 (m, 4 H)	406.2 [M+H]+	94.4%
1170	(CD3OD) δ 8.17-8.28 (m, 1 H), 7.68 (s, 1 H), 7.45-7.53 (m, 1 H), 7.40 (s, 0.3 H), 7.05-7.12 (m, 1H), 6.92 (s, 0.7 H), 6.43-6.58 (m, 1 H), 4.94 (br d, 1 H), 3.69-3.80 (m, 0.7 H), 3.34-3.43 (m, 0.3 H), 2.78-3.19 (m, 2 H), 2.28-2.35 (m, 3 H), 1.90-1.94 (m, 3 H), 1.84-1.88 (m, 3 H)	410.2 [M+H]+	100%
1171	(CD3OD) δ 8.18-8.28 (m, 1 H), 7.68 (s, 1 H), 7.45-7.53 (m, 1 H), 7.40 (br s, 0.3 H), 7.04-7.13 (m, 1 H), 6.91 (br s, 0.7 H), 6.43-6.57 (m, 1 H), 4.93-4.96 (m, 1 H), 3.67-3.80 (m, 0.7 H), 3.34-3.44 (m, 0.3 H), 2.78-3.19 (m, 2 H), 2.27-2.37 (m, 3 H), 1.91 (d, 3 H), 1.86 (d, 3 H)	410.2 [M+H]+	98.5%
1172	(CD3OD) δ 8.43-8.54 (m, 1 H), 7.56-7.69 (m, 2 H), 7.20 (br dd, 1H), 7.06 (d. 1 H), 6.05-6.94 (m, 2 H), 3.45-3.99 (m, 2 H), 2.78-3.00 (m, 2 H)	437.1 [M+H]+	100%
1173	(CD3OD) δ 8.40-8.51 (m, 1 H), 7.54-7.68 (m, 2 H), 7.14-7.23 (m, 1 H), 7.03 (d, 1 H), 6.05-6.94 (m, 2 H), 3.42-3.94 (m, 2 H), 2.76-2.99 (m, 2 H)	437.1 [M+H]+	100%
1174	(CD3OD) δ 8.26 (s, 1 H), 7.67 (s, 1 H), 7.61 (br d, 1 H), 7.18 (dd, 1 H), 7.04 (dd, 1 H), 6.49-6.94 (m, 2 H), 4.25-4.44 (m, 1 H), 3.85 (td, 1 H), 2.76-3.07 (m, 2 H), 2.39 (s, 3 H)	383.1 [M+H]+	100%
1175	(CD3OD) δ 8.26 (s, 1 H), 7.68 (br s, 1 H), 7.61 (br d, 1 H), 7.18 (t, 1 H), 7.00-7.05 (m, 1 H), 6.57-6.91 (m, 2 H), 4.35 (br s, 1 H), 3.74-3.97 (m, 1 H), 2.78-3.07 (m, 2 H), 2.39 (s, 3 H)	383.1 [M+H]+	99.7%
1176	(CD3OD) δ 8.35 (s, 1 H), 7.56-7.83 (m, 2 H), 7.12-7.29 (m, 2 H), 6.70-6.84 (m, 1.4 H), 6.47 (s, 0.3 H), 6.03 (s, 0.3 H), 3.60-3.88 (m, 1.6 H), 3.37 (td, 0.4 H), 2.61-2.91 (m, 2 H)	471.1 [M+H]+	99.1%
1177	(CD3OD) δ 8.48 (s, 1 H), 7.75-8.01 (m, 1 H), 7.64-7.73 (m, 1 H), 7.24-7.43 (m, 2 H), 6.80-6.95 (m, 1.4 H), 6.59 (s, 0.3 H), 6.14 (s, 0.3H), 3.78-4.01 (m, 1.5 H), 3.42-3.55 (m, 0.5 H), 2.75-3.02 (m, 2H)	471.1 [M+-H]+	98.6%
1178	(CD3OD) δ 7.80-7.95 (m, 1 H), 7.61-7.77 (m, 1 H), 7.23-7.48 (m, 2 H), 6.80-7.00 (m, 1.3 H), 6.66 (s, 0.3 H), 5.91-6.40 (m, 0.4 H), 4.96-5.00 (m, 0.2 H), 3.75-4.10 (m, 1.4 H), 3.51 (br d, 0.4 H), 2.90-3.08 (m, 1 H), 2.82 (br t, 1 H), 1.57-1.70 (m, 6 H)	529.2 [M+H]+	96.3%
1179	(CD3OD) δ 7.81-7.93 (m, 1 H), 7.54-7.78 (m, 1 H), 7.13-7.46 (m, 2 H), 6.79-7.06 (m, 1.3 H), 6.66 (s, 0.4 H), 6.21 (br s, 0.3 H), 4.93-4.98 (m, 0.2 H), 3.77-4.00 (m, 1.4 H), 3.52 (td, 0.4 H), 2.75-3.08 (m, 2 H), 1.55-1.73 (m, 6 H)	529.2 [M+H]+	97.8%
1180	(CD3OD) δ 7.88 (br d, 1 H), 7.68 (s, 1 H), 7.34-7.40 (m, 1 H), 7.25-7.33 (m, 1 H), 6.92-7.25 (m, 1H), 6.68-6.91 (m, 2H), 4.98 (br s, 1.5 H), 4.25-4.48 (m, 0.5 H), 3.78-4.02 (m, 0.5 H), 3.35-3.50 (m, 0.5 H), 2.90-3.22 (m, 1 H), 2.83 (br d, 1 H), 1.46-1.75 (m, 3 H)	497.2 [M+H]+	96.9%
1181	(CD3OD) δ 7.87 (br d, 1 H), 7.68 (s, 1 H), 7.36 (d, 1 H), 7.25-7.33 (m, 1 H), 6.92-7.24 (m, 1 H), 6.69-6.91 (m, 2 H), 4.98 (br s, 1.5 H), 4.26-4.47 (m, 0.5 H), 3.78-4.02 (m, 0.5 H), 3.36-3.49 (m, 0.5 H), 2.90-3.20 (m, 1 H), 2.83 (br d, 1 H), 1.44-1.76 (m, 3 H)	497.2 [M+-H]+	95.5%
1182	(CD3OD) δ 7.85-8.07 (m, 1 H), 7.46-7.65 (m, 1 H), 7.28 (s, 0.3 H), 6.81 (s, 0.7 H), 6.63-6.72 (m, 1 H), 6.39-6.58 (m, 2 H), 4.85 (br d, 1 H), 3.80-3.89 (m, 3 H), 3.24-3.69 (m, 1 H), 2.65-3.10 (m, 2 H), 1.37 (s, 9 H)	422.2 [M+H]+	100%
1183	(CD3OD) δ 7.87-8.06 (m, 1 H), 7.58 (br s, 1 H), 7.28 (br s, 0.3 H), 6.81 (br s, 0.6 H), 6.63-6.72 (m, 1 H), 6.35-6.58 (m, 2 H), 4.81-4.93 (m, 1 H), 3.78-3.90 (m, 3 H), 3.24-3.70 (m, 1 H), 2.64-3.09 (m, 2 H), 1.37 (s, 9 H)	422.2 [M+H]+	99.7%
1184	(CD3OD) δ 8.23-8.42 (m, 2 H), 7.70-8.14 (m, 1 H), 7.66 (s, 1 H), 7.34 (s, 1 H), 6.25-6.92 (m, 3 H), 4.75 (br s, 0.5H), 4.46 (br s, 0.5 H), 3.74 (br s, 0.5 H), 3.35 (br s, 0.5 H), 2.66-3.19 (m, 2 H), 2.36 (s, 3 H)	349.2 [M+H]+	99.5%
1185	(CD3OD) δ 8.25-8.44 (m, 2 H), 7.71-8.13 (m, 1 H), 7.67 (s, 1 H), 7.33 (s, 1 H), 6.28-6.93 (m, 3 H), 4.76 (br s, 0.5 H), 4.46 (br s, 0.5 H), 3.74 (br s, 0.5 H), 3.35 (br s, 0.5 H), 2.67-3.19 (m, 2 H), 2.36 (s, 3 H)	349.2 [M+H]+	98.4%
1186	(CD3OD) δ 8.15-8.42 (m, 2 H), 7.66-8.10 (m, 2 H), 7.49 (d, 1 H), 7.08 (d, 1 H), 6.29-6.96 (m, 2 H), 4.69-4.85 (m, 1 H), 4.46 (br s, 0.5 H), 3.62-3.85 (m, 0.5 H), 2.73-3.13 (m, 2 H), 2.32 (s, 3 H)	349.1 [M+H]+	100%
1187	(CD3OD) δ 8.11-8.41 (m, 2 H), 7.55-8.08 (m, 2 H), 7.49 (d, 1 H), 7.08 (d, 1 H), 6.29-6.96 (m, 2 H), 4.76 (br s, 1 H), 4.45 (br s, 0.5H), 3.74 (br s, 0.5 H), 2.65-3.16 (m, 2 H), 2.32 (s, 3 H)	349.2 [M+H]+	99.4%
1188	(CD3OD) δ 7.98 (br s, 1 H), 7.71 (d, 1 H), 7.40-7.50 (m, 1.5 H), 7.05-7.14 (m, 1 H), 6.98 (s, 0.5 H), 6.68 (br dd, 1 H), 6.61 (s, 0.6 H), 6.46 (s, 0.4 H), 5.03-5.12 (m, 0.6 H), 3.84-3.95 (m, 4 H), 3.33-3.42 (m, 0.4 H), 3.11-3.22 (m, 0.6 H), 2.93-3.03 (m, 0.4 H), 2.80-2.88 (m, 1 H), 2.6-4-2.68 (m, 5 H), 2.50 (s, 1 H)	444.2 [M+H]+	98.4%
1189	(CD3OD) δ 7.98 (d, 1 H), 7.69 (d, 1 H), 7.40-7.50 (m, 1.5 H), 7.10 (dt, 1 H), 6.98 (s, 0.5 H), 6.69 (dd, 1 H), 6.61 (s, 0.6H), 6.45 (s, 0.4 H), 5.08 (br dd, 0.6 H), 3.82-3.95 (m, 4 H), 3.34-3.41 (m, 0.4 H), 3.11-3.22 (m, 0.6 H), 2.93-3.04 (m, 0.4 H), 2.80-2.88 (m, 1 H), 2.64-2.68 (m, 5 H), 2.51 (s, 1 H)	444.2 [M+-H]+	92.9%
1190	(CD3OD) δ 7.99 (d, 1 H), 7.79-7.90 (m, 1 H), 7.73 (s, 0.5 H), 7.67 (s, 0.5 H), 7.58 (s, 0.5 H), 7.21-7.37 (m, 2 H), 6.96 (s, 0.5 H), 6.86 (s, 0.5 H), 6.66 (s, 0.5 H), 5.11 (br dd, 0.5 H), 4.93-4.99 (m, 1 H), 3.91-3.99 (m, 0.5 H), 3.89 (d, 3 H), 3.11-3.22 (m, 0.5 H), 2.93-3.04 (m, 0.5H), 2.85 (br d, 1 H), 2.67 (s, 3 H)	498.2 [M+-H]+	98.5%
1191	(CD3OD) δ 7.99 (br d, 1 H), 7.79-7.90 (m, 1 H), 7.74 (br s, 0.5 H), 7.61-7.70 (m, 0.5H), 7.59 (br s, 0.5H), 7.22-7.37 (m, 2H), 6.97 (br s, 0.5H), 6.86 (s, 0.5H), 6.66 (s, 0.5H), 5.06-5.15 (m, 0.5 H), 4.96 (br d, 1 H), 3.92-4.00 (m, 0.5H), 3.89 (br d, 3H), 3.11-3.25 (m, 0.5 H), 2.92-3.05 (m, 0.5 H), 2.80-2.91 (m, 1 H), 2.67 (s, 3 H)	498.2 [M+H]+	95.2%
1192	(CD3OD) δ 7.54-7.73 (m, 2 H), 7.20 (br t, 1 H), 7.06 (d, 1 H), 6.57-6.97 (m, 1.6 H), 6.14 (br s, 0.4 H), 3.78-4.03 (m, 1.5 H), 3.52 (td, 0.5 H), 2.72-3.08 (m, 2 H), 1.61-1.70 (m, 6 H)	495.2 [M+H]+	100%
1193	(CD3OD) δ 7.45-7.59 (m, 2 H), 7.09 (br t, 1 H), 6.94 (d, 1 H), 6.42-6.85 (m, 1.6 H), 6.02 (br s, 0.4 H), 3.75 (br d, 1.5 H), 3.33-3.49 (m, 0.5 H), 2.64-2.94 (m, 2 H), 1.49-1.57 (m, 6 H)	495.1 [M+H]+	97.0%
1194	(CD3OD) δ 7.57-7.71 (m, 2 H), 7.12-7.32 (m, 1.7 H), 6.98-7.10 (m, 1.3 H), 6.54-6.95 (m, 2 H), 4.96-5.02 (m, 1 H), 4.77-4.86 (m, 0.5 H), 4.40 (br d, 0.5 H), 3.88 (br s, 0.5 H), 3.38-3.54 (m, 0.5 H), 2.76-3.20 (m, 2 H), 1.49-1.72 (m, 3 H)	463.1 [M+H]+	100%
1195	(CD3OD) δ 7.54-7.69 (m, 2 H), 7.10-7.30 (m, 1.8 H), 6.97-7.08 (m, 1.2 H), 6.58-6.96 (m, 2 H), 4.97 (br d, 1 H), 4.77-4.85 (m, 0.5 H), 4.38 (br d, 0.5 H), 3.86 (br s, 0.5 H), 3.45 (br d, 0.5 H), 2.74-3.18 (m, 2 H), 1.60 (br s, 3 H)	463.1 [M+H]+	91.7%
1196	(CD3OD) δ 7.68 (s, 1 H), 7.62 (br d, 1 H), 7.14-7.31 (m, 2 H), 7.00-7.08 (m, 1 H), 6.61-6.92 (m, 2 H), 4.99 (br d, 1 H), 4.64-4.68 (m, 1 H), 4.34-4.44 (m, 0.5 H), 3.81-3.93 (m, 0.5 H), 2.80-3.14 (m, 2 H), 1.55-1.66 (m, 3 H)	463.1 [M+H]+	97.3%
1197	(CD3OD) 3 7.68 (s, 1 H), 7.62 (br d, 1 H), 7.14-7.29 (m, 2 H), 7.01-7.07 (m, 1 H), 6.64-6.92 (m, 2 H), 4.99 (br d, 1 H), 4.64-4.67 (m, 1 H), 4.40 (br dd, 0.5 H), 3.88 (br s, 0.5 H), 2.81-3.17 (m, 2 H), 1.62 (br s, 3 H)	463.1 [M+H]+	98.7%
1198	(CD3OD) δ 8.26 (s, 1 H), 7.86 (br d, 1 H), 7.68 (s, 1 H), 7.24-7.41 (m, 2 H), 6.86 (br s, 2 H), 4.33 (br s, 0.9 H), 3.55-4.05 (m, 1.1 H), 3.01 (br s, 1 H), 2.80 (dd, 1 H), 2.37 (s, 3 H)	417.1 [M+H]+	99.8%
1199	(CD3OD) δ 8.14 (s, 1 H), 7.75 (br d, 1 H), 7.56 (s, 1 H), 7.08-7.31 (m, 2 H), 6.39-6.83 (m, 2 H), 4.22 (br s, 1 H), 3.51-3.90 (m, 1 H), 2.81-3.00 (m, 1 H), 2.68 (br dd, 1 H), 2.25 (s, 3 H)	417.1 [M+H]+	99.7%
1200	(CD3OD) δ 7.75 (br d, 1 H), 7.57 (s, 1 H), 7.14-7.28 (m, 2 H), 6.55-7.12 (m, 3 H), 4.86 (br s, 1 H), 4.25 (br s, 1 H), 3.26-3.86 (m, 1 H), 2.82-3.03 (m, 1 H), 2.71 (dd, 1 H), 1.41-1.56 (m, 3 H)	497.2 [M+H]+	88.2%
1201	(CD3OD) δ 7.87 (br d, 1 H), 7.68 (s, 1 H), 7.23-7.42 (m, 2 H), 6.60-7.23 (m, 3 H), 4.98 (br s, 1 H), 4.36 (br s, 1 H), 3.41-4.06 (m, 1 H), 2.94-3.17 (m, 1 H), 2.83 (br d, 1 H), 1.43-1.73 (m, 3 H)	497.1 [M+H]+	98.7%
1202	(CD3OD) δ 8.44 (s, 1 H), 7.69 (s, 1 H), 7.48 (br d, 1 H), 7.00-7.33 (m, 2 H), 6.73-6.95 (m, 1.4 H), 6.48-6.72 (m, 1.6 H), 4.79-4.86 (m, 0.3 H), 4.36 (br d, 0.7 H), 3.71-3.97 (m, 0.7 H), 3.37-3.49 (m, 0.3 H), 3.08 (br s, 1 H), 2.82 (br d, 1 H)	403.1 [M+H]+	99.8%
1203	(CD3OD) δ 8.44 (s, 1 H), 7.69 (s, 1 H), 7.48 (br d, 1 H), 6.99-7.33 (m, 2 H), 6.72-6.94 (m, 1.5 H), 6.51-6.71 (m, 1.5 H), 4.85 (br s, 0.3 H), 4.36 (br d, 0.7 H), 3.80 (br s, 0.7 H), 3.37-3.48 (m, 0.3 H), 3.09 (br s, 1 H), 2.82 (br d, 1 H)	403.2 [M+H]+	99.1%
1204	(CD3OD) δ 8.59-8.76 (m, 1 H), 7.91-8.05 (m, 1 H), 7.70 (s, 1 H), 7.52-7.67 (m, 1.4 H), 6.91-7.05 (m, 1.6 H), 6.72-6.83 (m, 1 H), 4.94-5.15 (m, 1 H), 3.83-3.95 (m, 3 H), 3.68-3.82 (m, 0.7 H), 3.39 (td, 0.3 H), 2.79-3.25 (m, 2 H), 2.59-2.72 (m, 3 H)	498.2 [M+-H]+	100%
1205	(CD3OD) δ 8.57-8.79 (m, 1 H), 7.94-8.07 (m, 1H), 7.70 (s, 1 H), 7.52-7.67 (m, 1.3 H), 6.90-7.06 (m, 1.7 H), 6.73-6.83 (m, 1 H), 5.12 (br dd, 1 H), 3.86-3.95 (m, 3 H), 3.69-3.83 (m, 0.7 H), 3.39 (td, 0.3 H), 2.78-3.25 (m, 2 H), 2.63-2.71 (m, 3 H)	498.2 [M+H]+	100%
1206	(CD3OD) δ 7.93-8.15 (m, 2 H), 7.69 (s, 1 H), 7.53 (s, 0.3 H), 6.94 (s, 0.7 H), 6.73-6.85 (m, 1 H), 6.66 (s, 0.6 H), 6.53-6.63 (m, 1.4 H), 5.06 (dd, 1 H), 3.83-4.01 (m, 6 H), 3.70-3.79 (m, 0.7 H), 3.39 (td, 0.3 H), 2.77-3.24 (m, 2 H), 2.62-2.71 (m, 3 H)	460.2 [M+H]+	98.2%
1207	(CD3OD) δ 7.95-8.16 (m, 2 H), 7.69 (s, 1 H), 7.53 (br s, 0.3 H), 6.93 (s, 0.7 H), 6.72-6.85 (m, 1 H), 6.66 (s, 0.7 H), 6.52-6.63 (m, 1.3 H), 5.06 (br dd, 1 H), 3.85-4.01 (m, 6H), 3.70-3.82 (m, 0.7 H), 3.35-3.44 (m, 0.3 H), 2.79-3.23 (m, 2 H), 2.61-2.73 (m, 3 H)	460.2 [M+H]+	97.2%
1208	(CD3OD) δ 7.98 (br s, 1 H), 7.65-7.72 (m, 1 H), 7.49-7.64 (m, 1.5 H), 7.11-7.21 (m, 1 H), 6.94-7.06 (m, 1.5 H), 6.78 (s, 0.5 H), 6.64 (s, 0.5 H), 5.11 (dd, 0.6 H), 4.95 (br d, 0.4 H), 3.93 (br d, 0.5 H), 3.88 (s, 3 H), 3.38 (td, 0.5 H), 3.12-3.23 (m, 0.6 H), 2.93-3.04 (m, 0.4 H), 2.85 (br dd, 1 H), 2.62-2.70 (m, 3 H)	464.2 [M+H]+	98.9%
1209	(CD3OD) δ 7.95-8.03 (m, 1 H), 7.67-7.72 (m, 1 H), 7.50-7.65 (m, 1.5 H), 7.11-7.21 (m, 1 H), 6.94-7.08 (m, 1.5 H), 6.79 (d, 0.5 H), 6.64 (s, 0.5 H), 5.11 (dd, 0.6 H), 4.94-4.96 (m, 0.4 H), 3.92 (br d, 0.5 H), 3.89 (s, 3 H), 3.38 (td, 0.5 H), 3.11-3.24 (m, 0.6 H), 2.93-3.05 (m, 0.4 H), 2.85 (br dd, 1 H), 2.62-2.71 (m, 3H)	464.2 [M+H]+	94.5%
1210	(CD3OD) δ 7.55-7.76 (m, 2 H), 7.17 (dd, 1H), 6.97-7.06 (m, 1 H), 6.49-6.94 (m, 2 H), 4.96-4.97 (m, 0.5 H), 4.36 (br s, 0.5 H), 3.85 (br s, 0.5 H), 3.38-3.44 (m, 0.5 H), 2.71-3.18 (m, 2 H), 2.36 (s, 3 H), 1.62 (br s, 6 H)	441.2 [M+H]+	98.9%
1211	(CD3OD) δ 7.56-7.69 (m, 2 H), 7.14-7.26 (m, 1 H), 7.02 (d, 1 H), 6.42-6.98 (m, 2H), 4.98-5.00 (m, 0.5H), 4.35 (br s, 0.5H), 3.85 (br s, 0.5 H), 3.38-3.48 (m, 0.5 H), 2.68-3.19 (m, 2 H), 2.36 (s, 3H), 1.62 (br s, 6 H)	441.2 [M+H]+	97.8%
1212	(CD3OD) δ 7.57-7.69 (m, 2 H), 7.17 (dd, 1 H), 7.02 (dd, 1 H), 6.50-6.94 (m, 2 H), 4.98-5.01 (m, 1.5 H), 4.36 (br s, 0.5 H), 3.84 (br s, 0.5 H), 3.37-3.43 (m, 0.5 H), 2.72-3.10 (m, 2 H), 2.36 (s, 3 H), 1.56 (br s, 3 H)	427.1 [M+H]+	98.6%
1213	(CD3OD) δ 7.52-7.73 (m, 2 H), 7.09-7.24 (m, 1 H), 7.02 (d. 1 H), 6.47-6.90 (m, 2 H), 4.99-5.05 (m, 1.5 H), 4.37 (br s, 0.5 H), 3.84 (br s, 0.5 H), 3.38-3.47 (m, 0.5 H), 2.74-3.14 (m, 2 H), 2.36 (s, 3 H), 1.56 (br s, 3 H)	427.1 [M+H]+	99.5%
1214	(CD3OD) δ 8.30-8.54 (m, 1 H), 7.91-8.07 (m, 1 H), 7.71 (s, 1 H), 7.56 (s, 0.3 H), 7.19-7.36 (m, 1 H), 6.95 (s, 0.6 H), 6.69-6.89 (m, 2 H), 5.10 (br dd, 1 H), 3.88 (s, 3 H), 3.72-3.80 (m, 0.6 H), 3.37-3.43 (m, 0.4 H), 2.78-3.24 (m, 2 H), 2.61-2.73 (m, 3 H)	464.1 [M+H]+	100%
1215	(CD3OD) δ 8.31-8.50 (m, 1 H), 7.82-8.07 (m, 1 H), 7.70 (s, 1 H), 7.55 (s, 0.3 H), 7.30 (br t, 1 H), 6.95 (s, 0.7 H), 6.67-6.88 (m, 2 H), 5.10 (br dd, 1 H), 3.89 (s, 3 H), 3.72-3.80 (m, 0.5 H), 3.39-3.44 (m, 0.5 H), 2.82-3.23 (m. 2 H), 2.57-2.73 (m, 3 H)	464.2 [M+H]+	99.4%
1216	(CD3OD) δ 8.30 (br d, 1 H), 7.68 (s, 1 H), 7.28 (s, 0.4 H), 7.15 (s, 0.6 H), 6.96-7.03 (m, 1 H), 6.73-6.90 (m, 2 H), 6.52-6.64 (m, 1 H), 4.29 (br d, 1 H), 3.75 (br t, 0.6 H), 3.36-3.47 (m, 0.4 H), 2.77-3.14 (m, 2 H), 2.44 (br s, 3 H), 1.72-1.91 (m, 6 H)	459.2 [M+H]+	99.7%
1217	(CD3OD) δ 8.29 (br d, 1 H), 7.68 (br s, 1 H), 7.28 (s, 0.4 H), 7.15 (s, 0.6 H), 6.96-7.03 (m, 1 H), 6.71-6.89 (m, 2 H), 6.52-6.65 (m, 1 H), 4.29 (br d, 1 H), 3.75 (br t, 0.6 H), 3.37-3.50 (m, 0.4 H), 2.74-3.15 (m, 2 H), 2.44 (br s, 3 H), 1.68-1.93 (m, 6 H)	459.2 [M+H]+	98.6%
1218	(CD3OD) δ 8.69 (d. 1 H), 7.61-7.71 (m, 2 H), 7.27 (s, 0.5 H), 7.14 (s, 0.5 H), 6.96-7.02 (m, 1 H), 6.76-6.90 (m, 1.5 H), 6.57 (br d, 0.5 H), 4.28-4.37 (m, 0.8 H), 3.69-3.80 (m, 1 H), 3.41-3.51 (m, 0.2 H), 2.79-3.15 (m, 2 H), 1.69-1.91 (m, 6 H)	513.2 [M+H]+	98.8%
1219	(CD3OD) δ 8.69 (d, 1 H), 7.60-7.75 (m, 2 H), 7.27 (s, 0.5 H), 7.14 (s, 0.5 H). 6.96-7.02 (m, 1 H), 6.76-6.89 (m, 1.5 H), 6.57 (br s, 0.5 H), 4.25-4.40 (m, 1 H), 3.67-3.83 (m, 0.8 H), 3.40-3.51 (m, 0.2 H), 2.77-3.15 (m, 2 H), 1.67-1.93 (m, 6 H)	513.2 [M+H]+	98.5%
1220	(CD3OD) δ 8.32 (d, 1 H), 7.69 (s, 1 H), 6.99-7.33 (m, 2 H), 6.43-6.90 (m, 3 H), 4.35-4.46 (m, 1 H), 3.45-3.79 (m, 1 H), 2.81-3.13 (m, 2 H), 2.46 (s, 3 H), 1.28-1.43 (m, 4 H)	455.2 [M+H]+	99.8%
1221	(CD3OD) δ 8.32 (d, 1 H), 7.69 (s, 1 H), 6.99-7.28 (m, 2 H), 6.55-6.89 (m, 3 H), 4.34-4.47 (m, 1 H), 3.65-3.81 (m, 1 H), 2.80-3.11 (m, 2 H), 2.46 (s, 3 H), 1.26-1.42 (m, 4 H)	455.2 [M+H]+	98.5%
1222	(CD3OD) δ 8.71 (d, 1 H), 7.62-7.74 (m, 2 H), 6.98-7.28 (m, 2 H), 6.54-6.90 (m, 2 H), 4.44 (br d, 1 H), 3.74 (br s, 1 H), 2.81-3.17 (m, 2 H), 1.21-1.46 (m, 4 H)	509.1 [M+H]+	99.4%
1223	(CD3OD) δ 8.71 (br d, 1 H), 7.60-7.76 (m, 2 H), 6.96-7.30 (m, 2 H), 6.53-6.92 (m, 2 H), 4.35-4.57 (m, 1 H), 3.76 (br d, 1 H), 2.81-3.16 (m, 2 H), 1.22-1.46 (m, 4 H)	509.2 [M+H]+	99.6%
1224	(CD3OD) δ 8.41 (s, 1 H), 8.07-8.19 (m, 1 H), 7.71 (s, 1 H), 7.60 (s, 0.3 ), 7.42-7.53 (m, 1 H), 7.19-7.33 (m, 1 H), 6.98 (s, 0.7 H), 6.80 (d, 0.7 H), 6.58-6.73 (m, 1.3 H), 5.12 (dd, 1 H), 4.02 (s, 3 H), 3.73-3.91 (m, 0.7 H), 3.43 (td, 0.3 H), 3.13-3.25 (m, 0.7 H), 2.95-3.07 (m, 0.3 H), 2.80-2.90 (m, 1 H)	434.2 [M+H]+	100%
1225	(CD3OD) δ 8.42 (s, 1 H), 8.09-8.18 (m, 1 H), 7.77 (s, 1 H), 7.61 (s, 0.3 H), 7.41-7.54 (m, 1 H), 7.20-7.36 (m, 1 H), 6.99 (s, 0.7 H), 6.70-6.87 (m, 1 H), 6.62-6.70 (m, 1 H), 5.13 (br dd, 1 H), 4.02 (s, 3 H), 3.75-3.91 (m, 0.7 H), 3.43 (td, 0.3 H), 3.13-3.26 (m, 0.7 H), 2.94-3.07 (m, 0.3 H), 2.87 (br dd, 1 H)	434.2 [M+H]+	97.8%
1226	(CD3OD) δ 8.33 (d, 1 H), 7.68 (s, 1 H), 7.27 (s, 0.5 H), 7.14 (s, 0.5 H), 6.93-7.01 (m, 1 H), 6.68-6.85 (m, 2.5 H), 6.56 (br s, 0.5 H), 4.31 (br d, 1 H), 3.75 (br t, 0.6 H), 3.40 (br s, 0.4 H), 2.74-3.15 (m, 2 H), 1.68-1.90 (m, 6 H)	463.2 [M+H]+	99.1%
1227	(CD3OD) δ 8.30-8.36 (m, 1 H), 7.70 (br s, 1 H), 7.27 (s, 0.5 H), 7.14 (s, 0.5 H), 6.91-7.02 (m, 1 H), 6.68-6.87 (m, 2.5 H), 6.57 (br s, 0.5 H), 4.31 (br dd, 1 H), 3.75 (br t, 0.6 H), 3.34-3.46 (m, 0.4 H), 2.74-3.16 (m, 2 H), 1.69-1.92 (m. 6 H)	463.1 [M+H]+	99.6%
1228	(CD3OD) δ 8.45 (br d, 1 H), 7.69 (s, 1 H), 7.01-7.33 (m, 2 H), 6.70-6.89 (m, 2.5 H), 6.56 (br s, 0.5 H), 4.32 (br d, 1 H), 3.70-3.80 (m, 0.6 H), 3.38-3.50 (m, 0.4 H), 2.75-3.16 (m, 2 H), 1.72-1.91 (m, 6 H)	479.1 [M+H]+	99.6%
1229	(CD3OD) δ 8.38-8.44 (m, 1 H), 7.68 (br s, 1 H), 6.99-7.30 (m, 2 H), 6.70-6.88 (m. 2.5 H), 6.55 (br s, 0.5 H), 4.26-4.37 (m, 1 H), 3.74 (br t, 0.6 H), 3.41 (br s, 0.4 H), 2.75-3.15 (m, 2 H), 1.69-1.89 (m, 6 H)	479.1 [M+H]+	98.9%
1230	(CD3OD) δ 7.68 (s, 1 H), 7.47 (br s, 1 H), 6.97-7.31 (m, 2 H), 6.37-6.95 (m, 3 H), 4.65-4.75 (m, 0.4 H), 4.22-4.41 (m, 0.6 H), 3.45-3.97 (m, 1 H), 2.80-3.12 (m, 2 H), 2.65 (br d, 3 H), 1.65-2.03 (m, 6 H)	459.2 [M+H]+	99.1%
1231	(CD3OD) δ 7.56 (s, 1 H), 7.35 (br d, 1 H), 6.85-7.20 (m, 2 H), 6.21-6.83 (m, 3 H). 4.54-4.64 (m, 0.4 H), 4.19 (br d, 0.6 H), 3.36-3.83 (m, 1 H), 2.67-3.01 (m, 2 H), 2.40-2.66 (m, 3 H), 1.48-2.07 (m, 6 H)	459.2 [M+H]+	96.3%
1232	(CD3OD) δ 7.70 (s, 1 H), 7.61 (br s, 1 H), 7.10-7.44 (m, 2 H), 7.00-7.09 (m, 1 H), 6.61-6.93 (m, 2 H), 4.71-4.84 (m, 0.5 H), 4.23-4.45 (m, 0.5 H), 3.37-4.01 (m, 1 H), 2.73-3.21 (m, 2 H), 1.70-1.97 (m, 6 H)	479.2 [M+H]+	99.8%
1233	(CD3OD) δ 7.69 (s, 1 H), 7.62 (br s, 1 H), 7.07-7.43 (m, 2 H), 7.02-7.07 (m, 1 H), 6.57-6.96 (m, 2 H), 4.75-4.88 (m, 0.5 H), 4.25-4.44 (m, 0.5 H), 3.38-3.99 (m, 1 H), 2.72-3.21 (m. 2 H), 1.72-1.96 (m, 6 H)	479.1 [M+H]+	99.4%
1234	(CD3OD) δ 8.36 (d, 1 H), 7.70 (s, 1 H), 7.07-7.28 (m, 1 H), 6.96-7.01 (m, 1 H), 6.56-6.89 (m, 3 H), 4.29-4.55 (m, 1 H), 3.54-3.87 (m, 1 H), 2.80-3.14 (m, 2 H), 1.26-1.43 (m, 4 H)	459.2 [M+H]+	99.1%
1235	(CD3OD) δ 8.36 (d, 1 H), 7.70 (s, 1 H), 7.09-7.32 (m, 1 H), 6.96-7.01 (m, 1 H), 6.58-6.90 (m, 3 H), 4.33-4.55 (m, 1 H), 3.51-3.84 (m, 1 H), 2.82-3.16 (m, 2 H), 1.26-1.43 (m, 4 H)	459.1 [M+H]+	93.9%
1236	(CD3OD) δ 7.55-7.74 (m, 2 H), 7.00-7.28 (m, 3 H), 6.52-6.93 (m, 2 H), 5.02-5.17 (m, 0.2 H), 4.28-4.55 (m, 0.8 H), 3.52-4.00 (m, 1 H), 2.79-3.16 (m, 2 H), 1.26-1.46 (m, 4 H)	475.1 [M+H]+	99.6%
1237	(CD3OD) δ 7.57-7.73 (m, 2 H), 6.99-7.29 (m, 3 H), 6.65-6.95 (m, 2 H), 4.99-5.12 (m, 0.2 H), 4.36-4.55 (m, 0.8 H), 3.51-4.01 (m, 1 H), 2.80-3.10 (m, 2 H), 1.26-1.43 (m, 4 H)	475.1 [M+H]+	98.0%
1238	(CD3OD) δ 7.69 (s, 1 H), 7.48 (br d, 1 H), 6.96-7.33 (m, 2 H), 6.71-6.93 (m, 1.7 H), 6.66 (t. 1.3 H). 4.79-4.84 (m, 0.4 H), 4.38 (br d, 0.6 H), 3.81 (br s, 0.6 H), 3.45 (br s, 0.4 H), 2.95-3.23 (m, 1 H), 2.86 (br s, 1 H), 1.52-1.71 (m, 6 H)	461.2 [M+H]+	95.1%
1239	(CD3OD) δ 7.73 (br s, 1 H), 7.49 (br d, 1 H), 6.97-7.34 (m, 2 H), 6.72-6.93 (m, 1.7 H), 6.58-6.71 (m, 1.3 H), 4.74-4.82 (m, 0.5 H), 4.39 (br d, 0.5 H), 3.80 (br s, 0.5 H), 3.37-3.49 (m, 0.5 H), 2.93-3.22 (m, 1 H), 2.85 (br d, 1 H), 1.59-1.71 (m, 6 H)	461.2 [M+H]+	97.3%
1240	(CD3OD) δ 8.43 (s, 1 H), 7.68 (s, 1 H), 7.21 (br d, 3 H), 6.90 (br s, 0.7 H), 6.40-6.71 (m, 1.3 H), 6.23-6.38 (m, 1 H), 4.42 (q, 2.8 H), 3.82 (br s, 1.2 H), 3.07 (br s, 1 H), 2.82 (br d, 1 H), 1.57 (t, 3 H)	429.2 [M+H]+	99.6%
1241	(CD3OD) δ 8.43 (s, 1 H), 7.68 (s, 1 H), 7.21 (br d, 3 H), 6.90 (br s, 0.6 H), 6.61 (br s, 1.4 H), 6.26-6.37 (m, 1 H), 4.42 (q, 2.7 H), 3.82 (br s, 1.3 H), 3.07 (br s, 1 H), 2.81 (br d, 1 H), 1.57 (t, 3 H)	429.1 [M+H]+	98.3%
1242	(CD3OD) δ 7.59-7.85 (m, 1 H), 6.89-7.55 (m, 3 H), 6.23-6.72 (m, 2 H), 4.33-4.51 (m, 2 H), 3.38-3.89 (m, 2 H), 2.78-3.25 (m, 2 H), 1.79-2.03 (m, 6 H), 1.46-1.65 (m, 3 H)	440.2 [M+H]+	99.7%
1243	(CD3OD) δ 7.57 (s, 1 H), 6.78-7.47 (m, 3 H), 6.05-6.57 (m, 2 H), 4.22-4.37 (m, 2 H), 3.24-3.77 (m, 2 H), 2.67-3.10 (m, 2 H), 1.62-1.94 (m, 6 H), 1.33-1.56 (m, 3 H)	440.2 [M+H]+	98.5%
1244	(CD3OD) δ 7.68 (s, 1 H), 7.21 (br d, 3 H), 6.80-7.12 (m, 0.8 H), 6.45-6.66 (m, 1.2 H), 6.25-6.39 (m, 1 H), 4.82 (br s, 0.3 H), 4.26-4.49 (m, 2.7 H), 3.83 (br s, 0.6 H), 3.37-3.48 (m, 0.4 H), 2.94-3.20 (m, 1 H), 2.83 (br d, 1 H), 1.55-1.70 (m, 9 H)	487.2 [M+H]+	99.9%
1245	(CD3OD) δ 7.69 (s, 1 H), 7.11-7.41 (m, 3 H), 6.81-7.10 (m, 0.8 H), 6.48-6.67 (m, 1.2 H), 6.23-6.40 (m, 1 H), 4.76-4.81 (m, 0.3 H), 4.32-4.47 (m, 2.7 H), 3.83 (br s, 0.6 H), 3.38-3.48 (m, 0.4 H), 2.93-3.21 (m, 1 H), 2.84 (br d, 1 H), 1.54-1.71 (m, 9 H)	487.2 [M+H]+	99.8%
1246	(CD3OD) δ 7.63-7.81 (m, 1 H), 7.42-7.55 (m, 1.4 H), 7.20-7.34 (m, 1 H), 6.93 (s, 0.6 H), 6.78 (d, 0.6 H), 6.59-6.73 (m, 1.4 H), 5.03 (br dd, 1 H), 3.71-3.87 (m, 0.6 H), 3.37-3.45 (m, 0.4 H), 3.08-3.23 (m, 0.7 H), 2.93-3.04 (m, 0.3 H), 2.83 (dd, 1 H), 2.27-2.41 (m, 1 H), 1.20-1.32 (m, 4 H)	394.1 [M+H]+	100%
1247	(CD3OD) δ 7.70 (d, 1 H), 7.42-7.55 (m, 1.3 H), 7.21-7.33 (m, 1 H), 6.93 (s, 0.7 H), 6.78 (d, 0.7 H), 6.60-6.70 (m, 1.3 H), 5.03 (br dd, 1 H), 3.67-3.86 (m, 0.7 H), 3.37-3.44 (m, 0.3 H), 2.93-3.21 (m, 1 H), 2.75-2.89 (m, 1 H), 2.28-2.42 (m, 1 H), 1.23-1.32 (m, 4 H)	394.2 [M+H]+	97.1%
1248	(CD3OD) δ 7.59-7.80 (m, 1 H), 7.40-7.53 (m, 1.3 H), 7.18-7.34 (m, 1 H), 6.95 (s, 0.7 H), 6.79 (d, 0.7 H), 6.59-6.72 (m, 1.3 H), 5.01 (br dd, 1 H), 3.70-3.92 (m, 0.7 H), 3.37-3.44 (m, 0.3 H), 3.08-3.22 (m, 0.7 H), 2.92-3.05 (m, 0.3 H), 2.86 (br s, 1 H), 1.45-1.53 (m, 9 H)	410.2 [M+H]+	100%
1249	(CD3OD) δ 7.64-7.81 (m, 1 H), 7.41-7.55 (m, 1.3 H), 7.20-7.32 (m, 1 H), 6.95 (s, 0.7 H), 6.79 (d, 0.7 H), 6.66 (q, 1.3 H), 5.01 (br dd, 1 H), 3.71-3.92 (m, 0.6 H), 3.36-3.43 (m, 0.4 H), 3.10-3.23 (m, 0.7 H), 2.94-3.08 (m, 0.3 H), 2.84 (br dd, 1 H), 1.42-1.58 (m, 9 H)	410.2 [M+H]+	100%
1250	(CD3OD) δ 8.46 (d, 1 H), 7.53-7.74 (m, 2 H), 7.21 (ddd, 1 H), 6.41-6.95 (m, 3 H), 4.05-4.55 (m, 1 H), 3.45-3.87 (m, 1 H), 2.77-3.18 (m, 2 H), 2.40 (s, 3 H), 1.66-1.90 (m, 6 H)	409.2 [M+H]+	99.8%
1251	(CD3OD) δ 8.43-8.50 (m, 1 H), 7.55-7.76 (m, 2 H), 7.21 (ddd, 1 H), 6.40-6.96 (m, 3 H), 4.04-4.51 (m, 1 H), 3.47-3.88 (m, 1 H), 2.74-3.16 (m, 2 H), 2.40 (s, 3 H), 1.59-1.91 (m, 6 H)	409.2 [M+H]+	99.7%
1252	(CD3OD) δ 7.67 (s, 1 H), 7.47 (brd, 1 H), 7.12 (dd, 1 H), 6.72 (d, 3 H), 4.14-4.52 (m, 1 H), 3.44-4.04 (m, 1 H), 2.78-3.12 (m. 2 H), 2.67 (s, 3 H), 2.38 (s, 3 H), 1.67-1.90 (m, 6 H)	423.2 [M+H]+	99.8%
1253	(CD3OD) δ 7.67 (s, 1 H), 7.48 (br d, 1 H). 7.12 (dd, 1 H), 6.72 (d, 3 H), 4.10-4.52 (m, 1 H), 3.45-4.06 (m, 1 H), 2.78-3.14 (m, 2 H), 2.67 (s, 3 H). 2.38 (s, 3 H), 1.67-1.91 (m. 6 H)	423.2 [M+H]+	99.7%
1254	(CD3OD) δ 8.43 (d, 1 H), 7.53-7.70 (m, 2 H), 6.99-7.30 (m, 2 H), 6.83-6.87 (m, 2 H), 6.53-6.62 (m, 1 H), 4.81 (br d, 0.4 H), 4.29 (br d, 0.6 H), 3.74 (br t, 0.6 H), 3.37-3.50 (m, 0.4 H), 2.71-3.15 (m, 2 H), 1.69-1.93 (m, 6 H)	445.2 [M+H]+	97.0%
1255	(CD3OD) δ 8.44 (d, 1 H), 7.56-7.70 (m, 2 H), 7.00-7.30 (m, 2 H), 6.85 (br t, 2 H), 6.54-6.63 (m, 1 H), 4.77-4.83 (m, 0.4 H), 4.29 (br dd, 0.6 H), 3.74 (br t, 0.6 H), 3.37-3.47 (m, 0.4 H), 2.76-3.15 (m, 2 H), 1.69-1.90 (m, 6 H)	445.2 [M+H]+	98.4%
1256	(CD3OD) δ 7.74 (br s, 1 H), 7.58 (s, 1 H), 7.12-7.34 (m, 2 H), 6.45-7.11 (m, 3 H), 4.01-4.41 (m, 0.7 H), 3.26-3.98 (m, 1.3 H), 2.80-3.07 (m, 1 H), 2.63-2.79 (m, 1 H), 1.45-1.98 (m, 6 H)	485.2 [M+H]+	99.3%
1257	(CD3OD) δ 7.86 (br s, 1 H), 7.69 (s, 1 H), 7.33-7.40 (m, 1 H), 7.25-7.32 (m, 1 H), 6.62-7.24 (m, 3 H), 4.07-4.58 (m, 0.7 H), 3.34-4.07 (m, 1.3 H), 2.92-3.20 (m, 1 H), 2.83 (br dd, 1 H), 1.65-2.04 (m, 6 H)	485.2 [M+H]+	99.3%
1258	(CD3OD) δ 9.42 (d, 1 H), 9.11 (d, 1 H), 8.27-8.42 (m, 2 H), 6.91-7.86 (m, 3 H), 6.75-6.90 (m, 2 H). 4.93-5.07 (m, 1 H), 3.43-3.89 (m, 1 H), 2.97-3.26 (m, 1 H), 2.88 (br dd, 1 H)	432.1 [M+H]+	100%
1259	(CD3OD) δ 9.30 (d, 1 H), 9.00 (d, 1 H), 8.00-8.35 (m, 3 H), 6.82-7.56 (m, 2 H), 6.68-6.85 (m, 2 H), 4.82-5.04 (m, 1 H), 3.31-3.76 (m, 1 H), 2.89-3.18 (m, 1 H), 2.74-2.88 (m, 1 H)	432.2 [M+H]+	94.5%
1260	(CD3OD) δ 8.30 (d, 1 H), 7.66 (s, 1 H), 6.98 (d, 1 H), 6.39-6.91 (m, 3 H), 4.74 (br s, 0.5 H), 4.27 (br d, 0.5 H), 3.73 (br s, 0.5 H), 3.36-3.50 (m, 0.5 H), 2.70-3.17 (m, 2 H), 2.35-2.48 (m, 6 H), 1.64-1.90 (m, 6 H)	423.2 [M+H] +	100%
1261	(CD3OD) δ 8.29 (d, 1 H), 7.67 (s, 1 H), 6.97 (d, 1 H), 6.40-6.91 (m, 3 H), 4.75 (br s, 0.5 H), 4.27 (br d, 0.5 H), 3.74 (br s, 0.5 H), 3.36-3.56 (m, 0.5 H), 2.69-3.18 (m, 2 H), 2.34-2.50 (m, 6 H), 1.63-1.91 (m, 6 H)	423.2 [M+H]+	99.6%
1262	(CD3OD) δ 8.69 (d, 1 H), 7.57-7.75 (m, 2 H), 6.98 (t, 1 H), 6.40-6.93 (m, 2 H), 4.71-4.81 (m, 0.5 H), 4.31 (br d, 0.5 H), 3.72 (br s, 0.5 H), 3.38-3.55 (m, 0.5 H), 2.73-3.16 (m, 2 H), 2.39 (s, 3 H), 1.61-1.93 (m, 6 H)	477.2 [M+H]+	100%
1263	(CD3OD) δ 8.69 (d, 1 H), 7.52-7.82 (m, 2 H), 6.98 (t, 1 H), 6.32-6.93 (m, 2 H), 4.78 (br s, 0.5 H), 4.31 (br d, 0.5 H), 3.72 (br s, 0.5 H), 3.46 (br d, 0.5 H), 2.72-3.22 (m, 2 H), 2.39 (s, 3 H), 1.62-1.91 (m, 6 H)	477.2 [M+H]+	100%
1264	(CD3OD) δ 7.74 (br d, 1 H), 7.56 (s, 1 H), 7.21-7.26 (m, 1 H), 7.11-7.19 (m, 1 H), 6.45-6.87 (m, 2 H), 4.50 (br s, 0.5 H), 4.05-4.31 (m, 0.5 H), 3.72-3.89 (m, 0.5 H), 3.23-3.39 (m, 0.5 H), 2.64-2.98 (m, 2 H), 2.25 (s, 3 H), 1.55-1.79 (m, 6 H)	477.2 [M+H]+	100%
1265	(CD3OD) δ 7.87 (br d, 1 H), 7.68 (s, 1 H), 7.36 (br d, 1 H), 7.24-7.32 (m, 1 H), 6.55-6.97 (m, 2 H), 4.62 (br s, 0.5 H), 4.17-4.44 (m, 0.5 H), 3.79-4.04 (m, 0.5 H), 3.37-3.56 (m, 0.5 H), 2.78-3.10 (m, 2 H), 2.37 (s, 3 H), 1.66-1.90 (m, 6 H)	477.2 [M+H]+	98.4%
1266	(CD3OD) δ 7.67 (s, 1 H), 7.62 (br d, 1 H), 7.17-7.22 (m, 1 H), 7.05 (d, 1 H), 6.80 (br d, 2 H), 4.62 (s, 0.5 H), 4.23-4.41 (m, 0.5 H), 3.76-4.00 (m, 0.5 H), 3.39-3.55 (m, 0.5 H), 2.79-3.13 (m, 2 H), 2.40 (s, 3 H), 1.71-1.90 (m, 6 H)	443.1 [M+H]+	100%
1267	(CD3OD) δ 7.55 (s, 1 H), 7.49 (br d, 1 H), 7.06 (dd, 1 H), 6.92 (d, 1 H), 6.40-6.80 (m, 2 H), 4.50 (s, 0.5 H), 4.16-4.31 (m, 0.5 H), 3.68-3.86 (m, 0.5 H), 3.24-3.41 (m, 0.5 H), 2.67-3.00 (m, 2 H), 2.27 (s, 3 H), 1.59-1.77 (m, 6 H)	443.1 [M+H]+	99.8%
1268	(CD3OD) δ 7.87 (br d, 1 H), 7.69 (br s, 1 H). 7.33-7.40 (m, 1 H). 7.24-7.33 (m, 1 H), 6.94-7.23 (m, 1 H), 6.74 - 6.98 (m, 2 H), 4.40 (br s, 1 H), 3.90 (br s, 1 H). 2.68-3.24 (m, 2 H), 1.19-1.46 (m, 4 H)	509.2 [M+H]+	98.1%
1269	(CD3OD) δ 7.87 (br d, 1 H), 7.69 (br s, 1 H), 7.32-7.42 (m, 1 H), 7.25-7.32 (m, 1 H), 7.08 (br s, 1 H), 6.72-6.96 (m, 2 H), 4.40 (br s, 1 H), 3.90 (br s, 1 H), 2.61-3.20 (m, 2 H), 1.33 (br d, 4 H)	509.2 [M+H]+	95.2%
1270	(CD3OD) δ 8.15-8.87 (m, 3 H), 7.96 (d, 1 H), 7.59-7.71 (m, 2 H), 7.44 (ddd, 1 H), 6.49-7.14 (m, 4 H), 4.60 (br s, 1 H), 3.33-3.89 (m, 1 H), 3.01-3.13 (m, 1 H), 2.78 (br dd, 1 H)	452.2 [M+H]+	1 00%
1271	(CD3OD) δ 8.23-9.01 (m, 3 H), 7.97 (d, 1 H), 7.60-7.71 (m, 2 H), 7.40-7.48 (m, 1 H), 6.47-7.14 (m, 4 H), 4.62 (br s, 1 H), 3.35-3.96 (m, 1 H), 3.04-3.14 (m, 1 H), 2.74-2.83 (m, 1 H)	452.2 [M+H]+	98.8%
1272	(CD3OD) δ 6.58-7.25 (m, 3 H), 6.36-6.44 (m, 1 H), 6.09 (s, 1 H), 5.85 (ddd, 1 H), 5.70 (d, 1 H), 4.78-5.58 (m, 4 H), 3.06 (br s, 1 H), 1.79-2.37 (m, 1 H), 1.44-1.55 (m, 1 H), 1.19 (br dd, 1 H)	418.1 [M+H]+	97.4%
1273	(CD3OD) δ 8.21-8.83 (m, 3 H), 7.97 (d, 1 H), 7.67 (s, 1 H), 7.43 (dd, 1 H), 7.29 (d, 1 H), 6.43-7.13 (m, 4 H), 4.61 (br s, 1 H), 3.35-3.95 (m, 1 H), 3.01-3.13 (m, 1 H), 2.77 (br dd, 1 H)	418.1 [M+H]+	98.4%
1274	(CD3OD) δ 8.33 (br d, 1 H), 7.67 (s, 1 H), 6.41-7.05 (m, 4 H). 4.77 (br s, 0.5 H), 4.30 (br s, 0.5 H), 3.73 (br s, 0.5 H), 3.39 (br s, 0.5 H), 2.71-3.15 (m, 2 H), 2.38 (s, 3 H), 1.64-1.92 (m, 6 H)	427.2 [M+H]+	100%
1275	(CD3OD) δ 8.34 (d, 1 H), 7.67 (s, 1 H), 6.40-7.07 (m, 4 H), 4.77 (br s, 0.5 H), 4.29 (br d, 0.5 H), 3.72 (br s, 0.5 H), 3.48 (br s, 0.5 H), 2.74-3.17 (m, 2 H), 2.38 (s, 3 H), 1.65-1.87 (m, 6 H)	427.2 [M+H]+	98.1%
1276	(CD3OD) δ 8.44 (d, 1 H). 7.67 (s, 1 H), 7.29 (d, 1 H), 6.39-6.97 (m, 3 H), 4.77 (br s, 0.5 H), 4.29 (br d, 0.5 H), 3.72 (br s, 0.5 H), 3.37-3.52 (m, 0.5 H), 2.76-3.16 (m, 2 H), 2.39 (s, 3 H), 1.68-1.91 (m, 6 H)	443.2 [M+H]+	100%
1277	(CD3OD) δ 8.44 (br d, 1 H), 7.67 (br s, 1 H), 7.29 (d, 1 H), 6.40-7.02 (m, 3 H), 4.76 (br s, 0.5 H), 4.29 (br s, 0.5 H), 3.72 (br s, 0.5 H), 3.40 (br s, 0.5 H), 2.70-3.15 (m, 2 H), 2.39 (s, 3 H), 1.63-1.90 (m, 6 H)	443.2 [M+H]+	98.5%
1278	(CD3OD) δ 7.68 (s, 1 H), 7.47 (br d, 1 H), 7.24 (ddd, 1 H), 6.42-7.00 (m, 3 H), 4.91-5.12 (m, 0.5 H), 4.32 (dt, 0.5 H), 3.38-3.94 (m, 1 H), 2.72-3.15 (m, 2 H), 2.40 (s, 3 H), 1.67-1.91 (m, 6 H)	427.1 [M+H]+	100%
1279	(CD3OD) δ 7.68 (s, 1 H), 7.47 (br d, 1 H), 7.24 (ddd, 1 H), 6.52-6.89 (m, 3 H), 4.93-5.07 (m, 0.5 H), 4.25-4.38 (m, 0.5 H), 3.46-3.96 (m, 1 H), 2.80-3.15 (m, 2 H), 2.40 (s, 3 H), 1.70-1.89 (m, 6 H)	427.1 [M+H]+	99.9%
1280	(CD3OD) δ 7.70 (s, 1 H), 7.48 (br d, 1 H), 6.96-7.27 (m, 2 H), 6.67-6.91 (m, 2 H), 6.46-6.64 (m, 1 H), 4.42 (br s, 1 H), 3.87 (br s, 1 H), 2.77-3.15 (m, 2 H), 2.67 (br s, 3 H), 1.26-1.41 (m, 4 H)	455.2 [M+H]+	98.1%
1281	(CD3OD) δ 7.68 (s, 1 H), 7.48 (br d, 1 H), 6.96-7.27 (m, 2 H), 6.65-6.91 (m, 2 H), 6.43-6.63 (m, 1 H), 4.40 (br s, 1 H), 3.88 (br s, 1 H), 2.82 (br d, 2 H), 2.67 (br s, 3 H), 1.27-1.44 (m, 4 H)	455.2 [M+H]+	100%
1282	(CD3OD) δ 8.52-8.62 (m, 1 H), 7.69 (s, 1 H), 7.38-7.51 (m, 1.3 H), 7.08-7.14 (m, 0.2 H), 6.70-7.01 (m, 3.5 H), 4.97 (br dd, 1 H), 3.65-3.83 (m, 0.5 H), 3.35-3.41 (m, 0.5 H), 2.79-3.18 (m, 2 H), 2.59-2.69 (m. 3 H)	400.2 [M+H]+	100%
1283	(CD3OD) δ 8.52-8.63 (m. 1 H), 7.69 (s, 1 H), 7.37-7.52 (m, 1.3 H), 7.07-7.14 (m, 0.2 H), 6.70-7.02 (m, 3.5 H), 4.97 (br dd, 1 H), 3.67-3.78 (m, 0.5 H), 3.35-3.42 (m, 0.5 H), 2.78-3.18 (m, 2 H), 2.61-2.69 (m, 3 H)	400.2 [M+H]+	100%
1284	(CD3OD) δ 8.46 (br d, 1 H), 7.54-7.73 (m, 2 H), 7.43-7.49 (m, 0.3 H), 7.14-7.25 (m, 1 H). 6.85-6.94 (m, 1.7 H), 6.51-6.67 (m. 1 H), 4.97 (br s, 1 H), 3.38-3.82 (m, 1 H), 2.81-3.20 (m, 2 H), 1.61 (s, 3 H), 1.39-1.46 (m, 2 H), 1.11 (d, 2 H)	390.2 [M+H]+	100%
1285	(CD3OD) δ 8.40-8.52 (m, 1 H), 7.54-7.76 (m, 2 H), 7.46 (s, 0.3 H), 7.14-7.26 (m, 1 H), 6.83-6.97 (m, 1.7 H), 6.53-6.66 (m, 1 H), 5.00 (br d, 1 H), 3.40-3.79 (m, 1 H), 2.80-3.19 (m, 2 H), 1.61 (s, 3 H), 1.39-1.46 (m, 2 H), 1.11 (d, 2 H)	390.2 [M+H]+	94.1%
1286	(CD3OD) δ 8.24-8.88 (m, 3 H), 7.97 (d, 1 H), 7.66 (s, 1 H), 7.44 (dd, 1 H), 6.32-7.19 (m, 5 H), 4.61-4.74 (m, 1 H), 3.39-3.95 (m, 1 H), 3.02-3.12 (m, 1 H), 2.77 (br dd, 1 H), 2.44 (s, 3 H)	398.2 [M+H]+	100%
1287	(CD3OD) δ 8.20-9.02 (m, 3 H), 7.97 (d, 1 H), 7.66 (s, 1 H), 7.39-7.48 (m, 1 H), 6.38-7.12 (m, 5 H), 4.60-4.78 (m, 1 H), 3.36-3.94 (m, 1 H), 3.01-3.12 (m, 1 H), 2.77 (br dd, 1 H), 2.44 (s. 3 H)	398.2 [M+H]+	98.9%
1288	(CD3OD) δ 8.21-8.92 (m, 3 H), 797 (d, 1 H), 7.66 (s, 1 H), 7.41-7.46 (m, 1 H), 6.47-7.11 (m, 5 H), 4.62 (br s, 1 H), 3.33-3.92 (m, 1 H), 3.02-3.14 (m, 1 H), 2.77 (br dd, 1 H)	402.2 [M+H]+	100%
1289	(CD3OD) δ 8.20-8.90 (m, 3 H), 7.96 (d, 1 H), 7.66 (s, 1 H), 7.43 (dd, 1 H), 6.48-7.12 (m, 5 H), 4.62 (br s, 1 H), 3.34-3.93 (m, 1 H), 3.01-3.14 (m, 1 H), 2.77 (br dd, 1 H)	402.2 [M+H]+	100%
1290	(CD3OD) δ 8.69 (d, 1 H), 8.44 (d, 1 H), 8.13 (d, 1 H), 8.00 (td, 1 H), 7.69 (s, 1 H), 7.51-7.61 (m, 2 H), 7.12-7.23 (m, 1 H), 6.84 (t, 1 H), 6.64 (s, 1 H), 6.53 (s, 1 H), 4.44 (dd, 1 H), 3.69-3.85 (m, 1 H), 3.02-3.17 (m, 1 H), 2.84 (dd, 1 H)	385.1 [M+H]+	99.3%
1291	(CD3OD) δ 8.69 (d, 1 H), 8.44 (d, 1 H), 8.13 (d, 1 H), 7.96-8.05 (m, 1 H), 7.69 (s, 1 H), 7.52-7.63 (m, 2 H), 7.18 (dd, 1 H), 6.85 (t, 1 H), 6.64 (s, 1 H), 6.54 (s, 1 H), 4.44 (dd, 1 H), 3.75-3.87 (m, 1 H), 3.04-3.17 (m, 1 H), 2.85 (dd, 1 H)	385.1 [M+H]+	96.9%
1292	(CD3OD) δ 9.31 (s, 1 H), 8.80 (d, 1 H), 8.33-8.61 (m, 2 H), 7.64-7.77 (m, 2 H), 7.56 (s, 0.3 H), 7.23-7.37 (m, 1 H), 6.97 (s, 0.7 H), 6.68-6.92 (m, 2 H), 5.10 (br dd, 1 H), 3.73-3.86 (m, 0.7 H), 3.43 (td. 0.3 H), 2.79-3.26 (m, 2 H)	447.1 [M+H]+	1 00%
1293	(CD3OD) δ 9.31 (s, 1 H), 8.80 (d, 1 H), 8.32-8.60 (m, 2 H), 7.64-7.76 (m, 2 H), 7.56 (s, 0.3 H), 7.25-7.35 (m, 1 H), 6.97 (s, 0.7 H), 6.68-6.90 (m, 2 H), 5.10 (dd, 1 H), 3.66-3.89 (m, 0.7 H), 3.43 (td, 0.3 H), 2.82-3.25 (m, 2 H)	447.1 [M+H]+	98.5%
1294	(CD3OD) δ 8.67 (d, 1 H), 8.40-8.52 (m, 1 H), 7.94 (d, 1 H), 7.69-7.83 (m, 2 H), 7.47 (s, 0.4 H), 7.26-7.38 (m, 1 H), 6.99 (s, 0.6 H), 6.77-6.92 (m, 2 H), 4.95-5.03 (m, 1 H), 3.76-3.86 (m, 0.5 H), 3.42-3.51 (m, 0.5 H), 3.02-3.24 (m, 1 H), 2.88 (br d, 1 H)	465.1 [M+H]+	99.9%
1295	(CD3OD) δ 8.67 (d, 1 H), 8.36-8.53 (m, 1 H), 7.95 (t, 1 H), 7.71-7.80 (m, 2 H), 7.47 (s, 0.3 H), 7.21-7.36 (m, 1 H), 6.99 (s, 0.7 H), 6.77-6.92 (m, 2 H), 4.98 (br d, 1 H), 3.71-3.93 (m, 0.5 H), 3.40-3.55 (m, 0.5 H), 2.99-3.29 (m, 1 H), 2.81-2.96 (m, 1 H)	465.1 [M+H]+	99.5%
1296	(CD3OD) δ 7.69 (d, 1 H), 7.56-7.65 (m, 1 H), 7.44 (s, 0.4 H), 7.14-7.23 (m, 1 H), 7.05 (d, 1 H), 6.94 (s, 0.6 H), 6.61-6.81 (m, 1 H), 4.92-5.07 (m, 1 H), 3.80-3.92 (m, 0.6 H), 3.35-3.42 (m, 0.4 H), 2.81-3.19 (m, 2 H), 1.60 (s, 3 H), 1.38-1.46 (m, 2 H), 1.10 (d, 2 H)	424.2 [M+H]+	100%
1297	(CD3OD) δ 7.58 (d, 1 H), 7.44-7.53 (m, 1 H), 7.32 (s. 0.4 H). 7.03-7.11 (m, 1 H), 6.90-6.96 (m, 1 H), 6.83 (s, 0.6 H), 6.50-6.69 (m, 1 H), 4.90 (br dd, 1 H), 3.75 (ddd, 0.6 H), 3.28 (br d, 0.4 H). 2.74 (br d, 2 H), 1.48 (s, 3 H), 1.29 (br d, 2 H), 0.98 (d, 2 H)	424.1 [M+H]+	92.3%
1298	(CD3OD) δ 8.80-9.04 (m, 1 H), 8.39-8.60 (m, 2 H), 8.29 (d, 1 H), 7.82 (s, 0.3 H), 7.64 (dd, 1 H), 7.26-7.43 (m, 1 H), 7.20 (s, 0.7 H), 7.06 (s, 0.3 H), 6.89-6.97 (m, 1.7 H), 5.25 (br dd, 1 H), 4.01 (s, 3 H), 3.65-3.84 (m, 1 H), 3.38-3.55 (m, 1 H, 2.94-3.19 (m, 1 H)	477.2 [M+H]+	90.8%
1299	(CD3OD) δ 8.87-9.06 (m, 1 H), 8.41-8.65 (m, 2 H), 8.28 (br d, 1 H), 7.82 (s, 0.3 H), 7.63 (dd, 1 H), 7.38 (d, 1 H), 7.20 (s, 0.7 H), 7.06 (s, 0.3 H), 6.86-6.97 (m, 1.7 H), 5.25 (br dd, 1 H). 4.01 (s, 3 H), 3.75 (br t, 1 H), 3.38-3.54 (m, 1 H), 2.93-3.18 (m, 1 H)	477.1 [M+H]+	94.0%
1300	(CD3OD) δ 9.48 (d, 1 H), 8.81-8.90 (m, 2 H), 8.63-8.76 (m, 1 H), 7.73-7.84 (m, 1 H), 7.59-7.73 (m, 1 H), 6.80-7.57 (m, 3 H), 4.94-5.13 (m, 1 H), 3.40-3.91 (m, 1 H), 2.81-3.28 (m, 2 H)	482.2 [M+H]+	100%
1301	(CD3OD) δ 9.48 (s, 1 H), 8.81-9.04 (m, 2 H), 8.63-8.81 (m, 1 H), 7.73-7.91 (m, 1 H), 7.59-7.72 (m, 1 H). 6.79-7.59 (m, 3 H). 5.07 (br dd, 1 H), 3.41-3.96 (m, 1 H), 2.82-3.30 (m, 2 H)	482.1 [M+H]+	99.9%
1302	(CD3OD) δ 9.31 (brs, 1 H), 8.46-8.83 (m, 3 H), 7.71 (s, 3.5 H), 6.91-7.04 (m, 1.5 H), 6.66-6.87 (m, 1 H), 5.12 (dd, 0.7 H), 4.95 (br dd, 0.3 H), 3.70-3.86 (m, 0.7 H), 3.37-3.50 (m, 0.3 H), 2.78-3.26 (m, 2 H)	481.1 [M+H]+	100%
1303	(CD3OD) δ 9.31 (d, 1 H), 8.48-8.87 (m, 3 H), 7.54-7.74 (m, 3.5 H), 6.92-7.06 (m, 1.5 H), 6.73-6.85 (m, 1 H), 5.12 (dd, 0.7 H), 4.95 (br dd. 0.3 H). 3.75-3.84 (m, 0.7 H), 3.43 (td, 0.3 H), 2.82-3.26 (m, 2 H)	481.1 [M+H]+	99.3%
1304	(CD3OD) δ 8.61-8.72 (m, 2 H), 8.42-8.49 (m, 1 H), 7.71 (s, 1 H), 7.46-7.66 (m, 2 H), 6.94-7.03 (m, 2 H), 6.77-6.83 (m. 1 H), 5.12 (dd, 0.6 H), 4.95 (br dd, 0.4 H), 3.80 (td, 0.7 H), 3.42 (td, 0.3 H), 3.17-3.26 (m, 1 H). 2.81-3.05 (m, 4 H)	495.1 [M+H|+	100%
1305	(CD3OD) δ 8.61-8.72 (m, 2 H). 8.41-8.49 (m, 1 H), 7.71 (s. 1 H), 7.45-7.66 (m, 2 H), 6.94-7.02 (m, 2 H), 6.78-6.83 (m, 1 H), 5.12 (br dd. 0.6 H). 4.92-4.97 (m, 0.4 H), 3.75-3.85 (m, 0.7 H), 3.42 (td, 0.3 H), 3.15-3.27 (m, 1 H), 2.82-3.06 (m, 4 H)	495.1 [M+H]	99.6%
1306	(CD3OD) δ 9.31 (s, 1 H), 8.75-8.90 (m, 1 H), 8.44-8.63 (m, 1 H), 7.50-7.73 (m, 3.5 H), 7.11-7.25 (m, 1 H), 6.98-7.06 (m, 1.5 H), 6.80 (s, 0.6 H), 6.65 (s, 0.4 H), 5.12 (dd, 0.6 H), 4.95 (br dd, 0.4 H), 3.87-4.00 (m, 0.6 H), 3.40 (td, 0.4 H), 2.97-3.25 (m, 1 H), 2.87 (dd. 1 H)	447.2 [M+H]+	100%
1307	(CD3OD) δ 9.31 (br s, 1 H), 8.74-8.85 (m, 1 H), 8.55 (br d, 1 H), 7.47-7.73 (m, 3.5 H), 7.11-7.22 (m, 1 H), 6.95-7.07 (m, 1.5 H), 6.80 (s, 0.6 H), 6.64 (s, 0.4 H), 5.11 (br dd. 0.6 H). 4.95 (br dd. 0.4 H), 3.87-3.98 (m, 0.6 H), 3.40 (td, 0.4 H), 2.96-3.26 (m, 1 H), 2.87 (br dd, 1 H)	447.1 [M+H]+	95.4%
1308	(CD3OD) δ 9.31 (br s, 1 H), 8.80 (br d, 1 H), 8.55 (br d, 1 H), 7.85 (d, 1 H), 7.67 (br d, 1 H), 7.39-7.53 (m, 1.4 H), 7.06-7.18 (m, 1 H), 7.03 (s. 0.6 H). 6.61-6.75 (m, 1.6 H), 6.50 (s, 0.4 H), 5.10 (br dd, 0.6 H), 4.95 (br d, 0.4 H), 3.87-3.99 (m, 0.6 H), 3.37-3.46 (m, 0.4 H). 2.83-3.26 (m, 2 H), 2.49-2.68 (m, 3 H)	427.2 [M+H]+	100%
1309	(CD3OD) δ 9.31 (s, 1 H), 8.72-8.94 (m, 1 H), 8.54 (br d, 1 H), 7.62-7.81 (m, 2 H), 7.37-7.55 (m, 1.4 H), 7.05-7.17 (m, 1 H), 7.00 (s, 0.6 H). 6.59-6.76 (m, 1.6 H), 6.48 (s, 0.4 H), 5.08 (br dd, 0.5 H), 4.95 (br d, 0.5 H), 3.89-3.98 (m, 0.5 H), 3.41 (td, 0.5 H), 2.83-3.25 (m. 2 H), 2.48-2.70 (m, 3 H)	427.2 [M+H]+	96.9%
1310	(CD3OD) δ 9.05 (d, 2 H). 8.21-8.40 (m, 1 H). 7.69-7.75 (m, 2 H), 6.76-7.05 (m. 3 H), 6.61-6.69 (m, 1 H), 4.98 (br d, 1 H), 3.79-3.86 (m, 0.5 H), 3.46-3.50 (m, 0.5 H), 2.85-3.21 (m, 2 H), 2.44-2.49 (m. 3 H)	428.1 [M+H]+	100%
1311	(CD3OD) δ 9.00-9. 10 (m, 2 H), 8.21-8.37 (m, 1 H), 7.67-7.75 (m, 2 H), 7.48 (s, 0.3 H), 6.76-7.03 (m, 2.7 H), 6.60-6.71 (m, 1 H), 4.97-5.01 (m, 1 H), 3.79-3.87 (m, 0.5 H), 3.46 (br d, 0.5 H), 2.84-3.26 (m, 2 H), 2.42-2.50 (m, 3 H)	428.1 [M+H]+	98.6%
1312	(CD3OD) δ 9.03-9.07 (m, 2 H), 8.28-8.41 (m, 1 H), 7.66-7.75 (m, 2 H), 7.38-7.55 (m, 0.3 H), 6.73-7.07 (m, 3.7 H), 4.95-5.04 (m, 1 H), 3.81-3.86 (m, 0.6 H), 3.42-3.51 (m, 0.4 H), 2.83-3.24 (m, 2 H)	432.2 [M+H]+	100%
1313	(CD3OD) δ 9.05 (d, 2 H). 8.27-8.41 (m, 1 H), 7.67-7.77 (m, 2 H), 7.47 (br s, 0.3 H), 6.78-7.03 (m, 3.7 H), 4.96-5.05 (m, 1 H), 3.79-3.87 (m, 0.6 H), 3.42-3.50 (m. 0.4 H), 2.85-3.27 (m, 2 H)	432.2 [M+H]+	99.6%
1314	(CD3OD) δ 8.77 (d, 1 H), 8.50-8.64 (m, 1 H). 8.31 (d, 1 H), 8.02-8.16 (m, 1 H), 7.61-7.76 (m, 2 H), 7.52 (s, 0.2 H), 7.37-7.47 (m, 1 H), 6.75-7.17 (m, 3.8 H), 4.93-5.07 (m, 1 H), 3.72-3.86 (m, 0.5 H), 3.42 (td, 0.5 H), 2.80-3.27 (m, 2 H)	463.2 [M+H]+	100%
1315	(CD3OD) δ 8.77 (d, 1 H), 8.49-8.64 (m, 1 H), 8.31 (d, 1 H), 8.08 (t, 1 H), 7.62-7.75 (m, 2 H), 7.52 (s, 0.2 H), 7.37-7.48 (m, 1 H), 6.77-7.15 (m, 3.8 H), 4.93-5.06 (m, 1 H), 3.71-3.85 (m, 0.5 H), 3.42 (td. 0.5 H). 2.81-3.26 (m, 2 H)	463.2 [M+H]+	99.1%
1316	(CD3OD) δ 8.50-8.63 (m, 1 H), 8.36-8.45 (m, 1 H), 8.04-8.15 (m, 1 H), 7.70 (s, 1 H), 7.58 (s, 0.2 H), 7.37-7.49 (m, 1 H), 6.67-7.18 (m, 3.8 H), 5.09 (dd. 0.5 H). 4.93 (br d. 0.5 H). 4.00 (s, 3 H), 3.69-3.83 (m, 0.5 H), 3.35-3.45 (m, 0.5 H), 2.74-3.24 (m, 2 H)	466.2 [M+H]+	100%
1317	(CD3OD) δ 8.51-8.62 (m, 1 H), 8.33-8.43 (m, 1 H), 8.02-8.17 (m, 1 H), 7.70 (s, 1 H), 7.58 (s, 0.2 H), 7.34-7.47 (m, 1 H), 6.70-7.17 (m, 3.8 H), 5.09 (dd, 0.5 H), 4.93 (br d, 0.5 H), 4.00 (s, 3 H), 3.69-3.82 (m, 0.5 H), 3.39 (td, 0.5 H), 2.79-3.23 (m, 2 H)	466.2 [M+H]+	100%
1318	(CD3OD) δ 7.68 (d, 1 H), 7.35-7.52 (m, 1.5 H), 7.08-7.16 (m, 1 H), 6.95 (s, 0.5 H), 6.43-6.76 (m, 2 H), 4.93-5.03 (m, 1 H), 3.83-3.92 (m, 0.6 H), 3.36-3.42 (m, 0.4 H), 2.82-3.17 (m, 2 H), 2.61-2.69 (m, 3 H), 1.61 (s, 3 H), 1.38-1.44 (m, 2 H), 1.08-1.13 (m, 2 H)	404.2 [M+H]+	100%
1319	(CD3OD) δ 7.71 (d. 1 H), 7.36 (dd, 1.5 H), 7.07-7.17 (m, 1 H), 6.96 (s, 0.5 H), 6.42-6.78 (m, 2 H), 4.99 (br dd, 1 H), 3.77-3.94 (m, 0.6 H), 3.40 (br d, 0.4 H), 2.81-3.14 (m, 2 H), 2.61-2.69 (m, 3 H), 1.61 (s, 3 H), 1.38-1.46 (m, 2 H), 1.08-1.14 (m, 2 H)	404.2 [M+H]+	99.6%
1320	(CD3OD) δ 8.19-8.75 (m, 1 H), 7.71 (s, 1 H), 7.24-7.54 (m, 1.4 H), 6.83-6.96 (m, 1.6 H), 6.68-6.77 (m, 1 H), 5.01 (dd, 0.8 H), 4.87 (br s, 0.2 H), 3.35-3.80 (m, 1 H), 2.90-3.23 (m, 1 H), 2.83 (br d, 1 H). 1.54-1.68 (m, 3 H). 1.36-1.48 (m, 2 H), 1.06-1.16 (m, 2 H)	424.2 [M+H]+	100%
1321	(CD3OD) δ 8.22-8.66 (m, 1 H), 7.71 (s, 1 H), 7.17-7.55 (m, 1.5 H), 6.81-6.98 (m, 1.5 H). 6.67-6.79 (m, 1 H). 5.01 (br dd. 0.8 H). 4.87 (br s, 0.2 H), 3.36-3.80 (m. 1 H), 2.91-3.23 (m, 1 H), 2.83 (br d, 1 H), 1.51-1.66 (m, 3 H), 1.36-1.49 (m, 2 H), 1.04-1.17 (m, 2 H)	424.2 [M+H]+	100%
1322	(CD3OD) δ 8.09-8.55 (m. 1 H), 7.70 (s, 1 H). 7.37-7.52 (m, 0.3 H), 6.86-7.06 (m, 1.7 H), 6.76-6.84 (m, 1 H), 6.51-6.67 (m, 1 H), 4.98 (dd, 0.8 H), 4.85 (br d, 0.2 H), 3.36-3.84 (m, 1 H), 2.90-3.24 (m, 1 H), 2.73-2.89 (m, 1 H), 2.44-2.50 (m, 3 H), 1.61 (s, 3 H), 1.35-1.49 (m. 2 H), 1.04-1.18 (m. 2 H)	404.2 [M+-H]+	100%
1323	(CD3OD) δ 8.13-8.50 (m. 1 H), 7.70 (s, 1 H). 7.36-7.53 (m, 0.3 H), 6.86-7.10 (m, 1.7 H), 6.74-6.86 (m, 1 H), 6.50-6.68 (m, 1 H), 4.99 (br dd, 1 H). 3.40-3.80 (m, 1 H), 3.15 (br s, 1 H). 2.76-2.90 (m, 1 H), 2.44-2.50 (m, 3 H), 1.61 (s, 3 H), 1.37-1.49 (m, 2 H), 1.03-1.22 (m. 2 H)	404.2 [M+H]+	100%
1324	(CD3OD) δ 8.44-8.80 (m, 1 H), 7.59-7.77 (m, 2 H), 7.42-7.48 (m, 0.3 H), 6.83-7.12 (m, 1.7 H), 6.73-6.82 (m, 1 H), 5.03 (br dd, 0.8 H), 4.88 (br s, 0.2 H). 3.37-3.80 (m, 1 H). 2.92-3.24 (m, 1 H), 2.83 (br d, 1 H), 1.57-1.65 (m, 3 H), 1.36-1.48 (m, 2 H), 1.03-1.21 (m. 2 H)	458.2 [M+H]+	100%
1325	(CD3OD) δ 8.71 (br d, 1 H), 7.60-7.75 (m, 2 H), 7.45 (br d, 0.3 H), 6.84-7.10 (m, 1.7 H), 6.69-6.83 (m, 1 H), 5.03 (dd, 0.8 H), 4.86-4.89 (m, 0.2 H), 3.40-3.80 (m, 1 H), 3.15 (br d, 1 H), 2.83 (br d, 1 H). 1.57-1.65 (m, 3 H). 1.38-1.49 (m, 2 H), 1.07-1.15 (m, 2 H)	458.2 [M+H]+	100%
1326	(CD3OD) δ 8.11-8.93 (m, 3 H), 7.96 (d, 1 H), 7.65 (s, 1 H), 7.43 (dd, 1 H), 6.29-7.25 (m, 5 H), 4.31-4.86 (m, 1 H), 3.95 (s, 3 H), 3.34-3.87 (m, 1 H), 2.98-3.14 (m, 1 H), 2.76 (br dd, 1H)	414.2 [M+H]+	100%
1327	(CD3OD) δ 8.05-8.87 (m, 3 H), 7.97 (d, 1 H), 7.65 (s, 1 H), 7.39-7.48 (m, 1 H), 6.23-7.15 (m, 5 H), 4.60 (br s, 1 H), 3.95 (s, 3 H), 3.38-3.80 (m, 1 H), 3.00-3.12 (m, 1 H), 2.76 (br d, 1 H)	414.2 [M+H]+	100%
1328	(CD3OD) δ 8.61-8.66 (m, 1 H), 8.44 (dd, 1 H), 8.27-8.36 (m, 1 H), 7.70 (br s, 1 H), 7.44-7.57 (m, 1 H), 6.90-7.03 (m, 2 H), 6.73-6.86 (m, 2 H). 5.10 (br dd, 0.6 H), 4.94 (br d, 0.4 H), 3.74-3.84 (m, 0.6 H), 3.38-3.47 (m, 0.4 H), 2.84-3.25 (m, 5 H)	445.2 [M+H]+	100%
1329	(CD3OD) δ 8.61-8.66 (m, 1 H), 8.44 (dd, 1 H), 8.27-8.36 (m, 1 H), 7.70 (br s, 1 H), 7.44-7.57 (m, 1 H), 6.90-7.03 (m, 2 H), 6.73-6.86 (m, 2 H), 5.10 (br dd, 0.6 H), 4.94 (br d, 0.4 H), 3.74-3.84 (m, 0.6 H), 3.38-3.47 (m, 0.4 H), 2.84-3.25 (m, 5 H)	445.2 [M+-H]+	99.7%
1330	(CD3OD) δ 8.64 (d, 1 H). 8.43-8.48 (m, 1 H). 8.24-8.33 (m, 1 H), 7.69 (s, 1 H), 7.46-7.54 (m, 1 H), 6.95-7.03 (m, 2 H), 6.73-6.81 (m, 1 H), 6.57-6.66 (m, 1 H). 5.07 (dd, 0.6 H), 4.90-4.94 (m, 0.4 H), 3.76-3.86 (m, 0.6 H), 3.40-3.49 (m, 0.4 H), 2.82-3.26 (m. 5 H), 2.41-2.47 (m. 3 H)	441.2 [M+H]+	100%
1331	(CD3OD) δ 8.64 (br d, 1 H), 8.43-8.48 (m, 1 H), 8.24-8.32 (m, 1 H), 7.70 (s, 1 H), 7.46-7.53 (m, 1 H), 6.95-7.02 (m, 2 H), 6.74-6.82 (m, 1 H), 6.58-6.66 (m, 1 H), 5.08 (br dd, 0.7 H), 4.90-4.95 (m, 0.3 H), 3.77-3.86 (m, 0.6 H), 3.44 (td, 0.4 H), 2.80-3.26 (m, 5 H), 2.40-2.47 (m, 3 H)	441.2 [M+H]+	99.2%
1332	(CD3OD) δ 9.36 (d, 1 H). 8.66-8.84 (m, 2 H). 8.24-8.43 (m, 1 H). 7.63 (br s, 1 H), 6.84-7.43 (m, 2 H), 6.62-6.82 (m, 2 H). 4.93 (br dd, 1 H), 3.30-3.79 (m, 1 H), 2.66-3.17 (m, 2 H)	448.1 [M+-H]+	100%
1333	(CD3OD) δ 9.36 (d, 1 H), 8.65-8.84 (m, 2 H), 8.21-8.42 (m, 1 H), 7.64 (br s, 1 H), 6.84-7.45 (m, 2 H), 6.60-6.83 (m, 2 H), 4.87-5.03 (m, 1 H), 3.31-3.77 (m, 1 H), 2.66-3.13 (m, 2 H)	448.1 [M+H]+	98.9%
1334	(CD3OD) δ 8.63-8.67 (m, 1 H), 8.45-8.50 (m, 1 H), 7.47-7.72 (m, 3 H), 7.14-7.22 (m, 1 H), 6.96-7.08 (m, 2 H), 6.81 (s, 0.6 H), 6.66 (s, 0.4 H), 5.12 (dd, 0.5 H), 4.96 (br dd, 0.5 H), 3.88-3.99 (m, 0.6 H), 3.41 (td, 0.4 H), 2.83-3.26 (m, 5 H)	461.1 [M+H]+	100%
1335	(CD3OD) δ 8.63-8.67 (m, 1 H), 8.47 (br d, 1 H), 7.48-7.73 (m, 3 H), 7.13-7.22 (m, 1 H), 6.95-7.08 (m, 2 H), 6.81 (s, 0.6 H), 6.66 (s, 0.4 H), 5.12 (br dd, 0.5 H), 4.93-4.99 (m, 0.5 H), 3.89-3.98 (m, 0.6 H), 3.36-3.45 (m, 0.4 H), 2.83-3.27 (m, 5 H)	461.2 [M+H]+	99.6%
1336	(CD3OD) δ 9.03 (t, 2 H), 7.62-7.77 (m, 2 H), 7.37-7.54 (m, 1.5 H), 6.99-7.15 (m, 1.5 H), 6.39-6.76 (m, 2 H), 4.95 (br d, 1 H), 3.79-4.08 (m, 0.8 H), 3.36-3.42 (m, 0.2 H), 2.94-3.26 (m, 1 H), 2.78-2.92 (m. 1 H), 2.42-2.70 (m, 3 H)	428.2 [M+-H]+	100%
1337	(CD3OD) δ 9.03 (t, 2 H), 7.64-7.77 (m, 2 H), 7.36-7.55 (m, 1.5 H), 6.99-7.15 (m, 1.5 H), 6.42-6.74 (m, 2 H), 4.95 (br d, 1 H), 3.80-4.01 (m, 0.8 H), 3.37-3.43 (m, 0.2 H), 2.96-3.26 (m, 1 H), 2.82-2.92 (m, 1 H). 2.43-2.70 (m, 3 H)	428.2 [M+H]+	96.5%
1338	(CD3OD) δ 9.36 (dd, 1 H), 8.65-8.85 (m, 2 H), 7.60 (d, 1 H), 6.83-7.45 (m, 3 H), 6.29-6.70 (m, 2 H), 4.89 (td, 1 H), 3.74-3.92 (m, 0.5 H), 3.24-3.38 (m, 0.5 H), 2.84-3.16 (m, 1 H), 2.69-2.82 (m, 1 H), 2.32-2.66 (m, 3 H)	428.1 [M+H]+	100%
1339	(CD3OD) δ 9.36 (dd, 1 H), 8.68-8.81 (m, 2 H), 7.59 (d, 1 H), 6.83-7.43 (m, 3 H), 6.32-6.66 (m, 2 H), 4.84-4.95 (m, 1 H), 3.77-3.93 (m, 0.5 H), 3.24-3.37 (m, 0.5 H), 2.83-3.18 (m, 1 H), 2.70-2.83 (m, 1 H), 2.34-2.64 (m, 3 H)	428.1 [M+H]+	98.4%
1340	(CD3OD) δ 9.31 (s, 1 H), 8.74-8.89 (m, 1 H), 8.34-8.63 (m, 1 H), 7.78-7.92 (m, 1 H), 7.65-7.76 (m, 2 H), 7.56 (br s, 0.5 H), 7.19-7.42 (m, 2 H), 6.80-7.05 (m, 1 H), 6.65 (s, 0.5 H), 4.93-5.16 (m, 1 H), 3.57-4.07 (m, 1 H), 2.96-3.25 (m, 1 H), 2.84-2.92 (m, 1 H)	481.1 [M+H]+	100%
1341	(CD3OD) δ 9.30 (s, 1 H), 8.73-8.95 (m, 1 H), 8.44-8.66 (m, 1 H), 7.78-7.94 (m, 1 H), 7.62-7.77 (m, 2 H), 7.56 (br s, 0.5 H), 7.18-7.39 (m, 2 H), 6.83-7.05 (m, 1 H), 6.65 (s, 0.5 H), 4.92-5.16 (m, 1 H), 3.98 (br t, 1 H), 2.96-3.24 (m, 1 H), 2.87 (br d, 1 H)	481.1 [M+H]+	97.5%
1342	(CD3OD) δ 8.64 (td, 1 H), 8.42-8.49 (m, 1 H), 7.79-7.89 (m, 1 H), 7.67-7.75 (m, 1 H), 7.45-7.60 (m, 1.5 H), 7.21-7.39 (m, 2 H), 6.84-7.00 (m, 1 H), 6.66 (s, 0.5 H), 5.12 (dd, 0.5 H), 4.96 (br dd, 0.5 H), 3.94-4.03 (m, 0.5 H), 3.34 (br d, 0.5 H), 2.85-3.29 (m, 5 H)	495.2 [M+H]+	100%
1343	(CD3OD) δ 8.64 (br t, 1 H), 8.46 (br t, 1 H), 7.80-7.90 (m, 1 H), 7.66-7.77 (m, 1 H), 7.46-7.60 (m, 1.5 H), 7.21-7.38 (m, 2 H), 6.86-7.01 (m, 1 H), 6.67 (s, 0.5 H), 5.12 (br dd, 0.4 H), 4.96 (br dd, 0.6 H), 3.93-4.03 (m, 0.5 H), 3.32-3.36 (m, 0.5 H), 2.85-3.29 (m, 5 H)	495.2 [M+H]+	99.8%
1344	(CD3OD) δ 8.46 (dd, 1 H), 8.27 (d, 1 H), 7.81-7.94 (m, 1 H), 7.68-7.76 (m, 1 H), 7.63 (ddd, 1.5 H), 7.35-7.40 (m, 0.5 H), 7.23-7.33 (m, 1.5 H), 7.00 (br s, 0.5 H), 6.89 (s, 0.5 H), 6.69 (s, 0.5 H), 4.97-5.10 (m, 1 H), 4.01 (d, 3.5 H), 3.39 (br d, 0.5 H), 3.14-3.27 (m, 0.5 H). 2.96-3.07 (m, 0.5 H), 2.82-2.94 (m, 1 H)	511.1 [M+H]+	96.1%
1345	(CD3OD) δ 8.45 (dd, 1 H), 8.26 (d, 1 H), 7.81-7.93 (m, 1 H), 7.68-7.76 (m, 1 H), 7.58-7.66 (m, 1.5 H), 7.35-7.40 (m, 0.5 H), 7.22-7.34 (m, 1.5 H), 7.00 (s, 0.5 H). 6.67-6.90 (m, 1 H), 4.96-5.10 (m, 1 H), 4.01 (d, 3.5 H), 3.37-3.45 (m, 0.5 H), 3.12-3.26 (m, 0.5 H), 2.95-3.10 (m, 0.5 H), 2.82-2.95 (m, 1 H)	511.1 [M+H]+	92.3%
1346	(CD3OD) δ 9.30 (s, 1 H), 8.80 (d, 1 H), 8.32-8.61 (m, 2 H), 7.54-7.74 (m, 3.3 H), 7.13-7.27 (m, 1 H), 6.80-7.03 (m, 1.7 H), 6.54-6.71 (m, 1 H), 4.91-5.11 (m, 1 H), 3.37-3.85 (m, 1 H), 2.82-3.25 (m, 2 H)	413.2 [M+H]+	100%
1347	(CD3OD) δ 9.30 (s, 1 H), 8.80 (dd, 1 H), 8.34-8.62 (m, 2 H), 7.54-7.72 (m, 3.3 H), 7.12-7.27 (m, 1 H), 6.78-7.03 (m, 1.7 H), 6.49-6.69 (m, 1 H), 5.06 (br dd, 0.5 H), 4.93 (br d, 0.5 H), 3.72-3.87 (m, 0.7 H), 3.43 (td, 0.3 H), 2.81-3.24 (m, 2 H)	413.1 [M+H]+	100%
1348	1H NMR(METHANOL-d4) δ 8.51-8.62 (m, 1 H), 7.94-8.03 (m, 1 H), 7.70 (s, 1 H), 7.58 (s, 0.2 H), 7.37-7.50 (m, 1 H), 6.71-7.16 (m, 3.8 H), 5.10 (br dd, 0.5 H), 4.93 (br d, 0.5 H), 3.88 (s, 3 H), 3.70-3.83 (m, 0.5 H), 3.37-3.42 (m, 0.5 H), 2.78-3.25 (m, 2 H), 2.61-2.71 (m, 3 H)	480.2 [M+H]+	100%
1349	(CD3OD) δ 8.46-8.65 (m, 1 H), 7.92-8.07 (m, 1 H), 7.70 (s, 1 H), 7.58 (s, 0.2 H), 7.33-7.50 (m, 1 H), 6.66-7.15 (m, 3.8 H), 5.10 (br dd, 0.5 H), 4.93 (br d, 0.5 H), 3.88 (s, 3 H), 3.68-3.81 (m, 0.5 H), 3.37-3.45 (m, 0.5 H), 2.78-3.26 (m, 2 H), 2.60-2.76 (m, 3 H)	480.2 [M+H]+	100%
1350	(CD3OD) δ 8.47-8.64 (m, 1 H), 7.70 (s, 1 H), 7.39-7.49 (m, 1.3H), 6.67-7.15 (m, 3.7 H). 4.92-5.00 (m, 1 H). 3.68-3.82 (m, 0.5 H), 3.34-3.43 (m, 0.5 H), 2.77-3.21 (m, 2 H), 1.79-1.97 (m, 6 H)	446.2 [M+H]+	96.2%
1351	(CD3OD) δ 8.49-8.64 (m, 1 H), 7.70 (s, 1 H), 7.38-7.48 (m, 1.3 H), 6.67-7.15 (m, 3.7 H), 4.92-5.01 (m, 1 H), 3.67-3.83 (m, 0.5 H, 3.35-3.43 (m, 0.5 H), 2.80-3.20 (m, 2 H), 1.81-1.95 (m, 6 H)	446.2 [M+H]+	91.3%
1352	(CD3OD) δ 8.43-8.63 (m, 1 H), 7.64-7.85 (m, 2 H), 7.36-7.59 (m, 1.3 H), 6.71-7.15 (m, 4.7 H), 4.92-5.09 (m, 1 H), 4.02 (s, 3 H), 3.67-3.86 (m, 0.5 H), 3.39 (td, 0.5 H), 2.76-3.26 (m, 2 H)	466.2 [M+H]+	100%
1353	(CD3OD) δ 8.59 (br s, 1 H), 7.80 (br s, 2 H), 7.38-7.56 (m, 1 H), 6.74-7.14 (m, 5 H), 5.03 (br d, 1 H), 4.02 (d, 3 H), 3.77 (br 1, 0.5 H), 3.39 (br s, 0.5 H), 2.79-3.25 (m, 2 H)	466.2 [M+H]+	100%
1354	(CD3OD) δ 7.86 (dd, 1 H), 7.64-7.76 (m, 1 H), 7.52 (br s, 0.5 H), 7.25-7.41 (m, 2 H), 6.83-7.01 (m, 1 H), 6.66 (s, 0.5 H), 4.99-5.04 (m, 1 H). 3.59-4.01 (m, 1 H). 2.80-3.19 (m, 2 H). 1.61 (s, 3 H), 1.38-1.46 (m, 2 H), 1.06-1.16 (m, 2 H)	458.1 [M+H]+	100%
1355	(CD3OD) & 7.74 (dd, 1 H), 7.52-7.63 (m, 1 H), 7.41 (br s, 0.5 H), 7.11-7.27 (m, 2 H), 6.70-6.85 (m, 1 H), 6.53 (s, 0.5 H), 4.81-4.94 (m, 1 H), 3.24-3.88 (m, 1 H), 2.68-3.05 (m, 2 H), 1.48 (s, 3 H), 1.26-1.33 (m, 2 H), 0.95-1.03 (m, 2 H)	458.2 [M+H]+	98.8%
1356	(CD3OD) δ 8.61-8.66 (m, 1 H), 8.37-8.47 (m, 2 H), 7.71 (s, 1 H), 7.45-7.54 (m, 1.4 H), 7.25-7.32 (m, 1 H), 6.96 (s, 0.6 H), 6.72-6.87 (m, 2 H), 5.10 (dd, 0.6 H), 4.94 (br d, 0.4 H), 3.74-3.84 (m, 0.6 H), 3.43 (td, 0.3 H), 3.14-3.26 (m, 0.7 H), 2.92-3.06 (m, 3 H), 2.80-2.90 (m, 1 H)	461.1 [M+H]+	100%
1357	(CD3OD) δ 8.64 (br d, 1 H), 8.37-8.47 (m, 2 H), 7.70 (br s, 1 H), 7.45-7.55 (m, 1 H), 7.26-7.32 (m, 1 H), 6.96 (br s, 1 H), 6.72-6.87 (m, 2 H), 5.10 (br dd, 0.6 H), 4.93 (br dd, 0.4 H), 3.75-3.84 (m, 0.6 H), 3.43 (td, 0.4 H), 2.80-3.26 (m, 5 H)	461.1 [M+H]+	99.7%
1358	(CD3OD) δ 8.60-8.65 (m, 1 H), 8.38-8.45 (m, 1 H), 7.70 (d, 1 H), 7.39-7.51 (m, 2 H), 6.95-7.14 (m, 2 H), 6.60-6.72 (m, 1.6 H), 6.48 (s, 0.4 H), 5.08 (dd, 0.6 H), 4.94 (br s, 0.4 H), 3.88-3.98 (m, 0.6 H), 3.41 (td, 0.4 H), 3.13-3.24 (m, 0.5 H), 2.81-3.04 (m, 4.5 H), 2.65 (s, 1.8 H), 2.47 (s, 1.2 H)	441.2 [M+H]+	100%
1359	(CD3OD) δ 8.63 (br d, 1 H), 8.43 (br s, 1 H), 7.73 (br s, 1 H), 7.39-7.52 (m, 2 H), 6.96-7.16 (m, 2 H), 6.60-6.75 (m, 1.6 H), 6.49 (s, 0.4 H), 5.09 (br dd, 1 H), 3.88-3.98 (m, 0.6 H), 3.41 (br t, 0.4 H), 3.14-3.25 (m, 0.6 H), 2.81-3.05 (m, 4.4 H), 2.66 (br s, 1.8 H), 2.48 (br s, 1.2 H)	441.2 [M+H]+	99.4%
1360	(CD3OD) δ 9.35 (s, 1 H), 8.69-8.83 (m, 2 H), 7.69-7.83 (m, 1 H), 7.54-7.66 (m, 1 H), 7.23-7.50 (m, 1 H), 6.84-7.23 (m, 2 H), 6.54-6.81 (m, 1 H), 4.86-4.99 (m, 1 H), 3.82-3.95 (m, 0.5 H), 3.25-3.33 (m, 0.5 H), 2.85-3.16 (m, 1 H), 2.71-2.82 (m, 1 H)	482.1 [M+H]+	100%
1361	(CD3OD) δ 9.35 (s, 1 H), 8.65-8.83 (m, 2 H), 7.67-7.86 (m, 1 H), 7.53-7.67 (m, 1 H), 7.24-7.51 (m, 1 H), 6.84-7.23 (m, 2 H), 6.49-6.84 (m, 1 H), 4.89-5.00 (m, 1 H), 3.82-3.95 (m, 0.5 H), 3.24-3.32 (m, 0.5 H), 2.86-3.15 (m, 1 H), 2.70-2.84 (m, 1 H)	482.1 [M+H]+	98.6%
1362	(CD3OD) δ 9.30-9.42 (m, 1 H), 8.74 (br d, 2 H), 8.24-8.41 (m, 1 H), 7.60 (br s, 1 H), 6.83-7.54 (m, 3 H), 6.67-6.83 (m, 1 H), 6.46-6.61 (m, 1 H), 4.90 (br dd, 1 H), 3.62-3.76 (m, 0.5 H), 3.33 (td, 0.5 H), 2.84-3.17 (m, 1 H), 2.76 (br d, 1 H)	414.2 [M+H]+	100%
1363	(CD3OD) δ 9.33-9.44 (m, 1 H), 8.71-8.80 (m, 2 H), 8.26-8.39 (m, 1 H), 7.60-7.73 (m, 1 H), 6.85-7.54 (m, 3 H), 6.68-6.82 (m, 1 H), 6.47-6.62 (m, 1 H), 4.91 (br dd, 1 H), 3.62-3.76 (m, 0.5 H), 3.26-3.39 (m, 0.5 H), 2.86-3.16 (m, 1 H), 2.69-2.83 (m, 1 H)	414.2 [M+H]+	100%
1364	(CD3OD) δ 8.63 (br d, 1 H), 8.37-8.48 (m, 2 H), 7.70 (br s, 1 H), 7.45-7.61 (m, 2.4 H), 7.13-7.23 (m, 1 H), 6.96 (s, 0.6 H), 6.80-6.88 (m, 1 H), 6.57-6.65 (m, 1 H), 5.07 (br dd, 1 H), 3.75-3.84 (m, 0.7 H), 3.42 (td, 0.3 H), 3.15-3.24 (m, 0.6 H), 2.82-3.04 (m, 4.4 H)	427.1 [M+H]+	100%
1365	(CD3OD) δ 8.64 (dd, 1 H), 8.38-8.48 (m, 2 H), 7.70 (br s, 1 H), 7.47-7.62 (m, 2.4 H), 7.15-7.23 (m, 1 H), 6.97 (s, 0.6 H), 6.81-6.89 (m, 1 H), 6.59-6.66 (m, 1 H), 5.07 (dd, 0.6 H). 4.93 (br d, 0.4 H), 3.75-3.85 (m, 0.7 H), 3.43 (td, 0.3 H), 3.15-3.25 (m, 0.7 H), 2.83-3.06 (m, 4.3 H)	427.1 [M+H]+	99.7%
1366	(CD3OD) δ 7.88 (s, 1 H), 7.54-7.67 (m, 2 H), 7.24-7.49 (m, 1 H), 6.83-7.20 (m, 3 H), 6.48-6.69 (m, 1 H), 4.81-5.03 (m, 1 H), 3.78 (d, 3.6 H), 3.24-3.30 (m, 0.4 H), 2.69-3.09 (m, 2 H), 2.56 (d, 3 H)	480.2 [M+H]+	100%
1367	(CD3OD) δ 7.87 (s, 1 H), 7.54-7.67 (m, 2 H), 7.24-7.48 (m, 1 H), 6.84-7.20 (m, 3 H), 6.51-6.68 (m, 1 H), 4.81-5.04 (m, 1 H), 3.78 (d, 3.6 H), 3.25-3.31 (m, 0.4 H), 2.70-3.12 (m, 2 H), 2.56 (d, 3 H)	480.1 [M+H]+	99.2%
1368	(CD3OD) δ 8.43-8.57 (m, 1 H), 7.69 (s, 1 H), 7.29 (d, 1 H), 6.73-7.03 (m, 4 H), 6.28-6.64 (m, 1 H), 4.05-4.12 (m, 1 H), 3.95 (s, 3 H), 3.66-3.77 (m, 0.6 H), 3.20-3.28 (m, 0.3 H), 2.94-3.03 (m, 1 H), 2.72-2.82 (m, 1 H)	432.1 [M+H]+	100%
1369	(CD3OD) δ 8.42-8.55 (m, 1 H), 7.69 (s, 1 H), 7.29 (d, 1 H), 6.73-7.05 (m, 4 H), 6.32-6.64 (m, 1 H), 4.04-4.14 (m, 1 H), 3.95 (s, 3 H), 3.72 (br t, 0.6 H), 3.25 (br t, 0.4 H), 2.93-3.04 (m, 1 H), 2.71-2.83 (m, 1 H)	432.1 [M+H]+	100%
1370	(CD3OD) δ 8.68-8.83 (m, 1 H), 7.60-7.71 (m, 2 H), 6.74-7.06 (m. 4 H), 6.31-6.65 (m, 1 H), 4.06-4.13 (m, 1 H), 3.96 (s, 3 H), 3.67-3.76 (m, 0.6 H), 3.19-3.25 (m, 0.4 H), 2.93-3.05 (m, 1 H), 2.70-2.84 (m, 1 H)	466.1 [M+H]+	99.8%
1371	(CD3OD) δ 8.67-8.82 (m, 1 H), 7.58-7.73 (m, 2 H), 6.72-7.05 (m, 4 H), 6.31-6.65 (m, 1 H), 4.09 (br d, 1 H), 3.96 (s, 3 H), 3.66-3.78 (m. 0.6 H), 3.25 (br d. 0.4 H), 2.99 (br t, 1 H). 2.72-2.85 (m, 1 H)	466.2 [M+H]+	99.4%
1372	(CD3OD) δ 8.55-8.71 (m, 1 H), 7.69 (s, 1 H), 7.43 (br d, 1 H), 6.72-7.14 (m, 5 H), 6.32-6.66 (m, 1 H), 4.04-4.14 (m, 1 H), 3.95 (s, 3 H), 3.65-3.78 (m, 0.6 H), 3.17-3.27 (m, 0.4 H), 2.92-3.05 (m, 1 H). 2.70-2.83 (m, 1 H)	448.2 [M+H]+	99.7%
1373	(CD3OD) δ 8.57-8.71 (m, 1 H), 7.69 (s, 1 H), 7.43 (br d, 1 H), 6.73-7.14 (m, 5 H), 6.31-6.63 (m, 1 H), 4.04-4.14 (m, 1 H), 3.95 (s, 3 H), 3.65-3.78 (m, 0.6 H). 3.20-3.27 (m, 0.4 H), 2.93-3.05 (m, 1 H), 2.77 (br t, 1 H)	448.2 [M+H]+	99.0%
1374	(CD3OD) δ 8.91 (br s, 1 H), 8.47-8.66 (m, 1 H), 8.34 (s, 1 H), 7.56-7.82 (m, 2 H), 7.37-7.52 (m, 1 H), 6.72-7.14 (m, 4 H), 5.08 (br dd, 1 H), 3.77 (br t, 0.5 H), 3.36-3.47 (m, 0.5 H), 2.76-3.25 (m, 2 H)	502.2 [M+H]+	100%
1375	(CD3OD) δ 8.88-8.96 (m, 1 H), 8.51-8.63 (m, 1 H), 8.35 (s, 1 H), 7.55-7.84 (m, 2 H), 7.38-7.52 (m, 1 H), 6.74-7.16 (m. 4 H), 5.10 (br dd, 1 H), 3.71-3.88 (m, 0.5 H), 3.42 (td, 0.5 H), 2.79-3.26 (m, 2 H)	502.2 [M+H]+	100%
1376	(CD3OD) δ 8.48-8.61 (m, 1 H), 8.33 (d, 1 H), 7.82 (s, 0.3 H), 7.64-7.76 (m, 1.5 H), 7.53 (d, 0.5 H), 7.38-7.47 (m, 1 H), 7.21 (d. 1 H), 6.75-7.13 (m, 3.7 H). 4.94-5.10 (m, 1 H), 3.73-3.83 (m, 0.5 H), 3.35-3.46 (m, 0.5 H), 2.80-3.26 (m, 2 H)	502.2 [M+H]+	100%
1377	(CD3OD) δ 8.49-8.61 (m, 1 H), 8.33 (d, 1 H), 7.82 (s, 0.3 H), 7.69 (br d. 1.5 H). 7.53 (d, 0.5 H), 7.37-7.47 (m, 1 H), 7.21 (d, 1 H), 6.73-7.15 (m, 3.7 H), 4.92-5.11 (m, 1 H), 3.71-3.86 (m, 0.5 H), 3.35-3.50 (m, 0.5 H), 2.79-3.26 (m, 2 H)	502.2 [M+H]+	99.3%
1378	(CD3OD) δ 8.29-8.39 (m, 1 H), 7.70 (s, 1 H), 7.45 (s, 0.3 H), 6.65-7.02 (m, 3.7 H), 5.01 (dd, 1H), 3.74 (ddd, 0.7 H), 3.37-3.46 (m, 0.3 H), 2.80-3.18 (m, 2 H), 1.58-1.63 (m, 3 H), 1.39-1.47 (m, 2 H), 1.08-1.14 (m, 2 H)	408.2 [M+H]+	100%
1379	(CD3OD) δ 8.30-8.39 (m, 1 H), 7.70 (s, 1 H), 7.45 (s, 0.3 H), 6.68-7.02 (m, 3.7 H), 5.01 (dd, 1 H), 3.64-3.81 (m, 0.7 H), 3.36-3.44 (m, 0.3 H), 2.79-3.18 (m, 2 H), 1.61 (s, 3 H), 1.39-1.47 (m, 2 H), 1.05-1.16 (m, 2 H)	408.1 [M+H]+	99.6%
1380	(CD3OD) δ 9.03 (d, 2 H), 8.71 (d, 1 H), 7.44-7.74 (m, 3.5 H), 6.81-7.01 (m, 2.5 H), 4.92-5.04 (m, 1 H). 3.80 (ddd, 0.7 H), 3.44 (td, 0.3 H), 3.17-3.27 (m, 0.7 H), 3.00-3.07 (m, 0.3 H), 2.78-2.94 (m, 1 H)	482.1 [M+H]+	100%
1381	(CD3OD) δ 9.03 (d, 2 H), 8.71 (d, 1 H), 7.43-7.79 (m, 3.5 H), 6.81-7.01 (m, 2.5 H), 4.92-5.06 (m, 1 H), 3.74-3.85 (m, 0.7 H), 3.41-3.49 (m, 0.3 H), 2.98-3.28 (m, 1 H), 2.86 (br d, 1 H)	482.2 [M+H]+	93.5%
1382	(CD3OD) δ 8.37-8.52 (m, 1 H), 8.07-8.16 (m, 1 H), 7.95 (t, 1 H), 7.78-7.88 (m, 1 H), 6.98-7.68 (m, 4 H), 6.82-6.92 (m, 1 H), 6.60-6.74 (m, 1 H), 4.93-5.10 (m, 1 H), 3.75-3.87 (m, 0.5 H), 3.36-3.52 (m, 0.5 H), 2.98-3.29 (m, 1 H), 2.80-2.92 (m, 1 H), 2.66 (s, 3 H)	427.2 [M+H]+	100%
1383	(CD3OD) δ 8.38-8.53 (m, 1 H), 8.04-8.16 (m, 1 H), 7.95 (t, 1 H), 7.72 (s, 1 H), 6.95-7.67 (m, 4 H), 6.80-6.96 (m, 1 H), 6.55-6.74 (m, 1 H), 5.02 (dd, 1 H), 3.74-3.92 (m, 0.5 H), 3.38-3.52 (m, 0.5 H), 2.93-3.29 (m, 1 H), 2.76-2.92 (m, 1 H), 2.66 (s, 3 H)	427.2 [M+H]+	100%
1384	(CD3OD) δ 7.75-7.98 (m, 1 H), 7.62 (br s, 1 H), 6.97-7.39 (m, 3 H), 6.60-6.97 (m, 2 H), 6.33-6.53 (m, 1 H), 4.75 (s, 0.5 H), 4.08 (br s, 0.5 H), 4.02 (s, 3 H), 3.70-3.87 (m, 0.5 H), 3.15 (s, 0.5 H), 2.95-3.08 (m, 1 H), 2.81 (br d, 1 H)	432.1 [M+H]+	99.9%
1385	(CD3OD) δ 7.70 (s, 1 H), 7.61 (br s, 1 H), 6.95-7.37 (m. 3 H), 6.61-6.95 (m, 2 H), 6.33-6.51 (m, 1 H), 4.85 (br d, 0.5 H), 4.06-4.12 (m, 0.5 H), 4.02 (br d, 3 H), 3.79 (br s, 0.5 H), 3.28 (br s, 0.5 H), 3.00 (br d, 1 H), 2.68-2.87 (m, 1 H)	432.1 [M+H]+	99.6%
1386	(CD3OD) δ 7.87 (br d, 1 H), 7.71 (br d, 1 H), 6.95-7.53 (m, 3 H), 6.59-6.95 (m, 2 H), 6.29-6.59 (m, 1 H), 4.82 (br d, 0.5 H), 4.07 (br d, 0.5 H), 3.97 (br d, 3 H), 3.78 (br t, 0.5 H), 3.18-3.30 (m, 0.5 H), 3.01 (br d, 1 H), 2.67-2.88 (m, 1 H)	466.1 [M+H]+	99.6%
1387	(CD3OD) δ 7.88 (br d, 1 H), 7.70 (br s, 1 H), 6.95-7.54 (m, 3 H), 6.59-6.95 (m, 2 H), 6.27-658 (m, 1 H), 4.83 (br d, 0.5 H), 4.07 (br d, 0.5 H), 3.97 (br d, 3 H), 3.70-3.86 (m, 0.5 H), 3.29 (br s, 0.5 H), 3.01 (br d, 1 H), 2.66-2.87 (m, 1 H)	466.1 [M+H]+	98.2%
1388	(CD3OD) δ 7.68 (br d. 1 H), 6.97-7.57 (m, 3 H), 6.58-6.97 (m, 3 H), 6.28-6.44 (m, 1 H), 4.76-4.86 (m, 0.5 H), 4.06 (br d, 0.5 H), 3.97 (br d, 3 H), 3.81 (br t, 0.5 H), 3.37 (br s, 0.5 H), 3.00 (br d, 1 H), 2.82 (br s, 1 H), 2.63-2.77 (m, 3 H)	412.2 [M+H]+	96.9%
1389	(CO3OD) δ 7.68 (br d, 1 H), 6.96-7.56 (m, 3 H), 6.58-6.96 (m, 3 H), 6.26-6.43 (m, 1 H), 4.82 (br d, 0.5 H), 4.06 (br d, 0.5 H), 3.97 (br d, 3 H), 3.74-3.88 (m, 0.5 H), 3.35-3.42 (m, 0.5 H), 3.00 (br d, 1 H), 2.82 (br s, 1 H), 2.63-2.79 (m, 3 H)	412.2 [M+H]+	99.6%
1390	(CD3OD) δ 7.66-7.80 (m, 2 H), 7.38-7.60 (m, 1 H), 7.14-7.34 (m, 2.5 H), 6.93 (s, 0.5 H), 6.60-6.79 (m, 1 H), 5.01 (dd, 1 H), 3.81-3.93 (m, 0.6 H), 3.35-3.39 (m, 0.4 H), 2.80-3.17 (m, 2 H), 2.28-2.38 (m, 1 H), 1.26-1.32 (m, 2 H), 1.20-1.25 (m, 2 H)	426.1 [M+H]+	100%
1391	(CD3OD) δ 7.66-7.80 (m, 2 H), 7.52 (s, 1 H), 7.13-7.37 (m, 2.5 H), 6.93 (s, 0.5 H), 6.61-6.78 (m, 1 H), 5.01 (dd, 1 H), 3.79-3.92 (m, 0.6 H), 3.35-3.40 (m, 0.4 H), 2.81-3.18 (m, 2 H), 2.28-2.38 (m, 1 H), 1.26-1.32 (m, 2 H), 1.23 (br dd, 2 H)	426.2 [M+H]+	92.9%
1392	(CD3OD) δ 8.84-9.11 (m, 2 H), 7.47-7.73 (m, 3 H), 6.94-7.36 (m, 3 H), 6.59-6.88 (m, 1 H), 4.99 (ddd. 1 H), 3.88-3.99 (m, 0.5 H), 3.34-3.46 (m, 0.5 H), 2.82-3.27 (m, 2 H)	448.1 [M+H]+	100%
1393	(CD3OD) δ 9.03 (dd, 2 H), 7.52-7.76 (m, 3 H), 7.45-7.50 (m, 0.3 H), 6.96-7.21 (m, 2.7 H), 6.58-6.86 (m, 1 H), 4.94-5.05 (m, 1 H), 3.87-3.99 (m, 0.5 H), 3.34-3.44 (m, 0.5 H), 2.83-3.25 (m, 2 H)	448.1 [M+H]+	99.4%
1394	(CD3OD) δ 8.51-8.68 (m, 2 H), 8.41-8.50 (m, 1 H), 7.70-7.77 (m, 1 H), 7.39-7.59 (m, 2.3 H), 6.77-7.16 (m, 3.7 H), 4.93-5.18 (m, 1 H), 3.72-3.86 (m, 0.5 H), 3.42 (td, 0.5 H), 3.18-3.26 (m, 0.5 H), 2.83-3.00 (m, 4.5 H)	477.2 [M+H]+	100%
1395	(CD3OD) δ 8.51-8.70 (m, 2 H), 8.37-8.50 (m, 1 H), 7.74 (br s, 1 H), 7.37-7.59 (m, 2.5 H), 6.75-7.16 (m, 3.5 H), 4.93-5.17 (m, 1 H), 3.72-3.88 (m, 0.5 H), 3.37-3.51 (m, 0.5 H), 3.18-3.26 (m, 0.5 H), 2.82-3.06 (m, 4.5 H)	477.2 [M+H]+	99.5%
1396	(CD3OD) δ 8.07-8.17 (m, 1 H), 7.95 (t, 1 H), 7.72 (d, 1 H), 7.58-7.69 (m, 1 H). 7.03-7.58 (m, 3 H), 6.96-7.03 (m, 1 H), 6.62-6.87 (m, 1 H), 4.93-5.12 (m, 1 H), 3.88-4.01 (m, 0.5 H), 3.41 (td, 0.5 H), 2.95-3.28 (m, 1 H), 2.79-2.94 (m, 1 H), 2.66 (s, 3 H)	461.1 [M+H]+	100%
1397	(CD3OD) δ 8.08-8.19 (m, 1 H), 7.95 (td, 1 H), 7.72 (d, 1 H), 7.57-7.68 (m, 1 H), 7.04-7.57 (m, 3 H), 6.95-7.04 (m, 1 H), 6.60-6.88 (m, 1 H), 4.95-5.09 (m, 1 H), 3.88-4.01 (m, 0.5 H), 3.38-3.47 (m, 0.5 H). 2.96-3.30 (m, 1 H), 2.82-2.96 (m, 1 H), 2.66 (d, 3 H)	461.1 [M+H]+	98.3%
1398	(CD3OD) δ 8.11 (dd, 1 H), 7.95 (td, 1 H), 7.71 (d, 1 H), 6.97-7.61 (m, 4 H), 6.65-6.77 (m, 1 H), 6.43-6.65 (m, 1 H), 4.94-5.09 (m, 1 H), 3.89-4.02 (m, 0.5H), 3.36-3.44 (m, 0.5 H), 2.96-3.28 (m, 1 H), 2.80-2.96 (m, 1 H), 2.45-2.74 (m, 6 H)	441.2 [M+H]+	100%
1399	(CD3OD) δ 8.11 (dd, 1 H), 7.95 (td, 1 H), 7.71 (d, 1 H), 6.98-7.58 (m, 4 H), 6.66-6.77 (m, 1 H), 6.44-6.66 (m, 1 H), 5.00 (td, 1 H), 3.88-4.02 (m, 0.5 H), 3.36-3.44 (m, 0.5 H), 2.94-3.26 (m, 1 H), 2.81-2.94 (m, 1 H), 2.45-2.76 (m, 6 H)	441.2 [M+H]+	99.6%
1400	(CD3OD) δ 7.98 (d, 1 H). 7.68-788 (m, 2 H), 7.53-7.66 (m, 1 H), 7.22-7.51 (m, 2 H), 6.83-7.22 (m, 2 H), 6.53-6.81 (m, 1 H), 4.83-4.99 (m, 1 H), 3.82-3.94 (m, 0.5 H), 3.24-3.31 (m, 0.5 H), 2.84-3.16 (m, 1 H), 2.71-2.84 (m, 1 H), 2.54 (d, 3 H)	495.1 [M+H]+	100%
1401	(CD3OD) δ 7.99 (d, 1 H), 7.67-7.88 (m, 2 H), 7.53-7.67 (m, 1 H), 7.23-7.51 (m, 2 H), 6.82-7.23 (m, 2 H), 6.52-6.82 (m, 1 H), 4.83-5.00 (m, 1 H), 3.87 (br t, 0.5 H), 3.24-3.32 (m, 0.5 H), 2.85-3.16 (m, 1 H), 2.68-2.85 (m, 1 H), 2.54 (d. 3 H)	495.1 [M+H]+	88.1%
1402	(CD3OD) δ 7.76 (br d, 1 H), 7.69 (br d, 1 H), 7.29-7.63 (m, 2 H), 6.94-7.29 (m, 2 H), 6.61-6.94 (m, 2 H), 6.25-6.52 (m, 1 H), 4.83 (br s, 1 H), 4.07 (br d, 0.5 H), 3.96 (br d, 3 H), 3.69-3.86 (m, 0.5 H), 3.00 (br d, 1 H), 2.64-2.90 (m, 1 H)	448.2 [M+H]+	99.9%
1403	(CD3OD) δ 7.76 (br d, 1 H), 7.70 (br d, 1 H), 7.29-7.59 (m, 2 H), 6.94-7.29 (m, 2 H), 6.61-6.94 (m, 2 H), 6.27-6.53 (m, 1 H), 4.83 (br s, 1 H), 4.07 (br d, 0.5 H), 3.96 (br d, 3 H), 3.78 (br t, 0.5 H), 3.00 (br d, 1 H), 2.69-2.87 (m, 1 H)	448.2 [M+H]+	98.2%
1404	(CD3OD) δ 8.35 (d, 1 H), 7.43-7.88 (m, 3.5 H), 7.19-7.36 (m, 2 H), 6.99 (s, 0.5 H), 6.72-6.88 (m, 1 H), 6.60-6.71 (m, 1 H), 5.08 (br dd, 0.7 H), 4.96-4.98 (m, 0.3 H), 3.78-3.93 (m, 0.5 H), 3.40-3.53 (m, 0.5 H), 2.96-3.24 (m, 1 H), 2.87 (br d, 1 H)	470.1 [M+H]+	100%
1405	(CD3OD) δ 8.36 (d, 1 H), 7.96-8.16 (m, 1 H), 7.43-7.89 (m, 2.5 H), 7.19-7.36 (m, 2 H), 7.06 (s, 0.5 H), 6.79-6.93 (m, 1 H), 6.58-6.75 (m, 1 H), 5.13 (br dd, 0.7 H). 4.95-497 (m, 0.3 H), 3.75-3.90 (m, 0.7 H), 3.41-3.54 (m, 0.3 H), 3.24 (br d, 0.8 H), 3.04 (br d, 0.2 H), 2.84-2.97 (m, 1 H)	470.1 [M+H]+	100%
1406	(CD3OD) δ 8.40 (s, 1 H), 8.11 (s, 1 H), 7.66-7.80 (m, 2 H), 7.36-7.60 (m, 1 H), 6.97-7.34 (m, 3 H), 6.61-6.81 (m, 1 H), 4.95-5.15 (m, 1 H), 4.02 (d, 3 H). 3.82-397 (m, 0.6 H), 3.36-3.43 (m, 0.4 H), 2.83-3.24 (m, 2 H)	466.2 [M+H]+	100%
1407	(CD3OD) δ 8.41 (s, 1 H), 8.11 (s, 1 H), 7.67-7.82 (m, 2 H), 7.36-7.61 (m, 1 H), 6.95-7.33 (m, 3 H), 6.61-6.83 (m, 1 H), 4.93-5.15 (m, 1 H), 4.02 (d, 3 H), 3.82-3.95 (m, 0.6 H), 3.36-3.44 (m, 0.4 H), 2.82-3.24 (m, 2 H)	466.2 [M+H]+	99.2%
1408	(CD3OD) δ 8.45-8.65 (m, 1 H), 7.69 (s, 1 H), 7.43 (br t, 1.3 H), 6.65-7.17 (m, 3.7 H), 4.98 (br dd, 1 H), 3.63-3.83 (m, 0.5 H), 3.34-3.44 (m, 0.5 H), 2.73-3.22 (m, 2 H), 1.45-1.51 (m, 9 H)	442.1 [M+H]+	100
1409	(CD3OD) δ 8.43-8.68 (m, 1 H), 7.69 (s, 1 H), 7.43 (br t, 1.3 H), 6.70-7.14 (m, 3.7 H), 4.98 (br dd, 1 H), 3.63-3.81 (m, 0.5 H), 3.34-3.43 (m, 0.5 H), 2.73-3.22 (m, 2 H), 1.43-1.58 (m, 9 H)	442.2 [M+H]+	99.1%
1410	(DMSO-d6) δ 9.02-9.18 (m, 2 H), 8.56-8.81 (m, 1 H), 8.23 (s, 0.3 H), 7.74-7.85 (m, 1 H), 7.63 (s. 1 H), 7.36-7.49 (m, 1 H), 6.68-6.94 (m, 2.7 H), 4.70-4.92 (m, 1 H), 3.60-3.81 (m, 0.6 H), 2.98-3.09 (m, 1 H), 2.62-2.92 (m, 1.4 H)	448.1 [M+H]+	100%
1411	(DMSO-d6) δ 8.99-9.17 (m, 2 H), 8.61-8.72 (m, 0.8 H), 8.23 (s, 0.2 H), 7.36-7.87 (m, 3 H), 7.19 (br d, 0.3 H), 6.67-6.95 (m, 2.7 H), 4.85 (br dd, 1H), 3.66-3.75 (m, 0.5 H), 2.97-3.10 (m, 1 H), 2.73-2.94 (m, 1.5 H)	448.1 [M+H]+	97.3%
1412	(CD3OD) δ 9.02 (d. 2 H), 8.49-8.62 (m, 1 H), 7.65-7.77 (m, 2 H), 7.38-7.51 (m, 1.3 H), 7.08-7.15 (m, 0.2 H), 6.80-7.02 (m, 3.5 H), 4.94-5.03 (m, 1 H), 3.79 (ddd, 0.5 H), 3.37-3.49 (m, 0.5 H), 2.83-3.25 (m, 2 H)	464.1 [M+H]+	100%
1413	(CD3OD) δ 9.03 (d, 2 H), 8.51-8.62 (m, 1 H), 7.64-7.75 (m, 2 H), 7.39-7.49 (m, 1.3 H), 7.09-7.15 (m, 0.2 H). 6.81-7.00 (m, 3.5 H), 4.92-5.04 (m, 1 H), 3.73-3.87 (m, 0.5 H), 3.43 (td, 0.5 H), 2.83-3.26 (m, 2 H)	464.2 [M+H]+	95.7%
1414	(CD3OD) δ 9.46 (s, 1 H), 8.80-8.89 (m, 2 H). 8.50-8.64 (m, 1 H), 7.71 (s, 1 H), 7.39-7.52 (m, 1.4 H), 7.09-7.14 (m, 0.2 H), 6.80-7.00 (m, 3.4 H), 4.94-5.10 (m, 1 H), 3.72-3.89 (m, 0.5 H), 3.43 (td, 0.5 H), 2.83-3.24 (m, 2 H)	464.2 [M+H]+	100%
1415	(CD3OD) δ 9.41-9.53 (m, 1 H), 8.80-8.90 (m, 2 H), 8.50-8.66 (m, 1 H), 7.74 (br s, 1 H), 7.40-7.52 (m, 1.4 H), 7.09-7.14 (m, 0.2 H), 6.81-7.00 (m, 3.4 H), 5.03 (br dd, 1 H), 3.70-3.87 (m, 0.5 H), 3.37-3.50 (m, 0.5 H), 2.85-3.24 (m, 2 H)	464.2 [M+H]+	94.7%
1416	(CD3OD) δ 9.27 (s, 1 H), 8.37-8.92 (m, 3 H), 7.88-8.11 (m, 4 H), 7.55-7.68 (m, 2 H), 7.12-7.43 (m, 2 H), 6.39-6.99 (m, 3 H), 4.49-4.75 (m, 1 H), 3.38-3.86 (m, 1 H), 3.01-3.14 (m, 1 H), 2.77 (br dd, 1 H)	461.2 [M+H]+	100%
1417	(CD3OD) δ 9.20-9.35 (m, 1 H), 8.24-8.97 (m, 3 H), 7.86-8.13 (m, 4 H), 7.54-7.72 (m, 2 H), 7.33-7.44 (m, 1 H), 7.13-7.26 (m, 1 H), 6.35-7.03 (m, 3 H), 4.43-4.79 (m, 1 H), 3.38-3.97 (m, 1 H), 3.02-3.16 (m, 1 H), 2.78 (br d, 1 H)	461.2 [M+H]+	100%
1418	(CD3OD) δ 7.67-7.80 (m, 2 H), 7.44 (d, 1 H), 6.94-7.32 (m, 3 H), 6.60-6.80 (m, 1 H), 4.93-5.03 (m, 1 H), 3.81-3.93 (m, 0.6 H), 3.36-3.42 (m, 0.4 H), 2.82-3.19 (m, 2 H), 1.49 (d, 9 H)	442.2 [M+H]+	100%
1419	(CD3OD) δ 7.55-7.69 (m, 2 H), 7.29-7.47 (m, 1 H), 6.82-7.21 (m, 3 H), 6.48-6.69 (m, 1 H), 4.82-4.91 (m, 1 H), 3.69-3.83 (m, 0.6 H), 3.24-3.28 (m, 0.4 H), 2.70-3.07 (m, 2 H), 1.37 (d, 9 H)	442.2 [M+H]+	99.1%
1420	(CD3OD) δ 8.61-8.71 (m, 1 H), 8.15-8.26 (m, 1 H), 7.98 (tt, 1 H), 7.53-7.67 (m, 3 H), 7.25-7.48 (m, 1 H), 6.87-7.21 (m, 3 H), 6.50-6.70 (m, 1 H), 4.83-4.95 (m, 1 H), 3.77-3.87 (m, 0.6 H), 3.24-3.30 (m, 0.4 H), 2.73-3.15 (m, 2 H)	463.1 [M+H]+	100%
1421	(CD3OD) δ 8.61-8.75 (m, 1 H), 8.12-8.29 (m, 1 H), 7.98 (tt, 1 H), 7.53-7.69 (m, 3 H), 7.26-7.49 (m, 1 H), 6.87-7.21 (m, 3 H), 6.48-6.72 (m, 1 H), 4.81-4.93 (m, 1 H), 3.76-3.87 (m, 0.6 H), 3.24-3.30 (m, 0.4 H), 2.72-3.14 (m, 2 H)	463.1 [M+H]+	100%
1422	(CD3OD) δ 9.32 (s, 1 H), 8.80 (br d, 1 H), 8.50-8.65 (m, 2 H), 7.64-7.77 (m, 2 H), 7.42-7.58 (m, 1.2 H), 6.91-7.17 (m, 2.6 H), 6.77-6.87 (m, 1.2 H), 5.10 (br d, 1 H), 3.79 (br t, 0.5 H), 3.42 (br s, 0.5 H). 2.78-3.23 (m, 2 H)	463.2 [M+H]+	100%
1423	(CD3OD) δ 9.31 (br s, 1 H), 8.80 (br d, 1 H), 8.47-8.66 (m, 2 H), 7.64-7.76 (m, 2 H), 7.44 (br d, 1.2 H), 6.90-7.16 (m, 3.6 H), 6.76-6.87 (m, 1.2 H), 5.10 (br d, 1 H), 3.72-3.89 (m, 0.5 H), 3.43 (br s, 0.5 H), 2.81-3.24 (m, 2 H)	463.2 [M+H]+	97.7%
1424	(CD3OD) δ 8.52-8.64 (m, 1 H), 8.45 (d, 1 H), 8.26 (d, 1 H), 7.73 (br s, 1 H), 7.62 (dd, 1 H), 7.40-7.57 (m, 1.3 H), 6.78-7.16 (m, 3.7 H), 4.95-5.10 (m, 1 H), 4.00 (s, 3 H), 3.72-3.87 (m, 0.5 H), 3.43 (td, 0.5 H), 2.75-3.28 (m, 2 H)	493.1 [M+H]+	100%
1425	(CD3OD) δ 8.51-8.65 (m, 1 H), 8.44 (d, 1 H), 8.25 (d, 1 H), 7.73 (br s, 1 H), 7.52-7.64 (m, 1.3 H), 7.38-7.49 (m, 1 H), 6.78-7.16 (m, 3.7 H), 4.95-5.10 (m, 1 H), 4.00 (s, 3 H), 3.74-3.86 (m, 0.5 H), 3.39-3.48 (m, 0.5 H), 2.81-3.27 (m, 2 H)	493.2 [M+H]+	94.4%
1426	(CD3OD) δ 8.40-8.63 (m, 2 H), 7.87 (t, 1 H), 7.58-7.75 (m, 2 H), 7.29-7.48 (m, 1.3 H), 6.68-7.14 (m, 3.7 H), 4.94 (br dd, 1 H), 3.68-3.81 (m, 0.5 H), 3.36-3.43 (m, 0.5 H), 2.77-3.22 (m, 2 H)	481.1 [M+H]+	100%
1427	(CD3OD) δ 8.45-8.70 (m, 2 H), 7.93 (t, 1 H), 7.65-7.79 (m, 2 H), 7.36-7.51 (m, 1.3 H), 6.77-7.16 (m, 3.7 H), 4.94-5.04 (m, 1 H), 3.69-3.86 (m, 0.5 H), 3.42 (td, 0.5 H), 2.81-3.27 (m, 2 H)	481.2 [M+H]+	99.5%
1428	(CD3OD) δ 8.23-8.38 (m, 1 H), 8.11 (br d, 1 H), 7.95 (br t, 1 H), 7.72 (s, 1 H), 7.54 (br d, 1.3 H), 6.94-7.08 (m, 1.7 H), 6.73-6.86 (m, 1 H), 6.54-6.72 (m, 1 H), 5.02 (br dd, 1 H), 3.82 (br t, 0.6 H), 3.39-3.51 (m, 0.4 H), 2.96-3.28 (m, 1 H), 2.87 (br d, 1 H), 2.66 (s, 3 H), 2.36-2.56 (m, 3 H)	441.1 [M+H]+	100%
1429	(CD3OD) δ 8.24-8.37 (m, 1 H), 8.11 (br d, 1 H), 7.95 (t, 1 H), 7.73 (s, 1 H), 7.54 (d, 1.3 H), 6.95-7.05 (m, 1.7 H), 6.72-6.85 (m, 1 H), 6.57-6.70 (m, 1 H), 4.93-5.06 (m, 1 H), 3.78-3.87 (m, 0.6 H), 3.45 (td, 0.4H), 299-3.27 (m, 1 H), 2.81-2.94 (m, 1 H), 2.66 (s, 3 H), 2.40-2.52 (m, 3 H)	441.2 [M+H]+	99.3%
1430	(CD3OD) δ 8.38-8.51 (m, 1H), 8.11 (d, 1 H), 7.95 (t, 1 H), 7.75 (br s, 1 H), 7.54 (d, 1.3 H), 7.26-7.36 (m, 1 H), 7.00 (s, 0.7 H), 6.82-6.92 (m, 1 H), 6.71-6.82 (m, 1 H), 4.92-5.11 (m, 1 H), 3.75-3.87 (m, 0.6 H), 3.40-3.51 (m, 0.4 H), 2.98-3.28 (m, 1 H), 2.79-2.94 (m, 1 H), 2.66 (s, 3 H)	461.1 [M+H]+	100%
1431	(CD3OD) δ 8.27-8.42 (m, 1 H), 7.99 (d, 1 H), 7.83 (t, 1 H), 7.66 (br s, 1 H), 7.42 (d, 1.3 H), 7.13-7.27 (m, 1 H), 6.88 (s, 0.7 H), 6.70-6.81 (m, 1 H), 6.60-6.70 (m, 1 H), 4.82-4.98 (m, 1 H), 3.62-3.76 (m, 0.6 H), 3.27-3.40 (m, 0.4 H), 2.84-3.16 (m, 1 H), 2.68-2.84 (m, 1 H), 2.54 (s, 3 H)	461.2 [M+H]+	98.7%
1432	(CD3OD) δ 8.51-8.65 (m, 1 H), 8.00 (d, 1 H), 7.77-7.89 (m, 1 H), 7.62 (s, 1 H), 7.47-758 (m, 1 H), 7.36-7.47 (m, 1.3 H), 6.80-6.95 (m, 1.7 H), 6.62-6.76 (m, 1 H), 4.83-4.99 (m, 1 H), 3.63-3.75 (m, 0.6 H), 3.26-3.40 (m, 0.4 H), 2.86-3.16 (m, 1 H), 2.70-2.82 (m, 1 H), 2.50-2.58 (m, 3 H)	495.1 [M+H]+	100%
1433	(CD3OD) δ 8.52-8.66 (m, 1 H), 7.99 (d, 1 H), 7.77-7.90 (m, 1 H), 7.60-7.70 (m, 1 H), 7.49-7.57 (m, 1 H), 7.38-7.46 (m, 1.3 H), 6.81-6.96 (m, 1.7 H), 6.64-6.77 (m, 1 H), 4.82-4.99 (m, 1 H), 3.62-3.75 (m, 0.6 H), 3.27-3.40 (m, 0.4 H), 2.85-3.17 (m, 1H), 2.69-2.82 (m, 1H), 2.43-2.60 (m, 3 H)	495.1 [M+H]+	96.5%
1434	(CD3OD) δ 8.98 (s, 1 H), 8.23-8.78 (m, 2 H), 7.83-8.04 (m, 2 H), 7.56-7.70 (m, 3 H), 7.16-7.22 (m, 1 H), 6.35-6.95 (m, 4 H), 4.46-4.73 (m, 1 H), 3.95 (s, 3 H), 3.46-3.77 (m, 1 H), 3.01-3.15 (m, 1 H), 2.70-2.80 (m, 1 H)	464.2 [M+H]+	100%
1435	(CD3OD) δ 8.97 (s, 1 H), 8.27-8.77 (m, 2 H), 7.85-8.02 (m, 2 H), 7.55-7.70 (m, 3 H), 7.15-7.22 (m, 1 H), 6.39-7.02 (m, 4 H), 4.47-4.71 (m, 1 H), 3.95 (s, 3 H), 3.36-3.80 (m, 1 H), 3.00-3.14 (m, 1 H), 2.71-2.81 (m, 1 H)	464.2 [M+H]+	99.8%
1436	(CD3OD) δ 7.66-7.81 (m, 2 H), 7.37-7.60 (m, 1 H), 6.95-7.32 (m, 3 H), 6.60-6.81 (m, 1 H), 4.94-5.02 (m, 1 H), 3.82-3.96 (m, 0.6 H), 3.35-3.40 (m, 0.4 H), 2.82-3.20 (m, 2 H), 1.86-1.97 (m, 6 H)	446.1 [M+H]+	99.9%
1437	(CD3OD) δ 7.56-7.69 (m, 2 H), 7.26-7.49 (m, 1 H), 6.83-7.20 (m, 3 H), 6.48-6.68 (m, 1 H), 4.82-4.90 (m, 1 H), 3.72-3.84 (m, 0.6 H), 3.23-3.27 (m, 0.4 H), 2.70-3.08 (m, 2 H), 1.75-1.83 (m, 6 H)	446.1 [M+H]+	99.4%
1438	(CD3OD) δ 7.83 (dd, 1 H), 7.69-7.80 (m, 2 H), 7.38-7.61 (m, 1 H), 6.98-7.34 (m, 4 H), 6.61-6.80 (m, 1 H), 4.95-5.09 (m, 1 H), 4.05 (d, 3 H), 3.91 (ddd, 0.6 H), 3.36-3.41 (m, 0.4 H), 2.83-3.24 (m, 2 H)	466.1 [M+H]+	98.9%
1439	(CD3OD) δ 7.71 (dd, 1 H), 7.56-7.68 (m, 2 H), 7.26-7.48 (m, 1 H), 6.84-7.22 (m, 4 H), 6.48-6.70 (m, 1 H), 4.83-4.96 (m, 1 H), 3.93 (d, 3 H), 3.79 (ddd, 0.6 H), 3.23-3.30 (m, 0.4 H), 2.71-3.13 (m, 2 H)	466.1 [M+H]+	100%
1440	(CD3OD) δ 8.93 (d, 1 H), 8.36 (s, 1 H), 7.66-7.82 (m, 3 H), 7.45-7.58 (m, 1 H), 7.16-7.34 (m, 2.5 H), 6.98 (s, 0.5 H), 6.61-6.83 (m, 1 H), 4.96-5.14 (m, 1 H), 3.86-3.98 (m, 0.6 H), 3.36-3.43 (m, 0.4 H), 2.84-3.21 (m, 2 H)	502.1 [M+H]+	100%
1441	(CD3OD) δ 8.93 (d, 1 H), 8.36 (s, 1 H), 7.66-7.83 (m, 3 H), 7.44-7.58 (m, 1 H), 7.16-7.34 (m, 2.5 H), 6.98 (s, 0.5 H), 6.63-6.80 (m, 1 H), 4.95-5.13 (m, 1 H), 3.86-3.99 (m, 0.6 H), 3.37-3.43 (m, 0.4 H), 2.84-3.22 (m, 2 H)	502.1 [M+H]+	99.6%
1442	(CD3OD) δ 8.21 (dd, 1 H), 7.53-7.73 (m, 3 H), 7.29-7.45 (m, 1 H), 6.98-7.20 (m, 3.5 H), 6.85 (s, 0.5 H), 6.45-6.67 (m, 1 H), 4.83-4.98 (m, 1 H), 3.74-3.85 (m, 0.6 H), 3.22-3.28 (m, 0.4 H), 2.71-3.11 (m, 2 H)	502.2 [M+H]+	100%
1443	(CD3OD) δ 8.23 (dd, 1 H), 7.54-7.73 (m, 3 H), 7.30-7.47 (m, 1 H), 7.02-7.20 (m, 3.5 H), 6.86 (s, 0.5 H), 6.49-6.69 (m, 1 H), 4.83-4.97 (m, 1 H), 3.73-3.86 (m, 0.6 H), 3.24-3.29 (m, 0.4 H), 2.72-3.12 (m, 2 H)	502.1 [M+H]+	99.9%
1444	(CD3OD) δ 9.14 (d, 1 H), 8.47 (s, 1 H), 7.71 (br d, 1 H), 7.50-7.67 (m, 1.5 H), 7.13-7.27 (m, 1 H), 6.94-7.10 (m, 1.5 H), 6.59-6.86 (m, 1 H), 5.11 (br dd, 1 H), 3.83-4.02 (m, 0.5 H), 3.36-3.48 (m, 0.5 H), 2.80-3.25 (m, 2 H)	504.1 [M+H]+	100%
1445	(CD3OD) δ 9.02 (d, 1 H), 8.36 (s, 1 H), 7.60 (br d, 1 H), 7.36-7.55 (m, 1.5 H), 7.01-7.13 (m, 1 H), 6.84-6.99 (m, 1.5 H), 6.48-6.79 (m, 1 H), 4.99 (br dd, 1 H), 3.74-3.86 (m, 0.5 H), 3.25-3.36 (m, 0.5 H), 2.66-3.15 (m, 2 H)	504.1 [M+H]+	99.6%
1446	(CD3OD) δ 9.15 (d, 1 H), 8.48 (s, 1 H), 7.72 (d, 1 H), 7.40-7.54 (m, 1.5 H), 7.13 (ddd, 1 H), 7.00 (s, 0.5 H), 6.72 (dd, 1 H), 6.45-6.65 (m, 1 H), 5.07 (dd, 1 H), 3.87-4.01 (m, 0.5 H), 3.36-3.47 (m, 0.5 H), 2.82-3.25 (m, 2 H), 2.51-2.73 (m, 3 H)	484.1 [M+H]+	100%
1447	(CD3OD) δ 9.15 (d, 1 H), 8.48 (s, 1 H), 7.71 (d, 1 H), 7.40-7.56 (m, 1.5 H), 7.07-7.21 (m, 1 H), 7.00 (s, 0.5 H), 6.66-6.78 (m, 1 H), 6.43-6.65 (m, 1 H), 5.07 (br dd, 1 H), 3.84-4.04 (m, 0.5 H), 3.39-3.47 (m, 0.5 H), 2.80-3.26 (m, 2 H), 2.50-2.74 (m, 3 H)	484.1 [M+H]+	99.7%
1448	(CD3OD) δ 8.38-8.50 (m, 1 H), 7.70 (s, 1 H), 7.56-7.64 (m, 1 H), 7.41-7.52 (m, 0.3 H), 7.13-7.28 (m, 1 H), 6.92-6.99 (m, 0.7 H), 6.79-6.91 (m, 1 H), 6.46-6.71 (m, 1 H), 4.93-5.04 (m, 1 H), 3.65-3.84 (m, 0.7 H), 3.34-3.43 (m, 1 H), 3.28-3.31 (m, 0.3 H), 2.92-3.22 (m, 1 H), 2.83 (br dd, 1 H), 1.45 (d, 6 H)	378.2 [M+H]+	100%
1449	(CD3OD) δ 8.33-8.52 (m, 1 H), 7.71 (s, 1 H), 7.55-7.64 (m, 1 H), 7.45-7.49 (m, 0.3 H), 7.14-7.25 (m, 1 H), 6.92-6.97 (m, 0.7 H), 6.83-6.90 (m, 1 H), 6.53-6.65 (m, 1 H), 4.91 - 5.02 (m, 1 H), 3.75 (ddd, 0.7 H), 3.34-3.44 (m, 1 H), 3.29-3.31 (m, 0.3 H), 2.90-3.24 (m, 1 H), 2.83 (br dd, 1 H), 1.45 (d, 6 H)	378.2 [M+H]+	100%
1450	(CD3OD) δ 8.24-8.37 (m, 1 H), 7.68-7.75 (m, 1 H), 7.46 (s, 0.3 H), 6.97-7.03 (m, 1 H), 6.95 (s, 0.7H), 6.76-6.82 (m, 1 H), 6.53-6.66 (m, 1 H), 4.97 (br dd, 1 H), 3.70-3.80 (m, 1 H), 3.34-3.44 (m, 1 H), 2.93-3.21 (m, 1 H), 2.83 (br dd, 1 H), 2.38-2.49 (m, 3 H), 1.45 (d, 6 H)	392.2 [M+H]+	100%
1451	(CD3OD) δ 8.23-8.37 (m, 1 H), 7.70 (s, 1 H), 7.40-7.50 (m, 0.3 H), 6.97-7.03 (m, 1 H), 6.95 (s, 0.7 H), 6.75-6.83 (m, 1 H), 6.52-6.67 (m, 1 H), 4.97 (br dd, 1 H), 3.68-3.82 (m, 0.7 H), 3.34-3.44 (m, 1 H), 3.29-3.32 (m, 0.3 H), 2.93-3.21 (m, 1 H), 2.77-2.88 (m, 1 H), 2.37-2.50 (m, 3 H), 1.45 (d, 6 H)	392.2 [M+H]+	99.3%
1452	(CD3OD) δ 8.27-8.43 (m, 1 H), 7.71 (s, 1 H), 7.37 (br d, 0.3 H), 6.90-7.04 (m, 1.7 H), 6.80-6.89 (m, 1 H), 6.68-6.79 (m, 1 H), 5.00 (dd, 1 H), 3.69-3.80 (m, 0.7 H), 3.34-3.44 (m, 1 H), 3.30 (br d, 0.3 H), 2.94-3.22 (m, 1 H), 2.84 (br dd, 1 H), 1.45 (d, 6 H)	396.2 [M+H]+	100%
1453	(CD3OD) δ 8.26-8.43 (m, 1 H), 7.71 (s, 1 H), 7.36-7.54 (m, 0.3 H), 6.59-7.09 (m, 3.7 H), 4.92-5.04 (m, 1 H), 3.68-3.81 (m, 0.7 H), 3.34-3.45 (m, 1 H), 3.25-3.30 (m, 0.3 H), 2.92-3.23 (m, 1 H), 2.84 (br dd, 1 H), 1.45 (d, 6 H)	396.1 [M+H]+	99.5%
1454	(CD3OD) δ 8.45 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.85 (t, 1 H), 6.65 (s, 1 H), 6.27 (s, 1 H), 4.21 (dd, 1 H), 3.62-3.77 (m, 1 H), 2.95-3.08 (m, 1 H), 2.79 (br dd, 1 H), 2.04-2.13 (m, 1 H), 1.04-1.15 (m, 4 H)	382.1 [M+H]+	100%
1455	(CD3OD) δ 8.45 (d, 1 H), 7.68 (s, 1 H), 7.31 (d, 1 H), 6.86 (t, 1 H), 6.65 (s, 1 H), 6.27 (br s, 1 H), 4.21 (dd, 1 H), 3.61-3.74 (m, 1 H), 2.97-3.11 (m, 1 H), 2.80 (br dd, 1 H), 1.98-2.16 (m, 1 H), 1.03-1.14 (m, 4 H)	382.1 [M+H]+	99.5%
1456	(DMSO-d6) δ 12.02-12.24 (m, 1 H), 8.00 (d, 1 H), 7.47-7.71 (m, 2 H), 7.17-7.42 (m, 1.4 H), 6.94-7.02 (m, 1 H), 6.66-6.93 (m, 2.6 H), 4.77-4.96 (m, 1 H), 4.00 (s, 3 H), 3.60-3.86 (m, 0.8 H), 3.37 (br s, 0.2 H), 2.85-3.10 (m, 1 H), 2.69-2.84 (m, 1 H)	434.2 [M+H]+	92.8%
1457	(DMSO-d6) δ 12.09 (br s, 1 H), 8.00 (d, 1 H), 7.48-7.70 (m, 2 H), 7.19-7.42 (m, 1.4 H), 6.94-7.01 (m, 1 H), 6.70-6.94 (m, 2.6 H), 4.72-4.96 (m, 1 H), 4.00 (s, 3 H), 3.64-3.84 (m, 0.7 H), 3.35-3.40 (m, 0.3 H), 2.84-3.11 (m, 1 H), 2.70-2.84 (m, 1 H)	434.2 [M+H]+	97.8%
1458	(DMSO-d6) δ 11.87-12.43 (m, 1 H), 8.70 (br d, 1 H), 8.10 (br t, 1 H), 7.83 (dt, 1 H), 7.49-7.67 (m, 2 H), 7.29 (br d, 1 H), 7.15 (br s, 0.3 H), 6.69-6.96 (m, 2.7 H), 4.83 (br dd, 1 H), 3.76 (br s, 0.7 H), 3.36-3.46 (m, 0.3 H), 2.69-3.13 (m, 2 H)	449.2 [M+H]+	100%
1459	(DMSO-d6) δ 11.96-12.28 (m, 1 H), 8.70 (br d, 1 H), 8.11 (br t, 1 H), 7.83 (dt, 1 H), 7.47-7.69 (m, 2 H), 7.21-7.39 (m, 1 H), 7.14 (s, 0.3 H), 6.69-6.99 (m, 2.7 H), 4.83 (br dd, 1 H), 3.62-3.86 (m, 0.7 H), 3.36-3.44 (m, 0.3 H), 2.71-3.13 (m, 2 H)	449.1 [M+H]+	100%
1460	(DMSO-d6) δ 12.11 (br s, 1 H), 9.32-9.65 (m, 1 H), 8.83-9.01 (m, 2 H), 7.50-7.72 (m, 2 H), 7.21-7.39 (m, 1 H), 7.12 (s, 0.3 H), 6.68-7.00 (m, 2.7 H), 4.83 (br dd, 1 H), 3.64-3.87 (m, 0.7 H), 3.40 (br t, 0.3 H), 2.72-3.13 (m, 2 H)	432.1 [M+H]+	100%
1461	(DMSO-d6) δ 12.05-12.26 (m, 1 H), 9.18-9.73 (m, 1 H), 8.94 (br d, 2 H), 7.49-7.70 (m, 2 H), 7.22-7.39 (m, 1 H), 7.12 (s, 0.3 H), 6.71-6.97 (m, 2.7 H), 4.83 (br d, 1 H), 3.78 (br t, 0.7 H), 3.40 (br s, 0.3 H), 2.71-3.15 (m, 2 H)	432.1 (M+H]+	100%
1462	(CD3OD) δ 7.92-8.21 (m, 1 H), 7.71 (d, 1 H), 7.59 (s, 0.3 H), 7.37-7.53 (m, 1 H), 7.16-7.33 (m, 1 H), 6.98 (s, 0.7 H), 6.55-6.87 (m, 2 H), 5.13 (br dd, 1 H), 3.91 (s, 3 H), 3.41-3.85 (m, 1 H), 2.95-3.26 (m, 1 H), 2.79-2.93 (m, 1 H), 2.64-2.74 (m, 3 H)	448.1 [M+H]+	100%
1463	(CD3OD) δ 7.91-8.13 (m, 1 H), 7.71 (d, 1 H), 7.59 (s, 0.4 H), 7.42-7.54 (m, 1 H), 7.15-7.37 (m, 1 H), 6.98 (s, 0.6 H), 6.50-6.89 (m, 2 H), 5.07-5.17 (m, 1 H), 3.91 (s, 3 H), 3.45-3.85 (m, 1 H), 2.98-3.23 (m, 1 H), 2.80-2.92 (m, 1 H), 2.66-2.74 (m, 3 H)	448.1 [M+H]+	96.8%
1464	(CD3OD) δ 8.41-8.63 (m, 1 H), 8.05 (d, 1 H), 7.65-7.96 (m, 2 H), 7.34-7.60 (m, 2.3 H), 6.73-7.15 (m, 3.7 H), 5.03 (br dd, 1 H), 3.71-3.86 (m, 0.5 H), 3.35-3.46 (m, 0.5 H), 2.79-3.24 (m, 2 H), 2.62 (s, 3 H)	477.2 [M+H]+	100%
1465	(CD3OD) δ 8.49-8.63 (m, 1 H), 8.09 (d, 1 H), 7.80-7.99 (m, 2 H), 7.38-7.60 (m, 2.3 H), 6.74-7.17 (m, 3.7 H), 4.95-5.11 (m, 1 H), 3.78 (ddd, 0.5 H), 3.41 (td, 0.5 H), 2.80-3.27 (m, 2 H), 2.64 (s, 3 H)	477.1 [M+H]+	98.5%
1466	(CD3OD) δ 8.49-8.63 (m, 1 H), 8.18-8.35 (m, 1 H), 7.39-7.73 (m, 2.3 H), 6.75-7.13 (m, 3.7 H), 5.09 (dd, 1 H), 3.91 (s, 3 H), 3.70-3.81 (m, 0.5 H), 3.39 (td, 0.5 H), 2.79-3.24 (m, 2 H), 2.47-2.60 (m, 3 H)	480.2 [M+H]+	100%
1467	(CD3OD) δ 8.49-8.63 (m, 1 H), 8.20-8.32 (m, 1 H), 7.35-7.75 (m, 2.3 H), 6.76-7.14 (m, 3.7 H), 5.09 (br dd, 1 H), 3.91 (s, 3 H), 3.70-3.81 (m, 0.5 H), 3.39 (td, 0.5 H), 2.80-3.24 (m, 2 H), 2.43-2.61 (m, 3 H)	480.2 [M+H]+	99.8%
1468	(CD3OD) δ 9.32 (s, 1 H), 8.82 (dd, 1 H), 8.56 (ddt, 1 H), 7.65-7.81 (m, 3 H). 6.99-7.61 (m, 4 H), 6.62-6.84 (m, 1 H), 4.96-5.16 (m, 1 H), 3.88-4.00 (m, 0.6 H), 3.36-3.44 (m, 0.4 H), 2.84-3.26 (m, 2 H)	463.2 [M+H]+	100%
1469	(CD3OD) δ 9.32 (s, 1 H), 8.76-8.86 (m, 1 H), 8.56 (ddt, 1 H), 7.65-7.80 (m, 3 H), 6.99-7.59 (m, 4 H), 6.62-6.83 (m, 1 H), 4.95-5.14 (m, 1 H), 3.89-3.99 (m, 0.6 H), 3.36-3.44 (m, 0.4 H), 2.85-3.27 (m, 2 H)	463.1 [M+H]+	99.6%
1470	(CD3OD) δ 8.27-8.44 (m, 1 H), 8.10-8.18 (m, 1 H), 7.96 (t, 1 H), 7.75 (br s, 1 H), 7.54 (d, 1.3 H), 6.90-7.08 (m, 1.7 H), 6.74-6.89 (m, 2 H), 5.05 (br dd, 1 H), 3.75-3.87 (m. 0.5 H). 3.39-3.53 (m, 0.5 H), 2.82-3.29 (m, 2 H), 2.67 (s, 3 H)	445.2 [M+H]+	99.3%
1471	(CD3OD) δ 8.17-8.29 (m, 1 H), 7.97-8.03 (m, 1 H), 7.84 (t, 1 H), 7.67 (br d, 1 H). 7.42 (d, 1.3 H), 6.81-6.92 (m, 1.7 H). 6.66-6.79 (m, 2 H), 4.94 (br dd, 1 H), 3.64-3.74 (m, 0.5 H), 3.26-3.39 (m, 0.5 H), 2.70-3.17 (m, 2 H), 2.54 (s, 3 H)	445.1 [M+H]+	88.9%
1472	(CD3OD) δ 9.02 (s, 1 H), 8.35 (s. 1 H), 8.11-8.26 (m, 1 H), 7.34-7.84 (m, 1.3 H), 6.88 (br t, 1.7 H), 6.68 (br s, 1 H), 6.40-6.59 (m, 1 H), 4.94 (br dd, 1 H), 3.68 (br t. 0.7 H), 3.31 (br t, 0.3 H), 2.67-3.16 (m, 2 H), 2.26-2.41 (m, 3 H)	484.1 [M+H]+	100%
1413	(CD3OD) δ 9.02 (s, 1 H), 8.35 (s, 1 H), 8.11-8.23 (m, 1 H), 7.43-7.64 (m, 1.3 H), 6.82-6.91 (m, 1.7 H), 6.61-6.71 (m, 1 H), 6.42-6.57 (m, 1 H), 4.94 (br dd, 1 H), 3.60-3.75 (m, 0.7 H), 3.25-3.35 (m, 0.3 H), 2.67-3.14 (m, 2 H), 2.26-2.39 (m, 3 H)	484.1 [M+H]+	99.6%
1474	(CD3OD) δ 8.52 (d. 1 H), 7.71 (s, 1 H). 7.41-7.59 (m, 1.4 H), 7.18-7.32 (m, 2 H), 6.99 (s, 0.6 H), 6.72-6.87 (m, 1 H), 6.61-6.71 (m, 1 H) 5.08 (br dd. 1 H), 3.79-3.94 (m, 0.6 H), 3.40-3.51 (m, 0.4 H), 3.14-3.24 (m, 0.7 H), 3.03 (br t, 0.3 H), 2.87 (br d, 1 H)	488.1 [M+H]+	100%
1475	(CD3OD) δ 8.52 (d, 1 H), 7.72 (br s, 1 H), 7.42-7.59 (m, 1.3 H), 7.19-7.34 (m, 2 H), 6.99 (s, 0.7 H), 6.72-6.88 (m, 1 H), 6.56-6.71 (m, 1 H), 5.08 (br dd, 0.6 H), 4.97 (br d, 0.4 H), 3.80-3.91 (m, 0.6 H), 3.40-3.54 (m, 0.4 H), 3.13-3.28 (m, 0.8 H), 2.98-3.09 (m, 0.2 H), 287 (br d, 1 H)	488.1 [M+H]+	100%
1476	(CD3OD) δ 8.35-8.54 (m, 2 H), 7.49-7.75 (m, 1 H), 7.25-7.34 (m, 2 H), 6.70-7.00 (m, 3 H), 4.94-5.09 (m, 1 H), 3.73-3.84 (m, 0.6 H), 3.41 (br dd, 0.4 H), 3.15-3.26 (m, 0.7 H), 3.00 (br d, 0.3 H), 2.80-2.90 (m, 1 H)	504.1 [M+H]+	100%
1477	(CD3OD) δ 8.37-8.53 (m, 2 H), 7.49-7.73 (m, 1 H), 7.25-7.32 (m, 2 H), 6.71-6.98 (m, 3 H), 4.92-5.09 (m, 1 H), 3.72-3.84 (m, 0.7 H), 3.41 (td, 0.3 H), 3.14-3.25 (m, 0.7 H), 2.95-3.07 (m, 0.3 H), 2.81-2.89 (m, 1 H)	504.1 [M+H]+	88.6%
1478	(CD3OD) δ 8.49 (d, 1 H), 8.23-8.33 (m, 1 H), 7.50-7.75 (m, 1 H), 7.26 (d, 1 H), 6.94-7.01 (m, 2 H), 6.73-6.81 (m, 1 H), 6.58-6.67 (m, 1 H), 4.91-5.06 (m, 1 H), 3.74-3.84 (m, 0.7 H), 3.43 (td, 0.3 H), 3.14-3.25 (m, 0.7 H), 2.96-3.06 (m, 0.3 H), 2.78-2.89 (m, 1 H), 2.39-2.48 (m, 3 H)	484.2 [M+H]+	100%
1479	(CD3OD) δ 8.50 (d, 1 H), 8.22-8.33 (m, 1 H), 7.53-7.90 (m, 1 H), 7.26 (d, 1 H, 6.94-7.03 (m, 2 H), 6.74-6.82 (m, 1 H), 6.59-6.68 (m, 1 H), 4.91-5.09 (m, 1 H), 3.72-3.84 (m, 0.7 H), 3.43 (td, 0.3 H), 3.16-3.26 (m, 0.7 H), 2.97-3.08 (m, 0.3 H), 2.87 (br dd, 1 H), 2.38-2.48 (m, 3 H)	484.1 [M+H]+	87.8%
1480	(CD3OD) δ 8.48-8.63 (m, 2 H), 7.70 (s, 1.3 H), 7.44 (br d, 1 H), 7.08-7.30 (m, 1.2 H), 6.73-7.01 (m, 3.5 H), 4.93-5.09 (m, 1 H), 3.71-3.87 (m, 0.7 H), 3.36-3.44 (m, 0.3 H), 3.15-3.26 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.79-2.90 (m, 1 H)	520.2 [M+H]+	100%
1481	(CD3OD) δ 8.47-8.64 (m, 2 H), 7.53-7.73 (m, 1.3 H), 7.44 (br d, 1 H), 7.09-7.29 (m, 1.2 H), 6.74-7.01 (m, 3.5 H), 4.93-5.10 (m, 1 H), 3.73-3.83 (m, 0.7 H), 3.40 (td, 0.3 H), 3.16-3.25 (m, 0.7 H), 3.01 (br s, 0.3 H), 2.81-2.90 (m, 1 H)	520.2 [M+H]+	89.6%
1482	(CD3OD) δ 8.49 (d, 1 H), 8.26-8.38 (m, 1 H), 7.46-7.73 (m, 1.3 H), 7.27 (d, 1 H), 6.72-7.01 (m, 3.7 H), 4.92-5.08 (m, 1 H), 3.79 (ddd, 0.7 H), 3.43 (td. 0.3 H). 3.12-3.24 (m, 0.7 H), 2.95-3.06 (m, 0.3 H), 2.79-2.90 (m, 1 H)	488.2 [M+H]+	87.1%
1483	(CD3OD) δ 8.49 (d, 1 H), 8.27-8.37 (m, 1 H), 7.49-7.71 (m, 1.3 H), 7.26 (d, 1 H), 6.73-7.00 (m, 3.7 H), 4.92-5.08 (m, 1 H), 3.79 (ddd, 0.7 H), 3.43 (td, 0.3 H), 3.12-3.24 (m, 0.7 H), 2.95-3.07 (m, 0.3 H), 2.78-2.90 (m, 1 H)	488.2 [M+H]+	90.0%
1484	(CD3OD) δ 8.37-8.53 (m, 1 H), 7.71 (s, 1 H), 7.45 (s, 0.3 H), 7.28-7.35 (m, 1 H), 6.94 (s, 0.7 H), 6.81-6.90 (m, 1 H), 6.64-6.79 (m, 1 H), 5.00 (br dd, 1 H). 3.67-3.81 (m, 0.7 H), 3.34-3.45 (m, 1.3 H), 2.93-3.21 (m, 1 H), 2.84 (br dd, 1 H), 1.46 (d, 6 H)	412.1 [M+H]+	100%
1485	(CD3OD) δ 8.39-8.50 (m, 1 H), 7.71 (s, 1 H), 7.45 (s, 0.3 H), 7.27-7.36 (m, 1 H), 6.94 (s, 0.7 H), 6.83-6.91 (m, 1 H), 6.64-6.79 (m, 1 H), 5.00 (br dd, 1 H), 3.64-3.85 (m, 0.7 H), 3.34-3.45 (m, 1.3 H). 2.92-3.22 (m, 1 H), 2.84 (br dd, 1 H), 1.46 (d, 6 H)	412.1 [M+H]+	96.2%
1486	(CD3OD) δ 8.62-8.75 (m, 1 H), 7.60-7.76 (m, 2 H), 7.41 (s, 0.3 H), 6.89-7.07 (m, 1.7 H). 6.70-6.84 (m, 1 H), 4.95-5.07 (m, 1 H), 3.69-3.79 (m, 1 H), 3.35-3.45 (m, 1 H), 2.91-3.25 (m, 1 H), 2.84 (br d, 1 H), 1.38-1.51 (m, 6 H)	446.2 [M+H]+	100%
1487	(CD3OD) δ 8.62-8.78 (m, 1 H), 7.60 (s, 2 H), 7.40-7.51 (m, 0.3 H), 6.90-7.06 (m, 1.7 H), 6.69-6.85 (m, 1 H), 4.93-5.06 (m, 1 H), 3.84 (br d, 1 H), 3.35-3.46 (m. 1 H), 2.91-3.24 (m. 1 H), 2.84 (br dd, 1 H), 1.36-1.51 (m, 6 H)	446.2 [M+H]+	99.8%
1488	(CD3OD) δ 7.70 (d, 1 H), 7.54-7.66 (m, 1 H), 7.38-7.51 (m, 0.4 H), 7.14-7.24 (m, 1 H), 7.01-7.09 (m, 1 H), 6.96 (br s, 0.6 H), 6.79 (s, 0.6 H), 6.65 (s, 0.4 H), 4.92-5.05 (m, 1 H), 3.80-3.97 (m, 0.6 H), 3.34-3.44 (m. 1.4 H), 2.91-3.23 (m, 1 H), 2.74-2.90 (m, 1 H), 1.45 (d, 6 H)	412.1 [M+H]+	100%
1489	(CD3OD) δ 7.80 (d, 1 H), 7.56-7.68 (m, 1 H), 7.49 (s, 0.4 H), 7.14-7.24 (m, 1 H), 7.02-7.09 (m, 1 H), 6.98 (s, 0.6 H), 6.80 (s, 0.6 H), 6.67 (s, 0.4 H), 4.93-5.06 (m, 1 H), 3.78-3.94 (m, 0.7 H), 3.34-3.44 (m, 1.3 H), 2.91-3.24 (m, 1 H), 2.86 (dd, 1 H), 1.45 (d, 6 H)	412.1 [M+H]+	99.7%
1490	(CD3OD) δ 7.69 (d, 1 H), 7.37-7.52 (m, 1.4 H), 7.08-7.18 (m, 1 H), 6.97 (br s, 0.6 H). 6.68-6.77 (m, 1 H), 6.41-6.63 (m, 1 H), 4.92-5.01 (m, 1 H), 3.82-3.95 (m, 0.7 H), 3.34-3.42 (m, 1.3 H), 2.92-3.21 (m, 1 H), 2.84 (br d, 1 H), 2.55-2.73 (m, 3 H), 1.45 (d, 6 H)	392.2 [M+H]+	100%
1491	(CD3OD) δ 7.70 (d, 1 H), 7.37-7.54 (m, 1.4 H), 7.07-7.19 (m, 1 H), 6.97 (s, 0.6 H), 6.68-6.78 (m, 1 H), 6.41-6.65 (m, 1 H), 4.92-5.01 (m, 1 H), 3.81-3.96 (m, 0.7 H), 3.34-3.43 (m, 1.3 H), 2.91-3.20 (m, 1 H), 2.78-2.90 (m, 1 H), 2.56-2.72 (m, 3 H), 1.45 (d, 6 H)	392.2 [M+H]+	99.2%
1492	(CD3OD) δ 7.65-7.80 (m, 2 H), 7.58 (s. 0.2 H), 7.40-7.50 (m, 1 H), 7.25-7.32 (m, 1.3 H), 7.14-7.24 (m, 1 H), 6.95 (s, 0.5 H), 6.58-6.81 (m. 1 H), 4.92-5.03 (m, 1 H), 3.79-3.95 (m. 0.6 H), 3.34-3.40 (m, 1.4 H), 2.92-3.21 (m, 1 H), 2.84 (br d, 1 H), 1.45 (d, 6 H)	428.2 [M+H]+	100%
1493	(CD3OD) δ 7.64-7.81 (m, 2 H), 7.58 (s, 0.2 H), 7.39-7.48 (m, 1.3 H), 7.24-7.35 (m, 1 H), 7.12-7.23 (m, 1 H), 6.95 (s, 0.5 H), 6.54-6.80 (m, 1 H), 4.92-5.05 (m. 1 H), 3.77-3.96 (m, 0.6 H). 3.34-3.41 (m, 1.4 H), 2.91-3.22 (m, 1 H), 2.75-2.89 (m, 1 H), 1.45 (d, 6 H)	428.2 [M+H]+	94.2%
1494	(DMSO-d6) δ 11.64-12.72 (m, 1 H), 8.50-9.07 (m, 1 H), 8.17-8.49 (m, 1 H), 7.61-7.74 (m, 1 H), 7.45-7.61 (m, 2 H), 7.21-7.36 (m, 1 H), 6.52-7.19 (m, 3 H), 4.74-4.96 (m, 1 H), 3.69-3.83 (m, 1 H), 2.97-3.10 (m, 2 H). 2.82-2.90 (m, 3 H). 2.75-2.80 (m, 1 H)	445.1 [M+H]+	100%
1495	(DMSO-d6) δ 11.80-12.36 (m, 1 H), 8.70 (br s, 1 H), 8.14-8.47 (m, 1 H), 7.41-7.73 (m, 3 H), 7.19-7.37 (m, 1 H), 7.10 (s, 1 H), 6.64-6.95 (m, 3 H), 4.67-4.95 (m, 1 H), 3.58-3.94 (m, 1 H), 2.98-3.14 (m, 1 H), 2.82-2.90 (m, 3 H), 2.69-2.80 (m, 1 H)	445.1 [M+H]+	98.2%
1496	(CD3OD) δ 8.03-8.27 (m, 1 H), 7.95 (t, 1 H), 7.71 (s, 1 H), 7.32-7.63 (m, 2.3 H), 7.20-7.31 (m, 1 H), 7.00 (s, 0.7 H), 6.71-6.87 (m, 1 H), 6.56-6.71 (m, 1 H), 5.01-5.13 (m, 1 H), 3.79-3.93 (m, 0.7 H), 3.48 (br dd, 0.3 H), 2.98-3.25 (m, 1 H), 2.88 (br dd, 1 H), 2.66 (s, 3 H)	445.1 [M+H]+	100%
1497	(CD3OD) δ 8.06-8.31 (m, 1 H), 7.96 (t, 1 H), 7.71 (s, 1 H), 7.35-7.64 (m, 2.4 H), 7.18-7.34 (m, 1 H). 7.00 (s, 0.6 H), 6.50-6.91 (m, 2 H), 4.97-5.09 (m, 1 H), 3.43-3.91 (m, 1 H), 2.97-3.25 (m, 1 H), 2.88 (br dd, 1 H), 2.66 (s. 3 H)	445.2 [M+H]+	91.5%
1498	(CD3OD) δ 9.04 (dd. 2 H), 7.68-7.77 (m, 3 H), 6.97-7.45 (m, 4 H), 6.60-6.80 (m, 1 H), 4.96-5.04 (m, 1 H), 3.88-3.99 (m, 0.6 H), 3.34-3.39 (m, 0.4 H), 2.84-3.23 (m, 2 H)	464.2 [M+H]+	100%
1499	(CD3OD) δ 9.05 (dd, 2 H), 7.68-7.80 (m, 3 H), 6.98-7.47 (m, 4 H), 6.59-6.82 (m, 1 H), 4.96-5.04 (m, 1 H), 3.87-4.00 (m, 0.6 H), 3.35-3.40 (m, 0.4 H), 2.84-3.27 (m, 2 H)	464.2 [M+H]+	99.7%
1500	(CD3OD) δ 8.64-8.69 (m, 1 H), 8.47 (d, 1 H), 7.68-7.81 (m, 2 H), 7.35-7.61 (m, 2 H), 6.96-7.32 (m, 3 H), 6.64-6.83 (m, 1 H), 4.96-5.16 (m, 1 H), 3.89-4.01 (m, 0.5 H), 3.36-3.45 (m, 0.5 H), 2.86-3.27 (m, 5 H)	477.1 [M+H]+	100%
1501	(CD3OD) δ 8.63-8.68 (m, 1 H), 8.47 (br d, 1 H), 7.68-7.81 (m, 2 H), 7.35-7.61 (m, 2 H), 6.97-7.33 (m, 3 H), 6.62-6.85 (m, 1 H), 4.98-5.17 (m, 1 H), 3.88-4.00 (m, 0.5 H), 3.37-3.46 (m, 0.5 H), 2.85-3.26 (m, 5 H)	477.2 [M+H]+	99.4%
1502	(CD3OD) δ 9.03 (s, 1 H), 8.36 (s, 1 H), 7.58-7.79 (m, 2 H), 7.24-7.51 (m, 1 H), 6.83-7.24 (m, 3 H), 6.49-6.73 (m, 1 H), 4.84-5.05 (m, 1 H), 3.72-3.87 (m, 0.5 H), 3.25-3.32 (m, 0.5 H), 2.84-3.14 (m, 1 H), 2.72-2.84 (m, 1 H)	520.1 [M+H]+	100%
1503	(CD3OD) δ 9.03 (s, 1 H), 8.36 (s, 1 H), 7.55-7.74 (m, 2 H), 7.31-7.50 (m, 1 H), 6.83-7.28 (m, 3 H), 6.49-6.71 (m, 1 H), 4.85-4.98 (m, 1 H), 3.75-3.85 (m, 0.5 H), 3.24-3.31 (m, 0.5 H), 2.85-3.13 (m, 1 H), 2.69-2.85 (m, 1 H)	520.1 [M+H]+	97.1%
1504	(CD3OD) δ 8.98-9.09 (m, 1 H), 8.25-8.42 (m, 2 H), 7.60 (s, 1 H), 7.45 (s, 0.3 H), 7.14-7.26 (m, 1 H), 6.85 (s, 0.7 H), 6.70-6.81 (m. 1 H), 6.59-6.69 (m, 1 H), 4.83-5.03 (m, 1 H), 3.67 (ddd, 0.7 H), 3.30 (td, 0.3 H), 2.83-3.14 (m, 1 H), 2.66-2.81 (m, 1 H)	504.1 [M+H]+	100%
1505	(CD3OD) δ 9.09-9.19 (m, 1 H), 8.37-8.51 (m, 2 H), 7.72 (s, 1 H), 7.57 (br s, 0.3 H), 7.26-7.37 (m, 1 H), 6.97 (br s, 0.7 H), 6.81-6.91 (m, 1 H), 6.71-6.80 (m, 1 H), 4.94-5.13 (m, 1 H), 3.73-3.85 (m, 0.7 H), 3.42 (td, 0.3 H), 2.94-3.28 (m, 1 H), 2.77-2.94 (m, 1 H)	504.1 [M+H]+	99.5%
1506	(CD3OD) δ 8.52 (d, 1 H), 8.38-8.50 (m, 1 H), 7.71 (s, 1 H), 7.48-7.67 (m, 1.3 H), 7.14-7.33 (m, 2 H), 6.93-7.05 (m, 0.7 H), 6.78-6.92 (m, 1 H), 6.57-6.70 (m, 1 H), 4.94-5.09 (m, 1 H), 3.66-3.91 (m, 0.7 H), 3.42-3.54 (m, 0.3 H), 2.94-3.27 (m, 1 H), 2.74-2.91 (m, 1 H)	470.1 [M+H]+	100%
1507	(CD3OD) δ 8.52 (d, 1 H), 8.39-8.49 (m, 1 H), 7.71 (s, 1 H), 7.53-7.65 (m, 1.3 H), 7.29 (d, 1 H), 7.16-7.25 (m, 1 H), 6.99 (s, 0.7 H), 6.82-6.91 (m, 1 H), 6.59-6.68 (m, 1 H), 4.94-5.08 (m, 1 H), 3.74-3.86 (m, 0.7 H), 3.39-3.47 (m, 0.3 H), 2.97-3.26 (m, 1 H), 2.78-2.91 (m, 1 H)	470.2 [M+H]+	98.9%
1508	(CD3OD) δ 8.40-8.59 (m, 1 H), 7.72 (d, 1 H), 7.54-7.66 (m, 1 H), 7.44-7.53 (m, 0.4 H), 7.29 (t, 1 H), 7.12-7.24 (m, 1 H), 6.95-7.09 (m, 1.6 H), 6.54-6.87 (m, 1 H), 4.93-5.13 (m, 1 H), 3.80-4.06 (m, 0.5 H), 3.34-3.48 (m, 0.5 H), 2.96-3.28 (m, 1 H), 2.88 (br d, 1 H)	504.1 [M+H]+	100%
1509	(CD3OD) δ 8.52 (t, 1 H), 7.72 (d, 1 H), 7.55-7.67 (m, 1 H), 7.49 (s, 0.4 H), 7.29 (br s, 1 H), 7.12-7.23 (m, 1 H), 6.95-7.09 (m, 1.6 H), 6.60-6.85 (m, 1 H), 4.93-5.13 (m, 1 H), 3.84-4.00 (m, 0.5 H), 3.35-3.45 (m, 0.5 H), 2.95-3.27 (m, 1 H), 2.82-2.93 (m, 1 H)	504.1 [M+H]+	99.5%
1510	(CD3OD) δ 8.43-8.61 (m, 1 H), 7.65-7.79 (m, 1 H), 7.36-7.56 (m, 1.5 H), 7.29 (t, 1 H), 7.07-7.20 (m, 1 H), 7.01 (s, 0.5 H), 6.66-6.78 (m, 1 H), 6.40-6.66 (m, 1 H). 4.95-5.12 (m, 1 H). 4.03 (br d, 0.5 H), 3.36-3.45 (m, 0.5 H), 3.09 (s, 1 H), 2.79-2.93 (m, 1 H), 2.42-2.74 (m, 3 H)	484.2 [M+H]+	100%
1511	(CD3OD) δ 8.39-8.61 (m, 1 H), 7.71 (d, 1 H), 7.38 (s, 1.5 H), 7.29 (t, 1 H), 6.93-7.19 (m, 1.5 H), 6.66-6.78 (m, 1 H), 6.37-6.65 (m, 1 H), 4.97-5.11 (m, 1 H), 3.78-4.16 (m, 0.5 H), 3.37-3.43 (m, 0.5 H), 2.95-3.27 (m, 1 H), 2.80-2.93 (m, 1 H), 2.45-2.73 (m, 3 H)	484.2 [M+H]+	97.6%
1512	(CD3OD) δ 8.62-8.72 (m, 1 H), 8.50 (d, 1 H), 7.51-7.74 (m, 2 H), 7.27 (d, 1 H), 6.93-7.03 (m, 2 H), 6.76-6.83 (m, 1 H), 4.93-5.09 (m, 1 H), 3.74-3.83 (m, 0.7 H), 3.37-3.46 (m, 0.3 H), 3.20 (br t, 0.7 H), 2.96-3.06 (m, 0.3 H), 2.85 (br d, 1 H)	538.2 [M+H]+	99.0%
1513	(CD3OD) δ 8.63-8.72 (m, 1 H), 8.50 (d, 1 H), 7.52-7.73 (m, 2 H), 7.27 (d, 1 H), 6.93-7.04 (m, 2 H), 6.75-6.84 (m, 1 H), 4.93-5.11 (m, 1 H), 3.73-3.84 (m, 0.7 H), 3.41 (td, 0.3 H), 3.14-3.27 (m, 0.7 H), 2.95-3.06 (m, 0.3 H), 2.80-2.90 (m, 1 H)	538.2 [M+H]+	91.3%
1514	(CD3OD) δ 8.37-8.54 (m, 1 H), 7.45-7.86 (m, 2 H), 7.13-7.31 (m, 1 H), 6.48-7.00 (m, 3 H), 4.99 (br dd, 1 H), 3.68-4.01 (m, 1.6 H), 3.39 (td, 0.4 H), 2.72-3.27 (m, 2 H), 2.42-2.61 (m. 4 H), 1.96-2.34 (m, 2 H)	390.2 [M+H]+	99.3%
1515	(CD3OD) δ 8.34-8.53 (m, 1 H), 7.40-7.73 (m, 2 H), 7.09-7.26 (m, 1 H), 6.48-7.02 (m, 3 H), 4.96 (br dd, 1 H), 3.67-3.99 (m, 1.6 H), 3.34-3.46 (m, 0.4 H), 2.73-3.22 (m, 2 H), 2.37-2.64 (m, 4 H), 1.90-2.29 (m, 2 H)	390.2 [M+H]+	96.0%
1516	(CD3OD) δ 8.32-8.53 (m, 1 H), 7.69 (s. 1 H), 7.19-7.50 (m, 1 H), 6.60-7.01 (m, 3 H), 4.99 (dd, 1 H), 3.69-3.98 (m, 1.6 H), 3.34-3.44 (m, 0.4 H), 2.72-3.20 (m. 2 H), 2.39-2.62 (m. 4 H), 1.87-2.31 (m, 2 H)	424.1 [M+H]+	100%
1517	(CD3OD) δ 8.30-8.60 (m, 1 H), 7.69 (s, 1 H), 7.23-7.51 (m, 1 H), 6.62-6.97 (m, 3 H), 4.99 (br dd, 1 H), 3.65-3.98 (m, 1.6 H), 3.36 (br dd, 0.4 H), 2.77-3.21 (m, 2 H), 2.39-2.63 (m, 4 H), 1.93-2.33 (m, 2 H)	424.1 [M+H]+	100%
1518	(CD3OD) δ 8.57-8.79 (m, 1 H), 7.39-7.78 (m, 2 H). 6.65-7.11 (m, 3 H), 4.92-5.10 (m, 1 H), 3.60-3.95 (m, 2 H), 2.75-3.25 (m, 2 H), 2.43-2.61 (m. 4 H), 1.93-2.33 (m, 2 H)	458.2 [M+H]+	100%
1519	(CD3OD) δ 8.55-8.78 (m, 1 H), 7.42-7.74 (m, 2 H), 6.56-7.17 (m, 3 H), 4.92-5.09 (m, 1 H), 3.65-3.94 (m, 1.6 H), 3.38 (td, 0.4 H), 2.74-3.25 (m, 2 H), 2.37-2.62 (m, 4 H), 1.92-2.32 (m, 2 H)	458.1 [M+H]+	100%
1520	(CD3OD) δ 8.49-8.67 (m. 1 H), 7.69 (s, 1 H), 7.38-7.53 (m, 1 H), 6.66-7.16 (m, 4 H), 4.99 (br dd, 1 H), 3.64-3.99 (m, 1.6 H), 3.34-3.43 (m, 0.4 H), 2.75-3.22 (m, 2 H), 2.32-2.61 (m, 4 H), 1.94-2.29 (m, 2 H)	440.2 [M+H]+	100%
1521	(CD3OD) δ 8.48-8.67 (m, 1 H), 7.69 (s, 1 H), 7.35-7.55 (m, 1 H), 6.64-7.15 (m, 4 H), 4.99 (br dd, 1 H), 3.65-4.01 (m, 1.6 H), 3.37 (br dd, 0.4 H), 2.71-3.25 (m, 2 H), 2.38-2.61 (m, 4 H), 1.92-2.28 (m, 2 H)	440.2 [M+H]+	97.0%
1522	(DMSO-d6) δ 12.13 (br s, 1 H), 9.04-9.71 (m, 1 H), 8.73-9.01 (m, 1 H), 8.33-8.59 (m, 1 H), 7.44-7.80 (m, 3 H), 7.22-7.41 (m, 1 H), 7.06-7.19 (m, 0.3 H), 6.54-6.99 (m, 2.7 H), 4.82 (br dd, 1 H), 3.40-3.88 (m, 1 H), 2.73-3.16 (m, 2 H)	431.1 [M+H]+	100%
1523	(DMSO-d6) δ 12.10 (br s, 1 H), 9.05-9.83 (m, 1 H), 8.86 (br d, 1 H), 8.22-8.68 (m, 1 H), 7.46-7.81 (m, 3 H), 7.19-7.43 (m, 1 H), 7.10 (s, 0.3 H), 6.60-7.00 (m, 2.7 H), 4.82 (br dd, 1 H), 3.41-3.82 (m, 1 H), 2.77-3.11 (m, 2 H)	431.1 [M+H]+	97.4%
1524	(DMSO-d6) δ 12.11 (br s, 1 H), 8.52 (d, 1 H), 8.11-8.34 (m, 1 H), 7.48-7.76 (m, 3 H), 7.25-7.38 (m, 1 H), 7.21 (br d, 0.3 H), 6.31-7.10 (m, 2.7 H), 4.87 (br dd, 1 H), 3.96 (s, 3 H), 3.38-3.82 (m, 1 H), 2.72-3.12 (m, 2 H)	461.1 [M+H]+	99.4%
1525	(DMSO-d6) δ 12.11 (br s, 1 H), 8.52 (d, 1 H), 8.15-8.30 (m, 1 H), 7.49-7.75 (m, 3 H), 7.25-7.35 (m, 1 H), 7.23 (br s, 0.4 H), 6.45-7.02 (m, 2.6 H), 4.68-4.99 (m, 1 H), 3.95 (s, 3 H), 3.38-3.81 (m, 1 H), 2.71-3.13 (m, 2 H)	461.1 [M+H]+	98.2%
1526	(CD3OD) δ 7.62-7.72 (m, 2 H), 7.40-7.55 (m, 1 H), 7.20-7.29 (m, 1 H), 6.94-7. 10 (m, 2 H), 6.60-6.81 (m, 2 H), 4.95-5.12 (m, 1 H), 4.27-4.37 (m, 3 H), 3.77-3.90 (m, 0.7 H), 3.40-3.50 (m, 0.3 H), 2.95-3.22 (m, 1 H), 2.80-2.91 (m, 1 H)	434.2 [M+H]+	100%
1527	(CD3OD) δ 7.60-7.76 (m, 2 H), 7.39-7.57 (m, 1 H), 7.19-7.29 (m, 1 H), 6.92-7.11 (m, 2 H), 6.59-6.81 (m, 2 H), 5.09 (br dd, 1 H), 4.27-4.36 (m, 3 H), 3.83 (br s, 0.5 H), 3.37-3.51 (m, 0.5 H), 2.94-3.22 (m, 1 H), 2.77-2.92 (m, 1 H)	434.2 [M+H]+	99.4%
1528	(CD3OD) δ 7.67-7.73 (m, 1 H), 7.41-7.52 (m, 2 H), 7.18-7.28 (m, 1 H), 6.96 (s. 1 H), 6.59-6.81 (m, 2 H), 5.10 (br dd, 0.5 H), 4.94 (br d, 0.5 H), 4.20-4.26 (m, 3 H), 3.84 (ddd, 0.5 H), 3.41 (td, 0.5 H), 3.15-3.25 (m, 1 H), 2.80-3.06 (m, 1 H), 2.32-2.41 (m, 3 H)	448.1 [M+H]+	98.6%
1529	(CD3OD) δ 7.70 (br d, 1 H), 7.42-7.52 (m, 2 H), 7.24 (ddd, 1 H), 6.96 (s, 1 H), 6.60-6.80 (m, 2 H), 5.10 (dd, 0.7 H). 4.92-4.97 (m, 0.3 H), 4.21-4.24 (m, 3 H), 3.81-3.89 (m, 0.6 H), 3.41 (td, 0.4 H), 3.16-3.25 (m, 1 H), 2.82-3.05 (m, 1 H), 2.32-2.40 (m, 3 H)	448.2 [M+H]+	98.3%
1530	(CD3OD) δ 8.52-8.63 (m, 1 H), 7.72 (s, 1 H). 7.39-7.58 (m, 1.3 H), 6.75-7.18 (m, 4.7 H), 4.92-5.09 (m, 1 H), 3.92 (s, 3 H), 3.78 (ddd, 0.5 H), 3.36-3.46 (m, 0.5 H), 2.79-3.27 (m, 2 H), 2.40 (s, 3 H)	480.1 [M+H]+	100%
1531	(CD3OD) δ 8.50-8.64 (m, 1 H), 7.72 (s, 1 H), 7.35-7.59 (m, 1.3 H), 6.74-7.17 (m. 4.7 H), 4.92-5.13 (m, 1 H), 3.92 (s, 3 H), 3.72-3.85 (m, 0.5 H), 3.36-3.45 (m, 0.5 H), 2.80-3.27 (m, 2 H), 2.41 (s, 3 H)	480.1 [M+H]+	99.6%
1532	(CD3OD) δ 8.52-8.68 (m, 1 H), 7.40-7.79 (m, 3.3 H), 6.76-7.17 (m, 4.7 H), 5.09 (br dd, 1 H), 4.23-4.39 (m. 3 H), 3.74-3.86 (m. 0.5 H), 3.38-3.50 (m, 0.5 H), 2.79-3.26 (m, 2 H)	466.1 [M+H]+	92.4%
1533	(CD3OD) δ 8.37-8.56 (m, 1 H), 7.28-7.65 (m, 3.3 H), 6.64-7.05 (m, 4.7 H), 4.82-5.04 (m, 1 H), 4.15-4.27 (m, 3 H), 3.58-3.77 (m, 0.5 H), 3.25-3.38 (m, 0.5 H), 2.69-3.16 (m, 2 H)	466.1 [M+H|+	98.1%
1534	(CD3OD) δ 9.48 (dd, 1 H), 8.82-8.90 (m, 2 H), 7.68-7.81 (m, 2 H), 7.39-7.61 (m, 1 H), 6.99-7.33 (m, 3 H), 6.62-6.84 (m, 1 H), 4.96-5.07 (m, 1 H), 3.89-3.99 (m, 0.6 H), 3.36-3.41 (m, 0.4 H), 2.86-3.26 (m, 2 H)	464.1 [M+H]+	100%
1535	(CD3OD) δ 9.48 (dd, 1 H), 8.81-8.90 (m, 2 H), 7.69-782 (m, 2 H), 7.38-7.61 (m, 1 H), 6.99-7.34 (m, 3 H), 6.61-6.83 (m, 1 H), 4.96-5.08 (m, 1 H), 3.89-4.00 (m, 0.6 H), 3.36-3.42 (m, 0.4 H), 2.85-3.26 (m, 2 H)	464.1 [M+H]+	99.1%
1536	(CD3OD) δ 7.68-7.79 (m, 2 H), 7.39-7.60 (m, 1 H), 6.97-7.31 (m, 3 H), 6.60-6.79 (m, 2 H), 4.95-5.08 (m, 1 H), 3.91 (d, 3.6 H), 3.35-3.41 (m, 0.4 H), 2.84-3.20 (m, 2 H), 2.40 (d, 3 H)	480.1 [M+H]+	100%
1537	(CD3OD) δ 7.68-7.79 (m, 2 H), 7.38-7.60 (m, 1 H), 6.96-7.32 (m, 3 H), 6.60-6.79 (m, 2 H), 4.94-5.11 (m, 1 H), 3.91 (d, 3.6 H), 3.34-3.40 (m, 0.4 H), 2.82-3.23 (m, 2 H), 2.40 (d, 3 H)	480.2 [M+H]+	99.0%
1538	(CD3OD) δ 8.99-9.06 (m, 1 H), 8.53-8.64 (m, 1 H), 8.37 (s, 1 H), 7.63 (br s, 1 H), 7.43-7.57 (m, 1.3 H), 6.82-6.95 (m, 1.7 H), 6.64-6.75 (m, 1 H), 4.83-5.04 (m, 1 H), 3.63-3.73 (m, 0.7 H), 3.31 (td, 0.3 H), 2.84-3.15 (m, 1 H), 2.76 (br d, 1 H)	538.2 [M+H]+	100%
1539	(CD3OD) δ 8.98-9.07 (m, 1 H), 8.54-8.63 (m, 1 H), 8.33-8.40 (m, 1 H), 7.60 (br s, 1 H), 7.43-7.56 (m, 1.3 H), 6.82-6.94 (m, 1.7 H), 6.66-6.75 (m, 1 H), 4.82-5.04 (m, 1 H), 3.61-3.74 (m, 0.7 H), 3.31 (td, 0.3 H), 2.83-3.15 (m, 1 H), 2.77 (br s, 1 H)	538.2 [M+H]+	98.8%
1540	(CD3OD) δ 9.15 (s, 1 H), 8.48 (s, 1 H), 8.28-8.39 (m, 1 H), 7.55-7.74 (m, 1.3 H), 6.93-7.03 (m, 1.7 H), 6.80-6.89 (m, 1 H), 6.72-6.79 (m, 1 H), 4.94-5.13 (m, 1 H), 3.80 (ddd, 0.7 H), 3.43 (td, 0.3 H), 2.95-3.25 (m, 1 H), 2.82-2.91 (m, 1 H)	488.2 [M+H]+	99.9%
1541	(CD3OD) δ 9.03 (s, 1 H), 8.36 (s, 1 H), 8.16-8.27 (m, 1 H), 7.40-7.66 (m, 1.3 H), 6.81-6.92 (m, 1.7 H), 6.68-6.79 (m, 1 H), 6.60-6.68 (m, 1 H), 4.82-5.01 (m, 1 H), 3.63-3.73 (m, 0.7 H), 3.31 (td, 0.3 H), 2.84-3.14 (m, 1 H), 2.74 (br d, 1 H)	488.1 [M+H]+	99.3%
1542	(CD3OD) δ 8.52 (dd, 1 H). 7.79-7.93 (m, 1 H), 7.65-7.77 (m, 1 H), 7.50-7.60 (m, 0.5 H), 7.20-7.41 (m, 3 H), 6.99 (s, 0.5 H), 6.63-6.91 (m, 1 H), 4.93-5.12 (m, 1 H), 3.88-4.07 (m, 0.5 H), 3.34-3.41 (m, 0.5 H), 2.96-3.26 (m, 1 H), 2.81-2.93 (m, 1 H)	538.1 [M+H]+	100%
1543	(CD3OD) δ 8.46 (s, 1 H), 7.80-7.93 (m, 1 H), 7.65-7.78 (m, 1 H), 7.56 (s. 0.5 H), 7.21-7.41 (m, 3 H), 7.03 (s. 0.5 H), 6.63-6.92 (m, 1 H), 4.93-5.12 (m, 1 H), 4.05 (br d, 0.5 H), 3.37 (br d, 0.5 H), 2.96-3.25 (m, 1 H), 2.82-2.94 (m, 1 H)	538.1 [M+H]+	99.9%
1544	(CD3OD) δ 8.44-8.56 (m, 1 H), 7.68-7.81 (m, 2 H), 7.59 (s, 0.1 H), 7.14-7.50 (m, 4.3 H), 7.11 (s, 0.1 H), 6.93-7.01 (m, 0.5 H), 6.56-6.83 (m 1 H), 4.93-5.10 (m, 1 H), 3.83-4.01 (m, 0.5 H), 3.35-3.41 (m, 0.5 H), 2.95-3.27 (m, 1 H), 2.80-2.93 (m, 1 H)	520.1 [M+H]+	100%
1545	(CD3OD) δ 8.52 (t, 1 H), 7.64-7.82 (m, 2 H), 7.59 (s, 0.2 H), 7.36-7.47 (m, 0.8 H), 7.07-7.34 (m, 3.5 H), 6.99 (s, 0.5 H), 6.59-6.82 (m, 1 H), 4.94-5.10 (m, 1 H), 3.83-3.98 (m, 0.6 H), 3.37 (br s, 0.4 H), 2.95-3.26 (m, 1 H), 2.80-2.93 (m, 1 H)	520.2 [M+H]+	99.7%
1546	(CD3OD) δ 8.27-8.97 (m, 3 H), 7.94 (d, 1 H), 7.60-7.71 (m, 2 H), 7.46 (br d, 1 H), 6.39-7.18 (m, 3 H), 4.61 (br s, 1 H), 3.55 (s, 3 H), 3.01-3.16 (m, 1 H), 2.78 (br d, 1 H), 2.30 (s, 6 H)	509.2 [M+H]+	100%
1547	(CD3OD) δ 8.14-9.03 (m, 3 H), 7.94 (d, 1 H), 7.60-7.70 (m, 2 H), 7.46 (d, 1 H), 6.28-7.19 (m, 3 H), 4.61 (br s, 1 H), 3.55 (s, 3 H), 3.02-3.14 (m, 1 H), 2.78 (br d, 1 H), 2.30 (s, 6 H)	509.2 [M+-H]+	99.0%
1548	(CD3OD) δ 8.12-9.00 (m, 3 H), 7.97 (d, 1 H), 7.56-7.83 (m, 2 H), 7.45 (d. 1 H), 6.45-7.19 (m, 3 H), 4.59-4.79 (m, 1 H), 4.54 (s, 2 H), 3.52-4.12 (s, 1 H)3.32-3.48 (m, 3 H)2.98-3.22 (m, 1 H), 2.68-2.89 (m, 1 H)	496.2 [M+H]+	100%
1549	(CD3OD) δ 8.69-8.94 (m, 3 H), 7.97 (d, 1 H), 7.58-7.78 (m, 2 H), 7.45 (d, 1 H), 6.39-7.14 (m, 3 H), 4.59-4.80 (m, 1 H), 4.55 (s, 2 H), 3.40-4.05 (m, 4 H), 3.01-3.20 (m, 1 H), 2.70-2.90 (m, 1 H)	496.2 [M+H]+	99.4%
1550	(DMSO-d6) δ 12.06 (br s, 1 H), 9.50 (s, 1 H), 9.04 (br s, 1 H), 8.41-8.78 (m, 2 H), 8.14-8.26 (m, 2 H), 7.88-8.07 (m, 2 H), 7.74 (brd, 1 H), 7.60 (s, 1 H), 7.38-7.45 (m, 1 H), 6.30-7.15 (m, 3 H), 4.48 (br s, 1 H), 3.73 (br s, 1 H), 3.00 (br s, 1 H), 2.65-2.75 (m, 1 H)	529.1 [M+H]+	98.2%
1551	(DMSO-d6) δ 12.05 (br s, 1 H), 9.50 (s, 1 H), 9.03 (br s, 1 H), 8.39-8.79 (m, 2 H), 8.12-8.26 (m, 2 H), 7.89-8.07 (m. 2 H), 7.74 (br d, 1 H), 7.60 (s, 1 H), 7.34-7.47 (m, 1 H), 6.26-7.21 (m, 3 H), 4.50 (br s, 1 H), 3.75 (s, 1 H), 3.00 (br s, 1 H), 2.71 (br d, 1 H)	529.1 [M+H]+	91.5%
1552	(DMSO-d6) δ 12.05 (br s, 1 H), 8.93-9.18 (m, 2 H), 8.25-8.53 (m, 2 H), 7.88-8.07 (m, 2 H), 7.67-7.80 (m. 2 H), 7.59 (s, 1 H), 6.32-7.10 (m, 3 H), 4.51 (br s, 1 H), 3.88 (s, 3 H), 3.70 (s, 1 H), 2.99 (br s, 1 H), 2.66-2.73 (m, 1 H)	532.3 [M+H]+	100%
1553	(DMSO-d6) δ 12.05 (br s, 1 H), 8.88-9.19 (m, 2 H), 8.29 (s, 2 H), 7.90-8.07 (m, 2 H), 7.67-7.80 (m, 2 H), 7.59 (s, 1 H), 6.21-7.14 (m, 3 H), 4.51 (br s, 1 H), 3.88 (s, 3 H). 3.70 (br s, 1 H), 2.99 (br s, 1 H), 2.70 (br d, 1 H)	532.2 [M+H]+	99.8%
1554	(CD3OD) δ 7.67-7.74 (m, 1 H), 7.41-7.53 (m, 1.3 H), 7.16-7.31 (m, 1 H), 6.95 (s, 0.7 H), 6.79 (d, 0.7 H), 6.59-6.69 (m, 1.3 H), 5.01 (br dd, 1 H), 3.73-3.84 (m, 0.7 H), 3.34-3.44 (m, 1.3 H), 2.91-3.22 (m, 1 H), 2.77-2.89 (m, 1 H), 1.45 (d. 6 H)	396.2 [M+H]+	100%
1555	(CD3OD) δ 7.67-7.73 (m, 1 H), 7.41-7.52 (m, 1.3 H), 7.19-7.31 (m, 1 H), 6.95 (s, 0.7 H), 6.76-6.82 (m, 0.7 H), 6.59-6.69 (m, 1.3 H). 4.95-5.06 (m, 1 H). 3.73-3.85 (m, 0.7 H), 3.34-3.44 (m. 1.3 H), 2.94-3.22 (m, 1 H), 2.78-2.90 (m, 1 H), 1.46 (d, 6 H)	396.2 [M+H]+	99.5%
1556	(CD3OD) δ 8.13-8.40 (m, 1 H), 7.35-7.78 (m, 1 H), 6.44-7.12 (m, 4 H), 4.97 (br dd, 1 H), 3.69-3.93 (m, 1.6 H), 3.39 (td. 0.4 H), 2.72-3.21 (m, 2 H), 2.31-2.61 (m, 7 H), 1.97-2.28 (m, 2 H)	404.2 [M+H]+	100%
1557	(CD3OD) δ 8.14-8.40 (m, 1 H), 7.42-7.85 (m, 1 H), 6.35-7.18 (m, 4 H), 4.96 (br dd, 1 H), 3.68-3.92 (m, 1.6 H), 3.38 (td, 0.4 H), 2.77-3.21 (m, 2 H), 2.32-2.69 (m, 7 H), 1.89-2.31 (m, 2 H)	404.2 [M+H]+	95.9%
1558	(CD3OD) δ 8.21-8.43 (m, 1 H), 7.69 (s, 1 H), 6.59-7.11 (m, 4 H), 4.99 (br dd, 1 H), 3.66-3.92 (m, 1.6 H), 3.34-3.42 (m, 0.4 H), 2.77-3.21 (m, 2 H), 2.40-2.60 (m, 4 H), 1.95-2.27 (m, 2 H)	408.2 [M+H]+	100%
1559	(CD3OD) δ 8.24-8.43 (m, 1 H), 7.38-7.83 (m, 1 H), 6.60-7.07 (m, 4 H), 5.00 (br dd, 1 H), 3.71-3.94 (m, 1.6 H), 3.34-3.43 (m, 0.4 H), 2.76-3.22 (m, 2 H), 2.39-2.60 (m, 4 H), 2.00-2.25 (m, 2 H)	408.2 [M+H]+	98.5%
1560	(CD3OD) δ 7.42-7.71 (m, 2 H), 6.56-7.27 (m, 4 H), 5.00 (br dd, 1 H), 3.76-3.97 (m, 1.6 H), 3.34-3.41 (m, 0.4 H), 2.78-3.21 (m, 2 H), 2.40-2.60 (m, 4 H), 1.95-2.28 (m, 2 H)	424.2 [M+H]+	100%
1561	(CD3OD) δ 7.41-7.72 (m, 2 H), 6.59-7.23 (m, 4 H), 5.00 (br dd, 1 H), 3.76-3.94 (m, 1.6 H), 3.34-3.43 (m, 0.4 H). 2.77-3.20 (m, 2 H), 2.40-2.57 (m, 4 H), 1.95-2.27 (m, 2 H)	424.1 [M+H]+	98.7%
1562	(CD3OD) δ 7.68 (d, 1 H), 7.35-7.51 (m, 1.4 H), 7.11 (dt, 1 H), 6.95 (s. 0.6 H), 6.39-6.75 (m, 2 H), 4.96 (br dd, 1 H), 3.79-3.99 (m, 1.6 H), 3.34-3.43 (m, 0.4 H), 2.75-3.20 (m, 2 H), 2.38-2.71 (m, 7 H), 1.94-2.32 (m, 2 H)	404.2 [M+H]+	100%
1563	(CD3OD) δ 7.69 (d, 1 H), 7.36-7.51 (m, 1.4 H), 7.10 (dt, 1 H), 6.95 (s, 0.6 H), 6.31-6.80 (m, 2 H), 4.96 (br dd, 1 H), 3.77-3.98 (m, 1.5 H), 3.32-3.41 (m, 0.5 H), 2.76-3.20 (m, 2 H), 2.39-2.73 (m, 7 H), 1.94-2.29 (m, 2 H)	404.2 [M+H]+	94.5%
1564	(CD3OD) δ 7.66-7.80 (m, 1 H), 7.41-7.61 (m, 1.3 H), 7.18-7.32 (m, 1 H), 6.98 (s, 0.7 H), 6.70-6.86 (m, 2 H), 6.61-6.70 (m, 1 H), 5.06 (br dd, 0.8 H), 3.92 (s, 3 H), 3.41-3.88 (m, 1.2 H), 3.20 (br d, 1 H), 2.86 (br dd, 1 H), 2.41 (s, 3 H)	448.1 [M+H]+	1 00%
1565	(CD3OD) δ 7.71 (s, 1 H), 7.41-7.60 (m, 1.4 H), 7.20-7.31 (m, 1 H), 6.98 (s, 0.6 H), 6.70-6.84 (m, 2 H), 6.60-6.70 (m, 1 H), 5.06 (br dd, 1 H), 3.92 (s, 3 H), 3.42-3.88 (m, 1 H), 2.94-3.27 (m, 1 H), 2.86 (br dd, 1 H), 2.41 (s, 3 H)	448.1 [M+H]+	99.6%
1566	(CD3OD) δ 8.30 (br s, 1 H), 7.64-7.82 (m, 1 H), 7.58 (br s, 0.3 H), 7.37-7.54 (m, 1 H). 7.13-7.34 (m, 1 H), 6.97 (s, 0.7 H), 6.70-6.85 (m, 1 H), 6.60-6.70 (m, 1 H), 4.97-5.17 (m, 1 H), 3.94 (s, 3 H), 3.39-3.86 (m, 1 H), 2.96-3.25 (m, 1 H), 2.78-2.93 (m, 1 H), 2.47-2.61 (m, 3 H)	448.2 [M+H]+	1()()%
1567	(CD3OD) δ 8.30 (s, 1 H), 7.71 (s, 1 H), 7.58 (s, 0.3 H), 7.42-7.54 (m, 1 H), 7.19-7.33 (m, 1 H), 6.97 (s, 0.7 H), 6.70-6.85 (m, 1 H), 6.61-6.70 (m, 1 H), 5.02-5.18 (m, 1 H), 3.94 (s, 3 H), 3.42-3.88 (m, 1 H), 2.94-3.26 (m, 1 H), 2.79-2.93 (m, 1 H), 2.49-2.62 (m, 3 H)	448.2 [M+H]+	1 00%
1568	(CD3OD) δ 8.53-8.64 (m, 1 H), 7.72 (s, 1 H), 7.41-7.56 (m, 2 H), 6.73-7.15 (m, 4 H), 4.95-5.17 (m, 1 H), 4.16-4.27 (m, 3 H), 3.75-3.88 (m, 0.5 H), 3.42 (td, 0.5 H), 2.85-3.26 (m, 2 H), 2.29-2.44 (m, 3 H)	480.2 [M+H]+	1 00%
1569	(CD3OD) δ 8.54-8.64 (m, 1 H), 7.77 (br d, 1 H), 7.43-7.55 (m, 2 H), 6.78-7.17 (m, 4 H), 4.95-5.16 (m, 1 H), 4.20-4.27 (m, 3 H), 3.74-3.89 (m, 0.5 H), 3.39-3.49 (m, 0.5 H), 2.85-3.25 (m, 2 H), 2.33-2.46 (m, 3 H)	480.1 [M+H]+	97.3%
1570	(CD3OD) δ 9. 11-9.18 (m, 1 H), 8.46-8.62 (m, 2 H), 7.72 (s, 1 H), 7.40-7.62 (m, 1.4 H), 6.91-7.16 (m, 2.6 H), 6.75-6.88 (m, 1 H), 4.95-5.13 (m, 1 H), 3.74-3.84 (m, 0.7 H), 3.39-3.47 (m, 0.3 H), 2.95-3.26 (m, 1 H), 2.80-2.92 (m, 1 H)	520.1 [M+H]+	99.3%
1571	(CD3OD) δ 8.97-9.07 (m, 1 H), 8.32-8.52 (m, 2 H), 7.60 (s, 1 H), 7.28-7.49 (m, 1.4 H), 6.76-7.06 (m, 2.6 H), 6.62-6.74 (m, 1 H), 4.82-5.03 (m, 1 H), 3.62-3.72 (m, 0.7 H), 3.26-3.35 (m, 0.3 H), 2.83-3.14 (m, 1 H), 2.67-2.81 (m, 1 H)	520.1 [M+H]+	99.5%
1572	(CD3OD) δ 7.08-7.90 (m, 6 H), 6.53-6.99 (m, 1 H), 4.96-5.06 (m, 1 H), 3.76-3.97 (m, 1.6 H), 3.34 (br s, 0.4 H), 2.77-3.16 (m, 2 H), 2.36-2.63 (m, 4 H), 1.92-2.28 (m, 2 H)	440.1 [M+H]+	97.5%
1573	(CD3OD) δ 7.08-7.81 (m, 5 H), 6.52-6.99 (m, 2 H). 4.91-503 (m, 1 H), 3.75-3.95 (m, 1.6 H), 3.32-3.39 (m, 0.4 H), 2.74-3.19 (m, 2 H), 2.42-2.57 (m. 4 H), 1.94-2.26 (m, 2 H)	440.1 [M+H]+	98.2%
1574	(CD3OD) δ 7.61-7.75 (m, 1 H), 7.37-7.52 (m, 1 H), 7.17-7.30 (m, 1 H), 6.45-7.13 (m, 3 H), 5.00 (dd, 1 H), 3.73-3.94 (m, 1.6 H), 3.33-3.43 (m, 0.4 H), 2.74-3.21 (m, 2 H), 2.37-2.61 (m, 4 H), 1.94-2.29 (m, 2 H)	408.1 [M+H]+	100%
1575	(CD3OD) δ 7.62-7.74 (m, 1 H), 7.20-7.52 (m, 2 H), 6.58-6.98 (m, 3 H), 4.91-5.05 (m, 1 H), 3.65-3.98 (m, 1.7 H), 3.35-3.43 (m, 0.3 H), 2.75-3.22 (m, 2 H), 2.41-2.57 (m, 4 H), 1.95-2.28 (m, 2 H)	408.2 [M+H]+	99. 7%
1576	(CD3OD) δ 8.43 (d, 1 H), 7.66 (s. 1 H), 7.57 (d, 1 H), 7.39 (d, 1 H), 7.31 (d, 1 H), 7.14-7.22 (m, 2 H), 7.03-7.11 (m, 1 H), 6.83 (t, 1 H), 6.60 (d, 2 H), 4.54 (dd, 1 H), 3.72 (td, 1 H), 2.98-3.11 (m, 1 H), 2.81 (dd, 1 H)	357.1 [M+H]+	1 00%
1577	(CD3OD) δ 8.43 (br d, 1 H), 7.66 (s, 1 H), 7.57 (br d, 1 H), 7.39 (d, 1 H), 7.31 (d, 1 H), 7.13-7.23 (m, 2 H), 7.07 (t, 1 H), 6.83 (br t, 1 H), 6.50-6.66 (m, 2 H), 4.54 (dd, 1 H), 3.61-3.81 (m, 1 H), 2.94-3.12 (m, 1 H), 2.81 (br dd, 1 H)	357.2 [M+H]+	99.5%
1578	(CD3OD) δ 8.45 (dd, 1 H), 8.26 (dd, 1 H), 7.68-7.81 (m, 2 H), 7.38-7.64 (m, 2 H), 6.99-7.34 (m, 3 H), 6.61-6.83 (m, 1 H), 4.97-5.07 (m, 1 H), 4.00 (d, 3.6 H), 3.37-3.42 (m, 0.4 H), 2.84-3.25 (m, 2 H)	493.1 [M+H]+	1 00%
1579	(CD3OD) δ 8.34 (dd, 1 H), 8.15 (dd, 1 H), 7.57-7.68 (m, 2 H), 7.27-7.52 (m, 2 H), 6.86-7.20 (m, 3 H), 6.48-6.70 (m, 1 H), 4.83-4.94 (m, 1 H), 3.78-3.90 (m, 3.6 H), 3.24-3.29 (m, 0.4 H), 2.73-3.10 (m, 2 H)	493.1 [M+H]+	99.7%
1580	(CD3OD) δ 8.51-8.59 (m, 1 H), 7.79-7.91 (m, 1 H), 7.57-7.70 (m, 3 H), 6.86-7.48 (m, 4 H), 6.46-6.72 (m, 1 H), 4.83-4.93 (m, 1 H), 3.76-3.87 (m, 0.5 H), 3.22-3.31 (m, 0.5 H), 2.73-3.15 (m, 2 H)	481.1 [M+H]+	99.1%
1581	(CD3OD) δ 8.61-8.72 (m, 1 H), 7.91-8.00 (m, 1 H), 7.68-7.82 (m, 3 H), 6.99-7.60 (m, 4 H), 6.56-6.86 (m, 1 H), 4.95-5.02 (m, 1 H), 3.85-4.02 (m. 0.5 H), 3.36-3.45 (m, 0.5 H), 2.83-3.27 (m, 2 H)	481.1 [M+H]+	97.5%
1582	(CD3OD) δ 8.28 (s, 1 H), 7.68-7.81 (m, 2 H), 7.35-7.60 (m, 1 H), 6.95-7.33 (m, 3 H), 6.57-6.81 (m, 1 H), 4.94-5.14 (m, 1 H), 3.93 (d, 3.5 H), 3.34-3.44 (m, 0.5 H), 2.82-3.25 (m, 2 H), 2.51-2.58 (m, 3 H)	480.2 [M+H]+	98.6%
1583	(CD3OD) δ 8.15 (s, 1 H), 7.54-7.68 (m, 2 H), 7.23-7.48 (m, 1 H), 6.84-7.19 (m, 3 H), 6.51-6.68 (m, 1 H), 4.82-5.04 (m, 1 H), 3.80 (d, 3.5 H), 3.22-3.31 (m, 0.5 H), 2.72-3.07 (m, 2 H), 2.41 (d, 3 H)	480.2 [M+H]+	98.5%
1584	(CD3OD) δ 7.67-7.80 (m, 2 H), 7.35-7.59 (m, 2 H), 6.97-732 (m, 3 H), 6.65-6.81 (m, 1 H), 4.96-5.13 (m, 1 H), 4.23 (d, 3 H), 3.94 (ddd, 0.6 H), 3.37-3.44 (m, 0.4 H), 2.84-3.23 (m, 2 H), 2.37 (d, 3 H)	480.1 [M+H]+	100%
1585	(CD3OD) δ 7.56-7.68 (m, 2 H), 7.23-7.47 (m, 2 H), 6.85-7.20 (m, 3 H), 6.54-6.69 (m, 1 H), 4.84-5.01 (m, 1 H), 4.09-4. 1 6 (m, 3 H), 3.82 (ddd, 0.6 H), 3.25-3.33 (m, 0.4 H), 2.72-3.13 (m, 2 H), 2.25 (d. 3 H)	480.1 [M+H]+	96.4%
1586	(CD3OD) δ 8.39-8.46 (m, 1 H), 7.69 (s, 1 H), 7.37-7.49 (m, 0.3 H), 7.26-7.32 (m, 1 H), 6.92 (br s, 0.7 H), 6.81-6.89 (m, 1 H), 6.68-6.75 (m, 1 H), 4.99 (br dd, 1 H), 3.67-3.82 (m, 1.7 H), 3.35-3.44 (m, 0.3 H), 2.94-3.20 (m, 5 H), 2.82 (br d, 1 H)	460.1 [M+H]+	100%
1587	(CD3OD) δ 8.39-8.46 (m, 1 H), 7.69 (s, 1 H), 7.44 (s, 0.3 H), 7.26-7.32 (m, 1 H), 6.92 (s, 0.7 H), 6.82-6.88 (m, 1 H), 6.69-6.75 (m, 1 H), 4.99 (dd, 1 H), 3.68-3.81 (m, 1.7 H), 3.38 (td, 0.3 H), 2.97-3.19 (m, 5 H). 2.77-2.87 (m, 1 H)	460.1 [M+H]+	99.0%
1588	(CD3OD) δ 8.29 (d, 1 H), 7.65 (s, 1 H), 6.97 (d, 1 H), 6.77 (t, 1 H), 6.50 (s, 1 H), 6.24 (br s, 1 H), 4.17 (dd, 1 H), 3.67 (ddd, 1 H), 2.95-3.08 (m, 1 H), 2.77 (dd. 1 H), 2.42 (s, 3 H), 1.99-2.16 (m, 1 H), 1.04-1.13 (m, 4 H)	362.2 [M+H]+	1 00%
1589	(CD3OD) δ 8.28 (d, 1 H), 7.65 (s, 1 H), 6.96 (br d, 1 H), 6.76 (t, 1 H), 6.50 (s, 1 H), 6.24 (s, 1 H), 4.17 (dd, 1 H), 3.67 (ddd, 1 H), 2.95-3.06 (m, 1 H), 2.76 (dd, 1 H), 2.41 (s, 3 H), 2.01-2.12 (m, 1 H), 1.00-1.15 (m, 4 H)	362.2 [M+H]+	99.8%
1 590	(CD3OD) δ 8.68 (d, 1 H), 7.60-7.67 (m, 2 H), 6.98 (t, 1 H), 6.68 (s, 1 H), 6.27 (s, 1 H), 4.20 (dd, 1 H), 3.68 (ddd, 1 H), 2.96-3.06 (m, 1 H), 2.78 (dd, 1 H), 2.02-2.11 (m, 1 H), 1.00-1.16 (m, 4 H)	416.2 [M+H]+	98.7%
1591	(CD3OD) δ 8.68 (d, 1 H), 7.59-7.67 (m, 2 H), 6.98 (t, 1 H), 6.68 (s, 1 H), 6.27 (br s, 1 H), 4.20 (dd. 1 H), 3.64-3.72 (m, 1 H), 2.95-3.06 (m, 1 H), 2.78 (br dd, 1 H), 2.01-2.11 (m, 1 H), 1.00-1.13 (m, 4 H)	416.2 [M+H]+	98.9%
1592	(CD3OD) δ 8.29-8.53 (m, 3 H), 7.70-7.72 (m, 1 H), 7.64 (s, 1 H), 7.61-7.72 (m, 1 H), 7.56 (d, 1 H), 7.07-7.28 (m, 2 H), 6.83 (td, 1 H), 6.65 (t, 1 H), 6.54 (s, 1 H), 4.96-5.12 (m, 1 H), 3.40-3.56 (m, 1 H), 2.81-3.00 (m, 1 H), 2.70 (dd, 1 H)	318.2 [M+H]+	100%
1593	(CD3OD) δ 8.32-8.53 (m, 3 H), 7.67 (s, 1 H), 7.56 (d, 1 H), 7.07-7.26 (m, 2 H), 6.83 (t, 1 H), 6.66 (t, 1 H), 6.54 (s, 1 H), 5.04 (br dd, 1 H), 3.39-3.55 (m, 1 H), 2.83-3.00 (m, 1 H), 2.70 (dd, 1 H)	318.1 [M+H] +	99.4%
1594	(CD3OD) δ 7.92-8.04 (m, 1 H), 7.77-7.88 (m, 1 H), 7.55-7.69 (m, 2 H), 7.25-7.50 (m, 2 H), 6.85-7.22 (m, 3 H), 6.47-6.71 (m, 1 H), 4.85-4.96 (m, 1 H), 3.75-3.88 (m, 0.5 H), 3.24 (br d, 0.5 H), 2.71-3.13 (m, 2 H), 2.54 (br d, 3 H)	477.2 [M+H]+	1 00%
1595	(CD3OD) δ 8.07-8.19 (m, 1 H), 7.95 (td, 1 H), 7.68-7.84 (m, 2 H), 7.39-7.61 (m, 2 H), 6.98-7.34 (m, 3 H), 6.60-6.88 (m, 1 H), 4.97-5.08 (m, 1 H), 3.86-3.99 (m, 0.5 H), 3.36-3.42 (m, 0.5 H), 2.85-3.24 (m, 2 H), 2.67 (d, 3 H)	477.2 [M+H]+	98.2%
1596	(CD3OD) δ 9.01 (s, 1 H), 8.78 (br s, 2 H), 7.85-8.03 (m, 2 H), 7.56-7.75 (m, 3 H), 6.42-7.17 (m, 4 H), 4.65 (br s, 1 H), 3.96 (s, 3 H), 3.44-3.81 (m, 1 H), 3.03-3.16 (m, 1 H), 2.73-2.83 (m, 1 H)	532.2 [M+H]+	100%
1597	(CD3OD) δ 9.01 (d, 1 H). 8.24-8.89 (m, 2 H), 7.86-8.04 (m, 2 H), 7.56-7.74 (m, 3 H), 6.37-7.09 (m, 4 H), 4.66 (br s, 1 H), 3.96 (s, 3 H), 3.46-3.83 (m, 1 H), 3.04-3.15 (m, 1 H), 2.79 (br d, 1 H)	532.2 [M+H]+	98.4%
1598	(CD3OD) δ 8.23-8.37 (m, 1 H), 7.35-7.76 (m, 1.4 H), 6.90-7.07 (m, 1.6 H), 6.73-6.86 (m, 1 H), 6.52-6.69 (m, 1 H), 4.98 (dd, 1 H). 3.69-3.90 (m, 1.6 H), 3.36-3.47 (m, 0.4 H), 2.92-3.24 (m, 5 H), 2.84 (br dd, 1 H), 2.37-2.52 (m, 3 H)	440.1 [M+H]+	100%
1 599	(CD3OD) δ 8.22-8.38 (m, 1 H), 7.43-7.78 (m, 1.4 H), 6.91-7.06 (m, 1.6 H), 6.74-6.87 (m, 1 H), 6.53-6.70 (m, 1 H), 4.98 (br dd, 1 H), 3.69-3.87 (m, 1.6 H), 3.37-3.45 (m, 0.4 H), 2.92-3.27 (m, 5 H), 2.84 (br dd, 1 H), 2.37-2.54 (m, 3 H)	440.1 [M+H]+	99.3%
1 600	(CD3OD) δ 8.64-8.76 (m, 1 H), 7.71 (s, 1 H), 7.60-7.68 (m, 1 H), 7.47 (br s, 0.4 H), 6.92-7.06 (m, 1.6 H), 6.73-6.86 (m, 1 H), 4.94-5. 10 (m, 1 H), 3.68-3.88 (m, 1.6 H), 3.36-3.46 (m, 0.4 H), 2.93-3.25 (m, 5 H), 2.76-2.91 (m, 1 H)	494.1 [M+H]+	100%
1601	(CD3OD) δ 8.65-8.77 (m, 1 H), 7.72 (s. 1 H), 7.59-7.68 (m, 1 H), 7.47 (s, 0.4 H), 6.92-7.07 (m, 1.6 H), 6.73-6.85 (m, 1 H), 4.93-5.10 (m, 1 H), 3.69-3.87 (m, 1.6 H), 3.37-3.47 (m, 0.4 H), 2.94-3.25 (m, 5 H), 2.79-2.90 (m, 1 H)	494.1 [M+H]+	99.5%
1602	(CD3OD) δ 8.51-8.70 (m, 1 H), 7.71 (s, 1 H), 7.45 (br d, 1.3 H), 6.73-7.16 (m, 3.7 H), 4.92-5.05 (m, 1 H), 3.68-3.89 (m, 1.5 H), 3.36-3.47 (m, 0.5 H), 2.70-3.23 (m, 6 H)	476.2 [M+H]+	100%
1603	(CD3OD) δ 8.52-8.66 (m, 1 H), 7.71 (s, 1 H), 7.38-7.51 (m, 1.3 H), 6.72-7.19 (m, 3.7 H), 4.92-5.05 (m, 1 H), 3.69-3.86 (m, 1.5 H), 3.34-3.44 (m, 0.5 H), 2.82-3.22 (m, 6 H)	476.2 [M+H]+	99.5%
1604	(CD3OD) δ 8.26-8.42 (m, 1 H), 7.71 (s, 1 H), 7.46 (s, 0.5 H), 6.67-7.05 (m, 3.5 H), 5.01 (dd, 1 H), 3.68-3.88 (m, 1.5 H), 3.41 (td, 0.5 H), 2.76-3.24 (m, 6 H)	444.2 [M+H]+	100%
1605	(CD3OD) δ 8.16-8.30 (m, 1 H), 7.55-7.65 (m, 1 H), 7.34 (s, 0.5 H), 6.57-6.91 (m, 3.5 H), 4.89 (br dd, 1 H), 3.53-3.75 (m, 1.5 H), 3.29 (td, 0.5 H), 2.68-3.09 (m, 6 H)	444.1 [M+H]+	92.0%
1606	(CD3OD) δ 8.56 (br d, 1 H), 7.65 (s, 1 H), 7.41 (br d, 1 H), 6.68-7.12 (m, 3 H), 6.26 (s, 1 H), 4.13-4.25 (m, 1 H), 3.56-3.75 (m, 1 H), 3.00 (br d, 1 H), 2.78 (dd, 1 H), 1.97-2.13 (m, 1 H), 0.99-1.12 (m, 4 H)	398.2 [M+H]+	93.1%
1607	(CD3OD) δ 8.57 (d, 1 H), 7.66 (s, 1 H), 7.41 (br d, 1 H), 6.64-7.17 (m, 3 H), 6.27 (s, 1 H), 4.19 (dd, 1 H), 3.67 (ddd, 1 H), 2.94-3.07 (m, 1 H), 2.78 (dd, 1 H), 2.02-2.15 (m, 1 H), 0.96-1.16 (m, 4 H)	398.2 [M+H]+	98.1%
1608	(CD3OD) δ 7.60-7.82 (m, 3 H), 7.35-7.59 (m, 1 H), 6.97-7.33 (m, 4 H), 6.62-6.85 (m, 1 H), 5.09 (br dd, 1 H), 4.33 (br d, 3 H), 3.86-4.02 (m, 0.6 H). 3.37-3.43 (m, 0.4 H), 2.84-3.25 (m, 2 H)	466.1 [M+H]+	100%
1609	(CD3OD) δ 7.49-7.70 (m, 3 H), 7.24-7.47 (m, 1 H), 6.85-7.21 (m, 4 H), 6.49-6.70 (m, 1 H), 4.85-5.01 (m, 1 H), 4.21 (br d, 3 H), 3.73-3.89 (m, 0.6 H), 3.25-3.33 (m, 0.4 H), 2.73-3.13 (m, 2 H)	466.2 [M+H]+	95.3%
1610	(CD3OD) δ 8.68 (d, 2 H), 8.12 (d. 1 H), 8.00 (td, 1 H), 7.84 (s, 1 H), 7.48-7.66 (m, 2 H), 6.76-7.03 (m, 2 H), 6.58 (s, 1 H), 4.48 (dd, 1 H), 3.80 (ddd, 1 H), 3.00-3.21 (m, 1 H), 2.87 (dd, 1 H)	453.2 [M+H]+	98.9%
1611	(CD3OD) δ 8.57-8.78 (m, 2 H), 8.12 (d, 1 H), 8.00 (td, 1 H), 7.69 (s, 1 H), 7.49-7.64 (m, 2 H), 6.76-7.03 (m, 2 H), 6.55 (br s, 1 H), 4.47 (dd, 1 H), 3.80 (ddd, 1 H), 2.67-3.21 (m, 2 H)	453.2 [M+H]+	99.7%
1612	(CD3OD) δ 8.69 (d, 1 H), 8.33 (d, 1 H), 8.13 (d, 1 H), 8.01 (td, 1 H), 7.70 (s, 1 H), 7.55 (dd, 1 H), 6.95 (dd, 1 H), 6.77-6.86 (m, 2 H), 6.54 (s, 1 H), 4.47 (dd, 1 H), 3.75-3.86 (m, 1 H), 3.03-3.16 (m, 1 H), 2.86 (br dd, 1 H)	403.2 [M+H]+	100%
1613	(CD3OD) δ 8.68 (d, 1 H), 8.32 (d, 1 H), 8.12 (d, 1 H), 7.99 (td, 1 H), 7.71 (s, 1 H), 7.51-7.57 (m, 1 H), 6.94 (dd, 1 H), 6.75-6.84 (m, 2 H), 6.53 (s, 1 H), 4.45 (dd, 1 H), 3.75-3.86 (m, 1 H), 3.03-3.15 (m, 1 H), 2.84 (dd, 1 H)	403.2 (M+-H]+	99. 6%
1614	(CD3OD) δ 8.12-9.01 (m, 2 H), 8.07 (d, 1 H), 7.86 (d, 1 H), 7.57-7.72 (m, 2 H), 7.42 (dd, 1 H), 6.41-7.07 (m, 3 H), 4.65 (br s, 1 H), 3.79-3.95 (m, 4 H), 3.40-3.78 (m, 1 H), 3.02-3.17 (m, 5 H), 2.77 (br d, 1 H)	537.3 [M+H]+	99.2%
1615	(CD3OD) δ 8.12-8.93 (m, 2 H), 8.09 (d, 1 H), 7.86 (d, 1 H), 7.57-7.70 (m, 2 H), 7.44 (dd, 1 H), 6.43-7.08 (m, 3 H), 4.65 (br s, 1 H), 3.82-3.90 (m, 4 H), 3.38-3.80 (m, 1 H), 3.03-3.16 (m, 5 H), 2.78 (br d, 1 H)	537.2 [M+H]+	99.7%
1616	(CD3OD) δ 8.42 (d, 2 H), 8.32 (d, 1 H), 7.65 (s, 1 H), 7.19 (s, 1 H), 6.95 (dd, 1 H), 6.72-6.82 (m, 1 H), 6.62-6.70 (m, 2 H), 5.03-5.13 (m, 1 H), 3.42-3.55 (m, 1 H), 2.83-2.99 (m, 1 H), 2.71 (br dd, 1 H)	336.1 [M+H]+	100%
1617	(CD3OD) δ 8.41 (d, 2 H), 8.32 (d, 1 H), 7.64 (s, 1 H), 7.18 (s, 1 H), 6.94 (dd, 1 H), 6.75-6.84 (m, 1 H), 6.60-6.73 (m, 2 H), 5.06 (br dd, 1 H), 3.40-3.53 (m, 1 H), 2.82-2.97 (m, 1 H), 2.71 (br dd, 1 H)	336.2 [M+H]+	90.7%
1618	(CD3OD) δ 8.41 (d, 2 H), 8.28 (br d, 1 H), 7.64 (s, 1 H), 7.20 (s, 1 H), 6.96 (d, 1 H), 6.75 (t, 1 H), 6.65 (t, 1 H), 6.53 (s, 1 H), 5.03 (br dd, 1 H), 3.47 (ddd, 1 H), 2.83-3.04 (m, 1 H), 2.70 (br dd, 1 H), 2.43 (s, 3 H)	332.2 [M+H]+	100%
1619	(CD3OD) δ 8.28 (d, 2 H), 8.16 (br d, 1 H), 7.52 (s, 1 H), 7.08 (s, 1 H), 6.83 (br d, 1 H), 6.62 (t, 1 H), 6.52 (t, 1 H), 6.41 (s, 1 H), 4.91 (br dd, 1 H), 3.29-3.40 (m, 1 H), 2.72-2.86 (m, 1 H), 2.57 (br dd, 1 H), 2.30 (s, 3 H)	332.1 [M+-H]+	97.3%
1620	(500 MHz, CD3OD) δ 8.88 (s, 1 H), 8.05-8.80 (m, 2 H), 7.85-7.96(m, 1 H), 7.77 (dd, 1 H), 7.51-7.64 (m, 2 H), 6.23-7.01 (m, 5 H), 4.52 (br s, 1 H), 3.81-3.89 (m, 3 H), 3.28-3.77 (m, 1 H), 2.91-3.04 (m, 1 H), 2.67 (br d, 1 H), 2.34 (s, 3 H)	478.2 [M+H]+	100%
1621	(500 MHz, CD3OD) δ 9.01 (s, 1 H), 8.27-8.94 (m, 2 H), 8.01 (d, 1 H), 7.89 (dd, 1 H), 7.60-7.77 (m. 2 H), 6.39-7.09 (m, 5 H), 4.64 (br s, 1 H), 3.94-4.09 (m, 3 H), 3.43-3.89 (m, 1 H), 3.02-3.21 (m, 1 H), 2.79 (br d, 1 H), 2.38-2.61 (m, 3 H)	478.2 [M+H]+	98.8%
1622	(CD3OD) δ 8.69 (d, 1 H), 8.43 (d, 1 H), 8.13 (d, 1 H), 8.00 (t, 1 H), 7.68 (s, 1 H), 7.54 (dd, 1 H), 7.28 (d, 1 H), 6.83 (t, 1 H), 6.76 (s, 1 H), 6.53 (br s, 1 H), 4.46 (dd, 1 H), 3.79 (td, 1 H), 2.99-3.17 (m, 1 H), 2.84 (br d, 1 H)	419.1 [M+H]+	100%
1623	(CD3OD) δ 8.68 (d, 1 H), 8.43 (d, 1 H), 8.13 (d, 1 H), 8.00 (t, 1 H), 7.68 (s, 1 H), 7.44-7.57 (m, 1 H), 7.28 (d, 1 H), 6.82 (t, 1 H), 6.76 (s, 1 H), 6.53 (s, 1 H), 4.46 (dd, 1 H), 3.71-3.86 (m, 1 H), 3.02-3.17 (m, 1 H), 2.84 (dd, 1 H)	419.1 [M+H]+	99. 0%
1624	(CD3OD) δ 8.26-8.85 (m, 3 H), 7.97 (d, 1 H), 7.68 (s, 1 H), 7.43-7.52 (m, 1 H), 6.37-7.14 (m, 4 H), 4.63-4.87 (m, 1 H), 3.58 (s, 3 H), 3.03-3.18 (m, 1 H), 2.70-2.85 (m, 1 H), 2.47 (s, 3 H), 2.32 (s, 6 H)	455.3 [M+H]+	97.4%
1625	(CD3OD) δ 8.24-9.00 (m, 3 H), 7.97 (d, 1 H), 7.68 (s, 1 H), 7.48 (dd, 1 H), 6.28-7.14 (m, 4 H), 4.64-4.88 (m, 1 H), 3.58 (s, 3 H), 3.00-3.16 (m, 1 H), 2.69-2.86 (m, 1 H), 2.46 (s, 3 H), 2.32 (s, 6 H)	455.3 [M+H]+	99.0%
1626	(CD3OD) δ 8.61-8.82 (m, 1 H), 8.12 (d, 1 H), 7.99 (td, 1 H), 7.72 (dd, 1 H), 7.67 (s, 1 H), 7.54 (ddd, 1 H), 7.20-7.50 (m, 2 H), 7.16 (d, 1 H), 6.73 (s, 1 H), 6.53 (s, 1 H), 4.45 (dd, 1 H), 3.85 (ddd, 1 H). 3.01-3.15 (m, 1 H). 2.85 (dd, 1 H)	435.1 [M+H]+	100%
1627	(CD3OD) δ 8.69 (br s, 1 H), 8.13 (br d, 1 H), 8.01 (br t, 1 H), 7.64-7.81 (m, 2 H), 7.55 (br s, 1 H), 7.21-7.50 (m, 2 H), 7.17 (br d, 1 H), 6.74 (s, 1 H), 6.54 (br d, 1 H), 4.46 (br dd, 1 H), 3.78-3.97 (m, 1 H), 3.01-3.22 (m, 1 H), 2.76-2.95 (m, 1 H)	435.2 [M+H]+	99.0%
1628	Data provided above
1629	Data provided above
1630	(CD3OD) δ 8.24-8.97 (m, 3 H), 8.08 (s, 1 H), 7.85-8.03 (m, 2 H), 7.59-7.73 (m, 2 H), 6.41-7.11 (m, 4 H), 4.63 (br s. 1 H), 3.95 (s, 3 H), 3.39-3.83 (m, 1 H), 3.00-3.16 (m, 1 H), 2.77 (br d, 1 H), 2.44 (s, 3 H)	478.2 [M+H]+	100%
1631	(CD3OD) δ 8.29-8.96 (m, 3 H), 8.11 (s, 1 H), 7.88-8.04 (m, 2 H), 7.63-7.77 (m, 2 H), 6.45-7.12 (m, 4 H), 4.69-4.86 (m, 1 H), 3.97 (s, 3 H), 3.05-3.16 (m, 1 H), 2.80 (br d, 1 H), 2.46 (s, 3 H)	478.2 [M+H]+	98.7%
1632	(CD3OD) δ 9.03 (s, 1 H), 8.02 (d, 1 H), 7.90 (dd, 2 H), 7.63-7.76 (m, 2 H), 7.24-7.51 (m, 2 H), 6.76 (d, 2 H), 4.56-4.75 (m, 2 H), 3.98 (s, 3 H), 2.98-3.18 (m, 1 H), 2.78 (dd, 1 H)	532.2 [M+H]+	100%
1633	(CD3OD) δ 9.03 (s, 1 H), 8.03 (d, 1 H), 7.91 (dd, 2 H), 7.63-7.82 (m, 2 H), 7.28-7.50 (m, 2 H), 6.77 (d, 2 H), 4.56-4.73 (m, 2 H), 3.98 (s, 3 H), 3.01-3.19 (m, 1 H), 2.80 (dd, 1 H)	532.2 [M+H]+	100%
1634	(CD3OD) δ 8.22-9.20 (m, 3 H), 8.01 (d, 1 H), 7.71 (s, 1 H), 7.50 (dd, 1 H), 7.33 (d, 1 H), 6.89 (br t, 3 H), 4.62-4.72 (m, 1 H), 3.92 (s, 2 H), 3.37-3.60 (m, 1 H), 3.00-3.18 (m, 1 H), 2.80 (br dd, 1 H), 2.56 (s, 6 H)	475.2 [M+H]+	98.0%
1635	(CD3OD) δ 8.23-9.22 (m, 3 H), 8.01 (d, 1 H), 7.71 (s, 1 H), 7.50 (dd, 1 H), 7.33 (d, 1 H), 6.89 (s, 3 H), 4.60-4.73 (m, 1 H), 3.94 (s, 2 H), 3.36-3.58 (m, 1 H), 3.02-3.18 (m, 1 H), 2.72-2.88 (m, 1 H), 2.58 (s, 6 H)	475.2 [M+H]+	100%
1636	(CD3OD) δ 8.68 (d, 1 H), 8.28 (d, 1 H), 8.13 (d, 1 H), 8.00 (td, 1 H), 7.68 (s, 1 H), 7.54 (ddd, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.64 (s, 1 H), 6.52 (s, 1 H), 4.43 (dd, 1 H), 3.71-3.86 (m, 1 H), 3.01-3.15 (m, 1 H), 2.83 (br dd, 1 H), 2.42 (s, 3 H)	399.2 [M+H]+	99.6%
1637	(CD3OD) δ 8.69 (d, 1 H), 8.29 (br d, 1 H), 8.13 (d, 1 H), 8.00 (td, 1 H), 7.68 (s, 1 H), 7.40-7.59 (m, 1 H). 6.97 (br d, 1 H), 6.77 (t, 1 H), 6.64 (s, 1 H), 6.52 (br s, 1 H), 4.44 (dd, 1 H), 3.69-3.86 (m, 1 H), 3.01-3.18 (m, 1 H), 2.84 (br dd, 1 H), 2.43 (s, 3 H)	399.2 [M+H]+	99.6%
1638	(CD3OD) δ 8.68 (d, 1 H), 8.13 (d, 1 H), 8.00 (td, 1 H), 7.67 (s, 1 H), 7.52-7.62 (m, 2 H), 7.16 (dd, 1 H), 6.98-7.05 (m, 1 H), 6.76 (s, 1 H), 6.54 (s, 1 H), 4.45 (dd, 1 H), 3.87 (td, 1 H), 3.04-3.15 (m, 1 H), 2.85 (dd, 1 H)	419.1 [M+H]+	100%
1639	(CD3OD) δ 8.68 (d, 1 H), 8.13 (d, 1 H), 8.00 (td, 1 H), 7.67 (s, 1 H), 7.59 (d, 1 H), 7.54 (dd, 1 H), 7.16 (dd, 1 H), 7.01 (d, 1 H), 6.76 (s, 1 H), 6.54 (s, 1 H), 4.45 (dd, 1 H), 3.82-3.92 (m, 1 H), 3.03-3.15 (m, 1 H), 2.85 (dd, 1 H)	419.1 [M+H]+	95.0%
1640	(CD3OD) δ 8.68 (br d, 1 H), 8.12 (d, 1 H), 7.99 (td, 1 H), 7.74 (br s, 1 H), 7.54 (ddd, 1 H), 7.45 (d, 1 H), 7.09 (dd, 1 H), 6.87 (s, 1 H), 6.36-6.6-4 (m, 2 H), 4.43 (dd, 1 H), 3.74-3.99 (m, 1 H), 2.98-3.22 (m, 1 H), 2.85 (br d, 1 H), 2.56-2.67 (m, 3 H)	399.2 [M+H]+	98.5%
1641	(CD3OD) δ 8.67 (d, 1 H), 8.11 (d, 1 H), 7.99 (td, 1 H), 7.66 (s, 1 H), 7.50-7.58 (m, 1 H), 7.44 (d, 1 H), 7.08 (dd, 1 H), 6.68 (d, 1 H), 6.45-6.61 (m, 2 H), 4.42 (dd, 1 H), 3.85 (td, 1 H), 2.98-3.15 (m, 1 H), 2.83 (br dd, 1 H), 2.60 (s, 3 H)	399.2 [M+H]+	96.8%
1642	(CD3OD) δ 8.29 (d, 1 H), 7.68 (s, 1 H), 7.39 (d, 1 H), 7.31 (d, 1 H), 7.18 (td, 1 H), 7.03-7.12 (m, 1 H), 6.96 (d, 1 H), 6.76 (t, 1 H), 6.60 (d, 2 H), 4.54 (dd, 1 H), 3.73 (ddd, 1 H), 2.98-3.13 (m, 1 H), 2.82 (dd, 1 H), 2.42 (s, 3 H)	371.2 [M+H]+	99.7%
1643	(CD3OD) δ 8.28 (d, 1 H), 7.67 (s, 1 H), 7.38 (d, 1 H), 7.31 (d, 1 H), 7.18 (td, 1 H), 7.04-7.11 (m, 1 H), 6.96 (d, 1 H), 6.75 (t, 1 H), 6.55-6.65 (m, 2 H), 4.54 (dd, 1 H), 3.73 (ddd, 1 H), 2.98-3.13 (m, 1 H), 2.82 (dd, 1 H), 2.42 (s, 3 H)	371.2 [M+H]+	98.0%
1644	(CD3OD) δ 9.24 (s, 1 H), 8.75-8.96 (m, 1 H), 8.25-8.45 (s, 1 H), 7.99-8.10 (m, 2 H), 7.84-7.97 (m, 2 H), 7.72 (s, 1 H), 7.31-7.45 (m, 1 H), 6.49-7.09 (m, 4 H), 4.67-4.88 (m, 1 H), 3.37-3.96 (m, 1 H), 3.02-3.19 (m, 1 H), 2.78 (br dd, 1 H)	479.2 [M+H]+	99.3%
1645	(CD3OD) δ 9.18 (s, 1 H), 8.24-8.59 (m, 4 H), 7.80-8.04 (m, 4 H), 7.25-7.37 (m, 1 H), 6.61-6.96 (m, 4 H), 4.58 (br s, 1 H), 3.30-3.68 (m, 1 H), 2.98-3.16 (m, 1 H), 2.78 (br dd, 1 H)	479.2 [M+H]+	99.1%
1646	(CD3OD) δ 9.01 (s, 1 H), 8.16-8.90 (m, 2 H), 8.02 (d, 1 H), 7.90 (dd, 1 H), 7.60-7.74 (m, 2 H), 6.49-7.07 (m, 5 H), 4.62 (br s, 1 H), 3.97 (s, 3 H), 3.41-3.86 (m, 1 H), 3.00-3.22 (m, 1 H), 2.80 (br dd, 1 H)	482.2 [M+H]+	94.3%
1647	(CD3OD) δ 9.02 (s, 1 H), 8.44 (br s, 2 H). 8.02 (dd, 1 H), 7.91 (dd, 1 H), 7.59-7.78 (m, 2 H), 6.49-7.15 (m, 5 H), 4.62 (s, 1 H), 3.98 (s, 3 H), 3.42-3.90 (m, 1 H), 3.02-3.21 (m, 1 H), 2.69-2.89 (m, 1 H)	482.2 [M+H]+	98.6%
1648	(CD3OD) δ 9.27 (s, 1 H), 8.22-9.01 (m, 3 H), 7.89-8.11 (m, 4 H), 7.67 (s, 1 H), 7.29-7.45 (m, 1 H), 6.35-7.11 (m, 4 H), 4.64-4.79 (m, 1 H), 3.40-3.84 (m, 1 H), 3.02-3.18 (m, 1 H), 2.70-2.86 (m, 1 H), 2.44 (s, 3 H)	475.2 [M+H]+	96.4%
1649	(CD3OD) δ 9.30 (s, 1 H), 8.23-9.07 (m, 3 H), 7.91-8.12 (m, 4 H), 7.70 (s, 1 H), 7.35-7.45 (m, 1 H), 6.45-7.06 (m, 4 H), 4.66-4.81 (m, 1 H), 3.39-4.00 (m, 1 H), 3.05-3.16 (m, 1 H), 2.80 (br d, 2 H), 2.37-2.52 (m, 3 H)	475.2 [M+H]+	97.5%
1650	(CD3OD) δ 8.43-8.76 (m, 3 H), 7.98 (d, 1 H),, 7.68-7.69 (m, 1 H), 7.40-7.40 (m, 1 H), 7.33 (d, 1 H), 6.57-7.02 (m, 3 H), 4.94-5.07 (m, 1 H), 4.55 (s, 2 H), 3.40-3.78 (m, 4 H), 3.04-3.18 (m, 1 H), 2.80 (br dd, 1 H)	462.1 [M+H]+	96.2%
1651	(CD3OD) δ 8.37-8.83 (m, 3 H), 7.91-8.02 (m, 1 H), 7.66-7.79 (m, 1 H), 7.41-7.49 (m, 1 H), 7.32 (d, 1 H), 6.56-6.99 (m, 3 H), 4.93-4.60-4.75 (m, 1 H), 4.54 (s, 2 H), 3.38-3.87 (m, 4 H), 3.03-3.16 (m, 1 H), 2.80 (br dd, 1 H)	462.1 [M+H]+	98.9%
1652	(CD3OD) δ 8.51 (d, 1 H), 8.02 - 8.42 (d, 1 H), 7.72 (s, 1 H), 7.52 (s, 0.3 H), 7.29 (d, 1 H), 6.97 (s, 0.7 H), 6.52 - 6.86 (m, 3 H), 5.02- 5.10 (m, 1 H), 3.91-4.01 (m, 3 H), 3.74-3.84 (m, 0.7 H), 3.38-3.46 (m, 0.3 H), 3.14-3.25 (m, 0.7 H), 3.02 (ddd, 0.3 H), 2.77-2.91 (m, 1 H)	500.1 [M+H]+	99.7%
1653	(CD3OD) δ 8.50 (d, 1 H), 7.92 - 8.22 (d, 1 H), 7.72 (s, 1 H), 7.50 (s, 0.3 H), 7.30 (d, 1 H), 6.97 (s, 0.7 H), 6.48 - 6.76 (m, 3 H), 4.92-5.15 (m, 1 H), 3.94-4.06 (m, 3 H), 3.71-3.80 (m, 0.7 H), 3.35-3.43 (m, 0.3 H), 3.10-3.24 (m, 0.7 H), 3.03 (ddd, 0.3 H), 2.77-2.91 (m, 1 H)	500.1 [M+H]+	99.4%
1654	(CD3OD) δ 8.36 (br d, 1 H), 7.71 (br s, 1 H), 7.46 (br s, 0.3 H), 7.18-7.28 (m, 0.2 H), 7.02-7.07 (m, 0.5 H), 6.95-7.02 (m, 1 H), 6.81-6.95 (m, 2 H), 6.63-6.79 (m, 1 H), 5.01 (br dd, 0.4 H), 4.85-4.87 (m, 0.6 H), 3.64-3.81 (m, 0.7 H), 3.37-3.42 (m, 0.3 H), 2.92-3.22 (m, 1 H). 2.85 (br s, 1 H), 2.27-2.38 (m, 1 H), 1.20-1.32 (m, 4 H)	442.1 [M+H]+	97.4%
1655	(CD3OD) δ 8.28-8.51 (m, 1 H), 7.70 (s, 1 H), 7.46 (br s, 0.3 H), 7.18-7.26 (m, 0.2 H), 7.02-7.09 (m, 0.5 H), 6.95-7.02 (m, 1 H), 6.81-6.95 (m, 2 H), 6.65-6.77 (m, 1 H), 5.01 (br dd, 0.5 H), 4.84-4.87 (m, 0.5 H), 3.66-3.82 (m. 0.7 H), 3.38-3.44 (m, 0.3 H), 2.91-3.23 (m, 1 H), 2.83 (br d, 1 H), 2.28-2.42 (m, 1 H), 1.19-1.32 (m, 4 H)	442.2 [M+H]+	95.2%
1656	(CD3OD) δ 8.63-8.69 (m, 1 H), 8.28-8.42 (m, 1 H), 7.89-8.00 (m, 1 H), 7.68-7.81 (m, 2 H), 7.20-7.50 (m, 0.7 H), 6.92-7.07 (m, 2 H), 6.74-6.90 (m, 2.3 H), 4.94-5.03 (m, 1 H), 3.81 (ddd, 0.7 H), 3.45 (td, 0.3 H), 2.98-3.29 (m, 1 H), 2.87 (br dd, 1 H)	497.1 [M+H]+	100%
1657	(CD3OD) δ 8.50-8.59 (m, 1 H), 8.16-8.30 (m, 1 H), 7.83 (t, 1 H), 7.57-7.70 (m, 2 H), 7.05-7.40 (m, 0.7 H), 6.82-6.97 (m, 2 H), 6.60-6.81 (m, 2.3 H), 4.84-4.92 (m, 1 H), 3.63-3.75 (m, 0.7 H), 3.33 (td, 0.3 H), 2.85-3.17 (m, 1 H), 2.76 (br dd, 1 H)	497.1 [M+H]+	99.4%
1658	(CD3OD) δ 8.30-8.40 (m, 1 H), 7.97-8.05 (m, 1 H), 7.71 (s, 1 H), 7.57 (s, 0.3 H), 7.19-7.25 (m, 0.2 H), 6.70-7.07 (m, 4.5 H), 4.94-5.17 (m, 1 H), 3.90 (s, 3 H), 3.72-3.83 (m, 0.7 H), 3.35-3.46 (m, 0.3 H), 2.96-3.26 (m, 1 H), 2.80-2.91 (m, 1 H), 2.63-2.73 (m, 3 H)	496.2 [M+H]+	98.9%
1659	(CD3OD) δ 8.28-8.41 (m, 1 H), 7.96-8.06 (m, 1 H), 7.71 (s, 1 H), 7.57 (s, 0.3 H), 7.17-7.27 (m. 0.2 H), 6.68-7.09 (m, 4.5 H), 4.94-5.16 (m, 1 H), 3.90 (s, 3 H), 3.71-3.83 (m, 0.7 H), 3.36-3.47 (m, 0.3 H), 2.95-3.26 (m, 1 H), 2.78-2.92 (m, 1 H), 2.62-2.75 (m, 3 H)	496.2 [M+H]+	99.4%
1660	(CD3OD) δ 8.89-9.00 (m, 1 H), 8.29-8.43 (m, 2 H), 7.49-7.87 (m, 2.3 H), 7.18-7.30 (m, 0.2 H). 6.66-7.09 (m, 4.5 H), 4.95-5.15 (m, 1 H), 3.73-3.86 (m, 0.7 H), 3.42 (td, 0.3 H), 2.95-3.27 (m, 1 H), 2.87 (br dd, 1 H)	518.1 [M+H]+	100%
1661	(CD3OD) δ 8.77-8.85 (m, 1 H), 8.17-8.28 (m, 2 H), 7.37-7.73 (m, 2.3 H), 7.07-7.14 (m, 0.2 H), 6.55-6.96 (m, 4.5 H), 4.81-5.03 (m, 1 H), 3.61-3.72 (m, 0.7 H), 3.30 (td, 0.3 H), 2.83-3.14 (m, 1 H), 2.74 (br d, 1 H)	518.2 [M+H]+	100%
1662	(CD3OD) δ 8.21-8.52 (m, 2 H), 7.84 (s, 0.3 H), 7.66-7.76 (m, 1.5 H), 7.48-7.59 (m, 0.5 H), 7.18-7.29 (m, 1.2 H), 6.94-7.08 (m, 2.2 H), 6.81-6.91 (m, 1.3 H), 6.70-6.79 (m, 1 H), 5.06 (dd, 0.8 H), 4.96 (br s, 0.2 H), 3.74-3.87 (m, 0.7 H), 3.43 (td, 0.3 H), 2.95-3.28 (m, 1 H), 2.87 (br d, 1 H)	518.1 [M+H]+	100%
1663	(CD3OD) δ 8.27-8.48 (m, 2 H), 7.84 (s, 0.3 H), 7.71 (d, 1.4 H), 7.49-7.63 (m. 0.6 H), 7.19-7.28 (m, 1.2 H), 6.93-7.08 (m, 2.1 H). 6.80-6.91 (m, 1.3 H), 6.70-6.79 (m, 1 H), 5.06 (dd, 0.7 H), 4.96 (br s, 0.3 H), 3.74-3.88 (m, 0.7 H), 3.42 (br t, 0.3 H), 2.97-3.27 (m, 1 H), 2.87 (br d, 1 H)	518.2 [M+H]+	99.4%
1664	(CD3OD) δ 8.30 (d, 3 H), 7.53 (s, 1 H), 7.01-7.20 (m, 2 H), 6.69 (t, 1 H), 6.47-6.61 (m, 2 H), 4.95 (br dd, 1 H), 3.35 (td, 1 H), 2.70-2.87 (m, 1 H), 2.59 (br dd, 1 H)	352.1 [M+H]+	99.0%
1665	(CD3OD) δ 8.27-8.49 (m, 3 H), 7.64 (s, 1 H), 7.11-7.34 (m, 2 H), 6.81 (t, 1 H), 6.58-6.71 (m, 2 H), 5.06 (br dd, 1 H), 3.37-3.53 (m, 1 H), 2.81-2.99 (m, 1 H), 2.70 (br dd, 1 H)	352.1 [M+H]+	98.5%
1666	(CD3OD) δ 8.79 (br d, 1 H), 8.22-8.66 (m, 2 H), 7.89 (d, 1 H), 7.63-7.72 (m, 2 H), 7.35 (dd, 1 H), 6.62-7.06 (m, 3 H), 4.61-4.72 (m, 1 H), 3.35-3.88 (m, 1 H), 3.05-3.14 (m, 1 H), 2.79 (br dd, 1 H), 2.41 (s, 3 H)	466.2 [M+H]+	98.8%
1667	(CD3OD) δ 8.78 (br d, 1 H), 8.21-8.67 (m, 2 H), 7.89 (d, 1 H), 7.63-7.72 (m, 2 H), 7.34 (dd, 1 H), 6.60-7.09 (m, 3 H), 4.61-4.72 (m, 1 H), 3.36-3.85 (m, 1 H), 3.05-3.14 (m, 1 H), 2.79 (dd, 1 H), 2.40 (s, 3 H)	466.1 [M+H]+	98.5%
1668	(CD3OD) δ 8.32-8.61 (m, 3 H), 7.89 (d, 1 H), 7.67 (s, 1 H), 7.32-7.35 (m, 1 H), 7.00 (d, 1 H), 6.49-6.83 (m, 3 H), 4.61-4.74 (m, 1 H), 3.40-3.75 (m, 1 H), 3.03-3.12 (m, 1 H), 2.78 (br dd, 1 H), 2.45 (s, 3 H), 2.40 (s, 3 H)	412.2 [M+H]+	98.6%
1669	(CD3OD) δ 8.33-8.68 (m, 3 H), 7.90 (d, 1 H), 7.67 (s, 1 H), 7.34 (d, 1 H), 7.01 (d, 1 H), 6.43-6.89 (m, 3 H). 4.61-4.75 (m, 1 H). 3.35-3.79 (m, 1 H), 3.03-3.12 (m, 1 H), 2.78 (br dd, 1 H), 2.46 (s, 3 H), 2.40 (s, 3 H)	412.2 [M+H]+	96.8%
1670	(CD3OD) δ 8.20-8.65 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.33 (d, 1 H), 6.61-7.01 (m, 4 H), 4.63 (br dd, 1 H), 3.44-3.80 (m, 1 H), 3.04-3.15 (m, 1 H), 2.78 (br dd, 1 H), 2.40 (s, 3 H)	416.2 [M+H]+	98.5%
1671	(CD3OD) δ 8.20-8.69 (m, 3 H), 7.89 (d, 1 H), 7.62-7.73 (m, 1 H), 7.34 (dd, 1 H), 6.60-7.03 (m, 4 H), 4.56-4.72 (m, 1 H), 3.37-3.80 (m, 1 H), 3.04-3.15 (m, 1 H), 2.79 (br dd, 1 H), 2.40 (s, 3 H)	416.2 [M+H]+	99.6%
1672	(CD3OD) δ 8.43 (br s, 3 H), 7.87 (br d, 1 H), 7.66 (s, 1 H), 7.16-7.39 (m, 1 H), 6.49-7.03 (m, 4 H), 4.62-4.69 (m, 1 H), 3.40-3.96 (m, 1 H), 2.96-3.18 (m, 1 H), 2.77 (br d. 1 H), 1.89-2.14 (m, 1 H), 0.90-1.12 (m, 2 H), 0.61-0.83 (m, 2 H)	442.2 [M+H]+	96.1%
1673	(CD3OD) δ 8.43 (s, 3 H), 7.87 (d, 1 H), 7.66 (s, 1 H), 7.21 (dd, 1 H), 6.41-7.08 (m, 4 H), 4.62-4.70 (m, 1 H), 3.42-3.97 (m, 1 H), 2.92-3.16 (m, 1 H), 2.77 (br d, 1 H), 1.83-2.18 (m, 1 H), 0.94-1.10 (m, 2 H), 0.67-0.88 (m, 2 H)	442.2 [M+H]+	99.5%
1674	(DMSO-d6) δ 12.04 (br s, 1 H), 9.01 (br s, 1 H), 8.17-8.66 (m, 2 H), 7.52-7.87 (m, 3 H), 6.47-7.35 (m, 4 H), 4.33-4.66 (m, 1 H), 3.84 (s, 3 H), 3.16-3.32 (m, 1 H), 2.61-3.08 (m, 2 H)	482.1 [M+H]+	100%
1675	(DMSO-d6) δ 12.04 (br s, 1 H), 9.01 (br s, 1 H), 8.24-8.62 (m, 2 H), 7.52-8.00 (m, 3 H), 6.34-7.35 (m, 4 H), 4.40-4.63 (m, 1 H), 3.84 (s, 3 H), 3.31-3.33 (m, 1 H), 2.57-3.07 (m, 2 H)	482.2 [M+H]+	100%
1676	(DMSO-d6) δ 11.93-12.14 (m, 1 H), 8.88 (br s, 1 H), 8.51 (d, 2 H), 7.85 (d, 1 H), 7.39-7.61 (m. 2 H), 7.12-7.31 (m, 2 H), 6.97 (br s, 1 H), 6.49-6.79 (m, 2 H), 4.38-4.63 (m, 1 H), 3.85 (s, 4 H), 2.65-3.06 (m, 2 H)	464.2 [M+H]+	99.0%
1677	(DMSO-d6) δ 11.89-12.99 (m, 1 H), 8.88 (br s, 1 H), 8.27-8.56 (m, 2 H), 7.62-7.91 (m, 2 H), 7.38-7.57 (m, 1 H), 7.09-7.34 (m, 2 H), 6.98 (br t, 1 H), 6.70 (br s, 2 H), 4.30-4.67 (m, 1 H), 3.85 (s, 4 H), 2.64-3.05 (m, 2 H)	464.2 [M+H]+	99.0%
1678	(CD3OD) δ 8.28-8.94 (m. 2 H), 7.95 (t, 1 H), 7.62-7.86 (m, 2 H), 7.35-7.60 (m, 0.4 H), 7.10-7.34 (m, 1 H), 6.71-7.09 (m, 2.6 H), 5.01 (br dd, 1 H), 3.73-3.90 (m, 0.6 H), 3.42-3.49 (m, 0.4 H), 2.98-3.29 (m, 1 H), 2.88 (br d, 1 H)	515.1 [M+H]+	100%
1679	(CD3OD) δ 8.18-8.76 (m, 2 H), 7.75-7.93 (m, 1 H), 7.50-7.74 (m, 2 H), 7.34 (br s, 0.4 H), 7.01-7.22 (m, 1 H), 6.51-7.00 (m, 2.60 H), 4.89 (br dd, 1 H), 3.59-3.81 (m, 0.6 H), 3.30-3.36 (m, 0.4 H), 2.86-3.17 (m, 1 H), 2.67-2.83 (m, 1 H)	515.1 [M+H]+	96.1%
1680	(CD3OD) δ 9.48 (d, 1 H), 8.70-9.09 (m, 2 H), 8.35-8.63 (m, 1 H), 7.73 (s, 1 H), 7.51 (s, 0.4 H), 7.14-7.34 (m, 1 H), 6.76-7.02 (m, 2.6 H), 5.06 (br dd, 1 H), 3.72-3.92 (m, 0.6 H), 3.42-3.50 (m, 0.4 H), 2.98-3.30 (m, 1 H), 2.77-2.95 (m, 1 H)	498.1 [M+H]+	100%
1681	(CD3OD) δ 9.09-9.84 (m, 1 H), 8.72-9.06 (m, 2 H), 8.29-8.67 (m, 1 H), 7.72 (s, 1 H), 7.51 (br s, 0.4 H), 7.11-7.37 (m, 1 H), 6.58-7.09 (m, 2.6 H), 5.06 (br dd, 1 H), 3.77-3.87 (m, 0.6 H), 3.45 (br dd, 0.4 H), 3.22 (br d, 1 H), 2.88 (br d, 1 H)	498.1 [M+H]+	99.6%
1682	(CD3OD) δ 8.35-8.54 (m, 2 H), 8.06-8.15 (m, 1 H), 7.73 (s, 1 H), 7.59 (s, 0.3 H), 7.12-7.28 (m, 1 H), 6.73-7.03 (m, 2.7 H), 5.12 (br dd, 1 H), 4.02 (s, 3 H), 3.44-3.83 (m, 1 H), 2.83-3.25 (m, 2 H)	500.1 [M+H]+	100%
1683	(CD3OD) δ 8.27-8.40 (m, 2 H), 7.96-8.02 (m, 1 H), 7.62 (s, 1 H), 7.47 (s, 0.3 H), 7.05-7.13 (m, 1 H), 6.62-6.86 (m, 2.7 H), 5.00 (br dd, 1 H), 3.90 (s, 3 H), 3.32-3.72 (m, 1 H), 2.70-3.12 (m, 2 H)	500.2 [M+H]+	99.7%
1684	(CD3OD) δ 8.43-8.53 (m, 1 H), 7.96-8.03 (m, 1 H), 7.71-7.79 (m, 1 H), 7.59 (s, 0.3 H). 7.17-7.25 (m, 1 H), 6.76-6.99 (m, 2.7 H), 5.13 (br dd, 1 H), 3.90 (s, 3 H), 3.43-3.81 (m, 1 H), 2.84-3.24 (m, 2 H), 2.63-2.71 (m, 3 H)	514.2 [M+H]+	99.8%
1685	(CD3OD) δ 8.32-8.40 (m, 1 H), 7.85-7.93 (m, 1 H), 7.61 (s, 1 H), 7.46 (s, 0.3 H), 7.06-7.13 (m, 1 H), 6.63-6.86 (m, 2.7 H), 5.01 (br dd, 1 H), 3.75-3.83 (m, 3 H), 3.32-3.68 (m, 1 H), 2.74-3.13 (m, 2 H), 2.52-2.61 (m, 3 H)	514.2 [M+H]+	99.2%
1686	(CD3OD) δ 8.28-8.41 (m, 1 H), 7.71 (br s, 1 H), 7.01-7.48 (m, 1 H), 6.81-7.01 (m, 3 H), 6.61-6.78 (m, 1 H), 4.93-5.03 (m, 1 H), 3.69-3.79 (m, 0.6 H), 3.36-3.45 (m, 0.4 H), 2.93-3.22 (m, 1 H), 2.84 (br dd, 1 H), 1.43-1.58 (m, 9 H)	458.2 [M+H]+	100%
1687	(CD3OD) δ 8.28-8.41 (m, 1 H), 7.71 (s, 1 H), 7.01-7.46 (m, 1 H), 6.80-7.01 (m, 3 H), 6.64-6.78 (m, 1 H), 4.92-5.03 (m, 1 H), 3.74 (ddd, 0.6 H), 3.40 (td, 0.4 H), 2.93-3.23 (m, 1 H), 2.84 (dd, 1 H), 1.41-1.58 (m, 9 H)	458.2 [M+H]+	99.5%
1688	(CD3OD) δ 8.76-8.81 (m, 1 H), 8.28-8.41 (m, 2 H), 8.10 (td, 1 H), 7.64-7.74 (m, 2 H), 7.04-7.54 (m, 1 H), 6.72-7.04 (m, 4 H), 4.94-5.07 (m, 1 H), 3.81 (ddd, 0.7 H), 3.45 (td, 0.3 H), 2.96-3.29 (m, 1 H), 2.87 (br d, 1 H)	479.1 [M+H]+	98.7%
1689	(CD3OD) δ 8.63-8.71 (m, 1 H), 8.16-8.29 (m, 2 H), 7.98 (td, 1 H), 7.51-7.65 (m, 2 H), 6.92-7.43 (m, 1 H), 6.61-6.92 (m, 4 H), 4.81-4.95 (m, 1 H), 3.69 (ddd, 0.7 H), 3.33 (td, 0.3 H), 2.86-3.16 (m, 1 H), 2.66-2.80 (m, 1 H)	479.1 [M+H]+	98.4%
1690	(DMSO-d6) δ 12.00 (br s, 1 H), 8.68 (s, 2 H), 7.91 (d, 1 H), 7.34-7.65 (m, 3 H), 6.24-7.25 (m, 4 H), 4.33-4.68 (m, 1 H), 3.38-4.08 (m, 3 H), 2.84-3.05 (m, 1 H), 2.69 (br s, 4 H), 2.17 (s, 6 H)	455.2 [M+H]+	100%
1691	(DMSO-d6) δ 12.00 (br s, 1 H), 8.68 (s, 2 H), 7.91 (br d, 1 H), 7.31-7.61 (m, 3 H), 6.43-7.23 (m, 4 H), 4.31-4.65 (m, 1 H), 3.44 (s, 3 H), 2.94 (br s, 1 H), 2.69 (br s, 4 H), 2.17 (s, 6 H)	455.2 [M+H]+	100%
1692	(CD3OD) δ 8.54 (br d, 1 H), 8.29 (d, 2 H), 7.41-7.60 (m, 2 H), 7.08 (s, 1 H), 6.74-6.92 (m, 1 H), 6.38-6.66 (m, 2 H), 4.96 (br dd, 1 H), 3.27-3.48 (m, 1 H), 2.70-2.88 (m, 1 H), 2.59 (br dd, 1 H)	386.1 [M+H]+	100%
1693	(CD3OD) δ 8.54 (br d, 1 H), 8.29 (d, 2 H), 7.40-7.58 (m, 2 H), 7.09 (s, 1 H), 6.82 (br t, 1 H), 6.44-6.62 (m, 2 H), 4.96 (br dd, 1 H), 3.25-3.44 (m, 1 H), 2.70-2.91 (m, 1 H), 2.59 (br dd, 1 H)	386.1 [M+H]+	97.0%
1694	(CD3OD) δ 8.42 (s, 1 H), 8.37 (br d, 1 H), 7.86 (d, 1 H), 7.65 (s, 1 H), 7.19 (d, 1 H), 6.99 (br d, 1 H), 6.79 (br t, 1 H), 6.53 (br s, 1 H), 4.60 (br s, 1 H), 3.37-3.91 (m, 1 H), 2.98-3.11 (m, 1 H), 2.70-2.89 (m, 1 H), 2.44 (s, 3 H), 1.93-2.06 (m, 1 H), 0.95-1.06 (m, 2 H), 0.70-0.82 (m, 2 H)	438.2 [M+H]+	100%
1695	(CD3OD) δ 8.42 (s, 1 H), 8.37 (br s, 1 H), 7.87 (d, 1 H), 7.65 (s, 1 H), 7.20 (dd, 1 H), 6.99 (d, 1 H), 6.79 (t, 1 H), 6.53 (br s, 1 H), 4.60 (s, 1 H), 3.48 (s, 1 H), 2.97-3.13 (m, 1 H), 2.63-2.85 (m, 1 H), 2.44 (s, 3 H), 1.89-2.12 (m, 1 H), 0.97-1.14 (m, 2 H), 0.73-0.86 (m, 2 H)	438.2 [M+H]+	98.7%
1696	(DMSO-d6) δ 12.02 (br s, 1 H), 8.19-8.77 (m, 3 H), 7.85 (dd, 1 H), 7.56 (d, 1 H), 7.04-7.33 (m, 2 H), 6.50-6.95 (m, 3 H), 4.26-4.74 (m, 1 H), 3.84 (d, 4 H), 2.61-3.08 (m, 2 H)	432.2 [M+H]+	100%
1697	(DMSO-d6) δ 11.94-12.13 (m, 1 H), 8.20-8.75 (m, 3 H), 7.85 (d, 1 H), 7.57 (s, 1 H), 7.06-7.31 (m, 2 H), 6.47-6.91 (m, 3 H), 4.29-4.72 (m, 1 H), 3.84 (s, 3 H), 3.25-3.33 (m, 1 H), 2.62-3.05 (m, 2 H)	432.2 [M+H]+	100%
1698	(DMSO-d6) δ 12.02 (br s, 1 H), 8.74 (br d, 1 H), 8.51 (s, 2 H), 7.85 (d, 1 H), 7.18-7.65 (m, 3 H), 6.30-7.02 (m, 3 H), 4.36-4.68 (m, 1 H), 3.85 (s, 3 H), 3.30 (br s, 1 H), 2.59-3.06 (m, 2 H)	448.1 [M+H]+	97.5%
1699	(DMSO-d6) δ 12.02 (br s, 1 H), 8.73 (br s, 1 H), 8.51 (s, 2 H), 7.85 (d, 1 H), 7.18-7.65 (m, 3 H), 6.40-6.95 (m, 3 H), 4.30-4.67 (m, 1 H), 3.85 (s, 3 H), 3.29-3.32 (m, 1 H), 2.57-3.07 (m, 2 H)	448.1 [M+H]+	93.6%
1700	(CD3OD) δ 8.34-8.55 (m, 2 H), 8.15 (dd, 1 H), 7.79 (d, 1 H), 7.63 (s, 1 H), 7.56 (d, 1 H), 7.12-7.20 (m, 1 H), 6.75-6.91 (m, 2 H), 6.52 (s, 1 H), 4.69 (dd, 1 H), 3.62 (ddd, 1 H), 2.90-3.06 (m, 1 H), 2.75 (dd, 1 H)	318.2 [M+H]+	100%
1701	(CD3OD) δ 8.25-8.53 (m, 2 H), 8.04 (dd, 1 H), 7.67 (d, 1 H), 7.51 (s, 1 H), 7.38-7.47 (m, 1 H), 7.06 (s, 1 H), 6.70 (s, 2 H), 6.40 (s, 1 H), 4.57 (dd, 1 H), 3.50 (ddd, 1 H), 2.78-2.93 (m, 1 H), 2.63 (dd, 1 H)	318.2 [M+H]+	100%
1702	(CD3OD) δ 8.39-8.84 (m, 1 H), 7.67-7.93 (m, 2 H), 7.53 (s, 0.4 H), 7.14-7.37 (m, 1 H), 6.56-7.14 (m, 3.6 H), 5.06 (br dd, 1 H), 4.04 (s, 3 H), 3.79 (ddd, 0.6 H), 3.39-3.46 (m, 0.4 H), 3.21 (br t, 1 H), 2.75-2.94 (m, 1 H)	500.1 [M+H]+	100%
1703	(CD3OD) δ 8.15-9.00 (m, 1 H), 7.68-7.98 (m, 2 H), 7.53 (br s, 0.4 H), 7.11-7.31 (m, 1 H), 6.59-7.09 (m, 3.6 H), 5.06 (br dd, 1 H), 4.05 (s, 3 H), 3.79 (br dd, 0.6 H), 3.42 (br s, 0.4 H), 3.21 (br s, 1 H), 2.86 (br d, 1 H)	500.1 [M+H]+	99.7%
1704	(CD3OD) δ 8.22-8.82 (m, 2 H), 7.38-8.13 (m, 2.4 H), 7.11-7.37 (m, 2 H), 6.65-7.09 (m, 2.6 H), 5.07 (dd, 1 H), 3.76-3.84 (m, 0.6 H), 3.39-3.47 (m, 0.4 H), 3.22 (br s, 1 H), 2.78-2.94 (m, 1 H)	536.1 [M+H]+	100%
1705	(CD3OD) δ 8.18-8.80 (m, 2 H), 7.41-8.03 (m, 2.4 H), 7.11-7.36 (m, 2 H), 6.65-7.07 (m, 2.6 H), 5.07 (br dd, 1 H), 3.76-3.85 (m, 0.6 H), 3.43 (td, 0.4 H), 2.96-3.29 (m, 1 H), 2.87 (br d, 1 H)	536.1 [M+H]+	100%
1706	(CD3OD) δ 8.38-8.57 (m, 2 H), 7.72 (s, 1 H), 7.41-7.59 (m, 0.3 H), 7.12-7.33 (m, 2 H), 6.85-7.02 (m, 1.7 H), 6.73-6.83 (m, 1 H), 4.94-5.13 (m, 1 H), 3.73-3.88 (m, 0.6 H), 3.44 (td, 0.4 H), 2.96-3.25 (m, 1 H), 2.79-2.92 (m, 1 H)	554.2 [M+H]+	100%
1707	(CD3OD) δ 8.42-8.56 (m, 2 H), 7.72 (s, 1 H), 7.53 (s, 0.3 H), 7.16-7.34 (m, 2 H), 6.86-7.03 (m, 1.7 H), 6.73-6.85 (m, 1 H), 4.95-5.12 (m, 1 H), 3.75-3.86 (m, 0.6 H), 3.44 (td, 0.4 H), 2.97-3.27 (m, 1 H), 2.79-2.93 (m, 1 H)	554.2 [M+H]+	100%
1708	(CD3OD) δ 8.51 (d, 1 H), 8.25-8.42 (m, 1 H), 7.72 (s, 1 H), 7.40-7.59 (m, 0.3 H), 7.29 (d, 1 H), 7.17-7.25 (m, 0.2 H), 6.93-7.09 (m, 2.2 H), 6.80-6.91 (m, 1.3 H), 6.70-6.80 (m, 1 H), 4.95-5.12 (m, 1 H), 3.74-3.87 (m, 0.6 H), 3.43 (td, 0.4 H), 2.95-3.27 (m, 1 H), 2.87 (br d, 1 H)	536.1 [M+H]+	100%
1709	(CD3OD) δ 8.39 (d, 1 H), 8.16-8.30 (m, 1 H), 7.60 (s, 1 H), 7.30-7.44 (m, 0.3 H), 7.17 (d, 1 H), 7.06-7.13 (m, 0.2 H), 6.80-6.97 (m, 2.2 H), 6.68-6.79 (m, 1.3 H), 6.57-6.68 (m, 1 H), 4.94 (br dd, 1 H), 3.63-3.73 (m, 0.6 H), 3.31 (td, 0.4 H), 2.85-3.15 (m, 1 H), 2.75 (br d, 1 H)	536.1 [M+H]+	99.6%
1710	(CD3OD) δ 8.30 (d, 1 H), 7.68 (s, 1 H), 6.92-7.19 (m, 1.7 H), 6.67-6.91 (m, 1.3 H), 6.58 (s, 1 H), 6.39 (s, 1 H), 4.32 (dd, 1 H), 3.62-3.89 (m, 1 H), 2.98-3.16 (m, 1 H), 2.83 (br dd, 1 H), 2.44 (s, 3 H)	372.1 [M+H]+	100%
1711	(CD3OD) δ 8.31 (d, 1 H), 7.68 (s, 1 H), 6.94-7.22 (m, 1.7 H), 6.70-6.92 (m, 1.3 H), 6.58 (s, 1 H), 6.39 (br s, 1 H), 4.32 (dd, 1 H), 3.78 (ddd, 1 H), 2.98-3.18 (m, 1 H), 2.84 (br dd, 1 H), 2.45 (s, 3 H)	372.2 [M+H]+	99.7%
1712	(CD3OD) δ 8.29-8.96 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.45 (br d, 1 H), 7.33 (d, 1 H), 6.63-7.16 (m, 4 H), 4.58-4.74 (m, 1 H), 3.39-3.82 (m, 1 H), 2.75-3.11 (m, 2 H), 2.40 (s, 3 H)	448.2 [M+H]+	100%
1713	(CD3OD) δ 8.25-8.92 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.45 (br d, 1 H), 7.34 (dd, 1 H), 6.60-7.15 (m, 4 H), 4.59-4.74 (m, 1 H), 3.35-3.79 (m, 1 H), 2.76-3.15 (m, 2 H), 2.40 (s, 3 H)	448.1 [M+H]+	99.5%
1714	(CD3OD) δ 8.28-8.72 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.28-7.35 (m, 2 H), 6.47-6.93 (m, 3 H), 4.62 (br s, 1 H), 3.38-3.84 (m, 1 H), 2.76-3.13 (m, 2 H), 2.39 (s, 3 H)	432.1 [M+H]+	100%
1715	(CD3OD) δ 8.24-8.77 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.28-7.36 (m, 2 H), 6.50-6.94 (m, 3 H), 4.58-4.72 (m, 1 H), 3.37 (br s, 1 H), 2.75-3.12 (m, 2 H), 2.39 (s, 3 H)	432.1 [M+H]+	99.7%
1716	(CD3OD) δ 8.77 (br d, 1 H), 8.43 (s, 2 H), 7.86 (d, 1 H), 7.57-7.73 (m, 2 H), 7.21 (d, 1 H), 7.00 (br t, 1 H), 6.49-6.90 (m, 2 H), 4.57-4.68 (m, 1.6 H), 3.40-3.72 (m, 0.4 H), 2.98-3.15 (m, 1 H), 2.77 (br dd, 1 H), 1.91-2.12 (m, 1 H), 0.96-1.10 (m, 2 H), 0.67-0.85 (m, 2 H)	492.2 [M+H]+	98.0%
1717	(CD3OD) δ 8.77 (br d, 1 H), 8.42 (s, 2 H), 7.86 (d, 1 H), 7.52-7.73 (m, 2 H), 7.21 (dd, 1 H), 7.00 (t, 1 H), 6.47-6.92 (m, 2 H), 4.59 (s, 1.5 H), 3.40-3.69 (m, 0.5 H), 2.97-3.17 (m, 1 H), 2.77 (br dd, 1 H), 1.92-2.09 (m, 1 H), 0.96-1.09 (m, 2 H), 0.71-0.83 (m, 2 H)	492.2 [M+H]+	98.1%
1718	(DMSO-d6) δ 11.99 (br s, 1 H), 8.51 (d, 2 H), 7.86 (d, 1 H), 7.45-7.62 (m, 2 H), 7.08-7.29 (m, 2 H), 6.24-6.94 (m, 3 H), 4.35-4.71 (m, 1 H), 3.42-4.33 (m, 4 H), 2.86-3.01 (m, 1 H), 2.56-2.78 (m, 4 H)	428.2 [M+H]+	99.9%
1719	(DMSO-d6) δ 11.99 (br s, 1 H), 8.51 (d, 2 H), 7.87 (d, 1 H), 7.55 (br s, 2 H), 7.10-7.32 (m, 2 H), 6.33-6.92 (m, 3 H), 4.51 (br d, 1 H), 3.53-4.28 (m, 4 H), 2.85-3.00 (m, 1 H), 2.69 (br s, 4 H)	428.2 [M+H]+	99.8%
1720	(DMSO-d6) δ 12.02 (br s, 1 H), 8.08-8.84 (m, 2 H), 7.86 (br d, 1 H), 7.46-7.66 (m, 2 H), 7.24 (br d, 2 H), 6.34-7.02 (m, 3 H), 4.28-4.74 (m, 1 H), 3.54-4.26 (m, 4 H), 2.89-3.05 (m, 1 H), 2.69 (br d, 1 H)	432.2 [M+H]+	99.7%
1721	(DMSO-d6) δ 11.84-12.18 (m, 1 H), 8.15-8.69 (m, 2 H), 7.86 (d, 1 H), 7.44-7.65 (m, 2 H), 7.15-7.38 (m, 2 H), 6.27-6.95 (m, 3 H), 4.49 (br d, 1 H), 3.85 (s, 4 H), 2.86-3.05 (m, 1 H), 2.63-2.76 (m, 1 H)	432.1 [M+H]+	98.5%
1722	(CD3OD) δ 8.32-8.38 (m, 1 H), 8.02-8.13 (m, 1 H), 7.84 (s, 0.3 H), 7.71 (d, 1.5 H), 7.53 (d, 0.5 H), 7.21-7.27 (m, 1 H), 6.97 (s, 0.7 H), 6.75-6.84 (m, 1 H), 6.56-6.71 (m, 2 H), 4.97-5.08 (m, 1 H), 3.94-4.01 (m, 3 H), 3.74-3.84 (m, 0.5 H), 3.39-3.53 (m, 0.5 H), 3.13-3.26 (m, 0.8 H), 2.95-3.08 (m, 0.2 H), 2.81-2.91 (m, 1 H)	482.1 [M+H]+	99.6%
1723	(CD3OD) δ 8.19-8.27 (m, 1 H), 7.89-8.03 (m, 1 H), 7.72 (s, 0.3 H), 7.54-7.63 (m, 1.5 H), 7.37-7.45 (m, 0.5 H), 7.08-7.14 (m, 1 H), 6.85 (s, 0.7 H), 6.63-6.72 (m, 1 H), 6.43-6.59 (m, 2 H), 4.84-4.94 (m, 1 H), 3.81-3.89 (m, 3 H), 3.61-3.73 (m, 0.6 H), 3.27-3.36 (m, 0.4 H), 3.02-3.15 (m, 0.7 H), 2.84-2.96 (m, 0.3 H), 2.69-2.81 (m, 1 H)	482.2 [M+H]+	98.7%
1724	(CD3OD) δ 8.32-8.65 (m, 1 H), 7.70 (s, 1 H), 7.46 (br s, 0.3 H), 7.22 (br d, 1 H), 6.86-6.97 (m, 1.7 H), 6.69-6.79 (m, 1 H), 4.94-5.07 (m, 1 H), 3.74 (ddd, 0.6 H), 3.36-3.47 (m, 0.4 H), 2.83 (br d, 2H), 2.29-2.38 (m, 1 H), 1.20-1.33 (m, 4 H)	460.2 [M+H]+	100%
1725	(CD3OD) δ 8.38-8.56 (m, 1 H), 7.70 (s, 1 H), 7.47 (s, 0.3 H), 7.16-7.27 (m, 1 H), 6.83-6.99 (m, 1.7 H), 6.66-6.79 (m, 1 H), 5.02 (br dd, 1 H), 3.74 (ddd, 0.6 H), 3.35-3.45 (m, 0.4 H), 2.80-3.21 (m, 2 H), 2.26-2.39 (m, 1 H), 1.19-1.33 (m, 4 H)	460.2 [M+H]+	100%
1726	(CD3OD) δ 8.39-8.57 (m, 1 H), 7.71 (s, 1 H), 7.41 (s, 0.3 H), 7.17-7.25 (m, 1 H), 6.88-6.98 (m, 1.7 H), 6.70-6.82 (m, 1 H), 4.99 (br dd, 1 H), 3.77 (ddd, 0.6 H), 3.40 (br d, 0.4 H), 2.85 (br dd, 2 H), 1.83-1.97 (m, 6 H)	480.1 [M+H]+	100%
1727	(CD3OD) δ 8.39-8.56 (m, 1 H), 7.71 (s, 1 H), 7.41 (s, 0.3 H), 7.17-7.25 (m, 1 H), 6.88-6.98 (m, 1.7 H), 6.70-6.80 (m, 1 H), 4.94-5.03 (m, 1 H), 3.77 (ddd, 0.6 H), 3.40 (td, 0.4 H), 2.81-3.21 (m, 2 H), 1.78-2.01 (m, 6 H)	480.2 [M+H]+	99.4%
1728	(CD3OD) δ 8.17-8.54 (m, 1 H), 7.72 (br s, 1 H), 7.42 (br s, 0.3 H), 7.18-7.25 (m, 0.2 H), 6.91-7.10 (m, 2 H), 6.80-6.90 (m, 1.3 H), 6.56-6.79 (m, 1.2 H), 4.98 (br dd, 1 H), 3.68-3.83 (m, 0.7 H), 3.37-3.46 (m, 0.3 H), 3.09-3.23 (m, 0.8 H), 2.99 (br d, 0.2 H), 2.85 (br d, 1 H), 1.75-2.00 (m, 6 H)	462.1 [M+H]+	100%
1729	(CD3OD) δ 8.27-8.41 (m, 1 H), 7.71 (s, 1 H), 7.42 (s, 0.3 H), 7.18-7.26 (m, 0.2 H), 6.92-7.09 (m, 2.2 H), 6.82-6.90 (m, 1.3 H), 6.64-6.79 (m, 1 H), 4.98 (br dd, 1 H), 3.64-3.88 (m, 0.7 H), 3.38-3.44 (m, 0.3 H), 3.13-3.23 (m, 0.7 H), 2.94-3.06 (m, 0.3 H), 2.85 (dd, 1 H), 1.78-2.00 (m, 6 H)	462.2 [M+H]+	100%
1730	(CD3OD) δ 8.62 (br d, 3 H), 7.96 (d, 1 H), 7.67 (br s, 1 H), 7.31-7.51 (m, 2 H), 6.49-7.20 (m, 5 H), 4.94-5.29 (m, 1 H), 3.33-3.92 (m, 1 H), 2.97-3.14 (m, 1 H), 2.78 (br d, 1 H)	434.1 [M+H]+	99.5%
1731	(CD3OD) δ 8.62 (br d, 3 H), 7.96 (d, 1 H), 7.66 (s, 1 H), 7.36-7.51 (m, 2 H), 6.63-7.16 (m, 5 H), 4.93-5.21 (m, 1 H), 3.57 (br s, 1 H), 3.00-3.16 (m, 1 H), 2.77 (br dd, 1 H)	434.1 [M+H]+	99.8%
1732	(CD3OD) δ 8.59 (d, 1 H), 7.69 (s, 1 H), 7.44 (br d, 1 H), 7.12 (d, 0.5 H), 6.90-7.05 (m, 2 H), 6.85 (d, 0.5 H), 6.76 (s, 1 H), 6.41 (br s, 1 H), 4.34 (dd, 1 H), 3.77 (ddd, 1 H), 2.99-3.17 (m, 1 H), 2.84 (br dd, 1 H)	408.1 [M+H]+	97.2%
1733	(CD3OD) δ 8.59 (d, 1 H), 7.69 (s, 1 H), 7.44 (d, 1 H), 7.12 (d, 0.5 H), 6.90-7.04 (m, 2 H), 6.85 (d, 0.5 H), 6.76 (s, 1 H), 6.41 (s, 1 H), 4.35 (dd, 1 H), 3.77 (ddd, 1 H), 2.98-3.19 (m, 1 H), 284 (dd, 1 H)	408.1 [M+H]+	97.1%
1734	(CD3OD) δ 8.70 (d, 1 H), 7.54-7.84 (m, 2 H), 6.93-7.21 (m, 1.7 H), 6.69-6.90 (m, 1.3 H), 6.42 (s, 1 H), 4.36 (dd, 1 H), 3.78 (ddd, 1 H), 3.07 (br d, 1 H), 2.85 (dd, 1 H)	426.1 [M+H]+	98.6%
1735	(CD3OD) δ 8.58 (d, 1 H), 7.32-7.74 (m, 2 H), 6.81-7.05 (m, 1.7 H), 6.56-6.78 (m, 1.3 H), 6.30 (s, 1 H), 4.24 (dd, 1 H), 3.66 (ddd, 1 H), 2.96 (br s, 1 H), 2.73 (dd, 1 H)	426.1 [M+H]+	97.4%
1736	(CD3OD) δ 8.35 (d, 1 H), 7.69 (s, 1 H), 7.12 (s, 0.3 H), 6.78-7.03 (m, 2.7 H), 6.72 (s, 1 H), 6.39 (s, 1 H), 4.34 (dd, 1 H), 3.78 (ddd, 1 H), 2.98-3.18 (m, 1 H), 2.84 (dd, 1 H)	376.1 [M+H]+	98.9%
1737	(CD3OD) δ 8.35 (d, 1 H), 7.70 (s, 1 H), 7.12 (s, 0.3 H), 6.76-7.06 (m, 2.7 H), 6.72 (s, 1 H), 6.40 (s, 1 H), 4.34 (dd, 1 H), 3.78 (ddd, 1 H), 2.99-3.21 (m, 1 H), 2.84 (dd, 1 H)	376.1 [M+H]+	100%
1738	(CD3OD) δ 8.45 (d, 1 H), 7.69 (s, 1 H), 7.31 (d, 1 H), 7.12 (s, 0.3 H), 6.99 (s, 0.5 H), 6.81-6.91 (m, 1.2 H), 6.71 (s, 1 H), 6.39 (br s, 1 H), 4.34 (dd, 1 H), 3.78 (ddd, 1 H), 2.98-3.15 (m, 1 H), 2.84 (br dd, 1 H)	392.1 [M+H]+	98.2%
1739	(CD3OD) δ 8.45 (d, 1 H), 7.70 (s, 1 H), 7.30 (d, 1 H), 7.12 (s, 0.3 H), 6.99 (s, 0.5 H), 6.78-6.91 (m, 1.2 H), 6.71 (s, 1 H), 6.39 (s, 1 H), 4.34 (dd, 1 H), 3.78 (ddd, 1 H), 2.96-3.19 (m, 1 H), 2.84 (dd, 1 H)	392.1 [M+H]+	99.6%
1740	(CD3OD) 3 7.66 (s, 1 H), 7.45 (d, 1 H), 6.82-7.15 (m, 2 H), 6.70 (d, 1 H), 6.50 (s, 1 H), 6.38 (s, 1 H), 4.31 (dd, 1H), 3.78 (ddd, 1 H), 2.98-3.12 (m, 1 H), 2.82 (dd, 1 H), 2.62 (s, 3 H)	372.1 [M+H]+	98.9%
1741	(CD3OD) δ 7.66 (s, 1 H), 7.44 (br d, 1 H), 6.82-7.16 (m, 2 H), 6.68 (br d, 1 H), 6.50 (s, 1 H), 6.38 (s, 1 H), 4.30 (dd, 1 H), 3.72-3.84 (m, 1 H), 3.03 (br d, 1 H), 2.81 (br dd, 1 H), 2.61 (s, 3 H)	372.2 [M+H]+	98.5%
1742	(CD3OD) δ 8.30-8.76 (m, 3 H), 7.86 (d, 1 H), 7.66 (s, 1 H), 7.43 (br d, 1 H), 6.51-7.24 (m, 5 H), 4.62 (br d, 1 H), 3.39-3.70 (m, 1 H), 3.01-3.11 (m, 1 H), 2.77 (br dd. 1 H), 1.92-2.07 (m. 1 H), 0.97-1.07 (m, 2 H), 0.69-0.83 (m, 2 H)	474.2 [M+H]+	92.4%
1743	(CD3OD) δ 8.30-8.76 (m, 3 H), 7.86 (d, 1 H), 7.66 (s, 1 H), 7.43 (br d, 1 H), 6.48-7.24 (m, 5 H), 4.62 (br s, 1 H), 3.39-3.75 (m, 1 H), 2.98-3.14 (m, 1 H), 2.77 (br dd, 1 H), 1.93-2.08 (m, 1 H), 0.94-1.08 (m. 2 H), 0.70-0.82 (m, 2 H)	474.2 [M+H]+	93.8%
1744	(CD3OD) δ 8.62-9.24 (m, 1 H), 8.40 (s, 1 H), 7.88 (d, 1 H), 7.55-7.68 (m, 2 H), 7.13-7.24 (m, 2 H), 7.05 (d, 1 H), 6.45-6.94 (m, 2 H), 4.63 (br s, 1 H), 3.35-3.64 (m, 1 H), 2.98-3.11 (m. 1 H), 2.75 (dd, 1 H), 1.94-2.06 (m, 1 H), 0.97-1.07 (m, 2 H), 0.71-0.80 (m, 2H)	458.2 [ M+H]+	100%
1745	(CD3OD) δ 8.52-9.28 (m, 1 H), 8.41 (s, 1 H), 7.88 (d, 1 H), 7.56-7.68 (m, 2 H), 6.98-7.25 (m, 3 H), 6.49-6.92 (m, 2 H), 4.61-4.72 (m, 1 H), 3.36-3.68 (m, 1 H), 2.96-3.12 (m, 1 H), 2.75 (dd, 1 H), 1.94-2.06 (m, 1 H), 0.96-1.08 (m, 2 H), 0.73-0.83 (m, 2 H)	458.2 [M+H]+	99.0%
1746	(CD3OD) δ 8.77 (br d, 1 H), 8.35 (br s, 1 H), 7.92 (d, 1 H), 7.84 (d, 1 H), 7.57-7.71 (m, 2 H), 7.38 (dd, 1 H), 7.00 (t, 1 H), 6.59-6.92 (m. 2 H), 4.64 (br s, 1 H), 3.42-3.78 (m, 1 H), 3.02-3.16 (m, 1 H), 2.95 (s, 6 H), 2.71-2.83 (m, 1 H)	495.2 [M+H]+	100%
1747	(CD3OD) δ 8.78 (br s, 1 H), 8.37 (br s, 1 H), 7.92 (d, 1 H), 7.84 (d, 1 H), 7.55-7.72 (m, 2 H), 7.39 (dd, 1 H), 7.00 (br t, 1 H), 6.56-6.92 (m, 2 H), 4.65 (br s, 1 H), 3.56 (br s, 1 H), 3.03-3.18 (m, 1 H), 2.95 (s. 6 H), 2.77 (br d, 1 H)	495.2 [M+H]+	99.8%
1748	(CD3OD) δ 9.00 (s, 2 H), 8.15 (br d, 1 H), 7.99 (d, 1 H), 7.88 (d, 1 H), 7.61-7.69 (m, 2 H), 6.65-7.16 (m, 3 H), 6.58 (d, 2 H), 4.59 (br d, 1 H), 3.96 (s, 7 H), 3.07 (br d, 1 H), 2.72-2.83 (m, 1 H)	494.3 [M+H]+	98.4%
1749	(CD3OD) δ 8.95 (br d, 2 H), 8.13 (br s, 1 H), 7.96 (br d, 1 H), 7.73-7.90 (m, 1 H), 7.57-7.72 (m, 2 H), 6.61-7.20 (m, 3 H), 6.54 (br d, 2 H), 4.59 (br s, 1 H), 3.41-3.98 (m, 7 H), 2.92-3.18 (m, 1 H), 2.76 (br d, 1 H)	494.2 [M+H]+	99.2%
1750	(CD3OD) δ 8.37 (br d, 2 H), 7.92 (d, 1 H), 7.85 (d, 1 H), 7.65 (s, 1 H), 7.38 (dd, 1 H), 6.99 (d. 1 H), 6.38-6.91 (m, 3 H), 4.63-4.71 (m, 1 H), 3.58 (br s, 1 H), 3.00-3.16 (m, 1 H), 2.95 (s, 6 H), 2.76 (br d, 1 H), 2.44 (s, 3 H)	441.2 [M+H]+	100%
1751	(CD3OD) δ 8.37 (br d, 2 H), 7.91 (d, 1 H), 7.84 (d, 1 H), 7.65 (s, 1 H), 7.38 (dd, 1 H), 6.99 (d, 1 H), 6.43-6.91 (m, 3 H), 4.61-4.70 (m, 1 H), 3.56 (br s, 1 H), 3.00-3.14 (m, 1 H), 2.95 (s, 6 H), 2.76 (br d, 1 H), 2.44 (s, 3 H)	441.2 [M+H]+	100%
1752	(CD3OD) δ 8.64 (s, 2 H), 8.40 (d, 1 H), 7.44-7.72 (m, 2 H), 7.07-7.30 (m, 2 H), 6.80 (td, 1 H), 6.54 (s, 1 H), 5.15 (dd, 1 H), 3.42-3.60 (m, 1 H), 2.58-3.02 (m, 2 H)	386.1 [ M+H]	100%
1753	(CD3OD) δ 8.63 (s, 2 H), 8.39 (dd, 1 H), 7.63 (s, 1 H), 7.53 (d, 1 H), 7.23 (s, 1 H), 7.14 (ddd, 1 H), 6.80 (td, 1 H), 6.45-6.61 (m, 1 H), 5.14 (dd, 1 H), 3.50 (td, 1 H), 2.71-2.99 (m, 2 H)	386.2 [M+H]+	99.5%
1754	(CD3OD) δ 8.65 (s, 2 H), 8.26 (d, 1 H), 7.65 (s, 1 H), 7.24 (s, 1 H), 6.95 (d, 1 H), 6.74 (t, 1 H), 6.54 (s, 1 H), 5.16 (dd, 1 H), 3.52 (td, 1 H), 2.68-2.98 (m, 2 H), 2.41 (s, 3 H)	400.2 [M+H]+	100%
1755	(CD3OD) δ 8.65 (s, 2 H). 8.26 (d, 1 H), 7.64 (s, 1 H), 7.24 (s, 1 H), 6.95 (d, 1 H), 6.74 (t, 1 H), 6.54 (s, 1 H), 5.15 (dd, 1 H), 3.52 (td, 1 H), 2.67-3.00 (m, 2 H), 2.41 (s, 3 H)	400.2 [M+H]+	99.5%
1756	Data provided above
1757	Data provided above
1758	(CD3OD) δ 8.30-8.40 (m, 1 H), 7.59 (s, 1 H), 7.29 (s, 0.3 H), 7.05-7.13 (m, 1 H), 6.76-6.85 (m, 1.7 H), 6.56-6.68 (m, 1 H), 4.89 (br dd, 1 H), 3.63 (ddd, 0.6 H), 3.28 (td, 0.4 H), 2.69-3.08 (m, 2 H), 1.32-1.42 (m, 9 H)	476.2 [M+H]+	99.8%
1759	(CD3OD) δ 8.30-8.40 (m, 1 H), 7.59 (s, 1 H), 7.29 (s, 0.3 H), 7.05-7.12 (m, 1 H), 6.75-6.84 (m, 1.7 H), 6.57-6.69 (m, 1 H), 4.88 (br dd, 1 H), 3.58-3.67 (m, 0.6 1-1). 3.28 (td, 0.4 H), 2.70-3.08 (m, 2 H), 1.33-1.41 (m, 9 H)	476.1 [M+H]+	99.4%
1760	(CD3OD) δ 8.78 (d, 1 H), 8.42-8.53 (m, 1 H), 8.32 (d, 1 H), 8.09 (t, 1 H), 7.65-7.76 (m, 2 H), 7.51 (s, 0.3 H), 7.17-7.25 (m, 1 H), 6.86-7.00 (m, 1.7 H), 6.75-6.82 (m, 1 H), 4.94-5.09 (m, 1 H), 3.77-3.85 (m, 0.6 H), 3.45 (td, 0.4 H), 2.84-3.24 (m, 2 H)	497.1 [M+H]+	100%
1761	(CD3OD) δ 8.78 (d, 1 H), 8.42-8.56 (m, 1 H), 8.32 (d, 1 H), 8.09 (td, 1 H), 7.63-7.76 (m, 2 H), 7.51 (s, 0.3 H), 7.15-7.26 (m, 1 H), 6.86-7.01 (m, 1.7 H), 6.77-6.84 (m, 1 H), 4.94-5.09 (m, 1 H), 3.77-3.85 (m, 0.6 H), 3.40-3.49 (m, 0.4 H), 2.85-3.27 (m, 2 H)	497.1 [M+H]+	99.5%
1762	(CD3OD) δ 8.56 (br d, 1 H), 8.41 (d, 2 H), 7.64 (s, 1 H), 7.40 (br d, 1 H), 7.21 (s, 1 H), 6.81-7.13 (m, 2 H), 6.71 (s, 1 H), 6.66 (t, 1 H), 5.06 (dd, 1 H), 3.40-3.51 (m, 1 H), 2.84-2.97 (m, 1 H), 2.70 (br dd, 1 H)	368.1 [M+H]+	100%
1763	(CD3OD) δ 8.56 (d, 1 H), 8.41 (d, 2 H), 7.64 (s, 1 H), 7.40 (br d, 1 H), 7.21 (s, 1 H), 6.81-7.12 (m, 2 H), 6.71 (s, 1 H), 6.66 (t, 1 H), 5.06 (dd, 1 H), 3.40-3.52 (m, 1 H), 2.84-2.99 (m, 1 H), 2.70 (dd, 1 H)	368.2 [M+H]+	98.2%
1764	(CD3OD) δ 8.39 (d, 2 H), 7.82 (d, 1 H), 7.61 (s, 1 H), 7.09-7.34 (m, 3 H), 6.75 (s, 1 H), 6.64 (t, 1 H), 5.08 (dd, 1 H), 3.61 (td, 1 H), 2.83-2.97 (m, 1 H), 2.71 (dd, 1 H)	386.1 [M+H]+	99.3%
1765	(CD3OD) δ 8.39 (d, 2 H), 7.82 (d, 1 H), 7.61 (s, 1 H), 7.08-7.38 (m, 3 H), 6.75 (s, 1 H), 6.64 (t, 1 H), 5.08 (br dd, 1 H), 3.54-3.68 (m, 1 H), 2.83-2.97 (m, 1 H), 2.71 (br dd, 1 H)	386.1 [M+H]+	98.4%
1766	(CD3OD) δ 8.60 (d, 1 H), 7.70 (s, 1 H), 7.45 (br d, 1 H), 6.83-7.15 (m, 2 H), 6.76 (s, 1 H), 6.43 (s, 1 H), 4.36 (dd, 1 H), 3.73-3.84 (m, 1 H), 3.02-3.16 (m, 1 H), 2.85 (dd, 1 H)	426.1 [M+H]+	99.8%
1767	(CD3OD) δ 8.60 (br d, 1 H), 7.70 (s, 1 H), 7.45 (br d, 1 H), 6.83-7.15 (m, 2 H), 6.76 (s, 1 H), 6.43 (br s, 1 H), 4.36 (dd, 1 H), 3.79 (td, 1 H), 3.02-3.15 (m, 1 H), 2.85 (br dd, 1 H)	426.1 [M+H]+	99.6%
1768	(CD3OD) δ 8.22-8.77 (m, 3 H), 7.86 (d, 1 H), 7.66 (s, 1 H), 7.29 (d, 1 H), 7.20 (dd, 1 H), 6.54-7.03 (m, 3 H), 4.60 (br s, 1 H), 3.61 (q, 1 H), 3.00-3.17 (m, 1 H), 2.66-2.83 (m, 1 H), 1.97-2.06 (m, 1 H), 0.98-1.07 (m, 2 H), 0.73-0.81 (m, 2 H)	458.2 [M+H]+	98.1%
1769	(CD3OD) δ 8.25-8.68 (m, 3 H), 7.86 (d, 1 H), 7.67 (s, 1 H), 7.29 (d, 1 H), 7.19 (br d, 1 H), 6.40-6.97 (m, 3 H), 4.61 (br s, 1 H), 3.44-3.80 (m, 1 H), 3.01-3.18 (m, 1 H), 2.77 (br d, 1 H), 1.95-2.05 (m, 1 H), 0.97-1.07 (m, 2 H), 0.71-0.80 (m, 2 H)	458.1 [M+H]+	97.8%
1770	(CD3OD) δ 8.03-8.83 (m, 2 H), 7.80-7.95 (m, 2 H), 7.66 (s, 1 H), 7.33-7.49 (m, 2 H), 6.59-7.17 (m, 4 H), 4.64 (br s, 1 H), 3.40-3.81 (m, 1 H), 3.01-3.17 (m, 1 H), 2.95 (s, 6 H), 2.77 (br d, 1 H)	477.2 [M+H]+	99.4%
1771	(CD3OD) δ 8.00-8.80 (m, 2 H), 7.77-7.97 (m, 2 H), 7.66 (s, 1 H), 7.31-7.47 (m, 2 H), 6.55-7.18 (m, 4 H), 4.64 (br s, 1 H), 3.43-3.92 (m, 1 H), 3.01-3.13 (m, 1 H), 2.95 (s, 6 H), 2.77 (br d, 1 H)	477.2 [M+H]+	99.4%
1772	(CD3OD) δ 8.41 (br d, 2 H), 7.92 (d, 1 H), 7.85 (d, 1 H), 7.66 (s, 1 H), 7.38 (dd, 1 H), 6.97 (dd, 1 H), 6.55-6.91 (m, 3 H), 4.63 (br s, 1 H). 3.45-3.80 (m, 1 H), 3.02-3.16 (m, 1 H), 2.95 (s, 6 H), 2.77 (br dd, 1 H)	445.2 [M+H]+	100%
1773	(CD3OD) δ 8.41 (br d, 2 H), 7.91 (d, 1 H), 7.84 (d, 1 H), 7.65 (s, 1 H), 7.37 (dd, 1 H), 6.96 (dd, 1 H), 6.56-6.89 (m, 3 H), 4.63 (br s, 1 H), 3.43-3.78 (m, 1 H), 3.02-3.13 (m, 1 H), 2.94 (s, 6 H), 2.76 (br dd, 1 H)	445.2 [M+H]+	99.8%
1774	(CD3OD) δ 8.57-8.74 (m, 3 H), 7.55-7.71 (m, 2 H), 7.24 (s, 1 H), 6.95 (t, 1 H), 6.71 (s, 1 H), 5.20 (dd, 1 H), 3.45-3.63 (m, 1 H), 2.67-3.00 (m, 2 H)	454.1 [M+H]+	99.4%
1775	(CD3OD) δ 8.56-8.75 (m, 3 H), 7.54-7.69 (m, 2 H), 7.24 (s, 1 H), 6.95 (t, 1 H), 6.71 (s, 1 H), 5.20 (dd, 1 H), 3.44-3.58 (m, 1 H), 2.69-2.98 (m, 2 H)	454.1 [M+H]+	98.1%
1776	(CD3OD) δ 8.49-8.69 (m, 3 H), 7.65 (s, 1 H), 7.39 (br d, 1 H), 7.25 (s, 1 H), 7.09 (s, 0.2 H), 6.78-7.00 (m, 1.8 H), 6.72 (s, 1 H), 5.18 (dd, 1 H), 3.51 (td, 1 H), 2.69-2.96 (m, 2 H)	436.1 [M+H]+	100%
1777	(CD3OD) δ 8.47-8.71 (m, 3 H), 7.65 (s, 1 H), 7.39 (br d, 1 H), 7.25 (s, 1 H), 7.09 (s, 0.2 H), 6.78-6.99 (m, 1.8 H), 6.72 (s, 1 H), 5.18 (dd, 1 H), 3.51 (td, 1 H), 2.68-2.98 (m, 2 H)	436.1 [M+H]+	100%
1778	(CD3OD) δ 8.67 (s, 2 H), 8.32 (d, 1 H), 7.66 (s, 1 H), 7.24 (s, 1 H), 6.94 (dd, 1 H), 6.81 (td, 1 H), 6.70 (s, 1 H), 5.20 (dd, 1 H), 3.48-3.63 (m, 1 H), 2.69-3.03 (m, 2 H)	404.1 [M+H]+	99.5%
1779	(CD3OD) δ 8.64 (s, 2 H), 8.28 (d, 1 H), 7.65 (s, 1 H), 7.22 (s, 1 H), 6.91 (dd, 1 H), 6.73-6.82 (m, 1 H), 6.67 (s, 1 H), 5.17 (dd, 1 H), 3.51 (td, 1 H), 2.67-2.98 (m, 2 H)	404.2 [M+H]+	99.3%
1780	(CD3OD) δ 8.65 (s, 2 H), 8.40 (d, 1 H), 7.65 (s, 1 H), 7.17-7.34 (m, 2 H), 6.80 (t, 1 H). 6.66 (s, 1 H), 5.18 (dd, 1 H), 3.51 (td, 1 H), 2.72-2.97 (m, 2 H)	420.1 [M+H]+	99.0%
1781	(CD3OD) δ 8.66 (s, 2 H), 8.40 (br d, 1 H), 7.65 (s, 1 H), 7.13-7.33 (m, 2 H), 6.81 (t, 1 H), 6.66 (s, 1 H), 5.19 (dd, 1 H), 3.42-3.59 (m, 1 H), 2.66-2.98 (m, 2 H)	420.1 [M+H]+	99.4%
1782	(CD3OD) δ 8.91-8.95 (m, 1 H), 8.44-8.53 (m, 1 H), 8.34-8.39 (m, 1 H), 7.78-7.82 (m, 1.2 H), 7.51-7.67 (m, 1 H), 7.16-7.26 (m, 1 H), 6.88-6.99 (m, 1.8 H), 6.76-6.83 (m, 1 H), 5.12 (dd, 1 H), 3.75-3.83 (m, 0.6 H), 3.40-3.48 (m, 0.4 H), 2.84-3.22 (m, 2 H)	536.1 [M+H]+	100%
1783	(CD3OD) δ 8.89-8.96 (m, 1 H), 8.43-8.52 (m, 1 H), 8.36 (s, 1 H), 7.72-7.82 (m, 1.2 H), 7.51-7.67 (m. 1 H), 7.17-7.28 (m, 1 H), 6.87-7.00 (m, 1.8 H), 6.74-6.83 (m, 1 H), 4.97-5.16 (m, 1 H), 3.75-3.83 (m, 0.6 H), 3.43 (td, 0.4 H), 2.85-3.22 (m, 2 H)	536.2 [M+H]+	100%
1784	(CD3OD) δ 8.38-8.98 (m, 3 H), 7.91 (d, 1 H), 7.63-7.72 (m, 2 H), 7.42 (dd, 1 H), 7.02 (br t, 1 H), 6.58-6.92 (m, 2 H), 4.89-4.96 (m, 1 H), 3.69 (t, 2 H), 3.35-3.51 (m, 4 H), 3.04-3.19 (m, 1 H), 2.95 (t, 2 H), 2.73-2.84 (m, 1 H)	510.2 [M+H]+	99.5%
1785	(CD3OD) δ 8.28-8.95 (m, 3 H), 7.91 (d, 1 H), 7.63-7.73 (m, 2 H), 7.43 (dd, 1 H), 6.58-7.10 (m, 3 H), 4.90-5.03 (m, 1 H), 3.69 (t, 2 H), 3.37 (s, 4 H), 3.04-3.16 (m, 1 H), 2.95 (t, 2 H), 2.80 (br dd, 1 H)	510.2 [M+H]+	100%
1786	(CD3OD) δ 8.05-8.86 (m, 2 H), 7.76 (d, 1 H), 7.54 (s, 1 H), 7.33 (d, 1 H), 7.18 (dd, 1 H), 7.11 (ddd, 1 H), 6.42-6.87 (m, 3 H), 4.49-4.58 (m, 1 H), 3.24 (br s, 1 H), 2.89-3.01 (m, 1 H), 2.65 (br dd, 1 H), 2.26 (s, 3 H)	416.2 [M+H]+	99.5%
1787	(CD3OD) δ 8.22-8.92 (m, 2 H), 7.90 (d, 1 H), 7.66 (s, 1 H), 7.47 (dd, 1 H), 7.33 (dd, 1 H), 7.25 (ddd, 1 H), 6.55-6.96 (m, 3 H), 4.62 (br s, 1 H), 3.35-3.77 (m, 1 H), 3.03-3.12 (m, 1 H), 2.78 (dd, 1 H), 2.40 (s, 3 H)	416.2 [M+H]+	99.5%
1788	(CD3OD) δ 8.42 (s, 2 H), 8.14 (br d, 1 H), 7.86 (d, 1 H), 7.64 (s, 1 H), 7.20 (dd. 1 H), 6.39-6.93 (m, 4 H), 4.60-4.70 (m, 1 H), 3.95 (s, 3 H), 3.37-3.74 (m, 1 H), 2.98-3.11 (m, 1 H), 2.75 (br dd, 1 H), 1.94-2.07 (m, 1 H), 0.94-1.08 (m, 2 H), 0.71-0.85 (m, 2 H)	454.2 [M+H]+	97.5%
1789	(CD3OD) δ 8.42 (s, 2 H), 8.14 (br d, 1 H), 7.86 (d, 1 H), 7.64 (s, 1 H), 7.20 (d, 1 H), 6.37-7.01 (m, 4 H), 4.59-4.71 (m, 1 H), 3.95 (s, 3 H), 3.49 (br s, 1 H), 3.00-3.10 (m, 1 H), 2.70-2.81 (m, 1 H), 1.95-2.08 (m, 1 H), 0.94-1.08 (m, 2 H), 0.72-0.83 (m, 2 H)	454.2 [M+H]+	97.8%
1790	(CD3OD) δ 8.42 (s, 2 H), 7.87 (d, 1 H), 7.64 (s, 1 H), 7.46 (d, 1 H), 7.14-7.30 (m, 2 H), 6.38-7.05 (m, 3 H), 4.59-4.71 (m, 1 H), 3.45-3.98 (m, 1 H), 2.96-3.15 (m, 1 H), 2.76 (br d, 1 H), 1.96-2.09 (m, 1 H), 0.95-1.07 (m, 2 H), 0.72-0.84 (m, 2 H)	442.2 [M+H]+	99.7%
1791	(CD3OD) δ 8.42 (s, 2 H), 7.87 (d, 1 H), 7.65 (s, 1 H), 7.45 (d, 1 H), 7.13-7.31 (m, 2 H), 6.44-7.01 (m, 3 H), 4.60-4.70 (m, 1 H), 3.47-3.92 (m, 1 H), 2.96-3.11 (m, 1 H), 2.76 (br dd, 1 H), 1.91-2.08 (m, 1 H), 0.97-1.11 (m, 2 H), 0.68-0.84 (m, 2 H)	442.2 [M+H]+	99.7%
1792	(CD3OD) δ 8.51 (br d, 2 H), 7.77-7.94 (m, 2 H), 7.67 (s, 1 H), 7.37 (dd, 1 H), 7.29 (d, 1 H), 6.36-6.96 (m, 3 H), 4.63 (br s, 1 H), 3.38-3.72 (m, 1 H), 3.00-3.14 (m, 1 H), 2.94 (s, 6 H), 2.71-2.82 (m, 1 H)	461.2 [M+H]+	100%
1793	(CD3OD) δ 8.51 (br d, 2 H), 7.80-7.95 (m, 2 H), 7.66 (s, 1 H), 7.37 (dd, 1 H), 7.29 (d, 1 H), 6.49-6.98 (m, 3 H), 4.65 (br s, 1 H), 3.43-3.83 (m, 1 H), 3.01-3.15 (m, 1 H), 2.94 (s, 6 H), 2.77 (br dd, 1 H)	461.2 [M+H]+	99.4%
1794	(CD3OD) δ 8.49-9.39 (m, 1 H), 7.80-7.94 (m, 2 H), 7.63 (s, 1 H), 7.47 (d, 1 H), 7.36 (dd, 1 H), 7.13 (dd, 1 H), 6.34-6.91 (m, 3 H), 4.62-4.71 (m, 1 H), 3.49 (br s, 1 H), 3.00-3.10 (m, 1 H), 2.94 (s, 6 H), 2.69-2.78 (m, 4 H)	441.2 [M+H]+	99.9%
1795	(CD3OD) δ 8.23-9.44 (m, 1 H), 7.78-7.95 (m, 2 H), 7.64 (s, 1 H), 7.47 (d, 1 H), 7.37 (dd, 1,H), 7.13 (dd, 1 H), 6.33-6.97 (m, 3 H), 4.63-4.73 (m, 1 H), 3.39-3.86 (m, 1 H), 2.99-3.14 (m, 1 H), 2.95 (s, 6 H), 2.70-2.78 (m, 4 H)	441.3 [M+H]+	99.7%
1796	(CD3OD) δ 8.24-8.53 (m, 3 H), 7.79 (d, 1 H), 7.56 (s, 1 H), 7.30 (dd, 1 H), 6.87 (dd, 1 H), 6.40-6.82 (m, 3 H), 4.82 (br s, 1 H), 3.57 (t, 2 H), 3.24 (s, 4 H), 2.91-3.04 (m, 1 H), 2.83 (t, 2 H), 2.67 (br dd, 1 H)	460.2 [M+H]+	100%
1797	(CD3OD) δ 8.25-8.55 (m, 3 H), 7.80 (d, 1 H), 7.56 (s, 1 H), 7.30 (dd, 1 H), 6.87 (dd, 1 H), 6.49-6.80 (m, 3 H), 4.81 (br s, 1 H), 3.57 (t, 2 H), 3.22-3.33 (m, 4 H), 2.88-3.05 (m, 1 H), 2.83 (t, 2 H), 2.67 (br dd, 1 H)	460.2 [M+H]+	99.2%
1798	(CD3OD) δ 8.17 (d, 1 H), 7.55 (s, 1 H), 6.86 (d, 1 H), 6.66 (t, 1 H), 6.42 (s, 1 H), 6.17 (s, 1 H), 4.10 (dd, 1 H), 3.60 (ddd, 1 H), 2.83-3.00 (m, 1 H), 2.69 (dd, 1 H), 2.31 (s, 3 H), 1.28 (s, 9 H)	378.2 [M+H]+	99.8%
1799	(CD3OD) δ 8.17 (br d, 1 H), 7.55 (s, 1 H), 6.86 (br d, 1 H), 6.66 (t, 1 H), 6.42 (s, 1 H), 6.17 (s, 1 H), 4.10 (br dd, 1 H), 3.51-3.70 (m, 1 H), 2.84-2.99 (m, 1 H), 2.69 (br dd, 1 H), 2.31 (s, 3 H), 1.28 (s, 9 H)	378.2 [M+H]+	99.7%
1800	(CD3OD) δ 8.63 (s, 2 H), 7.51-7.65 (m, 2 H), 7.24 (s, 1 H), 7.13 (dd, 1 H), 6.98 (dd, 1 H), 6.69 (s, 1 H), 5.19 (dd, 1 H), 3.62 (td, 1 H), 2.71-2.97 (m, 2 H)	420.1 [M+H]+	99.5%
1801	(CD3OD) δ 8.64 (s, 2 H), 7.50-7.67 (m, 2 H), 7.24 (s, 1 H), 7.14 (dd, 1 H), 6.98 (dd, 1 H), 6.69 (s, 1 H), 5.19 (dd, 1 H), 3.55-3.71 (m, 1 H), 2.72-2.95 (m, 2 H)	420.1 [M+H]+	99.8%
1802	(CD3OD) δ 8.63 (s, 2 H), 7.61 (s, 1 H), 7.42 (d, 1 H), 7.24 (s, 1 H), 7.07 (dd, 1 H), 6.66 (d, 1 H), 6.51 (s, 1 H), 5.17 (dd, 1 H), 3.63 (td, 1 H), 2.70-2.95 (m, 2 H), 2.64 (s, 3 H)	400.2 [M+H]+	99.6%
1803	(CD3OD) δ 8.64 (s, 2 H), 7.61 (s, 1 H), 7.43 (d, 1 H), 7.24 (s, 1 H), 7.08 (dd, 1 H), 6.67 (d, 1 H), 6.51 (s, 1 H), 5.17 (dd, 1 H), 3.63 (td, 1 H), 2.71-2.94 (m, 2 H), 2.64 (s, 3 H)	400.2 [M+H]+	99.2%
1804	(CD3OD) δ 8.46 (d, 1 H), 8.31 (d, 1 H), 8.16 (dd, 1 H), 7.80 (d, 1 H), 7.64 (s, 1 H), 6.98 (d, 1 H), 6.82 (br s, 1 H), 6.77 (t, 1 H), 6.53 (s, 1 H), 4.70 (br dd, 1 H), 3.57-3.72 (m, 1 H), 2.91-3.06 (m, 1 H), 2.76 (dd, 1 H), 2.43 (s, 3 H)	332.2 [M+H]+	100%
1805	(CD3OD) δ 8.46 (d, 1 H), 8.31 (d, 1 H), 8.13-8.22 (m, 1 H), 7.80 (d, 1 H), 7.64 (s, 1 H), 6.98 (d, 1 H), 6.82 (s, 1 H), 6.77 (t, 1 H), 6.53 (s, 1 H), 4.70 (br dd, 1 H), 3.63 (ddd, 1 H), 2.88-3.06 (m, 1 H), 2.76 (dd, 1 H), 2.43 (s, 3 H)	332.2 [M+H]+	97.6%
1806	(CD3OD) δ 8.46 (d, 1 H), 7.69 (s, 1 H), 7.60 (d, 1 H), 7.21 (ddd, 1 H), 6.88 (td, 1 H), 6.59 (s, 1 H), 6.40 (s, 1 H), 4.34 (dd, 1 H), 3.79 (ddd, 1 H), 3.02-3.14 (m, 1 H), 2.84 (dd, 1 H)	376.1 [M+H]+	99.6%
1807	(CD3OD) δ 8.46 (d, 1 H), 7.69 (s, 1 H), 7.60 (d, 1 H), 7.15-7.27 (m, 1 H), 6.81-6.93 (m, 1 H), 6.59 (s, 1 H), 6.40 (s, 1 H), 4.34 (dd, 1 H), 3.79 (ddd, 1 H), 3.00-3.14 (m, 1 H), 2.84 (dd, 1 H)	376.1 [M+H]+	99.9%
1808	(CD3OD) δ 8.31 (d, 1 H), 7.70 (s, 1 H), 7.00 (d, 1 H), 6.80 (t, 1 H), 6.59 (s, 1 H), 6.41 (s, 1 H), 4.34 (dd, 1 H), 3.79 (ddd, 1 H), 3.00-3.16 (m, 1 H), 2.85 (dd, 1 H), 2.45 (s, 3 H)	390.2 [M+H]+	100%
1809	(CD3OD) δ 8.31 (d, 1 H), 7.70 (s, 1 H), 7.00 (d, 1 H), 6.80 (t, 1 H), 6.59 (s, 1 H), 6.41 (s, 1 H), 4.34 (dd, 1 H), 3.79 (ddd, 1 H), 3.00-3.16 (m, 1 H), 2.85 (dd, 1 H), 2.45 (s, 3 H)	390.1 [M+H]+	100%
1810	(CD3OD) δ 8.63 (s, 2 H), 7.80 (d, 1 H), 7.62 (s, 1 H), 7.18-7.30 (m, 3 H), 6.77 (s, 1 H), 5.21 (dd, 1 H), 3.65 (td, 1 H), 2.83-2.96 (m, 1 H), 2.70-2.81 (m, 1 H)	454.2 [M+H]+	98.9%
1811	(CD3OD) δ 8.53 (s, 2 H), 7.70 (d, 1 H), 7.52 (s, 1 H), 7.06-7.23 (m, 3 H), 6.67 (s, 1 H), 5.11 (dd, 1 H), 3.48-3.63 (m, 1 H), 2.57-2.89 (m, 2 H)	454.1 [M+H]+	99.7%
1812	(CD3OD) δ 8.54 (s, 2 H), 7.47-7.66 (m, 2 H), 7.26-7.44 (m, 1 H), 7.02-7.16 (m, 3 H), 6.56 (s, 1 H), 5.10 (dd, 1 H), 3.52 (td, 1 H), 2.58-2.87 (m, 2 H)	436.1 [M+H]+	99.8%
1813	(CD3OD) δ 8.53 (s, 2 H), 7.49-7.63 (m, 2 H), 7.26-7.44 (m, 1 H), 6.97-7.15 (m, 3 H), 6.56 (s, 1 H), 5.10 (dd, 1 H), 3.43-3.59 (m, 1 H), 2.59-2.86 (m, 2 H)	436.1 [M+H]+	99.8%
1814	(CD3OD) δ 8.45 (d, 1 H), 8.13 (br d, 1 H), 7.49-7.71 (m, 3 H), 7.12-7.24 (m, 1 H), 7.05 (d, 1 H), 6.83 (t, 1 H), 6.77 (br s, 1 H), 6.66 (dd, 1 H), 6.50 (s, 1 H), 4.56 (br dd, 1 H), 3.51-3.63 (m, 1 H), 2.87-3.06 (m, 1 H), 2.68 (br d, 1 H)	317.2 [M+H]+	100%
1815	(CD3OD) δ 8.45 (br d, 1 H), 8.13 (br d, 1 H), 7.47-7.69 (m, 3 H), 7.12-7.25 (m, 1 H), 7.05 (d, 1 H), 6.71-6.89 (m, 2 H), 6.66 (dd, 1 H), 6.50 (s, 1 H), 4.56 (br dd, 1 H), 3.51-3.64 (m, 1 H), 2.89-3.04 (m, 1 H), 2.68 (br d, 1 H)	317.2 [M+H]+	100%
1816	(CD3OD) δ 8.58 (br d, 1 H), 8.47 (d, 1 H), 8.16 (dd, 1 H), 7.80 (d, 1 H), 7.67 (br s, 1 H), 7.42 (br d, 1 H), 6.79-7.15 (m, 3 H), 6.70 (s, 1 H), 4.71 (dd, 1 H), 3.61 (ddd, 1 H), 2.91-3.04 (m, 1 H), 2.77 (br d, 1 H)	368.1 [M+H]+	100%
1817	(CD3OD) δ 8.59 (d, 1 H), 8.47 (d, 1 H), 8.17 (dd, 1 H), 7.80-7.86 (m, 2 H), 7.42 (br d, 1 H), 6.79-7.16 (m, 3 H), 6.71 (s, 1 H), 4.71 (dd, 1 H), 3.61 (ddd, 1 H), 2.93-3.05 (m, 1 H), 2.78 (br dd, 1 H)	368.1 [M+H]+	98.2%
1818	(CD3OD) δ 8.69 (d, 1 H), 8.47 (d, 1 H), 8.17 (dd, 1 H), 7.81 (d, 1 H), 7.57-7.72 (m, 2 H), 6.97 (t, 1 H), 6.86 (br s, 1 H), 6.69 (s, 1 H), 4.72 (br dd, 1 H), 3.61 (ddd, 1 H), 2.92-3.06 (m, 1 H), 2.77 (br dd, 1 H)	386.2 [M+H]+	100%
1819	(CD3OD) δ 8.69 (d, 1 H), 8.47 (d, 1 H), 8.17 (dd, 1 H), 7.81 (d, 1 H), 7.57-7.72 (m, 2 H), 6.97 (t, 1 H), 6.86 (br s, 1 H), 6.69 (s, 1 H), 4.72 (br dd, 1 H), 3.61 (ddd, 1 H), 2.92-3.05 (m, 1 H), 2.77 (br dd, 1 H)	386.2 [M+H]+	99.6%
1820	(CD3OD) δ 8.71 (d, 1 H), 7.71 (s, 1 H), 7.64 (d, 1 H), 7.01 (t, 1 H), 6.77 (s, 1 H), 6.43 (s, 1 H), 4.38 (dd, 1 H), 3.80 (td, 1 H), 3.03-3.15 (m, 1 H), 2.86 (dd, 1 H)	444.1 [M+H]+	95.6%
1821	(CD3OD) δ 8.71 (d, 1 H), 7.70 (s, 1 H), 7.64 (d, 1 H), 7.00 (t, 1 H), 6.77 (s, 1 H), 6.43 (br s, 1 H), 4.38 (dd, 1 H), 3.72-3.86 (m, 1 H), 3.02-3.16 (m, 1 H), 2.86 (br dd, 1 H)	444.1 [M+H]+	93.2%
1822	(CD3OD) δ 8.24 (d, 1 H), 7.58 (s, 1 H), 6.86 (dd, 1 H), 6.73 (td, 1 H), 6.61 (s, 1 H), 6.29 (s, 1 H), 4.24 (dd, 1 H), 3.68 (ddd, 1 H), 2.91-3.03 (m, 1 H), 2.73 (dd, 1 H)	394.1 [M+H]+	99.7%
1823	(CD3OD) δ 8.23 (d, 1 H), 7.58 (s, 1 H), 6.86 (dd, 1 H), 6.73 (td, 1 H), 6.61 (s, 1 H), 6.29 (s, 1 H), 4.24 (dd, 1 H), 3.68 (ddd, 1 H), 2.90-3.03 (m, 1 H), 2.73 (dd, 1 H)	394.1 [M+H]+	99.8%
1824	(CD3OD) δ 8.57 (d, 1 H), 7.67 (s, 1 H), 7.43 (br d, 1 H), 6.67-7.18 (m, 3 H), 6.31 (s, 1 H), 4.24 (dd, 1 H), 3.72 (ddd, 1 H), 2.95-3.14 (m, 1 H), 2.83 (dd, 1 H), 1.41 (s, 9 H)	414.2 [M+H]+	98.4%
1825	(CD3OD) δ 8.57 (d, 1 H), 7.67 (s, 1 H), 7.43 (br d, 1 H), 6.62-7.19 (m, 3 H), 6.31 (br s, 1 H), 4.24 (dd, 1 H), 3.72 (ddd, 1 H), 2.97-3.11 (m, 1 H), 2.83 (br dd, 1 H), 1.41 (s, 9 H)	414.2 [M+H]+	99.8%
1826	(CD3OD) δ 8.27 (d, 1 H), 8.06 (s, 2 H), 7.61 (s, 1 H), 7.05 (s, 1 H), 6.95 (d, 1 H), 6.74 (t, 1 H), 6.49 (s, 1 H), 4.81 (br dd, 1 H), 3.43 (ddd, 1 H), 2.84-2.95 (m, 1 H), 2.59-2.68 (m, 1 H), 2.42 (s, 3 H)	347.2 [M+H]+	97.1%
1827	(CD3OD) δ 8.16 (d, 1 H), 7.91-7.99 (m, 2 H), 7.50 (s, 1 H), 6.93 (s, 1 H), 6.80-6.86 (m, 1 H), 6.62 (t, 1 H), 6.37 (s, 1 H), 4.65-4.70 (m, 1 H), 3.27-3.36 (m, 1 H), 2.72-2.83 (m, 1 H), 2.52 (dd. 1 H), 2.30 (s, 3 H)	347.2 [M+H]+	93.3%
1828	(CD3OD) δ 8.59 (d, 1 H), 8.40 (s, 1 H), 7.81 (s, 1 H), 7.69 (s, 1 H), 7.42 (d, 1 H), 6.81-7.14 (m, 2 H), 6.75 (d. 2 H), 4.72 (br dd, 1 H), 3.61 (ddd, 1 H), 2.91-3.05 (m, 1 H), 2.79 (dd, 1 H)	402.1 [M+H]+	100%
1829	(CD3OD) δ 8.59 (d, 1 H), 8.41 (s, 1 H), 7.81 (s, 1 H), 7.69 (s, 1 H), 7.43 (d, 1 H), 6.81-7.15 (m, 2 H), 6.75 (d, 2 H), 4.73 (dd, 1 H), 3.61 (ddd, 1 H), 2.92-3.04 (m, 1 H), 2.79 (dd, 1 H)	402.1 [M+H]+	99.9%
1830	(CD3OD) δ 8.41 (d, 1 H), 7.66 (s, 1 H), 7.26 (d, 1 H), 6.82 (t, 1 H), 6.65 (s, 1 H), 6.30 (s, 1 H), 4.23 (dd, 1 H), 3.60-3.76 (m, 2 H), 2.95-3.09 (m, 1 H), 2.79 (br dd, 1 H), 2.33-2.48 (m, 4 H), 1.95-2.17 (m, 2 H)	396.1 [M+H]+	99.7%
1831	(CD3OD) δ 8.36-8.51 (m, 1 H), 7.68 (s, 1 H), 7.28 (d, 1 H), 6.84 (t, 1 H), 6.67 (s, 1 H), 6.31 (s, 1 H), 4.25 (dd, 1 H), 3.60-3.76 (m, 2 H), 2.98-3.09 (m, 1 H), 2.77-2.86 (m, 1 H), 2.33-2.49 (m, 4 H), 1.97-2.20 (m, 2 H)	396.1 [M+H]+	98.9%
1832	(CD3OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.86 (t, 1 H), 6.67 (s, 1 H), 6.30 (br s, 1 H), 4.24 (dd, 1 H), 3.71 (ddd, 1 H), 2.97-3.11 (m, 1 H), 2.82 (br dd, 1 H), 1.41 (s. 9 H)	398.2 [M+H]+	100%
1833	(CD3OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.85 (t, 1 H), 6.67 (s, 1 H), 6.30 (br s, 1 H), 4.24 (dd, 1 H), 3.71 (ddd, 1 H), 2.96-3.10 (m, 1 H), 2.76-2.90 (m, 1 H), 1.41 (s, 9 H)	398.2 [M+H]+	100%
1834	(CD3OD) δ 8.66 (d, 1 H), 8.06 (s, 2 H), 7.63 (s, 1 H), 7.59 (d, 1 H), 7.05 (s, 1 H), 6.94 (t, 1 H), 6.66 (s, 1 H), 4.84 (br d, 1 H), 3.42 (ddd, 1 H), 2.86-2.96 (m, 1 H), 2.61-2.69 (m, 1 H)	401.1 [M+H]+	89.0%
1835	(CD3OD) δ 8.54 (d, 1 H), 7.94 (s, 2 H), 7.52 (s, 1 H), 7.43-7.50 (m, 1 H), 6.94 (s, 1 H), 6.82 (t, 1 H), 6.54 (s, 1 H), 4.72 (br d, 1 H), 3.30 (ddd, 1 H), 2.73-2.84 (m, 1 H), 2.53 (dd, 1 H)	401.2 [M+H]+	97.7%
1836	(CD3OD) δ 8.31 (d, 1 H), 8.06 (s, 2 H), 7.62 (s, 1 H), 7.03 (s, 1 H), 6.92 (dd, 1 H), 6.78 (td, 1 H), 6.62 (s, 1 H), 4.78-4.84 (m, 1 H), 3.42 (ddd, 1 H), 2.83-2.97 (m, 1 H), 2.65 (dd, 1 H)	351.1 [M+H]+	98.8%
1837	(CD3OD) δ 8.19 (d, 1 H), 7.94 (s, 2 H), 7.50 (s, 1 H), 6.91 (s, 1 H), 6.80 (dd, 1 H), 6.67 (td, 1 H), 6.50 (s, 1 H), 4.70 (br d, 1 H), 3.30 (ddd, 1 H), 2.70-2.88 (m. 1 H), 2.53 (dd, 1 H)	351.2 [M+H]+	90.6%
1838	(CD3OD) δ 8.18-8.32 (m, 1 H), 7.68 (s, 1 H), 7.45 (br s, 0.3 H), 6.93 (s, 0.7 H), 6.58-6.84 (m, 3 H), 4.97 (br dd, 1 H), 3.65-3.78 (m, 0.7 H), 3.34-3.42 (m, 0.3 H), 3.06-3.18 (m, 0.7 H), 2.91-3.03 (m, 0.3 H), 2.81 (br dd, 1 H), 2.26-2.36 (m, 1 H), 2.01-2.14 (m, 1 H), 1.19-1.30 (m, 4 H), 0.97-1.08 (m, 2 H), 0.72-0.83 (m, 2 H)	416.2 [M+H]+	96.5%
1839	(CD3OD) δ 8.20-8.35 (m, 1 H), 7.68 (s, 1 H), 7.45 (br s, 0.3 H), 6.93 (s, 0.7 H), 6.65-6.84 (m, 3 H), 4.97 (br dd, 1 H), 3.66-3.77 (m, 0.6 H), 3.33-3.44 (m. 0.4 H). 3.06-3.18 (m, 0.6 H), 2.91-3.03 (m, 0.4 H), 2.76-2.87 (m, 1 H), 2.24-2.44 (m, 1 H), 2.09 (td, 1 H), 1.20-1.30 (m. 4 H), 0.94-1.09 (m, 2 H), 0.69-0.86 (m, 2 H)	416.2 [M+H]+	91.5%
1840	(CD3OD) δ 8.19-8.32 (m, 1 H), 7.69 (s, 1 H), 6.93-7.48 (m, 1 H), 6.66-6.85 (m, 3 H), 4.93-5.00 (m, 1 H), 3.75 (ddd, 0.7 H), 3.40 (td, 0.3 H), 3.09-3.21 (m, 0.7 H), 2.92-3.02 (m, 0.3 H), 2.83 (br dd, 1 H), 2.00-2.17 (m, 1 H), 1.42-1.53 (m, 9 H), 0.96-1.07 (m, 2 H), 0.71-0.82 (m, 2 H)	432.2 [M+H]+	100%
1841	(CD3OD) δ 8.18-8.33 (m, 1 H), 7.69 (s, 1 H), 7.41 (br s, 0.3 H), 6.95 (s, 0.7 H), 6.63-6.84 (m, 3 H), 4.96 (dd, 1 H), 3.75 (ddd, 0.7 H), 3.35-3.45 (m, 0.3 H), 3.09-3.20 (m, 0.7 H), 2.92-3.03 (m, 0.3 H), 2.83 (br dd, 1 H), 2.01-2.15 (m, 1 H), 1.43-1.53 (m, 9 H), 0.98-1.07 (m, 2 H), 0.73-0.81 (m, 2 H)	432.2 [M+H]+	95.1%
1842	Data provided above
1843	Data provided above
1844	(CD3OD) δ 8.31 (d, 1 H), 7.52-7.79 (m, 2 H), 7.23 (t, 2 H), 7.00 (d, 1 H), 6.79 (t, 1 H), 6.62 (s, 1 H), 6.42 (s, 1 H), 4.36 (dd, 1 H), 3.81 (ddd, 1 H), 3.02-3.17 (m, 1 H), 2.86 (br dd, 1 H), 2.45 (s, 3 H)	434.1 [M+H]+	99.7%
1845	(CD3OD) δ 8.31 (d, 1 H), 7.54-7.78 (m, 2 H), 7.22 (t, 2 H), 6.99 (d, 1 H), 6.79 (t, 1 H), 6.61 (s, 1 H), 6.42 (s, 1 H), 4.36 (dd, 1 H), 3.80 (ddd, 1 H), 3.00-3.18 (m, 1 H), 2.85 (dd, 1 H), 2.45 (s, 3 H)	434.2 [M+H]+	99.7%
1846	(CD3OD) δ 8.70 (br d, 1 H), 7.48-7.85 (m, 3 H), 7.22 (t, 2 H), 6.99 (t, 1 H), 6.79 (s, 1 H), 6.43 (br s, 1 H), 4.40 (dd, 1 H), 3.65-3.95 (m, 1 H), 2.99-3.19 (m, 1 H), 2.87 (br dd, 1 H)	488.1 [M+H]+	97.8%
1847	(CD3OD) δ 8.70 (d, 1 H), 7.47-7.87 (m, 3 H), 7.22 (t, 2 H), 6.99 (t, 1 H), 6.79 (s, 1 H), 6.44 (s. 1 H), 4.40 (dd, 1 H), 3.67-3.99 (m. 1 H), 3.00-3.20 (m, 1 H), 2.87 (br dd, 1 H)	488.1 [M+H]+	99.4%
1848	(CD3OD) δ 8.46 (br d, 1 H), 7.77 (br s, 1 H), 7.32 (d, 1 H), 6.87 (t, 1 H), 6.72 (s, 1 H), 6.42 (s, 1 H), 4.36 (dd, 1 H), 3.69-3.86 (m, 1 H), 3.01-3.16 (m, 1 H), 2.86 (br d, 1 H)	410.1 [M+H]+	99.8%
1849	(CD3OD) δ 8.34 (d, 1 H), 7.65 (s, 1 H), 7.20 (d, 1 H), 6.75 (t, 1 H), 6.60 (s, 1 H), 6.31 (s, 1 H), 4.24 (dd, 1 H), 3.67 (ddd, 1 H), 2.90-3.02 (m, 1 H), 2.74 (dd, 1 H)	410.1 [M+H]+	99.6%
1850	(CD3OD) δ 7.60 (s, 1 H), 7.36 (d, 1 H), 7.02 (dd, 1 H), 6.62 (d, 1 H), 6.41 (s, 1 H), 6.29 (s, 1 H), 4.23 (dd, 1 H), 3.69 (ddd, 1 H), 2.90-3.02 (m, 1 H), 2.74 (dd, 1 H), 2.52 (s, 3 H)	390.1 [M+H]+	99.4%
1851	(CD3OD) δ 7.73 (s, 1 H), 7.48 (d, 1 H), 7.13 (dd, 1 H), 6.73 (d, 1 H), 6.53 (s, 1 H), 6.41 (s, 1 H), 4.35 (dd, 1 H), 3.80 (ddd, 1 H), 3.02-3.14 (m, 1 H), 2.85 (dd, 1 H), 2.63 (s, 3 H)	390.1 [M+H]+	93.6%
1852	(CD3OD) δ 8.43 (d, 1 H), 7.94 (s. 2 H), 7.51 (s, 1 H), 7.28 (br d, 1 H), 6.83-6.99 (m, 1.8 H), 6.77 (t, 1 H), 6.70 (s, 0.2 H), 6.55 (s, 1 H), 4.70 (br d, 1 H), 3.25-3.34 (m, 1 H), 2.72-2.84 (m, 1 H), 2.53 (dd, 1 H)	383.2 [M+H]+	1 00%
1853	(CD3OD) δ 8.43 (d, 1 H), 7.94 (s, 2 H), 7.51 (s, 1 H), 7.27 (br d, 1 H), 6.92-6.99 (m, 1.2 H), 6.84 (s, 0.6 H), 6.77 (t, 1 H), 6.70 (s, 0.2 H), 6.55 (s, 1 H), 4.70 (br d, 1 H), 3.26-3.34 (m, 1 H), 2.73-2.83 (m, 1 H), 2.52 (dd, 1 H)	383.2 [M+H]+	99.3%
1854	(CD3OD) δ 8.63 (br d, 1 H), 8.17-8.32 (m, 1 H), 7.92 (br t, 1 H), 7.68-7.80 (m, 2 H), 7.47 (br s, 0.3 H), 6.99 (s, 0.7 H), 6.71-6.82 (m, 3 H). 4.93-4.99 (m, 1 H), 3.77-3.87 (m, 0.7 H), 3.45 (td, 0.3 H), 3.17-3.26 (m, 0.7 H), 2.98-3.07 (m, 0.3 H), 2.85 (br d, 1 H), 2.02-2.15 (m, 1 H), 0.95-1.07 (m, 2 H), 0.70-0.81 (m, 2 H)	471.2 [M+H]+	98.6%
1855	(CD3OD) δ 8.62 (d, 1 H), 8.19-8.31 (m, 1 H), 7.91 (t, 1 H), 7.69-7.77 (m, 2 H), 7.47 (s, 0.3 H), 6.99 (s, 0.7 H), 6.71-6.82 (m, 3 H), 4.93-4.99 (m, 1 H), 3.77-3.86 (m, 0.7 H). 3.45 (td, 0.3 H), 3.17-3.26 (m, 0.7 H), 2.97-3.06 (m, 0.3 H). 2.86 (br dd, 1 H), 2.01-2.14 (m, 1 H), 0.96-1.07 (m, 2 H), 0.72-0.81 (m, 2 H)	471.2 [M+H]+	97.9%
1856	(CD3OD) δ 9.44 (s, 1 H), 8.79-8.86 (m, 2 H), 8.19-8.30 (m, 1 H), 7.70 (s, 1 H), 7.50 (br s, 0.3 H), 6.98 (s, 0.7 H), 6.67-6.85 (m, 3 H), 5.01- 4.89 (br dd, 1 H), 3.77-3.86 (m, 0.6 H), 3.45 (td, 0.4 H). 3.14-3.27 (m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.80-2.91 (m, 1 H), 2.00-2.15 (m, 1 H), 0.96-1.08 (m, 2 H), 0.71-0.82 (m, 2 H)	454.2 [M+H]+	99.9%
1857	(CD3OD) δ 9.45 (s, 1 H), 8.83 (br d, 2 H), 8.17-8.34 (m, 1 H), 7.70 (s, 1 H), 7.50 (s, 0.3 H), 6.99 (s, 0.7 H), 6.72-6.82 (m, 3 H). 4.93-5.05 (m, 1 H), 3.78-3.86 (m, 0.7 H), 3.45 (td, 0.3 H), 3.15-3.26 (m, 0.7 H), 2.97-3.06 (m, 0.3 H). 2.86 (br dd, 1 H), 1.99-2.15 (m, 1 H), 0.97-1.08 (m, 2 H), 0.72-0.82 (m, 2 H)	454.2 [M+H]+	99.3%
1858	(CD3OD) δ 8.13-8.23 (m, 1 H), 7.58 (s, 1 H), 7.35 (s, 0.3 H), 6.91-6.97 (m, 1 H), 6.82 (s, 0.7 H), 6.65-6.76 (m, 1 H), 6.49-6.61 (m, 1 H), 4.82-4.87 (m, 1 H), 3.60-3.69 (m, 0.6 H), 3.24-3.34 (m, 0.4 H), 2.83-3.13 (m, 2 H), 2.71 (br dd, 1 H). 2.48-2.55 (m, 3 H). 1.18-1.26 (m, 6 H)	392.2 [M+H]+	100%
1859	(CD3OD) δ 8.14-8.23 (m, 1 H), 7.58 (s, 1 H), 7.35 (s, 0.3 H), 6.91-6.98 (m, 1 H), 6.82 (s, 0.7 H), 6.68-6.76 (m, 1 H), 6.48-6.61 (m, 1 H), 4.81-4.88 (m, 1 H), 3.60-3.70 (m, 0.6 H), 3.24-3.34 (m, 0.4 H), 2.81-3.14 (m, 2 H), 2.65-2.77 (m, 1 H), 2.48-2.58 (m, 3 H), 1.18-1.26 (m, 6 H)	392.2 [M+H]+	99.7%
1860	(CD3OD) δ 8.46 (d, 1 H), 8.03 (dd, 2 H), 7.69 (s, 1 H), 7.60 (d, 1 H), 7.30 (t, 2 H), 7.16-7.24 (m, 1 H), 6.86 (t, 1 H), 6.60 (s, 1 H), 6.45 (s, 1 H), 4.37 (dd, 1 H), 3.73-3.83 (m, 1 H), 3.02-3.21 (m, 1 H), 2.85 (dd, 1 H)	402.2 [M+H]+	1 00%
1861	(CD3OD) δ 8.46 (br d, 1 H), 7.97-8.09 (m, 2 H), 7.67-7.73 (m, 1 H), 7.60 (br d. 1 H), 7.27-7.34 (m, 2 H), 7.16-7.24 (m, 1 H), 6.83-6.92 (m, 1 H), 6.60 (s, 1 H), 6.45 (s, 1 H), 4.32-4.45 (m, 1 H), 3.73-3.86 (m, 1 H), 3.04-3.18 (m, 1 H), 2.78-2.92 (m, 1 H)	402.2 [M+H]+	95.2%
1862	(CD3OD) δ 8.58 (br d, 1 H), 7.50-7.82 (m, 2 H), 7.42 (br d, 1 H), 7.20 (t, 2 H), 6.83-7.14 (m, 2 H), 6.79 (s, 1 H), 6.44 (br s, 1 H), 4.38 (br dd, 1 H), 3.70-3.90 (m, 1 H), 3.01-3.17 (m, 1 H), 2.86 (br d, 1 H)	470.1 [M+H]+	99.7%
1863	(CD3OD) δ 8.59 (d, 1 H), 7.55-7.79 (m, 2 H), 7.44 (br d, 1 H), 7.22 (t. 2 H), 6.84-7.15 (m, 2 H), 6.79 (s, 1 H), 6.44 (s, 1 H), 4.38 (dd, 1 H), 3.80 (ddd, 1 H), 3.01-3.20 (m, 1 H), 2.86 (dd, 1 H)	470.2 [M+H]+	99.5%
1864	(CD3OD) δ 8.35 (d, 1 H), 7.52-7.80 (m, 2 H), 7.22 (t, 2 H), 6.97 (dd, 1 H), 6.84 (td, 1 H), 6.74 (s, 1 H), 6.42 (br s, 1 H), 4.38 (dd, 1 H), 3.81 (ddd, 1 H), 3.01-3.18 (m, 1 H), 2.86 (dd, 1 H)	438.1 [M+H]+	99.4%
1865	(CD3OD) δ 8.23 (d, 1 H), 7.36-7.70 (m, 2 H), 7.10 (t, 2 H), 6.85 (dd, 1 H), 6.72 (td, 1 H), 6.62 (s, 1 H), 6.30 (br s, 1 H), 4.26 (dd, 1 H), 3.69 (ddd. 1 H), 2.88-3.06 (m, 1 H), 2.74 (br dd, 1 H)	438.2 [M+H]+	99.3%
1866	(CD3OD) δ 8.35 (br s, 1 H), 7.30-7.91 (m, 3 H), 6.94-7.19 (m, 1 H), 6.27-6.87 (m, 3 H), 4.56-4.75 (m, 1 H), 4.26-4.43 (m, 0.5 H), 3.64 (br s, 0.5 H), 2.53-3.10 (m, 2 H), 1.31 (br s, 9 H)	391.2 [M+H]+	100%
1867	(CD3OD) δ 8.31 (br s, 1 H), 7.33-7.96 (m, 3 H), 7.04 (br t, 1 H), 6.21-6.89 (m, 3 H), 4.70-4.81 (m, 1 H), 4.14-4.47 (m, 0.5 H), 3.63 (br s, 0.5 H), 2.47-3.08 (m, 2 H), 1.29 (br s, 9 H)	391.2 [M+H]+	99.5%
1868	(CD3OD) δ 8.32-8.56 (m, 2 H), 8.11 (s, 1 H), 7.79 (br s, 1 H), 7.58 (s, 0.3 H), 7.41-7.51 (m, 1 H), 6.96 (s. 0.7 H), 6.60-6.86 (m, 2 H), 5.10 (br dd, 1 H), 4.00 (s, 3 H), 3.68-3.81 (m, 0.7 H), 3.37-3.45 (m, 0.3 H). 3.12-3.23 (m, 0.7 H), 2.94-3.05 (m, 0.3 H), 2.85 (br d, 1 H)	494.1 [M+H]+	100%
1869	(CD3OD) δ 8.29-8.57 (m, 2 H), 8.11 (s, 1 H), 7.83 (br d, 1 H), 7.59 (s, 0.3 H), 7.43-7.50 (m, 1 H), 6.97 (s. 0.7 H), 6.65-6.85 (m, 2 H), 5.11 (br dd, 1 H), 4.01 (s, 3 H), 3.68-3.84 (m, 0.7 H), 3.41 (br d, 0.3 H), 295-3.24 (m, 1 H), 2.86 (br d, 1 H)	494.1 [M+H]+	99.4%
1870	(CD3OD) δ 8.69 (d. 1 H), 8.14 (br d, 1 H). 7.71 (s, 1 H), 7.54-7.66 (m, 2 H), 7.06 (d, 1 H), 6.96 (t, 1 H), 6.86 (s, 1 H), 6.60-6.74 (m, 2 H), 4.57 (br dd, 1 H), 3.46-3.62 (m, 1 H), 2.90-3.03 (m, 1 H), 2.70 (br dd, 1 H)	385.1 [M+H]+	98.2%
1871	(CD3OD) δ 8.69 (d, 1 H), 8.09-8.23 (m, 1 H), 7.77 (s, 1 H), 7.55-7.69 (m, 2 H), 7.06 (d, 1 H), 6.96 (t, 1 H), 6.89 (s, 1 H), 6.62-6.75 (m, 2 H), 4.57 (br dd, 1 H), 3.49-3.61 (m, 1 H), 2.91-3.05 (m, 1 H), 2.70 (br dd, 1 H)	385.2 [M+H]+	95.9%
1872	(CD3OD) δ 8.41 (d, 1 H), 8.06 (s, 2 H), 7.63 (s, 1 H), 7.26 (d, 1 H), 7.03 (s. 1 H), 6.80 (t, 1 H), 6.61 (s, 1 H), 4.83 (br d, 1 H), 3.39-3.46 (m, 1 H), 2.84-2.95 (m, 1 H), 2.65 (br dd, 1 H)	367.1 [M+H]+	99.7%
1873	(CD3OD) δ 8.41 (d, 1 H), 8.06 (s, 2 H), 7.62 (s, 1 H), 7.26 (d, 1 H), 7.03 (s, 1 H), 6.80 (t, 1 H). 6.61 (s, 1 H), 4.83 (br d, 1 H), 3.39-3.46 (m, 1 H), 2.85-2.95 (m, 1 H), 2.65 (dd, 1 H)	367.1 [M+H]+	98.5%
1874	(CD3OD) δ 8.16-8.43 (m, 1 H), 7.68 (s, 1 H), 7.44 (s, 0.5 H), 6.76-7.09 (m, 2.5 H), 6.41-6.71 (m, 1 H), 4.97 (br dd, 1 H), 3.66-3.78 (m, 0.5 H), 3.38 (td, 0.5 H), 2.89-3.21 (m, 1 H), 2.71-2.88 (m, 3 H), 2.19-2.40 (m, 1 H), 1.13-1.34 (m, 7 H)	404.2 [M+H]+	100%
1875	(CD3OD) δ 8.19-8.36 (m, 1 H), 7.68 (s, 1 H), 7.44 (br s, 0.5 H), 6.75-7.05 (m, 2.5 H), 6.50-6.68 (m, 1 H), 4.97 (br dd, 1 H), 3.65-3.84 (m, 0.5 H), 3.32-3.44 (m, 0.5 H), 2.90-3.22 (m, 1 H), 2.69-2.87 (m, 3 H), 2.18-2.39 (m, 1 H), 1.13-1.42 (m, 7 H)	404. 2 [M+H]+	94.8%
1876	(CD3OD) δ 8.39 (s, 1 H), 8.20-8.30 (m, 1 H), 8.07-8.12 (m, 1 H), 7.69 (s, 1 H), 7.57 (s, 0.3 H), 6.97 (s, 0.7 H), 6.70-6.83 (m, 3 H), 5.07 (br dd, 1 H), 4.00 (s, 3 H), 3.74-3.82 (m, 0.7 H), 3.42 (td. 0.3 H), 3.13-3.23 (m, 0.7 H), 2.95-3.03 (m, 0.3 H), 2.80-2.87 (m, 1 H), 2.01-2.15 (m, 1 H), 0.97-1.07 (m, 2 H), 0.73-0.81 (m, 2 H)	556.2 [M+H]+	100%
1877	(CD3OD) δ 8.38 (s, 1 H), 8.20-8.29 (m, 1 H), 8.06-8.12 (m, 1 H), 7.69 (s, 1 H), 7.58 (s, 0.3 H), 6.96 (s, 0.7 H), 6.69-6.83 (m, 3 H), 5.07 (dd, 1 H), 4.00 (s, 3 H), 3.74-3.82 (m, 0.7 H), 3.42 (td, 0.3 H), 3.12-3.22 (m, 0.7 H), 2.93-3.04 (m, 0.3 H), 2.77-2.89 (m, 1 H), 2.01-2.15 (m, 1 H), 0.96-1.07 (m, 2 H), 0.72-0.81 (m, 2 H)	556.1 [M+H]+	95.1%
1878	(CD3OD) δ 8.91 (s, 1 H), 8.34 (s, 1 H), 8.21-8.30 (m, 1 H), 7.92-8.00 (m, 1 H), 7.61-7.81 (m, 1 H), 7.50 (s, 0.2 H), 7.02 (s, 0.8 H), 6.74-6.84 (m, 3 H), 5.10 (br dd, 1 H), 3.74-3.83 (m, 0.7 H), 3.39-3.48 (m, 0.3 H), 3.17-3.24 (m, 0.7 H), 2.97-3.05 (m, 0.3 H), 2.83-2.92 (m, 1 H), 2.01-2.15 (m, 1 H), 0.98-1.06 (m, 2 H), 0.74-0.81 (m, 2 H)	492.2 [M+H]+	98.9%
1879	(CD3OD) δ 8.92 (s, 1 H), 8.35 (s, 1 H), 8.21-8.30 (m, 1 H), 7.89-7.99 (m, 1 H), 7.61-7.82 (m, 1 H), 7.50 (s, 0.2 H), 7.02 (s, 0.8 H), 6.75-6.84 (m, 3 H), 5.10 (br dd, 1 H), 3.72-3.85 (m, 0.7 H), 3.39-3.47 (m, 0.3 H), 3.17-3.24 (m, 0.7 H), 3.00 (br dd, 0.3 H), 2.82-2.92 (m, 1 H), 2.03-2.15 (m, 1 H), 0.98-1.07 (m. 2 H), 0.74-0.81 (m, 2 H)	492.2 [M+H]+	98.2%
1880	(CD3OD) δ 8.49 (d, 1 H), 8.19-8.33 (m, 1 H), 7.70 (s, 1 H), 7.52 (s, 0.3 H), 7.26 (d, 1 H), 6.98 (s, 0.7 H), 6.70-6.83 (m, 3 H), 4.92-5.05 (m, 1 H), 3.73-3.87 (m, 0.7 H), 3.43 (td, 0.3 H), 3.15-3.24 (m, 0.7 H), 2.97-3.06 (m, 0.3 H). 2.85 (br dd, 1 H), 2.01-2.15 (m, 1 H), 0.96-1.07 (m, 2 H), 0.71-0.82 (m, 2 H)	510.2 [M+H]+	100%
1881	(CD3OD) δ 8.49 (d, 1 H), 8.16-8.32 (m, 1 H), 7.70 (s, 1 H), 7.52 (s, 0.3 H), 7.26 (br s, 1 H), 6.98 (s, 0.7 H), 6.67-6.85 (m, 3 H), 4.92-5.06 (m, 1 H), 3.70-3.89 (m, 0.7 H), 3.43 (td, 0.3 H), 3.14-3.25 (m, 0.7 H), 2.96-3.06 (m, 0.3 H), 2.85 (br dd, 1 H), 2.00-2.15 (m, 1 H), 0.95-1.10 (m, 2 H), 0.74 -0.79 (dt, 2 H)	510.2 [M+H]+	99.5%
1882	(CD3OD) δ 8.08-8.25 (m, 1 H), 7.58 (s, 1 H), 7.34 (s, 0.3 H), 6.91-6.98 (m, 1 H). 6.69-6.83 (m, 1.7 H), 6.46-6.60 (m, 1 H), 4.87 (br dd, 1 H), 3.58-3.67 (m, 0.7 H), 3.26-3.34 (m, 0.3 H), 2.81-3.09 (m, 2 H). 2.71 (br dd. 1 H), 2.17-2.26 (m, 1 H), 1.08-1.26 (m, 10 H)	418.2 [M+H]+	100%
1883	(CD3OD) δ 8.08-8.25 (m, 1 H), 7.58 (s, 1 H), 7.34 (s, 0.3 H), 6.91-6.98 (m, 1 H), 6.69-6.83 (m, 1.7 H), 6.46-6.60 (m, 1 H), 4.87 (br dd, 1 H), 3.58-3.67 (m, 0.6 H), 3.26-3.34 (m, 0.4 H), 2.81-3.09 (m, 2 H), 2.71 (br dd, 1 H), 2.17-2.26 (m, 1 H), 1.08-1.26 (m, 10 H)	418.2 [M+H]+	99.4%
1884	(CD3OD) δ 8.07-8.23 (m, 1 H), 7.59 (s, 1 H), 7.29 (s, 0.3 H), 6.88-6.99 (m, 1 H), 6.84 (s, 0.7 H), 6.68-6.76 (m, 1 H), 6.48-6.62 (m, 1 H), 4.83-4.88 (m, 1 H), 3.66 (ddd, 0.6 H), 3.30 (td, 0.4 H), 2.83-3.12 (m, 2 H), 2.73 (br dd, 1 H), 1.73-1.84 (m, 6 H), 1.18-1.26 (m, 6 H)	438.2 [M+H]+	100%
1885	(CD3OD) δ 8.12-8.23 (m, 1 H), 7.59 (s, 1 H), 7.29 (s, 0.3 H), 6.91-6.99 (m, 1 H), 6.84 (s, 0.7 H), 6.68-6.76 (m, 1 H), 6.46-6.63 (m, 1 H), 4.82-4.88 (m, 1 H), 3.62-3.71 (m, 0.6 H), 3.26-3.35 (m, 0.4 H), 2.83-3.13 (m, 2 H), 2.73 (br dd, 1 H), 1.73-1.86 (m, 6 H), 1.19-1.26 (m. 6 H)	438.2 [M+H]+	99.1%
1886	(CD3OD) δ 8.37-8.44 (m, 1 H), 8.24-8.35 (m, 1 H), 8.06-8.16 (m, 1 H), 7.71 (s, 1 H), 7.57 (br s, 0.3 H), 7.02-7.11 (m, 1 H), 6.80-6.99 (m, 1.7 H), 6.62-6.74 (m, 1 H), 4.99-5.13 (m, 1 H), 4.02 (s, 3 H), 3.75-3.85 (m, 0.7 H), 3.38-3.50 (m, 0.3 H), 2.99-3.25 (m, 2 H), 2.81-2.92 (m, 1 H), 1.31-1.37 (m, 6 H)	458.2 [M+H]+	98.8%
1887	(CD3OD) δ 8.40 (s, 1 H), 8.23-8.35 (m, 1 H), 8.07-8.13 (m, 1 H), 7.71 (s, 1 H), 7.57 (s, 0.3 H), 7.02-7.10 (m, 1 H), 6.81-6.99 (m, 1.7 H), 6.62-6.74 (m, 1 H), 5.01-5.13 (m, 1 H), 4.01 (s, 3 H), 3.75-3.86 (m, 0.7 H), 3.38-3.50 (m, 0.3 H), 2.97-3.24 (m, 2 H), 2.81-2.90 (m, 1 H), 1.29-1.37 (m, 6 H)	458.2 [M+H]+	95.4%
1888	(CD3OD) δ 8.34-8.60 (m, 1 H), 7.62-7.91 (m, 2 H), 7.33-7.60 (m, 1.3 H), 6.89-7.17 (m, 1.7 H), 6.50-6.88 (m, 2 H), 5.03 (br dd, 1 H), 4.03 (s, 3 H), 3.71-3.81 (m, 0.6 H), 3.36-3.44 (m, 0.4 H), 3.12-3.24 (m, 0.5 H), 2.94-3.05 (m, 0.5 H), 2.84 (br d, 1 H)	494.1 [M+H]+	98.5%
1889	(CD3OD) δ 8.34-8.56 (m, 1 H), 7.63-7.89 (m, 2 H), 7.26-7.61 (m, 1.3 H), 6.87-7.12 (m, 1.6 H), 6.59-6.84 (m, 2 H), 5.04 (br dd, 1 H), 4.03 (s, 3 H), 3.72-3.81 (m, 0.5 H), 3.34-3.44 (m, 0.5 H), 3.10-3.25 (m, 0.7 H), 2.93-3.07 (m, 0.3 H), 2.78-2.89 (m, 1 H)	494.1 [M+H]+	98.0%
1890	(CD3OD) δ 8.32 (d, 1 H), 7.97-8.09 (m, 2 H), 7.69 (s, 1 H), 7.24-7.35 (m, 2 H), 6.99 (d, 1 H), 6.79 (t, 1 H), 6.59 (s, 1 H), 6.45 (s, 1 H), 4.37 (dd, 1 H), 3.79 (ddd, 1 H), 3.03-3.17 (m, 1 H), 2.85 (dd, 1 H), 2.45 (s, 3 H)	416.2 [M+H]+	99.4%
1891	(CD3OD) δ 8.20 (d, 1 H), 7.85-8.00 (m, 2 H), 7.57 (s, 1 H), 7.12-7.25 (m, 2 H), 6.87 (d, 1 H), 6.67 (t, 1 H), 6.47 (s, 1 H), 6.33 (s, 1 H), 4.25 (dd, 1 H), 3.60-3.74 (m, 1 H), 2.90-3.04 (m, 1 H), 2.66-2.79 (m, 1 H), 2.33 (s, 3 H)	416.2 [M+H]+	98.3%
1892	(CD3OD) δ 8.71 (d, 1 H), 7.97-8.09 (m, 2 H), 7.70 (s, 1 H), 7.63 (d, 1 H), 7.25-7.35 (m, 2 H), 6.99 (t, 1 H), 6.78 (s, 1 H), 6.48 (s, 1 H), 4.41 (dd, 1 H), 3.71-3.87 (m, 1 H), 3.03-3.19 (m, 1 H), 2.87 (dd, 1 H)	470.1 [M+H]+	99.9%
1893	(CD3OD) δ 8.70 (d, 1 H), 7.98-8.08 (m, 2 H), 7.71 (s, 1 H), 7.63 (d, 1 H), 7.23-7.34 (m, 2 H), 6.99 (t, 1 H), 6.78 (s, 1 H), 6.48 (s, 1 H), 4.41 (dd, 1 H), 3.79 (ddd, 1 H), 3.05-3.18 (m, 1 H), 2.87 (dd, 1 H)	470.1 [M+H]+	98.5%
1894	(CD3OD) δ 8.75 (d, 1 H), 8.17-8.35 (m, 2 H), 8.06 (td, 1 H), 7.58-7.75 (m, 2 H), 7.48 (s, 0.5 H), 6.92-7.05 (m, 1.5H), 6.55-6.86 (m, 2 H), 4.99 (br dd, 1 H), 3.81 (ddd. 0.5 H), 3.44 (td, 0.5 H), 2.91-3.25 (m, 1 H), 2.72-2.88 (m, 3 H), 1.22-1.35 (m, 3 H)	441.2 [M+H]+	99.0%
1895	(CD3OD) δ 8.76 (d, 1 H), 8.19-8.35 (m, 2 H), 8.06 (td, 1 H), 7.58-7.76 (m, 2 H), 7.48 (s, 0.5 H), 6.92-7.07 (m, 1.5 H), 6.73-6.85 (m, 1 H), 6.59-6.70 (m, 1 H), 5.00 (br dd, 1 H), 3.81 (ddd, 0.5 H), 3.44 (td, 0.5 H), 2.93-3.25 (m, 1 H), 2.71-2.89 (m. 3 H), 1.23-1.33 (m, 3 H)	441.2 [M+H]+	99.7%
1896	(CD3OD) δ 8.77 (d, 1 H), 8.19-8.33 (m, 2 H), 8.08 (td, 1 H), 7.62-7.72 (m, 2 H), 7.50 (s, 0.3 H), 6.99 (s, 0.7 H), 6.71-6.84 (m, 3 H), 4.92-5.04 (m, 1 H), 3.82 (ddd, 0.7 H), 3.45 (td. 0.3 H), 3.16-3.25 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.86 (br dd, 1 H), 2.02-2.15 (m, 1 H) 0.97-1.08 (m, 2 H). 0.72-0.82 (m, 2 H)	453.2 [M+H]+	100%
1897	(CD3OD) δ 8.76 (d, 1 H), 8.19-8.32 (m, 2 H), 8.07 (td, 1 H), 7.62-7.74 (m, 2 H), 7.50 (s, 0.3 H), 6.99 (s, 0.7 H), 6.71-6.82 (m, 3H), 4.92-5.04 (m, 1 H), 3.77-3.86 (m, 0.7 H), 3.44 (td. 0.3 H), 3.16-3.25 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.81-2.90 (m, 1 H), 2.02-2.15 (m, 1 H), 0.97-1.07 (m, 2 H), 0.73-0.82 (m, 2 H)	453.2 [M+H]+	99.7%
1898	(CD3OD) δ 8.19-8.38 (m, 1 H), 7.97-8.06 (m, 1 H), 7.71 (s, 1 H), 7.57 (s, 0.3), 6.99 (s, 0.7), 6.73-6.85 (m, 3 H), 5.07-5.12 (m, 1 H), 3.88-3.94 (m, 3 H), 3.76-3.85 (m. 0.7H), 3.46-3.51 (m, 0.3H), 3.14-3.26 (m, 1 H), 2.81-2.92 (m, 1 H), 2.62-2.76 (m, 3 H), 2.01-2.21 (m, 1 H), 0.99-1.10 (m, 2 H), 0.75-0.86 (m, 2 H)	470.2 [M+H]+	95.8%
1899	(CD3OD) δ 8.08-8.24 (m, 1 H), 7.84-7.94 (m, 1 H), 7.60 (br s, 1 H), 7.45 (br s, 0.3 H), 6.87 (br s, 0.7 H), 6.57-6.76 (m, 3 H), 4.82-5.07 (m, 1 H), 3.75-3.84 (m, 3 H), 3.60-3.74 (m, 0.7 H), 3.27-3.40 (m, 0.3 H), 3.02-3.14 (m, 0.7 H), 2.83-2.97 (m, 0.3 H), 2.68-2.81 (m, 1 H), 2.50-2.62 (m, 3 H), 1.91-2.07 (m, 1 H), 0.85-1.01 (m, 2 H), 0.62-0.72 (m, 2 H)	470.2 [M+H]+	95.0%
1900	(CD3OD) δ 8.21-8.33 (m, 1 H), 7.83 (d, 1 H), 7.72 (s, 1 H), 7.54 (s, 0.3 H), 6.95-7.05 (m, 1.7 H), 6.70-6.85 (m, 3 H), 4.99-5.08 (m, 1 H), 4.05 (s, 3 H), 3.75-3.87 (m, 0.7 H), 3.44 (td, 0.3 H), 3.14-3.26 (m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.81-2.91 (m, 1 H), 2.02-2.18 (m, 1 H), 0.98-1.11 (m, 2 H), 0.74-0.85 (m, 2 H)	456.2 [M+H]+	98.4%
1901	(CD3OD) δ 8.21-8.35 (m, 1 H), 7.83 (d, 1 H), 7.72 (s, 1 H), 7.55 (br s, 0.3 H), 6.97-7.03 (m, 1.7 H), 6.71-6.86 (m, 3 H), 5.04-5.09 (m, 1 H), 4.05 (s, 3 H), 3.75-3.88 (m, 0.7 H), 3.45-3.51 (m, 0.3 H), 3.15-3.26 (m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.87 (br dd, 1 H), 2.02-2.19 (m, 1 H), 0.98-1.10 (m, 2 H), 0.71-0.86 (m, 2 H)	456.2 [M+H]+	99.4%
1902	(CD3OD) δ 8.22-8.40 (m, 1 H), 7.71 (s, 1 H), 7.34-7.48 (m, 0.3 H), 7.03-7.11 (m, 1 H), 6.80-7.00 (m, 1.7 H), 6.59-6.75 (m, 1 H), 4.95-5.01 (m, 1 H), 3.70-3.82 (m, 0.6 H), 3.38-3.47 (m, 0.4 H), 2.92-3.25 (m, 2 H), 2.84 (br d, 1 H), 1.44-1.54 (m, 9 H), 1.30-1.40 (m, 6 H)	434.2 [M+H]+	100%
1903	(CD3OD) δ 8.24-8.36 (m, 1 H), 7.71 (s, 1 H), 7.41 (s, 0.3 H), 7.04-7.11 (m, 1 H), 6.80-6.99 (m, 1.7 H), 6.58-6.74 (m, 1 H), 4.98 (br dd, 1 H), 3.72-3.82 (m, 0.6 H), 3.42 (td, 0.4 H), 2.97-3.26 (m, 2 H), 2.84 (br d, 1 H), 1.45-1.53 (m, 9 H), 1.31-1.38 (m, 6 H)	434.2 [M+H]+	99.4%
1904	(DMSO-d6) & 7.97 (br s, 1 H), 7.41-7.55 (m, 2 H), 7.24-7.33 (m, 1 H), 6.83-6.95 (m, 2 H), 6.67 (br s, 0.3 H), 6.14-6.32 (m. 1.7 H), 5.86-6.07 (m, 2 H), 4.15-4.25 (m, 1 H), 2.96-3.06 (m, 0.6 H), 2.60-2.72 (m, 0.4 H), 2.03-2.43 (m, 3 H), 0.49-0.57 (m, 6 H)	455.2 [M+H]+	99.7%
1905	(DMSO-d6) δ 7.97 (br d, 1 H), 7.42-7.55 (m, 2 H), 7.28 (td, 1 H), 6.81-6.94 (m, 2 H), 6.68 (br s, 0.3 H), 6.16-6.29 (m, 1.7 H), 5.87-6.06 (m, 2 H), 4.22 (br s, 1 H), 2.99-3.08 (m, 0.6 H), 2.62-2.72 (m, 0.4 H), 2.03-242 (m, 3 H), 0.47-0.57 (m, 6 H)	455.2 [M+H]+	98.6%
1906	(CD3OD) δ 8.65 (d, 1 H), 8.21-8.38 (m, 1 H), 7.94 (t, 1 H), 7.68-7.79 (m, 2 H), 7.45 (br s, 0.3 H), 6.97-7.10 (m, 1.7 H), 6.68-6.88 (m, 2 H), 4.93-5.02 (m, 1 H), 3.76-3.87 (m, 0.6 H), 3.43-3.52 (m, 0.4 H), 3.01-3.28 (m, 2 H), 2.87 (br d, 1 H), 1.31-1.38 (m, 6 H)	473.2 [M+H]+	100%
1907	(CD3OD) δ 8.65 (d, 1 H), 8.23-8.36 (m, 1 H), 7.94 (t, 1 H), 7.68-7.79 (m, 2 H), 7.45 (br s. 0.3 H). 6.97-7.11 (m, 1.7 H), 6.68-6.89 (m, 2 H), 4.93-5.01 (m, 1 H), 3.79-3.89 (m, 0.6 H), 3.43-3.52 (m, 0.4 H), 3.00-3.27 (m, 2 H), 2.82-2.92 (m, 1 H), 1.31-1.37 (m, 6 H)	473.2 [M+H]+	99.7%
1908	(CD3OD) δ 8.36-8.57 (m, 1 H), 7.69 (s, 1 H), 7.35-7.56 (m, 1.3 H), 6.90 (s, 0.7 H), 6.74-6.82 (m, 1 H), 6.59-6.71 (m, 1 H), 4.99 (br dd, 1 H), 3.66-3.76 (m, 0.6 H), 3.34-3.40 (m, 0.4 H), 3.07-3.18 (m, 0.7 H), 2.91-3.01 (m, 0.3 H), 2.76-2.86 (m, 1 H), 2.24-2.38 (m, 1 H), 1.19-1.31 (m, 4 H)	454.1 [M+H]+	99.3%
1909	(CD3OD) δ 8.38-8.53 (m, 1 H), 7.69 (s, 1 H), 7.34-7.59 (m, 1.3 H), 6.90 (s, 0.7 H), 6.75-6.82 (m, 1 H), 6.60-6.72 (m, 1 H), 4.99 (br dd, 1 H), 3.67-3.75 (m, 0.6 H), 3.35-3.40 (m, 0.4 H), 3.08-3.17 (m, 0.7 H), 2.92-3.01 (m, 0.3 H), 2.81 (br d, 1 H), 2.26-2.39 (m, 1H), 1.19-1.29 (m, 4 H)	454.1 [M+H]+	93.7%
1910	(CD3OD) δ 8.78 (br d, 1 H), 8.40-8.52 (m, 1 H), 8.31 (d, 1 H), 8.08 (t, 1 H), 7.62-7.76 (m, 2 H), 7.39-7.55 (m, 1.4 H), 6.97 (s, 0.6 H), 6.67-6.84 (m, 2 H), 4.94-5.07 (m, 1 H), 3.74-3.83 (m, 0.7 H), 3.38-3.46 (m, 0.3 H), 3.16-3.25 (m, 0.7 H), 2.96-3.06 (m, 0.3 H), 2.81-2.89 (m, 1 H)	491.1 [M+H]+	99.9%
1911	(CD3OD) δ 8.77 (dd, 1 H), 8.39-8.52 (m, 1 H), 8.25-8.35 (m, 1 H), 8.08 (td, 1 H), 7.60-7.74 (m, 2 H), 7.40-7.53 (m, 1.3 H), 6.97 (s. 0.7 H), 6.66-6.86 (m, 2 H), 5.02 (br dd, 1 H), 3.74-3.83 (m, 0.5 H), 3.42 (td, 0.5 H), 3.16-3.25 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.80-2.92 (m, 1 H)	491.1 [M+H]+	98.6%
1912	(CD3OD) δ 8.47 (d, 1 H), 7.86-7.97 (m, 2 H), 7.58 (s, 1 H), 7.31 (br d, 1 H), 7.13-7.22 (m, 2 H), 7.00 (s, 0.2, 6.78-6.88 (m, 1.5, 6.73 (s, 0.3. 6.66 (s, 1 H), 6.35 (s, 1 H), 4.27 (dd, 1 H), 3.67 (ddd, 1 H), 2.91-3.07 (m, 1 H), 2.74 (dd, 1 H)	452.2 [M+H]+	99.3%
1913	(CD3OD) & 8.60 (br d, 1 H), 7.97-8. 10 (m, 2 H), 7.70 (s, 1 H), 7.44 (br d, 1 H), 7.25-7.34 (m, 2 H), 7.12 (s, 0.2, 6.90-7.01 (m, 1.5, 6.85 (s, 0.3) 6.78 (s, 1 H), 6.47 (s, 1 H), 4.39 (br dd, 1 H), 3.74-3.83 (m, 1 H), 3.06-3.16 (m, 1 H), 2.86 (br dd, 1 H)	452.2 [M+H]+	98.8%
1914	(CD3OD) δ 8.36-8.49 (m, 2 H), 7.76 (dd, 1 H), 7.64 (s, 1 H), 7.56 (d, 1 H), 7.10-7.24 (m, 2 H), 6.91 (s, 1 H), 6.83 (td, 1 H), 6.53 (s, 1 H), 4.71 (br dd, 1 H), 3.61 (ddd, 1 H), 2.89-3.02 (m, 1 H), 2.73 (dd, 1 H)	385.2 [M+H]+	100%
1915	(CD3OD) δ 8.26-8.36 (m, 2 H), 7.64 (dd, 1 H), 7.52 (s, 1 H), 7.44 (d, 1 H), 6.97-7.10 (m, 2 H), 6.79 (s, 1 H), 6.71 (td, 1 H), 6.41 (s, 1 H), 4.59 (br dd, 1 H), 3.40-3.55 (m, 1 H), 2.75-2.91 (m, 1 H), 2.61 (dd, 1 H)	385.1 [M+H]+	99.2%
1916	(CD3OD) δ 8.46 (br d, 1 H), 8.30 (s, 1 H), 7.65 (dd, 1 H), 7.53 (s, 1 H), 7.29 (br d, 1 H), 6.68-7.08 (m, 4 H), 6.58 (s, 1 H), 4.61 (br dd, 1 H), 3.42-3.54 (m, 1 H), 2.77-2.91 (m, 1 H), 2.62 (br dd, 1 H)	435.1 [M+H]+	100%
1917	(CD3OD) δ 8.58 (br d, 1 H), 8.42 (s, 1 H), 7.72-7.85 (m, 1 H), 7.66 (s. 1 H), 7.42 (br d, 1 H), 6.79-7.22 (m, 4 H). 6.70 (s, 1 H), 4.73 (br dd, 1 H), 3.53-3.65 (m, 1 H), 2.91-3.04 (m, 1 H), 2.69-2.82 (m, 1 H)	435.1 [M+H]+	100%
1918	(CD3OD) δ 8.18-8.44 (m, 1 H), 7.52-7.98 (m, 2 H), 6.98 (br d, 1 H), 6.43-6.89 (m, 3 H), 4.40-4.57 (m, 0.5 H), 3.57-3.84 (m, 0.5 H), 2.90-3.18 (m, 1 H), 2.61-2.88 (m, 1 H), 2.43 (s, 3 H), 2.08-2.31 (m, 1 H), 0.93-1.36 (m, 5 H)	389.2 [M+H]+	98.5%
1919	(CD3OD) δ 8.24-8.44 (m, 1 H), 7.53-7.95 (m, 2 H), 7.00 (br d, 1 H), 6.41-6.93 (m, 3 H), 4.39-4.55 (m, 0.5 H), 3.64-3.85 (m, 0.5 H), 2.93-3.11 (m, 1 H), 2.82 (br d, 1 H), 2.45 (s, 3 H), 2.19 (br d, 1 H), 0.95-1.39 (m, 5 H)	389.2 [M+H]+	97.4%
1920	(CD3OD) δ 8.19 (br s, 1 H), 7.35-7.98 (m, 2 H), 6.13-7.14 (m, 4 H), 4.42-4.67 (m, 1 H), 3.23-3.81 (m, 1 H), 2.57-3.08 (m, 2 H), 2.32 (s, 3 H), 1.32 (br s, 9 H)	405.2 [M+H]+	99.7%
1921	(CD3OD) δ 8.31 (br d, 1 H), 7.39-8.06 (m, 2 H), 6.28-7.19 (m, 4 H), 4.53-4.70 (m, 1 H), 3.35-3.96 (m, 1 H), 2.65-3.17 (m, 2 H), 2.45 (br s, 3 H), 1.42 (br s, 9 H)	405.2 [M+H]+	99.6%
1922	(CD3OD) δ 8.23-8.33 (m, 1 H), 7.69 (s, 1 H), 7.40 (s, 0.5 H), 6.88-7.04 (m, 1.5 H), 6.81 (q, 1 H), 6.52-6.69 (m, 1 H), 4.92-4.99 (m, 1 H), 3.76 (ddd, 0.5 H), 3.36-3.44 (m, 0.5 H), 2.77-3.21 (m, 4 H), 1.83-1.93 (m, 6 H), 1.27-1.35 (m, 3 H)	424.2 [M+H]+	99.1%
1923	(CD3OD) δ 8.17-8.38 (m, 1 H), 7.69 (s, 1 H), 7.40 (s, 0.5 H), 6.89-7.09 (m, 1.5 H), 6.75-6.87 (m, 1 H), 6.50-6.69 (m, 1 H), 4.96 (br d, 1 H), 3.76 (ddd, 0.5 H), 3.39 (br dd, 0.5 H), 2.74-3.20 (m, 4 H), 1.77-1.98 (m, 6 H), 1.27-1.34 (m, 3 H)	424.2 [M+H]+	98.6%
1924	(CD3OD) δ 8.21-8.42 (m, 2 H), 7.98-8.14 (m, 1 H), 7.48-7.76 (m, 1.5 H), 6.90-7.08 (m, 1.5 H), 6.76-6.86 (m, 1 H), 6.55-6.68 (m, 1 H), 5.06 (br dd, 1 H), 4.00 (s, 3 H), 3.72-3.83 (m, 0.5 H), 3.41 (td, 0.5 H), 2.75-3.22 (m, 4 H), 1.23-1.36 (m, 3 H)	444.2 [M+H]+	96.6%
1925	(CD3OD) δ 8.21-8.44 (m, 2 H), 8.02-8.16 (m, 1 H). 7.69 (s, 1.5 H), 6.91-7.10 (m, 1.5 H), 6.73-6.87 (m, 1 H), 6.46-6.72 (m, 1 H), 5.07 (br dd. 1 H), 4.00 (s, 3 H), 3.71-3.83 (m, 0.5 H), 3.38-3.45 (m, 0.5 H), 2.79-3.21 (m, 4 H), 1.24-1.36 (m, 3 H)	444.2 [M+H]+	95.6%
1926	(500 MHz, CD3OD) δ 8.18-8.35 (m, 1 H), 7.77-7.87 (m, 1 H), 7.71 (s, 1 H), 7.53 (s, 0.5 H), 6.94-7.07 (m, 2.5 H), 6.75-6.87 (m, 1 H), 6.56-6.73 (m, 1 H), 5.03 (br dd, 1 H), 4.03 (s, 3 H), 3.71-3.86 (m, 0.5 H), 3.43 (td. 0.5 H), 2.91-3.26 (m, 1 H), 2.72-2.88 (m, 3 H), 1.15-1.42 (m, 3 H)	444.2 (M+H]+	99.2%
1927	(CD3OD) δ 8.02-8.26 (m, 1 H), 7.68 (d, 1 H), 7.59 (s, 1 H), 7.40 (s, 0.5 H), 6.77-6.98 (m, 2.5 H), 6.61-6.74 (m, 1 H), 6.46-6.57 (m, 1 H), 4.91 (br dd, 1 H), 3.90 (s, 3 H), 3.60-3.76 (m, 0.5 H), 3.31 (td, 0.5 H), 2.82-3.13 (m, 1 H), 2.60-2.78 (m, 3 H), 1.04-1.26 (m, 3 H)	444.2 [M+H]+	99.3%
1928	(CD3OD) δ 9.08-9.19 (m, 1 H), 8.48 (s, 1 H), 8.21-8.33 (m, 1 H), 7.72 (s, 1 H), 7.50-7.62 (m, 0.3 H), 6.92-7.08 (m, 0.7 H), 6.72-6.85 (m, 3 H), 4.94-5.12 (m, 1 H), 3.77-3.88 (m, 0.7 H), 3.41-3.51 (m, 0.3 H), 3.14-3.24 (m, 0.7 H), 2.96-3.08 (m, 0.3 H), 2.80-2.92 (m, 1 H), 1.99-2.21 (m, 1 H). 0.96-1.12 (m, 2 H), 0.72-0.87 (m, 2 H)	510.2 [M+H]+	99.6%
1929	(CD3OD) δ 9.09-9.16 (m, 1 H), 8.48 (s, 1 H), 8.22-8.32 (m, 1 H), 7.72 (s, 1 H), 7.58 (s, 0.3 H), 6.99 (s, 0.7 H), 6.72-6.86 (m, 3 H), 5.07 (dd, 1 H), 3.77-3.87 (m, 0.7 H), 3.41-3.49 (m, 0.3 H), 3.15-3.23 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.82-2.91 (m, 1 H), 2.03-2.17 (m, 1 H), 1.00-1.09 (m, 2 H), 0.75-0.84 (m, 2 H)	510.2 [M+H]+	99.1%
1930	(CD3OD) δ 8.08-8.29 (m, 2 H), 7.72 (s, 0.3 H), 7.59 (d, 1.5 H), 7.42 (s, 0.5 H), 7.11 (d, 1 H), 6.88 (s, 0.7 H), 6.59-6.75 (m, 3 H), 4.92 (dd, 1 H), 3.63-3.77 (m, 0.7 H), 3.33 (td, 0.3 H), 3.03-3.14 (m, 0.7 H), 2.85-2.96 (m, 0.3 H), 2.75 (br dd, 1 H), 1.90-2.05 (m, 1 H), 0.85-0.98 (m, 2 H), 0.61-0.71 (m, 2 H)	492.2 [M+H]+	99.3%
1931	(CD3OD) δ 8.09-8.25 (m, 2 H), 7.72 (s, 0.3 H), 7.55-7.62 (m, 1.5 H), 7.42 (s, 0.5 H), 7.11 (d, 1 H). 6.88 (s, 0.7 H), 6.60-6.73 (m, 3 H), 4.92 (dd, 1 H). 3.64-3.75 (m, 0.7 H), 3.29-3.38 (m, 0.3 H), 3.04-3.13 (m, 0.7 H), 2.85-2.96 (m, 0.3 H), 2.70-2.80 (m, 1 H), 1.88-2.08 (m, 1 H), 0.87-0.98 (m, 2 H), 0.63-0.72 (m, 2 H)	492.2 [M+H]+	99.1%
1932	(CD3OD) δ 8.18-8.28 (m, 1 H), 7.69 (s, 1 H), 7.52 (s, 0.3 H), 6.96 (s, 0.7 H), 6.69-6.80 (m, 4 H), 5.00 (br dd, 1 H), 3.88 (s, 3 H), 3.74-3.82 (m, 0.7 H), 3.41 (td, 0.3 H), 3.12-3.23 (m, 0.7 H), 2.95-3.03 (m, 0.3 H), 2.79-2.87 (m, 1 H), 2.37 (s, 3 H), 2.00-2.13 (m, 1 H), 0.95-1.05 (m, 2 H), 0.70-0.80 (m, 2 H)	470.2 [M+H]+	99.8%
1933	(CD3OD) δ 8.18-8.29 (m, 1 H), 7.69 (s, 1 H), 7.52 (s, 0.3 H), 6.97 (s, 0.7 H), 6.68-6.81 (m, 4 H), 5.00 (br dd, 1 H), 3.88 (s, 3 H), 3.75-3.83 (m, 0.7 H), 3.41 (td, 0.3 H), 3.11-3.23 (m, 0.7 H), 2.94-3.04 (m, 0.3 H), 2.78-2.88 (m, 1 H), 2.37 (s, 3 H), 1.99-2.14 (m. 1 H), 0.94-1.07 (m, 2 H), 0.68-0.83 (m, 2 H)	470.2 [M+H]+	99.6%
1934	(CD3OD) δ 9.31-9.40 (m, 1 H), 8.73 (br d, 2 H), 8.12-8.22 (m, 1 H), 7.60 (s, 1 H), 7.36 (s, 0.3 H), 6.85-6.98 (m, 1.7 H), 6.58-6.76 (m, 2 H), 4.84-4.94 (m, 1 H), 3.65-3.79 (m, 0.7 H), 3.32-3.42 (m, 0.3 H), 2.87-3.13 (m, 2 H), 2.76 (br dd, 1 H), 1.19-1.25 (m, 6 H)	456.2 [M+H]+	100%
1935	(CD3OD) δ 9.29-9.41 (m, 1 H), 8.71-8.77 (m, 2 H), 8.12-8.23 (m, 1 H), 7.60 (s, 1 H), 7.37 (s, 0.3 H), 6.86-6.98 (m, 1.7 H), 6.58-6.76 (m, 2 H), 4.91 (br dd, 1 H), 3.67-3.78 (m, 0.7 H), 3.31-3.42 (m, 0.3 H), 2.88-3.13 (m, 2 H), 2.70-2.81 (m, 1 H), 1.20-1.26 (m, 6 H)	456.2 [M+H]+	99.7%
1936	(CD3OD) δ 8.77-8.84 (m, 1 H), 8.10-8.25 (m, 2 H), 7.39-7.69 (m, 2.5 H), 6.85-6.97 (m, 1.5 H), 6.51-6.75 (m, 2 H), 4.96 (br dd, 1 H), 3.65-3.76 (m, 0.7 H), 3.33 (td, 0.3 H), 2.86-3.13 (m, 2 H), 2.69-2.79 (m, 1 H), 1.18-1.25 (m, 6 H)	494.2 [M+H]+	100%
1937	(CD3OD) δ 8.90-8.95 (m, 1 H), 8.24-8.38 (m, 2 H), 7.50-7.84 (m, 2.5 H), 6.97-7.09 (m, 1.5 H), 6.65-6.88 (m, 2 H), 5.08 (br dd, 1 H), 3.76-3.87 (m, 0.7 H), 3.45 (td, 0.3 H), 2.98-3.25 (m, 2 H), 2.82-2.92 (m, 1 H), 1.31-1.37 (m, 6 H)	494.2 [M+H]+	99.8%
1938	(CD3OD) δ 8.31-8.54 (m, 1 H), 7.70 (s, 1 H), 7.29-7.50 (m, 1.4 H), 6.93 (br s, 0.6 H), 6.58-6.84 (m, 2 H), 4.97 (br dd, 1 H), 3.69-3.78 (m, 0.6 H), 3.35-3.41 (m, 0.4 H), 2.94-3.20 (m, 1 H), 2.78-2.88 (m, 1 H), 1.85-1.93 (m, 6 H)	474.1 [M+H]+	96.1%
1939	(CD3OD) δ 8.31-8.62 (m, 1 H), 7.70 (s, 1 H), 7.29-7.56 (m, 1.3 H), 6.93 (br s, 0.7 H), 6.52-6.85 (m, 2 H), 4.97 (br dd, 1 H), 3.35-3.79 (m, 1 H), 2.93-3.20 (m, 1 H), 2.83 (br d, 1 H), 1.78-1.97 (m, 6 H)	474.1 [M+H]+	91.2%
1940	(CD3OD) δ 8.42 (s, 1 H), 8.31 (d, 1 H), 7.77 (dd, 1 H), 7.64 (s, 1 H), 7.14 (d, 1 H), 6.86-7.01 (m, 2 H), 6.76 (t, 1 H), 6.53 (s, 1 H), 4.72 (br dd, 1 H), 3.55-3.68 (m, 1 H), 2.88-3.02 (m, 1 H), 2.74 (dd, 1 H), 2.43 (s, 3 H)	399.2 [M+H]+	99.9%
1941	(CD3OD) δ 8.42 (s, 1 H), 8.31 (d, 1 H), 7.77 (dd, 1 H), 7.64 (s, 1 H), 7.14 (d, 1 H), 6.87-7.01 (m, 2 H), 6.76 (t, 1 H), 6.53 (s, 1 H), 4.72 (br dd, 1 H), 3.55-3.68 (m, 1 H), 2.89-3.03 (m, 1 H), 2.74 (dd, 1 H), 2.43 (s, 3 H)	399.2 [M+H]+	98.8%
1942	(CD3OD) δ 8.41 (s, 1 H), 8.32 (d, 1 H), 7.76 (dd, 1 H), 7.70 (s, 1 H), 7.13 (d, 1 H), 6.88-6.99 (m, 2 H), 6.80 (td, 1 H), 6.65 (s, 1 H), 4.71 (br dd, 1 H), 3.59 (ddd, 1 H), 2.85-3.02 (m, 1 H), 2.73 (dd, 1 H)	403.1 [M+H]+	99.1%
1943	(CD3OD) δ 8.40 (s, 1 H), 8.32 (d, 1 H), 7.76 (dd, 1 H), 7.63 (s, 1 H), 7.13 (d, 1 H), 6.86-6.97 (m, 2 H), 6.79 (td, 1 H), 6.65 (s, 1 H), 4.72 (br dd, 1H), 3.59 (ddd, 1 H), 2.85-3.01 (m, 1 H), 2.73 (dd, 1 H)	403.2 [M+H]+	97.4%
1944	(CD3OD) δ 8.29 (d, 1 H), 8.14 (s, 1 H), 7.67 (s, 1 H), 6.31-7.05 (m, 4 H), 4.36 (br s, 1 H), 3.71 (br s, 1 H), 2.96-3.14 (m, 1 H), 2.78 (br dd, 1 H), 2.44 (s, 3 H), 2.19-2.38 (m, 1 H), 0.83-1.07 (m, 4 H)	389.2 [M+H]+	94.8%
1945	(CD3OD) δ 8.31 (d, 1 H), 8.15 (s, 1 H), 7.68 (s, 1 H), 6.55-7.05 (m, 4 H), 4.39 (br s, 1 H), 3.52-3.85 (m, 1 H), 3.06 (br s, 1 H), 2.80 (br dd, 1 H), 2.46 (s, 3 H), 2.24-2.41 (m, 1 H), 0.92-1.03 (m, 4 H)	389.2 [M+H]+	98.3%
1946	(CD3OD) δ 9.09-9.17 (m, 1 H), 8.48 (s, 1 H), 8.23-8.37 (m, 1 H), 7.71 (s, 1 H), 7.56 (s, 0.3 H), 7.03-7.11 (m, 1 H), 6.81-6.99 (m, 1.7 H), 6.64-6.74 (m, 1 H), 4.99-5.13 (m, 1 H), 3.77-3.87 (m, 0.7 H), 3.41-3.52 (m, 0.3 H), 2.98-3.25 (m, 2 H), 2.83-2.92 (m, 1 H), 1.32-1.38 (m, 6 H)	512.2 [M+H]+	99.4%
1947	(CD3OD) δ 9.07-9.17 (m, 1 H), 8.48 (s, 1 H), 8.24-8.35 (m, 1 H), 7.72 (s, 1 H), 7.56 (s, 0.3 H), 7.03-7.11 (m, 1 H), 6.81-6.99 (m, 1.7 H), 6.63-6.74 (m, 1 H), 5.07 (br dd, 1 H), 3.76-3.87 (m, 0.7 H), 3.45 (td, 0.3 H), 3.20 (td, 2 H), 2.80-2.92 (m, 1 H), 1.31-1.38 (m, 6 H)	512.2 [M+H]+	99.4%
1948	(CD3OD) δ 8.11-8.22 (m, 1 H), 7.83-7.89 (m, 1 H), 7.59 (s, 1 H), 7.44 (s, 0.3 H), 6.90-6.96 (m, 1 H), 6.67-6.87 (m, 1.7 H), 6.53-6.61 (m, 1 H), 4.84-5.04 (m, 1 H), 3.77 (s, 3 H), 3.64-3.73 (m, 0.7 H), 3.32 (td, 0.3 H), 2.84-3.13 (m, 2 H), 2.68-2.79 (m, 1 H), 2.51-2.59 (m, 3 H), 1.18-1.25 (m, 6 H)	472.2 [M+H]+	98.0%
1949	(CD3OD) δ 8.11-8.22 (m, 1 H), 7.83-7.90 (m, 1 H), 7.59 (s, 1 H), 7.43 (s, 0.3 H), 6.90-6.98 (m, 1 H), 6.66-6.86 (m, 1.7 H), 6.52-6.61 (m, 1 H), 4.98 (br dd, 1 H), 3.77 (s, 3 H), 3.63-3.72 (m, 0.7 H), 3.26-3.37 (m, 0.3 H), 2.84-3.14 (m, 2 H), 2.67-2.78 (m, 1 H), 2.52-2.59 (m, 3 H), 1.18-1.25 (m, 6 H)	472.2 [M+H]+	94.1%
1950	(CD3OD) δ 8.23-8.36 (m, 1 H), 7.82 (d, 1 H), 7.71 (s, 1 H), 7.48-7.56 (m, 0.3 H), 7.03-7.09 (m, 1 H), 6.79-7.01 (m, 2.7 H), 6.64-6.74 (m, 1 H), 5.04 (br dd, 1 H), 4.04 (s, 3 H), 3.81 (ddd, 0.7 H), 3.45 (td, 0.3 H), 2.98-3.25 (m, 2 H), 2.82-2.91 (m, 1 H), 1.28-1.38 (m, 6 H)	458.2 [M+H]+	99.7%
1951	(CD3OD) δ 8.24-8.36 (m, 1 H), 7.83 (d, 1 H), 7.71 (s, 1 H), 7.52 (s, 0.3 H), 7.03-7.10 (m, 1 H), 6.80-7.02 (m, 2.7 H), 6.64-6.75 (m, 1 H), 4.97-5.10 (m, 1 H), 4.04 (s, 3 H), 3.74-3.89 (m, 0.7 H), 3.41-3.51 (m, 0.3 H), 2.98-3.27 (m, 2 H), 2.81-2.91 (m, 1 H), 1.30-1.38 (m, 6 H)	458.2 [M+H]+	99.7%
1952	(CD3OD) δ 8.36 (d, 1 H), 7.97-8.09 (m, 2 H), 7.70 (s, 1 H), 7.30 (t, 2 H), 6.93-7.01 (m, 1 H), 6.80-6.87 (m, 1 H), 6.73 (s, 1 H), 6.46 (br s, 1 H), 4.39 (dd, 1 H), 3.73-3.86 (m, 1 H), 3.03-3.19 (m, 1 H), 2.86 (br dd, 1 H)	420.1 [M+H]+	99.1%
1953	(CD3OD) δ 8.31-8.41 (m, 1 H), 7.98-8.09 (m, 2 H), 7.67-7.75 (m, 1 H), 7.24-7.37 (m, 2 H), 6.92-7.03 (m, 1 H), 6.80-6.88 (m, 1 H), 6.73 (s, 1 H), 6.38-6.53 (m, 1 H), 4.34-4.45 (m, 1 H), 3.72-3.87 (m, 1 H), 3.04-3.18 (m, 1 H), 2.81-2.94 (m, 1 H)	420.1 [M+H]+	99.4%
1954	(CD3OD) δ 8.34 (d, 1 H), 7.57-7.75 (m, 2 H), 6.94 (dd, 1 H), 6.78-6.90 (m, 2 H), 6.62-6.76 (m, 2 H), 6.21 (dd, 1 H), 4.52-4.59 (m, 1 H), 3.56 (ddd, 1 H), 2.89-3.02 (m, 1 H), 2.62-2.77 (m, 1 H)	353.1 [M+H]+	99.8%
1955	(CD3OD) δ 8.34 (d, 1 H), 7.59-7.72 (m, 2 H), 6.94 (dd, 1 H), 6.77-6.89 (m, 2 H), 6.60-6.76 (m, 2 H), 6.21 (dd, 1 H), 4.58 (br s, 1 H), 3.49-3.64 (m, 1 H), 2.84-3.03 (m, 1 H), 2.70 (br dd, 1 H)	353.1 [M+H]+	99.6%
1956	(CD3OD) δ 8.22-8.50 (m, 1 H), 7.54-8.13 (m, 2 H), 7.48 (d, 1 H), 7.02-7.34 (m, 1 H), 6.76 (br d, 1.6 H), 6.33-6.65 (m, 1.4 H), 4.60-4.71 (m, 0.5 H), 4.34 (br s, 0.5 H), 3.66 (br s, 0.5 H), 3.27-3.37 (m, 0.5 H), 2.80-3.07 (m, 1 H), 2.73 (br d, 1 H), 1.58-2.02 (m, 6 H)	395.2 [M+H]+	99.1%
1957	(CD3OD) δ 8.35 (br s, 1 H), 7.91 (br s, 0.4 H), 7.54-7.73 (m, 1.6 H), 7.49 (d, 1 H), 7.02-7.20 (m, 1 H), 6.76 (br s, 1.6 H), 6.31-6.63 (m, 1.4 H), 4.57-4.70 (m, 0.5 H), 4.19-4.42 (m, 0.5 H), 3.66 (br s, 0.6 H), 3.27-3.34 (m, 0.4 H), 2.99 (br s, 1 H), 2.73 (br d, 1 H), 1.72 (br d, 6 H)	395.2 [M+H]+	99.3%
1958	(CD3OD) δ 8.20 (br s, 1 H), 7.90 (br s, 0.5 H), 7.48-7.72 (m, 1.5 H), 6.89 (br d, 1 H), 6.61-6.83 (m, 1.6 H), 6.32-6.59 (m, 1.4 H), 4.58-4.71 (m, 0.5 H), 4.35 (br s, 0.5 H), 3.66 (br s, 0.5 H), 3.25-3.36 (m, 0.5 H), 2.82-3.11 (m, 1 H), 2.72 (br s, 1 H), 2.34 (s, 3 H), 1.57-1.87 (m, 6 H)	409.2 [M+H]+	99.6%
1959	(CD3OD) δ 8.06-8.33 (m, 1 H), 7.91 (br s, 0.5 H), 7.50-7.72 (m, 1.5 H), 6.89 (br d. 1 H), 6.63-6.83 (m. 1.5 H), 6.34-6.61 (m, 1.5 H), 4.56-4.69 (m, 0.5 H), 4.25-4.42 (m, 0.5 H), 3.52-3.73 (m, 0.5 H), 3.27 (br d, 0.5 H), 2.80-3.08 (m. 1 H), 2.73 (br d, 1 H), 2.34 (s, 3 H), 1.55-1.83 (m, 6 H)	409.2 [M+H]+	99.4%
1960	(CD3OD) δ 8.28 (br s, 2 H), 7.73-8.16 (m, 2 H), 7.70 (s, 1 H), 7.00 (br d, 1 H), 6.70-6.96 (m, 2 H), 6.63 (br s, 1 H), 4.62 (br s, 1 H), 3.98 (s, 3 H), 3.80 (br s, 0.5 H), 3.37-3.54 (m, 0.5 H), 2.78-3.22 (m, 2 H), 2.45 (s, 3 H)	429.2 [M+H]+	98.3%
1961	(CD3OD) δ 8.04-8.35 (m, 2 H), 7.64-8.02 (m, 2 H), 7.59 (s, 1 H), 6.89 (br d, 1 H), 6.56-6.83 (m. 2 H), 6.51 (br s, 1 H), 4.49 (br s, 1 H), 3.86 (s, 3 H), 3.68 (br s, 0.5 H), 3.25-3.43 (m, 0.5 H), 2.58-3.12 (m, 2 H), 2.34 (s, 3 H)	429.2 [M+H]+	89.5%
1962	(CD3OD) δ 8.23 (br s, 1 H), 7.67-8.02 (m, 2 H), 7.64 (s, 1 H), 6.89 (br d, 1 H), 6.57-6.84 (m, 2 H), 6.50 (br s, 1 H), 4.60-4.69 (m, 1 H), 3.74 (br s, 3 H), 3.24-3.68 (m, 1 H), 2.63-3.12 (m, 2 H), 2.52 (br d, 3 H), 2.34 (s, 3 H)	443.2 [M+H]+	100%
1963	(CD3OD) δ 8.23 (br s, 1 H), 7.82 (br s, 2 H), 7.65 (br s, 1 H), 6.89 (br d, 1 H), 6.58-6.84 (m, 2 H), 6.51 (br s, 1 H), 4.56-4.68 (m, 1 H), 3.74 (br s, 3 H), 3.25-3.69 (m, 1 H), 2.69-3.08 (m, 2 H), 2.39-2.63 (m, 3 H), 2.34 (s, 3 H)	443.2 [M+H]+	99.0%
1964	(CD3OD) δ 8.68-8.76 (m, 1 H), 8.33 (br s, 1 H), 8.23 (br d, 1.5 H), 7.87-8.10 (m, 1.5 H), 7.71 (br s, 1 H), 7.52-7.63 (m, 1 H), 7.01 (br d, 1 H), 6.57-6.97 (m, 3 H), 4.70-4.82 (m, 1 H), 3.41-3.95 (m, 1 H), 2.96-3.28 (m, 1 H), 2.86 (br s, 1 H), 2.47 (s, 3 H)	426.2 [M+H]+	100%
1 965	(CD3OD) δ 8.73 (d, 1 H), 8.33 (br s, 1 H), 8.24 (br s, 1.5 H), 7.87-8.10 (m, 1.5 H), 7.70 (br s, 1 H), 7.59 (dd, 1 H), 7.01 (br d, 1 H), 6.55-6.97 (m, 3 H), 4.63-4.80 (m, 1 H), 3.43-3.91 (m, 1 H), 2.95-3.28 (m, 1 H), 2.86 (br s, 1 H), 2.47 (s, 3 H)	426.2 [M+H]+	99.9%
1966	(CD3OD) δ 8.69 (br d, 1 H), 8.29-8.54 (m, 2 H), 8.02 (td, 1 H), 7.66-7.83 (m, 1.3 H), 7.48-7.66 (m, 2 H), 7.08-7.32 (m, 1 H), 6.75-7.06 (m, 1.7 H), 6.50-6.72 (m, 1 H), 5.13 (dd, 1 H), 3.66-3.88 (m, 0.6 H), 3.45 (td, 0.4 H), 2.95-3.28 (m, 1 H), 2.83 (dd, 1 H)	429.1 [M+H]+	100%
1967	(CD3OD) δ 8.70 (br d, 1 H), 8.25-8.53 (m, 2 H), 8.02 (td, 1 H), 7.47-7.87 (m, 3.3 H), 7.11-7.32 (m, 1 H), 6.77-7.04 (m, 1.7 H), 6.51-6.72 (m, 1 H), 5.13 (dd, 1 H), 3.65-3.89 (m, 0.7 H), 3.45 (td, 0.3 H), 2.97-3.27 (m, 1 H), 2.84 (dd, 1 H)	429.1 [M+H]+	99.8%
1968	(CD3OD) δ 8.70 (br d, 1 H), 8.25-8.45 (m, 2 H), 7.92-8.11 (m, 1 H), 7.65-7.82 (m, 1.4 H), 7.57 (dd, 1 H), 6.90-7.04 (m, 1.6 H), 6.70-6.90 (m, 2 H), 5.17 (dd, 1 H). 3.77 (ddd, 0.6 H), 3.44 (td, 0.4 H), 2.96-3.27 (m, 1 H), 2.84 (dd, 1 H)	447.1 [M+H]+	100%
1 969	(CD3OD) δ 8.58 (br d, 1 H), 8.08-8.35 (m, 2 H), 7.79-8.00 (m, 1 H), 7.64 (br s, 1.4 H), 7.45 (dd, 1 H), 6.44-7.08 (m, 3.6 H), 5.06 (br dd, 1 H), 3.57-3.76 (m, 0.6 H), 3.32 (td, 0.4 H), 2.85-3.16 (m, 1 H), 2.73 (br dd, 1 H)	447.1 [M+H]+	99.8%
1970	(CD3OD) δ 8.46-9.12 (m, 1 H), 8.19-8.43 (m, 2 H), 8.01 (td, 1 H), 7.64-7.87 (m, 1.3 H), 7.56 (dd, 1 H), 6.98 (q, 1.7 H), 6.71-6.84 (m, 1 H), 6.52-6.69 (m, 1 H), 5.13 (dd, 1 H), 3.69-3.85 (m, 0.7 H), 3.40-3.51 (m, 0.3 H), 2.96-3.27 (m, 1 H), 2.84 (dd, 1 H), 2.29-2.56 (m, 3 H)	443.1 [M+H]+	100%
1971	(CD3OD) δ 8.51-9.00 (m, 1 H), 8.19-8.48 (m, 2 H), 7.92-8.15 (m, 1 H), 7.47-7.86 (m, 2.3 H), 6.92-7.11 (m, 1.7 H), 6.71-6.89 (m, 1 H), 6.51-6.69 (m, 1 H), 5.13 (br dd, 1 H), 3.71-3.85 (m, 0.7 H), 3.41-3.50 (m, 0.3 H), 2.96-3.27 (m, 1 H), 2.84 (br dd, 1 H), 2.39-2.53 (m, 3 H)	443.2 [M+H]+	100%
1972	(CD3OD) δ 9.46-9.54 (m, 2 H), 9.41 (s, 1 H), 8.26-8.36 (m, 1 H), 7.72-7.79 (m, 1 H), 7.56 (s, 0.3 H), 6.98-7.05 (m, 1.7 H), 6.77-6.85 (m, 1 H), 6.59-6.69 (m, 1 H), 5.11 (br d, 1 H), 3.80-3.87 (m, 0.7 H), 3.50 (br d, 0.3 H), 3.16-3.24 (m, 0.7 H), 3.00-3.05 (m, 0.3 H), 2.84-2.92 (m, 1 H), 2.43-2.49 (m, 3 H)	428.2 [M+H]+	99.9%
1973	(CD3OD) δ 9.46-9.52 (m, 2 H), 9.40 (s, 1 H), 8.26-8.35 (m, 1 H), 7.72 (s, 1 H), 7.55 (br s, 0.3 H), 7.01 (br t, 1.7 H), 6.77-6.84 (m, 1 H), 6.60-6.68 (m. 1 H), 5.09 (br d, 1 H), 3.83 (ddd, 0.7 H), 3.46-3.52 (m, 0.3 H), 3.15-3.27 (m, 0.7 H), 2.98-3.08 (m, 0.3 H), 2.83-2.93 (m, 1 H), 2.42-2.49 (m, 3 H)	428.1 [M+H]+	98.8%
1974	(CD3OD) δ 9.47-9.53 (m, 2 H), 9.40 (s, 1 H), 8.31-8.39 (m, 1 H), 7.72 (s, 1 H), 7.51-7.60 (m, 0.3 H), 6.95-7.02 (m, 1.7 H), 6.81-6.90 (m, 1 H), 6.75-6.80 (m, 1 H), 5.11 (m, 1 H), 3.75-3.90 (m, 0.7 H), 3.39-3.51 (m, 0.3 H), 3.16-3.26 (m, 0.7 H), 2.99-3.05 (m, 0.3 H), 2.83-2.94 (m, 1 H)	432.2 [M+H]+	99.7%
1975	(CD3OD) δ 9.44-9.55 (m, 2 H), 9.40 (s, 1 H), 8.30-8.40 (m, 1 H), 7.72 (s, 1 H), 7.56 (s, 0.3 H), 6.94-7.04 (m, 1.7 H), 6.82-6.90 (m, 1 H), 6.76-6.81 (m, 1 H), 5.11 (br d, 1 H), 3.78-3.87 (m, 0.7 H), 3.46 (br d, 0.3 H), 3.17-3.27 (m, 0.7 H), 2.97-3.05 (m, 0.3 H), 2.90 (br s, 1 H)	432.1 [M+H]+	98.9%
1976	(CD3OD) δ 8.34 (d, 1 H), 8.07-8.18 (m, 1 H), 7.63 (s, 1 H), 7.54-7.61 (m, 1 H), 7.05 (d, 1 H), 6.94 (dd, 1 H), 6.76-6.85 (m, 2 H), 6.67 (dd, 1 H), 6.63 (s, 1 H), 4.57 (dd, 1 H), 3.52-3.64 (m, 1 H), 2.88-3.05 (m, 1 H), 2.69 (dd, 1 H)	335.1 [M+H]+	99.7%
1977	(CD3OD) δ 8.34 (d, 1 H), 8.10-8.17 (m, 1 H), 7.62 (s, 1 H), 7.55-7.61 (m, 1 H), 7.05 (d, 1 H), 6.94 (dd, 1 H), 6.76-6.86 (m, 2 H), 6.67 (dd, 1 H), 6.63 (s, 1 H), 4.52-4.60 (m, 1 H), 3.51-3.63 (m, 1 H), 2.88-3.03 (m, 1 H), 2.69 (dd, 1 H)	335.2 [M+H]+	98.6%
1978	(CD3OD) δ 8.58 (br d, 1 H), 8.13 (dd, 1 H), 7.54-7.66 (m, 2 H), 7.41 (br d, 1 H), 6.74-7.13 (m, 4 H), 6.62-6.72 (m, 2 H), 4.56 (br d, 1 H), 3.49-3.61 (m, 1 H), 2.90-3.03 (m, 1 H), 2.69 (br dd, 1 H)	367.2 [M+H]+	98.9%
1979	(CD3OD) δ 8.58 (br d, 1 H), 8.13 (dd, 1 H), 7.54-7.67 (m, 2 H), 7.41 (br d, 1 H), 6.75-7.12 (m, 4 H), 6.63-6.71 (m, 2 H), 4.55 (br s, 1 H), 3.56 (ddd, 1 H), 2.89-3.03 (m, 1 H), 2.69 (br dd, 1 H)	367.1 [M+H]+	96.6%
1980	(CD3OD) δ 9.04 (br d, 2 H), 8.22-8.38 (m, 1 H), 7.66-7.79 (m, 2 H), 7.46 (br s, 0.3 H), 6.95-7.13 (m, 1.7 H), 6.69-6.89 (m, 2 H), 5.00-5.02 (m, 1 H), 3.76-3.90 (m, 0.6 H), 3.44-3.51 (m, 0.4 H), 2.97-3.27 (m, 2 H), 2.88 (br d, 1 H), 1.30-1.42 (m, 6 H)	456.2 [M+H]+	99.6%
1981	(CD3OD) δ 9.02-9.08 (m, 2 H), 8.23-8.36 (m, 1 H), 7.68-7.75 (m, 2 H), 7.41-7.49 (m, 0.3 H), 6.97-7.11 (m, 1.7 H), 6.69-6.88 (m, 2 H), 4.99-5.03 (m, 1 H), 3.79-3.88 (m, 0.6 H), 3.43-3.53 (m, 0.4 H), 2.99-3.27 (m, 2 H), 2.88 (br d, 1 H), 1.31-1.38 (m, 6 H)	456.2 [M+H]+	99.0%
1982	(CD3OD) δ 8.22-8.39 (m, 2 H), 7.49-7.86 (m, 2.3 H), 7.23 (d, 1 H), 6.95-7.11 (m, 1.7 H), 6.64-6.89 (m, 2 H), 5.04 (br dd, 1 H), 3.77-3.88 (m, 0.6 H). 3.42-3.52 (m, 0.4 H), 3.21 (tt, 2 H). 2.83-2.93 (m, 1 H), 1.30-1.39 (m, 6 H)	494.2 [M+H]+	100%
1983	(CD3OD) δ 8.22-8.37 (m, 2 H), 7.47-7.86 (m, 2.3 H), 7.24 (d, 1 H), 6.96-7.11 (m. 1.7 H), 6.63-6.90 (m, 2 H), 5.04 (br dd, 1 H), 3.77-3.89 (m, 0.6 H), 3.41-3.52 (m, 0.4 H), 2.99-3.27 (m, 2 H), 2.83-2.92 (m, 1 H), 1.31-1.38 (m, 6 H)	494.2 [M+H]+	100%
1984	(CD3OD) δ 8.52 (d, 1 H), 8.21-8.37 (m, 2 H), 7.63 (s, 0.3 H), 7.29 (d, 1 H), 7. 10 (br t, 1.7 H), 6.78-6.91 (m, 2 H), 5.13 (br dd, 1 H), 3.77-3.86 (m, 0.6 H), 3.42-3.53 (m, 0.4 H), 3.03-3.29 (m, 2 H), 2.95 (br d, 1 H), 1.32-1.38 (m, 6 H)	512.2 [M+H]+	100%
1985	(CD3OD) δ 8.40 (d, 1 H). 8.12-8.26 (m, 1 H). 7.60 (br s, 1 H). 7.40 (br s, 0.3 H), 7.17 (d, 1 H), 6.84-7.00 (m, 1.7 H), 6.54-6.77 (m, 2 H), 4.90-4.95 (m, 1 H), 3.65-3.75 (m, 0.6 H), 3.29-3.39 (m, 0.4 H), 2.90-3.14 (m, 2 H), 2.70-2.81 (m, 1 H), 1.20-1.26 (m, 6 H)	512.2 [M+H]+	99.7%
1986	(CD3OD) δ 8.34 (d. 1 H), 8.14 (s, 1 H). 7.67 (s. 1 H), 6.42-7.07 (m, 4 H), 4.18-4.57 (m, 1 H), 3.70 (br s, 1 H), 2.93-3.18 (m, 1 H), 2.79 (br dd, 1 H), 2.20-2.45 (m, 1 H), 0.83-1.13 (m, 4 H)	393.2 [M+H]+	99.2%
1987	(CD3OD) δ 8.34 (d, 1 H). 8.14 (s. 1 H), 7.67 (s, 1 H). 6.46-7.05 (m, 4 H), 4.38 (br s, 1 H), 3.54-3.84 (m, 1 H), 3.01-3.15 (m, 1 H). 2.72-2.86 (m, 1 H). 2.35 (br s, 1 H). 0.91-1.00 (m, 4 H)	393.2 [M+H]+	98.0%
1988	(CD3OD) δ 8.23-8.32 (m, 1 H), 8.08-8.12 (m, 1 H), 7.65-7.73 (m, 1.3 H), 7.37-7.43 (m, 1 H), 6.81-7.14 (m, 1.7 H), 6.71-6.80 (m, 1 H). 6.49-6.64 (m, 1 H). 5.04 (dd, 1 H). 3.69 (ddd, 0.7 H), 3.33-3.40 (m, 0.3 H). 3.07-3.18 (m, 0.7 H), 2.90-3.00 (m. 0.3 H). 2.78 (dd, 1 H), 2.36-2.47 (m, 3 H)	349.2 [M+H]+	100%
1989	(CD3OD) δ 8.25-8.31 (m, 1 H), 8.09-8.12 (m, 1 H), 7.68 (s, 1 H), 7.38-7.44 (m, 1 H), 6.93-7.00 (m, 2 H). 6.73-6.81 (m, 1 H). 6.47-6.63 (m, 1 H), 4.94-5.08 (m, 1 H), 3.69 (ddd, 0.7 H), 3.35-3.41 (m, 0.3 H), 3.08-3.18 (m, 0.7 H), 290-2.98 (m, 0.3 H), 2.78 (dd, 1 H), 2.38-2.47 (m, 3 H)	349.1 [M+H]+	99.4%
1990	(CD3OD) δ 8.39-8.52 (m, 1 H), 7.65-7.80 (m, 1.3 H), 7.53-7.64 (m, 1 H), 7.14-7.27 (m, 1 H), 6.79-6.99 (m, 1.7 H), 6.51-6.67 (m, 1 H), 5.14 (br dd, 0.5 H), 4.79-4.87 (m, 0.5 H), 3.62-3.78 (m, 0.5 H), 3.36-3.48 (m, 0.5 H), 2.91-3.22 (m, 1 H), 2.80 (br d, 1 H), 2.48-2.63 (m, 1 H), 1.12-1.43 (m, 4 H)	392.1 [M+H]+	100%
1991	(CD3OD) δ 8.37-8.50 (m, 1 H), 7.65-7.78 (m, 1.3 H), 7.53-7.64 (m, 1 H), 7.12-7.27 (m, 1 H), 6.79-6.98 (m, 1.7 H), 6.51-6.68 (m, 1 H), 5.14 (dd, 0.5 H), 4.79-4.86 (m, 0.5 H), 3.64-3.78 (m, 0.5 H). 3.36-3.47 (m, 0.5 H), 2.92-3.21 (m, 1 H), 2.80 (br dd, 1 H), 2.49-2.63 (m, 1 H), 1.16-1.40 (m, 4 H)	392.1 [M+H]+	96.4%
1992	(CD3OD) δ 8.28-8.40 (m, 1 H), 7.66-7.78 (m, 1.3 H), 6.89-7.03 (m, 1.7 H), 6.79-6.89 (m, 1 H), 6.69-6.77 (m, 1 H), 5.17 (dd, 0.5 H), 4.85 (br d, 0.5 H), 3.66-3.78 (m, 0.5 H), 3.36-3.46 (m, 0.5 H), 2.92-3.21 (m, 1 H), 2.81 (dd, 1 H). 2.51-2.62 (m, 1 H). 1.17-1.40 (m, 4 H)	410.1 [M+H]+	99.6%
1993	(CD3OD) δ 8.26-8.42 (m, 1 H), 7.66-7.77 (m, 1.3 H), 6.89-7.04 (m, 1.7 H), 6.78-6.89 (m, 1 H), 6.67-6.77 (m, 1 H), 5.17 (dd, 0.5 H), 4.85 (br d, 0.5 H), 3.71 (ddd, 0.5 H), 3.36-3.49 (m, 0.5 H), 2.92-3.20 (m, 1 H), 2.81 (dd, 1 H), 2.49-2.63 (m, 1 H), 1.17-1.41 (m. 4 H)	410.1 [M+H]+	88.5%
1994	(CD3OD) δ 8.20-8.43 (m, 1 H), 7.63-7.84 (m, 2 H), 6.65-7.03 (m, 5 H), 5.22 (dd, 1 H), 3.99 (s, 3 H), 3.65-3.79 (m, 0.6 H), 3.42 (td, 0.4 H), 2.92-3.24 (m, 1 H), 2.82 (br dd, 1 H)	450.1 [M+H]+	99.2%
1995	(CD3OD) δ 8.17-8.41 (m, 1 H), 7.51-7.84 (m, 2 H). 6.60-7.02 (m, 5 H), 5.22 (dd, 1 H), 3.98 (s, 3 H), 3.65-3.78 (m, 0.6 H), 3.37-3.50 (m, 0.4 H), 2.94-3.25 (m. 1 H), 2.73-2.89 (m, 1 H)	450.1 [M+H]+	99.1%
1996	(CD3OD) δ 8.24-8.37 (m, 1 H), 7.64-7.78 (m, 1.3 H), 6.90-7.05 (m, 1.7 H), 6.74-6.84 (m, 1 H), 6.51-6.65 (m, 1 H), 5.14 (dd, 0.5 H), 4.80-4.87 (m, 0.5 H), 3.72 (ddd, 0.5 H), 3.42 (td, 0.5 H), 2.93-3.21 (m, 1 H), 2.80 (dd, 1 H), 2.52-2.63 (m, 1 H), 2.40-2.50 (m, 3 H), 1.16-1.41 (m, 4 H)	406.2 [M+H]+	100%
1997	(CD3OD) δ 8.25-8.37 (m, 1 H), 7.65-7.77 (m, 1.3 H), 6.89-7.05 (m, 1.7 H), 6.73-6.84 (m, 1 H), 6.54-6.66 (m, 1 H), 5.14 (dd, 0.5 H), 4.79-4.86 (m, 0.5 H). 3.65-3.78 (m, 0.5 H), 3.37-3.48 (m. 0.5 H), 2.93-3.22 (m, 1 H), 2.80 (dd, 1 H), 2.51-2.63 (m, 1 H), 2.39-2.50 (m, 3 H), 1.16-1.42 (m, 4 H)	406.2 [M+H]+	99.6%
1998	(CD3OD) δ 8.18-8.39 (m, 1 H), 7.59-7.82 (m, 2.5 H), 6.85-7.02 (m, 2.5 H), 6.69-6.81 (m, 1 H), 6.50-6.66 (m, 1 H), 5.18 (dd, 1 H), 3.98 (s, 3 H), 3.65-3.84 (m, 0.7 H), 3.43 (td. 0.3 H). 2.92-3.24 (m, 1 H), 2.81 (br dd, 1 H), 2.34-2.48 (m, 3 H)	446.2 [M+H]+	99.1%
1999	(CD3OD) δ 8.15-8.36 (m, 1 H), 7.54-7.80 (m, 2.5 H), 6.86-7.04 (m, 2.5 H), 6.70-6.82 (m, 1 H), 6.45-6.67 (m, 1 H), 5.18 (dd, 1 H), 3.98 (s, 3 H), 3.67-3.80 (m, 0.6 H), 3.43 (td, 0.4 H), 2.94-3.24 (m, 1 H), 2.81 (br dd, 1 H), 2.32-2.50 (m, 3 H)	446.2 [M+H]+	98.8%
2000	(CD3OD) δ 8.37-8.51 (m, 1 H), 8.01-8.27 (m, 2.5 H), 7.68 (d, 1 H), 7.46-7.64 (m, 3 H). 7.06-7.31 (m, 1 H). 6.98 (s. 0.5 H). 6.74-6.91 (m, 1 H), 6.47-6.71 (m, 1 H), 5.49 (dd, 0.5 H), 4.90-4.95 (m, 0.5 H), 3.64-3.81 (m, 0.7 H), 3.36-3.56 (m, 0.3 H), 3.10 (s, 1 H), 2.82 (br d, 1 H)	401.1 [M+H]+	100%
2001	(CD3OD) δ 8.38-8.50 (m, 1 H), 8.05-8.27 (m, 2.5 H), 7.69 (s, 1 H). 7.49-7.66 (m, 3 H). 7.08-7.27 (m, 1 H). 6.99 (s. 0.5 H). 6.73-6.92 (m, 1 H), 6.44-6.71 (m, 1 H), 5.35-5.59 (m, 0.5 H), 4.93 (s, 0.5 H), 3.64-3.85 (m, 0.5 H), 3.32-3.51 (m. 0.5 H). 2.98-3.20 (m, 1 H), 2.72-2.87 (m, 1 H)	401.1 [M+H]+	99.4%
2002	(CD3OD) δ 8.18-8.46 (m, 1.4 H), 7.94-8.16 (m, 2 H), 7.69 (s, 1 H). 7.58 (dq, 2 H). 6.89-7.08 (m, 1.6 H), 6.62-6.88 (m. 2 H), 5.53 (br dd, 0.5 H), 4.93-5.05 (m, 0.5H), 3.73 (td, 0.6 H), 3.38-3.52 (m, 0.4 H), 2.95-3.25 (m, 1 H), 2.82 (br d, 1 H)	419.1 [M+H]+	100%
2003	(CD3OD) δ 8.20-8.44 (m, 1.5 H), 8.00-8.19 (m, 2 H), 7.69 (s, 1 H), 7.46-7.63 (m. 2 H), 6.88-7.09 (m. 1.5 H). 6.58-6.87 (m, 2 H). 5.53 (br dd, 0.5 H), 4.94-4.99 (m, 0.5 H), 3.66-3.76 (m, 0.6 H), 3.40-3.49 (m, 0.4 H), 2.94-3.25 (m. 1 H), 2.77-2.88 (m, 1 H)	419.1 [M+H]+	99.6%
2004	(CD3OD) δ 8.28-8.55 (m, 1 H), 7.42-7.92 (m, 3.4 H), 7.14-7.26 (m, 1 H), 7.05-7.10 (m, 1 H), 6.96 (br s, 0.6 H), 6.81-6.89 (m, 1 H). 6.47-6.76 (m, 1 H). 5.04 (br dd. 1 H), 4.22-4.41 (m. 3 H), 3.39-3.86 (m, 1 H), 2.95-3.26 (m, 1 H), 2.75-2.93 (m, 1 H)	416.2 [M+H]+	98.4%
2005	(CD3OD) δ 8.33-8.55 (m, 1 H), 7.48-7.78 (m, 3.3 H), 7.14-7.24 (m, 1 H), 7.05-7.10 (m, 1 H), 6.96 (s, 0.7 H), 6.78-6.89 (m, 1 H), 6.55-6.68 (m, 1 H), 5.04 (dd, 1 H), 4.23-4.37 (m, 3 H), 3.74-3.85 (m, 0.6 H), 3.37-3.45 (m, 0.4 H), 2.94-3.24 (m, 1 H), 2.78-2.90 (m, 1 H)	416.2 [M+H]+	97.6%
2006	(CD3OD) δ 8.22-8.37 (m, 1 H). 7.64-7.75 (m, 1 H), 7.51 (s, 0.3 H), 6.95-7.22 (m, 1.7 H), 6.63-6.92 (m, 3 H), 5.02 (br dd, 1 H), 3.88-3.96 (m, 3 H), 3.75-3.86 (m, 0.6 H), 3.40-3.48 (m, 0.4 H), 2.98-3.27 (m, 2 H), 2.86 (br d, 1 H), 2.41 (s, 3 H), 1.30-1.39 (m, 6 H)	472.2 [M+H]+	100%
2007	(CD3OD) δ 8.24-8.36 (m, 1 H). 7.63-7.74 (m, 1 H). 7.51 (s. 0.3 H), 6.96-7.22 (m, 1.7 H), 6.60-6.92 (m, 3 H), 4.99-5.07 (m, 1 H), 3.88-3.96 (m, 3 H), 3.75-3.85 (m, 0.6 H), 3.40-3.49 (m, 0.4 H), 2.97-3.27 (m, 2 H), 2.86 (br d, 1 H), 2.41 (s, 3 H), 1.31-1.39 (m, 6 H)	472.2 [M+H]+	100%
2008	(CD3OD) δ 8.46 (d, 1 H), 7.99-8.06 (m, 2 H), 7.70 (s, 1 H), 7.26-7.34 (m, 3 H), 6.85 (t, 1 H), 6.72 (s, 1 H), 6.42-6.49 (m, 1 H), 4.39 (dd, 1 H), 3.79 (ddd, 1 H), 3.05-3.16 (m, 1 H), 2.81-2.92 (m, 1 H)	436.1 [M+H]+	99.1%
2009	(CD3OD) δ 8.45 (d, 1 H), 7.96-8.12 (m, 2 H), 7.70 (s, 1 H), 7.16-7.40 (m. 3 H), 6.85 (t, 1 H), 6.72 (s, 1 H). 6.45 (br s, 1 H). 4.39 (dd, 1 H), 3.71-3.84 (m, 1 H), 3.04-3.16 (m, 1 H), 2.80-2.91 (m, 1 H)	436.1 [M+H]+	99.3%
2010	(CD3OD) δ 7.97-8.14 (m, 2 H), 7.68 (s, 1 H), 7.47 (d, 1 H), 7.30 (t, 2 H), 7.12 (dd, 1 H), 6.71 (d, 1 H), 6.53 (s, 1 H). 6.46 (s, 1 H), 4.36 (dd, 1 H), 3.82 (td, 1 H), 3.04-3.15 (m, 1 H), 2.81-2.91 (m, 1 H). 2.63 (s. 3 H)	416.2 [M+H]+	100%
2011	(CD3OD) δ 7.99-8.08 (m, 2 H), 7.68 (s, 1 H), 7.47 (d, 1 H), 7.25-7.34 (m, 2 H), 7.12 (dd, 1 H), 6.71 (d, 1 H), 6.53 (s, 1 H), 6.46 (s. 1 H), 4.36 (dd, 1 H), 3.76-3.88 (m, 1 H), 3.03-3.17 (m, 1 H), 2.86 (dd, 1 H), 2.63 (s, 3 H)	416.2 [M+H]+	99.6%
2012	(CD3OD) δ 8.69 (d, 1 H), 8.43 (s, 1 H), 7.78 (dd, 1 H), 7.57-7.70 (m, 2 H), 7.16 (d, 1 H), 6.91-7.01 (m, 2 H), 6.70 (s, 1 H), 4.74 (br dd, 1 H), 3.53-3.67 (m, 1 H), 2.89-3.03 (m, 1 H), 2.75 (dd, 1 H)	453.1 [M+H]+	100%
2013	(CD3OD) δ 8.57 (d, 1 H), 8.31 (s, 1 H), 7.66 (dd, 1 H), 7.44-7.57 (m, 2 H), 7.04 (d, 1 H), 6.85 (br t, 2 H), 6.58 (s, 1 H), 4.62 (br dd. 1 H), 3.43-3.54 (m. 1 H), 2.76-2.91 (m. 1 H), 2.63 (dd, 1 H)	453.2 [M+H]+	79.7%
2014	(CD3OD) δ 8.69 (d, 1 H), 8.13 (s, 1 H), 7.53-7.75 (m, 2 H), 6.45-7.12 (m, 3 H), 4.39 (br s, 1 H), 3.37-3.87 (m, 1 H), 3.05 (br s, 1 H). 2.71-2.86 (m, 1 H). 2.36 (br s, 1 H). 0.89-1.03 (m, 4 H)	443.2 [M+H]+	99.9%
2015	(CD3OD) δ 8.68 (d, 1 H), 8.13 (s, 1 H), 7.55-7.74 (m, 2 H), 6.51-7.06 (m, 3 H), 4.41 (br s, 1 H), 3.39-3.85 (m, 1 H), 3.05 (br s, 1 H), 2.79 (br dd, 1 H), 2.36 (br s, 1 H), 0.74-1.15 (m, 4 H)	443.2 [M+H]+	98.8%
2016	(CD3OD) δ 8.31-8.53 (m, 1 H), 7.54-7.89 (m, 3 H), 7.09-7.29 (m, 1 H), 6.75-7.02 (m, 3 H), 6.48-6.69 (m, 1 H), 5.18 (br d, 1 H), 3.98 (s, 3 H), 3.72 (br t, 0.5 H), 3.40 (br d, 0.5 H), 2.72-3.25 (m, 2 H)	432.1 [M+H]+	100%
2017	(CD3OD) δ 8.29-8.53 (m, 1 H), 7.50-7.83 (m, 3 H), 7.09-7.26 (m, 1 H), 6.77-6.97 (m, 3 H), 6.50-6.67 (m, 1 H), 5.18 (br dd, 1 H), 3.98 (s, 3 H), 3.59-3.83 (m, 0.5 H), 3.42 (td, 0.5 H), 2.93-3.23 (m, 1 H), 2.81 (br dd, 1 H)	432.1 [M+H]+	98.0%
2018	(CD3OD) δ 8.28-8.41 (m, 2H), 8.08 (s, 1 H), 7.84 (s, 0.3 H), 7.65-7.76 (m, 1 H), 6.91-7.03 (m, 1.7 H), 6.72-6.90 (m, 2 H), 5.29 (dd, 0.6 H), 4.93-4.99 (m, 0.4 H), 4.00 (s, 3 H), 3.68-3.80 (m, 0.6 H), 3.45 (td, 0.4 H), 2.95-3.23 (m, 1 H), 2.77-2.90 (m, 1 H)	450.2 [M+H]+	100%
2019	(CD3OD) δ 8.28-8.40 (m, 2 H), 8.08 (s, 1 H), 7.84 (s, 0.3 H), 7.71 (s, 1 H), 6.89-7.03 (m, 1.7 H), 6.69-6.88 (m, 2 H), 5.29 (dd, 0.6 H), 4.93-4.98 (m, 0.4 H), 4.00 (d, 3 H), 3.68-3.81 (m, 0.6 H), 3.45 (td, 0.4 H), 2.96-3.24 (m, 1 H), 2.84 (br d, 1 H)	450.1 [M+H]+	99.8%
2020	(CD3OD) δ 8.19-8.44 (m, 1 H), 7.83-7.97 (m, 1 H), 7.63-7.82 (m, 2 H), 7.43-7.62 (m, 2.2 H), 6.93-7.13 (m, 1.8 H), 6.72-6.89 (m, 1 H), 6.42-6.71 (m, 1 H), 5.00 (br d, 1 H), 3.70-3.90 (m, 0.5 H), 3.39-3.49 (m, 0.5 H), 2.96-3.29 (m, 1 H), 2.78-2.91 (m, 1 H), 2.37-2.55 (m, 3 H)	399.2 [M+H]+	100%
2021	(CD3OD) δ 8.20-8.39 (m, 1 H), 7.82-7.96 (m, 1 H), 7.62-7.79 (m, 2 H), 7.40-7.61 (m, 2.2 H), 6.91-7.11 (m, 1.8 H), 6.71-6.85 (m, 1 H), 6.41-6.70 (m, 1 H), 4.98-5.03 (m, 1 H), 3.67-3.87 (m, 0.5 H), 3.36-3.47 (m, 0.5 H), 2.97-3.26 (m, 1 H), 2.73-2.90 (m, 1 H), 2.31-2.55 (m, 3 H)	399.2 [M+H]+	98.2%
2022	(DMSO-d6) δ 12.00-12.33 (m, 1 H), 8.59-9.05 (m, 1 H), 7.93-8.32 (m, 2.5 H), 7.44-7.77 (m, 4 H), 7.05-7.35 (m, 1 H), 6.85-7.04 (m, 1 H), 6.57-6.81 (m, 1.5 H), 5.40-5.56 (m, 0.6 H), 4.76-4.91 (m, 0.4 H), 3.62-3.78 (m, 0.6 H), 3.24-3.30 (m, 0.4 H), 2.73-3.11 (m, 2 H)	451.2 [M+H]+	100%
2023	(DMSO-d6) δ 11.96-12.33 (m, 1H), 8.65-8.97 (m, 1 H), 7.94-8.37 (m, 2.5 H), 7.44-7.71 (m, 4H), 7.09-7.44 (m, 1 H), 6.87-7.04 (m, 1 H), 6.64-6.84 (m, 1.5 H), 5.33-5.63 (m, 0.6 H), 4.84 (br dd, 0.4 H), 3.51-3.78 (m, 0.5 H), 3.22-3.31 (m, 0.5 H), 2.72-3.12 (m, 2 H)	451.1 [M+H]+	99.8%
2024	(CD3OD) δ 8.21-8.40 (m, 1 H), 7.64 (d, 1 H), 6.92-7.01 (m, 1 H), 6.88 (s, 0.6 H), 6.71-6.81 (m, 1 H), 6.48-6.67 (m, 1.4 H), 4.76 (br dd, 0.3 H), 4.51 (br dd, 0.7 H), 3.62-3.71 (m, 0.5 H), 3.22 (td, 0.5 H), 2.90-3.00 (m, 0.5H), 2.65-2.85 (m, 1.5 H), 2.06-2.44 (m, 4H), 0.78-1.13 (m, 4H)	322.1 [M+H]+	99.6%
2025	(CD3OD) δ 8.23-8.37 (m, 1 H), 7.64 (d, 1 H), 6.92-7.00 (m, 1 H), 6.88 (s, 0.6 H), 6.70-6.79 (m, 1 H), 6.47-6.64 (m, 1.4 H), 4.76 (br dd, 0.3 H), 4.51 (br dd, 0.7 H), 3.66 (ddd, 0.5 H), 3.22 (td, 0.5 H), 2.89-3.01 (m, 0.5 H), 2.64-2.85 (m, 1.5 H), 2.03-2.44 (m, 4 H), 0.76-1.13 (m, 4 H)	322.2 [M+H]+	99.6%
2026	(CD3OD) δ 8.28 (br d, 1 H), 7.61-7.69 (m, 1 H), 6.88-7.06 (m, 1.8 H), 6.71-6.80 (m, 1 H), 6.47-6.58 (m, 1.2 H), 4.84 (br d, 0.3 H), 4.33 (br dd, 0.7 H), 3.70 (ddd, 0.7 H), 3.35-3.43 (m, 0.3 H), 3.09 (td, 0.8 H), 2.69-2.96 (m, 2.2 H), 2.42 (s, 3 H), 1.99-2.12 (m, 1 H), 1.81 (br dd, 1H)	358.2 [M+H]+	100%
2027	(CD3OD) δ 8.23-8.40 (m, 1 H), 7.66 (d, 1 H), 6.96 (br dd, 1H), 6.68-6.88 (m, 1.5 H), 6.32-6.60 (m, 1.5 H), 4.75 (br dd, 0.5 H), 4.31 (br dd, 0.5 H), 3.65-3.81 (m, 0.5 H), 3.48 (td, 0.5 H), 2.95-3.25 (m, 1.5 H), 2.67-2.87 (m, 1.5 H), 2.41 (s, 3 H), 2.06-2.21 (m, 1 H), 1.70-1.95 (m, 1 H)	358.2 [M+H]+	100%
2028	(CD3OD) δ 8.25-8.32 (m, 1 H), 7.59-7.71 (m, 1 H), 6.91-7.02 (m, 2 H), 6.76 (t, 1 H), 6.47-6.57 (m, 1 H), 4.83 (br d, 0.2 H), 4.33 (dd, 0.8 H), 3.70 (ddd, 0.8 H), 3.34-3.42 (m, 0.2 H), 3.09 (ddd, 0.8 H), 2.69-2.94 (m, 2.2 H), 2.42 (s, 3 H), 2.05 (dtd, 1 H), 1.76-1.88 (m, 1 H)	358.2 [M+H]+	100%
2029	(CD3OD) δ 8.24-8.43 (m, 1 H), 7.66 (d, 1 H), 6.97 (br dd, 1 H), 6.68-6.87 (m, 1.5 H), 6.35-6.55 (m, 1.5 H), 4.75 (br dd, 1 H), 4.31 (dd, 0.5 H), 3.66-3.77 (m, 0.5 H), 3.43-3.53 (m, 0.5 H), 3.20 (td, 0.5 H), 2.95-3.14 (m, 1 H), 2.71-2.85 (m, 1 H), 2.41 (s, 3H), 2.04-2.18 (m, 1 H), 1.74-1.91 (m, 1 H)	358.2 [M+H]+	98.5%
2030	(CD3OD) δ 8.32 (d, 1 H), 7.66 (s, 1 H), 6.90-7.01 (m, 1.7 H), 6.81 (td, 1 H), 6.50-6.69 (m, 1.3 H), 4.85 (br d, 0.4 H), 4.36 (dd, 0.6 H), 3.69 (ddd, 0.8 H), 3.36-3.41 (m, 0.2 H), 3.04-3.15 (m, 0.8 H), 2.69-2.96 (m, 2.2 H), 1.99-2.11 (m, 1H), 1.73-1.91 (m, 1 H)	362.2 [M+H]+	100%
2031	(CD3OD) δ 8.28-8.44 (m, 1 H), 7.67 (d, 1 H), 6.89-7.00 (m, 1 H), 6.39-6.89 (m, 3 H), 4.76 (br dd, 0.7 H), 4.34 (br dd, 0.3 H), 3.66-3.77 (m, 0.5 H), 3.41-3.51 (m, 0.5 H), 3.09-3.22 (m, 1 H), 2.95-3.08 (m, 0.5 H), 2.69-2.88 (m, 1.5 H), 2.06-2.19 (m, 1 H), 1.76-1.96 (m, 1 H)	362.1 [M+H]+	90.8%
2032	(CD3OD) δ 8.72 (d, 1 H), 7.85-8.47 (m, 4 H), 7.68 (s, 1 H), 7.49-7.61 (m, 1 H), 6.65-7.04 (m, 4 H), 4.61-4.76 (m, 1 H), 3.41-3.90 (m, 1 H), 2.94-3.24 (m, 1 H), 2.70-2.93 (m, 1 H)	430.1 [M+H]+	100%
2033	(CD3OD) δ 8.71 (dt, 1 H), 7.85-8.50 (m, 4 H), 7.68 (br s, 1 H), 7.57 (dd, 1 H), 6.67-7.02 (m, 4 H), 4.61-4.74 (m, 1 H), 3.38-3.90 (m, 1 H), 2.95-3.25 (m, 1 H), 2.85 (br d, 1 H)	430.1 [M+H]+	99.6%
2034	(CD3OD) δ 8.50-8.80 (m, 2 H), 7.81-8.36 (m, 3 H), 7.69 (br s, 1 H), 7.53-7.61 (m, 1 H), 7.44 (br d, 1 H), 6.52-7.28 (m, 4 H), 4.62-4.79 (m, 1 H), 3.40-3.88 (m, 1 H), 2.68-3.27 (m, 2 H)	462.2 [M+H]+	100%
2035	(CD3OD) δ 8.42-8.80 (m, 2 H), 7.87-8.32 (m, 3 H), 7.68 (br s, 1 H), 7.57 (br dd, 1 H), 7.44 (br d, 1 H), 6.69-7.15 (m, 4 H), 4.62-4.78 (m, 1 H), 3.42-3.90 (m, 1 H), 2.74-3.25 (m, 2 H)	462.1 [M+H]+	99.7%
2036	(CD3OD) δ 8.50-8.86 (m, 2 H), 7.83-8.32 (m, 3 H), 7.46-7.77 (m, 3 H), 6.64-7.16 (m, 3 H), 4.62-4.79 (m, 1 H), 3.43-3.91 (m, 1 H), 2.70-3.25 (m, 2 H)	480.1 [M+H]+	99.9%
2037	(CD3OD) δ 8.57-8.85 (m, 2 H), 7.88-8.30 (m, 3 H), 7.50-7.72 (m, 3 H), 6.69-7.10 (m, 3 H), 4.62-4.79 (m, 1 H), 3.42-3.88 (m, 1 H), 2.78-3.25 (m, 2 H)	480.2 [M+H]+	99.8%
2038	(CD3OD) δ 8.58 (d, 1 H), 8.13 (s, 1 H), 7.68 (s, 1 H), 7.42 (br d, 1 H), 6.65-7.14 (m, 4 H), 4.38 (br s, 1 H), 3.69 (br s, 1 H), 2.94-3.15 (m, 1 H), 2.79 (br dd, 1 H), 2.36 (br s, 1 H), 0.90-0.99 (m, 4 H)	425.2 [M+H]+	99.0%
2039	(CD3OD) δ 8.58 (d, 1 H), 8.13 (s, 1 H), 7.67 (s, 1 H), 7.42 (br d, 1 H), 6.64-7.15 (m, 4 H), 4.37 (br s, 1H), 3.70 (br s, 1H), 2.96-3.19 (m, 1 H), 2.79 (br dd, 1H), 2.09-2.46 (m, 1 H), 0.90-1.00 (m, 4 H)	425.2 [M+H]+	100%
2040	(CD3OD) δ 8.43 (d, 1 H), 8.13 (s, 1 H), 7.68 (s, 1 H), 7.29 (d, 1 H), 6.42-6.94 (m, 3 H), 4.39 (br s, 1 H), 3.38-3.93 (m, 1 H), 2.95-3.16 (m, 1 H), 2.72-2.87 (m, 1 H), 2.36 (br s, 1 H), 0.89-1.03 (m, 4 H)	409.1 [M+H]+	99.5%
2041	(CD3OD) δ 8.43 (d, 1 H), 8.13 (s, 1 H), 7.67 (s, 1 H), 7.29 (d, 1 H), 6.35-7.00 (m, 3 H), 4.39 (br s, 1 H), 3.36-3.80 (m, 1 H), 3.05 (br s, 1 H), 2.79 (br dd, 1 H), 2.21-2.47 (m, 1 H), 0.92-1.04 (m, 4 H)	409.2 [M+H]+	99.1%
2042	(CD3OD) δ 8.03 (s, 1 H), 7.40-7.60 (m, 2 H), 6.43-7.08 (m, 4 H), 4.28 (br s, 1 H), 3.76 (br s, 1 H), 2.89 (br d, 1 H), 2.68 (br dd, 1 H), 2.25 (br s, 1H), 0.85 (br d, 4H)	409.2 [M+H]+	99.6%
2043	(CD3OD) δ 8.03 (s, 1 H), 7.37-7.60 (m, 2 H), 6.47-7.13 (m, 4 H), 4.29 (br s, 1 H), 3.27-3.87 (m, 1 H), 2.82-2.99 (m, 1 H), 2.68 (dd, 1 H), 2.25 (br s, 1H), 0.86 (br d, 4 H)	409.2 [M+H]+	99.8%
2044	(CD3OD) δ 8.30-8.38 (m, 1 H), 8.24 (s, 1 H), 7.96 (s, 1 H), 7.72 (s, 0.4 H), 7.55-7.60 (m, 1 H), 7.44-7.51 (m, 1 H), 7.04-7.14 (m, 1 H), 6.83 (s, 0.6 H), 6.75 (br dd, 1 H), 6.43-6.55 (m, 1 H), 5.13 (dd, 0.6 H), 4.80-4.85 (m, 0.4 H), 3.88 (s, 3H), 3.57-3.68 (m, 0.6 H), 3.32 (td, 0.4 H), 2.84-3.12 (m, 1 H), 2.71 (br d, 1 H)	432.1 [M+H]+	100%
2045	(CD3OD) δ 8.28-8.39 (m, 1H), 8.25 (s, 1 H), 7.96 (s, 1 H), 7.68-7.75 (m, 0.4 H), 7.54-7.61 (m, 1 H), 7.41-7.52 (m, 1 H), 7.02-7.14 (m, 1 H), 6.83 (s, 0.6 H), 6.69-6.79 (m, 1 H), 6.42-6.57 (m, 1 H), 5.13 (dd, 0.6H), 4.80-4.86 (m, 0.4H), 3.88 (s, 3 H), 3.57-3.68 (m, 0.6 H), 3.26-3.41 (m, 0.4 H), 2.84-3.11 (m, 1 H), 2.71 (br d, 1 H)	432.1 [M+H]+	100%
2046	(CD3OD) δ 8.12-8.27 (m, 2 H), 7.96 (s, 1 H), 7.72 (s, 0.4 H), 7.52-7.61 (m, 1 H), 6.79-6.93 (m, 1.6 H), 6.59-6.72 (m, 1 H), 6.44-6.54 (m, 1 H), 5.07-5.35 (m, 0.6 H), 4.80-4.86 (m, 0.4 H), 3.88 (s, 3 H), 3.58-3.68 (m, 0.6 H), 3.33 (td, 0.4 H), 2.84-3.13 (m, 1 H), 2.71 (br d, 1 H), 2.28-2.37 (m, 3 H)	446.2 [M+H]+	100%
2047	(CD3OD) δ 8.1 1-8.28 (m, 2 H), 7.96 (s, 1 H), 7.72 (s, 0.4 H), 7.52-7.62 (m, 1 H), 6.78-6.92 (m, 1.6 H), 6.60-6.73 (m, 1 H), 6.44-6.55 (m, 1 H), 5.08-5.35 (m, 0.6 H), 4.80-4.87 (m, 0.4 H), 3.88 (s, 3 H), 3.57-3.68 (m, 0.6 H), 3.28-3.38 (m, 0.4 H), 2.83-3.12 (m, 1 H), 2.62-2.77 (m, 1 H), 2.28-2.36 (m, 3 H)	446.2 [M+H]+	99.2%
2048	(CD3OD) 3 8.25-8.47 (m, 1 H), 7.76 (d, 1 H), 7.56-7.69 (m, 2.4 H), 7.42-7.53 (m, 2 H), 7.36-7.42 (m, 1 H), 7.00-7.16 (m, 1 H), 6.89 (s, 0.6 H), 6.67-6.82 (m, 1 H), 6.40-6.58 (m, 1 H), 4.85-4.92 (m, 1 H), 3.58-3.75 (m, 0.5 H), 3.23-3.37 (m, 0.5 H), 2.85-3.17 (m, 1 H), 2.73 (br dd, 1 H)	385.1 [M+H]+	98.2%
2049	(CD3OD) δ 8.20-8.44 (m, 1 H), 7.76 (d, 1 H), 7.55-7.69 (m, 2.3 H), 7.42-7.52 (m, 2 H), 7.35-7.42 (m, 1 H), 7.03-7.17 (m, 1 H), 6.90 (s, 0.7 H), 6.67-6.83 (m, 1 H), 6.39-6.60 (m, 1 H), 4.88 (br dd, 1 H). 3.59-3.74 (m, 0.6 H), 3.25-3.35 (m, 0.4 H), 2.87-3.16 (m, 1 H), 2.74 (br dd, 1 H)	385.2 [M+H]+	97.7%
2050	(CD3OD) δ 8.25-8.42 (m, 1 H), 7.84-7.91 (m, 1 H), 7.65-7.83 (m, 2.4 H), 7.45-7.62 (m, 2 H), 6.92-7.04 (m, 1.6 H), 6.81-6.91 (m, 1 H), 6.67-6.81 (m, 1 H), 4.98-5.06 (m, 1 H), 3.70-3.89 (m, 0.7 H), 3.41 (td, 0.3 H), 2.98-3.28 (m, 1 H), 2.85 (br dd, 1 H)	403.1 [M+H]+	100%
2051	(CD3OD) δ 8.27-8.45 (m, 1 H), 7.86-7.95 (m, 1 H), 7.71-7.84 (m, 2.3 H), 7.47-7.66 (m, 2 H), 6.93-7.08 (m, 1.7 H), 6.83-6.91 (m, 1 H), 6.70-6.82 (m, 1 H), 4.99-5.09 (m, 1 H), 3.73-3.87 (m, 0.6 H), 3.38-3.48 (m, 0.4 H), 3.00-3.31 (m, 1 H), 2.88 (dd, 1 H)	403.2 [M+H]+	99.2%
2052	(DMSO-d6) δ 11.98-12.19 (m, 1 H), 8.66-8.95 (m, 1 H), 7.81-8.06 (m, 2 H), 7.61-7.71 (m, 1 H), 7.56-7.61 (m, 1 H), 7.47-7.55 (m, 2 H), 7.08-7.45 (m, 1 H), 6.88-7.05 (m, 1 H), 6.58-6.83 (m, 2 H), 4.84 (br dd, 1 H), 3.55-3.80 (m, 0.6 H), 3.15-3.30 (m, 0.4 H), 2.85-3.11 (m, 1 H), 2.65-2.83 (m, 1 H)	435.2 [M+H]+	99.2%
2053	(DMSO-d6) δ 11.86-12.54 (m, 1 H), 8.57-9.00 (m, 1 H), 7.84-7.99 (m, 2 H), 7.63-7.70 (m, 1 H), 7.55-7.62 (m, 1 H), 7.46-7.54 (m, 2.3 H), 7.46 (br s, 1 H). 6.89-7.03 (m, 1 H). 6.62-6.86 (m, 1.7 H), 4.84 (br dd, 1 H), 3.64-3.75 (m, 0.5 H), 3.20-3.27 (m, 0.5 H), 2.84-3.12 (m, 1 H), 2.77 (br d, 1 H)	435.2 [M+H]+	98.8%
2054	(DMSO-d6) δ 11.83-12.41 (m, 1 H), 8.74-9.12 (m, 1 H), 7.83-8.06 (m, 2 H), 7.69-7.82 (m, 1 H), 7.62-7.68 (m, 1 H), 7.46-7.61 (m, 2.5 H), 6.93-7.09 (m, 1 H), 6.57-6.85 (m, 1.5 H), 4.86 (br dd, 1 H), 3.59-3.83 (m, 0.6 H), 3.16-3.28 (m, 0.4 H), 2.85-3.11 (m, 1 H), 2.71-2.83 (m, 1 H)	453.1 [M+H]+	99.4%
2055	(DMSO-d6) δ 11.98-12.28 (m, 1 H), 8.81-9.08 (m, 1 H), 7.81-8.03 (m, 2 H), 7.69-7.79 (m, 1 H), 7.62-7.69 (m, 1 H), 7.45-7.61 (m, 2.5 H), 6.95-7.10 (m, 1 H), 6.58-6.85 (m, 1.5 H), 4.86 (br dd, 1 H), 3.63-3.79 (m, 0.6 H), 3.20-3.30 (m, 0.4 H), 2.84-3.11 (m, 1 H), 2.72-2.83 (m, 1 H)	453.2 [M+H]+	99.0%
2056	(CD3OD) δ 8.28 (d, 1 H), 7.70 (s, 1 H), 6.69-6.86 (m, 3 H), 6.42 (s, 1 H), 4.35 (dd, 1 H), 3.73-3.87 (m, 1 H), 3.00-3.16 (m, 1 H), 2.85 (dd, 1 H), 2.00-2.17 (m, 1 H), 0.93-1.09 (m, 2 H), 0.67-0.84 (m, 2 H)	416.2 [M+H]+	99.5%
2057	(CD3OD) δ 8.29 (d, 1 H), 7.70 (s, 1 H), 6.72-6.89 (m, 3 H), 6.41 (s, 1 H), 4.35 (dd, 1 H), 3.73-3.87 (m, 1 H), 3.01-3.16 (m, 1 H), 2.85 (dd, 1 H), 2.02-2.16 (m, 1 H), 0.96-1.09 (m, 2 H), 0.71-0.85 (m, 2 H)	416.2 [M+H]+	99.8%
2058	(CD3OD) δ 8.28 (d, 1 H), 7.67 (s, 1 H), 6.65-6.87 (m, 3 H), 6.27 (s, 1 H), 4.19 (dd, 1 H), 3.62-3.79 (m, 1 H), 2.93-3.10 (m, 1 H), 2.80 (dd, 1 H), 2.00-2.18 (m, 2 H), 1.01-1.14 (m, 6 H), 0.75-0.82 (m, 2 H)	388.2 [M+H]+	99.8%
2059	(CD3OD) δ 8.28 (d, 1 H), 7.67 (s, 1 H), 6.64-6.86 (m, 3 H), 6.27 (s, 1 H), 4.19 (dd, 1 H), 3.62-3.75 (m, 1 H), 2.94-3.10 (m, 1 H), 2.80 (dd, 1 H), 2.03-2.15 (m, 2 H), 0.98-1.14 (m, 6 H), 0.71-0.82 (m, 2 H)	388.2 [M+H]+	99.7%
2060	(CD3OD) δ 8.16-8.34 (m, 1 H), 7.70 (s, 1 H), 7.42 (s, 0.3 H), 6.95 (s, 0.7 H),, 6.60-6.85 (m, 3 H), 4.97 (br d, 1 H), 3.76 (ddd, 0.7 H), 3.40 (td, 0.3 H), 3.08-3.23 (m, 0.7 H), 2.94-3.04 (m, 0.3 H), 2.84 (br dd, 1 H), 2.02-2.15 (m, 1 H), 1.80-1.97 (m, 6 H). 0.92-1.11 (m, 2 H), 0.71-0.83 (m, 2 H)	436.2 [M+H]+	99.9%
2061	(CD3OD) δ 8.15-8.35 (m, 1 H), 7.70 (s, 1 H), 7.42 (s, 0.3 H), 6.95 (s, 0.7 H), 6.66-6.87 (m, 3 H), 4.95-5.01 (m, 1 H), 3.70-3.84 (m, 0.7 H), 3.35-3.44 (m, 0.3 H), 3.10-3.22 (m, 0.7 H), 2.93-3.05 (m, 0.3 H), 2.78-2.89 (m, 1 H), 2.03-2.15 (m, 1 H), 1.80-1.97 (m, 6 H), 0.96-1.09 (m, 2 H), 0.73-0.83 (m, 2 H)	436.2 [M+H]+	99.1%
2062	(CD3OD) δ 8.44 (d, 1 H), 7.54-7.79 (m, 2 H), 7.15-7.38 (m, 3 H), 6.69-6.93 (m, 2 H), 6.42 (s, 1 H), 4.38 (dd, 1 H), 3.80 (ddd, 1 H), 3.00-3.20 (m, 1 H), 2.86 (dd, 1 H)	454.1 [M+H]+	100%
2063	(CD3OD) δ 8.32 (d, 1 H). 7.42-7.68 (m, 2 H). 7.00-7.24 (m, 3 H), 6.53-6.82 (m, 2 H), 6.30 (s, 1 H), 4.26 (dd, 1 H), 3.68 (ddd, 1 H). 2.90-3.06 (m, 1 H). 2.73 (dd, 1 H)	454.1 [M+H]+	96.6%
2064	(CD3OD) δ 8.37 (br s, 1 H). 8.01 (br s, 0.5 H), 7.64-7.84 (m, 1.5 H), 6.99 (br t, 1 H), 6.87 (br s, 1.6 H), 6.57-6.81 (m, 1.4 H), 4.73-4.83 (m, 0.4 H), 4.49 (br s, 0.6 H), 3.78 (br s, 0.6 H), 3.36-3.46 (m, 0.4 H), 3.12 (br s, 1 H), 2.84 (br s, 1 H), 1.73-1.95 (m, 6 H)	413.2 [M+H]+	100%
2065	(CD3OD) δ 8.36 (br s, 1 H). 8.01 (br s, 0.4 H), 7.62-7.88 (m, 1.6 H), 6.93-7.05 (m, 1 H), 6.86 (br s, 1.5 H), 6.52-6.80 (m, 1.5 H), 4.69-4.81 (m, 0.4 H), 4.46 (br s, 0.6 H), 3.78 (br s, 0.6 H), 3.37 (br s, 0.4 H), 2.94-3.19 (m, 1 H), 2.83 (br s, 1 H), 1.84 (br d, 6 H)	413.2 [M+H]+	100%
2066	(CD3OD) δ 8.38 (br s, 1 H). 7.74-8.15 (m, 2 H). 7.70 (s, 1 H), 6.94-7.07 (m, 1 H), 6.59-6.93 (m, 3 H), 4.66-4.87 (m, 1 H), 3.86 (br s, 3 H), 3.50 (s, 1 H), 2.78-3.23 (m, 2 H), 2.44-2.77 (m, 3 H)	447.2 [M+H]+	100%
2067	(CD3OD) δ 8.39 (br s, 1 H), 7.75-8.16 (m, 2 H), 7.70 (s, 1 H). 6.99 (br t, 1 H), 6.57-6.94 (m, 3 H), 4.65-4.84 (m, 1 H), 3.86 (br s, 3 H), 3.50 (s, 1 H), 2.79-3.26 (m, 2 H), 2.66 (br s, 3 H)	447.2 [M+H]+	100%
2068	(CD3OD) δ 8.62 (br s, 1 H), 7.76-8.15 (m, 2 H), 7.70 (s, 1 H), 7.46 (br d, 1 H). 6.63-7.18 (m, 4 H). 4.65-4.84 (m, 1 H). 3.86 (br s, 3 H), 3.38-3.82 (m, 1 H), 2.78-3.24 (m, 2 H), 2.42-2.76 (m, 3 H)	479.2 [M+H]+	99.7%
2069	(CD3OD) δ 8.62 (br s, 1 H), 7.75-8.13 (m, 2 H), 7.70 (s, 1 H), 7.45 (br d, 1 H), 6.67-7.18 (m, 4 H), 4.82 (br s, 1 H), 3.86 (br s, 3 H), 3.37-3.82 (m, 1 H), 2.79-3.25 (m, 2 H), 2.43-2.78 (m, 3 H)	479.2 [M+H]+	98.9%
2070	(CD3OD) δ 8.16 (s, 1 H), 7.43-7.68 (m, 2 H), 6.47-7.17 (m, 4 H), 4.38 (br s, 1 H), 3.58-3.99 (m, 1 H), 2.78-3.11 (m, 2 H), 2.66 (s, 3 H), 2.32 (br s, 1 H). 0.97 (br d, 4 H)	389.2 [M+H]+	100%
2071	(CD3OD) δ 8.16 (s, 1 H). 7.39-7.76 (m, 2 H). 6.22-7.18 (m, 4 H), 4.39 (br s, 1 H), 3.53-4.00 (m, 1 H), 2.76-3.14 (m, 2 H), 2.66 (s, 3 H), 2.32 (br s, 1 H), 0.97 (br d, 4 H)	389.2 [M+H]+	95.0%
2072	(CD3OD) δ 8.24 (br d, 1 H), 7.66-8.14 (m, 2 H), 7.57 (s, 1 H). 6.50-6.90 (m, 4 H), 4.37-4.63 (m, 1 H), 3.83 (s, 3 H), 3.51-3.73 (m, 0.7 H), 3.27-3.46 (m, 0.3 H), 2.86-3.11 (m, 1 H), 2.72 (br d, 1 H), 2.25-2.37 (m, 1 H), 0.80-0.95 (m, 4 H)	473.2 [M+H]+	99.0%
2073	(CD3OD) δ 8.23 (br s, 1 H), 7.65-8.14 (m, 2 H), 7.57 (s, 1 H), 6.48-6.91 (m, 4 H), 4.37-4.64 (m, 1 H), 3.82 (br s, 3 H), 3.49-3.71 (m, 0.7 H), 3.26-3.42 (m, 0.3 H), 2.88-3.08 (m, 1 H), 2.71 (br d, 1 H), 2.31 (quin, 1 H), 0.78-0.95 (m, 4 H)	473.2 [M+H]+	98.8%
2074	(CD3OD) δ 8.33 (br d, 1 H), 7.78-8.25 (m, 2 H), 7.69 (s, 1 H), 6.50-7.06 (m, 4 H), 4.48-4.76 (m, 1 H), 3.94 (br s, 3 H), 3.65-3.84 (m, 0.6 H), 3.41-3.59 (m, 0.4 H), 3.00-3.20 (m, 1 H), 2.73-2.93 (m, 1 H), 2.38-2.54 (m, 4 H), 0.86-1.14 (m, 4 H)	469.2 [M+H]+	99.5%
2075	(CD3OD) δ 8.15-8.31 (m, 1 H), 7.68-8.13 (m, 2 H), 7.57 (s, 1 H), 6.41-6.90 (m, 4 H), 4.42-4.70 (m, 1 H), 3.81 (br s, 3 H), 3.51-3.71 (m, 0.6 H), 3.25-3.38 (m, 0.4 H), 2.86-3.10 (m, 1 H), 2.60-2.81 (m, 1 H), 2.26-2.38 (m, 4 H), 0.80-0.94 (m, 4 H)	469.2 [M+H]+	99.5%
2076	(CD3OD) δ 8.47-8.63 (m, 1 H), 8.10 (s, 1 H), 7.65-7.77 (m, 1 H), 7.34-7.49 (m, 2 H), 6.67-7.15 (m, 4 H), 5.07 (dd, 1 H), 3.68 (ddd, 0.7 H), 3.33-3.38 (m, 0.3 H), 3.06-3.19 (m, 0.7 H), 2.89-3.01 (m, 0.3 H), 2.79 (dd, 1 H)	385.1 [M+H]+	100%
2077	(CD3OD) δ 8.50-8.60 (m, 1 H), 8.10 (s, 1 H), 7.64-7.78 (m, 1 H), 7.33-7.49 (m, 2 H), 6.68-7.16 (m, 4 H), 5.08 (dd, 1 H), 3.68 (ddd, 0.7 H), 3.33-3.38 (m, 0.3 H), 3.07-3.19 (m, 0.7 H), 2.91-3.01 (m, 0.3 H), 2.79 (dd, 1 H)	385.1 [M+H]+	98.1%
2078	(CD3OD) δ 8.61-8.73 (m, 1 H), 8.11 (s, 1 H), 7.68-7.79 (m, 1 H), 7.56-7.65 (m, 1 H), 7.34-7.46 (m, 1 H), 6.92-7.04 (m, 2 H), 6.64-6.82 (m, 1 H), 5.10 (dd, 1 H), 3.68 (ddd, 0.7 H), 3.33-3.38 (m, 0.3 H), 3.09-3.19 (m, 0.7 H), 2.91-3.01 (m, 0.3 H), 2.79 (dd, 1 H)	403.1 [M+H]+	99.9%
2079	(CD3OD) δ 8.62-8.73 (m, 1 H), 8.11 (s, 1 H), 7.67-7.78 (m, 1 H), 7.55-7.66 (m, 1 H), 7.35-7.46 (m, 1 H), 6.90-7.04 (m, 2 H), 6.64-6.80 (m, 1 H), 5.10 (dd, 1 H), 3.68 (ddd, 0.6 H), 3.33-3.38 (m, 0.4 H), 3.09-3.19 (m, 0.7 H), 2.92-3.01 (m, 0.3 H), 2.79 (dd, 1 H)	403.1 [M+H]+	98.8%
2080	(CD3OD) δ 8.27-8.42 (m, 1 H), 7.60-7.68 (m, 1 H), 6.74-6.99 (m, 2.7 H), 6.50-6.68 (m, 1 H), 6.11 (s, 0.3 H), 4.78 (br dd, 0.3 H), 4.01 (br dd, 0.7 H), 3.85 (t, 0.3 H), 3.45-3.62 (m, 1.4 H), 3.12 (td, 0.3 H), 2.47-2.86 (m, 2 H), 1.80-2.42 (m, 6 H)	340.2 [M+H]+	99.7%
2081	(CD3OD) δ 8.27-8.41 (m, 1 H), 7.61-7.67 (m, 1 H), 6.89-6.99 (m, 1 H), 6.74-6.87 (m, 1.7 H), 6.51-6.65 (m, 1 H), 6.11 (s, 0.3 H), 4.78 (br dd, 0.3 H), 4.02 (dd, 0.7 H), 3.86 (quin, 0.3 H), 3.47-3.60 (m, 1.4 H), 3.07-3.17 (m, 0.3 H), 2.47-2.86 (m, 2 H), 1.80-2.42 (m, 6 H)	340.2 [M+H]+	99.5%
2082	(CD3OD) δ 8.18 (d, 1 H), 7.55 (s, 1 H), 6.94 (d, 1 H), 6.72 (t, 1 H), 6.49 (s, 1 H), 6.18 (s, 1 H), 4.10 (dd, 1 H), 3.59 (ddd, 1 H), 2.86-3.12 (m, 2 H), 2.67 (dd, 1 H), 2.32 (s, 3 H), 1.22 (dd, 6 H)	364.2 [M+H]+	99.3%
2083	(CD3OD) δ 8.18 (d, 1 H), 7.55 (s, 1 H), 6.93 (d, 1 H), 6.61-6.78 (m, 1 H), 6.49 (s, 1 H), 6.18 (s, 1 H), 4.10 (dd, 1 H), 3.59 (ddd, 1 H), 2.87-3.12 (m, 2 H), 2.67 (dd, 1 H), 2.32 (s, 3 H), 1.17-1.25 (m, 6 H)	364.2 [M+H]+	99.3%
2084	(CD3OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 6.83-7.15 (m, 3 H), 6.66 (s, 1 H), 6.39 (s, 1 H), 4.33 (dd, 1 H), 3.79 (ddd, 1 H), 3.03-3.25 (m, 2 H), 2.84 (dd, 1 H), 1.35 (dd, 6 H)	400.2 [M+H]+	99.9%
2085	(CD3OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 6.83-7.15 (m, 3 H), 6.62-6.70 (m, 1 H), 6.39 (s, 1 H), 4.33 (dd, 1 H), 3.73-3.86 (m, 1 H), 3.02-3.24 (m, 2 H), 2.84 (dd, 1 H), 1.35 (dd, 6 H)	400.2 [M+H]+	99.8%
2086	(CD3OD) δ 8.03 (dd, 2 H), 7.68 (s, 1 H), 7.59 (dd, 1 H), 7.28 (t, 2 H), 7.17 (dd, 1 H), 7.03 (dd, 1 H), 6.71 (s, 1 H), 6.47 (s, 1 H), 4.38 (dd, 1 H), 3.76-3.91 (m, 1 H), 3.02-3.17 (m, 1 H), 2.87 (dd, 1 H)	436.1 [M+H]+	100%
2087	(CD3OD) δ 8.03 (dd, 2 H), 7.68 (s, 1 H), 7.60 (d, 1 H), 7.29 (t, 2 H), 7.17 (dd, 1 H), 7.03 (d, 1 H), 6.71 (s, 1 H), 6.47 (s, 1 H), 4.38 (dd, 1 H), 3.77-3.91 (m, 1 H), 3.04-3.16 (m, 1 H), 2.79-2.94 (m, 1 H)	436.1 [M+H]+	99.3%
2088	(CD3OD) δ 7.59-7.69 (m, 3 H), 7.15-7.26 (m, 3 H), 7.04 (dd, 1 H), 6.74 (s, 1 H), 6.43 (s, 1 H), 4.38 (dd, 1 H), 3.87 (ddd, 1 H), 3.01-3.19 (m, 1 H), 2.86 (dd, 1 H)	454.1 [M+H]+	100%
2089	(CD3OD) δ 7.57-7.71 (m, 3 H), 7.14-7.26 (m, 3 H), 7.03 (dd, 1 H), 6.73 (s, 1 H), 6.43 (s, 1 H), 4.38 (dd, 1 H), 3.87 (ddd, 1 H), 3.01-3.18 (m, 1 H), 2.86 (dd, 1 H)	454.1 [M+H]+	98.4%
2090	(CD3OD) δ 7.46-7.59 (m, 2 H), 7.35 (d, 1 H), 6.96-7.13 (m, 3 H), 6.59 (d, 1 H), 6.25-6.47 (m, 2 H), 4.24 (dd, 1 H), 3.72 (ddd, 1 H), 2.88-3.05 (m, 1 H), 2.73 (dd, 1 H), 2.51 (s, 3 H)	434.2 [M+H]+	100%
2091	(CD3OD) δ 7.57-7.69 (m, 2 H), 7.47 (d, 1 H), 7.08-7.25 (m, 3 H), 6.71 (d, 1 H), 6.38-6.56 (m, 2 H), 4.36 (dd, 1 H), 3.84 (ddd, 1 H), 3.01-3.16 (m, 1 H), 2.85 (dd, 1 H), 2.63 (s, 3 H)	434.2 [M+H]+	100%
2092	(CD3OD) δ 7.75 (d, 1 H), 7.58-7.71 (m, 2 H), 7.50 (s, 0.3 H), 7.36 (s, 0.5 H), 7.17-7.31 (m, 4.2 H), 6.70 (s, 1 H), 6.42 (br s, 1 H), 4.38 (dd, 1 H), 3.78-3.91 (m, 1 H), 3.01-3.18 (m, 1 H), 2.86 (br dd, 1 H)	470.2 [M+H]+	100%
2093	(CD3OD) δ 7.74 (d, 1 H), 7.58-7.71 (m, 2 H), 7.49 (s, 0.3 H), 7.36 (s, 0.5 H), 7.16-7.31 (m, 4.2 H), 6.70 (s, 1 H), 6.42 (s, 1 H), 4.38 (dd, 1 H), 3.75-3.94 (m, 1 H), 3.01-3.18 (m, 1 H), 2.86 (dd, 1 H)	470.2 [M+H]+	100%
2094	(CD3OD) δ 8.26-8.35 (m, 2 H), 7.65 (dd, 1 H), 7.53 (s, 1 H), 7.15 (d, 1 H), 7.02 (d, 1 H), 6.80 (s, 1 H), 6.70 (t, 1 H), 6.53 (s, 1 H), 4.61 (br dd, 1 H), 3.40-3.56 (m, 1 H), 2.76-2.91 (m, 1 H), 2.62 (br dd, 1 H)	419.1 [M+H]+	99.5%
2095	(CD3OD) δ 8.44 (br d, 2 H), 7.78 (dd, 1 H), 7.66 (s, 1 H), 7.28 (d, 1 H), 7.15 (d, 1 H), 6.92 (s, 1 H), 6.82 (t, 1 H), 6.65 (s, 1 H), 4.73 (br dd, 1 H), 3.53-3.66 (m, 1 H), 2.89-3.03 (m, 1 H), 2.75 (br dd, 1 H)	419.1 [M+H]+	98.6%
2096	(CD3OD) δ 8.39 (s, 1 H), 7.76 (dd, 1 H), 7.62 (s, 1 H), 7.44 (d, 1 H), 7.20 (d, 1 H), 7.10 (dd, 1 H), 6.80 (s, 1 H), 6.69 (d, 1 H), 6.48 (s, 1 H), 4.83 (br dd, 1 H), 3.60-3.73 (m, 1 H), 2.88-3.01 (m, 1 H), 2.74 (dd, 1 H), 2.69 (s, 3 H)	399.2 [M+H]+	97.4%
2097	(CD3OD) δ 8.28 (s, 1 H), 7.64 (dd, 1 H), 7.50 (s, 1 H), 7.33 (d, 1 H), 7.09 (d, 1 H), 6.98 (dd, 1 H), 6.68 (s, 1 H), 6.58 (d, 1 H), 6.36 (s, 1 H), 4.72 (br dd, 1 H), 3.50-3.62 (m, 1 H), 2.77-2.89 (m, 1 H), 2.62 (dd, 1 H), 2.57 (s, 3 H)	399.2 [M+H]+	96.1%
2098	(CD3OD) δ 8.20-8.54 (m, 1 H), 7.54-7.99 (m, 2 H), 6.91-7.05 (m, 1 H), 6.46-6.89 (m, 3 H), 4.34-4.81 (m, 1 H), 3.42-3.93 (m, 1 H), 2.69-3.21 (m, 2 H), 2.18 (br d, 1 H), 1.14 (br s, 4 H)	393.2 [M+H]+	99.4%
2099	(CD3OD) δ 8.20-8.54 (m, 1 H), 7.67 (s, 2 H), 6.91-7.07 (m, 1 H), 6.39-6.90 (m, 3 H), 4.42-4.79 (m, 1 H), 3.38-4.00 (m, 1 H), 2.61-3.15 (m, 2 H), 2.18 (br d, 1 H), 1.14 (br s, 4 H)	393.2 [M+H]+	98.4%
2100	(CD3OD) δ 8.36 (br s, 1 H), 7.58-8.04 (m, 2 H), 6.55-7.10 (m, 4 H), 4.58-4.84 (m, 1 H), 3.35-3.87 (m, 1 H), 2.68-3.21 (m, 2 H), 1.26-1.55 (m, 9 H)	409.2 [M+H]+	100%
2101	(CD3OD) δ 8.23 (br s, 1 H), 7.37-7.93 (m, 2 H), 6.38-7.02 (m, 4 H), 4.46-4.74 (m, 1 H), 3.24-3.81 (m, 1 H), 2.53-3.10 (m, 2 H), 1.08-1.49 (m, 9 H)	409.2 [M+H]+	99.6%
2102	(CD3OD) δ 8.58 (br d, 1 H), 7.50-7.95 (m, 2 H), 7.43 (br d, 1 H). 6.48-7.17 (m, 4 H), 4.38-4.83 (m, 1 H), 3.34-3.88 (m, 1 H), 2.69-3.12 (m, 2 H), 2.18 (br s, 1 H), 1.14 (br s, 4 H)	425.2 [M+H]+	100%
2103	(CD3OD) δ 8.41-8.77 (m, 1 H), 7.55-7.99 (m, 2 H), 7.43 (br d, 1 H), 6.39-7.20 (m, 4 H), 4.40-4.82 (m, 1 H), 3.43-3.88 (m, 1 H), 2.67-3.12 (m, 2 H), 2.18 (br d, 1 H), 1.14 (br s, 4 H)	425.2 [M+H]+	99.2%
2104	(CD3OD) δ 8.48-8.75 (m, 1 H), 7.34-8.01 (m, 3 H). 6.57-7.20 (m, 4 H), 4.60-4.85 (m, 1 H), 3.34-3.86 (m, 1 H), 2.68-3.20 (m, 2 H), 1.25-1.60 (m, 9 H)	441.2 [M+H]+	100%
2105	(CD3OD) δ 8.60 (br d, 1 H), 7.57-8.02 (m, 2 H), 7.45 (br d, 1 H), 6.58-7.18 (m, 4 H), 4.62-4.84 (m, 1 H), 3.34-3.88 (m, 1 H), 2.68-3.25 (m, 2 H), 1.25-1.58 (m, 9 H)	441.2 [M+H]+	99.5%
2106	(CD3OD) δ 8.42-8.92 (m, 1 H), 8.02 (br s, 0.4 H), 7.65-7.86 (m, 1.6 H), 7.46 (br d, 1 H), 7.14 (s, 0.2 H), 6.55-7.05 (m, 3.8 H), 4.73-4.83 (m, 0.3 H), 4.47 (br s, 0.7 H), 3.77 (br s, 0.6 H), 3.38-3.47 (m, 0.4 H), 2.96-3.22 (m, 1 H), 2.85 (brs, 1 H), 1.70-1.95 (m, 6 H)	445.2 [M+H]+	100%
2107	(CD3OD) δ 8.48-8.79 (m, 1 H), 8.01 (br s, 0.4 H), 7.70 (br s, 1.6 H), 7.46 (br d, 1 H), 7.13 (s, 0.2 H), 6.58-7.07 (m, 3.8 H), 4.82 (br s, 0.5 H), 4.47 (br s, 0.5 H), 3.77 (br s, 0.6 H), 3.38-3.47 (m, 0.4 H), 2.94-3.21 (m, 1 H), 2.86 (br d, 1 H), 1.69-1.99 (m, 6 H)	445.2 [M+H]+	99.1%
2108	(CD3OD) δ 8.70 (br s, 1 H), 7.58-8.11 (m, 4 H), 6.71-7.04 (m, 4 H), 4.67-4.83 (m, 1 H), 3.99 (s, 3 H), 3.39-3.86 (m, 1 H), 2.78-3.23 (m, 2 H)	483.1 [M+H]+	100%
2109	(CD3OD) δ 8.70 (br s, 1 H), 7.59-8.08 (m, 4 H), 6.77-7.05 (m, 4 H), 4.69-4.83 (m, 1 H), 3.99 (s, 3 H), 3.44-3.89 (m, 1 H), 2.81-3.24 (m, 2 H)	483.2 [M+H]+	98.5%
2110	(CD3OD) δ 8.74 (br s, 1 H), 7.97 (brs, 2 H), 7.57-7.75 (m, 2 H), 6.61-7.12 (m, 3 H), 4.64-4.85 (m, 1 H), 3.87 (br s, 3 H), 3.35-3.81 (m, 1 H), 2.79-3.23 (m, 2 H), 2.67 (br s, 3 H)	497.2 [M+H]+	99.8%
2111	(CD3OD) δ 8.60 (br s, 1 H), 7.63-8.03 (m, 2 H), 7.44-7.62 (m, 2 H), 6.51-6.95 (m, 3 H), 4.52-4.73 (m, 1 H), 3.69-3.82 (m, 3 H), 3.26-3.66 (m, 1 H), 2.62-3.12 (m, 2 H), 2.31-2.61 (m, 3 H)	497.2 [M+H]+	99.5%
2112	(CD3OD) δ 8.13 (s, 1 H), 7.62-7.76 (m, 2 H), 7.34-7.56 (m, 1 H), 7.15-7.29 (m, 2 H), 6.47-6.95 (m, 2 H), 4.37 (br s, 1 H), 3.83 (br s, 1 H), 3.01 (br s, 1 H), 2.78 (dd, 1 H), 2.30 (br d, 1 H), 0.96 (br d, 4 H)	425.2 [M+H]+	100%
2113	(CD3OD) δ 8.14 (s, 1 H), 7.62-7.77 (m, 2 H), 7.34-7.56 (m, 1 H), 7.13-7.31 (m, 2 H), 6.45-6.95 (m, 2 H), 4.39 (br s, 1 H), 3.56-3.98 (m, 1 H), 3.01 (br s, 1 H), 2.78 (dd, 1 H), 2.31 (br s, 1 H), 0.96 (br d, 4 H)	425.2 [M+H]+	100%
2114	(CD3OD) δ 8.60 (br d, 1 H), 7.86-8.45 (m, 2 H), 7.74 (s, 1 H), 7.43 (br d, 1 H), 7.14 (s, 0.3 H), 6.70-7.03 (m, 3.7 H), 4.45-4.86 (m, 1 H), 3.86-4.07 (m, 3 H), 3.39-3.83 (m, 1 H), 2.99-3.22 (m, 1 H), 2.84 (br d, 1 H), 2.35-2.52 (m, 1 H), 0.88-1.10 (m, 4 H)	505.2 [M+H]+	99.6%
2115	(CD3OD) δ 8.59 (br d, 1 H), 7.88-8.43 (m, 2 H), 7.81 (br s, 1 H), 7.42 (br d, 1 H), 7.13 (s, 0.3 H), 6.76-7.02 (m, 3.7 H), 4.41-4.81 (m, 1 H), 3.93 (br s, 3 H), 3.39-3.81 (m, 1 H), 2.99-3.22 (m, 1 H), 2.72-2.93 (m, 1 H), 2.36-2.50 (m, 1 H), 0.91-1.07 (m, 4 H)	505.2 [M+H]+	99.4%
2116	(CD3OD) δ 8.72 (br d, 1 H), 7.78-8.30 (m, 2 H), 7.70 (s, 1 H), 7.63 (br d, 1 H), 6.99 (t, 1 H), 6.70-6.94 (m, 2 H), 4.43-4.77 (m, 1 H), 3.94 (br s, 3 H), 3.40-3.84 (m, 1 H), 2.99-3.23 (m, 1 H), 2.75-2.92 (m, 1 H), 2.38-2.50 (m, 1 H), 0.94-1.06 (m, 4 H)	523.2 [M+H]+	99.3%
2117	(CD3OD) δ 8.71 (br d, 1 H), 7.77-8.34 (m, 2 H), 7.70 (s, 1 H), 7.63 (br d, 1 H), 6.98 (t, 1 H), 6.72-6.94 (m, 2 H), 4.44-4.79 (m, 1 H), 3.87-4.00 (m, 3 H), 3.38-3.82 (m, 1 H), 2.97-3.23 (m, 1 H), 2.84 (br d, 1 H), 2.33-2.52 (m, 1 H), 0.91-1.08 (m, 4 H)	523.2 [M+H]+	99.1%
2118	(CD3OD) δ 8.68 (d, 1 H), 8.35 (d, 1 H), 7.85-8.22 (m, 2 H), 7.45-7.76 (m, 2 H), 6.59-7.28 (m, 4 H), 4.44-4.81 (m, 1 H), 3.45-3.89 (m, 1 H), 2.96-3.28 (m, 1 H), 2.83 (br d, 1 H), 2.33-2.57 (m, 1 H), 0.94-1.16 (m, 4 H)	470.2 [M+H]+	100%
2119	(CD3OD) δ 8.68 (d, 1 H), 8.35 (d, 1 H), 7.83-8.25 (m, 2 H), 7.44-7.75 (m, 2 H), 6.62-7.25 (m, 4 H), 4.30-4.60 (m, 1 H), 3.46-3.87 (m, 1 H), 2.94-3.28 (m, 1 H), 2.83 (br d, 1 H), 2.43 (br s, 1 H), 0.97-1.19 (m, 4 H)	470.2 [M+H]+	99.7%
2120	(CD3OD) δ 8.67 (d, 1 H), 8.31 (d, 1 H), 7.83-8.21 (m, 2 H), 7.44-7.72 (m, 2 H), 6.55-7.06 (m, 4 H), 4.39-4.59 (m, 1 H), 3.50-3.90 (m, 1 H), 2.94-3.26 (m, 1 H), 2.73-2.90 (m, 1 H), 2.46 (s, 4 H), 0.93-1.19 (m, 4 H)	466.2 [M+H]+	100%
2121	(CD3OD) δ 8.67 (d, 1 H), 8.31 (d, 1 H), 7.84-8.19 (m, 2 H), 7.38-7.73 (m, 2 H), 6.43-7.05 (m, 4 H), 4.42-4.58 (m, 1 H), 3.48-3.91 (m, 1 H), 2.95-3.26 (m, 1 H), 2.75-2.90 (m, 1 H), 2.46 (s, 4 H), 0.90-1.20 (m, 4 H)	466.2 [M+H]+	99.7%
2122	(CD3OD) δ 8.68 (d, 1 H), 8.59 (br d, 1 H), 7.81-8.22 (m, 2 H), 7.68 (br s, 1 H), 7.48-7.59 (m, 1 H), 7.43 (br d, 1 H), 6.60-7.20 (m, 4 H), 4.38-4.60 (m, 1 H), 3.49-3.88 (m, 1 H), 2.98-3.27 (m, 1 H), 2.83 (br d, 1 H), 2.36-2.52 (m, 1 H), 0.92-1.19 (m, 4 H)	502.2 [M+H]+	100%
2123	(CD3OD) δ 8.67 (d, 1 H), 8.59 (br d, 1 H), 7.85-8.24 (m, 2 H), 7.68 (br s, 1 H), 7.48-7.58 (m, 1 H), 7.43 (br d, 1 H), 6.68-7.17 (m, 4 H), 4.28-4.59 (m, 1 H), 3.46-3.90 (m, 1 H), 2.96-3.28 (m, 1 H), 2.83 (br d, 1 H), 2.43 (br d, 1 H), 0.94-1.18 (m, 4 H)	502.2 [M+H+	99.6%
2124	(CD3OD) δ 8.55-8.80 (m, 2 H), 7.83-8.27 (m, 2 H), 7.59-7.78 (m, 2 H), 7.54 (br dd, 1 H), 6.98 (br t, 3 H), 4.59 (s, 1 H), 3.50-3.89 (m, 1 H), 3.01-3.25 (m, 1 H), 2.76-2.92 (m, 1 H), 2.35-2.54 (m, 1 H), 0.96-1.16 (m, 4 H)	520.2 [M+H]+	98.7%
2125	(CD3OD) δ 8.63-8.76 (m, 2 H), 7.81-8.28 (m, 2 H), 7.45-7.76 (m, 3 H), 6.57-7.30 (m, 3 H), 4.42-4.68 (m, 1 H), 3.50-3.92 (m, 1 H), 2.95-3.26 (m, 1 H), 2.83 (br dd, 1 H), 2.37-2.53 (m, 1 H), 0.98-1.16 (m. 4 H)	[M+H]+	91.1%
2126	(CD3OD) δ 8.31 (s, 1 H), 8.13 (br s, 1 H), 7.58 (br s, 1.7 H), 6.93-7.10 (m, 2.3 H), 6.40-6.87 (m, 4 H), 4.56 (br s, 1 H), 3.58 (br s, 1 H), 2.65-3.09 (m, 2 H), 2.44 (br s, 3 H)	331.2 [M+H]+	97.8%
2127	(CD3OD) δ 8.31 (d, 1 H), 8.13 (br d, 1 H), 7.62 (s, 1 H), 7.58 (t, 1 H), 7.05 (d, 1 H), 6.97 (d, 1 H), 6.72-6.85 (m, 2 H), 6.63-6.70 (m, 1 H), 6.50 (s, 1 H), 4.57 (br dd, 1 H), 3.53-3.66 (m, 1 H), 2.87-3.05 (m, 1 H), 2.60-2.75 (m, 1 H), 2.42 (s, 3 H)	331.2 [M+H]+	95.2%
2128	(CD3OD) δ 8.03 (dd, 2 H), 7.85 (d, 1 H), 7.69 (s, 1 H), 7.23-7.36 (m, 4 H), 6.74 (s, 1 H), 6.46 (br s, 1 H), 4.38 (dd, 1 H), 3.79 (td, 1 H), 3.01-3.21 (m, 1 H), 2.87 (br dd, 1 H)	470.2 [M+H]+	99.7%
2129	(CD3OD) δ 8.03 (dd, 2 H), 7.85 (d, 1 H), 7.69 (s, 1 H), 7.23-7.36 (m, 4 H), 6.74 (s, 1 H), 6.46 (br s, 1 H), 4.38 (dd, 1 H), 3.79 (td, 1 H), 3.01-3.21 (m, 1 H), 2.87 (br dd, 1 H)	470.2 [ M+H]+	94.3%
2130	(CD3OD) δ 8.02 (dd, 2 H), 7.74 (d, 1 H), 7.68 (s, 1 H), 7.49 (s, 0.3 H), 7.36 (s, 0.5 H), 7.25-7.33 (m, 3 H), 7.16-7.23 (m, 1.2 H), 6.70 (s, 1 H), 6.46 (s, 1 H), 4.39 (dd, 1 H), 3.77-3.89 (m, 1 H), 3.04-3.17 (m, 1 H), 2.81-2.92 (m, 1 H)	452.2 [ M+H]+	99.5%
2131	(CD3OD) δ 8.01 (br t, 2 H), 7.74 (br d, 1 H), 7.68 (s, 1 H), 7.49 (s, 0.3 H), 7.35 (s. 0.5 H), 7.28 (q, 3 H), 7.13-7.23 (m, 1.2 H), 6.69 (s, 1 H), 6.45 (br s, 1 H), 4.38 (br dd, 1 H), 3.83 (br t, 1 H), 3.02-3.17 (m, 1 H), 2.86 (br d, 1 H)	452.1 [M+H]+	98.6%
2132	(CD3OD) δ 7.86 (d, 1 H), 7.53-7.75 (m, 2 H), 7.11-7.41 (m, 4 H), 6.77 (s, 1 H), 6.42 (br s, 1 H), 4.39 (dd, 1 H), 3.73-3.93 (m, 1 H), 3.01-3.17 (m, 1 H), 2.86 (dd, 1 H)	488.2 [M+H]+	1 00%
2133	(CD3OD) δ 7.86 (d, 1 H), 7.55-7.76 (m, 2 H), 7.11-7.44 (m, 4 H), 6.77 (s, 1 H), 6.42 (br s, 1 H), 4.39 (dd, 1 H), 3.83 (td, 1 H), 3.00-3.20 (m, 1 H), 2.86 (dd, 1 H)	488.2 [M+H]+	97. 1%
2134	(CD3OD) δ 8.43 (d, 1 H), 7.50-7.75 (m, 3 H), 7.01-7.27 (m, 1 H), 6.76-6.94 (m, 2 H), 6.69 (s, 1 H), 6.50 (s, 1 H), 6.18 (dd, 1 H), 4.55 (dd, 1 H), 3.54 (ddd, 1 H), 2.83-3.01 (m, 1 H), 2.67 (br dd, 1 H)	335.1 [M+H]+	98.8%
2135	(CD3OD) δ 8.43 (d. 1 H), 7.40-7.75 (m, 3 H), 7.06-7.27 (m, 1 H), 6.75-6.91 (m, 2 H), 6.69 (s, 1 H), 6.50 (s, 1 H), 6.18 (dd, 1 H), 4.55 (dd, 1 H), 3.54 (ddd, 1 H), 2.84-3.00 (m, 1 H), 2.67 (br dd, 1 H)	335.2 [M+H]+	98.9%
2136	(CD3OD) δ 8.40 (s, 1 H), 7.76 (dd, 1 H), 7.63 (s, 1 H), 7.56 (dd, 1 H), 7.19 (d, 1 H), 7.15 (dd, 1 H), 7.00 (dd, 1 H), 6.85 (s, 1 H), 6.65 (s, 1 H), 4.81 (br dd, 1 H), 3.68 (ddd, 1 H), 2.87-3.04 (m, 1 H), 2.75 (dd, 1 H)	419.1 [M+H]+	100%
2137	(CD3OD) δ 8.28 (s, 1 H), 7.65 (dd, 1 H), 7.52 (s, 1 H), 7.46 (dd, 1 H), 7.08 (d, 1 H), 7.04 (dd, 1 H), 6.90 (dd, 1 H), 6.73 (s, 1 H), 6.54 (s, 1 H), 4.69 (br dd, 1 H), 3.56 (ddd, 1 H), 2.76-2.91 (m, 1 H), 2.63 (dd, 1 H)	419.1 [M+H]+	100%
2138	(CD3OD) δ 8.40 (s, 1 H), 7.76 (dd, 1 H), 7.67-7.73 (m, 1 H), 7.64 (s, 1 H), 7.30-7.60 (m, 1 H), 7.25 (dd, 1 H), 7.13-7.21 (m, 2 H), 6.82 (s, 1 H), 6.62 (s, 1 H), 4.83 (br dd, 1 H), 3.60-3.71 (m, 1 H), 2.89-3.02 (m, 1 H), 2.75 (dd, 1 H)	435.1 [M+H]+	100%
2139	(CD3OD) δ 8.40 (s, 1 H), 7.76 (dd, 1 H), 7.71 (d, 1 H), 7.63 (s, 1 H), 7.30-7.59 (m, 1 H), 7.22-7.28 (m, 1 H), 7.14-7.21 (m, 2 H), 6.81 (s, 1 H), 6.62 (s, 1 H), 4.84 (br dd, 1 H), 3.59-3.72 (m, 1 H), 2.89-3.02 (m, 1 H), 2.75 (dd, 1 H)	435.1 [ M+H]+	100%
2140	(CD3OD) δ 8.52-8.94 (m, 1 H), 7.47-8.03 (m, 3 H), 6.91-7.19 (m, 1 H), 6.51-6.88 (m, 2 H), 4.65-4.80 (m, 0.5 H), 4.32-4.56 (m, 0.5 H), 3.51-3.88 (m, 1 H), 2.69-3.10 (m, 2 H), 2.18 (br d, 1 H), 1.02-1.27 (m, 4 H)	443.2 [M+H]+	100%
2141	(CD3OD) δ 8.57-8.90 (m, 1 H), 7.44-8.06 (m, 3 H), 6.99 (br s, 1 H), 6.42-6.92 (m, 2 H). 4.64-4.82 (m, 0.5 H), 4.38-4.57 (m, 0.5 H), 3.42-3.89 (m, 1 H), 2.69-3.19 (m, 2 H), 2.18 (br s, 1 H), 0.98-1.23 (m, 4 H)	443.2 [M+H]+	99.6%
2142	(CD3OD) δ 8.47-8.79 (m, 1 H), 7.43-7.82 (m, 3 H). 6.89 (br t, 1 H), 6.46-6.80 (m, 2 H), 4.53-4.74 (m, 1 H), 3.24-3.72 (m, 1 H), 2.61-3.06 (m. 2 H), 1.17-1.38 (m, 9 H)	459.2 [M+H]+	100%
2143	(CD3OD) δ 8.71 (br s, 1 H), 7.51-7.94 (m, 3 H), 6.52-7.18 (m, 3 H), 4.66-4.88 (m, 1 H), 3.37-3.91 (m, 1 H), 2.69-3.23 (m, 2 H), 1.26-1.58 (m, 9 H)	459.2 [M+H]+	99.5%
2144	(CD3OD) δ 8.74 (br d, 1 H), 7.75-8.05 (m, 1 H), 7.60-7.73 (m, 2 H), 7.01 (br s, 1 H), 6.60-6.94 (m, 2 H), 4.82 (br s, 0.3 H), 4.48 (br s, 0.7 H), 3.78 (br s, 0.5 H), 3.36-3.48 (m, 0.5 H), 3.15 (br s, 1 H), 2.86 (brd, 1 H), 1.73-1.91 (m, 6 H)	463.2 [ M+H]+	100%
2145	(CD3OD) δ 8.72 (br s, 1 H), 7.75-8.09 (m, 1 H), 7.60-7.74 (m, 2 H), 7.01 (br s, 1 H), 6.56-6.95 (m, 2 H), 4.75-4.84 (m, 0.5 H), 4.48 (br s, 0.5 H), 3.78 (br s, 0.6 H), 3.36-3.47 (m, 0.4 H), 2.95-3.23 (m, 1 H), 2.84 (br s, 1 H), 1.69-1.92 (m, 6 H)	463.2 [M+H]+	98.5%
2146	(CD3OD) δ 8.29 (d, 1 H), 7.74 (s, 1 H), 7.05 (d, 1 H), 6.84 (t, 1 H), 6.66 (s, 1 H), 6.40 (s, 1 H), 4.33 (dd, 1 H), 3.79 (ddd, 1 H), 2.99-3.25 (m, 2 H), 2.84 (br dd, 1 H), 1.33 (dd, 6 H)	418.2 [M+H]+	100%
2147	(CD3OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 7.07 (d, 1 H), 6.86 (t, 1 H), 6.67 (s, 1 H), 6.40 (s, 1 H), 4.35 (dd, 1 H), 3.81 (ddd, 1 H), 3.05-3.26 (m, 2 H), 2.85 (dd, 1 H), 1.35 (dd, 6 H)	418.2 [M+H]+	99.6%
2148	(CD3OD) δ 8.42 (s, 1 H), 8.25-8.35 (m, 1 H), 7.73-7.82 (m, 1 H), 7.65 (s, 1 H), 7.11-7.18 (m, 1 H), 7.04 (d, 1 H), 6.92 (s, 1 H), 6.81 (t, 1 H), 6.60 (s, 1 H), 4.68-4.75 (m, 1 H), 3.56-3.70 (m, 1 H), 3.18 (dt, 1 H), 2.89-3.03 (m, 1 H), 2.74 (br dd, 1 H), 1.33 (dd, 6 H)	427.2 [ M+H]+	98.7%
2149	(CD3OD) δ 8.27-8.36 (m, 1 H), 8.13-8.23 (m, 1 H), 7.62-7.70 (m, 1 H), 7.46-7.57 (m, 1 H), 7.03 (d, 1 H), 6.92 (d, 1 H), 6.80 (s, 1 H), 6.70 (t, 1 H), 6.48 (s, 1 H), 4.60 (br dd, 1 H), 3.45-3.57 (m, 1 H), 3.07 (dt, 1 H), 2.77-2.91 (m, 1 H), 2.56-2.69 (m, 1 H), 1.21 (dd, 6 H)	427.2 [M+H]+	99.6%
2150	(CD3OD) δ 7.96 (d, 1 H), 7.56 (s, 1 H), 6.63-7.05 (m, 2 H), 6.39-6.54 (m, 2 H), 6.25 (s, 1 H), 4.19 (dd, 1 H), 3.84 (s, 3 H), 3.54-3.72 (m, 1 H), 2.84-3.04 (m, 1 H), 2.71 (dd, 1 H)	388.2 [M+H]+	99.7%
2151	(CD3OD) δ 8.07 (d, 1 H), 7.66 (s, 1 H), 7.10 (s, 0.2 H), 6.97 (s, 0.5 H), 6.73-6.87 (m, 1.3 H), 6.48-6.65 (m, 2 H), 6.35 (s, 1 H), 4.30 (dd, 1 H), 3.94 (s, 3 H), 3.66-3.79 (m, 1 H), 2.97-3.13 (m, 1 H), 2.81 (dd, 1 H)	388.2 [M+H]+	99.1%
2152	(CD3OD) δ 8.36 (d, 1 H), 7.69 (s, 1 H), 7.10-7.26 (m, 0.5 H), 6.92-7.07 (m, 2 H), 6.80-6.90 (m, 1.5 H), 6.70 (s, 1 H), 6.39 (s, 1 H), 4.34 (dd, 1 H), 3.77 (ddd, 1 H), 2.98-3.20 (m, 1 H), 2.84 (dd, 1 H)	424.1 [M+H]+	99.7%
2153	(CD3OD) δ 8.36 (d, 1 H), 7.69 (s, 1 H), 7.08-7.27 (m, 0.5 H), 6.93-7.07 (m, 2 H), 6.79-6.93 (m, 1.5 H), 6.70 (s, 1 H), 6.39 (s, 1 H), 4.34 (dd, 1 H), 3.77 (ddd, 1 H), 2.98-3.16 (m, 1 H), 2.84 (dd, 1 H)	424.1 [M+H]+	98.1%
2154	(CD3OD) δ 8.24 (br d, 1 H), 7.59 (br s, 1 H), 7.10 (s, 0.2 H), 6.82-6.97 (m, 1.5 H), 6.68-6.81 (m, 1.3 H), 6.58 (s, 1 H), 6.29 (br s, 1 H), 4.23 (dd, 1 H), 3.55-3.76 (m, 1 H), 2.86-3.06 (m, 1 H), 2.74 (br d, 1 H)	442.1 [M+H]+	99.6%
2155	(CD3OD) δ 8.24 (d, 1 H), 7.58 (s, 1 H), 7.10 (s, 0.3 H), 6.80-6.96 (m, 1.5 H), 6.70-6.78 (m, 1.2 H), 6.58 (s, 1 H), 6.29 (s, 1 H), 4.24 (dd, 1 H), 3.66 (ddd, 1 H), 2.88-3.05 (m, 1 H), 2.73 (dd, 1 H)	442.1 [M+H]+	99.1%
2156	(CD3OD) δ 9.23 (s, 1 H), 8.67 (br d, 2 H), 8.24 (br d, 1 H), 7.68 (s, 1 H), 6.92 (br d, 1 H), 6.67-6.78 (m, 1 H), 6.42-6.63 (m, 2 H), 4.41 (br dd, 1 H), 3.70-3.87 (m, 1 H), 2.96-3.14 (m, 1 H), 2.77-2.88 (m, 1 H), 2.38 (s, 3 H)	400.2 [M+H]+	99.4%
2157	(CD3OD) δ 9.28 (d, 1 H), 8.66-8.77 (m, 2 H), 8.29 (d, 1 H), 7.68 (s, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.63 (s, 1 H), 6.51 (s, 1 H), 4.43 (dd, 1 H), 3.81 (ddd, 1 H), 3.03-3.15 (m, 1 H), 2.84 (dd, 1 H), 2.43 (s, 3 H)	400.2 [M+H]+	99.4%
2158	(CD3OD) δ 9.24 (s, 1 H), 8.68 (br dd, 2 H), 8.30 (br d, 1 H), 7.68 (s, 1 H), 6.91 (br dd, 1 H), 6.69-6.84 (m, 2 H), 6.49 (br s, 1 H), 4.43 (br dd, 1 H), 3.73-3.86 (m, 1 H), 3.00-3.17 (m, 1 H), 284 (br dd, 1 H)	404.2 [M+H]+	99.9%
2159	(CD3OD) δ 9.23 (s, 1 H), 8.62-8.71 (m, 2 H), 8.28 (d, 1 H), 7.68 (s, 1 H), 6.90 (dd, 1 H), 6.69-6.82 (m, 2 H), 6.49 (s, 1 H), 4.42 (br dd, 1 H), 3.73-3.86 (m, 1 H), 3.00-3.14 (m, 1 H), 2.83 (br dd, 1 H)	404.2 [M+H]+	99.0%
2160	(CD3OD) δ 9.27 (s, 1 H), 8.70 (br dd, 2 H), 8.42 (br d, 1 H), 7.69 (s, 1 H), 7.27 (br d, 1 H), 6.82 (t, 1 H), 6.75 (s, 1 H), 6.51 (s, 1 H), 4.45 (br dd, 1 H), 3.75-3.86 (m, 1 H), 3.03-3.15 (m, 1 H), 2.85 (br dd, 1 H)	420.1 [M+H]+	100%
2161	(CD3OD) δ 9.26 (s, 1 H), 8.65-8.77 (m, 2 H), 8.40 (d, 1 H), 7.69 (s, 1 H), 7.25 (d, 1 H), 6.80 (t, 1 H), 6.74 (s, 1 H), 6.50 (s, 1 H), 4.44 (dd, 1 H), 3.69-3.89 (m, 1 H), 3.00-3.20 (m, 1 H), 2.84 (br dd, 1 H)	420.1 [M+H]+	98.8%
2162	(CD3OD) δ 9.27 (d, 1 H), 8.94 (d, 1 H), 8.67 (d, 1 H), 8.09 (dd, 1 H), 7.69 (s, 1 H), 7.61 (d, 1 H), 6.96 (t, 1 H), 6.82 (s, 1 H), 6.55 (s, 1 H), 4.49 (dd, 1 H), 3.82 (ddd, 1 H), 3.04-3.18 (m, 1 H), 2.86 (dd, 1 H)	454.2 [M+H]+	99.5%
2163	(CD3OD) δ 9.27 (d, 1 H), 8.94 (d, 1 H), 8.68 (d, 1 H), 8.10 (dd, 1 H), 7.69 (s, 1 H), 7.61 (d, 1 H), 6.97 (t, 1 H), 6.82 (s, 1 H), 6.55 (br s, 1 H), 4.49 (dd, 1 H), 3.72-3.92 (m, 1 H), 3.01-3.19 (m, 1 H), 2.86 (br dd, 1 H)	454.2 [M+H]+	96.9%
2164	(CD3OD) δ 8.07 (d, 1 H), 7.67 (s, 1 H), 6.79 (t, 1 H), 6.53-6.64 (m, 2 H), 6.36 (s, 1 H), 4.31 (dd, 1 H), 3.94 (s, 3 H), 3.75 (td, 1 H), 2.99-3.14 (m, 1 H), 2.82 (br dd, 1 H)	406.1 [M+H]+	100%
2165	(CD3OD) δ 8.07 (d, 1 H), 7.67 (s, 1 H), 6.79 (t, 1 H), 6.50-6.65 (m, 2 H), 6.36 (br s, 1 H), 4.31 (dd, 1 H), 3.95 (s, 3 H), 3.69-3.83 (m, 1 H), 2.99-3.12 (m, 1 H), 2.76-2.87 (m, 1 H)	406.1 [M+H]+	99.6%
2166	(CD3OD) δ 8.16 (d, 1 H), 7.57 (s, 1 H), 6.59-7.03 (m, 4 H), 6.28 (s, 1 H), 4.21 (dd, 1 H), 3.67 (ddd, 1 H), 2.83-3.03 (m, 1 H), 2.72 (dd, 1 H), 1.78-2.10 (m, 1 H), 0.88-0.96 (m, 2 H), 0.62-0.71 (m, 2 H)	398.2 [M+H]+	90.7%
2167	(CD3OD) δ 8.17 (d, 1 H), 7.58 (s, 1 H), 6.56-7.04 (m, 4 H), 6.28 (s, 1 H), 4.21 (dd, 1 H), 3.67 (td, 1 H), 2.85-3.06 (m, 1 H), 2.72 (dd, 1 H), 1.87-2.06 (m, 1 H), 0.86-1.01 (m, 2 H), 0.63-0.73 (m, 2 H)	398.2 [M+H]+	100%
2168	(CD3OD) δ 8.31 (br d, 1 H), 7.66 (s, 1 H), 7.06 (d, 1 H), 6.84 (t, 1 H), 6.59 (s, 1 H), 6.14-6.33 (m, 1 H), 4.19 (dd, 1 H), 3.70 (td, 1 H), 3.20 (dt, 1 H), 2.95-3.10 (m, 1 H), 2.73-2.87 (m, 1 H), 2.02-2.15 (m, 1 H), 1.34 (dd, 6 H), 1.04-1.15 (m, 4 H)	390.2 [M+H]+	98.6%
2169	(CD3OD) δ 8.19 (d, 1 H), 7.54 (s, 1 H), 6.94 (d, 1 H), 6.72 (t, 1 H), 6.47 (s, 1 H), 6.14 (br s, 1 H), 4.07 (dd, 1 H), 3.58 (td, 1 H), 3.08 (dt, 1 H), 2.85-2.96 (m, 1 H), 2.67 (br dd, 1 H), 1.92-2.05 (m, 1 H), 1.22 (dd, 6 H), 0.92-1.03 (m, 4 H)	390.2 [M+H]+	97.5%
2170	(CD3OD) δ 8.30 (s, 1 H), 8.16 (d, 1 H), 7.65 (dd, 1 H), 7.54 (s, 1 H), 7.03 (d, 1 H), 6.81 (s, 1 H), 6.59-6.70 (m, 2 H), 6.57 (s, 1 H), 4.60 (br dd, 1 H), 3.44-3.58 (m, 1 H), 2.78-2.91 (m, 1 H), 2.62 (dd, 1 H), 1.89-2.02 (m, 1 H), 0.86-0.96 (m, 2 H), 0.59-0.69 (m, 2 H)	425.2 [M+H]+	80.9%
2171	(CD3OD) δ 8.30 (s, 1 H), 8.16 (d, 1 H), 7.65 (dd, 1 H), 7.54 (s, 1 H), 7.03 (d, 1 H), 6.82 (s, 1 H), 6.60-6.70 (m, 2 H), 6.57 (s, 1 H), 4.60 (br dd, 1 H), 3.44-3.57 (m, 1 H), 2.79-2.90 (m, 1 H), 2.62 (dd, 1 H), 1.91-2.01 (m, 1 H), 0.85-0.96 (m, 2 H), 0.61-0.69 (m, 2 H)	425.2 [M+H]+	96.3%
2172	(CD3OD) δ 8.40 (d, 2 H), 8.25 (d, 1 H), 7.64 (s, 1 H), 7.22 (s, 1 H), 6.70-6.81 (m, 2 H), 6.69 (s, 1 H), 6.64 (t, 1 H), 5.03 (dd, 1 H), 3.48 (ddd, 1 H), 2.85-2.98 (m, 1 H), 2.70 (dd, 1 H), 2.01-2.13 (m, 1 H), 0.97-1.07 (m, 2 H), 0.71-0.81 (m, 2 H)	358.2 [M+H]+	100%
2173	(CD3OD) δ 8.41 (d, 2 H), 8.25 (d, 1 H), 7.64 (s, 1 H), 7.22 (s, 1 H), 6.71-6.80 (m, 2 H), 6.69 (s, 1 H), 6.65 (t, 1 H), 5.04 (dd, 1 H), 3.48 (ddd, 1 H), 2.84-3.00 (m, 1 H), 2.70 (dd, 1 H), 2.00-2.13 (m, 1 H), 0.97-1.07 (m, 2 H), 0.70-0.81 (m, 2 H)	358.2 [M+H]+	100%
2174	(CD3OD) δ 8.56 (s, 2 H), 8.14 (d, 1 H), 7.55 (s, 1 H), 7.16 (s, 1 H), 6.52-6.74 (m, 3 H), 5.06 (dd, 1 H), 3.42 (td, 1 H), 2.74-2.87 (m, 1 H), 2.60-2.69 (m, 1 H), 1.89-2.06 (m, 1 H), 0.84-0.95 (m, 2 H), 0.59-0.71 (m, 2 H)	426.2 [M+H]+	100%
2175	(CD3OD) δ 8.56 (s, 2 H), 8.14 (d, 1 H), 7.55 (s, 1 H), 7.16 (s, 1 H), 6.54-6.73 (m, 3 H), 5.07 (dd, 1 H), 3.42 (td, 1 H), 2.72-2.90 (m, 1 H), 2.57-2.71 (m, 1 H), 1.86-2.06 (m, 1 H), 0.85-0.97 (m, 2 H), 0.59-0.73 (m, 2 H)	426.2 [M+H]+	99.7%
2176	(CD3OD) δ 9.28 (d, 1 H), 8.67-8.75 (m, 2 H), 8.28 (d, 1 H), 7.68 (s, 1 H), 7.03 (d, 1 H), 6.81 (t, 1 H), 6.72 (s, 1 H), 6.51 (s, 1 H), 4.43 (dd, 1 H), 3.82 (td, 1 H), 3.04-3.23 (m, 2 H), 2.85 (dd, 1 H), 1.29-1.35 (m, 6 H)	428.2 [M+H]+	100%
2177	(CD3OD) δ 9.29 (d, 1 H), 8.68-8.75 (m, 2 H), 8.29 (d, 1 H), 7.68 (s, 1 H), 7.04 (d, 1 H), 6.82 (t, 1 H), 6.72 (s, 1 H), 6.51 (s, 1 H), 4.44 (dd, 1 H), 3.77-3.88 (m, 1 H), 3.04-3.25 (m, 2 H), 2.85 (dd, 1 H), 1.29-1.35 (m, 6 H)	428.2 [M+H]+	99.0%
2178	(CD3OD) δ 9.27 (d, 1 H), 8.94 (d, 1 H), 8.32 (br d, 1 H), 8.10 (dd, 1 H), 7.69 (br s, 1 H), 6.95 (dd, 1 H), 6.73-6.86 (m, 2 H), 6.52 (s, 1 H), 4.47 (dd, 1 H), 3.72-3.89 (m, 1 H), 2.98-3.17 (m, 1 H), 2.86 (br d, 1 H)	404.2 [M+H]+	100%
2179	(CD3OD) δ 9.28 (d, 1 H), 8.95 (d, 1 H), 8.33 (br d, 1 H), 8.10 (dd, 1 H), 7.69 (br s, 1 H), 6.95 (dd, 1 H), 6.73-6.87 (m, 2 H), 6.53 (s, 1 H), 4.47 (br dd, 1 H), 3.69-3.91 (m, 1 H), 3.01-3.16 (m, 1 H), 2.78-2.93 (m, 1 H)	404.2 [M+H]+	94.6%
2180	(CD3OD) δ 9.28 (d, 1 H), 8.95 (d, 1 H), 8.29 (d, 1 H), 8.11 (dd, 1 H), 7.68 (s, 1 H), 7.04 (d, 1 H), 6.82 (t, 1 H), 6.72 (s, 1 H), 6.52 (br s, 1 H), 4.46 (dd, 1 H), 3.83 (ddd, 1 H), 3.02-3.24 (m, 2 H), 2.86 (br dd, 1 H), 1.32 (dd, 6 H)	428.2 [M+H]+	100%
2181	(CD3OD) δ 9.27 (s, 1 H), 8.94 (d, 1 H), 8.28 (d, 1 H), 8.10 (d, 1 H), 7.68 (s, 1 H), 7.04 (d, 1 H), 6.82 (t, 1 H), 6.72 (s, 1 H), 6.52 (br s, 1 H), 4.46 (dd, 1 H), 3.75-3.93 (m, 1 H), 3.00-3.23 (m, 2 H), 2.86 (br dd, 1 H), 1.28-1.34 (m, 6 H)	428.2 [M+H]+	97.8%
2182	(CD3OD) δ 9.27 (s, 1 H), 8.94 (d, 1 H), 8.42 (d, 1 H), 8.10 (dd, 1 H), 7.69 (s, 1 H), 7.27 (d, 1 H), 6.82 (t, 1 H), 6.76 (s, 1 H), 6.53 (br s, 1 H), 4.47 (dd, 1 H), 3.81 (td, 1 H), 3.01-3.16 (m, 1 H), 2.86 (br dd, 1 H)	420.1 [M+H]+	100%
2183	(CD3OD) δ 9.26 (s, 1 H), 8.94 (d, 1 H), 8.42 (d, 1 H), 8.09 (d, 1 H), 7.69 (s, 1 H), 7.27 (d, 1 H), 6.82 (t, 1 H), 6.75 (s, 1 H), 6.52 (s, 1 H), 4.47 (dd, 1 H), 3.70-3.89 (m, 1 H), 3.00-3.16 (m, 1 H), 2.85 (br dd, 1H)	420.1 [M+H]+	96.9%
2184	(CD3OD) δ 8.68 (s, 2 H), 8.29 (d, 1 H), 7.66 (s, 1 H), 7.26 (s, 1 H), 7.05 (d, 1 H), 6.82 (t, 1 H), 6.63 (s, 1 H), 5.18 (dd, 1 H), 3.47-3.60 (m, 1 H), 3.19 (dt, 1 H), 2.86-2.99 (m, 1 H), 2.70-2.81 (m, 1 H), 1.34 (dd, 6 H)	428.2 [M+H]+	100%
2185	(CD3OD) δ 8.66 (s, 2 H), 8.27 (d, 1 H), 7.67 (s, 1 H), 7.25 (s, 1 H), 7.03 (d, 1 H), 6.80 (t, 1 H), 6.61 (s, 1 H), 5.17 (dd, 1 H), 3.46-3.59 (m, 1 H), 3.17 (dt, 1 H), 2.85-2.98 (m, 1 H), 2.69-2.79 (m, 1 H), 1.32 (dd, 6 H)	428.2 [M+H]+	100%
2186	(CD3OD) δ 8.29 (d, 1 H), 7.67 (s, 1 H), 6.74-6.85 (m, 2 H), 6.69 (s, 1 H), 6.31 (s, 1 H), 4.22 (dd, 1 H), 3.64-3.78 (m, 1 H), 2.97-3.10 (m, 1 H), 2.79 (dd, 1 H), 2.45 (s, 3 H), 2.04-2.15 (m, 1 H), 1.00-1.07 (m, 2 H), 0.75-0.83 (m, 2 H)	362.2 [M+H]+	99.7%
2187	(CD3OD) δ 8.29 (d, 1 H), 7.67 (s, 1 H), 6.75-6.85 (m, 2 H), 6.69 (s, 1 H), 6.31 (s, 1 H), 4.22 (dd, 1 H), 3.71 (ddd, 1 H), 2.95-3.12 (m, 1 H), 2.79 (dd, 1 H), 2.45 (s, 3 H), 1.99-2.21 (m, 1 H), 0.99-1.08 (m, 2 H), 0.73-0.82 (m, 2 H)	362.2 [M+H]+	91.9%
2188	(CD3OD) δ 8.31 (d, 1 H), 7.67 (s, 1 H), 6.99 (d, 1 H), 6.79 (t, 1 H), 6.52 (s, 1 H), 6.24 (s, 1 H), 4.18 (dd, 1 H), 3.64-3.76 (m, 1 H), 2.96-3.08 (m, 1 H), 2.79 (dd, 1 H), 2.44 (s, 3 H), 1.50 (s, 3 H), 1.23-1.31 (m, 2 H), 0.91-0.97 (m, 2 H)	376.2 [M+H]+	99.8%
2189	(CD3OD) δ 8.31 (d, 1 H), 7.67 (s, 1 H), 6.99 (d, 1 H), 6.79 (t, 1 H), 6.52 (s, 1 H), 6.24 (s, 1 H), 4.18 (dd, 1 H), 3.62-3.76 (m, 1 H), 2.94-3.09 (m, 1 H), 2.79 (dd, 1 H), 2.44 (s, 3 H), 1.50 (s, 3 H), 1.24-1.31 (m, 2 H), 0.90-0.99 (m, 2 H)	376.2 [M+H]+	99.8%
2190	(CD3OD) δ 8.32 (d, 1 H), 7.51-7.58 (m, 1 H), 7.46 (d, 1 H), 7.02-7.11 (m, 1 H), 6.70-6.78 (m, 1 H), 6.45 (s, 1 H), 6.25 (s, 1 H), 4.18 (dd, 1 H), 3.64 (ddd, 1 H), 2.85-3.00 (m, 1 H), 2.70 (dd, 1 H), 1.92-2.06 (m, 3 H)	372.1 [M+H]+	100%
2191	(CD3OD) δ 8.32 (d, 1 H), 7.56 (s, 1 H), 7.47 (d, 1 H), 6.99-7.13 (m, 1 H), 6.74 (t, 1 H), 6.45 (s, 1 H), 6.25 (s, 1 H), 4.18 (dd, 1 H), 3.64 (ddd, 1 H), 2.87-3.00 (m, 1 H), 2.70 (dd, 1 H), 1.99 (t, 3 H)	372.1 [M+H]+	99.9%
2192	(CD3OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 7.00 (d, 1 H), 6.80 (t, 1 H), 6.59 (s, 1 H), 6.38 (s, 1 H), 4.31 (dd, 1 H), 3.73-3.84 (m, 1 H), 3.00-3.15 (m, 1 H), 2.84 (dd, 1 H), 2.45 (s, 3 H), 2.12 (t, 3 H)	386.2 [M+H]+	100%
2193	(CD3OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 7.00 (d, 1 H), 6.80 (t, 1 H), 6.59 (s, 1 H), 6.38 (br s, 1 H), 4.31 (dd, 1 H), 3.78 (ddd, 1 H), 2.95-3.13 (m, 1 H), 2.83 (br dd, 1 H), 2.45 (s, 3 H), 2.12 (t, 3 H)	386.2 [M+H]+	100%
2194	(CD3OD) δ 8.70 (d, 1 H), 7.70 (s, 1 H), 7.64 (d, 1 H), 6.96-7.03 (m, 1 H), 6.71-6.80 (m, 1 H), 6.41 (s, 1 H), 4.35 (dd, 1 H), 3.71-3.85 (m, 1 H), 3.02-3.13 (m, 1 H), 2.85 (dd, 1 H), 2.03-2.19 (m, 3 H)	440.2 [M+H]+	99.9%
2195	(CD3OD) δ 8.69 (d, 1 H), 7.69 (s, 1 H), 7.63 (d, 1 H), 6.99 (t, 1 H), 6.76 (s, 1 H), 6.40 (br s, 1 H), 4.34 (dd, 1 H), 3.70-3.84 (m, 1 H), 3.01-3.14 (m, 1 H), 2.85 (br dd, 1 H), 2.11 (t, 3 H)	440.2 [M+H]+	99.4%
2196	(CD3OD) δ 8.35 (d, 1 H), 7.69 (s, 1 H), 6.97 (dd, 1 H), 6.80-6.87 (m, 1 H), 6.69-6.74 (m, 1 H), 6.38 (s, 1 H), 4.27-4.38 (m, 1 H), 3.71-3.85 (m, 1 H), 3.01-3.12 (m, 1 H), 2.84 (dd, 1 H), 2.12 (t, 3 H)	390.2 [M+H]+	99.4%
2197	(CD3OD) δ 8.35 (d, 1 H), 7.69 (s, 1 H), 6.97 (dd, 1 H), 6.84 (td, 1 H), 6.72 (s, 1 H), 6.38 (s, 1 H), 4.27-4.39 (m, 1 H), 3.78 (ddd, 1 H), 3.01-3.14 (m, 1 H), 2.84 (dd, 1 H), 2.12 (t, 3 H)	390.2 [M+H]+	99.8%
2198	(CD3OD) δ 9.29 (dd, 1 H), 8.25-8.52 (m, 2 H), 7.89 (dd, 1 H), 7.70 (s, 1 H), 7.29 (d, 1 H), 6.73-6.95 (m, 2 H), 6.57 (br s, 1 H), 4.50 (dd, 1 H), 3.74-3.95 (m, 1 H), 3.12 (br d, 1 H), 2.88 (br dd, 1 H)	420.1 [M+H]+	100%
2199	(CD3OD) δ 9.19-9.41 (m, 1 H), 8.25-8.55 (m, 2 H), 7.89 (dd, 1 H), 7.71 (s, 1 H), 7.29 (d, 1 H), 6.73-6.91 (m, 2 H), 6.57 (s, 1 H), 4.50 (dd, 1 H), 3.68-4.01 (m, 1 H), 3.03-3.23 (m, 1 H), 2.87 (dd, 1 H)	420.1 [M+H]+	98.6%
2200	(CD3OD) δ 8.65 (s, 2 H), 8.04 (d, 1 H), 7.63 (s, 1 H), 7.21 (s, 1 H), 6.75 (t, 1 H). 6.48-6.63 (m, 2 H), 5.15 (dd, 1 H), 3.93 (s. 3 H), 3.41-3.57 (m, 1 H), 2.84-2.95 (m, 1 H), 2.66-2.80 (m, 1 H)	416.2 [M+H]+	100%
2201	(CD3OD) δ 8.65 (s, 2 H), 8.04 (d, 1 H), 7.64 (s, 1 H), 7.21 (s, 1 H), 6.75 (t, 1 H), 6.45-6.61 (m, 2 H), 5.15 (dd, 1 H), 3.93 (s, 3 H), 3.41-3.57 (m, 1 H), 2.82-2.97 (m, 1 H), 2.69-2.78 (m, 1 H)	416.2 [M+H]+	98.9%
2202	(CD3OD) δ 8.59 (d, 1 H), 7.69 (s, 1 H), 7.44 (br d, 1 H), 6.83-7.14 (m, 2 H), 6.76 (s, 1 H), 6.40 (s. 1 H), 4.33 (dd, 1 H), 3.77 (ddd, 1 H), 3.00-3.14 (m, 1 H), 2.84 (dd, 1 H), 2.12 (t, 3 H)	422.2 [M+H]+	96.6%
2203	(CD3OD) δ 8.59 (d, 1 H), 7.69 (s, 1 H), 7.44 (br d, 1 H), 6.82-7.15 (m, 2 H), 6.76 (s, 1 H), 6.40 (s, 1 H), 4.33 (dd, 1 H), 3.77 (ddd, 1 H), 2.99-3.13 (m, 1 H), 2.84 (br dd, 1 H), 2.12 (t, 3 H)	422.2 [M+H]+	99.9%
2204	(CD3OD) δ 8.28 (d, 1 H), 7.69 (s, 1 H), 6.67-6.87 (m, 3 H), 6.39 (br s, 1 H), 4.32 (dd, 1 H), 3.79 (ddd, 1 H), 3.00-3.13 (m, 1 H), 2.84 (br dd, 1 H), 2.02-2.18 (m, 4 H), 0.97-1.08 (m, 2 H), 0.71-0.82 (m, 2 H)	412.2 [M+H]+	99.7%
2205	(CD3OD) δ 8.28 (br d, 1 H), 7.69 (br s, 1 H), 6.73-6.84 (m, 3 H), 6.39 (br s, 1 H). 4.32 (dd, 1 H), 3.72-3.88 (m, 1 H), 3.00-3.15 (m, 1 H), 2.77-2.92 (m, 1 H), 2.06-2.17 (m, 4 H), 1.00-1.08 (m, 2 H), 0.75-0.81 (m, 2 H)	412.2 (M+H]+	99.9%
2206	(CD3OD) δ 8.54 (dd, 1 H), 8.22-8.42 (m, 2 H), 7.69 (s, 1 H), 7.45 (dd, 1 H), 6.99 (d, 1 H), 6.78 (t, 1 H), 6.59 (s, 1 H), 6.46 (br s, 1 H), 4.39 (dd, 1 H), 3.71-3.92 (m, 1 H), 3.05-3.19 (m, 1 H), 2.88 (s, 4 H), 2.44 (s, 3 H)	413.2 [M+H]+	99.6%
2207	(CD3OD) δ 8.47-8.62 (m, 1 H), 8.32 (t, 2 H), 7.76 (s, 1 H), 7.45 (dd, 1 H), 6.99 (d, 1 H). 6.78 (t, 1 H), 6.60 (s, 1 H), 6.47 (s, 1 H), 4.40 (dd, 1 H), 3.73-3.90 (m, 1 H), 3.02-3.20 (m, 1 H), 2.81-2.93 (m, 4 H), 2.44 (s, 3 H)	413.2 [M+H]+	99.1%
2208	(CD3OD) δ 8.71 (br d, 1 H), 8.55 (d, 1 H), 8.33 (d, 1 H), 7.57-7.78 (m, 2 H), 7.45 (dd, 1 H), 6.99 (t, 1 H), 6.78 (s, 1 H), 6.49 (br s, 1 H), 4.43 (dd, 1 H), 3.74-3.90 (m, 1 H), 3.05-3.19 (m, 1 H), 2.80-2.94 (m, 4 H)	467.2 [M+H]+	100%
2209	(CD3OD) δ 8.71 (br d, 1 H), 8.55 (dd, 1 H), 8.33 (dd, 1 H), 7.56-7.80 (m, 2 H), 7.46 (dd, 1 H), 6.99 (br t, 1 H), 6.78 (s, 1 H), 6.49 (br s, 1 H), 4.43 (dd, 1 H), 3.82 (br d, 1 H), 3.02-3.20 (m, 1 H), 2.89 (s, 4 H)	467.2 [M+H]+	99.5%
2210	(CD3OD) δ 8.13-8.89 (m, 3 H), 7.71 (s, 1 H), 7.37-7.54 (m, 2 H), 6.72-7.18 (m, 3 H), 6.48 (s, 1 H), 4.41 (dd, 1 H), 3.67-3.94 (m, 1 H), 3.05-3.19 (m, 1 H), 2.74-3.01 (m, 4 H)	449.2 (M+H]+	99.9%
2211	(CD3OD) δ 8.48-8.70 (m, 2 H), 8.33 (dd, 1 H), 7.70 (s, 1 H), 7.36-7.60 (m, 2 H), 6.73-7.17 (m, 3 H), 6.48 (s, 1 H), 4.41 (dd, 1 H), 3.81 (ddd, 1 H), 3.03-3.18 (m, 1 H), 2.77-2.97 (m, 4 H)	449.2 [M+H]+	99.6%
2212	(CD3OD) δ 8.54 (dd, 1 H), 8.22-8.42 (m, 2 H), 7.69 (s, 1 H), 7.45 (dd, 1 H), 6.99 (d, 1 H), 6.78 (t, 1 H), 6.59 (s, 1 H), 6.46 (br s, 1 H), 4.39 (dd, 1 H), 3.71-3.92 (m, 1 H), 3.05-3.19 (m, 1 H), 2.88 (s, 4 H), 2.44 (s. 3 H)	413.2 [M+H]+	99.6%
2213	(CD3OD) δ 8.41 (dd, 1 H), 8.10-8.30 (m, 2 H), 7.58 (s, 1 H), 7.32 (dd, 1 H), 6.53-6.90 (m, 3 H), 6.34 (s, 1 H), 4.28 (dd, 1 H), 3.69 (ddd, 1 H), 2.90-3.07 (m, 1 H), 2.65-2.87 (m, 4 H)	417.2 [M+H]+	98.9%
2214	(CD3OD) δ 8.25-8.34 (m, 1 H), 7.69 (br d, 1 H), 6.92-7.01 (m, 2 H), 6.82-6.91 (m, 1 H), 6.77 (dt, 1 H), 6.34-6.72 (m, 1 H), 4.44 (dd, 1 H), 4.10 (s, 3 H), 3.62-3.77 (m, 0.6 H), 3.10-3.28 (m, 1 H), 2.92-3.05 (m, 0.4 H), 2.68-2.87 (m, 1 H), 2.34-2.48 (m, 3 H)	413.1 [M+H]+	100%
2215	(CD3OD) δ 8.23-8.38 (m, 1 H), 7.70 (br s, 1 H), 6.92-7.02 (m, 2 H), 6.82-6.91 (m, 1 H), 6.77 (dt, 1 H), 6.35-6.72 (m, 1 H), 4.44 (br dd, 1 H), 4.10 (s, 3 H), 3.58-3.77 (m, 0.6 H), 3.11-3.30 (m, 1 H), 2.93-3.03 (m, 0.4 H), 2.67-2.87 (m, 1 H), 2.35-2.49 (m, 3 H)	413.1 [M+H]+	100%
2216	(CD3OD) δ 8.46 (br s, 1 H), 7.70 (s, 2 H), 7.32 (d, 1 H), 6.59-6.92 (m, 3 H), 4.42-4.80 (m, 1 H), 3.75 (br s, 1 H), 2.96-3.22 (m, 1 H), 2.84 (br d, 1 H), 1.66 (br s, 6 H)	427.1 [M+H]+	100%
2217	(CD3OD) δ 8.46 (br s, 1 H), 7.59-8.02 (m, 2 H), 7.31 (br s, 1 H), 6.61-6.93 (m, 3 H), 4.35-4.65 (m, 1 H), 3.75 (br s, 1 H), 3.14 (br s, 1 H), 2.82 (br s, 1 H), 1.64 (br s, 6 H)	427.1 [M+H]	99.4%
2218	(CD3OD) δ 8.44-8.54 (m, 1 H), 7.70 (s, 1 H), 7.48 (s, 0.3 H), 7.16-7.25 (m, 1 H), 6.87-6.98 (m, 1.7 H), 6.66-6.81 (m, 1 H), 4.91-5.05 (m, 1 H), 3.75 (ddd, 0.6 H), 3.36-3.45 (m, 0.4 H), 2.81-3.20 (m, 2 H), 2.62-2.69 (m, 3 H)	434.1 [M+H]+	100%
2219	(CD3OD) δ 8.28-8.42 (m, 1 H), 7.58 (s, 1 H), 7.36 (s, 0.3 H), 6.98-7.14 (m, 1 H), 6.72-6.88 (m, 1.7 H), 6.58-6.68 (m, 1 H), 4.87 (br dd, 1 H), 3.63 (ddd, 0.6 H), 3.27 (td, 0.4 H), 2.67-3.09 (m, 2 H), 2.48-2.57 (m, 3 H)	434.1 [M+H]+	99.8%
2220	(CD3OD) δ 7.73 (d, 1 H), 7.66 (s, 1 H), 7.32-7.50 (m, 0.7 H), 7.23-7.30 (m, 1 H), 7.16-7.22 (m, 1.3 H), 6.78-7.12 (m, 1 H), 6.66 (s, 1 H), 6.37 (br s, 1 H), 4.33 (dd, 1 H), 3.70-3.89 (m, 1 H), 2.99-3.10 (m, 1 H), 2.76-2.88 (m, 1 H)	408.1 [M+H]+	99.5%
2221	(CD3OD) δ 7.72 (d, 1 H), 7.66 (s, 1 H), 7.31-7.50 (m, 0.8 H), 7.23-7.30 (m, 1 H), 7.18 (t, 1.2 H), 6.81-7.12 (m, 1 H), 6.66 (s, 1 H), 6.38 (s, 1 H), 4.33 (dd, 1 H), 3.79 (ddd, 1 H), 2.97-3.11 (m, 1 H), 2.82 (dd, 1 H)	408.2 (M+H]+	98.7%
2222	(CD3OD) δ 8.27-8.39 (m, 1 H), 7.65 (s, 1 H), 6.88-7.02 (m, 1.8 H), 6.81 (td, 1 H), 6.53-6.69 (m, 1.2 H), 4.85 (br s, 0.3 H), 4.36 (dd, 0.7 H), 3.70 (ddd, 0.8 H), 3.36-3.41 (m, 0.2 H), 3.10 (ddd, 0.8 H), 2.69-2.95 (m, 2.2 H), 2.01-2.11 (m, 1 H), 1.75-1.88 (m, 1 H)	362.1 [M+H]+	97.2%
2223	(CD3OD) δ 8.23-8.44 (m, 1 H), 7.67 (d, 1 H), 6.71-7.01 (m, 2.5 H), 6.33-6.67 (m, 1.5 H), 4.76 (dd, 0.5 H), 4.33 (dd, 0.5 H), 3.70 (ddd, 0.5 H), 3.39-3.52 (m, 0.5 H), 2.95-3.22 (m, 1.5 H), 2.66-2.88 (m, 1.5 H), 2.05-2.19 (m, 1 H), 1.76-1.93 (m, 1 H)	362.1 [M+H]+	90.7%
2224	(CD3OD) δ 8.34 (br s, 1 H), 7.95-8.23 (m, 2 H), 7.34-7.74 (m, 2 H), 6.49-6.80 (m, 4 H), 4.54 (br s, 1 H), 3.41-3.62 (m, 1 H), 2.78-2.94 (m, 1 H), 2.67 (br dd, 1 H), 1.86-2.04 (m, 1 H), 0.89 (br d, 2H), 0.63 (br d, 2 H)	358.2 [M+H]+	100%
2225	(CD3OD) δ 8.33 (br s, 1 H), 7.96-8.22 (m, 2 H), 7.35-7.76 (m, 2 H), 6.50-6.80 (m, 4 H), 4.55 (br s, 1 H), 3.42-3.61 (m, 1 H), 2.81-2.96 (m, 1 H), 2.56-2.79 (m, 1 H), 1.82-2.03 (m, 1 H), 0.88 (br d, 2 H), 0.63 (br d, 2 H)	358.2 [M+H]+	98.3%
2226	(CD3OD) δ 8.15 (d, 1 H), 7.55 (s, 1 H), 6.61-6.72 (m, 2 H), 6.55 (s, 1 H), 6.13 (s, 1 H), 4.06 (dd, 1 H). 3.59 (ddd, 1 H). 2.84-2.97 (m, 1 H), 2.68 (dd, 1 H), 1.91-2.02 (m, 1 H), 1.38 (s, 3 H), 1.12-1.18 (m. 2 H), 0.87-0.95 (m, 2 H), 0.78-0.85 (m. 2 H), 0.61-0.70 (m, 2 H)	402.2 [M+H]+	99.7%
2227	(CD3OD) δ 8.16 (d, 1 H), 7.55 (s, 1 H), 6.62-6.73 (m, 2 H), 6.56 (s, 1 H), 6.13 (br s, 1 H). 4.07 (dd, 1 H), 3.59 (ddd, 1 H), 2.84-2.96 (m, 1 H), 2.68 (br dd, 1 H), 1.92-2.03 (m, 1 H), 1.38 (s, 3 H), 1.12-1.19 (m, 2 H), 0.89-0.95 (m, 2 H), 0.80-0.85 (m, 2 H), 0.62-0.70 (m. 2 H)	402.2 [M+H]+	99.6%
2228	(CD3OD) δ 8.18 (d, 1 H), 7.54 (s, 1 H), 6.94 (d, 1 H), 6.72 (t, 1 H), 6.47 (s, 1 H), 6.12 (br s, 1 H), 4.06 (dd, 1 H), 3.59 (ddd, 1 H), 3.02-3.13 (m, 1 H), 2.83-2.97 (m, 1 H), 2.68 (dd. 1 H), 1.38 (s, 3 H), 1.22 (dd, 6 H), 1.12-1.17 (m, 2 H), 0.78-0.86 (m, 2 H)	404.3 [M+H]+	99.8%
2229	(CD3OD) δ 8.18 (d, 1 H), 7.54 (s, 1 H), 6.94 (d, 1 H), 6.72 (t, 1 H), 6.47 (s, 1 H), 6.12 (s, 1 H), 4.06 (dd, 1 H), 3.53-3.67 (m. 1 H), 3.01-3.14 (m, 1 H), 2.83-2.96 (m, 1 H), 2.68 (dd, 1 H), 1.38 (s, 3 H), 1.22 (dd, 6 H), 1.12-1. 18 (m, 2 H), 0.77-0.86 (m, 2 H)	404.3 [M+H]+	99.3%
2230	(CD3OD) δ 8.31 (d, 1 H), 7.62-7.73 (m. 1 H), 7.07 (d. 1 H), 6.81-6.90 (m, 1 H), 6.66 (s, 1 H), 6.38 (s, 1 H), 4.32 (dd, 1 H), 3.79 (ddd, 1 H), 3.20 (dt, 1 H), 3.01-3.12 (m, 1 H), 2.84 (dd, 1 H), 2.12 (t, 3 H), 1.32-1.37 (m, 6 H)	414.2 [M+H]+	100%
2231	(CD3OD) δ 8.31 (d, 1 H), 7.68 (s, 1 H), 7.07 (d, 1 H), 6.85 (t, 1 H), 6.66 (s, 1 H). 6.32-6.44 (m, 1 H). 4.32 (dd, 1 H), 3.79 (ddd, 1 H), 3.20 (dt, 1 H), 3.01-3.12 (m, 1 H), 2.84 (br dd, 1 H), 2.12 (t, 3 H), 1.35 (dd, 6 H)	414.2 [M+H]+	99.4%
2232	(CD3OD) δ 8.33 (d, 1 H), 7.58 (s, 1 H), 7.18 (d, 1 H), 6.74 (t, 1 H), 6.59 (s, 1 H), 6.27 (s, 1 H), 4.21 (dd, 1 H), 3.65 (ddd, 1 H), 2.89-3.01 (m, 1 H). 2.72 (dd, 1 H). 2.00 (t, 3 H)	406.1 [M+H]+	100%
2233	(CD3OD) δ 8.33 (d, 1 H), 7.57 (s, 1 H), 7.19 (d, 1 H). 6.74 (t, 1 H), 6.59 (s, 1 H), 6.26 (br s, 1 H). 4.21 (dd, 1 H), 3.65 (ddd, 1 H), 2.89-3.00 (m, 1 H), 2.72 (br dd, 1 H), 2.00 (t, 3 H)	406.1 [M+H]+	99.9%
2234	(CD3OD) δ 8.54 (dd, 1 H), 8.24-8.43 (m, 2 H), 7.72 (s, 1 H), 7.45 (dd, 1 H), 7.06 (d, 1 H), 6.84 (t, 1 H), 6.68 (s. 1 H), 6.46 (s, 1 H), 4.40 (dd, 1 H), 3.74-3.92 (m, 1 H), 3.03-3.28 (m, 2 H), 2.78-2.95 (m, 4 H). 1.34 (dd, 6 H)	441.2 [M+H]+	100%
2235	(CD3OD) δ 8.54 (dd, 1 H), 8.24-8.41 (m, 2 H), 7.70 (s, 1 H), 7.45 (dd, 1 H), 7.05 (d, 1 H), 6.83 (t, 1 H), 6.68 (s, 1 H), 6.46 (s, 1H). 4.40 (dd, 1H), 3.71-3.91 (m, 1H), 3.01-3.28 (m, 2 H), 2.88 (s, 4 H), 1.33 (dd, 6 H)	441.2 [M+H]+	99.8%
2236	(CD3OD) δ 8.26-8.61 (m, 3 H), 7.70 (s, 1 H), 7.45 (dd, 1 H), 7.29 (d. 1 H), 6.66-6.90 (m, 2 H), 6.46 (s, 1 H), 4.41 (dd, 1 H), 3.81 (br dd, 1 H), 3.02-3.20 (m, 1 H), 2.76-3.00 (m, 4 H)	433.1 [M+H]+	100%
2237	(CD3OD) δ 8.11-8.50 (m, 3 H), 7.58 (s, 1 H), 7.11-7.41 (m, 2 H), 6.54-6.79 (m. 2 H), 6.34 (s, 1 H). 4.29 (dd, 1 H). 3.54-3.81 (m, 1 H), 2.99 (br s, 1 H), 2.61-2.85 (m, 4 H)	433.2 [M+H]+	99.6%
2238	(CD3OD) δ 8.42 (d, 1 H), 7.60 (s, 1 H), 7.51 (d, 1 H), 7.06-7.23 (m, 5 H), 6.74-6.84 (m, 2 H), 6.35 (s, 1 H), 6.00 (s. 1 H), 3.84-3.92 (m, 1 H), 3.53-3.68 (m, 1 H), 2.87-2.98 (m, 1 H), 2.67 (br dd, 1 H)	316.1 [M+H]+	100%
2239	(CD3OD) δ 8.42 (d, 1 H), 7.85 (s, 1 H), 7.52 (d, 1 H), 7.06-7.25 (m, 5 H), 6.74-6.87 (m, 2 H), 6.37 (s, 1 H), 6.04 (s. 1 H), 3.78-3.97 (m, 1 H), 3.50-3.69 (m, 1 H), 2.94 (ddd, 1 H), 2.69 (br dd, 1 H)	316.1 [M+H]+	99.4%
2240	(CD3OD) δ 9.33-9.50 (m, 1 H), 8.70-8.89 (m, 2 H), 7.93-8.51 (m, 2 H), 7.64-7.88 (m, 1 H), 6.59-7.13 (m, 4 H), 4.64 (br s, 1 H), 3.46-3.93 (m, 1 H), 2.97-3.22 (m, 1 H), 2.89 (br d, 1 H), 2.48 (s, 3 H)	427.2 [M+H]+	100%
2241	(CD3OD) δ 9.42 (s, 1H), 8.72-8.86 (m, 2 H), 7.92-8.49 (m, 2 H), 7.70 (br s, 1 H), 6.64-7.07 (m, 4 H), 4.79 (br s, 0.5 H), 4.56-4.63 (m, 0.5 H), 3.43-3.93 (m, 1 H), 2.96-3.29 (m, 1 H), 2.77-2.93 (m, 1 H), 2.48 (s, 3 H)	427.2 [M+H]+	100%
2242	(CD3OD) δ 9.42 (s, 1 H), 8.73-8.82 (m, 2 H), 8.51-8.72 (m, 1 H), 7.92-8.33 (m, 1 H), 7.71 (br s, 1 H). 7.46 (br d. 1 H), 6.69-7.20 (m, 4 H), 4.60-4.83 (m, 1 H), 3.42-3.93 (m, 1 H), 2.99-3.25 (m, 1 H). 2.89 (br s, 1 H)	463.1 [M+H]+	100%
2243	(CD3OD) δ 9.42 (s. 1 H), 8.72-8.85 (m. 2 H), 8.54-8.71 (m. 1 H), 7.91-8.30 (m, 1 H), 7.71 (br s, 1 H), 7.46 (br d, 1 H), 6.72-7.19 (m, 4 H), 4.65-4.80 (m, 1 H), 3.44-3.92 (m, 1 H), 3.04 (br s, 1 H), 2.86 (br s, 1 H)	463.2 [M+H]+	96.3%
2244	(CD3OD) δ 9.42 (s, 1 H), 8.78 (s, 3 H), 7.91-8.27 (m, 1 H), 7.59-7.79 (m. 2 H), 6.71-7.18 (m, 3 H), 4.65-4.80 (m. 1 H), 3.42-3.92 (m, 1 H), 2.97-3.22 (m, 1 H), 2.88 (br s, 1 H)	481.2 [M+H]+	99.6%
2245	(CD3OD) δ 9.42 (s, 1 H), 8.78 (s, 3 H), 7.93-8.30 (m, 1 H), 7.57-7.80 (m, 2 H), 6.72-7.17 (m. 3 H), 4.82 (br s, 1 H), 3.43-3.93 (m, 1 H), 2.98-3.28 (m, 1 H), 2.88 (br s, 1 H)	481.2 [M+H]+	95.9%
2246	(CD3OD) δ 8.44 (s, 1 H), 8.08 (d, 1 H), 7.95 (s, 1 H), 7.79 (dd, 1 H), 7.15 (d, 1 H), 7.00 (s, 1 H), 6.78 (t, 1 H). 6.45-6.66 (m, 2 H). 4.70 (br dd, 1 H), 3.95 (s, 3 H), 3.55-3.67 (m, 1 H), 2.89-3.05 (m. 1 H), 2.65-2.84 (m. 1 H)	415.2 [M+H]+	100%
2247	(CD3OD) δ 8.43 (s, 1 H). 8.08 (d, 1 H), 7.69-7.91 (m, 2 H), 7.14 (d, 1 H), 6.96 (s, 1 H), 6.77 (t, 1H), 6.57 (t, 2 H), 4.70 (br dd, 1 H), 3.95 (s, 3 H), 3.52-3.69 (m, 1 H), 2.89-3.05 (m, 1 H), 2.65-2.83 (m, 1 H)	415.2 [M+H]+	96.9%
2248	(CD3OD) δ 8.49 (d, 1 H), 7.68 (s, 1 H), 7.14-7.27 (m, 1 H), 6.91 (t, 1 H), 6.70 (s, 1 H), 6.31 (s, 1 H), 4.24 (dd, 1 H), 3.70 (ddd, 1 H), 2.99-3.11 (m, 1 H), 2.80 (dd, 1 H), 2.44 (s, 3 H)	406.1 [M+H]+	100%
2249	(CD3OD) δ 8.49 (d, 1 H), 7.68 (s, 1 H), 7.21 (br d, 1 H), 6.91 (t, 1 H), 6.70 (s, 1 H), 6.31 (br s, 1 H), 4.24 (dd, 1 H), 3.64-3.78 (m, 1 H), 2.97-3.11 (m, 1 H), 2.80 (br dd, 1 H), 2.44 (s, 3 H)	406.1 [M+H]+	96.1%
2250	(CD3OD) δ 8.37 (d, 1 H). 7.58 (s, 1 H), 7.09 (d, 1 H), 6.72-7.01 (m, 2 H), 6.62 (s, 1 H), 6.28 (s, 1 H), 4.23 (dd, 1 H), 3.66 (ddd, 1 H), 2.85-3.03 (m. 1 H), 2.73 (dd. 1 H)	442.1 [M+H]+	99.6%
2251	(CD3OD) δ 8.37 (d. 1 H), 7.57 (s, 1 H). 7.09 (br d. 1 H), 6.73-7.00 (m, 2 H), 6.62 (s, 1 H), 6.28 (br s, 1 H), 4.23 (dd, 1 H), 3.60-3.73 (m, 1 H), 2.88-3.02 (m, 1 H), 2.73 (br dd, 1 H)	442.1 [M+H]+	98.9%
2252	(CD3OD) δ 8.38 (d, 1 H), 7.61 (s, 1 H), 7.10 (d, 1 H), 6.80 (t, 1 H), 6.63 (s, 1 H), 6.30 (s, 1 H), 4.25 (dd, 1 H), 3.67 (ddd, 1 H), 2.91-3.03 (m, 1 H). 2.74 (dd, 1 H)	460.1 [M+H]+	99.6%
2253	(CD3OD) δ 8.50 (d, 1 H), 7.71 (s, 1 H), 7.22 (d, 1 H), 6.93 (t, 1 H), 6.75 (s, 1 H), 6.42 (s, 1 H), 4.37 (dd, 1 H), 3.80 (td, 1 H), 3.03-3.14 (m, 1 H), 2.86 (dd, 1 H)	460.1 [M+H]+	96.9%
2254	(CD3OD) δ 8.07-8.59 (m, 3 H), 7.65 (s, 1 H), 6.95-7.28 (m, 2 H), 6.77-6.95 (m, 2 H), 6.55-6.72 (m, 2 H), 5.06 (dd, 1 H), 3.38-3.57 (m, 1 H), 2.82-2.99 (m, 1 H), 2.70 (br dd, 1 H)	384.2 [M+H]+	99.5%
2255	(CD3OD) δ 8.22-8.50 (m, 3 H), 7.65 (s, 1 H), 6.96-7.28 (m, 2 H), 6.76-6.96 (m, 2 H), 6.58-6.71 (m, 2 H), 5.06 (dd, 1 H), 3.46 (ddd, 1 H), 2.82-2.98 (m, 1 H), 2.70 (br dd, 1 H)	384.2 [M+H]+	98.7%
2256	(CD3OD) δ 8.68 (s, 2 H), 8.33 (d, 1 H), 7.67 (s, 1 H), 6.96-7.32 (m, 2 H), 6.79-6.96 (m, 2 H), 6.68 (s, 1 H), 5.20 (dd, 1 H), 3.53 (td, 1 H), 2.64-3.05 (m, 2 H)	452.1 [M+H]+	99.2%
2257	(CD3OD) δ 8.68 (s, 2 H), 8.33 (d, 1 H), 7.67 (s, 1 H), 6.98-7.30 (m, 2 H), 6.78-6.97 (m, 2 H), 6.68 (s, 1 H), 5.20 (dd, 1 H), 3.40-3.64 (m, 1 H), 2.51-3.02 (m, 2 H)	452.1 [M+H]+	98.2%
2258	(CD3OD) δ 8.33 (d, 1 H), 7.56 (s, 1 H), 7.18 (d, 1 H), 6.73 (t, 1 H), 6.52 (s, 1 H), 6.12 (s, 1 H), 4.08 (dd, 1 H), 3.57 (ddd, 1 H), 2.84-2.97 (m, 1 H), 2.68 (dd, 1 H), 1.38 (s, 3 H). 1.11-1.18 (m, 2 H), 0.78-0.86 (m, 2 H)	396.2 [M+H]+	100%
2259	(CD3OD) δ 8.33 (d, 1 H), 7.55 (s, 1 H), 7.18 (d, 1 H), 6.73 (t, 1 H), 6.52 (s, 1 H), 6.12 (s, 1 H), 4.08 (dd, 1 H), 3.57 (ddd, 1 H), 2.84-2.95 (m, 1 H), 2.68 (dd, 1 H), 1.38 (s, 3 H), 1.10-1.17 (m, 2 H), 0.79-0.85 (m, 2 H)	396.2 [M+H]+	99.4%
2260	(CD3OD) δ 9.16 (d, 1 H), 8.69 (dd, 1 H), 8.40 (br d, 1 H), 8.31 (br d, 1 H), 7.70 (s, 1 H), 7.61 (dd, 1 H), 7.06 (br d, 1 H), 6.84 (t, 1 H), 6.69 (s, 1 H), 6.42-6.53 (m, 1 H), 4.41 (dd, 1 H), 3.76-3.90 (m, 1 H), 3.04-3.25 (m, 2 H), 2.87 (br dd, 1 H), 1.33 (t, 6 H)	427.2 [M+H]+	99.0%
2261	(CD3OD) δ 9.16 (d, 1 H), 8.64-8.74 (m, 1 H), 8.40 (br d, 1 H), 8.31 (d, 1 H), 7.72 (s, 1 H), 7.61 (dd, 1 H), 7.06 (d, 1 H), 6.84 (t, 1 H), 6.69 (s, 1 H), 6.49 (s, 1 H), 4.42 (dd, 1 H), 3.74-3.91 (m, 1 H), 3.01-3.25 (m, 2 H), 2.87 (br dd, 1 H), 1.33 (t. 6 H)	427.2 [M+H]+	97.3%
2262	(CD3OD) δ 9.15 (s, 1 H), 8.69 (br d, 1 H), 8.45 (br d, 1 H), 8.39 (br dd, 1 H), 7.71 (s, 1 H), 7.56-7.64 (m, 1 H), 7.29 (dd, 1 H), 6.79-6.88 (m, 1 H), 6.73 (s, 1 H), 6.49 (s, 1 H), 4.43 (dd, 1 H), 3.81 (ddd, 1 H), 3.05-3.18 (m, 1 H), 2.87 (dd, 1 H)	419.1 [M+H]+	100%
2263	(CD3OD) δ 9.15 (d, 1 H), 8.69 (dd, 1 H), 8.45 (d, 1 H), 8.39 (dt, 1 H), 7.70 (s, 1 H), 7.61 (dd, 1 H), 7.30 (d, 1 H), 6.85 (t, 1 H), 6.73 (s, 1 H), 6.49 (s, 1 H), 4.43 (dd, 1 H), 3.74-3.86 (m, 1 H), 3.05-3.18 (m, 1 H), 2.87 (dd, 1 H)	419.1 [M+H]+	99.7%
2264	(CD3OD) δ 8.48-8.57 (m, 1 H), 8.28 (s, 2 H), 7.73 (s, 1 H), 7.43-7.56 (m, 1 H), 7.00 (d, 1 H), 6.79 (t, 1 H), 6.62 (s, 1 H), 6.47 (s, 1 H), 4.40 (dd, 1 H), 3.66-3.95 (m, 1 H), 3.01-3.20 (m, 1 H), 2.79-2.95 (m, 1 H), 2.45 (s, 3 H)	417.2 [M+H]+	100%
2265	(CD3OD) δ 8.45-8.61 (m, 1 H), 8.24-8.41 (m, 2 H), 7.75 (br s, 1 H), 7.44-7.56 (m, 1 H), 6.99 (d, 1 H), 6.79 (t, 1 H), 6.62 (s, 1 H), 6.47 (s, 1 H), 4.40 (dd, 1 H), 3.70-3.90 (m, 1 H), 3.04-3.22 (m, 1 H), 2.87 (br dd, 1 H), 2.44 (s, 3 H)	417.2 [M+H]+	99.3%
2266	(CD3OD) δ 8.51 (br d, 1 H), 8.41 (d, 1 H), 7.82 (br d, 1 H), 7.67 (s, 1 H), 7.55 (d, 1 H), 7.42 (dd, 1 H), 7.15 (t, 1 H), 6.76-6.87 (m, 1 H), 6.62 (s, 1 H), 6.54 (s, 1 H), 4.44 (dd, 1 H), 3.77 (ddd, 1 H), 3.01-3.15 (m, 1 H), 2.82 (dd, 1 H), 2.68 (s, 3 H)	399.2 [M+H]+	99.7%
2267	(CD3OD) δ 8.52 (br d, 1 H), 8.42 (br d, 1 H), 7.83 (br d, 1 H), 7.67 (s, 1 H), 7.56 (br d, 1 H), 7.43 (dd, 1 H), 7.16 (br t, 1 H), 6.78-6.88 (m, 1 H), 6.63 (s, 1 H), 6.54 (s, 1 H), 4.44 (dd, 1 H), 3.78 (ddd, 1 H), 3.02-3.15 (m, 1 H), 2.78-2.85 (m, 1 H), 2.68 (s, 3 H)	399.2 [M+H]+	99.0%
2268	(CD3OD) δ 8.54 (d, 1 H), 8.29 (d, 1 H), 7.86 (d, 1 H), 7.67 (s, 1 H), 7.45 (dd, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.53-6.67 (m, 2 H), 4.45 (dd, 1 H), 3.79 (ddd, 1 H), 3.04-3.15 (m, 1 H), 2.83 (br dd, 1 H), 2.70 (s, 3 H), 2.43 (s, 3 H)	413.2 [M+H]+	99.9%
2269	(CD3OD) δ 8.53 (d, 1 H), 8.29 (d, 1 H), 7.85 (d, 1 H), 7.67 (s, 1 H), 7.45 (dd, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.65 (s, 1 H), 6.55 (br s, 1 H), 4.45 (dd, 1 H), 3.74-3.84 (m, 1 H), 3.02-3.16 (m, 1 H), 2.83 (br dd, 1 H), 2.70 (s, 3 H), 2.43 (s, 3 H)	413.2 [M+H]+	98.8%
2270	(CD3OD) δ 8.44-8.47 (m, 1 H), 8.41 (d, 2 H), 7.65 (s, 1 H), 7.13-7.22 (m, 2 H), 6.86 (t, 1 H), 6.61-6.70 (m, 2 H), 5.07 (dd, 1 H), 3.39-3.51 (m, 1 H), 2.85-2.96 (m, 1 H), 2.71 (dd, 1 H)	402.2 [M+H]+	99.6%
2271	(CD3OD) δ 8.46 (d, 1 H), 8.41 (d, 2 H), 7.65 (s, 1 H), 7.15-7.21 (m, 2 H), 6.87 (t, 1 H), 6.64-6.69 (m, 2 H), 5.07 (dd, 1 H), 3.41-3.51 (m, 1 H), 2.85-2.97 (m, 1 H), 2.71 (dd, 1 H)	402.1 [M+H]+	98.9%
2272	(CD3OD) δ 8.28-8.49 (m, 2 H), 7.77 (dd, 1 H), 7.65 (s, 1 H), 6.98-7.23 (m, 2 H), 6.73-6.98 (m, 3 H), 6.64 (s, 1 H), 4.73 (br dd, 1 H), 3.52-3.72 (m, 1 H), 2.88-3.04 (m, 1 H), 2.74 (br dd, 1 H)	415.2 [M+H]+	99.1%
2273	(CD3OD) δ 8.22-8.53 (m, 2 H), 7.77 (dd, 1 H), 7.65 (s, 1 H), 7.00-7.25 (m, 2 H), 6.79-6.97 (m, 3 H), 6.64 (s, 1 H), 4.73 (br dd, 1 H), 3.61 (ddd, 1 H), 2.87-3.03 (m, 1 H), 2.74 (dd, 1 H)	415.2 [M+H]+	92.9%
2274	(CD3OD) δ 8.49-8.57 (m, 1 H), 8.37 (d, 1 H), 7.68 (s, 1 H), 7.45-7.54 (m, 2 H), 7.12 (dd, 1 H), 6.72 (d, 1 H), 6.43-6.59 (m, 2 H), 4.40 (dd, 1 H), 3.78-3.94 (m, 1 H), 3.05-3.16 (m, 1 H), 2.87 (br dd, 1 H), 2.64 (s, 3 H)	417.2 [M+H]+	100%
2275	(CD3OD) δ 8.52 (ddd, 1 H), 8.37 (d, 1 H), 7.68 (s, 1 H), 7.42-7.54 (m, 2 H), 7.12 (dd, 1 H), 6.72 (d, 1 H), 6.43-6.59 (m, 2 H), 4.40 (dd, 1 H), 3.87 (ddd, 1 H), 3.03-3.19 (m, 1 H), 2.86 (br dd, 1 H), 2.64 (s, 3 H)	417.2 [M+H]+	98.4%
2276	(CD3OD) δ 8.68 (d, 1 H), 8.51-8.55 (m, 1 H), 7.85 (d, 1 H), 7.69 (s, 1 H), 7.60 (d, 1 H), 7.45 (dd, 1 H), 6.96 (t, 1 H), 6.84 (s, 1 H), 6.58 (s, 1 H), 4.49 (dd, 1 H), 3.80 (ddd, 1 H), 3.04-3.16 (m, 1 H), 2.84 (dd, 1 H), 2.70 (s, 3 H)	467.2 [M+H]+	100%
2277	(CD3OD) δ 8.68 (d, 1 H), 8.53 (d, 1 H), 7.85 (d, 1 H), 7.68 (s, 1 H), 7.61 (d, 1 H), 7.45 (dd, 1 H), 6.96 (t, 1 H), 6.84 (s, 1 H), 6.58 (s, 1 H), 4.49 (dd, 1 H), 3.74-3.85 (m, 1 H), 3.05-3.16 (m, 1 H), 2.84 (br dd, 1 H), 2.70 (s, 3 H)	467.2 [M+H]+	98.7%
2278	(CD3OD) δ 8.51-8.62 (m, 2 H), 7.86 (d, 1 H), 7.68 (s, 1 H), 7.39-7.49 (m, 2 H), 6.81-7.12 (m, 3 H), 6.58 (br s, 1 H), 4.47 (dd, 1 H), 3.78 (ddd, 1 H), 3.04-3.15 (m, 1 H), 2.84 (br dd, 1 H), 2.70 (s, 3 H)	449.2 [M+H]+	98.6%
2279	(CD3OD) δ 8.50-8.63 (m, 2 H), 7.86 (d, 1 H), 7.68 (s, 1 H), 7.39-7.49 (m, 2 H), 6.79-7.15 (m, 3 H), 6.58 (s, 1 H), 4.47 (dd, 1 H), 3.78 (ddd, 1 H), 3.05-3.15 (m, 1 H), 2.84 (dd, 1 H), 2.70 (s, 3 H)	449.2 [M+H]+	96.9%
2280	(CD3OD) δ 8.54 (dd, 1 H), 8.34 (d, 1 H), 7.86 (d, 1 H), 7.70 (s, 1 H), 7.46 (dd, 1 H), 6.95 (dd, 1 H), 6.76-6.88 (m, 2 H), 6.56 (s, 1 H), 4.48 (dd, 1 H), 3.75-3.85 (m, 1 H), 3.05-3.15 (m, 1 H), 2.84 (br dd, 1 H), 2.71 (s, 3 H)	471.2 [M+H]+	98.2%
2281	(CD3OD) δ 8.53 (d, 1 H), 8.33 (d, 1 H), 7.86 (d, 1 H), 7.70 (s, 1 H), 7.45 (dd, 1 H), 6.95 (dd, 1 H), 6.76-6.85 (m, 2 H), 6.56 (s, 1 H), 4.47 (dd, 1 H), 3.75-3.85 (m, 1 H), 3.05-3.16 (m, 1 H), 2.84 (dd, 1 H), 2.70 (s, 3 H)	417.2 [M+H]+	99.6%
2282	(CD3OD) δ 8.53 (d, 1 H), 8.26 (d, 1 H), 7.85 (d, 1 H), 7.68 (s, 1 H), 7.44 (dd, 1 H), 6.71-6.84 (m, 3 H), 6.56 (s, 1 H), 4.46 (dd, 1 H), 3.73-3.87 (m, 1 H), 3.03-3.18 (m, 1 H), 2.83 (dd, 1 H), 2.70 (s, 3 H), 2.03-2.13 (m, 1 H), 0.96-1.05 (m, 2 H), 0.71-0.80 (m, 2 H)	439.2 [M+H]+	100%
2283	(CD3OD) δ 8.54 (d, 1 H), 8.26 (d, 1 H), 7.85 (d, 1 H), 7.76 (s, 1 H), 7.45 (dd, 1 H), 6.72-6.85 (m, 3 H), 6.58 (s, 1 H), 4.46 (dd, 1 H), 3.80 (ddd, 1 H), 3.00-3.16 (m, 1 H), 2.84 (dd, 1 H), 2.70 (s, 3 H), 2.04-2.14 (m, 1 H), 0.97-1.06 (m, 2 H), 0.72-0.80 (m, 2 H)	439.2 [M+H]+	92.5%
2284	(CD3OD) δ 8.53 (br d, 1 H), 8.23-8.31 (m, 1 H), 7.64-7.88 (m, 2 H), 7.36-7.49 (m, 1 H), 6.98-7.07 (m, 1 H), 6.72-6.84 (m, 2 H), 6.55 (s, 1 H), 4.45 (br dd, 1 H), 3.80 (td, 1 H), 3.04-3.22 (m, 2 H), 2.83 (br dd, 1 H), 2.63-2.72 (m, 3 H), 1.23-1.36 (m, 6 H)	441.2 [M+H]+	100%
2285	(CD3OD) δ 8.53 (d, 1 H), 8.28 (d, 1 H), 7.84 (d, 1 H), 7.67 (s, 1 H), 7.44 (dd, 1 H), 7.02 (d, 1 H), 6.73-6.83 (m, 2 H), 6.55 (s, 1 H), 4.45 (dd. 1 H), 3.80 (ddd, 1 H), 3.04-3.22 (m, 2 H), 2.83 (dd, 1 H), 2.69 (s, 3 H), 1.31 (t, 6 H)	441.2 [M+H]+	98.4%
2286	1H (METHANOL-d4) δ 8.52 (d, 1 H), 8.42 (d, 1 H), 7.84 (br d, 1 H), 7.68 (s, 1 H), 7.43 (dd, 1 H), 7.26 (d, 1 H), 6.74-6.85 (m, 2 H), 6.55 (s, 1 H), 4.47 (dd, 1 H), 3.79 (ddd, 1 H), 3.04-3.14 (m, 1 H), 2.83 (dd, 1 H), 2.69 (s, 3 H)	433.1 [M+H]+	100%
2287	(CD3OD) δ 8.51 (br d, 1 H), 8.40 (d, 1 H), 7.82 (br d, 1 H), 7.68 (s, 1 H), 7.42 (dd, 1 H), 7.24 (d, 1 H), 6.74-6.83 (m, 2 H), 6.55 (s, 1 H), 4.47 (br dd, 1 H), 3.73-3.84 (m, 1 H), 3.01-3.15 (m, 1 H), 2.63-2.73 (m, 1 H), 2.68 (s, 3 H)	433.1 [M+H]+	99.1%
2288	(CD3OD) δ 8.54-8.60 (m, 1 H), 8.31-8.37 (m, 1 H), 7.86 (ddd, 1 H), 7.68-7.71 (m, 1 H), 7.63 (dt, 1 H), 6.96 (dd, 1 H), 6.80-6.86 (m, 1 H), 6.78-6.80 (m, 1 H), 6.54 (s, 1 H), 4.47 (dd, 1 H), 3.78-3.86 (m, 1 H), 3.06-3.16 (m, 1 H), 2.86 (br dd, 1 H)	421.1 [M+H]+	100%
2289	(CD3OD) δ 8.57 (d, 1 H), 8.30-8.39 (m, 1 H), 7.80-7.92 (m, 1 H), 7.72 (s, 1 H), 7.64 (dt, 1 H), 6.96 (dd, 1 H), 6.81-6.86 (m, 1 H), 6.78-6.80 (m, 1 H), 6.54 (s, 1 H), 4.47 (dd, 1 H), 3.77-3.88 (m, 1 H), 3.00-3.17 (m, 1 H). 2.86 (dd, 1 H)	421.1 [M+H]+	99.0%
2290	(CD3OD) δ 8.10-8.24 (m, 1 H), 7.60 (s, 1 H), 7.40 (s, 0.3 H), 6.81-6.96 (m, 1.7 H), 6.61-6.71 (m, 2 H), 6.42-6.58 (m, 1 H), 4.89 (br dd, 1 H), 3.62-3.73 (m, 0.7 H), 3.31 (td, 0.3 H), 2.84-3.14 (m, 1 H), 2.73 (br dd, 1 H), 2.25-2.38 (m, 6 H)	430.2 [M+H]+	100%
2291	(CD3OD) δ 8.10-8.24 (m, 1 H), 7.61 (s, 1 H), 7.41 (s, 0.3 H), 6.82-6.92 (m, 1.7 H), 6.60-6.72 (m, 2 H), 6.44-6.57 (m, 1 H), 4.89 (br dd, 1 H), 3.62-3.72 (m, 0.7 H), 3.31 (td, 0.3 H), 2.84-3.15 (m, 1 H), 2.69-2.78 (m, 1 H), 2.26-2.37 (m, 6 H)	430.2 [M+H]+	98.8%
2292	(CD3OD) δ 8.11-8.25 (m, 1 H), 7.64 (d, 1 H), 7.57 (s, 1 H), 7.33-7.43 (m, 0.3 H), 6.83-6.93 (m, 1.7 H), 6.62-6.72 (m, 1 H), 6.47-6.58 (m, 1 H), 4.82-4.95 (m, 1H), 3.60-3.79 (m, 0.7 H), 3.27-3.39 (m, 0.3 H), 3.04-3.15 (m, 0.7 H), 2.86-2.96 (m, 0.3 H), 2.68-2.80 (m, 1 H), 2.28-2.37 (m, 6 H)	430.2 [M+H]+	100%
2293	(CD3OD) δ 8.12-8.24 (m, 1 H), 7.59 (d, 2 H), 7.38 (s, 0.3 H), 6.83-6.93 (m, 1.7 H), 6.62-6.72 (m, 1 H), 6.45 (s, 1 H), 4.82-4.94 (m, 1 H), 3.62-3.75 (m, 0.7 H), 3.27-3.39 (m, 0.3 H), 3.03-3.14 (m, 0.7 H), 2.84-2.97 (m, 0.3 H), 2.68-2.77 (m, 1 H), 2.27-2.40 (m, 6 H)	430.2 [M+H]+	96.9%
2294	(CD3OD) δ 8.13-8.27 (m, 1 H), 7.60 (s, 1 H), 7.41 (s, 0.3 H), 6.79-6.93 (m, 1.7 H), 6.59-6.78 (m, 3 H). 4.83-4.97 (m, 1 H), 3.61-3.73 (m, 0.7 H), 3.29 (td, 0.3 H), 2.82-3.13 (m, 1 H), 2.74 (br dd, 1 H), 2.29 (s, 3 H)	434.1 [M+H]+	99.2%
2295	(CD3OD) δ 8.15-8.28 (m, 1 H), 7.63 (s, 1 H), 7.42 (s, 0.3 H, 6.79-6.90 (m, 1.7 H), 6.59-6.77 (m, 3 H), 4.92 (br dd, 1 H), 3.60-3.72 (m, 0.7 H), 3.29 (td, 0.3 H), 2.83-3.15 (m, 1 H), 2.68-2.79 (m, 1 H), 2.29 (s, 3 H)	434.2 [M+H]+	96.8%
2296	(CD3OD) δ 8.15-8.30 (m, 1 H), 7.54-7.65 (m, 2 H), 7.36 (s, 0.3 H), 6.80-6.92 (m, 1.7 H), 6.61-6.78 (m, 2 H), 4.83-4.96 (m, 1 H), 3.61-3.75 (m, 0.7 H), 3.30 (td, 0.3 H), 3.02-3.15 (m, 0.7 H), 2.86-2.95 (m, 0.3 H), 2.69 (d, 1 H), 2.28-2.34 (m, 3 H)	434.2 [M+H]+	100%
2297	(CD3OD) δ 8.17-8.28 (m, 1 H), 7.53-7.67 (m, 2 H), 7.40 (s, 0.3 H), 6.80-6.91 (m, 1.7 H), 6.61-6.77 (m, 2 H), 4.84-4.96 (m, 1 H), 3.68 (ddd, 0.7 H), 3.30 (td, 0.3 H), 3.02-3.14 (m, 0.7 H), 2.84-2.96 (m, 0.3 H), 2.68-2.80 (m, 1 H), 2.26-2.37 (m, 3 H)	434.2 [M+H]+	98.2%
2298	(CD3OD) δ 8.39 (d, 2 H), 8.04 (d, 1 H), 7.61 (s, 1 H), 7.15 (s, 1 H), 6.73 (t, 1 H), 6.63 (t, 1 H), 6.46-6.57 (m, 2 H), 5.01 (dd, 1 H), 3.93 (s, 3 H), 3.36-3.49 (m, 1 H), 2.78-2.95 (m, 1 H), 2.68 (dd, 1 H)	348.1 [M+H]+	99.8%
2299	(CD3OD) δ 8.40 (d, 2 H), 8.05 (d, 1 H), 7.63 (s, 1 H), 7.17 (s, 1 H), 6.75 (t, 1 H), 6.64 (t, 1 H), 6.51-6.58 (m, 2 H), 5.03 (dd, 1 H), 3.94 (s, 3 H), 3.37-3.49 (m, 1 H), 2.83-2.95 (m, 1 H), 2.69 (dd, 1 H)	348.1 [M+H]+	98.7%
2300	(CD3OD) δ 8.43 (d, 1 H), 7.65 (s, 1 H), 7.57 (d, 1 H), 7.12-7.22 (m, 1 H), 6.85 (td, 1 H), 6.52 (s, 1 H), 6.27 (s, 1 H), 4.20 (dd, 1 H), 3.68 (ddd, 1 H), 2.94-3.15 (m, 2 H), 2.78 (dd, 1 H), 1.35 (d, 6 H)	350.2 [M+H]+	99.9%
2301	(CD3OD) δ 8.43 (d, 1 H), 7.65 (s, 1 H), 7.57 (d, 1 H), 7.14-7.25 (m, 1 H), 6.85 (td, 1 H), 6.52 (s, 1 H), 6.27 (s, 1 H), 4.20 (dd, 1 H), 3.68 (ddd, 1 H), 2.95-3.19 (m, 2 H), 2.78 (dd, 1 H), 1.35 (d, 6 H)	350.2 [M+H]+	99.6%
2302	(CD3OD) δ 8.28 (d, 1 H), 7.66 (s, 1 H), 6.97 (d, 1 H), 6.77 (t, 1 H), 6.52 (s, 1 H), 6.28 (s, 1 H), 4.20 (dd, 1 H), 3.69 (ddd, 1 H), 2.94-3.19 (m, 2 H). 2.78 (dd, 1 H), 2.42 (s, 3 H), 1.35 (dd, 6 H)	364.2 [M+H]+	98.6%
2303	(CD3OD) δ 8.28 (d, 1 H), 7.65 (s, 1 H), 6.98 (d, 1 H), 6.77 (t, 1 H), 6.52 (s, 1 H), 6.27 (br s, 1 H), 4.20 (dd, 1 H), 3.69 (ddd, 1 H), 2.95-3.18 (m, 2 H), 2.79 (br dd, 1 H), 2.43 (s, 3 H), 1.35 (dd, 6 H)	364.2 [M+H]+	99.6%
2304	(CD3OD) δ 8.70 (d, 1 H), 7.70 (s, 1 H), 7.64 (d, 1 H), 7.00 (t, 1 H), 6.73 (s, 1 H), 6.33 (s, 1 H), 4.26 (dd, 1 H), 3.72 (ddd, 1 H), 2.98-3.19 (m, 2 H), 2.82 (dd. 1 H), 1.37 (d. 6 H)	418.2 [M+H]+	99.9%
2305	(CD3OD) δ 8.67 (d, 1 H), 7.66 (s, 1 H), 7.62 (d, 1 H), 6.98 (t, 1 H), 6.71 (s, 1 H), 6.31 (s, 1 H), 4.24 (dd, 1 H), 3.64-3.77 (m, 1 H), 2.95-3.17 (m. 2 H), 2.80 (dd, 1 H), 1.35 (d, 6 H)	418.2 [M+H]+	98.9%
2306	(CD3OD) δ 8.51 (br d, 1 H), 7.83 (br d, 1 H), 7.67 (s, 1 H), 7.57 (br d, 1 H), 7.42 (dd, 1 H), 7.14 (dd. 1 H), 6.99 (br d, 1 H), 6.76 (s, 1 H), 6.56 (s, 1 H), 4.47 (dd, 1 H), 3.79-3.95 (m, 1 H), 3.03-3.17 (m, 1 H), 2.83 (dd, 1 H), 2.68 (s, 3 H)	433.2 [M+H]+	100%
2307	(CD3OD) δ 8.51 (br d, 1 H), 7.83 (br d, 1 H), 7.66 (s, 1 H), 7.57 (dd, 1 H), 7.42 (td, 1 H), 7.10-7.17 (m, 1 H), 6.99 (dd, 1 H), 6.76 (s, 1 H), 6.56 (s, 1 H), 4.47 (dd. 1 H), 3.79-3.92 (m. 1 H), 3.02-3.14 (m, 1 H), 2.83 (dd, 1 H), 2.68 (s, 3 H)	433.2 [M+H]+	99.4%
2308	(CD3OD) δ 8.47-8.54 (m, 1 H), 7.77-7.88 (m, 1 H), 7.66 (s, 1 H), 7.37-7.49 (m, 2 H), 7.01-7.14 (m, 1 H), 6.52-6.71 (m, 3 H), 4.45 (br dd, 1 H), 3.79-3.93 (m, 1 H), 2.99-3.16 (m, 1 H), 2.83 (br dd, 1 H), 2.56-2.72 (m, 6 H)	413.2 [M+H]+	100%
2309	(CD3OD) δ 8.52 (d, 1 H), 7.84 (br d. 1 H), 7.66 (s, 1 H), 7.39-7.48 (m, 2 H), 7.09 (dd, 1 H), 6.68 (br d, 1 H), 6.53-6.61 (m, 2 H), 4.45 (dd, 1 H), 3.85 (ddd, 1 H), 3.03-3.15 (m, 1 H), 2.83 (dd, 1 H), 2.58-2.71 (m, 6 H)	413.2 [M+H]+	99.4%
2310	(CD3OD) δ 8.27 (d, 1 H), 7.58 (s, 1 H), 7.15-7.23 (m, 2 H), 7.09 (d, 2 H), 6.93 (d, 1 H), 6.69-6.80 (m, 2 H), 6.34 (s, 1 H), 5.99 (s, 1 H), 3.88 (br dd, 1 H), 3.60-3.70 (m, 1 H), 2.87-2.98 (m, 1 H), 2.66 (br dd, 1 H), 2.38 (s, 3 H)	330.2 [M+H]+	99.5%
2311	(CD3OD) δ 8.28 (d, 1 H), 7.60 (s, 1 H), 7.17-7.24 (m, 2 H), 7.09 (d, 2 H), 6.94 (d, 1 H), 6.75 (dt, 2 H), 6.35 (s, 1 H), 6.00 (s, 1 H), 3.89 (br dd, 1 H), 3.60-3.71 (m, 1 H), 2.86-2.99 (m, 1 H), 2.67 (br dd, 1 H), 2.39 (s, 3 H)	330.2 [M+H]+	99.1%
2312	(CD3OD) δ 8.31 (d, 1 H), 7.60 (s, 1 H), 7.17-7.24 (m, 2 H), 7.09 (d, 2 H), 6.91 (dd, 1 H), 6.74-6.81 (m, 2 H), 6.47 (s, 1 H), 6.02 (s, 1 H), 3.89 (br dd, 1 H), 3.59-3.69 (m, 1 H), 2.93 (tt, 1 H), 2.68 (br dd, 1 H)	334.2 [M+H]+	100%
2313	(CD3OD) δ 8.31 (d, 1 H), 7.61 (s, 1 H), 7.17-7.24 (m, 2 H), 7.09 (d, 2 H), 6.91 (dd, 1 H), 6.74-6.82 (m, 2 H), 6.47 (s, 1 H), 6.02 (s, 1 H), 3.89 (br dd, 1 H), 3.59-3.68 (m, 1 H), 2.93 (ddd, 1 H), 2.68 (br dd, 1 H)	334.2 [M+H]+	99.7%
2314	(CD3OD) δ 8.37 (d. 1 H), 7.55 (s, 1 H), 7.09 (br d, 1 H), 6.79 (t, 1 H), 6.56 (s, 1 H), 6.15 (br s, 1 H), 4.09 (dd, 1 H), 3.51-3.63 (m, 1 H), 2.85-2.96 (m, 1 H), 2.68 (br dd, 1 H), 1.92-2.02 (m, 1 H), 0.89-1.07 (m, 4 H)	432.2 [M+H]+	100%
2315	(CD3OD) δ 8.37 (d, 1 H), 7.56 (s, 1 H), 7.09 (d, 1 H), 6.79 (t, 1 H), 6.56 (s, 1 H), 6.15 (s, 1 H), 4.06-4.13 (m, 1 H), 3.57 (ddd, 1 H), 2.85-2.97 (m, 1 H), 2.63-2.73 (m, 1 H), 1.93-1.99 (m, 1 H), 0.91-1.03 (m, 4 H)	432.2 [M+H]+	97.1%
2316	(CD3OD) δ 8.56 (s, 2 H), 8.30-8.38 (m, 1 H), 7.56 (s, 1 H), 7.13 (s, 1 H), 7.03-7.09 (m, 1 H), 6.76 (t, 1 H), 6.59 (s, 1 H), 5.09 (dd. 1 H), 3.35-3.48 (m, 1 H), 2.74-2.87 (m, 1 H), 2.65 (dd, 1 H)	470.1 [M+H]+	99.9%
2317	(CD3OD) δ 8.56 (s, 2 H), 8.34 (d, 1 H), 7.55 (s, 1 H), 7.13 (s, 1 H), 7.06 (br d, 1 H), 6.76 (t, 1 H), 6.59 (s, 1 H), 5.09 (dd, 1 H), 3.42 (td, 1 H), 2.76-2.86 (m, 1 H), 2.62-2.68 (m, 1 H)	470.1 [M+H]+	96.0%
2318	(CD3OD) δ 8.34 (s, 1 H), 8.23 (br d, 1 H), 7.97-8.12 (m, 1 H), 7.69 (d, 1 H), 7.57 (br s, 1 H), 6.78-7.14 (m, 2 H), 6.68-6.75 (m. 2 H), 6.52 (s, 1 H), 4.59 (br dd, 1 H), 3.42-3.56 (m, 1 H), 2.78-2.92 (m, 1 H), 2.67 (br s, 1 H)	384.1 [M+H]+	99.8%
2319	(CD3OD) δ 8.34 (d, 1 H), 8.23 (d, 1 H), 8.05 (dd, 1 H), 7.68 (d, 1 H), 7.53 (s, 1 H), 6.79-7.18 (m, 2 H), 6.66-6.76 (m, 2 H), 6.51 (s, 1 H), 4.59 (br dd, 1 H), 3.49 (br dd, 1 H), 2.86 (br s, 1 H), 2.67 (br d, 1 H)	384.1 [M+H]+	96.2%
2320	(CD3OD) δ 8.57 (br d, 1 H), 7.66 (s, 1 H), 742 (br d, 1 H), 6.80-7.14 (m, 2 H), 6.70 (s, 1 H), 6.30 (br s, 1 H), 4.22 (dd, 1 H), 3.61-3.78 (m, 1 H), 2.91-3.18 (m, 2 H), 2.80 (br dd, 1 H), 1.35 (d, 6 H)	400.2 [M+H]+	99.9%
2321	(CD3OD) δ 8.57 (d, 1 H), 7.66 (s, 1 H), 7.42 (br d, 1 H), 6.80-7.14 (m, 2 H), 6.70 (s, 1 H), 6.30 (s, 1 H), 4.22 (dd, 1 H), 3.69 (ddd, 1H), 2.97-3.18 (m, 2 H), 2.80 (dd, 1 H), 1.35 (dd, 6 H)	400.2 [M+H]+	99.0%
2322	(CD3OD) δ 8.32 (d, 1 H), 7.66 (s, 1 H), 6.73-7.04 (m, 2 H), 6.66 (s, 1 H), 6.29 (s, 1 H), 4.22 (dd, 1 H), 3.61-3.79 (m, 1 H), 2.94-3.17 (m, 2 H), 2.79 (br dd, 1 H), 1.35 (d, 6 H)	368.2 [M+H]+	99.9%
2323	(CD3OD) δ 8.32 (d, 1 H), 7.66 (s, 1 H), 6.77-7.01 (m, 2 H), 6.66 (s, 1 H), 6.29 (s, 1 H), 4.22 (dd, 1 H), 3.70 (td, 1 H), 2.94-3.18 (m, 2 H), 2.79 (br dd, 1 H), 1.35 (d, 6 H)	368.2 [M+H]+	99.3%
2324	(CD3OD) δ 8.43 (d, 1 H), 7.66 (s, 1 H), 7.29 (d, 1 H), 6.84 (t, 1 H), 6.65 (s, 1 H), 6.28 (br s, 1 H), 4.22 (dd. 1 H), 3.56-3.80 (m, 1 H), 2.93-3.17 (m, 2 H), 2.79 (br dd, 1 H), 1.35 (d, 6 H)	384.2 [M+H]+	100%
2325	(CD3OD) δ 8.43 (d, 1 H), 7.66 (s, 1 H), 7.29 (d, 1 H), 6.84 (t, 1 H), 6.65 (s, 1 H), 6.28 (br s, 1 H), 4.22 (dd, 1 H). 3.69 (ddd, 1 H), 2.92-3.20 (m, 2 H), 2.79 (br dd, 1 H), 1.35 (d, 6 H)	384.2 [M+H]+	99.2%
2326	(CD3OD) δ 7.68 (s, 1 H), 7.58-7.65 (m, 1 H), 7.20 (dd, 1 H), 7.06 (d, 1 H), 6.71 (s, 1 H), 6.40 (br s, 1 H), 4.29-4.40 (m, 1 H), 3.70-3.90 (m, 1 H), 2.99-3.15 (m, 1 H), 2.85 (dd, 1 H), 2.12 (t, 3 H)	406.1 [M+H]+	100%
2327	(CD3OD) δ 7.56 (s, 1 H), 7.49 (dd, 1 H), 7.07 (dd, 1 H), 6.93 (dd, 1 H), 6.58 (s, 1 H), 6.28 (s, 1 H), 4.20 (br d. 1 H), 3.70 (br s, 1 H), 2.88-3.01 (m, 1 H), 2.73 (dd, 1 H), 2.00 (t, 3 H)	406.1 [M+H]+	99.4%
2328	(CD3OD) δ 7.68 (s, 1 H), 7.48 (d, 1 H), 7.13 (dd, 1 H), 6.73 (d, 1 H), 6.51 (s, 1 H), 6.38 (br s, 1 H), 4.22-4.40 (m, 1 H), 3.71-3.87 (m, 1 H), 2.96-3.13 (m, 1 H), 2.84 (dd, 1 H), 2.65 (s, 3 H), 2.12 (t, 3 H)	386.2 [M+H]+	100%
2329	(CD3OD) δ 7.56 (s, 1 H), 7.35 (d, 1 H), 7.01 (dd, 1 H), 6.61 (d, 1 H), 6.39 (s, 1 H), 6.26 (s, 1 H), 4.19 (dd, 1 H), 3.67 (td, 1 H), 2.88-3.02 (m, 1 H), 2.72 (dd, 1 H), 2.52 (s, 3 H), 2.00 (t, 3 H)	386.2 [M+H]+	97.7%
2330	(CD3OD) δ 8.41 (dd, 1 H), 8.25 (dd, 1 H), 7.41-7.61 (m, 2 H), 7.32 (dd, 1 H), 7.05 (dd, 1 H), 6.91 (dd, 1 H), 6.57 (s, 1 H), 6.36 (s, 1 H), 4.28 (dd, 1 H), 3.62-3.81 (m, 1 H), 2.91-3.08 (m, 1 H), 2.68-2.85 (m, 4 H)	433.1 [M+H]+	100%
2331	(CD3OD) δ 8.41 (dd, 1 H), 8.25 (dd, 1 H), 7.43-7.66 (m, 2 H), 7.32 (dd, 1 H), 7.05 (dd, 1 H), 6.91 (dd, 1 H), 6.57 (s, 1 H), 6.36 (s, 1 H), 4.28 (dd, 1 H), 3.63-3.80 (m, 1 H), 2.88-3.07 (m, 1 H), 2.68-2.84 (m, 4 H)	433.1 [M+H]+	98.2%
2332	(CD3OD) δ 8.42 (dd, 1 H), 8.23 (dd, 1 H), 7.56 (s, 1 H), 7.24-7.40 (m, 2 H), 6.99 (dd, 1 H), 6.58 (d, 1 H), 6.30-6.45 (m, 2 H), 4.26 (dd, 1 H), 3.64-3.83 (m, 1 H), 2.88-3.07 (m, 1 H), 2.68-2.83 (m, 4 H), 2.50 (s, 3 H)	413.2 [M+H]+	99.9%
2333	(CD3OD) δ 8.40 (dd, 1 H), 8.21 (dd, 1 H), 7.57 (s, 1 H), 7.23-7.41 (m, 2 H), 6.97 (dd, 1 H), 6.57 (d, 1 H), 6.26-6.46 (m, 2 H), 4.26 (dd, 1 H), 3.62-3.82 (m, 1 H), 2.89-3.04 (m, 1 H), 2.68-2.82 (m, 4 H), 2.49 (s, 3 H)	413.2 [M+H]+	99.2%
2334	(CD3OD) δ 8.37-8.46 (m, 1 H), 8.23-8.27 (m, 1 H), 8.19 (d, 1 H), 7.58 (s, 1 H), 7.34-7.44 (m, 1 H), 6.94 (d, 1 H), 6.72 (t, 1 H), 6.58 (s, 1 H), 6.35 (s, 1 H), 4.28 (dd, 1 H), 3.64-3.77 (m, 1 H), 2.93-3.14 (m, 2 H), 2.75 (dd, 1 H), 1.22 (dd, 6 H)	445.2 [M+H]+	100%
2335	(CD3OD) δ 8.36-8.44 (m, 1 H), 8.24 (br d, 1 H), 8.18 (d, 1 H), 7.58 (s, 1 H), 7.38 (br t, 1 H), 6.93 (br d, 1 H), 6.67-6.76 (m, 1 H), 6.58 (s, 1 H), 6.34 (s, 1 H), 4.28 (dd, 1 H), 3.63-3.78 (m, 1 H), 2.92-3.15 (m, 2 H), 2.75 (dd, 1 H), 1.21 (t, 6 H)	445.2 [M+H]+	98.9%
2336	(CD3OD) δ 8.52 (d, 1 H), 7.81-7.88 (m, 2 H), 7.69 (s, 1 H), 7.44 (dd, 1 H), 7.20-7.35 (m, 2 H), 6.80 (s, 1 H), 6.57 (s, 1 H), 4.46 (dd, 1 H), 3.83 (td, 1 H), 3.04-3.15 (m, 1 H), 2.84 (dd, 1 H), 2.69 (s, 3 H)	467.1 [M+H]+	100%
2337	(CD3OD) δ 8.53 (d, 1 H), 7.82-7.91 (m, 3 H), 7.46 (dd, 1 H), 7.23-7.35 (m, 2 H), 6.83 (s, 1 H), 6.61 (s, 1 H), 4.48 (dd, 1 H), 3.77-3.87 (m, 1 H), 3.06-3.17 (m, 1 H), 2.84-2.90 (m, 1 H), 2.71 (s, 3 H)	467.2 [M+H]+	99.2%
2338	(CD3OD) δ 8.43 (d, 1 H), 8.30 (d, 1 H), 7.66-7.76 (m, 1 H), 7.57 (s, 1 H), 7.41-7.52 (m, 2 H), 7.05 (dd, 1 H), 6.71 (td, 1 H), 6.51 (s, 1 H), 6.40 (s, 1 H), 4.31 (dd, 1 H), 3.62-3.74 (m, 1 H), 2.91-3.05 (m, 1 H), 2.72 (dd, 1 H)	403.2 [M+H]+	100%
2339	(CD3OD) δ 8.43 (d, 1 H), 8.31 (d, 1 H), 7.72 (t, 1 H), 7.57 (s, 1 H), 7.42-7.53 (m, 2 H), 7.01-7.11 (m, 1 H), 6.71 (t, 1 H), 6.52 (s, 1 H), 6.40 (s, 1 H), 4.32 (dd, 1 H), 3.62-3.74 (m, 1 H), 2.91-3.05 (m, 1 H), 2.72 (dd, 1 H)	403.2 [M+H]+	94.1%
2340	(CD3OD) δ 8.44 (d, 1 H), 8.17 (d, 1 H), 7.65-7.81 (m, 1 H), 7.54-7.60 (m, 1 H), 7.50 (dt, 1 H), 6.82-6.88 (m, 1 H), 6.64 (t, 1 H), 6.53 (s, 1 H), 6.41 (s, 1 H), 4.32 (dd, 1 H), 3.64-3.78 (m, 1 H), 2.92-3.05 (m, 1 H), 2.73 (dd, 1 H), 2.31 (s, 3 H)	417.2 [M+H]+	99.9%
2341	(CD3OD) δ 8.44 (d, 1 H), 8.17 (d, 1 H), 7.72 (t, 1 H), 7.57 (s, 1 H), 7.50 (dt, 1 H), 6.85 (d, 1 H), 6.64 (t, 1 H), 6.53 (s, 1 H), 6.41 (s, 1 H), 4.33 (dd, 1 H), 3.70 (td, 1 H), 2.93-3.05 (m, 1 H), 2.73 (dd, 1 H), 2.31 (s, 3 H)	417.1 [M+H]+	99.3%
2342	(CD3OD) δ 8.44 (d, 1 H), 7.80-7.95 (m, 2 H), 7.68 (s, 1 H), 7.58 (d, 1 H), 7.40 (d, 1 H), 7.18 (dd, 1 H), 6.84 (td, 1 H), 6.62 (s, 1 H), 6.53 (s, 1 H), 4.44 (dd, 1 H), 3.64-3.84 (m, 1 H), 3.00-3.18 (m, 1 H), 2.83 (br dd, 1 H), 2.62 (s, 3 H)	399.1 [M+H]+	100%
2343	(CD3OD) δ 8.43 (d, 1 H), 7.79-7.97 (m, 2 H), 7.67 (s, 1 H), 7.57 (d, 1 H), 7.39 (d, 1 H), 7.12-7.22 (m, 1 H), 6.83 (td, 1 H), 6.62 (s, 1 H), 6.53 (s, 1 H), 4.43 (dd, 1 H), 3.77 (ddd, 1 H), 3.03-3.17 (m, 1 H), 2.75-2.88 (m, 1 H), 2.61 (s, 3 H)	399.1 [M+H]+	98.3%
2344	(CD3OD) δ 8.29 (d, 1 H), 7.79-7.98 (m, 2 H), 7.68 (s, 1 H), 7.40 (d, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.63 (s, 1 H), 6.53 (s, 1 H), 4.44 (dd, 1 H), 3.69-3.85 (m, 1 H), 3.00-3.18 (m, 1 H), 2.75-2.88 (m, 1 H), 2.62 (s, 3 H), 2.43 (s, 3 H)	413.2 [M+H]+	99.5%
2345	(CD3OD) δ 8.27 (d, 1 H), 7.77-7.93 (m, 2 H), 7.68 (s, 1 H), 7.37 (d, 1 H), 6.94 (d, 1 H), 6.73 (t, 1 H), 6.62 (s, 1 H), 6.52 (s, 1 H), 4.43 (dd, 1 H), 3.67-3.84 (m, 1 H), 3.02-3.15 (m, 1 H), 2.82 (br dd, 1 H), 2.60 (s, 3 H), 2.40 (s, 3 H)	413.2 [M+H]+	99.6%
2346	(CD3OD) δ 8.57 (d, 1 H), 7.80-7.97 (m, 2 H), 7.72 (s, 1 H), 7.29-7.49 (m, 2 H), 6.76-7.15 (m, 3 H), 6.56 (s, 1 H), 4.46 (dd, 1 H), 3.68-3.89 (m, 1 H), 3.02-3.19 (m, 1 H), 2.76-2.91 (m, 1 H), 2.62 (s, 3 H)	449.1 [M+H]+	99.6%
2347	(CD3OD) δ 8.57 (br d, 1 H), 7.79-7.96 (m, 2 H), 7.69 (s, 1 H), 7.35-7.51 (m, 2 H), 6.75-7.16 (m, 3 H), 6.56 (br s, 1 H), 4.46 (dd, 1 H), 3.66-3.90 (m, 1 H), 3.00-3.20 (m, 1 H), 2.74-2.92 (m, 1 H), 2.62 (s, 3 H)	449.1 [M+H]+	99.5%
2348	(CD3OD) δ 8.48 (d, 1 H), 8.43 (s, 1 H), 7.74-7.81 (m, 1 H), 7.65 (s, 1 H), 7.12-7.22 (m, 2 H), 6.85-6.97 (m, 2 H), 6.67 (s, 1 H), 4.74 (br dd, 1 H), 3.61 (ddd, 1 H), 2.91-3.01 (m, 1 H), 2.71-2.80 (m, 1 H)	469.1 [M+H]+	98.0%
2349	(CD3OD) δ 8.36 (d, 1 H), 8.28-8.33 (m, 1 H), 7.66 (dd, 1 H), 7.56 (s, 1 H), 7.00-7.10 (m, 2 H), 6.73-6.85 (m, 2 H), 6.55 (s, 1 H), 4.62 (br dd, 1 H), 3.42-3.55 (m, 1 H), 2.78-2.91 (m, 1 H), 2.63 (dd, 1 H)	469.1 [M+H]+	98.5%
2350	(CD3OD) δ 8.40 (ddd, 1 H), 8.33 (d, 1 H), 8.25 (d, 1 H), 7.59 (s, 1 H), 7.34-7.45 (m, 1 H), 7.18 (d, 1 H), 6.73 (t, 1 H), 6.62 (s, 1 H), 6.35 (s, 1 H), 4.30 (dd, 1 H), 3.61-3.76 (m, 1 H), 2.92-3.07 (m, 1 H), 2.75 (dd, 1 H)	437.1 [M+H]+	100%
2351	(CD3OD) δ 8.37-8.44 (m, 1 H), 8.34 (d, 1 H), 8.25 (br d, 1 H), 7.59 (s, 1 H), 7.31-7.44 (m, 1 H), 7.19 (d, 1 H), 6.73 (t, 1 H), 6.62 (s, 1 H), 6.35 (s, 1 H), 4.30 (dd, 1 H), 3.59-3.76 (m, 1 H), 2.91-3.07 (m, 1 H), 2.75 (br dd, 1 H)	437.1 [M+H]+	100%
2352	(CD3OD) δ 8.52 (br d, 1 H), 7.84 (br d, 1 H), 7.67-7.75 (m, 2 H), 7.13-7.51 (m, 4 H), 6.73 (s, 1 H), 6.56 (s, 1 H), 4.47 (dd, 1 H), 3.78-3.90 (m, 1 H), 3.03-3.16 (m, 1 H), 2.84 (dd, 1 H), 2.68 (s, 3 H)	449.2 [M+H]+	100%
2353	(CD3OD) δ 8.52 (d, 1 H), 7.84 (br d, 1 H), 7.65-7.75 (m, 2 H), 7.13-7.49 (m, 4 H), 6.73 (s, 1 H), 6.56 (s, 1 H), 4.47 (dd, 1 H), 3.79-3.90 (m, 1 H), 3.02-3.15 (m, 1 H), 2.84 (dd, 1 H), 2.68 (s, 3 H)	449.1 [M+H]+	99.8%
2354	(CD3OD) δ 8.45 (d, 1 H), 8.17 (d, 1 H), 7.73 (t, 1 H), 7.58 (s, 1 H), 7.51 (dt, 1 H), 6.92 (d, 1 H), 6.70 (t, 1 H), 6.63 (s, 1 H), 6.41 (s, 1 H), 4.33 (dd, 1 H), 3.64-3.78 (m, 1 H), 2.94-3.11 (m, 2 H), 2.74 (dd, 1 H), 1.21 (t, 6 H)	445.2 [M+H]+	99. 7%
2355	(CD3OD) δ 8.44 (br d, 1 H), 8.17 (d, 1 H), 7.73 (t, 1 H), 7.58 (s, 1 H), 7.50 (dt, 1 H), 6.92 (d, 1 H), 6.67-6.74 (m, 1 H), 6.63 (s, 1 H), 6.41 (s, 1 H), 4.33 (br dd, 1 H), 3.65-3.77 (m, 1 H), 2.94-3.10 (m, 2 H), 2.74 (br dd, 1 H), 1.20 (t, 6 H)	445.2 [M+H]+	98.6%
2356	(CD3OD) δ 8.68 (d, 1 H), 7.77-7.99 (m, 2 H), 7.69 (s, 1 H), 7.60 (d, 1 H), 7.40 (d, 1H), 6.96 (t, 1 H), 6.82 (s, 1 H), 6.56 (s, 1 H), 4.47 (dd, 1 H), 3.66-3.91 (m, 1 H), 3.02-3.17 (m, 1 H), 2.85 (dd, 1 H), 2.62 (s, 3 H)	467.2 [M+H]+	1 00%
2357	(CD3OD) δ 8.68 (d, 1 H), 7.78-7.97 (m, 2 H), 7.69 (s, 1 H), 7.60 (d, 1 H), 7.40 (d, 1 H), 6.96 (t, 1 H), 6.82 (s, 1 H), 6.56 (s, 1 H), 4.47 (dd, 1 H), 3.79 (td, 1 H), 3.05-3.20 (m, 1 H), 2.77-2.92 (m, 1 H), 2.61 (s, 3 H)	467.1 [M+H]+	97.8%
2358	(CD3OD) δ 8.25 (d, 1 H), 7.78-7.98 (m, 2 H), 7.68 (s, 1 H), 7.38 (d, 1 H), 6.68-6.87 (m, 3 H), 6.41-6.63 (m, 1 H), 4.44 (dd, 1 H), 3.79 (td, 1 H), 2.99-3.20 (m, 1 H), 2.76-2.93 (m, 1 H), 2.61 (s, 3 H), 2.00-2.16 (m, 1 H), 0.72-1.04 (m, 4 H)	439.2 [ M+H]+	100%
2359	(CD3OD) δ 8.26 (d, 1 H), 7.80-8.04 (m, 2 H), 7.68 (s, 1 H), 7.39 (d, 1 H), 6.67-6.97 (m, 3 H), 6.39-6.64 (m, 1 H), 4.44 (dd, 1 H), 3.66-3.91 (m, 1 H), 3.03-3.21 (m, 1 H), 2.76-2.97 (m, 1 H), 2.61 (s, 3 H), 1.97-2.28 (m, 1 H), 0.70-1.07 (m, 4 H)	439.2 [M+H]+	99.7%
2360	(CD3OD) δ 8.29 (d, 1H), 8.11 (q, 1 H), 8.00 (dd, 1 H), 7.68 (s, 1 H), 7.21 (dd, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.63 (s, 1 H), 6.50 (s, 1 H), 4.42 (dd, 1 H), 3.79 (ddd, 1 H), 3.00-3.16 (m, 1 H), 2.84 (dd, 1 H), 2.43 (s, 3 H)	417.2 [M+H]+	100%
2361	(CD3OD) δ 8.29 (d, 1 H), 8.11 (q, 1 H), 8.00 (dd, 1 H), 7.68 (s, 1 H), 7.21 (dd, 1 H), 6.97 (d, 1 H), 6.77 (t, 1 H), 6.63 (s, 1 H), 6.50 (s, 1 H), 4.42 (dd, 1 H), 3.79 (ddd, 1 H), 2.96-3.16 (m, 1 H), 2.84 (dd, 1 H), 2.43 (s, 3 H)	417.2 [M+H]+	99.8%
2362	(CD3OD) δ 8.69 (d, 1 H), 8.11 (q, 1 H), 8.00 (dd, 1 H), 7.69 (s, 1 H), 7.61 (d, 1 H), 7.22 (dd, 1 H), 6.97 (t, 1 H), 6.82 (s, 1 H), 6.53 (br s, 1 H), 4.46 (dd, 1 H), 3.80 (ddd, 1 H), 3.00-3.19 (m, 1 H), 2.85 (br dd, 1 H)	471.2 [M+H]+	99.9%
2363	(CD3OD) δ 8.68 (br d, 1 H), 8.07-8.16 (m, 1 H), 8.00 (br d, 1 H), 7.69 (s, 1 H), 7.61 (br d, 1 H), 7.22 (br d, 1 H), 6.97 (br t, 1 H), 6.82 (s, 1 H), 6.53 (br s, 1H), 4.46 (dd, 1 H), 3.73-3.87 (m, 1 H), 3.00-3.16 (m, 1 H), 2.85 (br dd, 1 H)	471.2 [M+H]+	97.4%
2364	(CD3OD) δ 8.71 (d, 1 H), 8.35-8.51 (m, 2 H), 7.90 (td, 1 H), 7.71 (s, 1 H), 7.51-7.66 (m, 1.3 H), 7.15-7.27 (m, 1 H), 6.99 (s, 0.7 H), 6.82-6.92 (m, 1 H), 6.58-6.70 (m, 1 H), 5.02 (br dd, 1 H), 3.75-3.87 (m, 0.7 H), 3.44 (td, 0.3 H), 3.15-3.26 (m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.86 (br dd, 1 H)	431.0 [M+H]+	100%
2365	(CD3OD) δ 8.71 (d, 1 H), 8.35-8.50 (m, 2 H), 7.90 (td, 1 H), 7.74-7.77 (m, 1 H), 7.52-7.66 (m, 1.3 H), 7.15-7.26 (m, 1 H), 6.99 (s, 0.7 H), 6.81-6.92 (m, 1 H), 6.60-6.70 (m, 1 H), 5.03 (dd, 1 H), 3.74-3.86 (m, 0.7 H), 3.44 (td, 0.3 H), 3.16-3.28 (m, 0.7 H), 2.98-3.08 (m, 0.3 H), 2.82-2.90 (m, 1 H)	431.0 [M+H]+	100%
2366	(CD3OD) δ 8.45 (br s, 1.4 H), 8.02 (br s, 0.6 H), 7.65 (s, 1 H), 7.58 (br d, 1 H), 7.15-7.25 (m, 1 H), 6.91-7.13 (m, 1.3 H), 6.73-6.90 (m, 1.3 H), 6.61 (br s, 0.7 H), 6.07-6.47 (m, 0.7 H), 4.67-4.84 (m, 0.6 H), 4.06 (br s, 0.4 H), 3.66 (br s, 0.5 H), 3.14-3.30 (m, 0.5 H), 2.93 (br s, 1 H), 2.70 (br d, 1 H)	384.1 [M+H]+	100%
2367	(CD3OD) δ 8.46 (br s, 1.4 H), 8.03 (br s, 0.6 H), 7.65 (s, 1 H), 7.58 (br d, 1 H), 7.16-7.23 (m, 1 H), 6.92-7.12 (m, 1.3 H), 6.77-6.91 (m, 1.4 H), 6.61 (br s, 0.6 H), 6.17-6.44 (m, 0.7 H), 4.64-4.85 (m, 0.6 H), 4.06 (br s, 0.4 H), 3.66 (br s, 0.4 H), 3.16-3.31 (m, 0.6 H), 2.96 (br d, 1 H), 2.70 (br d, 1 H)	384.1 [M+H]+	99.8%
2368	(CD3OD) δ 8.36-8.64 (m, 1 H), 7.77-8.34 (m, 1 H), 7.47-7.74 (m, 2 H), 7.02-7.42 (m, 2 H), 6.76-6.99 (m, 1.5 H), 6.09-6.70 (m, 1.5 H), 5.11 (q, 2 H), 4.06 (br d, 1 H), 3.70 (br s, 1 H), 2.90-3.04 (m, 1 H), 2.73 (dd, 1 H)	466.0 [M+H]+	100%
2369	(CD3OD) δ 8.37-8.62 (m, 1 H), 7.79-8.35 (m, 1 H), 7.49-7.76 (m, 2 H), 7.01-7.43 (m, 2 H), 6.80-6.99 (m, 1.4 H), 6.13-6.70 (m, 1.6 H), 5.11 (q, 2 H), 4.05 (br s, 1 H), 3.70 (br s, 1 H), 2.90-3.04 (m, 1 H), 2.73 (br dd, 1 H)	466.0 [M+H]+	100%
2370	(CD3OD) δ 8.26-8.62 (m, 1 H), 7.47-7.74 (m, 2.3 H), 7.09-7.43 (m, 1.7 H), 6.79-6.99 (m, 1.6 H), 5.98-6.71 (m, 2.4 H), 4.13 (br dd, 1 H), 3.56-3.79 (m, 0.6 H), 2.86-3.28 (m, 1.4 H), 2.74 (br d, 1 H)	399.0 [M+H]+	99.2%
2371	(CD3OD) δ 8.34-8.60 (m, 1 H), 7.50-7.75 (m, 2.2 H), 7.13-7.49 (m, 1.8 H), 6.77-7.03 (m, 1.5 H), 5.99-6.69 (m, 2.5 H), 4.13 (br dd, 1 H), 3.57-3.76 (m, 0.6 H), 2.87-3.29 (m, 1.4 H), 2.74 (br d, 1 H)	399.0 [M+H]+	99.4%
2372	(CD3OD) δ 8.35-8.53 (m, 1 H), 7.48-7.75 (m, 2 H), 7.08-7.28 (m, 1 H), 6.73-7.03 (m, 2 H), 6.28-6.70 (m, 1 H), 4.44 (dd, 1 H), 4.00-4.23 (m, 3 H), 3.68 (ddd, 1 H), 2.91-3.29 (m, 1 H), 2.67-2.87 (m, 1 H)	417.2 [M+H]+	100%
2373	(CD3OD) δ 8.37-8.51 (m, 1 H), 7.40-7.75 (m, 2 H), 7.10-7.26 (m, 1 H), 6.75-7.00 (m, 2 H), 6.31-6.70 (m, 1 H), 4.44 (dd, 1 H), 4.04-4.24 (m, 3 H), 3.68 (ddd, 1 H), 2.89-3.29 (m, 1 H), 2.71-2.87 (m, 1 H)	417.2 [M+H]+	100%
2374	(CD3OD) δ 8.34 (d, 1 H), 7.56 (s, 1 H), 7.49 (br d, 1 H), 7.04-7.17 (m, 1 H), 6.75 (td, 1.6 H), 6.25-6.56 (m, 1.4 H), 4.80-4.85 (m, 1 H), 4.02-4.21 (m, 1 H), 3.56-3.76 (m, 1 H), 2.61-3.10 (m, 2 H), 1.46 (br d, 3 H)	413.20 [M+H]+	100%
2375	(CD3OD) δ 8.46 (d, 1 H), 7.68 (s, 1 H), 7.61 (br d, 1 H), 7.15-7.28 (m, 1 H), 6.87 (td, 1.6 H), 6.35-6.71 (m, 1.4 H), 4.92-4.96 (m, 1 H), 4.21 (br d, 1 H), 3.64-3.86 (m, 1 H), 2.72-3.20 (m, 2 H), 1.59 (br d, 3 H)	413.20 [M+H]+	96.6%
2376	(CD3OD) δ 8.46 (d, 1 H), 7.68 (s, 1 H), 7.61 (br d, 1 H), 7.15-7.28 (m, 1 H), 6.87 (td, 1.6 H), 6.30-6.69 (m, 1.4 H), 4.93-4.96 (m, 1 H), 4.22 (br d, 1 H), 3.78 (br s, 1 H), 2.77-3.20 (m, 2 H), 1.48-1.65 (m, 3 H)	413.10 [M+H]+	100%
2377	(CD3OD) δ 8.34 (d, 1H), 7.56 (s, 1 H), 7.49 (br d, 1 H), 7.05-7.13 (m, 1 H), 6.75 (td, 1.6 H), 6.25-6.55 (m, 1.4 H), 4.80-4.85 (m, 1 H), 3.99-4.19 (m, 1 H), 3.66 (br s, 1 H), 2.59-3.09 (m, 2 H), 1.47 (br d, 3 H)	413.0 [M+H]+	97.3%
2378	(CD3OD) δ 8.37-8.44 (m, 1 H), 7.68 (s, 1 H), 7.19-7.45 (m, 1 H), 6.78-6.97 (m, 2 H). 6.61-6.75 (m, 1 H), 4.93 (br d. 1 H), 3.63-3.80 (m, 0.7 H), 3.35-3.44 (m, 0.3 H), 2.91-3.20 (m, 1 H), 2.81 (br d, 1 H), 1.67 (s, 6 H)	428.1 [M+H]+	100%
2379	(CD3OD) δ 8.37-8.44 (m, 1 H). 7.68 (s. 1 H), 7.22-7.42 (m. 1 H), 6.78-6.94 (m, 2 H), 6.60-6.73 (m, 1 H), 4.93 (br d, 1 H), 3.61 -3.78 (m, 0.6 H), 3.32-3.42 (m, 0.4 H), 2.91-3.19 (m, 1 H), 2.80 (dd, 1 H), 1.67 (s, 6 H)	428.1 [M+H]+	100%
2380	(CD3OD) δ 8.39 (s, 1 H), 8.17-8.28 (m, 1 H), 8.10 (s, 1 H), 7.68 (s, 1 H), 7.42-7.61 (m, 1 H), 7.02-7.12 (m, 1 H), 6.93 (br s, 1 H), 6.44-6.60 (m, 1 H), 5.05 (br dd, 1 H), 4.00 (s, 3 H), 3.67-3.84 (m, 1 H), 2.91-3.22 (m, 1 H), 2.82 (br d, 1 H), 2.23-2.36 (m, 3 H)	430.2 [M+H]+	100%
2381	(CD3OD) δ 8.39 (s. 1 H), 8.15-8.28 (m. 1 H), 8.10 (s, 1 H), 7.68 (s, 1 H), 7.42-7.58 (m, 1 H), 7.01-7.11 (m, 1 H), 6.93 (s, 1 H), 6.44-6.61 (m, 1 H), 5.05 (br dd, 1 H), 4.00 (s, 3 H), 3.70-3.83 (m, 0.7 H), 3.39-3.44 (m, 0.3 H), 2.92-3.22 (m, 1 H), 2.70-2.88 (m. 1 H), 2.21-2.34 (m. 3 H)	430.2 [M+H]+	99.8%
2382	(CD3OD) δ 8.35 (br s, 1 H), 7.93 (br s, 1 H), 7.67 (s, 2 H). 6.91-7.04 (m, 1 H), 6.60-6.90 (m, 3 H), 4.41-4.83 (m, 1 H), 3.36-3.87 (m, 1 H), 2.68-3.19 (m. 2 H), 1.64 (br s, 6 H)	411.2 [M+H]+	100%
2383	(CD3OD) δ 8.35 (br s, 1 H), 7.93 (br s, 1 H). 7.68 (s. 2 H), 6.92-7.08 (m, 1 H), 6.57-6.91 (m, 3 H), 4.42-4.83 (m, 1 H), 3.36-3.90 (m, 1 H). 2.73-3.24 (m, 2 H). 1.64 (br s, 6 H)	411.2 [M+H]+	99.1%
2384	(CD3OD) δ 8.79 (br d, 1 H), 8.24-8.38 (m, 2 H), 8.10 (t, 1 H). 7.64-7.73 (m, 2 H), 7.51 (s, 0.3 H), 7.32-7.39 (m, 1 H), 6.96 (s, 0.7 H). 6.67-6.77 (m, 1 H). 6.44-6.53 (m, 1 H). 5.00 (br dd. 1 H), 3.75-3.86 (m, 0.7 H), 3.43 (br dd, 0.3 H), 2.97-3.26 (m, 1 H), 2.80-2.90 (m. 1 H), 2.34-2.42 (m, 3 H)	427.2 [M+H]+	97.4%
2385	(CD3OD) δ 8.79 (br d, 1 H), 8.24-8.38 (m, 2 H), 8.10 (t, 1 H). 7.64-7.74 (m, 2 H), 7.51 (s, 0.3 H), 7.32-7.41 (m, 1 H), 6.96 (s, 0.7 H), 6.67-6.76 (m, 1 H), 6.44-6.55 (m, 1 H), 5.00 (br dd, 1 H), 3.75-3.86 (m, 0.7 H), 3.39-3.46 (m, 0.3 H), 298-3.27 (m, 1 H), 2.81-2.91 (m, 1 H), 2.33-2.41 (m, 3 H)	427.2 [M+H]+	99.6%
2386	(CD3OD) δ 8.34-8.71 (m, 1 H), 7.66-7.80 (m, 1 H), 7.55-7.66 (m, 1 H), 7.50 (d, 1 H), 7.17-7.27 (m, 1 H). 7.01 (s. 0.6 H). 6.83-6.93 (m, 1 H), 6.62-6.80 (m, 1 H), 6.27-6.58 (m, 1 H), 6.14 (br s, 0.4 H), 3.92 (br dd. 1 H), 3.57-3.82 (m, 1.6 H). 3.36-3.47 (m, 0.4 H), 2.87-3.10 (m, 1 H), 2.67-2.86 (m, 1 H), 1.10 (br s, 1 H), 0.64-0.98 (m, 3 H)	374.2 [M+H]+	99.9%
2387	(CD3OD) δ 8.40-8.62 (m, 1 H), 7.66-7.74 (m, 1 H). 7.54-7.66 (m, 1 H), 7.50 (d, 1 H), 7.21 (t, 1 H), 7.01 (s, 0.6 H), 6.83-6.94 (m, 1 H), 6.60-6.80 (m, 1 H), 6.29-6.60 (m, 1 H), 6.14 (s, 0.4 H), 3.85-4.00 (m, 1 H), 3.57-3.80 (m, 1.6 H), 3.35-3.46 (m, 0.4 H), 2.87-3.10 (m, 1 H). 2.69-2.85 (m, 1 H), 1.10 (br d. 1 H), 0.63-0.97 (m, 3 H)	374.2 [M+H]+	100%
2388	(CD3OD) δ 8.31-8.40 (m, 1 H), 7.79-7.91 (m, 3 H), 7.53-7.78 (m, 2 H). 7.06-7.19 (m, 1 H). 6.83-7.05 (m, 3 H). 6.44-6.81 (m, 1.6 H), 5.88 (s, 0.4 H), 3.38-3.84 (m, 2 H), 2.57-3.16 (m, 2 H)	429.2 [M+H]+	91.1%
2389	(CD3OD) δ 8.31-8.40 (m, 1 H), 7.79-7.92 (m, 3 H), 7.54-7.78 (m. 2 H), 7.07-7.19 (m. 1 H), 6.84-7.05 (m, 3 H), 6.44-6.80 (m. 1.6 H), 5.88 (s, 0.4 H), 3.40-3.83 (m, 2 H), 2.58-3.15 (m, 2 H)	429.2 [M+H]+	94.3%
2390	(CD3OD) δ 8.31-8.51 (m, 1 H), 7.70 (s, 1 H), 6.69-7.19 (m, 3 H), 6.32-6.61 (m, 2 H). 4.15 (br d, 1 H), 3.85 (s, 3 H). 3.63-3.78 (m, 1 H), 2.69-3.10 (m, 2 H), 2.28 (br s, 3 H)	380.2 [M+H]+	100%
2391	(CD3OD) δ 8.28-8.57 (m, 1 H), 7.70 (s, 1 H), 6.70-7.06 (m, 3 H), 6.29-6.63 (m, 2 H). 4.15 (br d. 1 H), 3.61-3.91 (m. 4 H), 2.67-3.10 (m, 2 H), 2.16-2.32 (m, 3 H)	380.2 [M+H]+	99.7%
2392	(CD3OD) δ 7.94-8.01 (m, 1 H), 7.58 (d, 1 H). 6.16-6.86 (m, 4 H), 4.74-4.76 (m, 0.4 H), 4.22 (dd, 0.6 H), 3.79-3.89 (m, 6 H), 3.55 (ddd. 0.5 H), 2.80-3. 18 (m, 1.5 H), 2.57-2.76 (m, 1 H), 2.25 (s, 3 H)	393.2 [M+H]+	100%
2393	(CD3OD) δ 8.04-8.14 (m, 1 H), 7.70 (d, 1 H), 6.27-6.98 (m, 4 H), 4.86-4.88 (m, 0.4 H), 4.34 (dd, 0.6 H), 3.90-4.00 (m, 6 H), 3.61-3.74 (m, 0.5 H), 2.92-3.29 (m, 1.5 H), 2.70-2.89 (m, 1 H), 2.37 (s, 3 H)	393.2 [M+H]+	99.0%
2394	(CD3OD) δ 7.98 (d, 1 H). 7.83 (dd, 1 H). 7.69 (d, 1 H), 7.46 (dd, 1.5 H), 7.11 (ddd, 1 H), 6.98 (s, 0.5 H), 6.70 (dd, 1 H), 6.42-6.64 (m, 1 H), 4.91-5.11 (m, 1 H), 4.10 (s, 3 H), 3.85-3.98 (m, 0.6 H), 3.35-3.43 (m, 0.4 H), 2.78-3.24 (m, 2 H), 2.49-2.71 (m, 3 H)	430.2 [M+H]+	100%
2395	(CD3OD) δ 7.98 (d, 1 H), 7.83 (d, 1 H), 7.69 (d, 1 H), 7.46 (dd, 1.4 H), 7.11 (ddd, 1 H), 6.98 (s, 0.6 H). 6.70 (dd, 1 H), 6.41-6.65 (m, 1 H), 4.92-5.11 (m, 1 H), 4.10 (s, 3 H), 3.85-3.99 (m, 0.5 H), 3.34-3.45 (m, 0.5 H). 2.79-3.23 (m, 2 H), 2.43-2.71 (m, 3 H)	430.2 [M+H]+	93.5%
2396	(CD3OD) δ 7.69 (d, 1 H). 7.51-7.63 (m, 1 H). 7.11-7.20 (m, 1 H), 6.90-7.05 (m, 2 H), 6.78-6.87 (m, 1 H), 6.45-6.73 (m, 1 H), 4.36 (dd, 1 H), 4.12 (d, 3 H), 3.69-3.81 (m. 0.5 H), 3.08-3.25 (m, 1 H), 2.92-3.03 (m, 0.5 H), 2.71-2.88 (m, 1 H)	433.1 [M+H]+	100%
2397	(CD3OD) δ 7.69 (d, 1 H), 7.50-7.62 (m, 1 H), 7.11-7.19 (m, 1 H), 6.90-7.04 (m, 2 H), 6.77-6.87 (m, 1 H), 6.43-6.73 (m, 1 H), 4.36 (br dd, 1 H), 4.12 (d, 3 H), 3.71-3.81 (m, 0.5 H), 3.09-3.24 (m, 1 H), 2.91-3.03 (m, 0.5 H), 2.71-2.87 (m, 1 H)	433.1 [M+H]+	96.7%
2398	(CD3OD) δ 8.30-8.38 (m, 1 H), 7.61-7.74 (m, 1 H), 6.89-7.00 (m, 2 H), 6.79-6.87 (m, 1 H), 6.76 (s, 0.6 H), 6.54 (s, 0.4 H), 4.48 (dd, 1 H), 4.06-4.23 (m, 3 H), 3.68 (ddd, 0.6 H), 3.11-3.29 (m, 1 H), 2.92-3.04 (m, 0.4 H), 2.72-2.88 (m, 1 H)	435.1 [M+H]+	100%
2399	(CD3OD) δ 8.26-8.40 (m, 1 H), 7.70 (d, 1 H). 6.89-7.03 (m, 2 H), 6.79-6.88 (m, 1 H), 6.76 (s, 0.6 H), 6.54 (s, 0.4 H), 4.48 (dd, 1 H), 4.12-4.17 (m, 3 H), 3.68 (ddd, 0.6 H), 3.11-3.28 (m, 1 H), 2.93-3.04 (m, 0.4 H), 2.72-2.88 (m, 1 H)	435.1 [M+H]+	100%
2400	(CD3OD) δ 8.35-8.62 (m, 2 H), 7.69 (s, 1 H), 7.00-7.47 (m, 2 H), 6.47-6.90 (m, 3 H). 4.34 (br d, 1 H), 3.73 (br s, 1 H), 2.94-3.25 (m, 1 H), 2.81 (br d, 1 H)	403.1 [M+H]+	97.1%
2401	(CD3OD) δ 8.39-8.57 (m, 2 H), 7.69 (s, 1 H), 6.97-7.40 (m, 2 H), 6.44-6.88 (m, 3 H), 4.34 (br d, 1 H), 3.73 (br t. 1 H), 2.92-3.25 (m, 1 H), 2.81 (br d, 1 H)	403.1 [M+H]+	97.0%
2402	(CDCl3) δ 8.04-8.19 (m, 1H), 7.56 (d, 1H), 7.33 (dd, 1H), 6.88-7.01 (m, 2 H), 6.55-6.86 (m, 1H), 6.29-6.54 (m, 1H), 4.69-4.98 (m, 1H), 3.23-3.85 (m, 1H), 2.91-3.22 (m, 1H), 2.74 (br d, 1H), 2.28 (s, 3 H)	413.2 [M+H]+	100%
2403	(CDCl3) δ 8.03-8.22 (m, 1H), 7.58 (d, 1H), 7.28-7.38 (m, 1H), 6.85-7.03 (m, 2 H), 6.22-6.85 (m, 2 H), 4.63-5.07 (m, 1H), 4.09-4.20 (m, 3 H), 3.26-3.83 (m, 1H), 2.89-3.25 (m, 1H), 2.69-2.86 (m, 1H), 2.29 (s, 3 H)	413.2 [M+H]+	99.2%
2404	(CD3OD) δ 8.51 (br s, 1H), 7.56-7.75 (m, 2 H), 7.44 (s, 0.3 H), 7.12-7.30 (m, 1H), 6.88 (s, 0.7 H), 6.52-6.72 (m, 1H), 4.97 (br dd, 1H), 3.34-3.78 (m, 1H), 2.70-3.20 (m, 2 H), 2.30 (br d, 1 H), 1.18-1.30 (m, 4 H)	394.1 [M+H]+	100%
2405	(CD3OD) δ 8.51 (br s, 1H), 7.56-7.72 (m, 2 H), 7.44 (s, 0.3 H), 7.22 (br t, 1H), 6.88 (s, 0.7 H), 6.53-6.75 (m, 1H), 4.97 (br dd, 1H), 3.34-3.79 (m, 1H), 2.74-3.19 (m, 2 H), 2.20-2.41 (m, 1H), 1.18-1.30 (m, 4 H)	394.2 [M+H]+	100%
2406	(CD3OD) δ 8.63 (d, 1H), 8.05 (br s, 1H), 7.69 (s, 1H), 6.96-7.31 (m, 2 H), 6.56-6.93 (m, 2 H), 4.76-4.81 (m, 0.3 H), 4.36 (br d, 0.7 H), 3.60-3.88 (m, 0.7 H), 3.39 (br s, 0.3 H), 2.72-3.25 (m, 2 H), 1.48-1.75 (m, 6 H)	511.1 [M+H]+	99.2%
2407	(CD3OD) δ 8.63 (d, 1H), 8.05 (br s, 1H), 7.68 (s, 1H), 6.95-7.30 (m, 2 H), 6.54-6.94 (m, 2 H), 4.84 (br s, 0.3 H), 4.36 (br d, 0.7 H), 3.73 (br t, 0.7 H), 3.39 (br s, 0.3 H), 2.70-3.23 (m, 2 H), 1.49-1.76 (m, 6 H)	511.2 [M+H]+	99.4%
2408	(CD3OD) δ 7.86 (dd, 1H), 7.53-7.77 (m, 1.5 H), 7.23-7.42 (m, 2 H), 6.81-7.04 (m, 1H), 6.67 (s, 0.5 H), 4.96-5.02 (m, 1H), 3.82-4.00 (m, 0.5 H), 2.93-3.32 (m, 1.5 H), 2.85 (dd, 1H), 1.49 (d, 9 H)	460.2 [M+H]+	100%
2409	(CD3OD) δ 7.75 (dd, 1H), 7.36-7.65 (m, 1.5 H), 7.09-7.31 (m, 2 H), 6.71-6.91 (m, 1H), 6.55 (s, 0.5 H), 4.85-4.92 (m, 1H), 3.71-3.88 (m, 0.5 H), 2.82-3.20 (m, 1.5 H), 2.73 (dd, 1H), 1.37 (d, 9 H)	460.2 [M+H]+	99.6%
2410	(CD3OD) δ 8.64 (br s, 1H), 7.86-8.18 (m, 1H), 7.69 (br s, 1H), 6.51-7.21 (m, 4 H), 4.47 (br d, 0.4 H), 4.11 (br d, 3 H), 3.67 (br s, 0.6 H), 2.64-3.25 (m, 3 H)	467.2 [M+H]+	100%
2411	(CD3OD) δ 8.60-8.68 (m, 1H), 7.89-8.21 (m, 1H), 7.70 (d, 1 H), 6.63-7.13 (m, 4 H), 4.47 (dd, 0.4 H), 4.04-4.18 (m, 3 H), 3.67 (ddd, 0.6 H), 2.68-3.28 (m, 3 H)	467.2 [M+H]+	100%
2412	(CD3OD) δ 7.71 (d, 1H), 7.54-7.66 (m, 1H), 7.14-7.23 (m, 1 H), 7.05 (d, 1H), 6.96 (br s, 1H), 6.46-6.86 (m, 1H), 4.96 (br d, 0.5 H), 4.41 (dd, 0.5 H), 4.18 (d, 3 H), 3.73-3.85 (m, 0.5 H), 2.76-3.26 (m, 2.5 H)	451.1 [M+H]+	100%
2413	(CD3OD) δ 7.57-7.63 (m, 1H), 7.42-7.53 (m, 1H), 7.02-7.11 (m, 1H), 6.94 (d, 1H), 6.84 (br s, 1H), 6.36-6.71 (m, 1H), 4.84 (br d, 0.5 H), 4.29 (br dd, 0.5 H), 4.06 (d, 3 H), 3.62-3.72 (m, 0.5 H), 2.64-3.12 (m, 2.5 H)	451.1 [M+H]+	98.4%
2414	(CD3OD) δ 8.85-8.98 (m, 1H), 8.77 (d, 1H), 8.30 (d, 1H), 8.08 (t, 1H), 7.63-7.83 (m, 3 H), 7.29-7.53 (m, 1.4 H), 6.79-6.99 (m, 1.6 H), 4.93-5.04 (m, 1H), 3.38-3.86 (m, 1H), 2.95-3.26 (m, 1 H), 2.85 (br d, 1H)	481.2 [M+H]+	100%
2415	(CD3OD) δ 8.84-8.99 (m, 1H), 8.77 (d, 1H), 8.30 (d, 1H), 8.08 (t, 1H), 7.63-7.82 (m, 3 H), 7.31-7.52 (m, 1.4 H), 6.78-6.98 (m, 1.6 H), 4.95-5.06 (m, 1H), 3.42-3.85 (m, 1H), 2.93-3.26 (m, 1 H), 2.85 (br d, 1H)	481.1 [M+H]+	99.8%
2416	(CD3OD) δ 8.87-8.95 (m, 1H), 8.35-8.43 (m, 1H), 8.05-8.13 (m, 1H), 7.67-7.81 (m, 2 H), 7.58 (s, 0.3 H), 7.31-7.38 (m, 1 H), 6.95 (s, 0.7 H), 6.76-6.84 (m, 1H), 5.10 (dd, 1H), 4.00 (s, 3 H), 3.37-3.81 (m, 1H), 2.95-3.21 (m, 1H), 2.78-2.87 (m, 1H)	484.2 [M+H]+	100%
2417	(CD3OD) δ 8.85-8.99 (m, 1H), 8.38 (s, 1H), 8.04-8.14 (m, 1H), 7.63-7.82 (m, 2 H), 7.58 (s, 0.3 H), 7.29-7.39 (m, 1H), 6.94 (s, 0.7 H), 6.74-6.85 (m, 1H), 5.10 (br dd, 1H), 4.00 (s, 3 H), 3.37-3.84 (m, 1 H), 2.93-3.22 (m, 1H), 2.75-2.91 (m, 1H)	484.2 [M+H]+	98.9%
2418	(CD3OD) δ 7.64-8.07 (m, 2 H), 7.20-7.47 (m, 2 H), 6.41-7.09 (m, 2 H), 4.20 (dd, 1H), 3.90 (d, 3 H), 3.62-3.78 (m, 0.5 H), 3.22 (td, 4.5 Hz, 0.5 H), 2.90-3.15 (m, 1H), 2.65-2.89 (m, 1H), 1.92-2.10 (m, 1H), 0.77-1.11 (m, 4 H)	457.2 [M+H]+	95.3%
2419	(CD3OD) δ 7.59-7.99 (m, 2 H), 7.15-7.54 (m, 2 H), 6.44-7.04 (m, 2 H), 4.03-4.29 (m, 1H), 3.89 (d, 3 H), 3.67-3.76 (m, 0.5 H), 3.22 (td, 4.6 Hz, 0.5 H), 2.89-3.13 (m, 1H), 2.60-2.89 (m, 1H), 1.91-2.13 (m, 1H), 0.83-1.03 (m, 4 H)	457.2 [M+H]+	81.0%
2420	(CD3OD) δ 8.86-8.96 (m, 1H), 7.72-7.81 (m, 1H), 7.69 (s, 1H), 7.29-7.45 (m, 1.3 H), 6.68-7.02 (m, 1.7 H), 4.93-5.01 (m, 1H), 3.35-3.80 (m, 1H), 2.94-3.20 (m, 1H), 2.82 (br dd, 1H), 1.84-1.93 (m, 6 H)	464.2 [M+H]+	99.5%
2421	(CD3OD) δ 8.86-8.96 (m, 1H), 7.72-7.81 (m, 1H), 7.69 (s, 1H), 7.31-7.44 (m, 1.3 H), 6.64-7.04 (m, 1.7 H), 4.97 (br dd, 1H), 3.35-3.81 (m, 1H), 2.93-3.20 (m, 1H), 2.82 (br dd, 1H), 1.78-1.97 (m, 6 H)	464.2 [M+H]+	98.2%
2422	(CD3OD) δ 7.86 (br d, 1H), 7.66 (s, 1H), 7.31-7.37 (m, 1H), 7.22-7.30 (m, 1H), 6.84 (br s, 2H), 4.78 (br s, 1H), 4.36 (br s, 1 H), 3.87 (br s, 0.5 H), 3.34-3.52 (m, 0.5 H), 3.05 (br s, 1H), 2.79 (dd, 3.6 Hz, 1H), 2.34 (s, 3 H), 1.56 (br s, 3 H)	461.2 [M+H]+	99.2%
2423	(CD3OD) δ 7.85 (br d, 1H), 7.65 (s, 1H), 7.31-7.40 (m, 1H), 7.22-7.30 (m, 1H), 6.83 (br s, 2 H), 4.68-4.77 (m, 1H), 4.35 (br s, 1H), 3.87 (br s, 0.5 H), 3.48 (br s, 0.5 H), 2.91-3.15 (m, 1H), 2.68-2.87 (m, 1H), 2.34 (s, 3H), 1.56 (br s, 3 H)	461.2 [M+H]+	99.7%
2424	(CD3OD) δ 8.63 (d, 2 H), 8.00 (d, 1H), 7.56-7.67 (m, 2 H), 7.40-7.45 (m, 1H), 7.19 (t, 1H), 7.02-7.09 (m, 2 H), 6.63 (br s, 2H), 4.63 (br s, 1H), 3.48 (br s, 1H), 3.00-3.10 (m, 1H), 2.75 (dd, 1H)	418.1 [M+H]+	96.8%
2425	(CD3OD) δ 8.63 (d, 2 H), 8.00 (d, 1H), 7.55-7.67 (m, 2 H), 7.39-7.47 (m, 1H), 7.18 (t, 1H), 7.02-7.11 (m, 2 H), 6.64 (br s, 2H), 4.64 (br s, 1H), 3.48 (br s, 1H), 3.00-3.10 (m, 1H), 2.75 (dd, 1H)	418.2 [M+H]+	98.7%
2426	(CD3OD) δ 9.02 (s, 1H), 8.36 (s, 2 H), 7.35-7.74 (m, 2.3 H), 7.02-7.18 (m, 1H), 6.65-6.93 (m, 1.7 H), 6.41-6.58 (m, 1H), 4.94 (br dd, 1H), 3.59-3.78 (m, 0.6 H), 3.25-3.40 (m, 0.4 H), 2.83-3.13 (m, 1H), 2.77 (br s, 1 H)	470.1 [M+H]+	100%
2427	(CD3OD) δ 9.14 (s, 1 H), 8.37-8.53 (m, 2 H), 7.54-7.77 (m, 2.3 H), 7.15-7.30 (m, 1 H), 6.80-7.03 (m, 1.7 H), 6.53-6.71 (m, 1 H), 4.92-5.13 (m, 1 H), 3.73-3.86 (m, 0.6 H), 3.38-3.52 (m, 0.4 H), 2.94-3.26 (m, 1 H), 2.86 (br d, 1 H)	470.1 [M+H]+	99.1%
2428	(CD3OD) δ 9.13 (s, 1 H), 8.47 (s, 1 H), 7.80-7.98 (m, 1 H), 7.76 (d, 1 H), 7.57 (s, 0.5 H), 7.22-7.44 (m, 2 H), 6.99 (s, 0.5 H), 6.65-6.92 (m, 1 H), 4.96-5.17 (m, 1 H), 3.92-4.04 (m, 0.5 H), 3.36 (br d, 0.5 H), 2.86-3.26 (m, 2 H)	538.1 [M+H]+	100%
2429	(CD3OD) δ 9.01 (s, 1 H), 8.34 (s, 1 H), 7.68-7.81 (m, 1 H), 7.62 (br d, 1 H), 7.45 (s, 0.5 H), 7.07-7.29 (m, 2 H), 6.87 (s, 0.5 H), 6.51-6.78 (m, 1 H), 4.84-5.07 (m, 1 H), 3.79-3.91 (m, 0.5 H), 3.24 (br d, 0.5 H), 2.70-3.13 (m, 2 H)	538.1 [M+H]+	99.4%
2430	(CD3OD) δ 7.20-7.90 (m, 4.5 H), 6.52-7.03 (m, 1.5 H), 4.92-5.05 (m, 1 H), 3.78-3.98 (m, 1.5 H), 2.80-3.28 (m, 2.5 H), 2.39-2.61 (m, 4 H), 1.98-2.29 (m, 2 H)	458.1 [M+H]+	100%
2431	(CD3OD) δ 7.21-7.88 (m, 4.5 H), 6.56-7.03 (m, 1.5 H), 4.92-5.04 (m, 1 H), 3.72-3.99 (m, 1.5 H), 2.80-3.25 (m, 2.5 H), 2.40-2.57 (m, 4 H), 1.96-2.27 (m, 2 H)	458.2 [M+H]+	94.4%
2432	(CD3OD) δ 8.33 (d, 1 H), 7.66 (s, 1 H), 6.95 (dd, 1 H), 6.82 (td, 1 H), 6.64 (s, 1 H), 6.25 (s, 1 H), 4.19 (dd, 1 H), 3.67 (ddd, 1 H), 2.96-3.08 (m, 1 H), 2.78 (br dd, 1 H), 1.99-2.11 (m, 1 H), 0.98-1.16 (m, 4 H)	366.2 [M+H]+	98.2%
2433	(CD3OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.93-7.03 (m, 1 H), 6.82 (td, 1 H), 6.64 (s, 1H), 6.25 (s, 1 H), 4.19 (dd, 1 H), 3.67 (ddd, 1 H), 2.90-3.08 (m, 1 H), 2.78 (dd, 1 H), 1.97-2.16 (m, 1 H), 0.89-1.18 (m, 4 H)	366.2 [M+H]+	98.8%
2434	(CD3OD) δ 8.25-8.90 (m, 3 H), 8.08 (s, 1 H), 7.87-8.01 (m, 2 H), 7.57-7.78 (m, 2 H), 6.48-7.07 (m, 4 H), 4.93-5.08 (m, 1 H), 3.95 (s, 3 H), 3.41-3.84 (m, 1 H), 2.72-3.15 (m, 2 H)	482.2 [M+H]+	97.7%
2435	(CD3OD) δ 8.26-8.89 (m, 3 H), 7.80-8.13 (m, 3 H), 7.55-7.76 (m, 2 H), 6.54-7.03 (m, 4 H), 4.92-5.07 (m, 1 H), 3.82-4.08 (m, 3 H), 3.40-3.81 (m, 1 H), 2.72-3.13 (m, 2 H)	482.2 [M+H]+	98.3%
2436	(CD3OD) δ 8.62 (s, 1.6 H), 8.17-8.52 (m, 1.4 H), 7.92 (s, 1 H), 7.69 (s, 1 H), 7.44 (d, 1 H), 7.01 (br d, 1 H), 6.81 (br t, 1 H), 6.45-6.65 (m, 1 H), 6.43-7.20 (m, 1 H), 4.63 (br s, 1 H), 4.54 (s, 2 H), 3.52-3.93 (m, 1 H), 3.44 (s, 3 H), 3.00-3.15 (m, 1 H), 2.72-2.85 (m, 1 H), 2.46 (s, 3 H)	444.2 [M+H]+	100%
2437	(CD3OD) δ 8.22-8.88 (m, 3 H), 7.97 (d, 1 H), 7.76 (br d, 1 H), 7.44 (dd, 1 H), 6.35-7.08 (m, 4 H), 4.58-4.75 (m, 1 H), 4.49-4.57 (m, 2 H), 3.50-3.89 (m, 1 H), 3.44 (s, 3 H), 3.00-3.17 (m, 1 H), 2.71-2.86 (m, 1 H), 2.46 (s, 3 H)	442.2 [M+H]+	90.1%
2438	(CD3OD) δ 8.88 (s, 2 H), 8.11 (s, 1 H), 7.85-8.04 (m, 3 H), 7.59-7.77 (m, 2 H), 7.21-7.53 (m, 2 H), 6.30-7.08 (m, 2 H), 4.65-4.80 (m, 1 H), 3.97 (s, 3 H), 3.37-3.51 (m, 1 H), 3.03-3.16 (m, 1 H), 2.78 (br dd, 1 H)	532.2 [M+H]+	100%
2439	(CD3OD) δ 8.88 (s, 2 H), 8.12 (s, 1 H), 7.85-8.03 (m, 3 H), 7.61-7.75 (m, 2 H), 7.28-7.52 (m, 2 H), 6.39-7.11 (m, 2 H), 4.66-4.78 (m, 1 H), 3.97 (s, 3 H), 3.36-3.52 (m, 1 H), 3.04-3.16 (m, 1 H), 2.78 (br dd, 1 H)	532.2 [M+H]+	99.6%
2440	(CD3OD) δ 8.68 (d, 1 H), 8.13 (d, 1 H), 8.01 (td, 1 H), 7.84 (d, 1 H), 7.69 (s, 1 H), 7.55 (ddd, 1 H), 7.17-7.37 (m, 2 H), 6.80 (s, 1 H), 6.55 (s, 1 H), 4.45 (dd, 1 H), 3.74-3.94 (m, 1 H), 3.00-3.16 (m, 1 H), 2.86 (dd, 1 H)	453.1 [M+H]+	100%
2441	(CD3OD) δ 8.67 (d, 1 H), 8.12 (d, 1 H), 8.00 (td, 1 H), 7.83 (d, 1 H), 7.67 (s, 1 H), 7.54 (ddd, 1 H), 7.12-7.34 (m, 2 H), 6.78 (s, 1 H), 6.53 (s, 1 H), 4.44 (dd, 1 H), 3.66-3.94 (m, 1 H), 2.96-3.22 (m, 1 H), 2.85 (dd, 1 H)	453.1 [M+H]+	98.3%
2442	(CD3OD) δ 8.29 (d, 1 H), 7.67 (s, 1 H), 6.96 (d, 1 H), 6.77 (t, 1 H), 6.54 (s, 1 H), 6.30 (s, 1 H), 4.21 (dd, 1 H), 3.59-3.85 (m, 1 H), 2.95-3.14 (m, 1 H), 2.78 (dd, 1 H), 2.42 (d, 3 H), 2.40 (d, 3 H)	336.2 [M+H]+	100%
2443	(CD3OD) δ 8.31 (br d, 1 H), 7.67 (s, 1 H), 7.00 (d, 1 H), 6.80 (t, 1 H), 6.54 (s, 1 H), 6.30 (s, 1 H), 4.22 (dd, 1 H), 3.70 (ddd, 1 H), 2.96-3.12 (m, 1 H), 2.79 (br dd, 1 H), 2.75 (s, 3 H), 2.43 (s, 3 H)	336.2 [M+H]+	99.7%
2444	(CD3OD) δ 8.22-8.57 (m, 2 H), 8.12 (s, 0.8 H), 7.47-7.84 (m, 1 H), 7.18-7.29 (m, 0.2 H), 6.91-7.15 (m, 2 H), 6.66-6.91 (m, 2 H), 5.10 (br dd, 1 H), 4.02 (s, 3 H), 3.68-3.87 (m, 0.6 H), 3.36-3.48 (m, 0.4 H), 2.94-3.25 (m, 1 H), 2.77-2.92 (m, 1 H)	482.2 [M+H]+	100%
2445	(CD3OD) δ 8.24-8.57 (m, 2 H), 8.12 (s, 0.8 H), 7.56-7.78 (m, 1 H), 7.17-7.30 (m, 0.2 H), 6.91-7.14 (m, 2 H), 6.66-6.90 (m, 2 H), 5.10 (dd, 1 H), 4.02 (s, 3 H), 3.67-3.89 (m, 0.6 H), 3.37-3.48 (m, 0.4 H), 2.95-3.27 (m, 1 H), 2.75-2.95 (m, 1 H)	482.1 [M+H]+	98.6%
2446	(CD3OD) δ 8.90-8.96 (m, 1 H), 8.37 (s, 1 H), 8.03-8.11 (m, 1 H), 7.82 (s, 0.2 H), 7.69 (d, 1.5 H), 7.51-7.57 (m, 0.5 H), 6.77-6.96 (m, 1.8 H), 6.57-6.69 (m, 2 H), 5.06 (br dd, 1 H), 3.94-3.98 (m, 3 H), 3.78 (br s, 0.6 H), 3.37-3.50 (m, 0.4 H), 2.84-3.21 (m, 2 H)	482.2 [M+H]+	97.1%
2447	(CD3OD) δ 8.94 (s, 1 H), 8.37 (s, 1 H), 8.00-8.14 (m, 1 H), 7.82 (s, 0.2 H), 7.65-7.73 (m, 1.5 H), 7.54 (br d, 0.5 H), 6.76-6.99 (m, 1.8 H), 6.57-6.72 (m, 2 H), 5.06 (br dd, 1 H), 3.93-3.99 (m, 3 H), 3.77 (br d, 0.6 H), 3.35-3.50 (m, 0.4 H), 2.85-3.16 (m, 2 H)	482.1 [M+H]+	99.0%
2448	(CD3OD) δ 9.31-9.40 (m, 1 H), 8.68-8.79 (m, 2 H), 8.16-8.32 (m, 1 H), 7.06-7.67 (m, 1.5 H), 6.61-6.96 (m, 4.5 H), 4.83-4.97 (m, 1 H), 3.69 (ddd, 0.7 H), 3.34 (td, 0.3 H), 2.86-3.15 (m, 1 H), 2.69-2.81 (m, 1 H)	480.1 [M+H]+	96.6%
2449	(CD3OD) δ 9.31-9.40 (m, 1 H), 8.68-8.79 (m, 2 H), 8.16-8.31 (m, 1 H), 7.08-7.65 (m, 1.5 H), 6.61-6.96 (m, 4.5 H), 4.83-4.98 (m, 1 H), 3.69 (ddd, 0.7 H), 3.34 (td, 0.3 H), 2.87-3.16 (m, 1 H), 2.75 (br d, 1 H)	480.2 [M+H]+	94.9%
2450	(DMSO-d6) δ 11.99 (br s, 1 H), 8.21-8.74 (m, 3 H), 7.85 (d, 1 H), 7.55 (s, 1 H), 7.24 (dd, 1 H), 6.33-7.07 (m, 4 H), 4.34-4.66 (m, 1 H), 3.84 (s, 3 H), 3.25-3.31 (m, 1 H), 2.85-3.06 (m, 1 H), 2.67 (br s, 1 H), 2.40 (s, 3 H)	428.1 [M+H]+	100%
2451	(DMSO-d6) δ 11.88-12.17 (m, 1 H), 8.20-8.87 (m, 3 H), 7.85 (d, 1 H), 7.55 (s, 1 H), 7.17-7.33 (m, 1 H), 6.37-7.09 (m, 4 H), 4.34-4.69 (m, 1 H), 3.84 (s, 3 H), 3.33 (br s, 1 H), 2.86-3.05 (m, 1 H), 2.63-2.73 (m, 1 H), 2.34-2.44 (m, 3 H)	428.2 [M+H]+	100%
2452	(CD3OD) δ 9.31 (s, 2 H), 8.67 (d, 1 H), 7.84-8.15 (m, 5 H), 7.65 (s, 1 H), 7.25-7.51 (m, 3 H), 6.66 (br s, 2 H), 4.66 (br s, 1 H), 3.36-3.64 (m, 1 H), 3.08 (br s, 1 H), 2.77 (dd, 1 H)	529.2 [M+H]+	100%
2453	(CD3OD) δ 9.31 (s, 2 H), 8.67 (d, 1 H), 7.87-8.12 (m, 5 H), 7.65 (s, 1 H), 7.15-7.52 (m, 3 H), 6.68 (br s, 2 H), 4.67 (br s, 1 H), 3.48 (br s, 1 H), 2.98-3.20 (m, 1 H), 2.77 (dd, 1 H)	529.2 [M+H]+	100%
2454	(CD3OD) δ 8.39 (d, 2 H), 7.48-7.70 (m, 2 H), 7.07-7.25 (m, 2 H), 6.99 (d, 1 H), 6.56-6.72 (m, 2 H), 5.06 (br dd, 1 H), 3.50-3.65 (m, 1 H), 2.82-2.98 (m, 1 H), 2.70 (dd, 1 H)	352.1 [M+H]+	100%
2455	(CD3OD) δ 8.27 (d, 2 H), 7.36-7.56 (m, 2 H), 6.95-7.16 (m, 2 H), 6.86 (d, 1 H), 6.46-6.62 (m, 2 H). 4.93-4.98 (m, 1 H), 3.38-3.50 (m, 1 H), 2.70-2.86 (m, 1 H), 2.58 (dd, 1 H)	352.1 [M+H]+	99.2%
2456	(CD3OD) δ 8.33 (d, 1 H), 7.56 (s, 1 H), 7.19 (d, 1 H), 6.74 (t, 1 H), 6.55 (s, 1 H), 6.18 (s, 1 H), 4.12 (dd, 1 H), 3.58 (ddd, 1 H), 2.84-3.00 (m, 1 H), 2.61-2.76 (m, 1 H), 2.33 (s, 3 H)	356.1 [M+H]+	100%
2457	(CD3OD) δ 8.33 (d, 1 H), 7.56 (s, 1 H), 7.19 (d, 1 H), 6.74 (t, 1 H), 6.55 (s, 1 H), 6.19 (s, 1 H), 4.12 (dd, 1 H), 3.58 (ddd, 1 H), 2.86-2.98 (m, 1 H), 2.67 (br dd, 1 H), 2.33 (s, 3 H)	356.1 [M+H]+	93.9%
2458	(CD3OD) δ 9.05-9.25 (m, 1 H), 8.48 (s, 1 H), 8.29-8.42 (m, 1 H), 7.71 (s, 1 H), 7.56 (s, 0.3 H), 7.17-7.28 (m, 0.3 H), 6.94-7.08 (m, 2.2 H), 6.81-6.91 (m, 1.2 H), 6.69-6.79 (m, 1 H), 5.08 (dd, 0.7 H), 4.95 (br d, 0.3 H), 3.72-3.88 (m, 0.7 H), 3.43 (td, 0.3 H), 3.12-3.26 (m, 0.7 H), 2.95-3.08 (m, 0.3 H), 2.78-2.92 (m, 1 H)	536.1 [M+H]+	100%
2459	(CD3OD) δ 9.05-9.26 (m, 1 H), 8.48 (s, 1 H), 8.29-8.42 (m, 1 H), 7.72 (s, 1 H), 7.56 (s, 0.3 H), 7.18-7.26 (m, 0.3 H), 6.94-7.08 (m, 2.2 H), 6.81-6.92 (m, 1.2 H), 6.69-6.79 (m, 1 H), 5.08 (dd, 0.7 H), 4.95 (br d, 0.3 H), 3.71-3.86 (m, 0.7 H), 3.43 (td, 0.3 H), 3.13-3.26 (m, 0.7 H), 2.96-3.09 (m, 0.3 H), 2.79-2.92 (m, 1 H)	536.2 [M+H]+	99.9%
2460	(CD3OD) δ 8.45 (d, 1 H), 7.43-7.85 (m, 2 H), 7.15-7.28 (m, 1 H), 6.78-7.13 (m, 2 H), 6.58 (s, 1 H), 6.38 (s, 1 H), 4.32 (dd, 1 H), 3.77 (ddd, 1 H), 2.97-3.18 (m, 1 H), 2.83 (br dd, 1 H)	358.1 [M+H]+	99.3%
2461	(CD3OD) δ 8.44 (d, 1 H), 7.44-7.84 (m, 2 H), 7.20 (dd. 1 H), 6.78-7.13 (m, 2 H), 6.57 (s, 1 H), 6.37 (s, 1 H), 4.31 (dd, 1 H), 3.76 (ddd, 1 H), 2.95-3.16 (m, 1 H), 2.82 (br dd. 1 H)	358.2 [M+H]+	99.4%
2462	(CD3OD) δ 8.07-9.10 (m, 2 H), 7.85 (d, 1 H), 7.75 (d. 1 H), 7.40-7.66 (m, 2 H), 7.27-7.35 (m, 1 H), 7.16-7.23 (m, 2 H), 6.62 (br s, 2 H), 4.61-4.73 (m, 1 H), 3.36-3.98 (m, 1 H), 2.98-3.10 (m, 1 H), 2.75 (dd, 1 H), 1.96-2.05 (m, 1 H), 0.98-1.06 (m, 2 H), 0.74-0.80 (m, 2 H)	474.2 [M+H]+	100%
2463	(CD3OD) δ 8.41 (s, 2 H), 7.85 (d, 1 H), 7.74 (d, 1 H), 7.43-7.68 (m, 2 H), 7.26-7.34 (m, 1 H), 7.16-7.24 (m, 2 H), 6.62 (br s, 2 H), 4.60-4.72 (m, 1 H), 3.32-3.77 (m, 1 H), 2.99-3.10 (m, 1 H), 2.75 (dd, 1 H), 1.97-2.04 (m, 1 H), 0.99-1.05 (m, 2 H), 0.74-0.80 (m, 2 H)	474.2 [M+H]+	99.4%
2464	(DMSO-d6) δ 12.02 (br s, 1 H), 8.50 (d, 2 H), 7.88 (d, 1 H), 7.69 (br d, 1 H), 7.56 (s, 1 H), 7.07-7.33 (m. 3 H), 6.70 (br d, 2 H), 4.33-4.72 (m, 1 H), 3.84 (s, 4 H), 2.93 (br d, 1 H), 2.56-2.75 (m, 1 H)	448.1 [M+H]+	99.8%
2465	(DMSO-d6) δ 12.02 (br s, 1 H), 8.51 (s. 2 H), 7.88 (d, 1 H), 7.69 (br d, 1 H), 7.56 (s, 1 H), 7.09-7.36 (m, 3 H), 6.33-6.93 (m, 2 H), 4.50 (br d, 1 H), 3.84 (s, 4 H), 2.95 (br s, 1 H), 2.57-2.78 (m, 1 H)	448.1 [M+H]+	99.5%
2466	(CD3OD) δ 8.59 (d, 1 H), 7.68 (s, 1 H), 7.35-7.50 (m, 1 H), 6.81-7.15 (m, 2 H), 6.71 (s, 1 H), 6.33 (s, 1 H), 4.24 (dd, 1 H), 3.69 (ddd, 1 H), 2.98-3.11 (m, 1 H), 2.79 (dd, 1 H), 2.45 (s, 3 H)	372.2 [M+H]+	99.6%
2467	(CD3OD) δ 8.47 (d, 1 H), 7.58 (s, 1 H), 7.32 (d, 1 H), 6.70-7.05 (m, 2 H), 6.60 (s, 1 H), 6.21 (s, 1 H), 4.12 (dd, 1 H), 3.49-3.65 (m, 1 H), 2.85-3.00 (m, 1 H), 2.62-2.74 (m, 1 H), 2.33 (s, 3 H)	372.1 [M+H]+	98.4%
2468	(CD3OD) δ 9.05 (d, 2 H), 8.43-8.56 (m, 1 H), 7.69-7.75 (m, 2 H), 7.47 (br s, 0.3 H), 7.18-7.26 (m, 1 H), 6.79-7.01 (m, 2.7 H), 5.00 (td, 1 H), 3.78-3.85 (m, 0.6 H), 3.46 (td, 0.4 H), 2.86-3.26 (m, 2 H)	498.1 [M+H]+	100%
2469	(CD3OD) δ 9.05 (d, 2 H), 8.42-8.53 (m, 1 H), 7.69-7.75 (m, 2 H), 7.47 (s, 0.3 H). 7.18-7.26 (m, 1 H), 6.80-7.01 (m, 2.7 H), 5.00 (td, 1 H), 3.82 (ddd, 0.6 H), 3.46 (td, 0.4 H), 2.85-3.26 (m, 2 H)	498.1 [M+H]+	100%
2470	(CD3OD) δ 7.99-8.70 (m, 3 H), 7.76 (d, 1 H), 7.54 (s, 1 H), 7.20 (d, 1 H), 6.34-6.87 (m, 4 H), 4.44-4.59 (m, 1 H), 3.84 (s, 3 H), 3.27-3.59 (m, 1 H), 2.62-3.00 (m, 2 H), 2.27 (s, 3 H)	428.2 [M+H]+	100%
2471	(CD3OD) δ 7.89-8.57 (m, 3 H), 7.74 (br d, 1 H), 7.54 (br s, 1 H), 7.17 (br d, 1 H), 6.29-6.79 (m, 4 H), 4.45-4.60 (m, 1 H), 3.82 (s, 3 H), 3.24-3.59 (m, 1 H), 2.60-3.01 (m, 2 H), 2.25 (br s, 3 H)	428.2 [M+H]+	100%
2472	(CD3OD) δ 8.21-9.59 (m, 1 H), 7.79-7.95 (m, 3 H), 7.63 (s, 1 H), 7.24-7.45 (m, 3 H), 6.67 (br s, 2 H), 4.64 (br d, 1 H), 3.48 (br s, 1 H), 3.00-3.11 (m, 1 H), 2.95 (s, 6 H), 2.75 (dd, 1 H)	495.2 [M+H]+	99.7%
2473	(CD3OD) δ 8.91 (br s, 1 H), 7.75-8.01 (m, 3 H), 7.64 (s, 1 H), 7.21-7.46 (m, 3 H), 6.47-6.98 (m, 2 H), 4.64 (br d, 1 H), 3.38-3.82 (m, 1 H), 2.99-3.11 (m, 1 H), 2.95 (s, 6 H), 2.75 (dd. 1 H)	495.2 [M+H]+	99.1%
2474	(CD3OD) δ 8.26-9.27 (m, 1 H), 7.80-7.96 (m, 2 H), 7.55-7.69 (m, 2 H), 7.36 (dd, 1 H), 7.18 (dd, 1 H), 7.05 (d, 1 H), 6.50-6.96 (m, 2 H), 4.64 (br s, 1 H), 3.42-3.97 (m, 1 H), 3.00-3.15 (m, 1 H), 2.94 (s, 6 H), 2.75 (dd, 1 H)	461.2 [M+H]+	99.5%
2475	(CD3OD) δ 8.11-9.10 (m, 1 H), 7.77-7.94 (m, 2 H), 7.53-7.70 (m, 2 H), 7.37 (dd, 1 H), 7.11-7.24 (m, 1 H), 7.06 (br d, 1 H), 6.47-6.92 (m, 2 H), 4.64 (br s, 1 H), 3.48 (br s, 1 H), 2.99-3.17 (m, 1 H), 2.95 (s, 6 H), 2.75 (br dd, 1 H)	461.2 [M+H]+	99.5%
2476	(CD3OD) δ 8.77 (br s, 1 H), 8.54 (s, 2 H), 7.91 (d, 1 H), 7.59-7.72 (m, 2 H), 7.39 (d, 1 H), 6.44-7.13 (m, 3 H), 4.59 (br s, 1 H), 3.48 (br s, 1 H), 3.03-3.12 (m, 1 H), 2.85-2.91 (m, 2 H), 2.78 (br d, 1 H), 2.63-2.70 (m, 2 H), 2.34 (s, 6 H)	523.2 [M+H]+	97.7%
2477	(CD3OD) δ 8.78 (br s, 1 H), 8.54 (s, 2 H), 7.91 (d, 1 H), 7.56-7.73 (m, 2 H), 7.39 (d, 1 H), 6.41-7.16 (m, 3 H), 4.59 (br s, 1 H), 3.38-3.76 (m, 1 H), 3.02-3.12 (m, 1 H), 2.84-2.90 (m, 2 H). 2.74-2.81 (m, 1 H), 2.62-2.69 (m, 2 H), 2.33 (s, 6 H)	523.3 [M+H]+	98.2%
2478	(CD3OD) δ 8.27-8.76 (m, 3 H), 7.84 (s, 1 H), 7.67 (s, 1 H), 7.42 (dd, 1 H), 6.99-7.06 (m, 1 H), 6.48-6.90 (m, 3 H). 4.96 (br s, 1 H), 3.69 (t, 2 H), 3.34-3.42 (m, 4 H), 3.02-3.14 (m, 1 H), 2.95 (t, 2 H), 2.73-2.84 (m, 1 H), 2.42-2.50 (m, 3 H)	456.2 [M+H]+	100%
2479	(CD3OD) δ 8.30 (s, 3 H), 7.85-7.95 (m, 1 H), 7.60-7.73 (m, 1 H), 7.42 (dd, 1 H), 6.97-7.06 (m, 1 H), 6.46-6.91 (m, 3 H), 4.94-5.08 (m, 1 H), 3.69 (t, 2 H), 3.37 (s, 4 H). 3.02-3.13 (m, 1 H). 2.89-2.99 (m, 2 H), 2.70-2.83 (m, 1 H), 2.50 (s, 3 H)	456.2 [M+H]+	91.8%
2480	(CD3OD) δ 8.30 (d, 1 H), 7.67 (s, 1 H), 6.98 (d, 1 H), 6.78 (t, 1 H), 6.54 (s, 1 H), 6.31 (s, 1 H), 4.23 (dd, 1 H), 3.61-3.78 (m, 2 H), 2.98-3.12 (m, 1 H), 2.80 (br dd, 1 H), 2.33-2.52 (m, 7 H), 1.98-2.22 (m. 2 H)	376.2 [M+H]+	99.8%
2481	(CD3OD) δ 8.30 (br d, 1 H), 7.69 (s, 1 H), 6.98 (br d, 1 H), 6.78 (t, 1 H), 6.54 (s, 1 H), 6.31 (s, 1 H), 4.23 (dd, 1 H), 3.61-3.77 (m, 2 H), 2.97-3.10 (m, 1 H), 2.80 (br dd, 1 H), 2.38-2.46 (m, 7 H), 2.00-2.18 (m, 2 H)	376.2 [M+H]+	99.8%
2482	(CD3OD) δ 8.57 (d, 1 H), 7.46-7.69 (m, 2 H), 6.88 (t, 1 H), 6.61 (s, 1 H), 6.22 (s, 1 H), 4.15 (dd, 1 H), 3.51-3.67 (m, 2 H), 2.87-3.00 (m, 1 H), 2.70 (dd, 1 H), 2.23-2.35 (m. 4 H), 1.86-2.09 (m. 2H)	430.2 [M+H]+	100%
2483	(CD3OD) δ 8.57 (d, 1 H), 7.47-7.59 (m, 2 H), 6.83-6.92 (m, 1 H), 6.61 (s, 1 H), 6.22 (s, 1 H), 4.15 (dd, 1 H), 3.50-3.63 (m, 2 H), 2.87-2.96 (m, 1 H), 2.66-2.73 (m, 1 H), 2.25-2.35 (m, 4 H), 1.88-2.05 (m, 2 H)	430.1 [M+H]+	100%
2484	(CD3OD) δ 8.46 (d, 1 H), 7.56 (s, 1 H), 7.32 (d, 1 H), 6.69-7.02 (m, 2 H), 6.16-6.64 (m, 2 H), 4.13 (dd, 1 H), 3.45-3.66 (m, 2 H), 2.85-2.98 (m, 1 H), 2.70 (dd, 1 H), 2.22-2.37 (m, 4 H), 1.85-2.08 (m, 2 H)	412.1 [M+H]+	99.9%
2485	(CD3OD) δ 8.49 (br d, 1 H), 7.59 (s, 1 H), 7.35 (br d, 1 H), 6.74-7.04 (m, 2 H), 6.64 (s, 1 H), 6.24 (s, 1 H), 4.16 (dd, 1 H), 3.50-3.71 (m, 2 H), 2.89-3.01 (m, 1 H), 2.73 (br dd, 1 H), 2.24-2.40 (m, 4 H), 1.92-2.11 (m, 2 H)	412.2 [M+H]+	99.6%
2486	(CD3OD) δ 7.67-7.79 (m, 2 H), 7.15-7.51 (m, 3 H), 6.69 (s, 1 H), 6.41 (s, 1 H), 4.37 (dd, 1 H), 3.73-3.87 (m, 1 H), 3.01-3.14 (m, 1 H), 2.86 (dd, 1 H)	426.1 [M+H]+	100%
2487	(CD3OD) δ 7.64-7.80 (m, 2 H), 7.15-7.51 (m, 3 H), 6.69 (s, 1 H), 6.41 (s, 1 H), 4.37 (dd, 1 H), 3.74-3.87 (m, 1 H), 3.02-3.14 (m, 1 H), 2.86 (dd, 1 H)	426.1 [M+H]+	99.0%
2488	(CD3OD) δ 8.58-8.75 (m, 1 H), 8.39 (s. 1 H), 8.10 (s, 1 H). 7.45-7.75 (m, 2.4 H), 7.17-7.37 (m, 1 H), 6.92 (s, 0.6 H), 6.55-6.75 (m, 1 H), 5.09 (br d, 1 H), 4.00 (s, 3 H), 3.68-3.83 (m, 0.7 H), 3.34-3.44 (m, 0.3 H), 3.07-3.23 (m, 1 H), 2.71-2.91 (m, 1 H)	494.1 [M+H]+	100%
2489	(CD3OD) δ 8.59-8.75 (m, 1 H), 8.40 (s, 1 H), 8.10 (s, 1 H), 7.70 (s, 1 H), 7.47-7.62 (m, 1.4 H), 7.23-7.39 (m, 1 H), 6.93 (s, 0.6 H), 6.57-6.75 (m, 1 H), 5.08 (dd, 1 H), 4.02 (s, 3 H), 3.71-3.86 (m, 0.7 H), 3.33-3.46 (m, 0.3 H), 2.93-3.24 (m, 1 H), 2.58-2.89 (m, 1 H)	494.1 [M+H]+	99.4%
2490	(CD3OD) δ 7.86 (d, 1 H), 7.73 (s, 1 H), 7.25-7.40 (m, 2 H), 6.74 (s, 1 H), 6.40 (s, 1 H), 4.37 (dd, 1 H), 3.73 (td, 1 H), 3.02-3.14 (m, 1 H), 2.86 (dd, 1 H)	444.1 [M+H]+	100%
2491	(CD3OD) δ 7.86 (d, 1 H), 7.71 (s, 1 H), 7.22-7.42 (m, 2 H), 6.73 (s, 1 H), 6.40 (s, 1 H), 4.37 (dd, 1 H), 3.65-3.79 (m, 1 H), 3.00-3.13 (m, 1 H), 2.86 (dd, 1 H)	444.1 [M+H]+	98.2%
2492	(CD3OD) δ 7.69 (s, 1 H), 7.62 (dd, 1 H), 7.20 (dd, 1 H), 7.06 (dd, 1 H), 6.71 (s, 1 H), 6.42 (s, 1 H), 4.37 (dd, 1 H), 3.83 (ddd, 1 H), 3.00-3.16 (m, 1 H), 2.86 (dd, 1 H)	410.1 [M+H]+	95.7%
2493	(CD3OD) δ 7.57 (s, 1 H), 7.50 (dd, 1 H), 7.08 (dd, 1 H), 6.94 (dd, 1 H), 6.59 (s, 1 H), 6.30 (s, 1 H), 4.25 (dd, 1 H), 3.71 (ddd, 1 H), 2.89-3.04 (m, 1 H), 2.74 (dd, 1 H)	410.1 [M+H]+	84.1%
2494	(CD3OD) δ 8.20-8.33 (m, 1 H), 7.70 (s, 1 H), 7.49 (br s, 0.3 H), 6.96 (s, 0.7 H), 6.70-6.85 (m, 3 H), 4.93-5.01 (m, 1 H), 3.77 (ddd, 0.7 H), 3.41 (td, 0.3 H), 2.93-3.21 (m, 1 H), 2.77-2.89 (m, 1 H), 2.60-2.70 (m, 3 H), 1.90-2.32 (m, 1 H), 0.96-1.10 (m, 2 H), 0.69-0.85 (m, 2 H)	390.2 [M+H]+	100%
2495	(CD3OD) δ 8.21-8.33 (m, 1 H), 7.70 (s, 1 H), 7.45-7.53 (m, 0.3 H), 6.96 (s, 0.7 H), 6.69-6.86 (m, 3 H), 4.98 (br d, 1 H), 3.77 (ddd, 0.6 H), 3.39-3.46 (m, 0.4 H), 2.93-3.21 (m, 1 H), 2.79-2.90 (m, 1 H), 2.63-2.68 (m, 3 H), 2.04-2.17 (m, 1 H), 0.99-1.13 (m, 2 H), 0.75-0.87 (m, 2 H)	390.2 [M+H]+	100%
2496	(CD3OD) δ 8.32-8.71 (m, 1 H), 7.49-8.01 (m, 3 H), 7.13-7.29 (m, 1 H), 6.37-6.98 (m, 3 H), 4.68-4.79 (m, 0.5 H), 4.38-4.57 (m, 0.5 H), 3.62-3.84 (m, 0.5 H), 2.93-3.14 (m, 1 H), 2.64-2.92 (m, 1 H), 2.20 (br d, 1 H), 0.92-1.40 (m, 4.5 H)	375.2 [M+H]+	100%
2497	(CD3OD) δ 8.35-8.60 (m, 1 H), 7.49-8.04 (m, 3 H), 7.13-7.30 (m, 1 H), 6.36-7.03 (m, 3 H), 4.70-4.80 (m, 0.5 H), 4.37-4.56 (m, 0.5 H), 3.62-3.89 (m, 0.5 H), 2.93-3.15 (m, 1 H), 2.65-2.92 (m, 1 H), 2.21 (br d, 1 H), 0.94-1.39 (m, 4.5 H)	375.2 [M+H]+	99.3%
2498	(CD3OD) δ 8.33 (br s, 1 H), 7.79-8.17 (m, 1 H), 7.74 (s, 1 H), 7.67 (s, 1 H), 6.96-7.05 (m, 1 H), 6.83-6.96 (m, 2 H), 6.79 (br t, 1 H), 6.65 (br s, 1 H), 4.80-4.82 (m, 1 H), 3.92-4.12 (m, 3 H), 3.71-3.86 (m, 0.5 H), 3.45-3.54 (m, 0.5 H), 3.01-3.21 (m, 1 H), 2.72-2.92 (m, 1 H), 2.45 (s, 3 H)	429.2 [M+H]+	100%
2499	(CD30D) δ 8.24-8.43 (m, 1 H), 7.79-8.16 (m, 1 H), 7.61-7.78 (m, 2 H), 6.99 (br d, 1 H), 6.85-6.95 (m, 2 H), 6.73-6.82 (m, 1 H), 6.51-6.68 (m, 1 H), 4.77 (br dd, 1 H), 4.00 (s, 3 H), 3.66-3.88 (m, 0.6 H), 3.34-3.61 (m, 0.5 H), 2.97-3.20 (m, 0.5 H), 2.71-2.91 (m, 1 H), 2.45 (s, 3 H)	429.2 [M+H]+	100%
2500	(500 MHz, CD3OD) δ 8.15-8.36 (m, 1 H), 7.54-7.78 (m, 1.5 H), 6.86-7.06 (m, 1.5 H), 6.70-6.85 (m, 1 H), 6.37-0.66 (m, 1 H), 5.09 (dd, 1 H), 3.63-3.79 (m, 0.5 H), 3.34-3.47 (m, 0.5 H), 2.91-3.20 (m, 1 H), 2.73-2.85 (m, 4 H), 2.35-2.49 (m, 3 H)	380.2 [M+H]+	100%
2501	(500 MHz, CD3OD) δ 8.12-8.41 (m, 1 H), 7.68 (d, 1.5 H), 6.88-7.07 (m, 1.5 H), 6.69-6.81 (m, 1 H), 6.47-6.64 (m, 1 H), 5.09 (dd, 1 H), 3.61-3.78 (m, 0.5 H), 3.32-3.47 (m, 0.5 H), 2.90-3.21 (m, 1 H), 2.73-2.87 (m, 4 H), 2.34-2.45 (m, 3 H)	380.1 [M+H]+	99.4%
2502	(CD3OD) δ 8.18-8.40 (m, 1.4 H), 8.01-8.17 (m, 2 H), 7.69 (s, 1 H), 7.44-7.64 (m, 2 H), 6.90-7.06 (m, 1.6 H), 6.70-6.84 (m, 1 H), 6.48-6.67 (m, 1 H), 5.49 (dd, 0.5 H), 4.90 (br s, 0.5 H), 3.61-3.86 (m, 0.7 H), 3.44 (td, 0.3 H), 2.98-3.25 (m, 1 H), 2.74-2.88 (m, 1 H), 2.29-2.51 (m, 3 H)	415.1 [M+H]+	100%
2503	(CD3OD) δ 8.21-8.40 (m, 1.4 H), 8.07-8.19 (m, 2 H), 7.71 (s, 1 H), 7.51-7.66 (m, 2 H), 6.94-7.06 (m, 1.6 H). 6.72-6.85 (m, 1 H), 6.49-6.69 (m, 1 H), 5.44-5.60 (m, 0.5 H), 4.93-4.98 (m, 0.5 H), 3.67-3.86 (m, 0.7 H), 3.41-3.55 (m, 0.3 H), 3.12 (s, 1 H), 2.76-2.91 (m, 1 H), 2.35-2.53 (m, 3 H)	415.2 [M+H]+	99.6%
2504	(CD3OD) δ 8.17-8.39 (m, 1 H), 7.71-8.05 (m, 1 H), 7.48-7.69 (m, 2 H), 6.52-6.99 (m, 5 H), 4.82-4.97 (m, 1 H), 3.83-4.06 (m, 3 H), 3.56-3.78 (m, 0.6 H), 3.34-3.49 (m, 0.4 H), 2.86-3.12 (m, 1 H), 2.59-2.82 (m, 1 H)	433.2 [M+H]+	100%
2505	(CD3OD) δ 8.28-8.53 (m, 1 H), 7.84-8.15 (m, 1 H), 7.61-7.82 (m, 2 H), 6.69-7.10 (m, 5 H), 4.95-5.05 (m, 1 H), 4.02 (s, 3 H), 3.70-3.91 (m, 0.5 H), 3.45-3.59 (m, 0.5 H), 3.00-3.24 (m, 1 H), 2.73-2.94 (m, 1 H)	433.2 [M+H]+	96.1%
2506	(CD3OD) δ 8.73 (br s, 1 H), 8.29 (br s, 1 H), 7.78-8.13 (m, 2 H), 7.58-7.77 (m, 2 H), 6.63-7.12 (m, 3 H), 4.51-4.84 (m, 1 H), 3.99 (s, 3 H), 3.37-3.88 (m, 1 H), 2.71-3.24 (m, 2 H)	483.2 [M+H]+	100%
2507	(CD3OD) δ 8.73 (br s, 1 H), 8.29 (br s, 1 H), 7.77-8.12 (m, 2 H), 7.58-7.77 (m, 2 H), 6.62-7.10 (m, 3 H), 4.63 (br s, 1 H), 3.98 (s, 3 H), 3.80 (br s, 1 H), 2.78-3.26 (m, 2 H)	483.2 [M+H]+	99.1%
2508	(CD3OD) δ 8.36 (d, 1 H), 7.67 (s, 1 H), 6.77-7.26 (m, 3 H), 6.64 (s, 1 H), 6.26 (s, 1 H), 4.20 (dd, 1 H), 3.59-3.80 (m, 1 H), 2.95-3.10 (m, 1 H), 2.80 (br dd, 1 H), 2.00-2.18 (m, 1 H), 0.94-1.22 (m, 4 H)	414.2 [M+H]+	100%
2509	(CD3OD) δ 8.24 (d, 1 H), 7.57 (s, 1 H), 6.64-7.16 (m, 3 H), 6.52 (s, 1 H), 6.14 (s, 1 H), 4.08 (dd, 1 H), 3.47-3.67 (m, 1 H), 2.82-3.01 (m, 1 H), 2.68 (br dd, 1 H), 1.90-2.02 (m, 1 H), 0.86-1.08 (m, 4 H)	414.2 [M+H]+	99.1%
2510	(CD3OD) δ 9.26 (s, 1 H), 8.60-8.77 (m, 3 H), 7.69 (s, 1 H), 7.59 (br d, 1 H), 6.95 (br t, 1 H), 6.81 (s, 1 H), 6.53 (s, 1 H), 4.46 (br dd, 1 H), 3.73-3.91 (m, 1 H), 3.03-3.18 (m, 1 H), 2.85 (br dd, 1 H)	454.1 [M+H]+	98.7%
2511	(CD3OD) δ 9.27 (d, 1 H), 8.57-8.79 (m, 3 H), 7.69 (s, 1 H), 7.60 (br d, 1 H), 6.96 (t, 1 H), 6.81 (s, 1 H), 6.54 (s, 1 H), 4.46 (dd, 1 H), 3.71-3.88 (m, 1 H), 2.99-3.21 (m, 1 H), 2.86 (br dd, 1 H)	454.2 [M+H]+	95.4%
2512	(CD3OD) δ 9.17 (dd, 1 H), 8.10-8.36 (m, 2 H), 7.77 (dd, 1 H), 7.58 (s, 1 H), 6.93 (d, 1 H), 6.56-6.82 (m, 2 H), 6.44 (s, 1 H), 4.37 (dd, 1 H), 3.63-3.86 (m, 1 H), 2.91-3.15 (m, 2 H), 2.75 (br dd, 1 H), 1.21 (t, 6 H)	428.2 [M+H]+	100%
2513	(CD3OD) δ 9.17 (dd, 1 H), 8.08-8.35 (m, 2 H), 7.77 (dd, 1 H), 7.58 (s, 1 H), 6.92 (d, 1 H), 6.59-6.84 (m, 2 H), 6.44 (s, 1 H), 4.37 (dd, 1 H), 3.63-3.85 (m, 1 H), 2.91-3.14 (m, 2 H), 2.75 (br dd, 1 H), 1.21 (t, 6 H)	428.2 [M+H]+	99.3%
2514	(CD3OD) δ 8.31-8.38 (m, 1 H), 7.67 (s, 1 H), 6.97 (dd, 1 H), 6.84 (td, 1 H), 6.65 (s, 1 H), 6.25 (s, 1 H), 4.20 (dd, 1 H), 3.62-3.76 (m, 1 H), 2.95-3.09 (m, 1 H), 2.80 (br dd, 1 H), 1.50 (s, 3 H), 1.21-1.29 (m, 2 H), 0.91-0.96 (m, 2 H)	380.2 [M+H]+	100%
2515	(CD3OD) δ 8.35 (d, 1 H), 7.67 (s, 1 H), 6.97 (dd, 1 H), 6.84 (td, 1 H), 6.58-6.71 (m, 1 H), 6.25 (s, 1 H), 4.20 (dd, 1 H), 3.59-3.80 (m, 1 H), 2.95-3.11 (m, 1 H), 2.80 (dd, 1 H), 1.50 (s, 3 H), 1.21-1.34 (m, 2 H), 0.84-0.98 (m, 2 H)	380.2 [M+H]+	100%
2516	(CD3OD) δ 9.42 (d, 1 H), 8.78 (s, 2 H), 8.32-8.65 (m, 1 H), 7.65-8.28 (m, 2 H), 6.67-7.17 (m, 4 H), 4.64 (br s, 1 H), 3.83 (br s, 0.5 H), 3.45-3.63 (m, 0.5 H), 2.99-3.30 (m, 1 H), 2.76-2.96 (m, 1 H)	431.2 [M+H]+	100%
2517	(CD3OD) δ 9.42 (s, 1 H), 8.78 (s, 2 H), 8.31-8.65 (m, 1 H), 7.61-8.28 (m, 2 H), 6.69-7.11 (m, 4 H), 4.82 (br s, 1 H), 3.82 (br s, 0.5 H), 3.40-3.63 (m, 0.5 H), 2.98-3.30 (m, 1 H), 2.78-2.96 (m, 1 H)	431.2 [M+H]+	99.1%
2518	(CD3OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 7.05 (d, 1 H), 6.83 (t, 1 H), 6.60 (s, 1 H), 6.30 (s, 1 H), 4.23 (dd, 1 H), 3.71 (ddd, 1 H), 3.49-3.62 (m, 1 H), 3.18 (dt, 1 H), 2.93-3.09 (m, 5 H), 2.80 (br dd, 1 H), 1.32 (dd, 6 H)	440.2 [M+H]+	99.6%
2519	(CD3OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 7.05 (d, 1 H), 6.83 (t, 1 H), 6.60 (s, 1 H), 6.29 (br s, 1 H), 4.23 (dd, 1 H), 3.71 (ddd, 1 H), 3.49-3.62 (m, 1 H), 3.18 (dt, 1 H), 2.90-3.09 (m, 5 H), 2.79 (br dd, 1 H), 1.33 (dd, 6 H)	440.2 [M+H]+	98.9%
2520	(CD3OD) δ 9.28 (d, 1 H), 8.68-8.75 (m, 2 H), 7.64-7.76 (m, 2 H), 7.14-7.51 (m, 3 H), 6.74 (s, 1 H), 6.52 (br s, 1 H), 4.45 (dd, 1 H), 3.80-3.95 (m, 1 H), 3.03-3.20 (m, 1 H), 2.86 (br dd, 1 H)	436.2 [M+H]+	100%
2521	(CD3OD) δ 9.26 (d, 1 H), 8.67-874 (m, 2 H), 7.63-7.76 (m, 2 H), 7.13-7.49 (m, 3 H), 6.73 (s, 1 H), 6.51 (s, 1 H), 4.45 (dd, 1 H), 3.77-3.96 (m, 1 H), 2.99-3.15 (m, 1 H), 2.85 (br dd, 1 H)	436.1 [M+H]+	99.4%
2522	(CD3OD) δ 7.53-7.70 (m, 2 H), 7.02-7.40 (m, 3 H), 6.56 (s, 1 H), 6.27 (s, 1 H), 4.13-4.29 (m, 1 H), 3.60-3.76 (m, 1 H), 2.86-3.00 (m, 1 H), 2.73 (dd, 1 H), 2.00 (t, 3 H)	422.2 [M+H]+	100%
2523	(CD3OD) δ 7.63 (d, 1 H), 7.57 (s, 1 H), 7.05-7.39 (m, 3 H), 6.55 (s, 1 H), 6.26 (s, 1 H), 4.21 (dd, 1 H), 3.67 (td, 1 H), 2.89-3.02 (m, 1 H), 2.73 (dd, 1 H), 2.00 (t, 3 H)	422.2 [M+H]+	96.4%
2524	(CD3OD) δ 8.30-8.65 (m, 1 H), 8.03 (d, 0.3 H), 7.41-7.84 (m, 3.7 H), 7.17-7.32 (m, 2.5 H), 6.54-6.97 (m, 2.5 H), 4.36-4.78 (m, 1 H), 3.38-3.86 (m, 1 H), 2.97-3.28 (m, 1 H), 2.76-2.91 (m, 1 H)	448.2 [M+H]+	N/A

Cell Based Phenylalanine Flux Assay

Cells expressing R408W PAH were made by transducing A375 cells with lentivirus encoding human PAH with the R408W mutation in pLVX-Puro, then selecting with puromycin until stable cell lines were generated. A375 R408W cells were seeded into 96 well plates in DMEM + 1 0% FBS at a density of 40,000 cells/well one hour prior to compound addition. Compounds were resuspended in DMSO, and 2-fold serial dilutions were performed to generate a 10-point dose curve. Compounds were added to plated cells in a total volume of 100 µl, and a final DMSO concentration of 0.5%. Each compound was tested in duplicate. Following compound addition, cells were placed in a 5% CO₂, 37° C. tissue culture incubator for 24 hrs. After the incubation period, 20 µM sepiapterin and 800 µM 13C9,15N-Phenylalanine were added. After 4 hours, cell media was removed. An aliquot of 10 µl of cell media was combined with 200 µl of extraction buffer (80% acetonitrile/20% H₂O) for each well. Determination of ¹³C-Tyrosine concentration was assessed by liquid chromatography mass spectrometry.

Specific compounds disclosed herein were tested in the foregoing assay and they were determined to have an AC₅₀ according to the following scores: (A) less than or equal to 0.500 µM, (B) greater than 0.500 and less than 1.000 µM, (C) greater than or equal to 1.000 and less than 5.000 µM, (D) greater than or equal to 5.000 µM, (E) no fit, and (NT) not tested, as shown below. Where a compound was tested multiple times, the average value of the tests is reported.

Ex. # AC50
600   B
601   D
602   A
603   C
604   D
605   B
606   A
607   D
608   C
609   D
610   A
611   C
612   A
613   C
614   A
615   C
616   B
617   D
618   A
619   C
620   C
621   D
622   B
623   C
624   C
625   C
626   C
627   E
628   A
629   C
630   A
631   C
632   A
633   D
634   A
635   C
636   A
637   C
638   A
639   C
640   B
641   D
642   B
643   D
644   A
645   C
646   C
647   D
648   A
649   D
650   C
651   C
652   A
653   D
654   A
655   C
656   A
657   D
658   C
659   C
660   B
661   D
662   A
663   C
664   D
665   A
666   B
667   D
668   D
669   A
670   A
671   D
672   D
673   B
674   C
675   D
676   A
677   D
678   C
679   D
680   A
681   D
682   B
683   D
684   B
685   D
686   A
687   C
688   A
689   D
690   A
691   D
692   A
693   D
694   A
695   D
696   A
697   D
698   C
699   A
700   A
701   C
702   A
703   C
704   A
705   C
706   A
707   E
708   A
709   E
710   A
711   D
712   A
713   D
714   A
715   D
716   A
717   B
718   A
719   D
720   A
721   D
722   A
723   C
724   A
725   D
726   B
727   C
728   A
729   D
730   A
731   D
732   D
733   A
734   D
735   A
736   A
737   C
738   A
739   C
740   D
741   A
742   D
743   A
744   A
745   C
746   A
747   D
748   A
749   D
750   A
751   D
752   A
753   C
754   A
755   D
756   A
757   C
758   A
759   C
760   C
761   C
762   A
763   C
764   B
765   C
766   A
767   D
768   A
769   D
770   A
771   C
772   A
773   B
774   A
775   D
776   A
777   D
778   D
779   B
780   A
781   C
782   A
783   C
784   A
785   C
786   A
787   C
788   A
789   C
790   D
791   A
792   A
793   B
794   A
795   C
796   A
797   D
798   A
799   D
800   B
801   D
802   A
803   D
804   A
805   C
806   B
807   D
808   D
809   B
810   A
811   C
812   B
813   D
814   A
815   D
816   D
817   A
818   D
819   A
820   A
821   D
822   A
823   C
824   D
825   A
826   A
827   D
828   A
829   D
830   A
831   C
832   A
833   D
834   B
835   D
836   A
837   D
838   A
839   C
840   B
841   C
842   A
843   C
844   A
845   D
846   A
847   D
848   A
849   E
850   A
851   D
852   B
853   E
854   A
855   D
856   A
857   E
858   A
859   E
860   A
861   E
862   A
863   E
864   A
865   E
866   E
867   A
868   D
869   B
870   D
871   A
872   D
873   B
874   D
875   A
876   D
877   A
878   D
879   A
880   D
881   A
882   D
883   A
884   B
885   E
886   A
887   D
888   D
889   B
890   D
891   A
892   A
893   E
894   A
895   D
896   A
897   D
898   A
899   E
900   A
901   D
902   A
903   C
904   D
905   A
906   A
907   D
908   C
909   A
910   B
911   D
912   A
913   D
914   B
915   D
916   A
917   E
918   A
919   D
920   E
921   A
922   A
923   D
924   A
925   D
926   A
927   D
928   A
929   D
930   D
931   A
932   A
933   D
934   B
935   D
936   A
937   D
938   A
939   D
940   B
941   D
942   A
943   D
944   B
945   D
946   A
947   D
948   A
949   C
950   A
951   C
952   B
953   C
954   A
955   D
956   D
957   A
958   A
959   C
960   B
961   C
962   A
963   D
964   A
965   D
966   B
967   D
968   C
969   A
970   D
971   B
972   A
973   D
974   C
975   A
976   A
977   D
978   C
979   A
980   A
981   C
982   A
983   D
984   B
985   C
986   C
987   B
988   A
989   C
990   B
991   E
992   B
993   E
994   A
995   E
996   A
997   A
998   E
999   E
1000  B
1001  E
1002  E
1003  B
1004  E
1005  A
1006  E
1007  B
1008  E
1009  B
1010  B
1011  E
1012  B
1013  D
1014  A
1015  D
1016  A
1017  D
1018  A
1019  D
1020  A
1021  C
1022  A
1023  D
1024  A
1025  C
1026  C
1027  A
1028  A
1029  C
1030  A
1031  D
1032  B
1033  C
1034  B
1035  D
1036  B
1037  D
1038  A
1039  D
1040  B
1041  D
1042  A
1043  D
1044  A
1045  E
1046  D
1047  A
1048  E
1049  B
1050  A
1051  D
1052  A
1053  C
1054  A
1055  C
1056  A
1057  D
1058  B
1059  D
1060  A
1061  E
1062  A
1063  E
1064  B
1065  C
1066  A
1067  D
1068  A
1069  C
1070  A
1071  D
1072  B
1073  C
1074  B
1075  E
1076  A
1077  E
1078  A
1079  E
1080  E
1081  A
1082  A
1083  E
1084  A
1085  C
1086  A
1087  E
1088  B
1089  D
1090  B
1091  D
1092  B
1093  C
1094  A
1095  D
1096  D
1097  B
1098  D
1099  B
1100  B
1101  D
1102  B
1103  D
1104  A
1105  C
1106  A
1107  C
1108  D
1109  A
1110  B
1111  D
1112  A
1113  C
1114  B
1115  E
1116  A
1117  D
1118  A
1119  D
1120  A
1121  C
1122  C
1123  A
1124  B
1125  C
1126  A
1127  C
1128  B
1129  C
1130  B
1131  C
1132  A
1133  C
1134  A
1135  C
1136  C
1137  B
1138  A
1139  C
1140  B
1141  E
1142  A
1143  E
1144  B
1145  E
1146  A
1147  E
1148  B
1149  C
1150  A
1151  E
1152  A
1153  E
1154  A
1155  E
1156  A
1157  E
1158  B
1159  E
1160  C
1161  B
1162  A
1163  E
1164  A
1165  C
1166  B
1167  E
1168  B
1169  D
1170  D
1171  B
1172  A
1173  E
1174  B
1175  C
1176  A
1177  E
1178  A
1179  E
1180  B
1181  E
1182  C
1183  B
1184  B
1185  C
1186  B
1187  C
1188  B
1189  C
1190  B
1191  C
1192  A
1193  C
1194  C
1195  B
1196  A
1197  C
1198  B
1199  C
1200  B
1201  B
1202  A
1203  C
1204  A
1205  D
1206  B
1207  D
1208  A
1209  D
1210  B
1211  E
1212  B
1213  E
1214  A
1215  D
1216  E
1217  A
1218  E
1219  B
1220  A
1221  C
1222  A
1223  C
1224  B
1225  C
1226  A
1227  B
1228  E
1229  B
1230  A
1231  C
1232  A
1233  C
1234  A
1235  C
1236  A
1237  C
1238  A
1239  C
1240  A
1241  C
1242  C
1243  C
1244  C
1245  B
1246  B
1247  C
1248  C
1249  A
1250  A
1251  B
1252  A
1253  C
1254  C
1255  A
1256  A
1257  C
1258  B
1259  C
1260  A
1261  E
1262  A
1263  E
1264  E
1265  A
1266  A
1267  E
1268  A
1269  E
1270  A
1271  E
1272  A
1273  E
1274  A
1275  A
1276  A
1277  A
1278  A
1279  E
1280  A
1281  C
1282  E
1283  B
1284  A
1285  C
1286  A
1287  B
1288  B
1289  A
1290  C
1291  B
1292  A
1293  C
1294  C
1295  A
1296  A
1297  C
1298  C
1299  A
1300  A
1301  D
1302  A
1303  C
1304  A
1305  C
1306  A
1307  C
1308  A
1309  C
1310  C
1311  B
1312  C
1313  B
1314  A
1315  C
1316  A
1317  C
1318  C
1319  A
1320  C
1321  A
1322  C
1323  A
1324  C
1325  A
1326  A
1327  E
1328  A
1329  D
1330  A
1331  C
1332  A
1333  C
1334  A
1335  D
1336  C
1337  B
1338  D
1339  A
1340  B
1341  C
1342  B
1343  C
1344  C
1345  C
1346  B
1347  C
1348  A
1349  D
1350  A
1351  D
1352  A
1353  D
1354  B
1355  C
1356  A
1357  D
1358  A
1359  C
1360  D
1361  B
1362  B
1363  D
1364  A
1365  D
1366  A
1367  C
1368  A
1369  C
1370  A
1371  E
1372  A
1373  C
1374  A
1375  D
1376  D
1377  A
1378  A
1379  D
1380  C
1381  B
1382  A
1383  D
1384  A
1385  E
1386  B
1387  E
1388  A
1389  D
1390  B
1391  C
1392  C
1393  A
1394  A
1395  D
1396  A
1397  C
1398  A
1399  C
1400  A
1401  C
1402  B
1403  E
1404  C
1405  A
1406  A
1407  D
1408  C
1409  A
1410  C
1411  A
1412  E
1413  B
1414  A
1415  C
1416  A
1417  C
1418  C
1419  B
1420  D
1421  A
1422  A
1423  D
1424  A
1425  C
1426  A
1427  D
1428  D
1429  A
1430  D
1431  A
1432  C
1433  A
1434  B
1435  C
1436  B
1437  C
1438  B
1439  D
1440  B
1441  D
1442  A
1443  C
1444  A
1445  C
1446  B
1447  D
1448  B
1449  C
1450  A
1451  D
1452  A
1453  D
1454  D
1455  A
1456  A
1457  C
1458  C
1459  A
1460  E
1461  B
1462  A
1463  C
1464  C
1465  A
1466  A
1467  C
1468  A
1469  D
1470  A
1471  C
1472  B
1473  C
1474  A
1475  C
1476  A
1477  C
1478  A
1479  C
1480  A
1481  C
1482  A
1483  C
1484  A
1485  C
1486  A
1487  D
1488  A
1489  C
1490  B
1491  C
1492  B
1493  C
1494  A
1495  D
1496  A
1497  C
1498  E
1499  B
1500  A
1501  D
1502  B
1503  D
1504  A
1505  D
1506  A
1507  D
1508  A
1509  D
1510  B
1511  C
1512  A
1513  C
1514  A
1515  D
1516  E
1517  A
1518  E
1519  A
1520  A
1521  C
1522  A
1523  D
1524  D
1525  B
1526  B
1527  D
1528  A
1529  C
1530  D
1531  A
1532  A
1533  D
1534  C
1535  B
1536  D
1537  B
1538  B
1539  D
1540  B
1541  C
1542  B
1543  C
1544  A
1545  C
1546  B
1547  D
1548  B
1549  C
1550  A
1551  C
1552  A
1553  E
1554  D
1555  C
1556  A
1557  C
1558  C
1559  A
1560  D
1561  A
1562  B
1563  C
1564  D
1565  A
1566  B
1567  C
1568  A
1569  D
1570  A
1571  C
1572  C
1573  B
1574  C
1575  A
1576  E
1577  B
1578  B
1579  D
1580  A
1581  D
1582  B
1583  D
1584  B
1585  D
1586  C
1587  A
1588  D
1589  B
1590  E
1591  B
1592  B
1593  C
1594  A
1595  D
1596  A
1597  D
1598  B
1599  D
1600  B
1601  E
1602  B
1603  E
1604  B
1605  D
1606  E
1607  B
1608  B
1609  D
1610  B
1611  E
1612  D
1613  A
1614  B
1615  E
1616  A
1617  D
1618  A
1619  C
1620  D
1621  A
1622  C
1623  A
1624  B
1625  D
1626  B
1627  D
1628  B
1629  E
1630  B
1631  E
1632  B
1633  E
1634  B
1635  E
1636  E
1637  A
1638  E
1639  B
1640  B
1641  D
1642  D
1643  B
1644  A
1645  D
1646  B
1647  D
1648  B
1649  D
1650  B
1651  E
1652  B
1653  D
1654  B
1655  E
1656  D
1657  B
1658  B
1659  E
1660  B
1661  E
1662  B
1663  D
1664  A
1665  C
1666  B
1667  D
1668  B
1669  D
1670  B
1671  E
1672  A
1673  D
1674  B
1675  E
1676  B
1677  D
1678  D
1679  A
1680  B
1681  E
1682  A
1683  E
1684  A
1685  E
1686  E
1687  B
1688  E
1689  A
1690  B
1691  D
1692  A
1693  C
1694  A
1695  D
1696  B
1697  E
1698  A
1699  D
1700  C
1701  B
1702  A
1703  E
1704  A
1705  E
1706  A
1707  D
1708  B
1709  D
1710  D
1711  B
1712  B
1713  D
1714  A
1715  E
1716  A
1717  D
1718  B
1719  C
1720  B
1721  E
1722  D
1723  B
1724  A
1725  E
1726  B
1727  E
1728  B
1729  D
1730  A
1731  D
1732  E
1733  A
1734  E
1735  A
1736  E
1737  B
1738  E
1739  A
1740  D
1741  B
1742  A
1743  C
1744  C
1745  D
1746  A
1747  D
1748  B
1749  E
1750  B
1751  D
1752  A
1753  E
1754  A
1755  D
1756  D
1757  A
1758  E
1759  B
1760  A
1761  E
1762  A
1763  C
1764  C
1765  B
1766  E
1767  A
1768  A
1769  C
1770  B
1771  D
1772  B
1773  D
1774  A
1775  D
1776  A
1777  D
1778  A
1779  E
1780  A
1781  D
1782  B
1783  E
1784  B
1785  E
1786  B
1787  C
1788  B
1789  D
1790  B
1791  D
1792  A
1793  E
1794  B
1795  D
1796  B
1797  E
1798  D
1799  B
1800  A
1801  E
1802  B
1803  D
1804  C
1805  A
1806  E
1807  B
1808  E
1809  A
1810  B
1811  E
1812  B
1813  E
1814  A
1815  D
1816  D
1817  A
1818  D
1819  A
1820  D
1821  A
1822  D
1823  B
1824  E
1825  B
1826  E
1827  B
1828  C
1829  A
1830  D
1831  B
1832  E
1833  B
1834  E
1835  B
1836  E
1837  B
1838  A
1839  D
1840  A
1841  D
1842  D
1843  A
1844  D
1845  A
1846  E
1847  A
1848  D
1849  A
1850  B
1851  C
1852  B
1853  C
1854  D
1855  A
1856  E
1857  B
1858  A
1859  E
1860  E
1861  A
1862  D
1863  A
1864  E
1865  A
1866  A
1867  E
1868  A
1869  D
1870  A
1871  D
1872  D
1873  B
1874  D
1875  A
1876  B
1877  D
1878  B
1879  E
1880  A
1881  D
1882  A
1883  E
1884  A
1885  D
1886  A
1887  D
1888  D
1889  A
1890  E
1891  A
1892  E
1893  A
1894  D
1895  A
1896  D
1897  B
1898  A
1899  C
1900  A
1901  D
1902  A
1903  E
1904  D
1905  A
1906  A
1907  D
1908  A
1909  C
1910  D
1911  A
1912  D
1913  A
1914  A
1915  D
1916  A
1917  D
1918  B
1919  E
1920  A
1921  E
1922  A
1923  D
1924  A
1925  D
1926  D
1927  A
1928  B
1929  E
1930  A
1931  D
1932  D
1933  B
1934  A
1935  E
1936  A
1937  C
1938  A
1939  C
1940  D
1941  A
1942  E
1943  A
1944  A
1945  C
1946  A
1947  E
1948  A
1949  C
1950  D
1951  A
1952  D
1953  A
1954  C
1955  A
1956  E
1957  B
1958  E
1959  A
1960  B
1961  D
1962  B
1963  D
1964  B
1965  D
1966  A
1967  D
1968  A
1969  D
1970  A
1971  D
1972  B
1973  D
1974  B
1975  D
1976  D
1977  B
1978  D
1979  A
1980  E
1981  B
1982  D
1983  A
1984  A
1985  D
1986  A
1987  C
1988  E
1989  B
1990  E
1991  B
1992  D
1993  A
1994  D
1995  A
1996  C
1997  B
1998  A
1999  D
2000  C
2001  D
2002  B
2003  D
2004  B
2005  D
2006  E
2007  A
2008  E
2009  A
2010  A
2011  D
2012  E
2013  A
2014  A
2015  C
2016  A
2017  D
2018  A
2019  D
2020  A
2021  D
2022  B
2023  D
2024  A
2025  E
2026  E
2027  B
2028  A
2029  D
2030  A
2031  C
2032  A
2033  D
2034  B
2035  D
2036  A
2037  D
2038  C
2039  A
2040  A
2041  C
2042  B
2043  C
2044  D
2045  B
2046  D
2047  B
2048  B
2049  D
2050  A
2051  D
2052  B
2053  D
2054  B
2055  D
2056  D
2057  A
2058  E
2059  B
2060  D
2061  B
2062  D
2063  A
2064  A
2065  E
2066  B
2067  D
2068  B
2069  D
2070  A
2071  D
2072  D
2073  B
2074  A
2075  C
2076  B
2077  D
2078  B
2079  E
2080  A
2081  D
2082  E
2083  A
2084  D
2085  A
2086  A
2087  D
2088  D
2089  A
2090  D
2091  A
2092  D
2093  A
2094  E
2095  A
2096  D
2097  B
2098  A
2099  E
2100  A
2101  E
2102  A
2103  E
2104  A
2105  E
2106  A
2107  E
2108  E
2109  B
2110  A
2111  E
2112  B
2113  D
2114  B
2115  C
2116  A
2117  C
2118  A
2119  C
2120  A
2121  C
2122  A
2123  C
2124  A
2125  C
2126  D
2127  A
2128  E
2129  A
2130  D
2131  A
2132  C
2133  A
2134  C
2135  A
2136  A
2137  D
2138  A
2139  E
2140  A
2141  E
2142  A
2143  E
2144  A
2145  E
2146  E
2147  A
2148  A
2149  D
2150  D
2151  A
2152  E
2153  A
2154  D
2155  A
2156  E
2157  B
2158  E
2159  B
2160  D
2161  A
2162  B
2163  D
2164  A
2165  D
2166  D
2167  A
2168  C
2169  A
2170  A
2171  D
2172  A
2173  C
2174  A
2175  D
2176  D
2177  B
2178  B
2179  D
2180  B
2181  D
2182  B
2183  D
2184  E
2185  A
2186  E
2187  A
2188  D
2189  B
2190  E
2191  B
2192  E
2193  A
2194  E
2195  A
2196  E
2197  B
2198  B
2199  E
2200  A
2201  D
2202  D
2203  A
2204  E
2205  A
2206  B
2207  D
2208  B
2209  E
2210  C
2211  E
2212  A
2213  D
2214  A
2215  E
2216  B
2217  E
2218  C
2219  D
2220  D
2221  C
2222  E
2223  C
2224  C
2225  A
2226  D
2227  B
2228  D
2229  A
2230  D
2231  A
2232  D
2233  A
2234  B
2235  D
2236  A
2237  D
2238  C
2239  A
2240  B
2241  D
2242  B
2243  D
2244  B
2245  D
2246  D
2247  A
2248  E
2249  A
2250  E
2251  A
2252  E
2253  A
2254  A
2255  C
2256  A
2257  D
2258  D
2259  B
2260  D
2261  B
2262  B
2263  D
2264  B
2265  D
2266  D
2267  A
2268  D
2269  A
2270  A
2271  D
2272  A
2273  D
2274  B
2275  D
2276  A
2277  D
2278  D
2279  A
2280  A
2281  D
2282  D
2283  A
2284  D
2285  A
2286  D
2287  A
2288  E
2289  A
2290  E
2291  C
2292  A
2293  D
2294  D
2295  B
2296  A
2297  D
2298  C
2299  A
2300  E
2301  B
2302  E
2303  A
2304  E
2305  B
2306  D
2307  A
2308  D
2309  B
2310  C
2311  A
2312  C
2313  A
2314  A
2315  E
2316  A
2317  E
2318  D
2319  A
2320  E
2321  A
2322  D
2323  B
2324  D
2325  A
2326  E
2327  C
2328  D
2329  C
2330  B
2331  D
2332  B
2333  D
2334  D
2335  B
2336  B
2337  E
2338  B
2339  D
2340  D
2341  B
2342  C
2343  D
2344  D
2345  B
2346  D
2347  B
2348  B
2349  E
2350  B
2351  E
2352  B
2353  E
2354  D
2355  B
2356  E
2357  B
2358  D
2359  B
2360  D
2361  A
2362  E
2363  B
2364  D
2365  C
2366  C
2367  E
2368  C
2369  D
2370  C
2371  E
2372  C
2373  E
2374  E
2375  E
2376  C
2377  C
2378  C
2379  E
2380  C
2381  D
2382  C
2383  E
2384  C
2385  D
2386  C
2387  E
2388  C
2389  E
2390  C
2391  E
2392  E
2393  C
2394  D
2395  C
2396  C
2397  E
2398  C
2399  C
2400  A
2401  C
2402  E
2403  C
2404  C
2405  D
2406  A
2407  E
2408  E
2409  C
2410  B
2411  E
2412  C
2413  E
2414  C
2415  C
2416  C
2417  C
2418  E
2419  C
2420  C
2421  C
2422  C
2423  E
2424  C
2425  E
2426  C
2427  D
2428  C
2429  C
2430  C
2431  C
2432  E
2433  C
2434  C
2435  D
2436  C
2437  D
2438  C
2439  E
2440  C
2441  E
2442  E
2443  C
2444  E
2445  C
2446  C
2447  D
2448  C
2449  D
2450  C
2451  D
2452  C
2453  E
2454  C
2455  C
2456  C
2457  E
2458  C
2459  E
2460  E
2461  C
2462  C
2463  E
2464  C
2465  D
2466  E
2467  C
2468  E
2469  C
2470  C
2471  D
2472  C
2473  E
2474  C
2475  D
2476  C
2477  E
2478  C
2479  E
2480  D
2481  C
2482  C
2483  E
2484  E
2485  C
2486  E
2487  C
2488  C
2489  E
2490  E
2491  C
2492  E
2493  C
2494  C
2495  E
2496  C
2497  E
2498  E
2499  C
2500  E
2501  C
2502  C
2503  D
2504  D
2505  C
2506  C
2507  E
2508  E
2509  C
2510  C
2511  D
2512  C
2513  E
2514  E
2515  C
2516  C
2517  D
2518  E
2519  C
2520  E
2521  C
2522  E
2523  C
2524  B

Additionally, the following compounds were tested with an AC₅₀ of C, D, or E:

Compound(s)                      AC50
4S and 4R enantiomers of 1-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-3-(1,3-thiazol-2-yl)propan-1-one C, E
4S and 4R enantiomers of 3-(5-methyl-1,3,4-thiadiazol-2-yl)-1-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]propan-1-one D, E
4S and 4R enantiomers of 5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, C
4S and 4R enantiomers of 2-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-{4-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl }-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-(5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyridine C, D
4S and 4R enantiomers of 2-{4-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyridine C, D
4S and 4R enantiomers of 2-{5-[4-(pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of dimethyl({3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)amine C, E
4S and 4R enantiomers of 5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 1-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-2-{pyrazolo[1,5-a]pyridin-3-yl}ethan-1-one C, D
4S and 4R enantiomers of 5-cyclopropanecarbonyl-4-{pyrazolo[1,5-alpyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 1-[4-{pyrazolo[1,5-a]pyridin-2-yl}-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-2-(1,3,4-thiadiazol-2-yl)ethan-1-one C, E
4S and 4R enantiomers of 1-methyl-4-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}piperazine D, E
4S and 4R enantiomers of 4-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}morpholine C, E
4S and 4R enantiomers of 2-{4-cyclopropyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H,8H-imidazo[4,5-c]azepine-5-carbonyl]-1,3-oxazol-2-yl}pyridine C, E
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H,8H-imidazo[4,5-c]azepine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyridine D, E
4S and 4R enantiomers of 5-[(1R)-2,2-difluorocyclopropanecarbonyl]-4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine C, E
4S and 4R enantiomers of 5-[(1S)-2,2-difluorocyclopropanecarbonyll-4-{pyrazolor 1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 4-fluoro-1-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl}-1,3,4-oxadiazol-2-yl}piperidine C, E
4S and 4R enantiomers of N,N-dimethyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-amine C, E
4S and 4R enantiomers of 2-(3-fluoroazetidin-1-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of N-cyclopropyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl }-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-amine C, E
4S and 4R enantiomers of 2-(methoxymethyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-thiazole C, D
4S and 4R enantiomers of 2-(methoxymethyl)-3-[4-{pyrazolo[1,5-alpyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4′S and 4′R enantiomers of 5′-(4-methyl-1,3-oxazole-5-carbonyl)-4′-{pyrazolo[1,5-a|pyridin-2-yl}-1′,4′,5′,6′-tetrahydrospiro[cyclopropane-1,7′-imidazo[4,5-c]pyridine] C, E
4S and 4R enantiomers of N-(2-methoxyethyl)-5[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1.3,4-oxadiazol-2-amine D, D
4S and 4R enantiomers of dimethyl({5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}methyl)amine D, E
4S and 4R enantiomers of 3-(difluoromethyl)-1-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole C, D
4S and 4R enantiomers of 2-(methoxymethyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 5-(difluoromethyl)-1-methyl-4-[4-{pyrazolo[1,5-a]pyridin-2-yl }-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole C, C
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}-5-(trifluoromethyl)pyridine C, D
4S and 4R enantiomers of 2-(1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]azetidin-1-yl}pyridine C, E
4S and 4R enantiomers of 1-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-]pyridine-5-carbonyl]-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, C
4S and 4R enantiomers of methyl 3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]azetidine-1-carboxylate D, E
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-1-yl}pyridine C, E
4S and 4R enantiomers of 2-[1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 3-[4-(pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-(2,2,2-trifluoroethyl)azetidine D, E
4S and 4R enantiomers of 2-{5-chloro-4-[4-(pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-1-yl}pyridine C, D
4S and 4R enantiomers of 2-(1H-purazol-3-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl|-1,3-oxazole-4-carboxamide C, E
4S and 4R enantiomers of (1R)-1-{4-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}ethan-1-ol C, E
4S and 4R enantiomers of 5-[4-{3-biomopyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole-4-carbonitrile C, C
4S and 4R enantiomers of (1S)-1-14-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl-1,3-oxazol-2-yl}ethan-1-ol C, E
4S and 4R enantiomers of 2-[4-{3-bromopyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 5-chloro-4-[4-{pyrazolo[1,5-alpyridin-2-yl }-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole C. C
4S and 4R enantiomers of 5-[4-(pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole D, E
4S and 4R enantiomers of 4-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole D, E
4S and 4R enantiomers of 1-methyl-3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole D, E
4S and 4R enantiomers of 1-methyl-5-[4-{pyrazolo(1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-3-amine D, E
4S and 4R enantiomers of 5-chloro-4-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole C, E
4S and 4R enantiomers of (1S)-1-{5-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-(difluoromethyl)-1,3-oxazol-2-yl}ethan-1-ol C, E
4S and 4R enantiomers of 4-ethyl-3-[4-{pyrazolo[1,5-a]pyridin-2-yl }-1H,4H,5H,6H,7H-imidazol[4,5-c]pyridine-5-carbonyl]-4H-1,2,4-triazole C, E
4S and 4R enantiomers of 2-{5-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-(trifluoromethyl)-1,3-oxazol-2-yl}propan-2-ol E, E
4S and 4R enantiomers of 2-{5-[4-{pyrazolop,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,2-oxazol-3-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-{3-14-{pyrazolo[1,5-a)pyridin-2-yl}-IH,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,2-oxazol-5-yl}propan-2-ol D, E
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,2,4-oxadiazol-3-yl}propan-2-ol D, E
4S and 4R enantiomers of (1S)-1-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-methyl-1,3-oxazol-2-yl}ethan-1-ol C, E
4S and 4R enantiomers of 2-{3-[4-{pyrazolo[1,5-alpyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,2,4-oxadiazol-5-yl}propan-2-ol D, E
4S and 4R enantiomers of (1S)-1-[4-(difluoromethyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazol[4,5-c]pyridine-5-carbonyl-1,3-oxazol-2-yl]ethan-1-ol C, E
4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 5-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-(difluoromethyl)-1,3-oxazole C, E
4S and 4R enantiomers of 5-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-(trifluoromethyl)-1,3-oxazole E, E
4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 2-[4-(difluoromethyl)-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl]propan-2-ol D, E
4S and 4R enantiomers of 5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]4-(trifluoromethyl)-1,3-oxazole E, E
4S and 4R enantiomers of 1-(difluoromethyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole C, E
4S and 4R enantiomers of 2-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazoro[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl} propan-2-ol C, E
4S and 4R enantiomers of 2-(5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-(trifluoromethyl)-13-oxazol-2-yl}propan-2-ol E, E
4S and 4R enantiomers of 2-{5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl} pyridine C, E
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-3-yl)-5-(4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-{6-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yt}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazot-5-yl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-(difluoromethyl)-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl]propan-2-ol E, E
4S and 4R enantiomers of 2-(1-methyl-1H-imidazol-5-y1)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-(5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-3-yl)-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-(trifluoromethyl)-1H-pyrazole E, E
4S and 4R enantiomers of 2-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine-5-carbonyl]-1-(trifluoromethyl)1H-pyrazole E, E
4S and 4R enantiomers of 2-[4-(difluoromethyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl]pyridine C, E
4S and 4R enantiomers of 4-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}morpholine C, E
4S and 4R enantiomers of 1-methyl-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo(4,5-c]pyridine-5-carbonyl]-1H-pyrazole E, E
4S and 4R enantiomers of 5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl)-1-(propan-2-yl)-1H-pyrazole E, E
4S and 4R enantiomers of 1-cyclopropyl-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine-5-carbonyl]-1H-pyrazole E, E
4S and 4R enantiomers of 4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-3-yl)-5-[4-{pyrazolol[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole D, E
4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-2-(1-methyl-1H-pyrazol-3-yl)-1,3-oxazole D, E
4S and 4R enantiomers of 4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-3-yl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 4-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}morpholine C, D
4S and 4R enantiomers of 5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-dimethyl-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2.4-triazole E, E
4S and 4R enantiomers of 5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-(propan-2-yl)-1H-pyrazole E, E
4S and 4R enantiomers of 3-tert-butyl-1-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole C, C
4S and 4R enantiomers of 3-tert-butyl-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-pyrazole C, D
4S and 4R enantiomers of 3-tert-butyl-1-methyl-5-[4-{4-methylpyrazolo[1.5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole C, D
4S and 4R enantiomers of 1-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}-4-methylpiperazine C, E
4S and 4R enantiomers of 1,3-dimethyl-5-{4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-pyrazole E, E
4S and 4R enantiomers of 3-tert-butyl-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-pyrazole C, D
4S and 4R enantiomers of 4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole E, E
4S and 4R enantiomers of 2-{3-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-1-yl}pyridine C, C
4S and 4R enantiomers of 2-(3-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-1-yl}pyridine C, D
4S and 4R enantiomers of 1-methyl-4-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}piperazine C, E
4S and 4R enantiomers of 2-(1-methyl-1H-imidazol-5-yl)-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl[-1H,4H,5H,6H,7H-imidazo[4,5-c-]pyridine-5-carbonyll-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(1-methyl-1H-imidazol-5-yl)-5-[4-(7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[-4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-methyl-5-[4-{ 7-methylpyrazolo[1,5-a]pyridin-2-yl }-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyrdine-5-carbonyl]-5-methyl-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-(1-methyl-1H-imidazol-5-yl)-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 1-(difluoromethyl)-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole C, E
4S and 4R enantiomers of 2-methyl-5-[4-{5-mcthylpyrazolo[1,5-a]pyridin-2-yl }-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-{5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, D
4S and 4R enantiomers of 3-(difluoromethyl)-5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 3-cyclopropyl-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 3-(difluoromethyl)-1-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 1-methyl-5-{4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole C, D
4S and 4R enantiomers of 1-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-3-(trifluoromethyl)-1H-1,2,4-triazole C, D
4S and 4R enantiomers of 3-(difluoromethyl)-5-[4-{6-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 2-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 4-(2,2-difluoroethyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 3-cyclopropyl-1-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 1,3-dimethyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 2-{5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyridine C, D
4S and 4R enantiomers of 2-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-5-yl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-[4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-3-methyl-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl}-1,3,4-oxadiazol-2-yl}propan-2-ol D, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyrindine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 2-{5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, C
4S and 4R enantiomers of 2-{5-[4-{6-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole C. C
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 2-{5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyrindine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyridine C. C
4S and 4R enantiomers of 2-[4-{7-chloropyrazolol[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 2-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2,4-triazole C, C
4S and 4R enantiomers of 2-methyl-5-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-cyclopropyl-5-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-clpyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-cyclopropyl-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-cyclopropyl-5-[4-[5-(trifluoromethyl)pyrazolol[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-cyclopropyl-5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-3-cyclopropyl-1-methyl-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H.5H,6H.7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-dimethyl-1H-1,2,4-triazole D, E
4S and 4R enantiomers of 3-(difluoromethyl)-1-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole C, E
4S and 4R enantiomers of 1,3-dimethyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole C, D
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-3-yl)-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-methyl-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, C
4S and 4R enantiomers of 2-(5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridinc-5-carbonyl]-1,3-oxazole C, D
4S and 4R enantiomers of 5-[4-{3-methylpyrazololo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, C
4S and 4R enantiomers of 2-methyl-5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-(3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 5-[4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine-5-carbonyl|-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3.4-oxadiazol-2-yl}propan-2-ol D, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-[5-(trifluoromethyl)pyrazolof 1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-3-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{4-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of (1S)-1-{4-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-3-carbonyl]-1,3-oxazol-2-yl}ethan-1-ol C, E
4S and 4R enantiomers of (1R)-1-{4-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6R,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}ethan-1-ol C, E
4S and 4R enantiomers of 2-[4-(4-methoxyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-{5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol D, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-methyl-5-[4-{6-methylpyrazolo[1,5-a]pyridin-2-yl }-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-{6-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 2-{5-[4-{4-methoxypyrazolo[1,5-alpyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]puridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol D, E
4S and 4R enantiomers of 5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, D
4S and 4R enantiomers of 5-[4-{6-fluoropyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of (1R)-1-{5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-methyl-1,3-oxazol-2-yl}ethan-1-ol C, D
4S and 4R enantiomers of 2-{5-[4-[7-{trifluoromethyl)pyrazolo[1,5-a[pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-{4-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol C, C
4S and 4R enantiomers of (1R)-1-{4-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}ethan-1-ol C, E
4S and 4R enantiomers of 2-{5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-(1,5-dimethyl-1H-pyrazol-4-yl)-5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, C
4S and 4R enantiomers of (1S)-1-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl}-1,3,4-oxadiazol-2-yl}ethan-1-ol C, E
4S and 4R enantiomers of 1-methyl-3-(trifluoromethyl)-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole C, E
4S and 4R enantiomers of (1R)-1-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}ethan-1-ol C, E
4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 2-cyclopropyl-5-[4-(pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-3-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-5-{pyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 5-{pyrazolo[1,5-a]pyridine-3-carbonyl}-4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-3-methyl-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 2-{5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine C, D
4S and 4R enantiomers of 1-methyl4-(3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}-1H-pyrazole C, C
4S and 4R enantiomers of 4-{3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine C, D
4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(propan-2-yl)-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-{5-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol C, E
4S and 4R enantiomers of 2-{5-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-(propan-2-yl)-5-[4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, C
4S and 4R enantiomers of 2-cyclopropyl-5-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-[1-(trifluoromethyl)-1H-pyrazol-4-yl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-[7-{trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl)-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-cyclopropyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-5-yl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-5-yl)-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-cyclopropyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-cyclopropyl-5-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-3-carbonyl]-5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-(4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-cyclopropyl-1,3,4-oxadiazole C, E
4S and 4R enantiomers of N,N-dimethyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c[pyridin-5-yl]-1,3,4-oxadiazole-2-carboxamide C, E
4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1.5-a]pyridin-2-yl]-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, E
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3-benzoxazole C, E
4S and 4R enantiomers of ({3-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine C, E
4S and 4R enantiomers of 2-{5-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-1,3,4-oxadiazol-2-yl}pyridine C, E
4S and 4R enantiomers of 5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-N,N-dimethyl1,3,4-oxadiazole-2-carboxamide C, E
4S and 4R enantiomers of N,N-dimethyl-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole-2-carboxamide C, E
4S and 4R enantiomers of dimethyl({3-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)amine C, E
4S and 4R enantiomers of 5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 2-[4-[4-(difluoromethoxy)pyrazolo[1,5-a)pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazole C, D
4S and 4R enantiomers of ({3-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine C, E
4S and 4R enantiomers of ({3-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5]clpyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine C, E
4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 4-{3-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine C, E
4S and 4R enantiomers of 4-{3-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine C, E
4S and 4R enantiomers of 3-fluoro-2-{5-4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyridine C, E
4S and 4R enantiomers of 2-{5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine D, E
4S and 4R enantiomers of 4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 4-{3-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine C, E
4S and 4R enantiomers of 2-{5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrazine C, E
4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, D
4S and 4R enantiomers of 5-{6-methoxypyrazolo[1,5-a]pyridine-3-carbonyl}-4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of ({3-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine C, E
4S and 4R enantiomers of ({3-(4-[7-(difluoromethyl)pyrazolo[1,5-a[pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine C, D
4S and 4R enantiomers of 4-{3-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine D, E
4S and 4R enantiomers of 4-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-1,3,4-oxadiazol-2-yl}morpholine D, E
4S and 4R enantiomers of 4-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}morpholine C, E
4S and 4R enantiomers of 4-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}morpholine C, E
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl1-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 2-methyl-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-clpyridin-5-yl]-1,3-benzoxazole D, E
4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4.5-cl]pyridin-5-yl]pyrimidine C, D
4S and 4R enantiomers of 2-[5-{6-methylpyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-4-yl]-7-(trifluoromethyl)pyrazolo[1,5-alpyridine C, E
4S and 4R enantiomers of 7-(difluoromethyl)-2-[5-(6-methylpyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-4-yl]pyrazolo[1,5-a]pyridine C, E
4S and 4R enantiomers of 5-{6-cyclopropylpyrazolo[1,5-a]pyridine-3-carbonyl}-4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-5-{6-methoxypyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4H,5H.6,7H-imidazo[4.5-c]pyridine C, D
4S and 4R enantiomers of 2-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-[1-(trifluoromethyl)-1H-pyrazol-4-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-[4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 5-[6-(mcthoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-N,N-dimethyl-1,3,4-oxadiazole-2-carboxamide C, E
4S and 4R enantiomers of N,N-dimethyl-5-[4-|4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole-2-carboxamide C, E
4S and 4R enantiomers of 2-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidine C, E
4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazor[4.5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 5-{6-cyclopropylpyrazolo[1,5-a]pyridine-3-carbonyl}-4-{7-methylpyrazolo[1.5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine C, D
4S and 4R enantiomers of 4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-5-{6-methoxypyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, D
4S and 4R enantiomers of 2-[4-[4-(trifluoromethoxy)pyrazolo[1,5-alpyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridinc-5-carbony]-5-[1-(trifluoromethyl)-1H-pyrazol-4-vl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 7-(difluoromethyl)-2-[5-{pyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4,5H,6H,7H-imidazo[4,5-c]pyridin-4-yl]pyrazolo[1,5-a]pyridine C, E
4S and 4R enantiomers of 5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of ({3-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine C, E
4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3-benzoxazole D, D
4S and 4R enantiomers of 4-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}morpholine D, E
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, E
4S and 4R enantiomers of 4-{3-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}-1-methyl-1H-pyrazole C, D
4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidine C, C
4S and 4R enantiomers of 2-(difluoromethyl)-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-cyclopropyl-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 7-methyl-2-[5-{6-methylpyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-4-yl]pyrazolo[1,5-a]pyridine C, D
4S and 4R enantiomers of 3-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridine-5-carbonyl]-N,N-dimethylpyrazolo[1,5-a]pyridin-6-amine C, D
4S and 4R enantiomers of 5-[6-(2-methoxyethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine C, E
4S and 4R enantiomers of 4-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}morpholine D, E
4S and 4R enantiomers of 2-(difluoromethyl)-5-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(difluoromethyl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 7-chloro-2-[5-{6-methylpyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin4-yl]pyrazolo[1,5-a]pyridine C, D
4S and 4R enantiomers of 2-tert-butyl-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidin-5-amine C, E
4S and 4R enantiomers of 5-(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,H4-imidazo[4,5-c]pyridine D, E
4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 3-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-N,N-dimethylpyrazolo[1,5-a]pyridin-6-amine C, E
4S and 4R enantiomers of (2-{3-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}ethyl)dimethylamine C, E
4S and 4R enantiomers of dimethyl(2-{3-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}ethyl)amine C, E
4S and 4R enantiomers of 2-cyclobutyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-cyclobutyl-5-[4-{4-fluoropyrazolo[1.5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 6-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyridin-3-amine D, E
4S and 4R enantiomers of 3-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-[1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-N,N-dimethylpyrazolo[1,5-a]pyridin-6-amine C, E
4S and 4R enantiomers of 2-cyclobutyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,6H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidin-5-amine D, E
4S and 4R enantiomers of 2-[4-]7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidin-5-amine D, E
4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-yl]pyrimidin-5-amine D, E
4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbony]-5-(1H-pyrazol-4-yl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-thiazole C, E
4S and 4R enantiomers of 6-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyridin-3-amine C, E
4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole D, E
4S and 4R enantiomers of dimethyl(2-{3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}ethyl)amine D, E
4S and 4R enantiomers of dimethyl(2-{3-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}ethyl)amine C, D
4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-cyclobutyl-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-cyclobutyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-cyclobutyl-5-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-tert-butyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(trifluoromethyl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-tert-butyl-5-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1H-pyrazol-4-yl)-1,3,4-oxadiazole C, D
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4.5-c]pyridin-5-yl]pyrimidin-5-amine C, E
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-(pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-3-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, D
4S and 4R enantiomers of 2-(1,5-dimethyl-1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, D
4S and 4R enantiomers of 2-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine D, E
4S and 4R enantiomers of 2-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-thiadiazole C, E
4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-thiadiazole C, E
4S and 4R enantiomers of 2-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7TH-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, E
4S and 4R enantiomers of 2-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-benzothiazole C, E
4S and 4R enantiomers of 5-cyclopropanecarbonyl-4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine D, E
4S and 4R enantiomers of 2-fluoro-6-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyridine C, E
4S and 4R enantiomers of 2-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine D, D
4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H.6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine D, E
4S and 4R enantiomers of 2-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 4-cyclopropyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, D
4Sand 4Renantiomers of 4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole C, D
4S and 4R enantiomers of 5-cyclobutanecarbonyl-4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine D, E
4S and 4R enantiomers of 5-cyclobutanecarbonyl-4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine D, E
4S and 4R enantiomers of 5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazno[4,5-c]pyridine-5-carbonyl]-2-(1-methyl-1H-pyrazol-3-yl)-1,3-oxazole C, E
4S and 4R enantiomers of 5-(trifluoromethyl)-2-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyridine C, E
4S and 4R enantiomers of 5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-2-(1-methyl-1H-pyrazol-4-yl)-1,3-oxazole C, D
4S and 4R enantiomers of 5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl-2-(1-methyl-1H-pyrazol-4-yl)-1,3-oxazole C, E
4S and 4R enantiomers of 2-[4-[4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine C, E
4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine C, E
4S and 4R enantiomers of 4-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,2H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, D
4S and 4R enantiomers of 4-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, D
4S and 4R enantiomers of 2-(1-methylcyclopropyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-3-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine C, E
4S and 4R enantiomers of 4-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine E, E
4S and 4R enantiomers of 4-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, D
4S and 4R enantiomers of 3-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine C, E
4S and 4R enantiomers of 3-(5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine C, E
4S and 4R enantiomers of 3-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine C, E
4S and 4R enantiomers of 3-{5-[4-[4-(difluoromethyl)pyrazolo[1.5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine C, E
4S and 4R enantiomers of 3-{5-[4-{pyrazolo[1,5-a}pyridin-2-yl}-1H,4H,5H,6H,7TH-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, D
4S and 4R enantiomers of 2-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(1-methylcyclopropyl)-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(2-fluoropropan-2-yl)-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-{5-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 3-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine C, E
4S and 4R enantiomers of 3-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine C, E
4S and 4R enantiomers of 4-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1-methyl-1H-pyrazole C, E
4S and 4R enantiomers of 2-[4-[4-(propan-2-yl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidine E, E
4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(1-methylcyclopropyl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-[4(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-{5-[-[4-(propan-2-yl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-{5-[-{4-chloroprazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine C, E
4S and 4R enantiomers of 2-{5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine C, E
4S and 4R enantiomers of 2-{5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine C, D
4S and 4R enantiomers of 3-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, D
4S and 4R enantiomers of 3-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, E
4S and 4R enantiomers of 2-methyl-3-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, E
4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrazine C, D
4S and 4R enantiomers of 1-methyl-4-[4-(pyrazolo[1,5-a]pyridin-2-y1}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1H-pyrazole D, E
4S and 4R enantiomers of 2-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-{5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine C, E
4S and 4R enantiomers of 3-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, D
4S and 4R enantiomers of 3-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, D
4S and 4R enantiomers of 3-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-2-methylpyridine C, C
4S and 4R enantiomers of 1-methyl-4-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]1H-pyrazole C, E
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 3-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, D
4S and 4R enantiomers of 2-fluoro-3-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, D
4S and 4R enantiomers of 2-(3-methyl-1H-pyrazol-4-yl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]1-5-(3-methyl-1H-pyrazol-4-yl)-1,3,4-oxadizole C, E
4S and 4R enantiomers of 2-fluoro-3-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6R,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, E
4S and 4R enantiomers of 3-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-2-fluoropyridine C, D
4S and 4R enantiomers of 2-(4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6R,7H-imidazo[4,5-c]pyridin-5-yl]-5-(2-fluoropropan-2-yl)-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-[4-(propan-2-yl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 2-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(2-fluoropropan-2-yl)-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 3-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-2-fluoropyridine C, D
4S and 4R enantiomers of 2-[4-[4-(propan-2-yl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrazine D, E
4S and 4R enantiomers of 2-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(propan-2-yl)-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-(propan-2-yl)-5-[4-[4-(propan-2-yl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole D, E
4S and 4R enantiomers of 2-(1,1-difluoroethyl)-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole C, E
4S and 4R enantiomers of 3-fluoro-2-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, E
4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-3-fluoropyridine C, E
4S and 4R enantiomers of 2-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-3-fluoropyridine C, D
4S and 4R enantiomers of 2-fluoro-6-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine C, E
4S and 4R enantiomers of 5-fluoro-2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yt}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadizol-2-yl}pyridine C, D
2-[2-(3-fluoroazetidin-1-yl)ethyl]-5-(4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl)-1,3,4-oxadiazole D

Having now fully described the methods, compounds, and compositions of matter provided herein, it will be understood by those of skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the methods, compounds, and compositions provided herein or any embodiment thereof

All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.

Claims

1. A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: m is 1 or 2;R1 is x is 0 to 5;each Ra independently is halo, C1-6alkyl, C3-6cycloalkyl, C1-6haloalkyl, C1-6alkoxy or C1-6haloalkoxy;R2 is C1-4alkyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;R3 is H or C1-6alkyl;R4 is H or C1-6alkyl;or R3 and R4, together with the atom to which they are attached, form a C3-6cycloalkyl;R5 is H or D;R5A is H or D;L is a bond, carbonyl, optionally substituted C1-6alkylene, optionally substituted C1-6alkylenecarbonyl, optionally substituted C2-6alkenylenecarbonyl, optionally substituted C1-6haloalkylenecarbonyl, or optionally substituted -C(O)NRb(C1-6alkylene)-, wherein the carbon atom of the carbonyl group is connected to N in Formula I; andRb is H or C1-6alkyl.

2. (canceled)

3. (canceled)

4. The compound of claim 1, wherein the compound is of Formula I-A-1: , or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, wherein the compound is of Formula I-B-1: or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, wherein the compound is of Formula I-C-1: or a pharmaceutically acceptable salt thereof.

7. (canceled)

8. (canceled)

9. (canceled)

10. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein L is a bond, —C(O)—, —C(O)CH2—, or —C(O)CF2—.

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein R1 is .

16. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein Ra is F, Br, Cl, methyl, ethyl, isopropyl, methoxy, ethoxy, CF3, CHF2, OCF3, OCHF2, or cyclopropyl.

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R5 is H.

24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R2 is optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. The compound of claim 24, or a pharmaceutically acceptable salt thereof, wherein R2 is C3-8cycloalkyl, optionally substituted with one or more of halo, C1-6alkyl, C1-6haloalkyl, or OH.

31. The compound of claim 30, or a pharmaceutically acceptable salt thereof, wherein R2 is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, .

32. The compound of claim 24, or a pharmaceutically acceptable salt thereof, wherein R2 is aryl, optionally substituted with one or more of halo or C1-6alkoxy.

33. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein R2 is optionally substituted pyridinyl, optionally substituted pyrimidinyl, or optionally substituted pyrazinyl.

34. The compound of claim 33, or a pharmaceutically acceptable salt thereof, wherein the pyridinyl, pyrimidinyl, or pyrazinyl is substituted with one or more of halo, C1-6haloalkyl, cyano, or NRyRz, wherein Ry and Rz are independently H or C1-6alkyl.

35. (canceled)

36. (canceled)

37. (canceled)

38. (canceled)

39. (canceled)

40. (canceled)

41. (canceled)

42. (canceled)

43. (canceled)

44. (canceled)

45. (canceled)

46. (canceled)

47. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R2 is: wherein: R6 and R7 are, independently, H, CN, C1-6alkyl, C1-6haloalkyl, C1-6cyanoalkyl, C1-6hydroxyalkyl, C1-6alkoxy, C1-6alkoxy(alkylene), C1-6haloalkoxy, C1-6haloalkoxy(alkylene), C1-6deuteratedalkoxy(alkylene), halo, (CRvRx)pNRyRz, C(O)NRy2Rz2, C1-6alkylcarbonyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C2-6alkenyl; optionally substituted C3-8cycloalkenyl; optionally substituted C3-8cycloalkyl(alkylene); optionally substituted aryl(alkylene); optionally substituted heterocyclyl(alkylene); or C1-6alkylsulfonyl;R8 is H, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, C1-6alkylcarbonyl, C1-6hydroxyalkyl, (CRvRx)pNRyRz, optionally substituted C3-8cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted C3-8cycloalkyl(alkylene);Rv and Rx are, independently, H or C1-6alkyl;Ry and Rz are, independently, H, C1-6alkyl, C1-6alkoxy(alkylene), or C3-6cycloalkyl;Ry2 and Rz2 are, independently, H, C1-6alkyl, or C3-6cycloalkyl; andp is 0, 1, 2, or 3.

48. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R6, R7, and R8 are each H.

49. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R6 is C1-6alkyl, C1-6haloalky, C1-6cyanoalky, or C1-6hydroxyalkyl.

50. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R6 is C3-6cycloalkyl, optionally substituted with one or more of halo, OH, C1-6haloalkyl, C1-6alkyl, or C1-6alkoxy .

51. The compound of claim 50, or a pharmaceutically acceptable salt thereof, wherein R6 is .

52. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R6 is aryl, optionally substituted with one or more of halo, C1-6haloalkyl, C1-6alkyl, or C3-6cycloalkyl.

53. The compound of claim 52, or a pharmaceutically acceptable salt thereof, wherein R6 is .

54. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R6 is pyridinyl, pyrazolyl, pyrazinyl, pyridazinyl, imidazolyl, or pyrimidinyl, each optionally substituted with one or more of halo, C1-6haloalkyl, C1-6alkyl, C1-6alkoxy, C1-6haloalkoxy, 6cycloalkyl, or C3-6cycloalkylsulfonyl .

55. (canceled)

56. The compound of claim 54, or a pharmaceutically acceptable salt thereof, wherein R6 is .

57. The compound of claim 54, or a pharmaceutically acceptable salt thereof, wherein R6 is .

58. (canceled)

59. (canceled)

60. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R7 is H, CN, C1-6alkyl, C1-6haloalkyl, halo, C3-8cycloalky, phenyl, or pyridinyl.

61. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R2 is: wherein: R6 is H, C1-6alkyl, C1-6haloalkyl, C1-6cyanoalkyl, C1-6hydroxyalkyl, optionally substituted C3-6cycloalky, or optionally substituted heteroaryl ; andR7 is H, CN, C1-6alkyl, C1-6haloalkyl, halo, or C3-6cycloalkyl.

62. The compound according to claim 61, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heteroaryl is substituted with one or more C1-6alkyl.

63. The compound according to claim 61, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted C3-6cycloalkyl is substituted with one or more OH.

64. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R2 is: wherein: R6 is H, C1-6alkyl, C1-6haloalkyl, or C1-6hydroxyalkyl; andR7 is H.

65. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R2 is: wherein: R6 is H, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, optionally substituted C3-6cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl.

66. The compound according to claim 65, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heteroaryl is substituted with one or more of C1-6alkyl, C1-6haloalkyl, halo, C1-6alkoxy, C3-6cycloalkyl, or C3-6cycloalkylsulfonyl .

67. The compound according to claim 65, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted C3-6cycloalkyl and optionally substituted heterocyclyl are each substituted with one or more of halo or C1-6alkyl.

68. The compound according to claim 65, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted aryl is substituted with one or more of halo, C1-6alkyl, or C1-6haloalkyl.

69. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R2 is: wherein: R6 and R7 are independently H, halo, C1-6alkyl, C1-6haloalkyl, or NRyRz; andR8 is H, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, or heteroaryl.

70. The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R2 is: wherein: R6 is H, C1-6alkyl, halo, C1-6haloalkyl, or C3-6cycloalkyl; andR8 is H or C1-6alkyl.

71. The compound of claim 69, or a pharmaceutically acceptable salt thereof, wherein at least one of R6 and R7 is H.

72. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R2 is: wherein: W is S or NR15W1 is S, O, or NR15;R10, R11, R12, R13, and R14 are independently H, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, C1-6alkoxy(alkylene), C1-6hydroxyalkyl, C1-6haloalkoxy, C1-6haloalkoxy(alkylene), C2-6alkenyl, CN, halo, (CRvRx)pNRyRz, C(O)NRy2Rz2, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), optionally substituted aryl, or optionally substituted heteroaryl;Rv and Rx are independently H or C1-6alkyl;Ry and Rz are independently H, C1-6alkyl, C3-6cycloalkyl, C1-6hydroxyalkyl, C1-6haloalkyl, C1-6alkoxy(alkylene), or C(O)OC1-6alkyl;Ry2 and Rz2 are independently H, C1-6alkyl, or C3-6cycloalkyl;p is 0, 1, 2, or 3; andR15 is H or C1-6alkyl.

73. The compound of claim 72, or a pharmaceutically acceptable salt thereof, wherein R10, R11, R12, R13, and R14 are each H.

74. (canceled)

75. The compound of claim 72, or a pharmaceutically acceptable salt thereof, wherein R2 is: wherein: R10, R11, R12, R13 and R14 are independently H, C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy,C1-6alkoxy(alkylene), optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene) optionally substituted heteroaryl, or (CRvRx)pNRyRz; ;Rv and Rx are, independently, H or C1-6alkyl;Ry and Rz are, independently, H, C1-6alkyl, C3-6cycloalkyl, or C(O)OC1-6alkyl; andp is 0, 1, 2, or 3.

76. (canceled)

77. (canceled)

78. The compound of claim 75, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heteroaryl is substituted with one or more of halo, C1-6haloalkyl, or C1-6alkyl.

79. (canceled)

80. (canceled)

81. The compound of claim 75, or a pharmaceutically acceptable salt thereof, wherein R10, R11, R13, and R14 are each hydrogen.

82. The compound of claim 23, wherein the compound is an S-enantiomer, or a pharmaceutically acceptable salt thereof.

83. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following: .

84. (canceled)

85. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

86. (canceled)

87. A method for stabilizing a mutant PAH protein, comprising contacting the protein with a compound of claim 1, or a pharmaceutically acceptable salt thereof.

88. The method of claim 87, wherein the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation.

89. The method of claim 87, wherein the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

90. The method of claim 87, wherein the mutant PAH protein contains at least one R408W mutation.

91. (canceled)

92. A method for reducing blood phenylalanine concentration in a subject suffering from phenylketonuria comprising administering a compound of claim 1, or a pharmaceutically acceptable salt thereof.

93. The method of claim 92, wherein the blood phenylalanine concentration is reduced to a concentration less than or equal to about 600 µM.

94. The method of claim 93, wherein the blood phenylalanine concentration is reduced to a concentration less than or equal to about 360 µM.

95. The method of claim 92, wherein the subject has a blood phenylalanine concentration greater than about 600 µM prior to administration of the compound.

96. The method of claim 92, wherein the subject has a blood phenylalanine concentration greater than about 1200 µM prior to administration of the compound.